The	O
frameshift	O
takes	O
place	O
at	O
the	O
slippery	O
sequence	O
with	O
the	O
two	O
ribosome	B-PATH
-	O
bound	O
tRNAs	O
slipping	O
back	O
simultaneously	O
by	O
one	O
nucleotide	O
from	O
the	O
zero	O
phase	O
(	O
U	O
UUA	O
AAC	O
)	O
to	O
the	O
-	O
1	O
phase	O
(	O
UUU	O
AAA	O
).	O

0	O
.	O
6	O
years	O
,	O
49	O
males	O
and	O
31	O
females	O
),	O
were	O
admitted	O
to	O
the	O
Pediatric	O
Intensive	O
Care	O
Unit	O
(	O
PICU	O
)	O
with	O
acute	O
respiratory	O
syndrome	O
(	O
ARDS	O
)	O
(	O
27	O
%),	O
asthma	B-PATH
(	O
15	O
%),	O
bronchiolitis	O
(	O
10	O
%),	O
pneumonia	O
(	O
21	O
%),	O
pulmonary	O
congenital	O
diseases	O
(	O
9	O
%),	O
or	O
foreign	O
body	O
aspiration	O
(	O
18	O
%).	O

Previously	O
we	O
identified	O
the	O
first	O
cleavage	O
event	O
as	O
proteolysis	O
at	O
the	O
Gly	O
(	O
673	O
)-	O
Gly	O
(	O
674	O
)	O
dipeptide	O
bond	O
mediated	O
by	O
the	O
first	O
papain	O
-	O
like	O
proteinase	O
domain	O
(	O
PLPD	O
-	O
1	O
)	O
to	O
release	B-PATH
an	O
87	O
-	O
kDa	O
mature	O
protein	O
.	O

Expression	O
,	O
deletion	O
,	O
and	O
mutagenesis	O
studies	O
showed	O
that	O
the	O
product	O
encoded	O
between	O
nucleotides	O
2548	O
and	O
8865	O
was	O
further	O
cleaved	O
by	O
PLPD	O
-	O
1	O
at	O
the	O
Gly	O
(	O
2265	O
)-	O
Gly	O
(	O
2266	O
)	O
dipeptide	O
bond	O
to	O
release	B-PATH
an	O
N	O
-	O
terminal	O
195	O
-	O
kDa	O
and	O
a	O
C	O
-	O
terminal	O
41	O
-	O
kDa	O
cleavage	O
product	O
.	O

As	O
judged	O
by	O
their	O
colabeling	O
with	O
antibodies	O
to	O
E	O
and	O
to	O
Rab	O
-	O
1	O
,	O
a	O
marker	O
for	O
the	O
intermediate	O
compartment	O
and	O
endoplasmic	O
reticulum	O
,	O
the	O
E	O
protein	O
accumulates	O
in	O
and	O
induces	O
curvature	O
into	O
these	O
pre	O
-	O
Golgi	O
membranes	O
where	O
coronaviruses	O
have	O
been	O
shown	O
earlier	O
to	O
assemble	O
by	O
budding	B-PATH
.	O

In	O
this	O
particular	O
model	O
of	O
ARDS	O
the	O
monoclonal	O
antibody	O
against	O
the	O
CD11	O
-	O
CD18	O
complex	O
had	O
a	O
beneficial	O
effect	O
,	O
reducing	O
PMN	O
infiltration	O
and	O
oxygen	O
radical	O
release	B-PATH
in	O
the	O
lungs	O
,	O
preventing	O
alveolocapillary	O
membrane	O
damage	O
,	O
improving	O
gas	O
exchange	O
and	O
,	O
finally	O
,	O
significantly	O
reducing	O
mortality	O
.	O

HEV	O
infects	O
B	O
cells	O
and	O
macrophages	O
and	O
induces	O
necrosis	O
as	O
well	O
as	O
apoptosis	B-PATH
in	O
infected	O
and	O
possibly	O
in	O
by	O
-	O
stander	O
cells	O
.	O

While	O
a	O
massive	O
release	B-PATH
of	O
proinflammatory	O
cytokines	O
may	O
lead	O
to	O
systemic	O
shock	O
associated	O
with	O
haemorrhagic	O
enteritis	O
and	O
death	O
,	O
release	B-PATH
of	O
IFNs	O
may	O
protect	O
turkeys	O
from	O
the	O
disease	O
.	O

Apoptosis	B-PATH
is	O
coordinated	O
by	O
a	O
family	O
of	O
cysteine	O
proteases	O
,	O
called	O
caspases	O
,	O
that	O
are	O
activated	O
during	O
apoptosis	B-PATH
and	O
participate	O
in	O
dismantling	O
the	O
cell	O
by	O
cleaving	O
key	O
structural	O
and	O
regulatory	O
proteins	O
.	O

Indirect	O
immunofluorescence	O
microscopy	O
showed	O
that	O
E	O
is	O
localized	O
to	O
the	O
Golgi	O
complex	O
in	O
cells	O
transiently	O
expressing	O
IBV	O
E	O
.	O
When	O
coexpressed	O
with	O
IBV	O
M	O
,	O
both	O
from	O
cDNA	O
and	O
in	O
IBV	O
infection	O
,	O
the	O
two	O
proteins	O
are	O
colocalized	O
in	O
Golgi	O
membranes	O
,	O
near	O
the	O
coronavirus	O
budding	B-PATH
site	O
.	O

TITLE	O
:	O
Experiences	O
with	O
severe	O
P	O
.	O
falciparum	O
malaria	B-PATH
in	O
the	O
intensive	O
care	O
unit	O
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
clinical	O
profiles	O
and	O
therapies	O
instituted	O
for	O
patients	O
with	O
severe	O
malaria	B-PATH
admitted	O
to	O
an	O
ICU	O
.	O

Between	O
January	O
,	O
1992	O
,	O
and	O
February	O
,	O
1999	O
,	O
104	O
patients	O
with	O
malaria	B-PATH
were	O
admitted	O
to	O
the	O
General	O
Hospital	O
of	O
Vienna	O
.	O

Airway	O
pressure	O
release	B-PATH
ventilation	O
and	O
intermittent	O
prone	O
positioning	O
therapy	O
were	O
instituted	O
.	O

ABSTRACT	O
:	O
The	O
viral	O
membrane	O
proteins	O
M	O
and	O
E	O
are	O
the	O
minimal	O
requirements	O
for	O
the	O
budding	B-PATH
of	O
coronavirus	O
particles	O
.	O

The	O
observed	O
efficient	O
exclusion	O
from	O
budding	B-PATH
of	O
the	O
vesicular	O
stomatitis	O
virus	O
G	O
protein	O
and	O
the	O
equine	O
arteritis	O
virus	O
M	O
protein	O
indicates	O
that	O
envelope	O
assembly	O
is	O
indeed	O
a	O
highly	O
selective	O
sorting	O
process	O
.	O

We	O
examined	O
a	O
2	O
-	O
year	O
old	O
girl	O
with	O
hemorrhagic	O
shock	O
and	O
encephalopathy	O
syndrome	O
associated	O
with	O
acute	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
(	O
A	O
/	O
Nagasaki	O
/	O
76	O
/	O
98	O
;	O
H3N2	O
),	O
to	O
answer	O
several	O
questions	O
for	O
which	O
no	O
histologic	O
or	O
virologic	O
data	O
exist	O
.	O

ABSTRACT	O
:	O
Viral	B-PATH
myocarditis	I-PATH
has	O
been	O
suggested	O
as	O
an	O
etiology	O
for	O
cardiomyopathy	O
in	O
several	O
mammalian	O
species	O
.	O

The	O
patient	O
,	O
who	O
was	O
apparently	O
immunocompetent	O
,	O
was	O
admitted	O
with	O
severe	O
Plasmodium	O
falciparum	O
malaria	B-PATH
but	O
died	O
from	O
aspergillosis	O
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
case	O
of	O
multiple	O
organ	O
dysfunction	O
syndrome	O
with	O
acute	O
respiratory	O
failure	O
due	O
to	O
alveolar	O
haemorrhage	O
associated	O
with	O
antiphospholipid	O
antibodies	O
in	O
a	O
42	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
medical	O
history	O
of	O
antinuclear	O
antibody	O
-	O
negative	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
and	O
antiphospholipid	O
syndrome	O
.	O

TITLE	O
:	O
Imported	O
malaria	B-PATH
:	O
six	O
cases	O
of	O
severe	O
Plasmodium	O
falciparum	O
infection	O
in	O
Innsbruck	O
,	O
Austria	O
,	O
within	O
a	O
period	O
of	O
five	O
weeks	O
(	O
February	O
/	O
March	O
1999	O
)	O
ABSTRACT	O
:	O
Six	O
patients	O
(	O
age	O
,	O
30	O
-	O
76	O
;	O
3	O
male	O
,	O
3	O
female	O
)	O
with	O
severe	O
malaria	B-PATH
tropica	O
were	O
admitted	O
to	O
the	O
Department	O
of	O
Internal	O
Medicine	O
of	O
the	O
Innsbruck	O
University	O
Hospital	O
within	O
a	O
time	O
period	O
of	O
five	O
weeks	O
.	O

All	O
patients	O
had	O
recently	O
visited	O
classical	O
malaria	B-PATH
regions	O
some	O
days	O
before	O
admission	O
:	O
five	O
patients	O
the	O
sub	O
-	O
Saharan	O
Africa	O
and	O
one	O
patient	O
Thailand	O
and	O
Vietnam	O
.	O

TITLE	O
:	O
Adult	O
respiratory	O
distress	O
syndrome	O
complicating	O
Plasmodium	O
falciparum	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
In	O
people	O
who	O
do	O
not	O
have	O
clinical	O
immunity	O
to	O
malaria	B-PATH
,	O
infection	O
with	O
the	O
malaria	B-PATH
parasite	O
could	O
lead	O
to	O
severe	O
complications	O
.	O

We	O
describe	O
a	O
patient	O
who	O
had	O
acute	O
and	O
severe	O
lung	O
injury	O
from	O
malaria	B-PATH
.	O

Physicians	O
caring	O
for	O
patients	O
who	O
have	O
recently	O
traveled	O
to	O
malaria	B-PATH
-	O
endemic	O
areas	O
need	O
to	O
anticipate	O
the	O
possible	O
development	O
of	O
malaria	B-PATH
with	O
all	O
of	O
its	O
complications	O
,	O
including	O
acute	O
lung	O
injury	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
induces	O
apoptosis	B-PATH
in	O
swine	O
testicular	O
cell	O
lines	O
but	O
not	O
in	O
intestinal	O
enterocytes	O
.	O

Numerous	O
signs	O
of	O
apoptosis	B-PATH
were	O
detected	O
in	O
TGEV	O
-	O
infected	O
ST	O
cells	O
by	O
TUNEL	O
assay	O
,	O
the	O
positive	O
(	O
dark	O
brown	O
)	O
staining	O
reaction	O
being	O
present	O
in	O
the	O
majority	O
of	O
cell	O
nuclei	O
,	O
without	O
background	O
staining	O
.	O

Thus	O
,	O
it	O
would	O
appear	O
that	O
apoptosis	B-PATH
does	O
not	O
occur	O
in	O
the	O
enterocytes	O
of	O
piglets	O
infected	O
with	O
TGEV	O
.	O

In	O
the	O
host	O
infected	O
by	O
endotoxin	O
(	O
lipopolysaccharide	O
,	O
LPS	O
),	O
the	O
expression	O
and	O
release	B-PATH
of	O
proinflammatory	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNFalpha	O
)	O
rapidly	O
increases	O
,	O
and	O
this	O
cytokine	O
production	O
is	O
regulated	O
by	O
agents	O
elevating	O
cyclic	O
AMP	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
evidence	O
that	O
terbutaline	O
,	O
a	O
beta2	O
-	O
agonist	O
,	O
inhibits	O
TNFalpha	O
production	O
and	O
enhances	O
interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
release	B-PATH
in	O
the	O
anesthetized	O
rat	O
treated	O
with	O
LPS	O
.	O

The	O
predominant	O
clinical	O
syndromes	O
varied	O
by	O
age	O
:	O
pneumonia	O
and	O
bronchiolitis	O
in	O
children	O
aged	O
<	O
5	O
years	O
;	O
exacerbations	O
of	O
asthma	B-PATH
in	O
older	O
children	O
and	O
young	O
adults	O
;	O
and	O
pneumonia	O
and	O
exacerbations	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
congestive	O
heart	O
failure	O
in	O
older	O
adults	O
.	O

The	O
concentrations	O
of	O
adenosine	O
deaminase	O
and	O
gamma	O
-	O
interferon	O
in	O
pleural	O
fluid	O
are	O
useful	O
in	O
the	O
diagnosis	O
of	O
pleural	O
tuberculosis	B-PATH
.	O

Cleavage	O
of	O
MP1	O
and	O
release	B-PATH
of	O
a	O
150	O
-	O
kDa	O
intermediate	O
,	O
p150	O
,	O
are	O
likely	O
to	O
be	O
important	O
for	O
embedding	O
the	O
replicase	O
complex	O
in	O
cellular	O
membranes	O
.	O

Pulse	O
-	O
labeling	O
experiments	O
showed	O
that	O
newly	O
synthesized	O
,	O
unglycosylated	O
M	O
protein	O
interacted	O
with	O
N	O
protein	O
in	O
a	O
pre	O
-	O
Golgi	O
compartment	O
,	O
which	O
is	O
part	O
of	O
the	O
MHV	O
budding	B-PATH
site	O
.	O

The	O
M	O
protein	O
-	O
nucleocapsid	O
interaction	O
,	O
which	O
occurred	O
near	O
or	O
at	O
the	O
MHV	O
budding	B-PATH
site	O
,	O
most	O
probably	O
represented	O
the	O
process	O
of	O
specific	O
packaging	O
of	O
the	O
MHV	O
genome	O
into	O
MHV	O
particles	O
.	O

TITLE	O
:	O
Persistence	O
of	O
viruses	O
in	O
upper	O
respiratory	O
tract	O
of	O
children	O
with	O
asthma	B-PATH
.	O

TITLE	O
:	O
[	O
Late	O
spreading	O
of	O
tuberculosis	B-PATH
in	O
tubercular	O
spondylitis	O
].	O

ABSTRACT	O
:	O
A	O
65	O
-	O
year	O
-	O
old	O
man	O
,	O
known	O
to	O
have	O
had	O
a	O
gastric	O
ulcer	O
and	O
chronic	O
rheumatoid	B-PATH
arthritis	I-PATH
as	O
well	O
as	O
alcohol	O
and	O
nicotine	O
abuse	O
,	O
was	O
admitted	O
because	O
of	O
suspected	O
endocarditis	O
.	O

Tuberculosis	B-PATH
can	O
be	O
a	O
life	O
-	O
threatening	O
infection	O
.	O

Cardioselective	O
and	O
nonselective	O
beta	O
-	O
blockers	O
,	O
calcium	O
antagonists	O
and	O
dipyridamole	O
can	O
induce	O
asthma	B-PATH
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
including	O
aspirin	O
(	O
acetylsalicylic	O
acid	O
)	O
may	O
induce	O
asthma	B-PATH
.	O

Gold	O
is	O
mainly	O
related	O
to	O
IP	O
,	O
penicillamine	O
to	O
IP	O
,	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
,	O
bronchiolitis	O
obliterans	O
,	O
and	O
Goodpasture	O
'	O
s	O
syndrome	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
apoptosis	B-PATH
within	O
the	O
retina	O
of	O
coronavirus	O
-	O
infected	O
mice	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
possible	O
roles	O
of	O
apoptosis	B-PATH
in	O
the	O
murine	O
retinopathy	O
induced	O
by	O
coronavirus	O
.	O

Isolated	O
retinas	O
were	O
analyzed	O
for	O
infectious	O
virus	O
and	O
for	O
expression	O
of	O
apoptosis	B-PATH
-	O
associated	O
genes	O
.	O

Retinal	O
apoptosis	B-PATH
was	O
associated	O
with	O
retinal	O
inflammation	O
,	O
a	O
decrease	O
in	O
infectious	O
virus	O
,	O
and	O
upregulation	O
of	O
genes	O
associated	O
with	O
CTL	O
killing	O
.	O

These	O
studies	O
indicate	O
that	O
retinal	O
apoptosis	B-PATH
may	O
be	O
one	O
of	O
the	O
host	O
mechanisms	O
that	O
contribute	O
to	O
limiting	O
this	O
retinal	O
infection	O
.	O

The	O
development	O
of	O
apoptosis	B-PATH
,	O
regulative	O
gene	O
expression	O
,	O
and	O
viral	O
clearance	O
were	O
similar	O
in	O
both	O
retinal	O
degeneration	O
-	O
susceptible	O
(	O
BALB	O
/	O
c	O
)	O
and	O
-	O
resistant	O
(	O
CD	O
-	O
1	O
)	O
mice	O
.	O

Thus	O
,	O
MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	O
was	O
independent	O
of	O
the	O
activation	O
of	O
RNase	O
L	O
.	O
MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	O
was	O
also	O
different	O
from	O
apoptosis	B-PATH
-	O
related	O
rRNA	O
degradation	O
,	O
which	O
usually	O
occurs	O
concomitantly	O
with	O
DNA	O
fragmentation	O
.	O

In	O
MHV	O
-	O
infected	O
17Cl	O
-	O
1	O
cells	O
,	O
28S	O
rRNA	O
cleavage	O
preceded	O
DNA	O
fragmentation	O
by	O
at	O
least	O
18	O
h	O
.	O
Blockage	O
of	O
apoptosis	B-PATH
in	O
MHV	O
-	O
infected	O
17Cl	O
-	O
1	O
cells	O
by	O
treatment	O
with	O
a	O
caspase	O
inhibitor	O
did	O
not	O
block	O
28S	O
rRNA	O
cleavage	O
.	O

These	O
were	O
found	O
either	O
to	O
block	O
DI	O
RNA	O
replication	O
completely	O
or	O
to	O
be	O
removed	O
within	O
one	O
virus	O
passage	O
,	O
probably	O
due	O
to	O
homologous	B-PATH
recombination	I-PATH
with	O
the	O
helper	O
virus	O
genome	O
.	O

TITLE	O
:	O
[	O
Oxidative	B-PATH
phosphorylation	I-PATH
defects	O
with	O
neonatal	O
presentation	O
:	O
review	O
of	O
our	O
caseload	O
].	O

TITLE	O
:	O
Severe	O
asthma	B-PATH
and	O
ARDS	O
triggered	O
by	O
acute	O
short	O
-	O
term	O
exposure	O
to	O
commonly	O
used	O
cleaning	O
detergents	O
.	O

This	O
case	O
report	O
indicates	O
that	O
nonindustrial	O
exposures	O
due	O
to	O
household	O
product	O
misuse	O
,	O
especially	O
to	O
mixing	O
cleaning	O
agents	O
,	O
may	O
cause	O
adult	O
respiratory	O
distress	O
syndrome	O
and	O
not	O
only	O
irritant	O
-	O
induced	O
asthma	B-PATH
.	O

Onset	O
of	O
melon	O
-	O
induced	O
allergic	O
symptoms	O
occurred	O
from	O
6	O
to	O
45	O
years	O
(	O
median	O
,	O
20	O
years	O
),	O
preceded	O
by	O
seasonal	O
rhinitis	O
,	O
asthma	B-PATH
,	O
or	O
both	O
in	O
88	O
%	O
(	O
15	O
/	O
17	O
).	O

Isolated	O
melon	O
allergy	O
is	O
rare	O
,	O
with	O
most	O
patients	O
either	O
having	O
allergic	O
rhinitis	O
,	O
asthma	B-PATH
,	O
or	O
both	O
and	O
associated	O
food	O
allergies	O
.	O

Cells	O
were	O
co	O
-	O
infected	O
simultaneously	O
with	O
IBV	O
,	O
the	O
recombinant	O
FPV	O
(	O
rFPV	O
)	O
containing	O
the	O
D	O
-	O
RNA	O
sequence	O
and	O
a	O
second	O
rFPV	O
expressing	O
T7	O
RNA	B-PATH
polymerase	I-PATH
for	O
the	O
initial	O
expression	O
of	O
the	O
D	O
-	O
RNA	O
transcript	O
,	O
subsequently	O
rescued	O
by	O
helper	O
IBV	O
.	O

ABSTRACT	O
:	O
Five	O
recombinant	O
porcine	O
adenoviruses	O
of	O
serotype	O
5	O
(	O
PAdV	O
-	O
5	O
)	O
carrying	O
the	O
full	O
-	O
length	O
or	O
the	O
5	O
'	O
2	O
.	O
2	O
kb	O
half	O
of	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
spike	O
(	O
S	O
)	O
gene	O
were	O
generated	O
by	O
homologous	B-PATH
recombination	I-PATH
in	O
E	O
.	O
coli	O
strain	O
BJ5183	O
cells	O
and	O
subsequent	O
transfection	O
of	O
swine	O
testicle	O
cells	O
.	O

Severe	O
or	O
longlasting	O
exacerbations	O
of	O
a	O
chronic	O
obstructive	O
bronchitis	O
,	O
severe	O
and	O
rapidly	O
progressive	O
bronchial	O
asthma	B-PATH
or	O
infection	O
associated	O
with	O
bronchiectasis	O
in	O
an	O
underlying	O
antibody	O
deficiency	O
syndrome	O
,	O
primary	O
ciliary	O
dyskinesia	O
and	O
mucoviscidosis	O
.	O

In	O
the	O
case	O
of	O
systemic	O
immunodeficiencies	O
such	O
as	O
the	O
antibody	O
deficiency	O
syndrome	O
,	O
HIV	B-PATH
infection	I-PATH
or	O
immunosuppressive	O
therapy	O
,	O
the	O
indication	O
for	O
antibiotic	O
treatment	O
is	O
more	O
liberally	O
established	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
rare	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
induced	O
by	O
Influenza	B-PATH
A	I-PATH
(	O
H3	O
N2	O
)	O
without	O
secondary	O
microbiological	O
infection	O
.	O

TITLE	O
:	O
Airway	O
pressure	O
release	B-PATH
ventilation	O
and	O
prone	O
positioning	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
with	O
the	O
patient	O
'	O
s	O
superimposed	O
spontaneous	O
breathing	O
was	O
implemented	O
and	O
maintained	O
,	O
also	O
during	O
prone	O
episodes	O
.	O

TITLE	O
:	O
[	O
Schonlein	O
-	O
Henoch	O
purpura	O
associated	O
with	O
hepatitis	O
B	O
in	O
a	O
patient	O
with	O
HIV	B-PATH
infection	I-PATH
].	O

Hepatitis	O
serology	O
:	O
anti	O
-	O
HBc	O
,	O
HBs	O
-	O
Ag	O
and	O
HBe	O
-	O
Ag	O
positive	O
,	O
anti	O
-	O
HBs	O
and	O
anti	O
-	O
HBe	O
negative	O
,	O
hepatitis	O
A	O
-	O
Ab	O
(	O
IgG	O
)	O
positive	O
,	O
hepatitis	O
A	O
-	O
Ab	O
(	O
IgM	O
)	O
negative	O
,	O
hepatitis	B-PATH
C	I-PATH
-	O
Ab	O
negative	O
.	O

TITLE	O
:	O
Laparotomy	O
potentiates	O
cytokine	O
release	B-PATH
and	O
impairs	O
pulmonary	O
function	O
after	O
hemorrhage	O
and	O
resuscitation	O
in	O
mice	O
.	O

There	O
is	O
no	O
single	O
record	O
of	O
blackwater	O
fever	O
,	O
12	O
.	O
5	O
%	O
died	O
due	O
to	O
development	O
of	O
multiple	O
complications	O
like	O
severe	O
haemolytic	O
anaemia	O
,	O
haemolytic	O
jaundice	O
,	O
cerebral	O
malaria	B-PATH
and	O
acute	O
renal	O
failure	O
.	O

This	O
study	O
confirms	O
presence	O
of	O
severe	O
and	O
complicated	O
falciparum	O
malaria	B-PATH
in	O
this	O
part	O
of	O
the	O
country	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
small	O
envelope	O
protein	O
E	O
has	O
two	O
known	O
biological	O
functions	O
:	O
it	O
plays	O
a	O
pivotal	O
role	O
in	O
virus	O
envelope	O
formation	O
,	O
and	O
the	O
murine	O
coronavirus	O
E	O
protein	O
induces	O
apoptosis	B-PATH
in	O
E	O
protein	O
-	O
expressing	O
cultured	O
cells	O
.	O

The	O
third	O
domain	O
of	O
E	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
virus	O
budding	B-PATH
is	O
a	O
putative	O
transmembrane	O
domain	O
present	O
at	O
the	O
N	O
-	O
terminal	O
region	O
,	O
because	O
deletion	O
of	O
the	O
domain	O
resulted	O
in	O
a	O
free	O
distribution	O
of	O
the	O
mutant	O
protein	O
and	O
in	O
dysfunctional	O
viral	O
assembly	O
.	O

ABSTRACT	O
:	O
A	O
56	O
-	O
year	O
-	O
old	O
woman	O
with	O
rheumatoid	B-PATH
arthritis	I-PATH
(	O
RA	O
)	O
suddenly	O
developed	O
severe	O
respiratory	O
distress	O
and	O
laryngeal	O
stridor	O
,	O
which	O
required	O
endotracheal	O
intubation	O
.	O

She	O
was	O
finally	O
diagnosed	O
as	O
having	O
overlap	O
syndrome	O
with	O
RA	O
and	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
.	O

TITLE	O
:	O
[	O
Severe	O
malaria	B-PATH
].	O

ABSTRACT	O
:	O
Falciparum	O
malaria	B-PATH
remains	O
a	O
major	O
killer	O
in	O
developing	O
countries	O
,	O
particularly	O
for	O
African	O
children	O
.	O

Moreover	O
,	O
France	O
is	O
the	O
leading	O
European	O
country	O
in	O
term	O
of	O
incidence	O
of	O
imported	O
malaria	B-PATH
.	O

In	O
nonimmune	O
adults	O
,	O
besides	O
cerebral	O
malaria	B-PATH
,	O
pictures	O
of	O
severe	O
sepsis	O
with	O
shock	O
,	O
acute	O
renal	O
failure	O
and	O
respiratory	O
distress	O
syndrome	O
are	O
common	O
.	O

Prevention	O
of	O
severe	O
imported	O
malaria	B-PATH
lays	O
on	O
prophylactic	O
measures	O
during	O
travel	O
,	O
as	O
well	O
as	O
adequate	O
management	O
of	O
uncomplicated	O
disease	O
after	O
return	O
.	O

TITLE	O
:	O
Delayed	O
treatment	O
contributes	O
to	O
mortality	O
in	O
ICU	O
patients	O
with	O
severe	O
active	O
pulmonary	O
tuberculosis	B-PATH
and	O
acute	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
To	O
clarify	O
the	O
patterns	O
of	O
pulmonary	O
tuberculosis	B-PATH
(	O
TB	O
)	O
that	O
should	O
result	O
in	O
a	O
high	O
index	O
of	O
suspicion	O
,	O
to	O
increase	O
the	O
chances	O
of	O
early	O
therapy	O
and	O
to	O
identify	O
predictors	O
of	O
30	O
-	O
day	O
mortality	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
complicating	O
Plasmodium	O
vivax	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
one	O
of	O
the	O
most	O
common	O
infectious	O
diseases	O
in	O
the	O
world	O
,	O
and	O
severe	O
respiratory	O
complications	O
have	O
been	O
described	O
mainly	O
in	O
association	O
with	O
Plasmodium	O
falciparum	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
feline	O
(	O
FECV	O
and	O
FIPV	O
)	O
and	O
canine	O
(	O
CCoV	O
)	O
coronavirus	O
entry	O
into	O
and	O
release	B-PATH
from	O
polarized	O
porcine	O
epithelial	O
LLC	O
-	O
PK1	O
cells	O
,	O
stably	O
expressing	O
the	O
recombinant	O
feline	O
aminopeptidase	O
-	O
N	O
cDNA	O
,	O
were	O
investigated	O
.	O

These	O
observations	O
indicate	O
that	O
local	O
infections	O
as	O
caused	O
by	O
TGEV	O
,	O
FECV	O
and	O
CCoV	O
do	O
not	O
strictly	O
correlate	O
with	O
apical	O
release	B-PATH
,	O
as	O
suggested	O
by	O
earlier	O
work	O
.	O

The	O
results	O
show	O
that	O
both	O
necrosis	O
and	O
apoptosis	B-PATH
may	O
contribute	O
to	O
the	O
death	O
of	O
infected	O
cells	O
in	O
lytic	O
IBV	O
infection	O
.	O

Caspase	O
-	O
dependent	O
apoptosis	B-PATH
,	O
as	O
characterized	O
by	O
chromosomal	O
condensation	O
,	O
DNA	O
fragmentation	O
,	O
caspase	O
-	O
3	O
activation	O
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
degradation	O
,	O
was	O
detected	O
in	O
IBV	O
-	O
infected	O
Vero	O
cells	O
.	O

However	O
,	O
neither	O
the	O
necrotic	O
process	O
nor	O
the	O
productive	O
replication	O
of	O
IBV	O
in	O
Vero	O
cells	O
was	O
severely	O
affected	O
by	O
the	O
inhibition	O
of	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
A	O
stable	O
recombinant	O
fowl	O
poxvirus	O
(	O
rFPV	O
)	O
expressing	O
the	O
C	O
-	O
terminal	O
region	O
(	O
119	O
amino	O
acids	O
)	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
an	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strain	O
Ch3	O
was	O
constructed	O
by	O
inserting	O
the	O
coding	O
sequence	O
within	O
the	O
thymidine	O
kinase	O
gene	O
of	O
fowl	O
poxvirus	O
(	O
FPV	O
)	O
by	O
homologous	B-PATH
recombination	I-PATH
.	O

TITLE	O
:	O
The	O
autocatalytic	O
release	B-PATH
of	O
a	O
putative	O
RNA	O
virus	O
transcription	O
factor	O
from	O
its	O
polyprotein	O
precursor	O
involves	O
two	O
paralogous	O
papain	O
-	O
like	O
proteases	O
that	O
cleave	O
the	O
same	O
peptide	O
bond	O
.	O

ABSTRACT	O
:	O
The	O
Fas	O
/	O
Fas	O
ligand	O
(	O
FasL	O
)	O
system	O
has	O
been	O
implicated	O
in	O
alveolar	O
epithelial	O
cell	O
apoptosis	B-PATH
during	O
pulmonary	O
fibrosis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

An	O
adult	O
model	O
of	O
viral	O
wheeze	O
that	O
is	O
independent	O
of	O
atopy	O
and	O
therefore	O
,	O
of	O
classical	O
atopic	O
asthma	B-PATH
was	O
established	O
.	O

TITLE	O
:	O
Airway	O
pressure	O
release	B-PATH
ventilation	O
increases	O
cardiac	O
performance	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
/	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
most	O
likely	O
explanation	O
for	O
this	O
is	O
that	O
the	O
N	O
protein	O
induced	O
a	O
cell	B-PATH
cycle	I-PATH
delay	O
or	O
arrest	O
,	O
most	O
likely	O
in	O
the	O
G	O
(	O
2	O
)/	O
M	O
phase	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
frequency	O
of	O
hospitalization	O
,	O
pulmonary	O
illness	O
,	O
asthma	B-PATH
,	O
or	O
disabilities	O
.	O

ABSTRACT	O
:	O
Viral	O
respiratory	O
tract	O
infections	O
may	O
cause	O
both	O
harmless	O
common	O
colds	O
and	O
severe	O
asthma	B-PATH
exacerbations	O
;	O
the	O
differences	O
in	O
disease	O
expression	O
probably	O
depend	O
on	O
the	O
allergic	O
status	O
of	O
the	O
patient	O
.	O

RESULTS	O
:	O
Four	O
rhinovirus	O
,	O
four	O
coronavirus	O
,	O
three	O
RSV	O
,	O
one	O
Mycoplasma	O
pneumoniae	O
,	O
and	O
one	O
influenza	B-PATH
A	I-PATH
/	O
enterovirus	O
double	O
infection	O
were	O
confirmed	O
.	O

The	O
present	O
case	O
demonstrated	O
that	O
HIV	B-PATH
infection	I-PATH
was	O
not	O
an	O
essential	O
factor	O
in	O
the	O
development	O
of	O
bullous	O
changes	O
.	O

In	O
a	O
patient	O
with	O
a	O
long	O
history	O
of	O
smoking	O
and	O
emphysema	O
,	O
PCP	O
may	O
trigger	O
-	O
macrophage	O
activation	O
and	O
an	O
excessive	O
release	B-PATH
of	O
leukocyte	O
elastase	O
,	O
leading	O
to	O
elastin	O
destruction	O
in	O
the	O
alveoli	O
.	O

TITLE	O
:	O
Severe	O
acute	O
renal	O
failure	O
in	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
We	O
have	O
noticed	O
a	O
recent	O
rise	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
acute	O
renal	O
failure	O
(	O
ARF	O
)	O
in	O
malaria	B-PATH
.	O

To	O
study	O
the	O
incidence	O
,	O
severity	O
and	O
outcome	O
of	O
ARF	O
in	O
malaria	B-PATH
.	O

Out	O
of	O
402	O
detected	O
smear	O
positive	O
malaria	B-PATH
,	O
24	O
had	O
ARF	O
.	O

Seventeen	O
patients	O
recovered	O
completely	O
,	O
while	O
seven	O
showed	O
fatal	O
combination	O
of	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
severe	O
ARF	O
and	O
PF	O
malaria	B-PATH
.	O

ARF	O
necessitating	O
dialysis	O
was	O
seen	O
in	O
92	O
%	O
of	O
patients	O
with	O
ARF	O
in	O
malaria	B-PATH
.	O

RESULTS	O
:	O
Out	O
of	O
402	O
detected	O
smear	O
positive	O
malaria	B-PATH
,	O
24	O
had	O
ARF	O
.	O

TITLE	O
:	O
Neurovirulence	O
in	O
mice	O
of	O
soluble	O
receptor	O
-	O
resistant	O
(	O
srr	O
)	O
mutants	O
of	O
mouse	O
hepatitis	O
virus	O
:	O
intensive	O
apoptosis	B-PATH
caused	O
by	O
less	O
virulent	O
srr	O
mutant	O
.	O

The	O
apoptosis	B-PATH
in	O
the	O
brain	O
did	O
not	O
appear	O
to	O
result	O
from	O
the	O
direct	O
viral	O
attack	O
,	O
since	O
apoptotic	O
cells	O
were	O
found	O
in	O
the	O
lesion	O
where	O
viral	O
antigens	O
were	O
barely	O
detected	O
.	O

The	O
IBV	O
genomic	O
cDNA	O
was	O
assembled	O
immediately	O
downstream	O
of	O
a	O
T7	O
RNA	B-PATH
polymerase	I-PATH
promoter	O
by	O
in	O
vitro	O
ligation	O
and	O
cloned	O
directly	O
into	O
the	O
vaccinia	O
virus	O
genome	O
.	O

Infectious	O
IBV	O
RNA	O
was	O
generated	O
in	O
situ	O
after	O
the	O
transfection	O
of	O
restricted	O
recombinant	O
vaccinia	O
virus	O
DNA	O
into	O
primary	O
chick	O
kidney	O
cells	O
previously	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
RNA	B-PATH
polymerase	I-PATH
.	O

Egress	O
of	O
mature	O
virions	O
occurs	O
primarily	O
by	O
exocytosis	O
and	O
,	O
only	O
very	O
rarely	O
,	O
by	O
budding	B-PATH
directly	O
at	O
the	O
plasma	O
membrane	O
.	O

ABSTRACT	O
:	O
Toxoplasmosis	B-PATH
is	O
a	O
rare	O
but	O
severe	O
complication	O
of	O
bone	O
marrow	O
transplantation	O
.	O

All	O
patients	O
had	O
positive	O
pretransplantation	O
tests	O
for	O
Toxoplasma	O
gondii	O
and	O
were	O
therefore	O
at	O
risk	O
to	O
develop	O
toxoplasmosis	B-PATH
reactivation	O
.	O

She	O
also	O
had	O
a	O
7	O
-	O
year	O
history	O
of	O
rheumatoid	B-PATH
arthritis	I-PATH
and	O
a	O
26	O
-	O
year	O
history	O
of	O
SjÃ¶gren	O
'	O
s	O
syndrome	O
.	O

As	O
the	O
E	O
and	O
M	O
proteins	O
are	O
essential	O
for	O
TGEV	O
virion	O
budding	B-PATH
,	O
these	O
replicon	O
RNAs	O
should	O
replicate	O
but	O
not	O
result	O
in	O
the	O
production	O
of	O
infectious	O
virus	O
.	O

TITLE	O
:	O
Virus	O
-	O
induced	O
asthma	B-PATH
attacks	O
.	O

ABSTRACT	O
:	O
Viral	O
respiratory	O
tract	O
infections	O
are	O
a	O
common	O
cause	O
of	O
asthma	B-PATH
attacks	O
.	O

Changes	O
in	O
the	O
neural	O
control	O
of	O
the	O
airways	O
contribute	O
to	O
bronchoconstriction	O
,	O
which	O
is	O
reflected	O
in	O
an	O
increased	O
efficacy	O
of	O
anticholinergic	O
medications	O
during	O
acute	O
asthma	B-PATH
attacks	O
.	O

Clinical	O
management	O
of	O
this	O
problem	O
is	O
illustrated	O
in	O
this	O
article	O
by	O
the	O
case	O
of	O
a	O
40	O
-	O
year	O
-	O
old	O
woman	O
with	O
history	O
of	O
mild	O
asthma	B-PATH
who	O
was	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
with	O
severe	O
bronchospasm	O
and	O
an	O
upper	O
respiratory	O
tract	O
infection	O
.	O

The	O
nucleolus	O
is	O
the	O
site	O
of	O
ribosome	B-PATH
biogenesis	O
and	O
sequesters	O
cell	B-PATH
cycle	I-PATH
regulatory	O
complexes	O
.	O

These	O
proteins	O
are	O
involved	O
in	O
nucleolar	O
assembly	O
and	O
ribosome	B-PATH
biogenesis	O
and	O
act	O
as	O
chaperones	O
for	O
the	O
import	O
of	O
proteins	O
into	O
the	O
nucleolus	O
.	O

Nucleoli	O
,	O
and	O
proteins	O
that	O
localize	O
to	O
the	O
nucleolus	O
,	O
have	O
been	O
implicated	O
in	O
cell	O
growth	O
-	O
cell	B-PATH
cycle	I-PATH
regulation	O
.	O

This	O
result	O
could	O
not	O
to	O
be	O
attributed	O
to	O
apoptosis	B-PATH
.	O

Coronaviruses	O
might	O
therefore	O
delay	O
the	O
cell	B-PATH
cycle	I-PATH
in	O
interphase	O
,	O
where	O
maximum	O
translation	O
of	O
viral	O
mRNAs	O
can	O
occur	O
.	O

TITLE	O
:	O
Viral	O
,	O
parasitic	O
and	O
prion	B-PATH
diseases	I-PATH
of	O
farmed	O
deer	O
and	O
bison	O
.	O

Clinical	O
observations	O
have	O
suggested	O
that	O
patients	O
with	O
allergic	O
rhinitis	O
and	O
asthma	B-PATH
experience	O
more	O
pronounced	O
symptoms	O
during	O
a	O
viral	O
URI	O
than	O
patients	O
who	O
do	O
not	O
have	O
allergies	O
and	O
who	O
are	O
infected	O
with	O
the	O
same	O
virus	O
under	O
similar	O
circumstances	O
.	O

In	O
particular	O
,	O
malaria	B-PATH
and	O
TB	O
are	O
important	O
infections	O
that	O
predispose	O
patients	O
to	O
ARDS	O
in	O
the	O
tropics	O
.	O

Both	O
of	O
these	O
illnesses	O
give	O
lead	O
to	O
severe	O
forms	O
of	O
disease	O
,	O
such	O
as	O
falciparum	O
malaria	B-PATH
,	O
acute	O
miliary	O
TB	O
or	O
TB	O
bronchopneumonia	O
,	O
and	O
may	O
cause	O
ARDS	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
miliary	O
tuberculosis	B-PATH
complicated	O
by	O
acute	O
respiratory	O
failure	O
after	O
bronchofiberscopy	O
].	O

Examples	O
include	O
the	O
cytokine	O
network	O
and	O
its	O
receptors	O
,	O
antioxidants	O
,	O
and	O
endothelins	B-PATH
.	O

We	O
report	O
the	O
case	O
of	O
a	O
14	O
-	O
y	O
-	O
old	O
boy	O
with	O
a	O
history	O
of	O
asthma	B-PATH
who	O
was	O
exposed	O
to	O
chlorine	O
gas	O
as	O
a	O
result	O
of	O
an	O
ill	O
-	O
advised	O
science	O
experiment	O
.	O

ABSTRACT	O
:	O
Vocal	O
cord	O
dysfunction	O
(	O
VCD	O
)	O
has	O
been	O
frequently	O
discussed	O
as	O
confounding	O
the	O
diagnosis	O
of	O
asthma	B-PATH
,	O
and	O
it	O
is	O
recommended	O
to	O
examine	O
vocal	O
cord	O
function	O
in	O
cases	O
of	O
difficult	O
asthma	B-PATH
.	O

Gerhardt	O
'	O
s	O
syndrome	O
frequently	O
induces	O
severe	O
acute	O
respiratory	O
distress	O
requiring	O
ventilatory	O
support	O
,	O
and	O
this	O
condition	O
might	O
be	O
mistaken	O
for	O
a	O
severe	O
acute	O
asthma	B-PATH
attack	O
.	O

Here	O
,	O
a	O
case	O
of	O
bilateral	O
paralysis	O
of	O
the	O
vocal	O
cords	O
,	O
which	O
was	O
associated	O
with	O
asthma	B-PATH
,	O
is	O
described	O
.	O

ABSTRACT	O
:	O
The	O
ability	O
of	O
the	O
isolated	O
lung	O
tissue	O
to	O
take	O
up	O
glucose	O
and	O
to	O
release	B-PATH
lactate	O
is	O
potentially	O
similar	O
to	O
that	O
of	O
other	O
body	O
tissues	O
.	O

We	O
hypothesized	O
that	O
alveolar	O
macrophage	O
(	O
AMPhi	O
)	O
chemokine	O
and	O
cytokine	O
release	B-PATH
after	O
hemorrhage	O
and	O
sepsis	O
is	O
regulated	O
by	O
NF	O
-	O
kappaB	O
and	O
MAPK	O
.	O

AMPhi	O
were	O
harvested	O
,	O
and	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
and	O
macrophage	O
inflammatory	O
protein	O
(	O
MIP	O
)-	O
2	O
release	B-PATH
and	O
serum	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
alpha	O
levels	O
were	O
measured	O
at	O
5	O
h	O
after	O
HCLP	O
.	O

Serum	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
6	O
levels	O
and	O
spontaneous	O
AMPhi	O
TNF	O
-	O
alpha	O
and	O
MIP	O
-	O
2	O
release	B-PATH
were	O
elevated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
HCLP	O
,	O
concomitantly	O
with	O
the	O
development	O
of	O
lung	O
edema	O
and	O
leukocyte	O
activation	O
.	O

Bone	O
-	O
marrow	O
release	B-PATH
of	O
leukocytes	O
and	O
platelets	O
is	O
an	O
important	O
component	O
of	O
the	O
systemic	O
inflammatory	O
response	O
.	O

We	O
conclude	O
that	O
exposure	O
to	O
ambient	O
particulate	O
matter	O
air	O
pollution	O
induces	O
a	O
systemic	O
inflammatory	O
response	O
that	O
includes	O
the	O
release	B-PATH
of	O
inflammatory	O
mediators	O
into	O
the	O
circulation	O
that	O
stimulate	O
the	O
bone	O
marrow	O
to	O
release	B-PATH
leukocytes	O
and	O
platelets	O
.	O

TITLE	O
:	O
Differential	O
induction	O
of	O
apoptosis	B-PATH
in	O
demyelinating	O
and	O
nondemyelinating	O
infection	O
by	O
mouse	O
hepatitis	O
virus	O
.	O

TITLE	O
:	O
Effect	O
of	O
surfactant	O
on	O
ventilation	O
-	O
induced	O
mediator	O
release	B-PATH
in	O
isolated	O
perfused	O
mouse	O
lungs	O
.	O

Because	O
the	O
application	O
of	O
exogenous	O
surfactant	O
has	O
been	O
proposed	O
as	O
a	O
treatment	O
for	O
ARDS	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
surfactant	O
on	O
ventilation	O
-	O
induced	O
release	B-PATH
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
),	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
6	O
-	O
keto	O
-	O
PGF	O
(	O
1	O
alpha	O
)	O
(	O
the	O
stable	O
metabolite	O
of	O
prostacyclin	O
)	O
in	O
isolated	O
perfused	O
mouse	O
lungs	O
ventilated	O
with	O
high	O
end	O
-	O
inspiratory	O
pressures	O
.	O

Exogenous	O
surfactant	O
increased	O
the	O
ventilation	O
-	O
induced	O
liberation	O
of	O
TNF	O
and	O
IL	O
-	O
6	O
into	O
the	O
perfusate	O
,	O
but	O
had	O
no	O
effect	O
on	O
the	O
release	B-PATH
of	O
6	O
-	O
keto	O
-	O
PGF	O
(	O
1	O
alpha	O
).	O

The	O
findings	O
that	O
in	O
this	O
model	O
of	O
ventilation	O
-	O
induced	O
lung	O
injury	O
exogenous	O
surfactant	O
at	O
the	O
same	O
time	O
improved	O
lung	O
functions	O
and	O
enhanced	O
mediator	O
release	B-PATH
suggest	O
that	O
surfactant	O
treatment	O
may	O
prevent	O
barotrauma	O
and	O
augment	O
biotrauma	O
.	O

TITLE	O
:	O
In	O
vitro	O
detection	O
of	O
apoptosis	B-PATH
in	O
monocytes	O
/	O
macrophages	O
infected	O
with	O
human	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
(	O
HCoV	O
)	O
strain	O
229E	O
infection	O
,	O
but	O
not	O
HCoV	O
strain	O
OC43	O
infection	O
,	O
of	O
monocytes	O
/	O
macrophages	O
from	O
healthy	O
donors	O
and	O
patients	O
with	O
multiple	O
sclerosis	O
in	O
remission	O
resulted	O
in	O
increased	O
apoptosis	B-PATH
,	O
as	O
measured	O
by	O
DNA	O
changes	O
and	O
annexin	O
V	O
staining	O
.	O

Apoptosis	B-PATH
correlated	O
with	O
the	O
differential	O
release	B-PATH
of	O
infectious	O
virus	O
.	O

Inhibition	O
of	O
MHV	O
-	O
induced	O
apoptosis	B-PATH
by	O
the	O
pancaspase	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
FMK	O
promoted	O
virus	O
production	O
late	O
in	O
infection	O
,	O
indicating	O
that	O
apoptosis	B-PATH
could	O
be	O
a	O
host	O
response	O
to	O
limit	O
the	O
production	O
of	O
viral	O
progeny	O
.	O

Activation	O
of	O
the	O
mitochondria	O
-	O
mediated	O
apoptotic	O
pathway	O
was	O
indicated	O
by	O
the	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
delay	O
of	O
apoptosis	B-PATH
by	O
Bcl	O
-	O
2	O
overexpression	O
.	O

All	O
our	O
data	O
indicate	O
that	O
a	O
mitochondria	O
-	O
mediated	O
pathway	O
played	O
a	O
major	O
regulatory	O
role	O
in	O
apoptosis	B-PATH
in	O
MHV	O
-	O
infected	O
17Cl	O
-	O
1	O
cells	O
.	O

It	O
has	O
also	O
been	O
found	O
to	O
be	O
useful	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acute	O
cardiogenic	O
pulmonary	O
oedema	O
and	O
acute	O
severe	O
asthma	B-PATH
.	O

The	O
latter	O
possibility	O
where	O
axonal	O
injury	O
leads	O
to	O
other	O
changes	O
is	O
raised	O
from	O
the	O
rather	O
unexpected	O
similarity	O
between	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
and	O
MS	O
where	O
axonal	O
injury	O
,	O
oligodendrocyte	O
apoptosis	B-PATH
and	O
demyelination	O
are	O
all	O
present	O
.	O

In	O
SCI	O
,	O
transection	O
of	O
axons	O
leads	O
to	O
delayed	O
oligodendrocyte	O
apoptosis	B-PATH
with	O
secondary	O
demyelination	O
.	O

TITLE	O
:	O
Role	O
of	O
viruses	O
and	O
atypical	O
bacteria	O
in	O
exacerbations	O
of	O
asthma	B-PATH
in	O
hospitalized	O
children	O
:	O
a	O
prospective	O
study	O
in	O
the	O
Nord	O
-	O
Pas	O
de	O
Calais	O
region	O
(	O
France	O
).	O

ABSTRACT	O
:	O
We	O
studied	O
the	O
role	O
of	O
viruses	O
and	O
atypical	O
bacteria	O
in	O
children	O
hospitalized	O
with	O
exacerbated	O
asthma	B-PATH
by	O
a	O
prospective	O
study	O
of	O
children	O
with	O
acute	O
asthma	B-PATH
admitted	O
to	O
the	O
Department	O
of	O
Pediatrics	O
in	O
Lille	O
,	O
and	O
to	O
15	O
hospitals	O
in	O
the	O
Nord	O
-	O
Pas	O
de	O
Calais	O
region	O
,	O
from	O
October	O
1	O
,	O
1998	O
-	O
June	O
30	O
,	O
1999	O
.	O

The	O
severity	O
of	O
asthma	B-PATH
and	O
of	O
asthmatic	O
exacerbations	O
was	O
recorded	O
.	O

TITLE	O
:	O
Rhinovirus	O
-	O
induced	O
wheezing	O
in	O
infancy	O
--	O
the	O
first	O
sign	O
of	O
childhood	O
asthma	B-PATH
?	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
occurrence	O
of	O
RV	O
,	O
enterovirus	O
,	O
and	O
coronavirus	O
infections	O
in	O
wheezing	O
infants	O
and	O
to	O
evaluate	O
the	O
association	O
of	O
these	O
viral	O
findings	O
with	O
early	O
school	O
-	O
age	O
asthma	B-PATH
.	O

In	O
1999	O
,	O
outcome	O
in	O
relation	O
to	O
asthma	B-PATH
was	O
studied	O
in	O
82	O
of	O
100	O
initially	O
recruited	O
children	O
who	O
had	O
been	O
hospitalized	O
for	O
wheezing	O
in	O
infancy	O
during	O
the	O
period	O
1992	O
-	O
1993	O
.	O

The	O
association	O
with	O
atopy	O
and	O
subsequent	O
asthma	B-PATH
calls	O
for	O
reevaluation	O
of	O
the	O
role	O
of	O
rhinoviruses	O
in	O
the	O
development	O
of	O
asthma	B-PATH
.	O

A	O
51Cr	O
-	O
cytolytic	O
release	B-PATH
assay	O
was	O
used	O
to	O
determine	O
the	O
activity	O
of	O
the	O
NK	O
cells	O
harvested	O
via	O
lung	O
lavage	O
from	O
the	O
respiratory	O
tracts	O
of	O
infected	O
chickens	O
.	O

TITLE	O
:	O
Infection	O
with	O
human	O
herpesvirus	O
type	O
8	O
and	O
kaposi	O
'	O
s	O
sarcoma	O
in	O
a	O
central	O
Italian	O
area	O
formerly	O
endemic	O
for	O
malaria	B-PATH
.	O

These	O
results	O
were	O
comparable	O
to	O
those	O
derived	O
from	O
geographic	O
areas	O
at	O
low	O
risk	O
for	O
KS	O
where	O
malaria	B-PATH
was	O
not	O
endemic	O
(	O
e	O
.	O
g	O
.	O
Malta	O
).	O

CONCLUSIONS	O
:	O
These	O
results	O
were	O
comparable	O
to	O
those	O
derived	O
from	O
geographic	O
areas	O
at	O
low	O
risk	O
for	O
KS	O
where	O
malaria	B-PATH
was	O
not	O
endemic	O
(	O
e	O
.	O
g	O
.	O
Malta	O
).	O

Others	O
included	O
malaria	B-PATH
,	O
septicemia	O
,	O
urinary	O
tract	O
infection	O
,	O
acute	O
chest	O
syndrome	O
,	O
and	O
osteomyelitis	O
.	O

These	O
results	O
suggest	O
that	O
CCL3	O
not	O
only	O
mediates	O
macrophage	O
chemotaxis	O
but	O
also	O
significantly	O
enhances	O
differentiation	O
of	O
primed	O
CD8	O
(+)	O
T	O
cells	O
into	O
effector	O
cells	O
and	O
their	O
release	B-PATH
into	O
circulation	O
,	O
thus	O
potentiating	O
effective	O
migration	O
to	O
the	O
site	O
of	O
infection	O
.	O

Annexin	O
-	O
V	O
staining	O
of	O
the	O
spleen	O
cells	O
demonstrated	O
that	O
the	O
cells	O
collected	O
at	O
2	O
weeks	O
p	O
.	O
i	O
.	O
were	O
undergoing	O
significantly	O
more	O
apoptosis	B-PATH
than	O
cells	O
collected	O
at	O
10	O
days	O
p	O
.	O
i	O
.	O

Cortisol	O
has	O
putative	O
antifibrotic	O
activities	O
,	O
including	O
inhibition	O
of	O
fibroblast	O
growth	O
and	O
collagen	O
deposition	O
and	O
stimulation	O
of	O
T	O
-	O
cell	O
and	O
monocyte	O
apoptosis	B-PATH
.	O

Animal	O
studies	O
using	O
small	O
(<	O
4	O
mm	O
)	O
endotracheal	O
tubes	O
have	O
shown	O
reduced	O
histopathologic	O
evidence	O
of	O
lung	O
injury	O
and	O
inflammatory	O
mediator	O
release	B-PATH
,	O
suggesting	O
reduced	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

Mature	O
RCV	O
particles	O
were	O
distributed	O
around	O
the	O
ER	O
pools	O
,	O
cytoplasm	O
,	O
and	O
intercellular	O
space	O
,	O
and	O
the	O
RCVs	O
in	O
the	O
endosome	O
/	O
lysosome	B-PATH
were	O
devoid	O
of	O
the	O
envelop	O
and	O
nuclear	O
capsid	O
.	O

The	O
ER	O
lakes	O
are	O
involved	O
in	O
the	O
maturation	O
of	O
the	O
viruses	O
,	O
and	O
the	O
envelop	O
and	O
nuclear	O
capsid	O
of	O
the	O
virus	O
entering	O
the	O
cells	O
from	O
extracellular	O
space	O
are	O
removed	O
and	O
degraded	O
in	O
the	O
endosome	O
/	O
lysosome	B-PATH
.	O

CONCLUSIONS	O
:	O
The	O
ER	O
lakes	O
are	O
involved	O
in	O
the	O
maturation	O
of	O
the	O
viruses	O
,	O
and	O
the	O
envelop	O
and	O
nuclear	O
capsid	O
of	O
the	O
virus	O
entering	O
the	O
cells	O
from	O
extracellular	O
space	O
are	O
removed	O
and	O
degraded	O
in	O
the	O
endosome	O
/	O
lysosome	B-PATH
.	O

Among	O
the	O
patients	O
with	O
a	O
nonruptured	O
aneurysm	O
,	O
two	O
deaths	O
(	O
9	O
.	O
1	O
%)	O
occurred	O
because	O
of	O
aorto	O
-	O
broncho	O
-	O
esophageal	O
fistulae	O
or	O
cardiac	O
arrest	O
due	O
to	O
severe	O
asthma	B-PATH
attack	O
within	O
30	O
days	O
,	O
and	O
the	O
other	O
three	O
hospital	O
deaths	O
were	O
due	O
to	O
aspiration	O
pneumonia	O
,	O
multiple	O
organ	O
failure	O
with	O
preoperative	O
renal	O
dysfunction	O
,	O
or	O
low	O
cardiac	O
output	O
syndrome	O
due	O
to	O
perioperative	O
myocardial	O
infarction	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
characteristics	O
of	O
individuals	O
with	O
work	O
-	O
related	O
asthma	B-PATH
associated	O
with	O
exposure	O
to	O
cleaning	O
products	O
,	O
data	O
from	O
the	O
California	O
-,	O
Massachusetts	O
-,	O
Michigan	O
-,	O
and	O
New	O
Jersey	O
state	O
-	O
based	O
surveillance	O
systems	O
of	O
work	O
-	O
related	O
asthma	B-PATH
were	O
used	O
to	O
identify	O
cases	O
of	O
asthma	B-PATH
associated	O
with	O
exposure	O
to	O
cleaning	O
products	O
at	O
work	O
.	O

From	O
1993	O
to	O
1997	O
,	O
236	O
(	O
12	O
%)	O
of	O
the	O
1915	O
confirmed	O
cases	O
of	O
work	O
-	O
related	O
asthma	B-PATH
identified	O
by	O
the	O
four	O
states	O
were	O
associated	O
with	O
exposure	O
to	O
cleaning	O
products	O
.	O

Eighty	O
percent	O
of	O
the	O
reports	O
were	O
of	O
new	O
-	O
onset	O
asthma	B-PATH
and	O
20	O
%	O
were	O
work	O
-	O
aggravated	O
asthma	B-PATH
.	O

Their	O
potential	O
to	O
cause	O
or	O
aggravate	O
asthma	B-PATH
has	O
recently	O
been	O
recognized	O
.	O

Further	O
work	O
to	O
characterize	O
the	O
specific	O
agents	O
and	O
the	O
circumstances	O
of	O
their	O
use	O
associated	O
with	O
asthma	B-PATH
is	O
needed	O
.	O

ABSTRACT	O
:	O
Nutrition	O
support	O
in	O
the	O
severely	O
injured	O
trauma	O
patient	O
is	O
crucial	O
to	O
minimize	O
the	O
hypermetabolic	O
stress	B-PATH
response	I-PATH
.	O

These	O
Abs	O
are	O
postulated	O
to	O
activate	O
recipient	O
'	O
s	O
leucocytes	O
,	O
resulting	O
in	O
the	O
release	B-PATH
of	O
soluble	O
factors	O
such	O
as	O
reactive	O
oxygen	O
species	O
and	O
detrimental	O
cytokines	O
and	O
chemokines	O
.	O

Novel	O
aggressive	O
therapeutic	O
approaches	O
to	O
these	O
lung	O
disorders	O
are	O
required	O
,	O
and	O
prevention	O
of	O
NE	O
release	B-PATH
may	O
be	O
considered	O
as	O
a	O
promising	O
strategy	O
for	O
disease	O
outcome	O
.	O

It	O
has	O
been	O
shown	O
that	O
atypical	O
pneumonia	O
(	O
AP	O
),	O
with	O
similar	O
clinical	O
features	O
to	O
SARS	O
,	O
has	O
been	O
identified	O
in	O
Guangzhou	O
,	O
China	O
,	O
long	O
before	O
the	O
prevalence	O
of	O
SARS	O
,	O
a	O
fact	O
that	O
urges	O
further	O
understanding	O
of	O
SARS	O
in	O
regard	O
to	O
its	O
incidence	O
and	O
variable	O
clinical	O
courses	O
,	O
for	O
its	O
differential	O
diagnosis	O
with	O
such	O
diseases	O
as	O
AP	O
,	O
influenza	O
-	O
related	O
pneumonia	O
,	O
pulmonary	O
tuberculosis	B-PATH
,	O
fungal	O
and	O
cytomegalovirus	O
pneumonia	O
.	O

Infectious	O
virons	O
entered	O
cells	O
by	O
endocytosis	B-PATH
or	O
membrane	O
fusion	O
and	O
released	O
through	O
a	O
budding	B-PATH
process	O
.	O

Infectious	O
virons	O
entered	O
cells	O
by	O
endocytosis	B-PATH
or	O
membrane	O
fusion	O
and	O
released	O
through	O
a	O
budding	B-PATH
process	O
.	O

Outbreaks	O
of	O
multi	O
-	O
drug	O
resistant	O
(	O
MDR	O
)	O
tuberculosis	B-PATH
and	O
the	O
atypical	O
mycobacteria	O
simulate	O
SARS	O
on	O
clinical	O
,	O
radiologic	O
,	O
epidemiologic	O
,	O
and	O
diagnostic	O
laboratory	O
grounds	O
and	O
it	O
is	O
only	O
logical	O
then	O
to	O
include	O
them	O
in	O
the	O
differential	O
to	O
find	O
a	O
definitive	O
cause	O
and	O
cure	O
for	O
SARS	O
.	O

Potential	O
mechanisms	O
for	O
the	O
development	O
of	O
PE	O
include	O
cytokine	O
release	B-PATH
from	O
basiliximab	O
with	O
increased	O
capillary	O
permeability	O
,	O
volume	O
overload	O
and	O
ischemic	O
-	O
reperfusion	O
injury	O
.	O

Hopkins	O
syndrome	O
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
any	O
flaccid	O
paralysis	O
when	O
it	O
is	O
associated	O
with	O
an	O
asthma	B-PATH
attack	O
.	O

CONCLUSIONS	O
:	O
Hopkins	O
syndrome	O
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
any	O
flaccid	O
paralysis	O
when	O
it	O
is	O
associated	O
with	O
an	O
asthma	B-PATH
attack	O
.	O

We	O
provide	O
the	O
first	O
quantitative	O
analysis	O
of	O
the	O
polynucleic	O
acid	O
binding	O
and	O
NTPase	O
activities	O
of	O
a	O
Nidovirus	O
helicase	O
,	O
using	O
a	O
high	O
throughput	O
phosphate	O
release	B-PATH
assay	O
that	O
will	O
be	O
readily	O
adaptable	O
to	O
the	O
future	O
testing	O
of	O
helicase	O
inhibitors	O
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
cell	O
apoptosis	B-PATH
in	O
the	O
pathological	O
tissues	O
of	O
patients	O
with	O
SARS	O
and	O
its	O
significance	O
].	O

In	O
the	O
lung	O
tissue	O
of	O
the	O
patients	O
,	O
few	O
CD20	O
+/	O
CD45RA	O
+	O
B	O
cells	O
and	O
CD4	O
+/	O
CD8	O
+	O
T	O
cells	O
were	O
spotted	O
,	O
and	O
CD20	O
+/	O
CD45RA	O
+	O
B	O
cells	O
along	O
with	O
CD4	O
+/	O
CD8	O
+	O
T	O
cells	O
were	O
also	O
significantly	O
decreased	O
in	O
the	O
spleen	O
and	O
lymph	O
nodes	O
,	O
where	O
few	O
conserved	O
B	O
and	O
T	O
cells	O
underwent	O
apoptosis	B-PATH
.	O

Apoptosis	B-PATH
is	O
a	O
general	O
phenomenon	O
in	O
SARS	O
,	O
and	O
the	O
invasive	O
cells	O
in	O
the	O
pathological	O
tissues	O
are	O
primarily	O
monocytes	O
,	O
suggesting	O
that	O
apoptosis	B-PATH
and	O
invasion	O
of	O
monocyte	O
play	O
important	O
roles	O
in	O
the	O
progression	O
of	O
SARS	O
.	O

The	O
cell	O
apoptosis	B-PATH
and	O
decreased	O
number	O
of	O
T	O
cell	O
and	O
B	O
cells	O
in	O
the	O
lungs	O
and	O
CD4	O
+/	O
CD8	O
+	O
T	O
cells	O
and	O
CD20	O
+/	O
CD45RA	O
+	O
B	O
cells	O
in	O
the	O
spleen	O
and	O
lymph	O
nodes	O
indicate	O
that	O
the	O
SARS	O
virus	O
may	O
exercise	O
immune	O
cell	O
-	O
killing	O
effect	O
to	O
some	O
extent	O
during	O
its	O
pathogenesis	O
.	O

In	O
the	O
lung	O
tissue	O
of	O
the	O
patients	O
,	O
few	O
CD20	O
+/	O
CD45RA	O
+	O
B	O
cells	O
and	O
CD4	O
+/	O
CD8	O
+	O
T	O
cells	O
were	O
spotted	O
,	O
and	O
CD20	O
+/	O
CD45RA	O
+	O
B	O
cells	O
along	O
with	O
CD4	O
+/	O
CD8	O
+	O
T	O
cells	O
were	O
also	O
significantly	O
decreased	O
in	O
the	O
spleen	O
and	O
lymph	O
nodes	O
,	O
where	O
few	O
conserved	O
B	O
and	O
T	O
cells	O
underwent	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Clinical	O
review	O
:	O
Severe	O
malaria	B-PATH
.	O

Severe	O
malaria	B-PATH
is	O
almost	O
exclusively	O
caused	O
by	O
Plasmodium	O
falciparum	O
.	O

The	O
incidence	O
of	O
imported	O
malaria	B-PATH
is	O
increasing	O
and	O
the	O
case	O
fatality	O
rate	O
remains	O
high	O
despite	O
progress	O
in	O
intensive	O
care	O
and	O
antimalarial	O
treatment	O
.	O

Intravenous	O
quinine	O
and	O
quinidine	O
are	O
the	O
most	O
widely	O
used	O
drugs	O
in	O
the	O
initial	O
treatment	O
of	O
severe	O
falciparum	O
malaria	B-PATH
,	O
whereas	O
artemisinin	O
derivatives	O
are	O
currently	O
recommended	O
for	O
quinine	O
-	O
resistant	O
cases	O
.	O

Exchange	O
blood	O
transfusion	O
has	O
been	O
suggested	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
severe	O
malaria	B-PATH
and	O
high	O
parasitemia	O
.	O

For	O
early	O
diagnosis	O
,	O
it	O
is	O
paramount	O
to	O
consider	O
malaria	B-PATH
in	O
every	O
febrile	O
patient	O
with	O
a	O
history	O
of	O
travel	O
in	O
an	O
area	O
endemic	O
for	O
malaria	B-PATH
.	O

It	O
plays	O
essential	O
roles	O
in	O
a	O
variety	O
of	O
DNA	O
transactions	O
including	O
recombination	O
,	O
transcription	O
and	O
DNA	B-PATH
replication	I-PATH
.	O

Our	O
findings	O
also	O
suggest	O
that	O
HO	O
-	O
1	O
induction	O
may	O
play	O
an	O
important	O
role	O
in	O
conferring	O
protection	O
on	O
hepatocytes	O
from	O
oxidative	B-PATH
damage	I-PATH
caused	O
by	O
free	O
heme	O
.	O

The	O
ratio	O
of	O
EBC	O
NO	O
(	O
2	O
)(-)	O
to	O
VT	O
is	O
assumed	O
to	O
reflect	O
NO	O
(	O
2	O
)(-)	O
release	B-PATH
at	O
a	O
given	O
VT	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
expression	O
,	O
intracellular	O
localization	O
,	O
and	O
replication	O
complex	O
association	O
of	O
the	O
putative	O
mouse	O
hepatitis	O
virus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
synthesis	O
is	O
mediated	O
by	O
a	O
viral	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
on	O
membrane	O
-	O
bound	O
replication	O
complexes	O
in	O
the	O
host	O
cell	O
cytoplasm	O
.	O

We	O
used	O
a	O
Bayesian	O
phylogenetic	O
inference	O
approach	O
with	O
sliding	O
window	O
analyses	O
of	O
three	O
SARS	O
-	O
CoV	O
proteins	O
:	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RDRP	O
),	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
).	O

In	O
addition	O
,	O
candidate	O
targets	O
of	O
B6RA	O
and	O
BNP	O
could	O
be	O
adsorption	O
,	O
transcription	O
and	O
/	O
or	O
viral	O
RNA	O
replication	O
of	O
an	O
interestingly	O
wide	O
RNA	O
virus	O
selection	O
including	O
Picornaviridae	O
(	O
poliovirus	O
,	O
human	O
coxsackievirus	O
,	O
hepatitis	O
A	O
virus	O
),	O
Flaviviridae	O
(	O
yellow	O
fever	O
virus	O
,	O
Dengue	O
virus	O
,	O
West	O
Nile	O
virus	O
,	O
Kunjin	O
virus	O
,	O
St	O
.	O
Louis	O
encephalitis	O
virus	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
),	O
Togaviridae	O
(	O
rubella	O
virus	O
),	O
Coronaviridae	O
(	O
human	O
coronavirus	O
,	O
human	O
SARS	O
-	O
associated	O
coronavirus	O
),	O
Rhabdoviridae	O
(	O
rabies	O
virus	O
),	O
Paramyxoviridae	O
(	O
human	O
parainfluenza	O
virus	O
,	O
measles	B-PATH
virus	O
,	O
human	O
respiratory	O
syncytial	O
virus	O
),	O
Filoviridae	O
(	O
Marburg	O
virus	O
,	O
Ebola	O
virus	O
),	O
Bornaviridae	O
(	O
Borna	O
disease	O
virus	O
),	O
Bunyaviridae	O
(	O
Hantaan	O
virus	O
),	O
Arenaviridae	O
(	O
Lassa	O
virus	O
),	O
and	O
Reoviridae	O
(	O
human	O
rotavirus	O
).	O

Caveolin	O
-	O
1	O
may	O
serve	O
as	O
a	O
possible	O
receptor	O
of	O
the	O
SARS	O
-	O
CoV	O
proteins	O
,	O
which	O
may	O
be	O
associated	O
with	O
the	O
SARS	O
-	O
CoV	O
infection	O
,	O
replication	O
,	O
assembly	O
,	O
and	O
budding	B-PATH
.	O

CONCLUSIONS	O
:	O
Caveolin	O
-	O
1	O
may	O
serve	O
as	O
a	O
possible	O
receptor	O
of	O
the	O
SARS	O
-	O
CoV	O
proteins	O
,	O
which	O
may	O
be	O
associated	O
with	O
the	O
SARS	O
-	O
CoV	O
infection	O
,	O
replication	O
,	O
assembly	O
,	O
and	O
budding	B-PATH
.	O

ABSTRACT	O
:	O
A	O
patient	O
with	O
a	O
two	O
-	O
year	O
history	O
of	O
worsening	O
asthma	B-PATH
presented	O
with	O
chest	O
pain	O
and	O
shortness	O
of	O
breath	O
.	O

Following	O
the	O
introduction	O
of	O
nucleic	O
acid	O
testing	O
for	O
human	O
immunodeficiency	O
virus	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
the	O
American	O
Red	O
Cross	O
estimates	O
the	O
risk	O
of	O
transfusion	O
-	O
transmitted	O
human	O
immunodeficiency	O
virus	O
to	O
be	O
1	O
:	O
1	O
,	O
215	O
,	O
000	O
(	O
per	O
unit	O
transfused	O
)	O
and	O
1	O
:	O
1	O
,	O
935	O
,	O
000	O
for	O
transfusion	O
-	O
transmitted	O
hepatitis	B-PATH
C	I-PATH
virus	O
.	O

Although	O
NO	O
is	O
important	O
in	O
maintaining	O
vasodilator	O
tone	O
,	O
hypoxia	O
-	O
induced	O
pulmonary	O
vasoconstriction	O
is	O
accompanied	O
by	O
an	O
increase	O
instead	O
of	O
a	O
decrease	O
in	O
NO	O
release	B-PATH
.	O

In	O
this	O
report	O
we	O
present	O
results	O
of	O
comparative	O
sequence	O
analysis	O
of	O
the	O
spike	O
(	O
S	O
),	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
nucleoprotein	O
(	O
N	O
)	O
structural	O
proteins	O
,	O
and	O
the	O
two	O
most	O
conserved	O
replicase	O
domains	O
,	O
putative	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
and	O
RNA	O
helicase	O
(	O
HEL	O
),	O
aimed	O
at	O
a	O
revision	O
of	O
the	O
Coronaviridae	O
taxonomy	O
.	O

However	O
,	O
severe	O
exposure	O
by	O
any	O
route	O
may	O
result	O
in	O
an	O
acute	O
and	O
occasionally	O
fatal	O
illness	O
that	O
bears	O
all	O
the	O
hallmarks	O
of	O
being	O
mediated	O
by	O
uncoupling	O
of	O
oxidative	B-PATH
phosphorylation	I-PATH
.	O

TITLE	O
:	O
Induction	O
of	O
caspase	O
-	O
dependent	O
apoptosis	B-PATH
in	O
cultured	O
rat	O
oligodendrocytes	O
by	O
murine	O
coronavirus	O
is	O
mediated	O
during	O
cell	O
entry	O
and	O
does	O
not	O
require	O
virus	O
replication	O
.	O

However	O
,	O
whether	O
MHV	O
can	O
directly	O
induce	O
oligodendrocyte	O
apoptosis	B-PATH
has	O
not	O
been	O
documented	O
.	O

Significantly	O
,	O
oligodendrocytes	O
infected	O
with	O
both	O
live	O
and	O
ultraviolet	O
light	O
-	O
inactivated	O
viruses	O
underwent	O
apoptosis	B-PATH
to	O
a	O
similar	O
extent	O
,	O
which	O
was	O
readily	O
detectable	O
at	O
24	O
h	O
postinfection	O
as	O
revealed	O
by	O
apoptotic	O
bodies	O
and	O
DNA	O
fragmentation	O
,	O
indicating	O
that	O
MHV	O
-	O
induced	O
apoptosis	B-PATH
is	O
mediated	O
during	O
the	O
early	O
stages	O
of	O
the	O
virus	O
life	O
cycle	O
and	O
does	O
not	O
require	O
virus	O
replication	O
.	O

Prior	O
treatment	O
of	O
cells	O
with	O
the	O
lysosomotropic	O
agents	O
NH	O
(	O
4	O
)	O
Cl	O
and	O
chloroquine	O
as	O
well	O
as	O
the	O
vacuolar	O
proton	O
pump	O
-	O
ATPase	O
inhibitor	O
bafilomycin	O
A1	O
,	O
all	O
of	O
which	O
block	O
the	O
acidification	O
of	O
the	O
endosome	O
,	O
prevented	O
oligodendrocytes	O
from	O
succumbing	O
to	O
apoptosis	B-PATH
induced	O
by	O
MHV	O
mutant	O
OBLV60	O
,	O
which	O
enters	O
cells	O
via	O
endocytosis	B-PATH
,	O
indicating	O
that	O
fusion	O
between	O
the	O
viral	O
envelope	O
and	O
cell	O
membranes	O
triggers	O
the	O
apoptotic	O
cascade	O
.	O

Our	O
results	O
,	O
thus	O
,	O
for	O
the	O
first	O
time	O
provide	O
unequivocal	O
evidence	O
that	O
infection	O
of	O
oligodendrocytes	O
with	O
MHV	O
directly	O
results	O
in	O
apoptosis	B-PATH
.	O

This	O
finding	O
provides	O
an	O
explanation	O
for	O
the	O
destruction	O
of	O
oligodendrocytes	O
and	O
the	O
damage	O
of	O
myelin	O
sheath	O
in	O
MHV	O
-	O
infected	O
CNS	O
and	O
suggests	O
that	O
oligodendrocyte	O
apoptosis	B-PATH
may	O
be	O
one	O
of	O
the	O
underlying	O
mechanisms	O
for	O
the	O
pathogenesis	O
of	O
MHV	O
-	O
induced	O
demyelinating	O
diseases	O
in	O
animals	O
.	O

ABSTRACT	O
:	O
During	O
a	O
prospective	O
evaluation	O
of	O
malaria	B-PATH
prophylaxis	O
in	O
pregnancy	O
in	O
a	O
refugee	O
population	O
on	O
the	O
north	O
-	O
western	O
border	O
of	O
Thailand	O
from	O
1987	O
to	O
1990	O
,	O
an	O
extremely	O
high	O
infant	O
mortality	O
rate	O
(	O
18	O
%)	O
was	O
documented	O
despite	O
good	O
access	O
to	O
health	O
care	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
neutrophil	O
apoptosis	B-PATH
in	O
the	O
resolution	O
of	O
acute	O
lung	O
injury	O
in	O
newborn	O
infants	O
.	O

BAL	O
fluid	O
obtained	O
from	O
RDS	O
but	O
not	O
CLD	O
patients	O
was	O
proapoptotic	O
to	O
neutrophils	O
(	O
apoptosis	B-PATH
ratio	O
BAL	O
fluid	O
/	O
saline	O
control	O
:	O
day	O
1	O
,	O
RDS	O
9	O
.	O
8	O
(	O
5	O
.	O
5	O
)	O
v	O
CLD	O
1	O
.	O
2	O
(	O
0	O
.	O
1	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
);	O
day	O
2	O
,	O
RDS	O
4	O
.	O
32	O
(	O
2	O
.	O
8	O
)	O
v	O
CLD	O
0	O
.	O
5	O
(	O
0	O
.	O
4	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

Inappropriate	O
suppression	O
of	O
neutrophil	O
apoptosis	B-PATH
may	O
be	O
associated	O
with	O
a	O
poor	O
outcome	O
in	O
newborn	O
infants	O
with	O
respiratory	O
failure	O
.	O

RESULTS	O
:	O
Neutrophil	O
apoptosis	B-PATH
was	O
increased	O
in	O
the	O
RDS	O
group	O
(	O
mean	O
(	O
SEM	O
)	O
neutrophil	O
apoptosis	B-PATH
on	O
day	O
7	O
BAL	O
:	O
RDS	O
17	O
.	O
0	O
(	O
8	O
.	O
6	O
)%	O
v	O
CLD	O
0	O
.	O
7	O
(	O
0	O
.	O
2	O
)%	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

Moreover	O
,	O
chloroquine	O
has	O
immunomodulatory	O
effects	O
,	O
suppressing	O
the	O
production	O
/	O
release	B-PATH
of	O
tumour	O
necrosis	O
factor	O
alpha	O
and	O
interleukin	O
6	O
,	O
which	O
mediate	O
the	O
inflammatory	O
complications	O
of	O
several	O
viral	O
diseases	O
.	O

Moreover	O
,	O
during	O
FIP	O
many	O
lymphocytes	O
do	O
not	O
express	O
any	O
membrane	O
antigen	O
,	O
most	O
likely	O
due	O
to	O
early	O
apoptosis	B-PATH
.	O

Furthermore	O
,	O
treatment	O
of	O
cells	O
with	O
chloroquine	O
,	O
which	O
blocks	O
the	O
acidification	O
of	O
endosomes	O
,	O
significantly	O
inhibited	O
the	O
repression	O
of	O
the	O
BNip3	O
promoter	O
activity	O
induced	O
by	O
the	O
acidic	O
pH	O
-	O
dependent	O
MHV	O
mutant	O
OBLV60	O
,	O
which	O
enters	O
cells	O
via	O
endocytosis	B-PATH
,	O
indicating	O
that	O
the	O
down	O
-	O
regulation	O
of	O
BNip3	O
expression	O
is	O
mediated	O
by	O
fusion	O
between	O
viral	O
envelope	O
and	O
cell	O
membranes	O
during	O
entry	O
.	O

This	O
enzyme	O
catalyses	O
three	O
steps	O
in	O
the	O
beta	B-PATH
-	I-PATH
oxidation	I-PATH
of	O
long	O
-	O
chain	O
fatty	O
acids	O
.	O

In	O
situ	O
hybridization	O
was	O
used	O
to	O
detect	O
the	O
expression	O
and	O
location	O
of	O
SARS	O
-	O
CoV	O
RNA	B-PATH
polymerase	I-PATH
gene	O
in	O
autopsy	O
tissues	O
from	O
SARS	O
-	O
Cov	O
-	O
infected	O
subjects	O
,	O
including	O
the	O
lung	O
,	O
spleen	O
,	O
lymph	O
nodes	O
,	O
pituitary	O
,	O
pancreas	O
,	O
parathyroid	O
,	O
adrenal	O
glands	O
,	O
gastrointestinal	O
tract	O
,	O
skin	O
,	O
brain	O
,	O
liver	O
,	O
kidney	O
,	O
blood	O
vessels	O
,	O
striated	O
muscles	O
of	O
the	O
limbs	O
,	O
bone	O
marrow	O
,	O
heart	O
,	O
ovary	O
,	O
uterus	O
and	O
testicles	O
.	O

A	O
possible	O
role	O
for	O
TNF	O
-	O
alpha	O
in	O
the	O
previously	O
described	O
FIPV	O
-	O
induced	O
lymphocyte	O
apoptosis	B-PATH
is	O
also	O
suggested	O
.	O

Totally	O
,	O
572	O
cases	O
notified	O
were	O
collected	O
during	O
this	O
period	O
in	O
Dongcheng	O
District	O
,	O
Beijing	O
,	O
and	O
99	O
of	O
them	O
were	O
excluded	O
from	O
SARS	O
,	O
because	O
of	O
diagnosis	O
of	O
common	O
cold	O
,	O
pneumonia	O
,	O
measles	B-PATH
,	O
or	O
rubella	O
,	O
etc	O
.	O

RESULTS	O
:	O
Totally	O
,	O
572	O
cases	O
notified	O
were	O
collected	O
during	O
this	O
period	O
in	O
Dongcheng	O
District	O
,	O
Beijing	O
,	O
and	O
99	O
of	O
them	O
were	O
excluded	O
from	O
SARS	O
,	O
because	O
of	O
diagnosis	O
of	O
common	O
cold	O
,	O
pneumonia	O
,	O
measles	B-PATH
,	O
or	O
rubella	O
,	O
etc	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
previously	O
unidentified	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
of	O
SARS	O
-	O
CoV	O
plays	O
a	O
pivotal	O
role	O
in	O
viral	O
replication	O
and	O
is	O
a	O
potential	O
target	O
for	O
anti	O
-	O
SARS	O
therapy	O
.	O

We	O
predict	O
important	O
structural	O
attributes	O
of	O
potential	O
anti	O
-	O
SARS	O
-	O
CoV	O
RdRp	O
nucleotide	O
analog	O
inhibitors	O
:	O
hydrogen	O
-	O
bonding	O
capability	O
for	O
the	O
2	O
'	O
and	O
3	O
'	O
groups	O
of	O
the	O
sugar	O
ring	O
and	O
C3	O
'	O
endo	O
sugar	O
puckering	O
,	O
and	O
the	O
absence	O
of	O
a	O
hydrophobic	O
binding	O
pocket	O
for	O
non	O
-	O
nucleoside	O
analog	O
inhibitors	O
similar	O
to	O
those	O
observed	O
in	O
hepatitis	B-PATH
C	I-PATH
virus	O
RdRp	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
reverse	O
transcriptase	O
.	O

Recent	O
advances	O
have	O
been	O
made	O
in	O
our	O
knowledge	O
of	O
some	O
of	O
these	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
human	O
metapneumovirus	O
,	O
West	O
Nile	O
virus	O
and	O
Ebola	O
virus	O
.	O

ABSTRACT	O
:	O
We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
a	O
young	O
African	O
male	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
who	O
developed	O
an	O
acute	O
,	O
severe	O
Guillain	O
-	O
BarrÃ©	O
-	O
like	O
peripheral	O
neuropathy	O
associated	O
with	O
ascites	O
.	O

ABSTRACT	O
:	O
Positive	O
-	O
strand	O
RNA	O
viruses	O
are	O
the	O
largest	O
virus	O
class	O
and	O
include	O
many	O
pathogens	O
such	O
as	O
hepatitis	B-PATH
C	I-PATH
virus	O
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
).	O

IBV	O
replicates	O
not	O
only	O
in	O
respiratory	O
tissues	O
(	O
including	O
the	O
nose	O
,	O
trachea	O
,	O
lungs	O
and	O
airsacs	O
,	O
causing	O
respiratory	O
disease	O
),	O
but	O
also	O
in	O
the	O
kidney	O
(	O
associated	O
with	O
minor	O
or	O
major	O
nephritis	O
),	O
oviduct	O
,	O
and	O
in	O
many	O
parts	O
of	O
the	O
alimentary	O
tract	O
--	O
the	O
oesophagus	O
,	O
proventriculus	O
,	O
duodenum	O
,	O
jejunum	O
,	O
bursa	O
of	O
Fabricius	O
,	O
caecal	O
tonsils	O
(	O
near	O
the	O
distal	O
end	O
of	O
the	O
tract	O
),	O
rectum	O
and	O
cloaca	O
(	O
the	O
common	O
opening	O
for	O
release	B-PATH
of	O
eggs	O
and	O
faeces	O
),	O
usually	O
without	O
clinical	O
effects	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
cause	O
serious	O
medical	O
problems	O
and	O
social	O
disruption	O
every	O
year	O
in	O
particular	O
countries	O
of	O
the	O
world	O
.	O

The	O
neuraminidase	O
inhibitors	O
(	O
NAIs	O
)	O
are	O
a	O
new	O
class	O
of	O
antiviral	O
drug	O
targeting	O
a	O
viral	O
influenza	O
enzyme	O
,	O
the	O
neuraminidase	O
,	O
which	O
acts	O
both	O
to	O
facilitate	O
virus	O
infection	O
of	O
cells	O
by	O
clearing	O
a	O
passage	O
through	O
otherwise	O
protective	O
respiratory	O
fluids	O
and	O
also	O
by	O
helping	O
release	B-PATH
of	O
the	O
virus	O
by	O
cutting	O
the	O
chemical	O
umbilical	O
cord	O
which	O
links	O
up	O
the	O
virus	O
to	O
the	O
infected	O
cell	O
.	O

Extensive	O
laboratory	O
studies	O
of	O
the	O
two	O
molecules	O
zanamivir	O
and	O
oseltamivir	O
have	O
shown	O
that	O
they	O
block	O
all	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
yet	O
tested	O
and	O
would	O
,	O
in	O
theory	O
,	O
even	O
inhibit	O
the	O
1918	O
pandemic	O
virus	O
.	O

TITLE	O
:	O
Novel	O
N	O
-	O
thiolated	O
beta	O
-	O
lactam	O
antibiotics	O
selectively	O
induce	O
apoptosis	B-PATH
in	O
human	O
tumor	O
and	O
transformed	O
,	O
but	O
not	O
normal	O
or	O
nontransformed	O
,	O
cells	O
.	O

We	O
recently	O
reported	O
that	O
certain	O
N	O
-	O
methylthio	O
-	O
substituted	O
beta	O
-	O
lactam	O
antibiotics	O
had	O
DNA	O
-	O
damaging	O
and	O
apoptosis	B-PATH
-	O
inducing	O
activities	O
in	O
various	O
tumor	O
cells	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
first	O
show	O
that	O
a	O
lead	O
compound	O
(	O
lactam	O
1	O
)	O
selectively	O
induces	O
apoptosis	B-PATH
in	O
human	O
leukemic	O
Jurkat	O
T	O
,	O
but	O
not	O
in	O
the	O
nontransformed	O
,	O
immortalized	O
human	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

Additionally	O
,	O
we	O
screened	O
a	O
library	O
of	O
other	O
N	O
-	O
methylthiolated	O
beta	O
-	O
lactams	O
to	O
determine	O
their	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
),	O
and	O
found	O
lactam	O
12	O
to	O
have	O
the	O
highest	O
apoptosis	B-PATH
-	O
inducing	O
activity	O
against	O
human	O
leukemic	O
Jurkat	O
T	O
cells	O
,	O
associated	O
with	O
increased	O
DNA	O
-	O
damaging	O
potency	O
.	O

We	O
also	O
show	O
that	O
lactam	O
12	O
induces	O
apoptosis	B-PATH
in	O
human	O
breast	O
,	O
prostate	O
,	O
and	O
head	O
-	O
and	O
-	O
neck	O
cancer	O
cells	O
.	O

Finally	O
,	O
lactam	O
12	O
induces	O
apoptosis	B-PATH
selectively	O
in	O
Jurkat	O
T	O
and	O
simian	O
virus	O
40	O
-	O
transformed	O
,	O
but	O
not	O
in	O
nontransformed	O
NK	O
and	O
parental	O
normal	O
fibroblast	O
,	O
cells	O
.	O

TITLE	O
:	O
Mixed	O
cryoglobulinemia	O
due	O
to	O
chronic	O
hepatitis	B-PATH
C	I-PATH
with	O
severe	O
pulmonary	O
involvement	O
.	O

Results	O
of	O
studies	O
in	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
of	O
inflammation	O
and	O
malignancy	O
have	O
also	O
suggested	O
central	O
roles	O
for	O
NF	O
-	O
kappaB	O
in	O
programmed	O
cell	O
death	O
,	O
or	O
apoptosis	B-PATH
.	O

In	O
the	O
common	O
lung	O
diseases	O
associated	O
with	O
a	O
significant	O
inflammatory	O
component	O
such	O
as	O
severe	O
sepsis	O
,	O
acute	O
lung	O
injury	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
cystic	O
fibrosis	O
and	O
asthma	B-PATH
,	O
the	O
pathogenic	O
roles	O
of	O
NF	O
-	O
kappaB	O
have	O
been	O
extensively	O
investigated	O
.	O

TITLE	O
:	O
Avian	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H7N7	O
)	O
associated	O
with	O
human	O
conjunctivitis	O
and	O
a	O
fatal	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Since	O
the	O
Consultation	O
-	O
Liaison	O
"("""	O
C	O
-	O
L	O
""")"	O
psychiatrist	O
may	O
be	O
asked	O
to	O
consult	O
on	O
a	O
patient	O
with	O
any	O
medical	O
illness	O
,	O
e	O
.	O
g	O
.,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
malaria	B-PATH
,	O
cancer	O
,	O
stroke	O
,	O
amytrophic	O
,	O
lateral	O
sclerosis	O
,	O
and	O
a	O
patient	O
who	O
may	O
be	O
on	O
any	O
medical	O
drug	O
,	O
methods	O
need	O
to	O
be	O
developed	O
to	O
review	O
the	O
recent	O
literature	O
and	O
have	O
an	O
awareness	O
of	O
key	O
and	O
essential	O
current	O
findings	O
.	O

Respiratory	O
syncytial	O
virus	O
continues	O
to	O
be	O
a	O
major	O
source	O
of	O
viral	O
lower	O
respiratory	O
infection	O
illness	O
in	O
children	O
and	O
can	O
lead	O
to	O
childhood	O
asthma	B-PATH
.	O

This	O
review	O
uses	O
historical	O
data	O
from	O
20th	O
century	O
outbreaks	O
to	O
assess	O
the	O
risks	O
to	O
current	O
populations	O
(	O
which	O
have	O
declining	O
immunity	O
)	O
from	O
a	O
deliberate	O
release	B-PATH
of	O
virus	O
.	O

The	O
prominence	O
of	O
mitotic	O
activity	O
of	O
hepatocytes	O
is	O
unique	O
and	O
may	O
be	O
due	O
to	O
a	O
hyperproliferative	O
state	O
with	O
or	O
without	O
disruption	O
of	O
cell	B-PATH
cycle	I-PATH
by	O
the	O
coronavirus	O
.	O

Increased	O
apoptosis	B-PATH
appeared	O
to	O
contribute	O
to	O
the	O
diminished	O
presence	O
of	O
CD8	O
T	O
cells	O
in	O
MHV	O
-	O
JHM	O
-	O
infected	O
brain	O
with	O
the	O
consequence	O
of	O
a	O
lower	O
potential	O
for	O
IFNgamma	O
production	O
and	O
antiviral	O
activity	O
.	O

ABSTRACT	O
:	O
Chloroquine	O
and	O
related	O
anti	O
-	O
malarial	O
drugs	O
appear	O
to	O
promote	O
apoptosis	B-PATH
in	O
T	O
-	O
cells	O
by	O
suppressing	O
NF	O
-	O
kappa	O
-	O
B	O
,	O
which	O
enhances	O
the	O
expression	O
of	O
anti	O
-	O
apoptotic	O
proteins	O
(	O
e	O
.	O
g	O
.,	O
Bcl	O
-	O
2	O
).	O

Thus	O
,	O
chloroquine	O
has	O
found	O
applications	O
in	O
autoimmune	O
diseases	O
where	O
it	O
apparently	O
facilitates	O
apoptosis	B-PATH
of	O
abnormally	O
persistent	O
T	O
-	O
cell	O
clones	O
.	O

The	O
mode	O
of	O
action	O
of	O
chloroquine	O
in	O
prevention	O
of	O
malaria	B-PATH
is	O
not	O
known	O
,	O
but	O
it	O
may	O
be	O
to	O
minimize	O
replication	O
of	O
the	O
parasite	O
in	O
the	O
liver	O
cells	O
,	O
which	O
occurs	O
before	O
invasion	O
of	O
the	O
erythrocytes	O
,	O
by	O
facilitating	O
premature	O
apoptosis	B-PATH
of	O
the	O
infected	O
host	O
cells	O
.	O

Here	O
it	O
is	O
hypothesized	O
that	O
concurrent	O
with	O
emergence	O
of	O
chloroquine	O
-	O
resistant	O
malaria	B-PATH
(	O
presumably	O
with	O
enhanced	O
anti	O
-	O
apoptotic	O
capabilities	O
),	O
other	O
intracellular	O
parasites	O
have	O
evolved	O
to	O
enhance	O
their	O
ability	O
to	O
prevent	O
apoptosis	B-PATH
in	O
host	O
cells	O
.	O

Two	O
examples	O
of	O
viral	O
diseases	O
that	O
have	O
emerged	O
from	O
areas	O
of	O
high	O
incidence	O
of	O
chloroquine	O
-	O
resistant	O
malaria	B-PATH
are	O
AIDS	O
from	O
HIV	O
and	O
SARS	O
from	O
coronavirus	O
.	O

In	O
the	O
case	O
of	O
AIDS	O
,	O
the	O
HIV	O
(	O
which	O
has	O
had	O
a	O
long	O
-	O
term	O
symbiotic	O
relationship	O
with	O
primates	O
)	O
has	O
run	O
amuck	O
because	O
the	O
infected	O
cells	O
are	O
now	O
substantially	O
more	O
tolerant	O
to	O
the	O
toxins	O
(	O
i	O
.	O
e	O
.,	O
resistant	O
to	O
apoptosis	B-PATH
)	O
that	O
they	O
secrete	O
than	O
the	O
uninfected	O
bystander	O
cells	O
,	O
which	O
are	O
not	O
unusually	O
resistant	O
to	O
apoptosis	B-PATH
.	O

A	O
corollary	O
to	O
the	O
hypothesis	O
is	O
that	O
if	O
the	O
level	O
of	O
resistance	O
to	O
apoptosis	B-PATH
in	O
the	O
infected	O
cells	O
were	O
no	O
higher	O
than	O
the	O
level	O
of	O
resistance	O
in	O
the	O
bystander	O
cells	O
,	O
then	O
the	O
infected	O
cells	O
would	O
preferentially	O
kill	O
themselves	O
through	O
apoptosis	B-PATH
.	O

It	O
appears	O
that	O
in	O
the	O
case	O
of	O
HIV	O
,	O
the	O
increased	O
resistance	O
to	O
apoptosis	B-PATH
is	O
provided	O
by	O
expression	O
of	O
Bcl	O
-	O
2	O
and	O
suppression	O
of	O
p53	O
.	O

Hence	O
,	O
drugs	O
that	O
suppresses	O
Bcl	O
-	O
2	O
or	O
restore	O
p53	O
function	O
might	O
be	O
effective	O
in	O
restoring	O
the	O
parity	O
of	O
resistance	O
to	O
apoptosis	B-PATH
between	O
infected	O
and	O
uninfected	O
cells	O
.	O

TITLE	O
:	O
A	O
retrospective	O
study	O
of	O
malaria	B-PATH
infections	O
in	O
an	O
intensive	O
care	O
unit	O
of	O
a	O
general	O
hospital	O
in	O
Malaysia	O
.	O

All	O
cases	O
of	O
malaria	B-PATH
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
of	O
the	O
Sarawak	O
General	O
Hospital	O
from	O
January	O
1996	O
to	O
December	O
2001	O
were	O
identified	O
from	O
the	O
intensive	O
care	O
records	O
and	O
retrospectively	O
reviewed	O
.	O

A	O
total	O
of	O
31	O
cases	O
of	O
malaria	B-PATH
were	O
managed	O
in	O
the	O
intensive	O
care	O
unit	O
of	O
the	O
Sarawak	O
General	O
Hospital	O
in	O
the	O
six	O
-	O
year	O
period	O
.	O

The	O
major	O
complications	O
include	O
acute	O
renal	O
failure	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
cerebral	O
malaria	B-PATH
and	O
disseminated	O
intravascular	O
coagulopathy	O
,	O
haemolytic	O
anaemia	O
and	O
liver	O
dysfunction	O
.	O

Earlier	O
anti	O
-	O
malaria	B-PATH
treatment	O
may	O
improve	O
the	O
survival	O
rate	O
for	O
falciparum	O
malaria	B-PATH
.	O

RESULTS	O
:	O
A	O
total	O
of	O
31	O
cases	O
of	O
malaria	B-PATH
were	O
managed	O
in	O
the	O
intensive	O
care	O
unit	O
of	O
the	O
Sarawak	O
General	O
Hospital	O
in	O
the	O
six	O
-	O
year	O
period	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
a	O
child	O
with	O
malaria	B-PATH
:	O
favorable	O
response	O
to	O
prone	O
positioning	O
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
case	O
of	O
a	O
4	O
-	O
year	O
-	O
old	O
boy	O
with	O
malaria	B-PATH
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
severe	O
hypoxemia	O
refractory	O
to	O
mechanical	O
ventilation	O
and	O
inhaled	O
nitric	O
oxide	O
.	O

Cells	O
infected	O
with	O
HSV	O
-	O
1	O
demonstrated	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
the	O
G	O
(	O
1	O
)/	O
S	O
transition	O
;	O
however	O
,	O
treatment	O
with	O
GA	O
resulted	O
in	O
a	O
cell	B-PATH
cycle	I-PATH
distribution	O
pattern	O
identical	O
to	O
that	O
of	O
untreated	O
cells	O
,	O
indicating	O
a	O
restoration	O
of	O
cell	O
growth	O
in	O
HSV	O
-	O
1	O
-	O
infected	O
cells	O
by	O
GA	O
treatment	O
.	O

Recently	O
,	O
this	O
technique	O
was	O
employed	O
in	O
anti	O
-	O
virus	O
infections	O
in	O
human	O
immunodeficiency	O
virus	O
and	O
hepatitis	B-PATH
C	I-PATH
/	O
B	O
virus	O
.	O

TITLE	O
:	O
Presence	O
of	O
an	O
encephalomyocarditis	O
virus	O
internal	O
ribosome	B-PATH
entry	O
site	O
sequence	O
in	O
avian	O
infectious	O
bronchitis	O
virus	O
defective	O
RNAs	O
abolishes	O
rescue	O
by	O
helper	O
virus	O
.	O

CAT	O
protein	O
was	O
detected	O
from	O
T7	O
-	O
derived	O
IBV	O
D	O
-	O
RNA	O
transcripts	O
in	O
a	O
cell	O
-	O
free	O
protein	O
synthesis	O
system	O
and	O
in	O
situ	O
in	O
avian	O
chick	O
kidney	O
(	O
CK	O
)	O
cells	O
following	O
T7	O
-	O
derived	O
D	O
-	O
RNA	O
synthesis	O
from	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
the	O
bacteriophage	O
T7	O
DNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

The	O
system	O
has	O
uncovered	O
unreported	O
infectious	O
diseases	O
of	O
international	O
importance	O
including	O
cholera	O
,	O
plague	O
,	O
and	O
influenza	O
;	O
current	O
trends	O
of	O
acute	O
flaccid	O
paralysis	O
surveillance	O
in	O
polio	O
eradication	O
;	O
and	O
prevalence	O
of	O
HIV	O
,	O
syphilis	O
,	O
hepatitis	O
B	O
,	O
and	O
hepatitis	B-PATH
C	I-PATH
in	O
individual	O
areas	O
covered	O
by	O
the	O
sentinels	O
.	O

Children	O
(	O
aged	O
5	O
-	O
17	O
years	O
)	O
with	O
sickle	O
cell	O
crisis	O
were	O
randomized	O
to	O
receive	O
oral	O
sustained	O
-	O
release	B-PATH
morphine	O
,	O
1	O
.	O
9	O
mg	O
.	O

The	O
risk	O
of	O
acute	O
chest	O
syndrome	O
is	O
significantly	O
associated	O
with	O
high	O
systemic	O
exposure	O
to	O
morphine	O
and	O
its	O
active	O
metabolite	O
morphine	O
-	O
6	O
-	O
glucuronide	O
after	O
oral	O
administration	O
of	O
slow	O
-	O
release	B-PATH
morphine	O
.	O

Morphine	O
may	O
facilitate	O
respiratory	O
deterioration	O
by	O
eliciting	O
a	O
decrease	O
in	O
oxygen	O
saturation	O
,	O
by	O
inducing	O
histamine	O
release	B-PATH
,	O
or	O
through	O
an	O
as	O
-	O
yet	O
-	O
unidentified	O
mechanism	O
.	O

Outbreak	O
of	O
SARS	O
in	O
Dongcheng	O
District	O
started	O
on	O
March	O
14	O
,	O
2003	O
with	O
a	O
peak	O
in	O
mid	O
-	O
and	O
late	O
April	O
,	O
and	O
dropped	O
in	O
early	O
May	O
.	O
A	O
total	O
of	O
572	O
reported	O
cases	O
were	O
collected	O
during	O
this	O
period	O
in	O
Dongcheng	O
District	O
,	O
Beijing	O
,	O
and	O
99	O
of	O
them	O
were	O
excluded	O
from	O
SARS	O
,	O
because	O
of	O
diagnosis	O
of	O
common	O
cold	O
,	O
regular	O
pneumonia	O
,	O
measles	B-PATH
and	O
rubella	O
,	O
etc	O
.	O

RESULTS	O
:	O
Outbreak	O
of	O
SARS	O
in	O
Dongcheng	O
District	O
started	O
on	O
March	O
14	O
,	O
2003	O
with	O
a	O
peak	O
in	O
mid	O
-	O
and	O
late	O
April	O
,	O
and	O
dropped	O
in	O
early	O
May	O
.	O
A	O
total	O
of	O
572	O
reported	O
cases	O
were	O
collected	O
during	O
this	O
period	O
in	O
Dongcheng	O
District	O
,	O
Beijing	O
,	O
and	O
99	O
of	O
them	O
were	O
excluded	O
from	O
SARS	O
,	O
because	O
of	O
diagnosis	O
of	O
common	O
cold	O
,	O
regular	O
pneumonia	O
,	O
measles	B-PATH
and	O
rubella	O
,	O
etc	O
.	O

Rhinovirus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
adenovirus	O
,	O
parainfluenza	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
and	O
coronavirus	O
are	O
etiologies	O
most	O
often	O
associated	O
with	O
infections	O
of	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
preischemic	O
treatment	O
with	O
pioglitazone	O
,	O
a	O
peroxisome	B-PATH
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma	O
ligand	O
,	O
on	O
lung	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

TITLE	O
:	O
Respiratory	O
infections	O
:	O
SARS	O
and	O
tuberculosis	B-PATH
.	O

Its	O
release	B-PATH
could	O
possibly	O
be	O
from	O
blood	O
erythrocytes	O
and	O
body	O
tissues	O
other	O
than	O
the	O
myocardium	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
similar	O
structure	O
patterns	O
exist	O
in	O
SARS	O
-	O
CoV	O
main	O
proteinase	O
with	O
Poliovirus	O
3c	O
Proteinase	O
,	O
Rhinovirus	O
3c	O
Protease	O
,	O
Nsp4	O
Proteinase	O
From	O
Equine	O
Arteritis	O
Virus	O
,	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
Ns3	O
Protease	O
,	O
Hepatitis	O
A	O
Virus	O
3c	O
Protease	O
,	O
and	O
Dengue	O
Virus	O
Ns3	O
Protease	O
.	O

TITLE	O
:	O
Nosocomial	O
transmission	O
of	O
Mycobacterium	O
tuberculosis	B-PATH
found	O
through	O
screening	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
--	O
Taipei	O
,	O
Taiwan	O
,	O
2003	O
.	O

In	O
Taipei	O
,	O
Taiwan	O
,	O
an	O
area	O
with	O
moderate	O
to	O
high	O
incidence	O
of	O
tuberculosis	B-PATH
(	O
TB	O
)	O
(	O
50	O
-	O
74	O
cases	O
per	O
100	O
,	O
000	O
population	O
),	O
health	O
-	O
care	O
workers	O
(	O
HCWs	O
)	O
are	O
at	O
increased	O
risk	O
for	O
M	O
.	O
tuberculosis	B-PATH
(	O
Taiwan	O
Center	O
for	O
Disease	O
Control	O
,	O
unpublished	O
data	O
,	O
2002	O
).	O

Aerosol	O
-	O
generating	O
procedures	O
in	O
patients	O
with	O
tuberculosis	B-PATH
or	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
may	O
facilitate	O
airborne	O
transmission	O
.	O

The	O
airborne	O
spread	O
of	O
measles	B-PATH
,	O
tuberculosis	B-PATH
and	O
SARS	O
is	O
well	O
-	O
documented	O
in	O
the	O
medical	O
literature	O
.	O

The	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
release	B-PATH
Elispot	O
assay	O
revealed	O
that	O
only	O
SARS	O
-	O
CoV	O
-	O
specific	O
peptides	O
S1203	O
and	O
S978	O
induced	O
a	O
high	O
frequency	O
of	O
IFN	O
-	O
gamma	O
-	O
secreting	O
T	O
-	O
cell	O
response	O
in	O
HLA	O
-	O
A2	O
(+)	O
donors	O
who	O
had	O
fully	O
recovered	O
from	O
SARS	O
-	O
CoV	O
infection	O
;	O
such	O
a	O
T	O
-	O
cell	O
epitope	O
-	O
specific	O
response	O
was	O
not	O
observed	O
in	O
HLA	O
-	O
A2	O
(+)	O
healthy	O
donors	O
or	O
in	O
HLA	O
-	O
A2	O
(-)	O
donors	O
who	O
had	O
been	O
infected	O
with	O
SARS	O
-	O
CoV	O
after	O
full	O
recovery	O
.	O

Coronavirus	O
replication	O
and	O
transcription	O
are	O
highly	O
specialized	O
processes	O
of	O
cytoplasmic	O
RNA	O
synthesis	O
that	O
localize	O
to	O
virus	O
-	O
induced	O
membrane	O
structures	O
and	O
were	O
recently	O
proposed	O
to	O
involve	O
a	O
complex	O
enzymatic	O
machinery	O
that	O
,	O
besides	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
helicase	O
,	O
and	O
protease	O
activities	O
,	O
also	O
involves	O
a	O
series	O
of	O
RNA	O
-	O
processing	O
enzymes	O
that	O
are	O
not	O
found	O
in	O
most	O
other	O
RNA	O
virus	O
families	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
mediates	O
viral	O
entry	O
through	O
pH	O
-	O
dependent	O
endocytosis	B-PATH
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
replication	O
induces	O
cell	B-PATH
cycle	I-PATH
arrest	O
in	O
G0	O
/	O
G1	O
phase	O
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
replication	O
in	O
actively	O
growing	O
DBT	O
and	O
17Cl	O
-	O
1	O
cells	O
resulted	O
in	O
the	O
inhibition	O
of	O
host	O
cellular	O
DNA	O
synthesis	O
and	O
the	O
accumulation	O
of	O
infected	O
cells	O
in	O
the	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
phase	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
.	O

MHV	O
replication	O
inhibited	O
hyperphosphorylation	O
of	O
the	O
retinoblastoma	O
protein	O
(	O
pRb	O
),	O
the	O
event	O
that	O
is	O
necessary	O
for	O
cell	B-PATH
cycle	I-PATH
progression	O
through	O
late	O
G	O
(	O
1	O
)	O
and	O
into	O
the	O
S	O
phase	O
.	O

Our	O
data	O
suggested	O
that	O
a	O
reduction	O
in	O
the	O
amounts	O
of	O
G	O
(	O
1	O
)	O
cyclin	O
-	O
Cdk	O
complexes	O
in	O
MHV	O
-	O
infected	O
cells	O
led	O
to	O
a	O
reduction	O
in	O
Cdk	O
activities	O
and	O
insufficient	O
hyperphosphorylation	O
of	O
pRb	O
,	O
resulting	O
in	O
inhibition	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
in	O
the	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
phase	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
budding	B-PATH
at	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
)	O
requires	O
accumulation	O
of	O
the	O
viral	O
envelope	O
proteins	O
at	O
this	O
point	O
in	O
the	O
secretory	O
pathway	O
.	O

Interestingly	O
,	O
the	O
IBV	O
S	O
protein	O
also	O
contains	O
a	O
tyrosine	O
-	O
based	O
endocytosis	B-PATH
signal	O
in	O
its	O
cytoplasmic	O
tail	O
,	O
suggesting	O
that	O
any	O
S	O
protein	O
that	O
escapes	O
the	O
ERGIC	O
will	O
be	O
rapidly	O
endocytosed	O
when	O
it	O
reaches	O
the	O
plasma	O
membrane	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
a	O
murine	O
monoclonal	O
antibody	O
specific	O
for	O
SARS	O
-	O
CoV	O
nucleoprotein	O
,	O
and	O
probes	O
specific	O
for	O
a	O
SARS	O
-	O
CoV	O
RNA	B-PATH
polymerase	I-PATH
gene	O
fragment	O
,	O
for	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
,	O
respectively	O
,	O
to	O
detect	O
SARS	O
-	O
CoV	O
systematically	O
in	O
tissues	O
from	O
patients	O
who	O
died	O
of	O
SARS	O
.	O

This	O
increased	O
fluorescence	O
is	O
correlated	O
with	O
an	O
increased	O
transcription	O
of	O
eGFP	O
in	O
lesioned	O
cells	O
,	O
presumably	O
enhanced	O
by	O
a	O
release	B-PATH
of	O
the	O
translational	O
silencing	O
mediated	O
by	O
the	O
3	O
'	O
UTR	O
region	O
of	O
the	O
t	O
-	O
PA	O
mRNA	O
.	O

In	O
many	O
countries	O
,	O
blood	O
-	O
borne	O
occupational	O
infections	O
with	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
is	O
the	O
major	O
epidemiological	O
problem	O
among	O
health	O
care	O
workers	O
,	O
mostly	O
because	O
no	O
vaccine	O
against	O
this	O
virus	O
has	O
been	O
produced	O
to	O
date	O
.	O

Underlying	O
disease	O
includes	O
leukemia	O
,	O
malignant	O
lymphoma	O
,	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
),	O
multiple	O
injury	O
,	O
giant	O
ovarian	O
tumor	O
,	O
prostatic	O
cancer	O
with	O
multiple	O
bone	O
metastasis	O
,	O
lung	O
cancer	O
,	O
breast	O
cancer	O
with	O
multiple	O
lung	O
and	O
bone	O
metastasis	O
,	O
severe	O
pneumoniae	O
,	O
sepsis	O
,	O
hemophagocytic	O
syndrome	O
(	O
HPS	O
),	O
and	O
rheumatoid	B-PATH
arthritis	I-PATH
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
induces	O
apoptosis	B-PATH
in	O
Vero	O
E6	O
cells	O
.	O

Infection	O
-	O
induced	O
apoptosis	B-PATH
or	O
necrosis	O
is	O
suspected	O
but	O
no	O
direct	O
evidence	O
for	O
this	O
yet	O
exists	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
apoptosis	B-PATH
in	O
the	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
.	O

Indeed	O
,	O
the	O
results	O
do	O
show	O
that	O
the	O
CPE	O
was	O
induced	O
by	O
apoptosis	B-PATH
rather	O
than	O
necrosis	O
,	O
shown	O
by	O
typical	O
DNA	O
fragmentation	O
,	O
through	O
the	O
existence	O
of	O
apoptotic	O
bodies	O
and	O
swollen	O
mitochondria	O
.	O

It	O
was	O
found	O
that	O
the	O
SARS	O
coronavirus	O
entered	O
the	O
cells	O
through	O
membrane	O
fusion	O
instead	O
of	O
endocytosis	B-PATH
,	O
and	O
then	O
the	O
nucleocapsids	O
assembled	O
in	O
the	O
RER	O
and	O
matured	O
by	O
budding	B-PATH
into	O
the	O
smooth	O
vesicles	O
,	O
which	O
were	O
derived	O
from	O
the	O
Golgi	O
apparatus	O
.	O

TITLE	O
:	O
Detention	O
for	O
tuberculosis	B-PATH
:	O
public	O
health	O
and	O
the	O
law	O
.	O

ABSTRACT	O
:	O
Non	O
-	O
compliance	O
with	O
treatment	O
of	O
pulmonary	O
tuberculosis	B-PATH
(	O
TB	B-PATH
)	O
by	O
an	O
individual	O
can	O
put	O
the	O
community	O
at	O
risk	O
of	O
transmission	O
of	O
TB	B-PATH
.	O

Food	O
-	O
induced	O
asthma	B-PATH
is	O
more	O
common	O
in	O
young	O
pediatric	O
patients	O
,	O
especially	O
those	O
with	O
atopic	O
dermatitis	O
.	O

Asthma	B-PATH
induced	O
by	O
food	O
allergy	O
is	O
considered	O
a	O
risk	O
factor	O
for	O
fatal	O
and	O
near	O
-	O
fatal	O
anaphylactic	O
reactions	O
.	O

Therefore	O
,	O
evaluation	O
for	O
food	O
allergy	O
should	O
be	O
considered	O
among	O
patients	O
with	O
recalcitrant	O
or	O
otherwise	O
unexplained	O
acute	O
severe	O
asthma	B-PATH
exacerbations	O
;	O
asthma	B-PATH
triggered	O
by	O
ingestion	O
of	O
particular	O
foods	O
;	O
and	O
asthma	B-PATH
and	O
other	O
manifestations	O
of	O
food	O
allergy	O
(	O
eg	O
,	O
anaphylaxis	O
,	O
moderate	O
to	O
severe	O
atopic	O
dermatitis	O
).	O

ABSTRACT	O
:	O
In	O
the	O
Region	O
of	O
the	O
Americas	O
the	O
emerging	O
and	O
reemerging	O
infectious	O
diseases	O
that	O
had	O
the	O
greatest	O
impact	O
on	O
health	O
,	O
in	O
terms	O
of	O
their	O
incidence	O
and	O
the	O
number	O
of	O
deaths	O
that	O
they	O
caused	O
during	O
the	O
five	O
-	O
year	O
period	O
of	O
1999	O
-	O
2003	O
,	O
were	O
:	O
malaria	B-PATH
,	O
yellow	O
fever	O
,	O
dengue	O
hemorrhagic	O
fever	O
,	O
AIDS	O
,	O
anthrax	O
,	O
and	O
SARS	O
,	O
as	O
well	O
as	O
infection	O
by	O
hantavirus	O
and	O
by	O
West	O
Nile	O
virus	O
.	O

TITLE	O
:	O
Murine	O
viral	O
hepatitis	O
involves	O
NK	O
cell	O
depletion	O
associated	O
with	O
virus	O
-	O
induced	O
apoptosis	B-PATH
.	O

The	O
NK	O
cell	O
decreases	O
were	O
due	O
to	O
the	O
viral	O
permissivity	O
leading	O
to	O
cytopathic	O
effects	O
characterized	O
by	O
cell	O
rounding	O
,	O
syncytia	O
formation	O
and	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Childhood	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
coronavirus	O
infections	O
and	O
asthma	B-PATH
.	O

During	O
the	O
outbreak	O
of	O
SARS	O
,	O
there	O
did	O
not	O
appear	O
to	O
be	O
an	O
increase	O
in	O
asthma	B-PATH
exacerbations	O
in	O
children	O
.	O

The	O
expression	O
of	O
siRNAs	O
from	O
two	O
plasmids	O
,	O
which	O
specifically	O
target	O
the	O
viral	O
RNA	B-PATH
polymerase	I-PATH
,	O
effectively	O
blocked	O
the	O
cytopathic	O
effects	O
of	O
SARS	O
-	O
CoV	O
on	O
Vero	O
cells	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
and	O
pulmonary	O
tuberculosis	B-PATH
.	O

ABSTRACT	O
:	O
Health	O
care	O
facilities	O
need	O
to	O
review	O
their	O
infection	O
control	O
plans	O
to	O
prepare	O
for	O
the	O
possible	O
resurgence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
other	O
emerging	O
pathogens	O
,	O
familiar	O
infectious	O
agents	O
such	O
as	O
tuberculosis	B-PATH
and	O
influenza	O
,	O
and	O
bioterrorist	O
threats	O
.	O

This	O
article	O
describes	O
the	O
classic	O
""""	O
hierarchy	O
of	O
control	O
technologies	O
""""	O
that	O
was	O
successfully	O
used	O
by	O
occupational	O
and	O
environmental	O
medicine	O
professionals	O
to	O
protect	O
workers	O
from	O
illness	O
and	O
death	O
during	O
the	O
resurgence	O
of	O
tuberculosis	B-PATH
in	O
the	O
1990s	O
.	O

Moreover	O
,	O
SARS	O
-	O
CoV	O
may	O
also	O
directly	O
infect	O
hematopoietic	O
stem	O
/	O
progenitor	O
cells	O
via	O
CD13	O
or	O
CD66a	O
inducing	O
their	O
growth	O
inhibition	O
and	O
apoptosis	B-PATH
.	O

The	O
models	O
were	O
rigorously	O
trained	O
,	O
tested	O
and	O
validated	O
using	O
experimentally	O
identified	O
HLA	O
class	O
I	O
T	O
-	O
cell	O
epitopes	O
from	O
human	O
melanoma	B-PATH
related	O
proteins	O
and	O
human	O
papillomavirus	O
proteins	O
E6	O
and	O
E7	O
.	O

RESULTS	O
:	O
Our	O
predictions	O
against	O
experimental	O
data	O
from	O
four	O
melanoma	B-PATH
-	O
related	O
proteins	O
showed	O
that	O
MULTIPRED	O
ANN	O
and	O
HMM	O
models	O
could	O
predict	O
T	O
-	O
cell	O
epitopes	O
with	O
high	O
accuracy	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
N	O
is	O
capable	O
of	O
inducing	O
apoptosis	B-PATH
of	O
COS	O
-	O
1	O
monkey	O
kidney	O
cells	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
by	O
down	O
-	O
regulating	O
ERK	O
(	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
),	O
up	O
-	O
regulating	O
JNK	O
(	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
and	O
p38	O
MAPK	O
(	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
)	O
pathways	O
,	O
and	O
affecting	O
their	O
downstream	O
effectors	O
.	O

However	O
,	O
apoptosis	B-PATH
was	O
independent	O
of	O
the	O
p53	O
and	O
Fas	O
signalling	O
pathways	O
.	O

At	O
the	O
cytoskeletal	O
level	O
,	O
SARS	O
-	O
CoV	O
N	O
down	O
-	O
regulated	O
FAK	O
(	O
focal	B-PATH
adhesion	I-PATH
kinase	O
)	O
activity	O
and	O
also	O
down	O
-	O
regulated	O
fibronectin	O
expression	O
.	O

Second	O
,	O
the	O
decline	O
in	O
organ	O
function	O
is	O
triggered	O
by	O
a	O
decrease	O
in	O
mitochondrial	O
activity	O
and	O
oxidative	B-PATH
phosphorylation	I-PATH
,	O
leading	O
to	O
reduced	O
cellular	O
metabolism	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoV	O
)	O
mature	O
by	O
a	O
budding	B-PATH
process	O
at	O
intracellular	O
membranes	O
.	O

I	O
discuss	O
what	O
we	O
have	O
learned	O
about	O
the	O
movement	O
of	O
viruses	O
into	O
humans	O
from	O
studies	O
of	O
influenza	B-PATH
A	I-PATH
,	O
both	O
how	O
it	O
crossed	O
from	O
birds	O
to	O
humans	O
and	O
how	O
it	O
subsequently	O
evolved	O
within	O
the	O
human	O
population	O
.	O

Starting	O
with	O
a	O
brief	O
review	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
to	O
highlight	O
the	O
kinds	O
of	O
problems	O
we	O
face	O
in	O
learning	O
about	O
this	O
viral	O
disease	O
,	O
I	O
then	O
turn	O
to	O
influenza	B-PATH
A	I-PATH
,	O
focusing	O
on	O
three	O
topics	O
.	O

Although	O
influenza	B-PATH
A	I-PATH
and	O
SARS	O
-	O
CoV	O
differ	O
in	O
many	O
ways	O
,	O
our	O
knowledge	O
of	O
influenza	B-PATH
A	I-PATH
may	O
provide	O
important	O
clues	O
about	O
what	O
limits	O
or	O
favours	O
cross	O
-	O
species	O
transfers	O
and	O
subsequent	O
epidemics	O
of	O
newly	O
emerging	O
pathogens	O
.	O

Results	O
indicated	O
that	O
two	O
homologous	O
peptides	O
were	O
recognized	O
by	O
most	O
Ab	O
:	O
the	O
N	O
-	O
terminal	O
sequences	O
(	O
1	O
-	O
10	O
)	O
from	O
FAH	O
and	O
the	O
nucleocapside	O
,	O
both	O
sharing	O
50	O
%	O
of	O
identity	O
,	O
and	O
sequence	O
2317	O
-	O
2326	O
of	O
the	O
RNA	B-PATH
polymerase	I-PATH
,	O
a	O
peptide	O
showing	O
30	O
%	O
of	O
identity	O
with	O
FAH	O
11	O
-	O
20	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
and	O
tuberculosis	B-PATH
.	O

ABSTRACT	O
:	O
Respiratory	O
infectious	O
diseases	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
tuberculosis	B-PATH
create	O
unique	O
risks	O
for	O
anyone	O
who	O
may	O
be	O
exposed	O
.	O

Antibodies	O
directed	O
against	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
virions	O
and	O
against	O
the	O
putative	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
Pol	B-PATH
)	O
detected	O
SARS	O
-	O
CoV	O
nucleocapsid	O
and	O
nsp12	O
(	O
Pol	B-PATH
),	O
respectively	O
,	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
cells	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
with	O
hemophagocytic	O
syndrome	O
:	O
an	O
autopsy	O
report	O
.	O

ABSTRACT	O
:	O
This	O
report	O
concerns	O
a	O
patient	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
(	O
SLE	O
)	O
who	O
died	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
1	O
day	O
after	O
the	O
onset	O
of	O
pulmonary	O
symptoms	O
.	O

TITLE	O
:	O
Importance	O
of	O
Akt	O
signaling	O
pathway	O
for	O
apoptosis	B-PATH
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
indicated	O
that	O
before	O
cell	O
death	O
,	O
Akt	O
,	O
which	O
is	O
an	O
inhibitor	O
of	O
apoptosis	B-PATH
,	O
was	O
also	O
activated	O
in	O
response	O
to	O
viral	O
replication	O
.	O

These	O
results	O
suggested	O
that	O
weak	O
activation	O
of	O
Akt	O
cannot	O
prevent	O
apoptosis	B-PATH
induced	O
by	O
SARS	O
-	O
CoV	O
infection	O
in	O
Vero	O
E6	O
cells	O
.	O

Chloroquine	O
is	O
a	O
clinically	O
approved	O
drug	O
effective	O
against	O
malaria	B-PATH
.	O

The	O
IC50	O
of	O
chloroquine	O
for	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
in	O
vitro	O
approximates	O
the	O
plasma	O
concentrations	O
of	O
chloroquine	O
reached	O
during	O
treatment	O
of	O
acute	O
malaria	B-PATH
.	O

We	O
describe	O
two	O
patients	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
(	O
SLE	O
)	O
who	O
presented	O
with	O
fever	O
,	O
systemic	O
upset	O
and	O
pulmonary	O
infiltrates	O
between	O
April	O
and	O
June	O
,	O
2003	O
.	O

The	O
recent	O
literature	O
on	O
three	O
emerging	O
infections	O
--	O
avian	O
influenza	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
measles	B-PATH
--	O
describes	O
clinical	O
aspects	O
of	O
the	O
illnesses	O
and	O
their	O
epidemiology	O
.	O

Most	O
recently	O
,	O
outbreaks	O
of	O
measles	B-PATH
in	O
Chinese	O
orphanages	O
have	O
been	O
documented	O
.	O

These	O
findings	O
demonstrate	O
the	O
potential	O
of	O
such	O
infections	O
to	O
be	O
transmitted	O
during	O
the	O
process	O
of	O
international	O
adoption	O
,	O
and	O
in	O
the	O
case	O
of	O
measles	B-PATH
the	O
realization	O
of	O
this	O
potential	O
in	O
recent	O
reported	O
cases	O
from	O
Chinese	O
orphanages	O
brought	O
to	O
the	O
United	O
States	O
on	O
commercial	O
airlines	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
and	O
H3N2	O
)	O
and	O
B	O
viruses	O
were	O
detected	O
at	O
all	O
sites	O
.	O

In	O
July	O
2001	O
Hemispherx	O
Biopharma	O
announced	O
that	O
it	O
had	O
formed	O
a	O
strategic	O
alliance	O
with	O
Empire	O
Health	O
Resources	O
for	O
clinical	O
trials	O
of	O
Ampligen	O
in	O
the	O
treatment	O
of	O
HIV	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
infections	O
.	O

Empire	O
Health	O
Resources	O
,	O
a	O
healthcare	O
management	O
firm	O
,	O
will	O
be	O
responsible	O
for	O
accrual	O
and	O
retention	O
of	O
patients	O
for	O
HIV	O
trials	O
,	O
and	O
protocols	O
for	O
trials	O
in	O
patients	O
with	O
hepatitis	B-PATH
C	I-PATH
or	O
both	O
HIV	O
and	O
hepatitis	B-PATH
C	I-PATH
infections	O
.	O

In	O
the	O
US	O
,	O
Ampligen	O
has	O
been	O
granted	O
orphan	O
drug	O
status	O
for	O
the	O
treatment	O
of	O
AIDS	O
,	O
renal	B-PATH
cell	I-PATH
carcinoma	I-PATH
(	O
phase	O
II	O
,	O
completed	O
),	O
chronic	O
fatigue	O
syndrome	O
(	O
phase	O
III	O
)	O
and	O
invasive	O
/	O
metastatic	O
malignant	O
melanoma	B-PATH
(	O
phase	O
II	O
).	O

In	O
the	O
meantime	O
,	O
Ampligen	O
has	O
been	O
available	O
since	O
May	O
1996	O
under	O
the	O
Canadian	O
Emergency	O
Drug	O
Release	B-PATH
Programme	O
for	O
the	O
treatment	O
of	O
chronic	O
fatigue	O
syndrome	O
and	O
immune	O
dysfunction	O
syndrome	O
by	O
Rivex	O
Pharma	O
(	O
Helix	O
BioPharma	O
).	O

Nucleocapsid	O
protein	O
(	O
NP	O
)	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS_NP	O
)	O
functions	O
in	O
enveloping	O
the	O
entire	O
genomic	O
RNA	O
and	O
interacts	O
with	O
viron	O
structural	O
proteins	O
,	O
thus	O
playing	O
important	O
roles	O
in	O
the	O
process	O
of	O
virus	O
particle	O
assembly	O
and	O
release	B-PATH
.	O

The	O
sustained	O
morphological	O
abnormalities	O
of	O
the	O
bronchial	O
and	O
bronchiolar	O
wall	O
,	O
the	O
acute	O
pneumonitis	O
and	O
interstitial	O
pulmonary	O
fibrosis	O
induced	O
by	O
CKLF1	O
were	O
similar	O
to	O
phenomena	O
observed	O
in	O
chronic	O
persistent	O
asthma	B-PATH
,	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
nonstructural	O
protein	O
p28	O
arrests	O
cell	B-PATH
cycle	I-PATH
in	O
G0	O
/	O
G1	O
phase	O
.	O

Cell	B-PATH
cycle	I-PATH
analysis	O
by	O
flow	O
cytometry	O
demonstrated	O
that	O
p28	O
expression	O
induced	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
cell	B-PATH
cycle	I-PATH
arrest	O
.	O

Characterization	O
of	O
various	O
cellular	O
proteins	O
that	O
are	O
involved	O
in	O
regulating	O
cell	B-PATH
cycle	I-PATH
progression	O
demonstrated	O
that	O
p28	O
expression	O
resulted	O
in	O
an	O
accumulation	O
of	O
hypophosphorylated	O
retinoblastoma	O
protein	O
(	O
pRb	O
),	O
tumor	O
suppressor	O
p53	O
,	O
and	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
Cdk	O
)	O
inhibitor	O
p21	O
(	O
Cip1	O
).	O

Our	O
present	O
data	O
suggest	O
the	O
following	O
model	O
of	O
p28	O
-	O
induced	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
cell	B-PATH
cycle	I-PATH
arrest	O
.	O

TITLE	O
:	O
[	O
Occupational	O
asthma	B-PATH
].	O

Influenza	O
and	O
tuberculosis	B-PATH
(	O
TB	O
)	O
surveillance	O
were	O
used	O
as	O
models	O
.	O

In	O
addition	O
,	O
we	O
also	O
adopted	O
an	O
Agreement	O
and	O
Release	B-PATH
form	O
containing	O
15	O
provisions	O
requiring	O
risk	O
and	O
responsibility	O
assumption	O
on	O
the	O
part	O
of	O
the	O
student	O
participants	O
.	O

TITLE	O
:	O
Efficient	O
assembly	O
and	O
release	B-PATH
of	O
SARS	O
coronavirus	O
-	O
like	O
particles	O
by	O
a	O
heterologous	O
expression	O
system	O
.	O

Case	O
reports	O
(	O
single	O
or	O
case	O
series	O
)	O
with	O
details	O
on	O
their	O
treatment	O
and	O
outcome	O
in	O
the	O
English	O
literature	O
can	O
be	O
reviewed	O
for	O
pneumonia	O
caused	O
by	O
human	O
or	O
avian	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
50	O
patients	O
),	O
varicella	O
zoster	O
virus	O
(	O
120	O
),	O
adenovirus	O
(	O
29	O
),	O
hantavirus	O
(	O
100	O
)	O
and	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
(	O
841	O
).	O

There	O
is	O
compelling	O
evidence	O
that	O
the	O
primary	O
immunoevasive	O
strategy	O
utilized	O
by	O
the	O
SARS	O
virus	O
,	O
like	O
influenza	O
,	O
is	O
to	O
inhibit	O
its	O
host	O
'	O
s	O
corticosteroid	O
stress	B-PATH
response	I-PATH
.	O

Evidence	O
demonstrating	O
that	O
ACTH	O
autoantibodies	O
are	O
produced	O
during	O
influenza	B-PATH
infection	I-PATH
is	O
also	O
presented	O
.	O

Since	O
the	O
observed	O
per	O
-	O
base	O
replication	O
error	O
-	O
rate	O
of	O
RNA	B-PATH
polymerase	I-PATH
is	O
about	O
3	O
x	O
10	O
(-	O
5	O
),	O
RNA	O
virus	O
populations	O
typically	O
contain	O
genetic	O
variants	O
that	O
form	O
a	O
heterogeneous	O
virus	O
pool	O
.	O

Interaction	O
of	O
antibodies	O
,	O
with	O
white	O
blood	O
cells	O
in	O
the	O
transfusion	O
recipient	O
,	O
is	O
hypothesized	O
to	O
cause	O
cellular	O
activation	O
with	O
release	B-PATH
of	O
cytokines	O
resulting	O
in	O
pulmonary	O
vascular	O
endothelial	O
damage	O
and	O
exudation	O
of	O
fluid	O
across	O
the	O
pulmonary	O
basement	O
membrane	O
.	O

The	O
second	O
event	O
causes	O
release	B-PATH
of	O
cellular	O
activators	O
with	O
subsequent	O
endothelial	O
damage	O
and	O
exudation	O
of	O
fluid	O
into	O
the	O
pulmonary	O
alveoli	O
.	O

The	O
addition	O
of	O
a	O
third	O
gene	O
,	O
encoding	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
facilitated	O
budding	B-PATH
of	O
particles	O
that	O
contained	O
a	O
corona	O
-	O
like	O
halo	O
resembling	O
SARS	O
-	O
CoV	O
when	O
examined	O
by	O
transmission	O
electron	O
microscopy	O
,	O
with	O
a	O
buoyant	O
density	O
characteristic	O
of	O
coronaviruses	O
.	O

TITLE	O
:	O
Childhood	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
Taiwan	O
and	O
how	O
to	O
differentiate	O
it	O
from	O
childhood	O
influenza	B-PATH
infection	I-PATH
.	O

The	O
structural	O
proteins	O
E	O
,	O
M	O
and	O
N	O
of	O
SARS	O
-	O
CoV	O
play	O
important	O
roles	O
during	O
host	O
cell	O
entry	O
and	O
viral	O
morphogenesis	O
and	O
release	B-PATH
.	O

It	O
is	O
a	O
consequence	O
of	O
this	O
action	O
that	O
ACE2	O
participates	O
in	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
.	O

The	O
surface	O
form	O
of	O
the	O
cells	O
at	O
advanced	O
infection	O
displayed	O
prolific	O
pseudopodia	O
that	O
,	O
in	O
addition	O
to	O
the	O
rest	O
of	O
the	O
plasma	O
membrane	O
,	O
were	O
also	O
active	O
sites	O
of	O
virus	O
release	B-PATH
.	O

Serum	O
samples	O
were	O
grouped	O
into	O
acute	O
SARS	O
(	O
n	O
=	O
74	O
;	O
<	O
7	O
days	O
after	O
onset	O
of	O
fever	O
)	O
and	O
non	O
-	O
SARS	O
[	O
n	O
=	O
1067	O
;	O
fever	O
and	O
influenza	B-PATH
A	I-PATH
(	O
n	O
=	O
203	O
),	O
pneumonia	O
(	O
n	O
=	O
176	O
);	O
lung	O
cancer	O
(	O
n	O
=	O
29	O
);	O
and	O
healthy	O
controls	O
(	O
n	O
=	O
659	O
)]	O
cohorts	O
.	O

Promising	O
results	O
were	O
also	O
obtained	O
in	O
the	O
delivery	O
of	O
Epstein	O
-	O
Barr	O
virus	O
or	O
human	O
cytomegalovirus	O
antigens	O
and	O
from	O
the	O
clinical	O
testing	O
of	O
MVA	O
vectors	O
for	O
vaccination	O
against	O
immunodeficiency	O
virus	O
,	O
papilloma	O
virus	O
,	O
Plasmodium	O
falciparum	O
or	O
melanoma	B-PATH
.	O

TITLE	O
:	O
Overexpression	O
of	O
7a	O
,	O
a	O
protein	O
specifically	O
encoded	O
by	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
induces	O
apoptosis	B-PATH
via	O
a	O
caspase	O
-	O
dependent	O
pathway	O
.	O

We	O
showed	O
that	O
the	O
overexpression	O
of	O
7a	O
,	O
but	O
not	O
of	O
3a	O
or	O
the	O
viral	O
structural	O
proteins	O
,	O
nucleocapsid	O
,	O
membrane	O
,	O
and	O
envelope	O
,	O
induces	O
apoptosis	B-PATH
.	O

7a	O
induces	O
apoptosis	B-PATH
via	O
a	O
caspase	O
-	O
dependent	O
pathway	O
and	O
in	O
cell	O
lines	O
derived	O
from	O
different	O
organs	O
,	O
including	O
lung	O
,	O
kidney	O
,	O
and	O
liver	O
.	O

TITLE	O
:	O
Clinical	O
review	O
:	O
biphasic	O
positive	O
airway	O
pressure	O
and	O
airway	O
pressure	O
release	B-PATH
ventilation	O
.	O

In	O
addition	O
,	O
by	O
increasing	O
end	O
-	O
expiratory	O
lung	O
volume	O
,	O
as	O
occurs	O
when	O
using	O
biphasic	O
positive	O
airway	O
pressure	O
or	O
airway	O
pressure	O
release	B-PATH
ventilation	O
,	O
recruitment	O
of	O
collapsed	O
or	O
consolidated	O
lung	O
is	O
likely	O
to	O
occur	O
,	O
especially	O
in	O
juxtadiaphragmatic	O
lung	O
legions	O
.	O

Increasingly	O
we	O
have	O
found	O
that	O
proteomic	O
approaches	O
allow	O
the	O
rapid	O
analysis	O
of	O
a	O
whole	O
plethora	O
of	O
cell	B-PATH
cycle	I-PATH
proteins	O
that	O
may	O
be	O
affected	O
by	O
virus	O
infection	O
.	O

Manuscripts	O
address	O
the	O
use	O
of	O
molecular	O
techniques	O
in	O
the	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
bacterial	O
ribosome	B-PATH
mutations	O
,	O
which	O
may	O
lead	O
to	O
ribosome	B-PATH
-	O
targeted	O
drug	O
resistance	O
;	O
pharmacogenomics	O
as	O
a	O
clinical	O
laboratory	O
service	O
and	O
example	O
of	O
warfarin	O
dosing	O
using	O
CYP2C9	O
mutation	O
analysis	O
;	O
definition	O
of	O
the	O
potential	O
of	O
cytosine	O
arabinoside	O
incorporation	O
into	O
DNA	O
to	O
disrupt	O
transcription	O
using	O
an	O
in	O
vitro	O
model	O
of	O
oligonucleotides	O
;	O
use	O
of	O
laser	O
capture	O
microdissection	O
to	O
isolate	O
solid	O
tumor	O
cells	O
free	O
of	O
nontumor	O
cells	O
;	O
and	O
molecular	O
methods	O
used	O
to	O
classify	O
lymphomas	O
.	O

These	O
""""	O
exhaled	O
bioaerosols	O
""""	O
may	O
carry	O
airborne	O
pathogens	O
and	O
thereby	O
magnify	O
the	O
spread	O
of	O
certain	O
infectious	O
diseases	O
,	O
such	O
as	O
influenza	O
,	O
tuberculosis	B-PATH
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

The	O
identification	O
of	O
the	O
functional	O
domain	O
for	O
IL	O
-	O
8	O
release	B-PATH
will	O
provide	O
for	O
the	O
drug	O
design	O
on	O
targeting	O
specific	O
sequence	O
domains	O
of	O
S	O
protein	O
responsible	O
for	O
initiating	O
the	O
inflammatory	O
response	O
.	O

TITLE	O
:	O
[	O
Severe	O
imported	O
malaria	B-PATH
in	O
adults	O
:	O
a	O
retrospective	O
study	O
of	O
32	O
cases	O
admitted	O
to	O
intensive	O
care	O
units	O
].	O

ABSTRACT	O
:	O
Few	O
studies	O
have	O
focused	O
on	O
severe	O
imported	O
malaria	B-PATH
in	O
patients	O
admitted	O
to	O
intensive	O
care	O
units	O
.	O

Thirty	O
-	O
two	O
patients	O
were	O
included	O
,	O
representing	O
9	O
%	O
of	O
falciparum	O
malaria	B-PATH
cases	O
diagnosed	O
in	O
the	O
same	O
period	O
.	O

All	O
patients	O
acquired	O
falciparum	O
malaria	B-PATH
in	O
sub	O
-	O
Sahara	O
Africa	O
and	O
25	O
patients	O
were	O
nonimmune	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
two	O
patients	O
were	O
included	O
,	O
representing	O
9	O
%	O
of	O
falciparum	O
malaria	B-PATH
cases	O
diagnosed	O
in	O
the	O
same	O
period	O
.	O

CONCLUSIONS	O
:	O
Severe	O
imported	O
malaria	B-PATH
remains	O
associated	O
with	O
a	O
bad	O
outcome	O
.	O

TITLE	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-PATH
system	O
facilitates	O
the	O
transfer	O
of	O
murine	O
coronavirus	O
from	O
endosome	O
to	O
cytoplasm	O
during	O
virus	O
entry	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-PATH
system	O
is	O
involved	O
in	O
cellular	O
endocytosis	B-PATH
and	O
maturation	O
of	O
some	O
viruses	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
proteasome	B-PATH
inhibitors	O
blocked	O
mouse	O
hepatitis	O
virus	O
replication	O
at	O
an	O
early	O
step	O
in	O
the	O
viral	O
life	O
cycle	O
.	O

In	O
the	O
presence	O
of	O
MG132	O
,	O
the	O
entering	O
viruses	O
accumulated	O
in	O
both	O
the	O
endosome	O
and	O
denser	O
lysosome	B-PATH
,	O
suggesting	O
that	O
the	O
ubiquitin	O
-	O
proteasome	B-PATH
system	O
is	O
involved	O
in	O
the	O
release	B-PATH
of	O
virus	O
from	O
the	O
endosome	O
to	O
the	O
cytosol	O
during	O
the	O
virus	O
entry	O
step	O
.	O

We	O
describe	O
how	O
vaccinia	O
virus	O
-	O
mediated	O
homologous	B-PATH
recombination	I-PATH
can	O
be	O
used	O
to	O
introduce	O
specific	O
mutations	O
into	O
the	O
coronavirus	O
genomic	O
cDNA	O
during	O
its	O
propagation	O
in	O
vaccinia	O
virus	O
and	O
how	O
recombinant	O
coronaviruses	O
can	O
be	O
isolated	O
.	O

TITLE	O
:	O
Ventilator	O
strategies	O
for	O
posttraumatic	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
airway	O
pressure	O
release	B-PATH
ventilation	O
and	O
the	O
role	O
of	O
spontaneous	O
breathing	O
in	O
critically	O
ill	O
patients	O
.	O

Airway	O
pressure	O
release	B-PATH
ventilation	O
is	O
a	O
mode	O
of	O
mechanical	O
ventilation	O
that	O
maintains	O
lung	O
volume	O
to	O
limit	O
intra	O
tidal	O
recruitment	O
/	O
derecruitment	O
and	O
improves	O
gas	O
exchange	O
while	O
limiting	O
over	O
distension	O
.	O

Clinical	O
and	O
experimental	O
data	O
demonstrate	O
improvements	O
in	O
arterial	O
oxygenation	O
,	O
ventilation	O
-	O
perfusion	O
matching	O
(	O
less	O
shunt	O
and	O
dead	O
space	O
ventilation	O
),	O
cardiac	O
output	O
,	O
oxygen	O
delivery	O
,	O
and	O
lower	O
airway	O
pressures	O
during	O
airway	O
pressure	O
release	B-PATH
ventilation	O
.	O

Use	O
of	O
vaccinia	O
virus	O
as	O
a	O
vector	O
for	O
the	O
full	O
-	O
length	O
cDNA	O
of	O
the	O
IBV	O
genome	O
has	O
the	O
advantage	O
that	O
modifications	O
can	O
be	O
made	O
to	O
the	O
IBV	O
cDNA	O
using	O
homologous	B-PATH
recombination	I-PATH
,	O
a	O
method	O
frequently	O
used	O
to	O
insert	O
and	O
delete	O
sequences	O
from	O
the	O
vaccinia	O
virus	O
genome	O
.	O

We	O
describe	O
the	O
use	O
of	O
homologous	B-PATH
recombination	I-PATH
as	O
a	O
method	O
for	O
modifying	O
the	O
Beaudette	O
full	O
-	O
length	O
cDNA	O
,	O
within	O
the	O
vaccinia	O
virus	O
genome	O
,	O
without	O
the	O
requirement	O
for	O
in	O
vitro	O
assembly	O
of	O
the	O
IBV	O
cDNA	O
.	O

The	O
entire	O
ORF	O
(	O
open	O
-	O
reading	O
frame	O
)	O
encodes	O
for	O
two	O
major	O
enzyme	O
activities	O
,	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
and	O
proteinase	O
activities	O
.	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
ARDS	O
and	O
severe	O
pulmonary	O
hypertension	O
in	O
a	O
child	O
with	O
Bordetella	O
pertussis	B-PATH
infection	O
.	O

ABSTRACT	O
:	O
Infection	O
with	O
Bordetella	O
pertussis	B-PATH
can	O
cause	O
severe	O
illness	O
with	O
neurological	O
and	O
pulmonary	O
complications	O
in	O
children	O
.	O

We	O
report	O
a	O
4	O
1	O
/	O
2	O
-	O
year	O
-	O
old	O
boy	O
with	O
B	O
.	O
pertussis	B-PATH
infection	O
who	O
developed	O
severe	O
ARDS	O
and	O
pulmonary	O
hypertension	O
.	O

Most	O
patients	O
with	O
asthma	B-PATH
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
have	O
dynamic	O
hyperinflation	O
and	O
auto	O
-	O
PEEP	O
during	O
mechanical	O
ventilation	O
,	O
which	O
can	O
cause	O
hemodynamic	O
compromise	O
and	O
barotrauma	O
.	O

Although	O
less	O
sensitive	O
than	O
culture	O
-	O
based	O
methods	O
,	O
several	O
commercial	O
molecular	O
diagnostic	O
assays	O
have	O
been	O
developed	O
for	O
tuberculosis	B-PATH
and	O
are	O
useful	O
rapid	O
tests	O
for	O
selected	O
patients	O
.	O

PCR	O
can	O
now	O
be	O
considered	O
the	O
rapid	O
diagnostic	O
test	O
of	O
choice	O
for	O
pertussis	B-PATH
and	O
some	O
respiratory	O
virus	O
infections	O
.	O

They	O
were	O
tested	O
regularly	O
for	O
serum	O
levels	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	O
and	O
lung	O
function	O
and	O
were	O
given	O
chest	O
X	O
-	O
rays	O
and	O
/	O
or	O
high	O
resolution	O
computerized	O
tomography	O
(	O
HRCT	O
)	O
examinations	O
at	O
the	O
Chinese	O
PLA	O
General	O
Hospital	O
during	O
the	O
12	O
months	O
that	O
followed	O
their	O
release	B-PATH
from	O
the	O
hospital	O
.	O

A	O
total	O
of	O
118	O
nasopharyngeal	O
swab	O
samples	O
from	O
118	O
hospitalized	O
young	O
children	O
aged	O
less	O
than	O
2	O
years	O
with	O
bronchiolitis	O
who	O
were	O
not	O
infected	O
with	O
human	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
or	O
B	O
,	O
or	O
human	O
metaneumovirus	O
were	O
selected	O
.	O

Induction	O
of	O
IP	O
-	O
10	O
is	O
a	O
critical	O
event	O
in	O
the	O
initiation	O
of	O
immune	O
-	O
mediated	O
acute	O
lung	O
injury	O
and	O
lymphocyte	O
apoptosis	B-PATH
during	O
the	O
development	O
of	O
SARS	O
.	O

In	O
addition	O
,	O
by	O
increasing	O
end	O
-	O
expiratory	O
lung	O
volume	O
,	O
as	O
will	O
occur	O
when	O
airway	O
pressure	O
release	B-PATH
ventilation	O
is	O
used	O
,	O
recruitment	O
of	O
collapsed	O
or	O
consolidated	O
lung	O
is	O
likely	O
to	O
occur	O
,	O
especially	O
in	O
juxtadiaphragmatic	O
lung	O
regions	O
.	O

General	O
strategies	O
for	O
the	O
prevention	O
of	O
influenza	B-PATH
infection	I-PATH
are	O
expanded	O
to	O
include	O
many	O
infants	O
and	O
young	O
children	O
,	O
and	O
are	O
projected	O
to	O
significantly	O
reduce	O
morbidity	O
and	O
mortality	O
from	O
this	O
key	O
LRI	O
pathogen	O
.	O

Conditions	O
such	O
as	O
HIV	B-PATH
infection	I-PATH
or	O
treatment	O
with	O
immunosuppressors	O
(	O
in	O
cancer	O
or	O
autoimmune	O
diseases	O
)	O
are	O
not	O
among	O
the	O
bad	O
prognosis	O
factors	O
for	O
development	O
of	O
distress	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
pregnant	O
woman	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
,	O
complicated	O
by	O
severe	O
pre	O
-	O
eclampsia	O
(	O
the	O
HELLP	O
syndrome	O
)	O
and	O
adult	O
respiratory	O
distress	O
syndrome	O
,	O
who	O
died	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

A	O
33	O
-	O
year	O
-	O
old	O
multigravid	O
woman	O
was	O
referred	O
to	O
our	O
university	O
hospital	O
at	O
17	O
weeks	O
'	O
gestation	O
because	O
of	O
an	O
exacerbation	O
of	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
with	O
elevated	O
liver	O
enzymes	O
and	O
thrombocytopenia	O
.	O

The	O
initial	O
laboratory	O
tests	O
and	O
immunological	O
evaluation	O
confirmed	O
active	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
complicated	O
by	O
severe	O
pre	O
-	O
eclampsia	O
.	O

In	O
Japan	O
,	O
glycyrrhizin	O
(	O
GL	O
),	O
a	O
compound	O
isolated	O
from	O
licorice	O
,	O
is	O
daily	O
and	O
slowly	O
infused	O
intravenously	O
into	O
chronic	O
hepatitis	B-PATH
C	I-PATH
patients	O
.	O

This	O
theoretical	O
model	O
was	O
released	O
at	O
the	O
Protein	O
Data	O
Bank	O
(	O
PDB	O
;	O
code	O
:	O
1P76	O
)	O
before	O
the	O
release	B-PATH
of	O
the	O
first	O
X	O
-	O
ray	O
structure	O
of	O
CCP	O
(	O
PDB	O
code	O
:	O
1Q2W	O
).	O

ABSTRACT	O
:	O
Before	O
the	O
advent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
use	O
of	O
the	O
powered	O
air	O
-	O
purifying	O
respirator	O
(	O
PAPR	O
)	O
in	O
the	O
setting	O
of	O
pulmonary	O
tuberculosis	B-PATH
has	O
been	O
controversial	O
.	O

However	O
,	O
opinions	O
were	O
equally	O
divided	O
regarding	O
its	O
use	O
when	O
treating	O
patients	O
with	O
pulmonary	O
tuberculosis	B-PATH
;	O
with	O
51	O
%	O
being	O
in	O
favour	O
.	O

TITLE	O
:	O
A	O
child	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
infection	O
.	O

We	O
present	O
a	O
patient	O
in	O
Thailand	O
who	O
was	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
.	O

On	O
the	O
basis	O
of	O
available	O
data	O
,	O
any	O
child	O
with	O
suspected	O
avian	O
influenza	B-PATH
infection	I-PATH
should	O
be	O
treated	O
with	O
oseltamivir	O
.	O

TITLE	O
:	O
Plasmodium	O
vivax	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
We	O
report	O
11	O
cases	O
of	O
severe	O
Plasmodium	O
vivax	O
malaria	B-PATH
in	O
Bikaner	O
(	O
western	O
India	O
).	O

These	O
modifications	O
facilitate	O
(	O
i	O
)	O
the	O
mutagenesis	O
of	O
cloned	O
cDNA	O
by	O
using	O
vaccinia	O
virus	O
-	O
mediated	O
homologous	B-PATH
recombination	I-PATH
and	O
(	O
ii	O
)	O
the	O
rescue	O
of	O
recombinant	O
coronaviruses	O
by	O
using	O
a	O
stable	O
nucleocapsid	O
protein	O
-	O
expressing	O
cell	O
line	O
for	O
the	O
electroporation	O
of	O
infectious	O
full	O
-	O
length	O
genomes	O
.	O

The	O
diagnosis	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
was	O
established	O
by	O
isolation	O
of	O
the	O
virus	O
from	O
cerebrospinal	O
fluid	O
,	O
fecal	O
,	O
throat	O
,	O
and	O
serum	O
specimens	O
.	O

The	O
following	O
article	O
reports	O
how	O
a	O
young	O
girl	O
suffering	O
from	O
pulmonary	O
tuberculosis	B-PATH
was	O
erroneously	O
diagnosed	O
as	O
SARS	O
in	O
an	O
outbreak	O
.	O

The	O
treatment	O
of	O
SARS	O
and	O
tuberculosis	B-PATH
resulted	O
in	O
liver	O
dysfunction	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
several	O
previously	O
unrecognized	O
respiratory	O
viral	O
pathogens	O
have	O
been	O
identified	O
and	O
several	O
influenza	B-PATH
A	I-PATH
virus	O
subtypes	O
,	O
previously	O
known	O
to	O
infect	O
poultry	O
and	O
wild	O
birds	O
,	O
were	O
transmitted	O
to	O
humans	O
.	O

The	O
responses	O
against	O
bioterrorism	O
involving	O
anthrax	O
and	O
smallpox	O
after	O
the	O
terrorist	O
attacks	O
on	O
September	O
11	O
,	O
2001	O
,	O
in	O
the	O
United	O
States	O
of	O
America	O
(	O
a	O
notice	O
on	O
October	O
11	O
,	O
2001	O
by	O
the	O
Tuberculosis	B-PATH
and	O
Infectious	O
Diseases	O
Control	O
Division	O
,	O
MHLW	O
)	O
and	O
the	O
response	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
an	O
emerging	O
infectious	O
disease	O
upon	O
which	O
a	O
Global	O
Alert	O
was	O
issued	O
on	O
March	O
12	O
,	O
2003	O
,	O
by	O
WHO	O
,	O
were	O
discussed	O
.	O

When	O
encapsulated	O
in	O
liposomes	O
,	O
poly	O
ICLC	O
offers	O
complete	O
protection	O
(	O
100	O
%	O
survival	O
rate	O
in	O
pretreated	O
group	O
versus	O
0	O
%	O
survival	O
in	O
control	O
group	O
)	O
against	O
a	O
lethal	O
respiratory	O
challenge	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
mice	O
.	O

Other	O
genes	O
displaying	O
altered	O
transcription	O
included	O
those	O
associated	O
with	O
host	O
translation	O
,	O
cellular	O
metabolism	O
,	O
cell	B-PATH
cycle	I-PATH
,	O
signal	O
transduction	O
,	O
transcriptional	O
regulation	O
,	O
protein	O
trafficking	O
,	O
protein	O
modulators	O
,	O
and	O
cytoskeletal	O
proteins	O
.	O

In	O
addition	O
,	O
transcription	O
of	O
apoptosis	B-PATH
-	O
related	O
genes	O
DENN	O
and	O
hIAP1	O
was	O
upregulated	O
in	O
contrast	O
to	O
FAIM	O
.	O

We	O
observed	O
the	O
interplay	O
between	O
various	O
mechanisms	O
to	O
favor	O
virus	O
multiplication	O
before	O
full	O
-	O
blown	O
apoptosis	B-PATH
and	O
the	O
triggering	O
of	O
several	O
pathways	O
in	O
host	O
cells	O
in	O
an	O
attempt	O
to	O
eliminate	O
the	O
pathogen	O
.	O

Several	O
scenarios	O
can	O
be	O
proposed	O
:	O
1	O
)	O
the	O
appearance	O
of	O
a	O
new	O
infection	O
(	O
AIDS	O
or	O
SARS	O
);	O
2	O
)	O
the	O
appearance	O
of	O
a	O
known	O
infection	O
where	O
it	O
did	O
not	O
exist	O
previously	O
(	O
West	O
Nile	O
virus	O
infection	O
in	O
the	O
USA	O
);	O
3	O
)	O
an	O
infection	O
that	O
existed	O
but	O
that	O
was	O
not	O
diagnosed	O
or	O
could	O
not	O
be	O
linked	O
precisely	O
to	O
a	O
particular	O
infectious	O
agent	O
(	O
hepatitis	B-PATH
C	I-PATH
before	O
the	O
discovery	O
of	O
the	O
hepatitis	B-PATH
C	I-PATH
virus	O
;	O
4	O
)	O
a	O
known	O
infection	O
that	O
increases	O
its	O
usual	O
incidence	O
(	O
outbreaks	O
...);	O
5	O
)	O
infectious	O
diseases	O
for	O
which	O
current	O
conditions	O
may	O
facilitate	O
transmission	O
(	O
decrease	O
of	O
immunization	O
coverage	O
...).	O

The	O
deliberate	O
release	B-PATH
of	O
a	O
biological	O
agent	O
is	O
one	O
of	O
the	O
possible	O
scenarios	O
of	O
emergence	O
.	O

The	O
mechanism	O
for	O
viral	O
persistence	O
is	O
consistent	O
with	O
the	O
formation	O
of	O
a	O
carrier	O
culture	O
whereby	O
a	O
limited	O
number	O
of	O
cells	O
are	O
infected	O
with	O
each	O
round	O
of	O
virus	O
replication	O
and	O
release	B-PATH
.	O

Control	O
of	O
infectious	O
diseases	O
is	O
being	O
challenged	O
by	O
many	O
factors	O
,	O
like	O
standards	O
of	O
living	O
,	O
human	O
behaviour	O
,	O
mass	O
population	O
movements	O
,	O
emergence	O
of	O
infectious	O
like	O
HIV	O
/	O
AIDS	O
and	O
SARS	O
,	O
the	O
re	O
-	O
emergence	O
of	O
infections	O
such	O
as	O
tuberculosis	B-PATH
,	O
development	O
of	O
resistance	O
in	O
bacteria	O
,	O
viruses	O
and	O
parasites	O
,	O
modern	O
rate	O
of	O
global	O
travel	O
,	O
etc	O
.	O

Childhood	O
asthma	B-PATH
was	O
observed	O
in	O
40	O
,	O
4	O
%	O
of	O
children	O
without	O
any	O
associated	O
factor	O
wether	O
at	O
birth	O
or	O
in	O
PICU	O
related	O
to	O
such	O
outcome	O
.	O

Childhood	O
asthma	B-PATH
was	O
observed	O
in	O
40	O
,	O
4	O
%	O
of	O
children	O
without	O
any	O
associated	O
factor	O
wether	O
at	O
birth	O
or	O
in	O
PICU	O
related	O
to	O
such	O
outcome	O
.	O

TITLE	O
:	O
Annulling	O
a	O
dangerous	O
liaison	O
:	O
vaccination	O
strategies	O
against	O
AIDS	O
and	O
tuberculosis	B-PATH
.	O

Last	O
year	O
,	O
600	O
,	O
000	O
individuals	O
,	O
doubly	O
infected	O
with	O
HIV	O
and	O
M	O
.	O
tuberculosis	B-PATH
,	O
died	O
.	O

Last	O
year	O
,	O
5	O
million	O
and	O
50	O
million	O
were	O
newly	O
infected	O
with	O
HIV	O
or	O
M	O
.	O
tuberculosis	B-PATH
,	O
respectively	O
,	O
with	O
2	O
million	O
new	O
double	O
infections	O
.	O

Examples	O
are	O
emerging	O
infections	O
such	O
as	O
HIV	O
/	O
AIDS	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
deliberate	O
release	B-PATH
of	O
microorganisms	O
,	O
such	O
as	O
the	O
anthrax	O
episode	O
in	O
the	O
USA	O
,	O
the	O
increasing	O
problems	O
with	O
organisms	O
resistant	O
to	O
antimicrobial	O
treatment	O
,	O
such	O
as	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
,	O
and	O
the	O
threat	O
of	O
a	O
new	O
influenza	O
pandemic	O
with	O
a	O
case	O
fatality	O
rate	O
similar	O
to	O
that	O
in	O
the	O
1918	O
outbreak	O
.	O

They	O
are	O
subject	O
to	O
many	O
infectious	O
diseases	O
no	O
longer	O
seen	O
commonly	O
in	O
the	O
United	O
States	O
such	O
as	O
malaria	B-PATH
,	O
tuberculosis	B-PATH
,	O
and	O
HIV	O
.	O

This	O
overview	O
highlights	O
selected	O
NIAID	O
-	O
sponsored	O
research	O
advances	O
over	O
the	O
past	O
decade	O
,	O
with	O
a	O
focus	O
on	O
progress	O
in	O
combating	O
HIV	O
/	O
AIDS	O
,	O
malaria	B-PATH
,	O
tuberculosis	B-PATH
,	O
influenza	O
,	O
SARS	O
,	O
West	O
Nile	O
virus	O
,	O
and	O
potential	O
bioterror	O
agents	O
.	O

TITLE	O
:	O
Differential	O
maturation	O
and	O
subcellular	O
localization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
surface	O
proteins	O
S	O
,	O
M	O
and	O
E	O
.	O
ABSTRACT	O
:	O
Post	O
-	O
translational	O
modifications	O
and	O
correct	O
subcellular	O
localization	O
of	O
viral	O
structural	O
proteins	O
are	O
prerequisites	O
for	O
assembly	O
and	O
budding	B-PATH
of	O
enveloped	O
viruses	O
.	O

TITLE	O
:	O
Expression	O
,	O
purification	O
,	O
and	O
characterization	O
of	O
SARS	O
coronavirus	O
RNA	B-PATH
polymerase	I-PATH
.	O

ABSTRACT	O
:	O
The	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
essential	O
for	O
viral	O
replication	O
and	O
a	O
potential	O
target	O
for	O
anti	O
-	O
SARS	O
drugs	O
.	O

ABSTRACT	O
:	O
After	O
decades	O
of	O
neglect	O
,	O
the	O
resurgence	O
of	O
tuberculosis	B-PATH
in	O
the	O
United	O
States	O
between	O
1985	O
and	O
1992	O
renewed	O
interest	O
in	O
the	O
use	O
of	O
upper	O
room	O
ultraviolet	O
germicidal	O
irradiation	O
to	O
interrupt	O
the	O
transmission	O
of	O
airborne	O
infections	O
.	O

No	O
induction	O
of	O
apoptosis	B-PATH
or	O
maturation	O
was	O
detected	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
DCs	O
.	O

Electron	O
microscopy	O
of	O
purified	O
influenza	B-PATH
A	I-PATH
virus	O
showed	O
extensive	O
clumping	O
and	O
morphological	O
changes	O
in	O
spike	O
configuration	O
after	O
contact	O
with	O
the	O
virucidal	O
mixture	O
,	O
but	O
no	O
overt	O
destruction	O
of	O
the	O
viral	O
membrane	O
.	O

Mp	O
-	O
and	O
Dp	O
-	O
MART	O
(	O
anti	O
-	O
melanoma	B-PATH
lipopeptides	O
)	O
induce	O
strong	O
CTL	O
(	O
cytolytic	O
T	O
lymphocyte	O
)	O
response	O
.	O

As	O
suggested	O
by	O
in	O
silico	O
docking	O
of	O
these	O
molecules	O
to	O
a	O
theoretical	O
model	O
of	O
a	O
subunit	O
of	O
type	O
A	O
influenza	O
virus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
there	O
also	O
exists	O
a	O
remote	O
possibility	O
that	O
these	O
PIs	O
may	O
have	O
an	O
effect	O
on	O
avian	O
influenza	O
viruses	O
.	O

On	O
the	O
other	O
hand	O
,	O
there	O
was	O
no	O
appreciable	O
activity	O
against	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
poliovirus	O
or	O
SARS	O
corona	O
virus	O
when	O
tested	O
at	O
concentrations	O
ranging	O
from	O
3	O
.	O
2	O
-	O
400	O
microg	O
/	O
ml	O
as	O
shown	O
by	O
microscopic	O
image	O
analysis	O
for	O
cytopathic	O
effect	O
(	O
CPE	O
).	O

TITLE	O
:	O
[	O
Tuberculosis	B-PATH
as	O
an	O
occupational	O
disease	O
].	O

Those	O
most	O
frequently	O
reported	O
are	O
acquired	O
by	O
the	O
haematogenous	O
path	O
,	O
especially	O
hepatitis	O
due	O
to	O
virus	O
B	O
.	O
Numerous	O
infectious	O
diseases	O
are	O
transmitted	O
through	O
airways	O
and	O
until	O
the	O
coming	O
of	O
acute	O
severe	O
respiratory	O
syndrome	O
caused	O
by	O
a	O
coronavirus	O
,	O
tuberculosis	B-PATH
was	O
one	O
of	O
the	O
most	O
dreaded	O
.	O

In	O
this	O
paper	O
we	O
analyse	O
the	O
reasons	O
why	O
tuberculosis	B-PATH
is	O
considered	O
to	O
be	O
an	O
occupational	O
disease	O
in	O
health	O
personnel	O
;	O
which	O
activities	O
entail	O
most	O
risk	O
and	O
the	O
measures	O
that	O
should	O
be	O
adopted	O
to	O
reduce	O
nosocomial	O
transmission	O
.	O

Previous	O
studies	O
also	O
showed	O
that	O
the	O
activation	O
of	O
p38	O
MAPK	O
by	O
viral	O
infection	O
-	O
induced	O
apoptosis	B-PATH
,	O
and	O
a	O
weak	O
activation	O
of	O
Akt	O
was	O
not	O
sufficient	O
to	O
protect	O
from	O
apoptosis	B-PATH
.	O

Furthermore	O
,	O
immature	O
but	O
not	O
mature	O
recombinant	O
Hsp60	O
induced	O
in	O
vitro	O
the	O
release	B-PATH
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
from	O
RAW	O
264	O
.	O
7	O
murine	O
macrophages	O
.	O

Immature	O
but	O
mature	O
Hsp60	O
causes	O
in	O
vitro	O
the	O
release	B-PATH
of	O
NO	O
by	O
macrophages	O
,	O
suggesting	O
that	O
the	O
extracellular	O
release	B-PATH
of	O
the	O
immature	O
Hsp60	O
associated	O
with	O
traumatic	O
cell	O
necrosis	O
could	O
be	O
involved	O
in	O
the	O
release	B-PATH
of	O
NO	O
by	O
immune	O
competent	O
cells	O
,	O
leading	O
to	O
an	O
activation	O
of	O
the	O
inflammatory	O
response	O
within	O
the	O
lung	O
or	O
other	O
organs	O
.	O

The	O
gene	O
expression	O
profiles	O
of	O
macrophages	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
human	O
coronavirus	O
229E	O
,	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
were	O
compared	O
by	O
using	O
microarrays	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	O
PCR	O
.	O

The	O
cytokine	O
release	B-PATH
of	O
cultured	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
peritoneal	O
macrophages	O
,	O
splenocytes	O
,	O
and	O
splenic	O
macrophages	O
and	O
plasma	O
levels	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
from	O
those	O
animals	O
were	O
quantified	O
.	O

TITLE	O
:	O
The	O
3a	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
induces	O
apoptosis	B-PATH
in	O
Vero	O
E6	O
cells	O
.	O

These	O
data	O
showed	O
that	O
overexpression	O
of	O
a	O
single	O
SARS	O
-	O
CoV	O
protein	O
can	O
induce	O
apoptosis	B-PATH
in	O
vitro	O
.	O

Three	O
of	O
SARS	O
genes	O
,	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
spike	O
and	O
nucleocapsid	O
,	O
were	O
amplified	O
with	O
T7	O
promoter	O
-	O
flanked	O
primers	O
.	O

Here	O
,	O
to	O
extend	O
our	O
experimental	O
observation	O
,	O
we	O
have	O
incorporated	O
protein	O
structural	O
studies	O
(	O
with	O
positive	O
/	O
negative	O
controls	O
)	O
to	O
investigate	O
the	O
potential	O
binding	O
modes	O
/	O
sites	O
of	O
ATA	O
onto	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
from	O
SARS	O
-	O
CoV	O
and	O
other	O
pathogenic	O
positive	O
-	O
strand	O
RNA	O
-	O
viruses	O
,	O
as	O
well	O
as	O
other	O
proteins	O
in	O
SARS	O
-	O
CoV	O
based	O
on	O
the	O
fact	O
that	O
ATA	O
binds	O
to	O
Ca2	O
+-	O
activated	O
neutral	O
protease	O
(	O
m	O
-	O
calpain	O
),	O
the	O
protein	O
tyrosine	O
phosphatase	O
(	O
PTP	O
)	O
and	O
HIV	O
integrase	O
which	O
have	O
existing	O
crystal	O
structures	O
.	O

TITLE	O
:	O
Pulmonary	O
manifestations	O
of	O
multicentric	O
Castleman	O
'	O
s	O
disease	O
in	O
HIV	B-PATH
infection	I-PATH
:	O
a	O
clinical	O
,	O
biological	O
and	O
radiological	O
study	O
.	O

In	O
the	O
50	O
patients	O
with	O
RTI	O
,	O
a	O
microbial	O
etiology	O
was	O
identified	O
in	O
33	O
of	O
50	O
(	O
66	O
%)	O
and	O
included	O
rhinovirus	O
(	O
9	O
),	O
coronavirus	O
(	O
8	O
),	O
RSV	O
(	O
6	O
),	O
influenza	B-PATH
A	I-PATH
(	O
5	O
),	O
parainfluenza	O
(	O
4	O
)	O
and	O
human	O
metapneumovirus	O
(	O
1	O
).	O

Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
and	O
ACE2	O
are	O
homologues	O
with	O
different	O
key	O
functions	O
in	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
.	O

Tuberculosis	B-PATH
(	O
TB	O
)	O
commonly	O
causes	O
respiratory	O
failure	O
in	O
patients	O
with	O
extensive	O
pulmonary	O
parenchymal	O
involvement	O
,	O
but	O
it	O
is	O
a	O
rare	O
cause	O
of	O
ARDS	O
.	O

RESULTS	O
:	O
Nine	O
(	O
4	O
.	O
9	O
%)	O
of	O
187	O
patients	O
had	O
ARDS	O
secondary	O
to	O
tuberculosis	B-PATH
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbroke	O
in	O
2003	O
,	O
and	O
the	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
also	O
outbroke	O
in	O
2003	O
and	O
continued	O
to	O
2004	O
.	O

Human	O
influenza	B-PATH
A	I-PATH
consists	O
of	O
many	O
sub	O
-	O
types	O
of	O
coronaviruses	O
including	O
the	O
SARS	O
virus	O
and	O
the	O
avian	O
influenza	O
(	O
H5N1	O
)	O
that	O
are	O
all	O
variants	O
of	O
RNA	O
of	O
avian	O
coronavirus	O
.	O

TITLE	O
:	O
Congenital	O
neutropenia	O
and	O
primary	B-PATH
immunodeficiency	I-PATH
disorders	O
:	O
a	O
survey	O
of	O
26	O
Iranian	O
patients	O
.	O

Primary	B-PATH
immunodeficiency	I-PATH
disorders	O
of	O
these	O
patients	O
were	O
as	O
follows	O
:	O
cyclic	O
neutropenia	O
(	O
8	O
patients	O
),	O
Shwachman	O
-	O
Diamond	O
syndrome	O
(	O
7	O
patients	O
),	O
Kostmann	O
syndrome	O
(	O
6	O
patients	O
),	O
and	O
Chediak	O
-	O
Higashi	O
syndrome	O
(	O
5	O
patients	O
).	O

In	O
donors	O
,	O
the	O
presence	O
of	O
infectious	O
micro	O
-	O
organisms	O
,	O
like	O
human	O
immunodeficiency	O
virus	O
,	O
hepatitis	O
B	O
virus	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
and	O
human	O
T	O
cell	O
lymphotrophic	O
virus	O
,	O
should	O
be	O
evaluated	O
in	O
addition	O
to	O
the	O
possibility	O
of	O
other	O
new	O
infectious	O
agents	O
(	O
e	O
.	O
g	O
.	O
transmissible	O
spongiform	O
encephalopathies	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
).	O

TITLE	O
:	O
Apical	O
entry	O
and	O
release	B-PATH
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
in	O
polarized	O
Calu	O
-	O
3	O
lung	O
epithelial	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
MHV	O
release	B-PATH
does	O
not	O
involve	O
lipid	O
rafts	O
.	O

Although	O
the	O
development	O
of	O
autoimmune	O
antibodies	O
or	O
immune	O
complexes	O
triggered	O
by	O
viral	O
infection	O
may	O
play	O
a	O
significant	O
role	O
in	O
inducing	O
thrombocytopenia	O
,	O
SARS	O
-	O
CoV	O
may	O
also	O
directly	O
infect	O
hematopoietic	O
stem	O
/	O
progenitor	O
cells	O
,	O
megakaryocytes	O
and	O
platelets	O
inducing	O
their	O
growth	O
inhibition	O
and	O
apoptosis	B-PATH
.	O

To	O
evaluate	O
this	O
quantitative	O
RT	O
-	O
PCR	O
,	O
cRNA	O
standards	O
were	O
constructed	O
by	O
in	O
vitro	O
transcription	O
of	O
SARS	O
-	O
CoV	O
Frankfurt	O
1	O
RNA	O
using	O
T7	O
RNA	B-PATH
polymerase	I-PATH
,	O
followed	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

SARS	O
-	O
CoV	O
(	O
SARS	O
coronavirus	O
),	O
a	O
novel	O
coronavirus	O
that	O
has	O
been	O
etiologically	O
associated	O
with	O
SARS	O
cases	O
,	O
is	O
homologous	O
with	O
MHV	O
(	O
murine	O
hepatitis	O
coronavirus	O
),	O
and	O
MHV	O
small	O
envelope	O
E	O
protein	O
is	O
capable	O
of	O
inducing	O
apoptosis	B-PATH
.	O

Our	O
results	O
showed	O
that	O
SARS	O
-	O
CoV	O
E	O
protein	O
induced	O
apoptosis	B-PATH
in	O
the	O
transfected	O
Jurkat	O
T	O
-	O
cells	O
,	O
which	O
was	O
amplified	O
to	O
higher	O
apoptosis	B-PATH
rates	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
.	O

However	O
,	O
apoptosis	B-PATH
was	O
inhibited	O
by	O
overexpressed	O
antiapoptotic	O
protein	O
Bcl	O
-	O
xL	O
.	O
Moreover	O
,	O
we	O
found	O
that	O
SARS	O
-	O
CoV	O
E	O
protein	O
interacted	O
with	O
Bcl	O
-	O
xL	O
in	O
vitro	O
and	O
endogenous	O
Bcl	O
-	O
xL	O
in	O
vivo	O
and	O
that	O
Bcl	O
-	O
xL	O
interaction	O
with	O
SARS	O
-	O
CoV	O
E	O
protein	O
was	O
mediated	O
by	O
BH3	O
(	O
Bcl	O
-	O
2	O
homology	O
domain	O
3	O
)	O
of	O
Bcl	O
-	O
xL	O
.	O
Finally	O
,	O
we	O
identified	O
a	O
novel	O
BH3	O
-	O
like	O
region	O
located	O
in	O
the	O
C	O
-	O
terminal	O
cytosolic	O
domain	O
of	O
SARS	O
-	O
CoV	O
E	O
protein	O
,	O
which	O
mediates	O
its	O
binding	O
to	O
Bcl	O
-	O
xL	O
.	O
These	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
novel	O
molecular	O
mechanism	O
of	O
T	O
-	O
cell	O
apoptosis	B-PATH
that	O
contributes	O
to	O
the	O
SARS	O
-	O
CoV	O
-	O
induced	O
lymphopenia	O
observed	O
in	O
most	O
SARS	O
patients	O
.	O

Here	O
,	O
we	O
show	O
that	O
LSECtin	O
enhances	O
infection	O
driven	O
by	O
filovirus	O
glycoproteins	O
(	O
GP	O
)	O
and	O
the	O
S	O
protein	O
of	O
SARS	O
coronavirus	O
,	O
but	O
does	O
not	O
interact	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
envelope	O
proteins	O
.	O

To	O
this	O
end	O
,	O
ACE2	O
may	O
counterbalance	O
the	O
effects	O
of	O
ACE	O
within	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
).	O

ABSTRACT	O
:	O
The	O
threat	O
posed	O
by	O
emerging	O
and	O
re	O
-	O
emerging	O
communicable	O
diseases	O
and	O
,	O
more	O
recently	O
,	O
by	O
the	O
intentional	O
release	B-PATH
of	O
infectious	O
agents	O
in	O
a	O
susceptible	O
population	O
,	O
has	O
been	O
receiving	O
considerable	O
attention	O
at	O
the	O
national	O
and	O
international	O
levels	O
.	O

RESULTS	O
:	O
SARS	O
-	O
CoV	O
virus	O
is	O
able	O
to	O
induce	O
both	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
mRNA	O
accumulation	O
and	O
protein	O
release	B-PATH
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
MOI	O
10	O
being	O
the	O
most	O
effective	O
.	O

There	O
may	O
also	O
be	O
immune	O
-	O
mediated	O
lymphocyte	O
destruction	O
,	O
bone	O
marrow	O
or	O
thymus	O
suppression	O
,	O
or	O
apoptosis	B-PATH
.	O

It	O
is	O
believed	O
that	O
the	O
modulation	O
of	O
apoptosis	B-PATH
is	O
relevant	O
to	O
diseases	O
that	O
are	O
caused	O
by	O
various	O
viruses	O
.	O

To	O
examine	O
potential	O
apoptotic	O
mechanisms	O
related	O
to	O
SARS	O
,	O
we	O
investigated	O
features	O
of	O
apoptosis	B-PATH
induced	O
by	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
host	O
cells	O
.	O

The	O
results	O
indicated	O
that	O
the	O
SARS	O
-	O
CoV	O
-	O
induced	O
apoptosis	B-PATH
in	O
Vero	O
cells	O
in	O
a	O
virus	O
replication	O
-	O
dependent	O
manner	O
.	O

14	O
-	O
3	O
-	O
3	O
proteins	O
are	O
a	O
family	O
of	O
highly	O
conserved	O
,	O
ubiquitously	O
expressed	O
eukaryotic	O
proteins	O
that	O
function	O
primarily	O
as	O
adapters	O
that	O
modulate	O
interactions	O
between	O
components	O
of	O
various	O
cellular	O
signaling	O
and	O
cell	B-PATH
cycle	I-PATH
regulatory	O
pathways	O
through	O
phosphorylation	O
-	O
dependent	O
protein	O
-	O
protein	O
interactions	O
.	O

TITLE	O
:	O
G0	O
/	O
G1	O
arrest	O
and	O
apoptosis	B-PATH
induced	O
by	O
SARS	O
-	O
CoV	O
3b	O
protein	O
in	O
transfected	O
cells	O
.	O

Through	O
cell	B-PATH
cycle	I-PATH
analysis	O
,	O
it	O
was	O
found	O
that	O
over	O
-	O
expression	O
of	O
3b	O
-	O
EGFP	O
protein	O
in	O
Vero	O
,	O
293	O
and	O
COS	O
-	O
7	O
cells	O
could	O
induce	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
G0	O
/	O
G1	O
phase	O
,	O
and	O
that	O
especially	O
in	O
COS	O
-	O
7	O
cells	O
,	O
expression	O
of	O
3b	O
-	O
EGFP	O
was	O
able	O
to	O
induce	O
the	O
increase	O
of	O
sub	O
-	O
G1	O
phase	O
from	O
24	O
h	O
after	O
transfection	O
,	O
which	O
was	O
most	O
obvious	O
at	O
48	O
h	O
.	O
The	O
apoptosis	B-PATH
induction	O
of	O
3b	O
fusion	O
protein	O
in	O
COS	O
-	O
7	O
cells	O
was	O
further	O
confirmed	O
by	O
double	O
cell	O
labeling	O
with	O
7	O
-	O
AAD	O
and	O
Annexin	O
V	O
,	O
the	O
function	O
of	O
3b	O
protein	O
inducing	O
cell	O
G0	O
/	O
G1	O
arrest	O
and	O
apoptosis	B-PATH
may	O
provide	O
a	O
new	O
insight	O
for	O
further	O
study	O
on	O
the	O
mechanism	O
of	O
SARS	O
pathogenesis	O
.	O

Samples	O
taken	O
at	O
the	O
time	O
of	O
admission	O
proved	O
to	O
be	O
strongly	O
positive	O
for	O
Adenovirus	O
by	O
PCR	O
,	O
but	O
negative	O
for	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
virus	O
,	O
Influenza	B-PATH
A	I-PATH
/	O
H3N2	O
virus	O
,	O
Influenza	O
B	O
virus	O
,	O
Respiratory	O
syncytial	O
virus	O
,	O
and	O
SARS	O
coronavirus	O
.	O

However	O
,	O
the	O
replication	O
of	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
was	O
more	O
rapid	O
and	O
intense	O
on	O
MDCK	O
cells	O
than	O
on	O
HuH7	O
cells	O
.	O

Compared	O
to	O
the	O
healthy	O
control	O
or	O
the	O
convalescent	O
case	O
,	O
plenty	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
IL	O
-	O
1	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
8	O
,	O
and	O
MAPK	B-PATH
signaling	I-PATH
pathway	I-PATH
were	O
significantly	O
upregulated	O
in	O
the	O
acute	O
severe	O
case	O
.	O

The	O
others	O
are	O
used	O
in	O
the	O
treatment	O
of	O
herpesvirus	O
(	O
e	O
.	O
g	O
.	O
herpes	O
simplex	O
virus	O
,	O
varicella	O
zoster	O
virus	O
and	O
cytomegalo	O
virus	O
),	O
hepatitis	O
B	O
virus	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
or	O
influenza	O
virus	O
infections	O
.	O

As	O
we	O
assessed	O
or	O
re	O
-	O
assessed	O
some	O
effects	O
of	O
IFN	O
-	O
gamma	O
on	O
a	O
number	O
of	O
human	O
lung	O
epithelial	O
and	O
fibroblast	O
cell	O
lines	O
,	O
chosen	O
for	O
their	O
wide	O
use	O
in	O
the	O
literature	O
,	O
we	O
found	O
that	O
alveolar	O
epithelial	O
cells	O
were	O
more	O
sensitive	O
to	O
IFN	O
-	O
gamma	O
,	O
in	O
terms	O
of	O
proliferation	O
inhibition	O
and	O
enhancement	O
of	O
Fas	O
-	O
mediated	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Bcl	O
-	O
2	O
inhibits	O
the	O
caspase	O
-	O
dependent	O
apoptosis	B-PATH
induced	O
by	O
SARS	O
-	O
CoV	O
without	O
affecting	O
virus	O
replication	O
kinetics	O
.	O

Apoptosis	B-PATH
appeared	O
after	O
the	O
onset	O
of	O
CPE	O
and	O
completion	O
of	O
virus	O
replication	O
,	O
and	O
could	O
be	O
prevented	O
by	O
Bcl	O
-	O
2	O
expression	O
.	O

Apoptosis	B-PATH
is	O
likely	O
mediated	O
by	O
the	O
mitochondrial	O
pathway	O
,	O
as	O
demonstrated	O
by	O
its	O
inhibition	O
using	O
Bcl	O
-	O
2	O
,	O
and	O
by	O
the	O
activation	O
of	O
the	O
caspase	O
cascade	O
,	O
resulting	O
in	O
PARP	O
cleavage	O
.	O

Prevention	O
of	O
apoptosis	B-PATH
did	O
not	O
affect	O
susceptibility	O
to	O
infection	O
,	O
kinetics	O
and	O
extent	O
of	O
viral	O
replication	O
and	O
release	B-PATH
,	O
thus	O
implying	O
that	O
apoptosis	B-PATH
is	O
not	O
involved	O
in	O
facilitating	O
release	B-PATH
and	O
/	O
or	O
dissemination	O
of	O
SARS	O
-	O
CoV	O
in	O
Vero	O
cells	O
.	O

While	O
a	O
general	O
suppression	O
of	O
gene	O
expression	O
predominated	O
in	O
SARS	O
-	O
infected	O
blood	O
,	O
several	O
genes	O
including	O
those	O
involved	O
in	O
innate	O
immunity	O
,	O
such	O
as	O
defensins	B-PATH
and	O
eosinophil	O
-	O
derived	O
neurotoxin	O
,	O
were	O
upregulated	O
.	O

TITLE	O
:	O
Lethal	O
acute	O
respiratory	O
distress	O
syndrome	O
during	O
anti	O
-	O
TNF	O
-	O
alpha	O
therapy	O
for	O
rheumatoid	B-PATH
arthritis	I-PATH
.	O

We	O
report	O
on	O
a	O
patient	O
with	O
rheumatoid	B-PATH
arthritis	I-PATH
treated	O
with	O
etanercept	O
for	O
2	O
years	O
,	O
in	O
addition	O
to	O
methotrexate	O
and	O
prednyliden	O
,	O
who	O
developed	O
fulminant	O
pneumococcal	O
pneumonia	O
with	O
rapid	O
progression	O
to	O
fatal	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
septic	O
shock	O
.	O

ABSTRACT	O
:	O
Anthrax	O
,	O
like	O
tuberculosis	B-PATH
,	O
shows	O
a	O
new	O
epidemic	O
spread	O
in	O
industrialized	O
countries	O
,	O
revealing	O
some	O
ambiguous	O
aspects	O
to	O
the	O
disease	O
and	O
providing	O
new	O
challenges	O
to	O
medicine	O
.	O

We	O
provide	O
genetic	O
evidence	O
to	O
support	O
that	O
3a	O
is	O
functionally	O
related	O
to	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
.	O

We	O
further	O
found	O
that	O
3a	O
misexpression	O
induces	O
apoptosis	B-PATH
,	O
which	O
could	O
be	O
modulated	O
by	O
cellular	O
cytochrome	O
c	O
levels	O
and	O
caspase	O
activity	O
.	O

Coexisting	O
maternal	O
disease	O
,	O
including	O
asthma	B-PATH
and	O
anemia	O
,	O
increase	O
the	O
risk	O
of	O
contracting	O
pneumonia	O
in	O
pregnancy	O
.	O

TITLE	O
:	O
Mechanisms	O
of	O
decreased	O
intestinal	O
epithelial	O
proliferation	O
and	O
increased	O
apoptosis	B-PATH
in	O
murine	O
acute	O
lung	O
injury	O
.	O

Following	O
induction	O
of	O
acute	O
lung	O
injury	O
,	O
gut	O
epithelial	O
proliferation	O
and	O
apoptosis	B-PATH
were	O
assessed	O
in	O
a	O
)	O
C3H	O
/	O
HeN	O
wild	O
-	O
type	O
and	O
C3H	O
/	O
HeJ	O
mice	O
,	O
which	O
lack	O
functional	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
n	O
=	O
17	O
);	O
b	O
)	O
C57Bl	O
/	O
6	O
mice	O
that	O
received	O
monoclonal	O
anti	O
-	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
or	O
control	O
antibody	O
(	O
n	O
=	O
22	O
);	O
and	O
c	O
)	O
C57Bl	O
/	O
6	O
wild	O
-	O
type	O
and	O
transgenic	O
mice	O
that	O
overexpress	O
Bcl	O
-	O
2	O
in	O
their	O
gut	O
epithelium	O
(	O
n	O
=	O
21	O
).	O

Acute	O
lung	O
injury	O
caused	O
decreased	O
proliferation	O
and	O
increased	O
apoptosis	B-PATH
in	O
crypt	O
epithelial	O
cells	O
in	O
all	O
animals	O
studied	O
.	O

C3H	O
/	O
HeJ	O
mice	O
had	O
higher	O
levels	O
of	O
proliferation	O
than	O
C3H	O
/	O
HeN	O
animals	O
without	O
additional	O
changes	O
in	O
apoptosis	B-PATH
.	O

Overexpression	O
of	O
Bcl	O
-	O
2	O
did	O
not	O
change	O
proliferation	O
despite	O
decreasing	O
gut	O
apoptosis	B-PATH
.	O

Proliferation	O
and	O
apoptosis	B-PATH
were	O
not	O
correlated	O
to	O
severity	O
of	O
lung	O
injury	O
,	O
as	O
gut	O
alterations	O
were	O
lost	O
in	O
mice	O
with	O
more	O
severe	O
acute	O
lung	O
injury	O
.	O

Acute	O
lung	O
injury	O
causes	O
disparate	O
effects	O
on	O
crypt	O
proliferation	O
and	O
apoptosis	B-PATH
,	O
which	O
occur	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
differing	O
mechanisms	O
involving	O
Toll	O
-	O
like	O
receptor	O
4	O
and	O
Bcl	O
-	O
2	O
.	O

Severity	O
of	O
lung	O
injury	O
does	O
not	O
correlate	O
with	O
perturbations	O
in	O
proliferation	O
or	O
death	O
in	O
the	O
gut	O
epithelium	O
,	O
and	O
acute	O
lung	O
injury	O
-	O
induced	O
changes	O
in	O
intestinal	O
epithelial	O
proliferation	O
persist	O
longer	O
than	O
those	O
in	O
apoptosis	B-PATH
.	O

The	O
first	O
part	O
of	O
this	O
review	O
focuses	O
on	O
problems	O
not	O
yet	O
solved	O
,	O
such	O
as	O
1	O
)	O
surveillance	O
systems	O
,	O
which	O
should	O
be	O
active	O
and	O
extremely	O
flexible	O
;	O
2	O
)	O
infection	O
outbreaks	O
in	O
hospitals	O
and	O
strategies	O
to	O
avoid	O
them	O
;	O
3	O
)	O
hand	O
washing	O
and	O
alternatives	O
such	O
as	O
rapid	O
hand	O
antisepsis	O
;	O
4	O
)	O
water	O
and	O
food	O
in	O
the	O
hospital	O
as	O
potential	O
reservoirs	O
of	O
nosocomial	O
pathogens	O
;	O
5	O
)	O
upgrading	O
of	O
infection	O
control	O
programs	O
to	O
turn	O
them	O
into	O
systems	O
to	O
improve	O
the	O
quality	O
of	O
care	O
;	O
6	O
)	O
fatal	O
Gram	O
-	O
negative	O
bacteremias	O
in	O
hospitals	O
from	O
developing	O
countries	O
,	O
which	O
can	O
be	O
avoided	O
with	O
better	O
standards	O
of	O
care	O
;	O
7	O
)	O
the	O
elemental	O
role	O
of	O
the	O
microbiology	O
laboratory	O
in	O
the	O
prevention	O
and	O
control	O
of	O
infections	O
;	O
8	O
)	O
the	O
unprecedented	O
crisis	O
due	O
to	O
the	O
emergence	O
of	O
specific	O
multi	O
-	O
resistant	O
pathogens	O
;	O
9	O
)	O
the	O
risks	O
for	O
healthcare	O
workers	O
,	O
such	O
as	O
tuberculosis	B-PATH
,	O
hepatitis	O
,	O
HIV	O
,	O
SARS	O
,	O
and	O
hemorrhagic	O
fevers	O
;	O
and	O
10	O
)	O
the	O
need	O
for	O
the	O
consistent	O
application	O
of	O
guidelines	O
.	O

Recently	O
,	O
we	O
identified	O
a	O
dilysine	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
retrieval	O
signal	O
and	O
a	O
tyrosine	O
-	O
based	O
endocytosis	B-PATH
signal	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
S	O
protein	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

We	O
constructed	O
infectious	O
cDNA	O
clones	O
lacking	O
the	O
ER	O
retrieval	O
signal	O
,	O
the	O
endocytosis	B-PATH
signal	O
,	O
or	O
both	O
.	O

Recombinant	O
viruses	O
lacking	O
the	O
endocytosis	B-PATH
signal	O
(	O
in	O
combination	O
with	O
a	O
mutated	O
dilysine	O
signal	O
or	O
alone	O
)	O
could	O
not	O
be	O
recovered	O
,	O
even	O
though	O
transient	O
syncytia	O
were	O
formed	O
in	O
transfected	O
cells	O
.	O

With	O
an	O
internal	O
diameter	O
of	O
approximately	O
30	O
angstroms	O
,	O
the	O
central	O
channel	O
has	O
dimensions	O
and	O
positive	O
electrostatic	O
properties	O
favorable	O
for	O
nucleic	O
acid	O
binding	O
,	O
implying	O
that	O
its	O
role	O
is	O
to	O
confer	O
processivity	O
on	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

ABSTRACT	O
:	O
Last	O
month	O
'	O
s	O
article	O
considered	O
the	O
role	O
of	O
the	O
law	O
in	O
preventing	O
the	O
spread	O
of	O
infectious	O
disease	O
in	O
cases	O
such	O
as	O
tuberculosis	B-PATH
and	O
SARS	O
where	O
isolation	O
,	O
quarantine	O
and	O
treatment	O
are	O
effective	O
in	O
controlling	O
the	O
outbreak	O
.	O

There	O
will	O
usually	O
remain	O
a	O
probability	O
of	O
releasing	O
from	O
quarantine	O
some	O
infected	O
individuals	O
and	O
the	O
impact	O
of	O
early	O
release	B-PATH
will	O
depend	O
on	O
the	O
size	O
of	O
the	O
epidemic	O
.	O

TITLE	O
:	O
Severe	O
imported	O
malaria	B-PATH
:	O
clinical	O
presentation	O
at	O
the	O
time	O
of	O
hospital	O
admission	O
and	O
outcome	O
in	O
42	O
cases	O
diagnosed	O
from	O
1996	O
to	O
2002	O
.	O

The	O
objectives	O
of	O
this	O
retrospective	O
study	O
were	O
to	O
describe	O
initial	O
clinical	O
profiles	O
and	O
subsequent	O
outcome	O
of	O
adult	O
patients	O
in	O
France	O
who	O
were	O
diagnosed	O
with	O
severe	O
imported	O
malaria	B-PATH
,	O
as	O
defined	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
).	O

This	O
suggests	O
that	O
non	O
-	O
immune	O
persons	O
with	O
imported	O
malaria	B-PATH
who	O
present	O
with	O
jaundice	O
,	O
hyperparasitemia	O
,	O
or	O
prostration	O
should	O
be	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
close	O
monitoring	O
.	O

To	O
gain	O
the	O
recombinant	O
Canine	O
adenovirus	O
,	O
the	O
recombinant	O
plasmid	O
pCAV	O
-	O
2	O
-	O
CCV	O
-	O
S1	O
was	O
linearized	O
by	O
Cla	O
I	O
/	O
Asc	O
I	O
to	O
release	B-PATH
recombinant	O
genome	O
,	O
and	O
then	O
transfected	O
into	O
MDCK	O
cell	O
.	O

ABSTRACT	O
:	O
Ribavirin	O
,	O
the	O
only	O
small	O
molecule	O
available	O
so	O
far	O
for	O
treating	O
hepatitis	B-PATH
C	I-PATH
virus	O
infection	O
,	O
was	O
recently	O
used	O
in	O
an	O
emergency	O
context	O
to	O
treat	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
the	O
early	O
stages	O
of	O
the	O
disease	O
.	O

Of	O
the	O
travel	O
-	O
associated	O
systemic	O
infections	O
presenting	O
with	O
fever	O
,	O
diarrhea	O
occurs	O
in	O
patients	O
with	O
malaria	B-PATH
,	O
dengue	O
fever	O
and	O
SARS	O
.	O

Diarrhea	O
also	O
occurs	O
in	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	O
,	O
when	O
it	O
is	O
suggestive	O
of	O
legionellosis	B-PATH
.	O

ABSTRACT	O
:	O
A	O
24	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
4	O
-	O
year	O
history	O
of	O
bronchial	O
asthma	B-PATH
suffered	O
from	O
bloody	O
sputum	O
,	O
numbness	O
of	O
the	O
extremities	O
,	O
elevated	O
eosinophil	O
count	O
,	O
and	O
hypoxemia	O
.	O

TITLE	O
:	O
Lung	O
injury	O
in	O
uncomplicated	O
and	O
severe	O
falciparum	O
malaria	B-PATH
:	O
a	O
longitudinal	O
study	O
in	O
papua	O
,	O
Indonesia	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
severe	O
malaria	B-PATH
,	O
acute	O
respiratory	O
distress	O
syndrome	O
usually	O
develops	O
after	O
the	O
start	O
of	O
drug	O
treatment	O
and	O
is	O
a	O
major	O
cause	O
of	O
death	O
.	O

Respiratory	O
symptom	O
,	O
spirometry	O
,	O
and	O
gas	O
transfer	O
analyses	O
were	O
performed	O
longitudinally	O
in	O
adults	O
in	O
Papua	O
,	O
Indonesia	O
,	O
with	O
uncomplicated	O
(	O
n	O
=	O
50	O
)	O
and	O
severe	O
(	O
n	O
=	O
30	O
)	O
falciparum	O
malaria	B-PATH
;	O
normal	O
values	O
were	O
derived	O
from	O
109	O
control	O
subjects	O
.	O

Cough	O
was	O
frequent	O
in	O
both	O
patients	O
with	O
uncomplicated	O
malaria	B-PATH
(	O
50	O
%)	O
and	O
those	O
with	O
severe	O
malaria	B-PATH
(	O
30	O
%)	O
and	O
resolved	O
by	O
day	O
14	O
.	O

D	O
(	O
M	O
)	O
was	O
reduced	O
in	O
patients	O
with	O
severe	O
malaria	B-PATH
but	O
not	O
in	O
those	O
with	O
uncomplicated	O
malaria	B-PATH
and	O
only	O
returned	O
to	O
normal	O
levels	O
after	O
2	O
weeks	O
.	O

In	O
patients	O
with	O
severe	O
malaria	B-PATH
,	O
Vc	O
decreased	O
with	O
treatment	O
and	O
was	O
lowest	O
at	O
day	O
7	O
.	O

Our	O
results	O
suggest	O
that	O
pulmonary	O
vascular	O
occlusion	O
occurs	O
in	O
both	O
patients	O
with	O
uncomplicated	O
malaria	B-PATH
and	O
those	O
with	O
severe	O
malaria	B-PATH
,	O
likely	O
from	O
sequestration	O
of	O
both	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
and	O
white	O
blood	O
cells	O
.	O

There	O
was	O
also	O
impaired	O
alveolar	O
-	O
capillary	O
membrane	O
function	O
in	O
patients	O
with	O
severe	O
malaria	B-PATH
but	O
not	O
in	O
those	O
with	O
uncomplicated	O
malaria	B-PATH
.	O

RESULTS	O
:	O
Cough	O
was	O
frequent	O
in	O
both	O
patients	O
with	O
uncomplicated	O
malaria	B-PATH
(	O
50	O
%)	O
and	O
those	O
with	O
severe	O
malaria	B-PATH
(	O
30	O
%)	O
and	O
resolved	O
by	O
day	O
14	O
.	O

The	O
factors	O
associated	O
with	O
increased	O
mortality	O
during	O
ICU	O
stay	O
included	O
increased	O
patient	O
age	O
,	O
allogeneic	O
transplant	O
,	O
intubation	O
/	O
mechanical	O
ventilation	O
,	O
multiorgan	O
system	O
failure	O
(	O
MOSF	O
),	O
presumed	O
/	O
documented	O
infection	O
,	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
,	O
and	O
higher	O
APACHE	O
and	O
O	O
-	O
PRISM	O
score	O
at	O
ICU	O
transfer	O
.	O

We	O
developed	O
ASP	O
rat	O
models	O
,	O
and	O
anatomized	O
separately	O
after	O
1	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
and	O
9	O
h	O
.	O
We	O
took	O
out	O
blood	O
and	O
did	O
hemorrheologic	O
examination	O
and	O
erythrocyte	O
osmotic	O
fragility	O
test	O
,	O
checked	O
up	O
the	O
water	O
content	O
,	O
capillary	O
permeability	O
,	O
and	O
genetic	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
in	O
lung	O
tissues	O
,	O
examined	O
the	O
apoptosis	B-PATH
degree	O
of	O
blood	O
vessel	O
endothelium	O
while	O
we	O
tested	O
related	O
gene	O
expression	O
of	O
Bax	O
and	O
Bcl	O
-	O
2	O
in	O
lung	O
tissues	O
.	O

The	O
functional	O
damage	O
of	O
blood	O
vessel	O
endothelium	O
,	O
the	O
apoptosis	B-PATH
of	O
capillary	O
vessel	O
endothelium	O
,	O
WBC	O
edging	O
-	O
concentration	O
and	O
the	O
increasing	O
of	O
erythrocyte	O
fragility	O
are	O
the	O
main	O
reasons	O
of	O
ALI	O
.	O

ARDS	O
has	O
been	O
associated	O
with	O
the	O
administration	O
of	O
other	O
monoclonal	O
antibodies	O
,	O
such	O
as	O
infliximab	O
,	O
gemtuzumab	O
ozogamicin	O
,	O
and	O
OKT3	O
and	O
is	O
believed	O
to	O
be	O
directly	O
mediated	O
by	O
release	B-PATH
of	O
proinflammatory	O
cytokines	O
.	O

Here	O
,	O
we	O
observed	O
that	O
transient	O
expression	O
of	O
ORF7a	O
protein	O
fused	O
with	O
myc	O
or	O
GFP	O
tags	O
at	O
its	O
N	O
or	O
C	O
terminus	O
inhibited	O
cell	O
growth	O
and	O
prevented	O
BrdU	O
incorporation	O
in	O
different	O
cultural	O
cells	O
,	O
suggesting	O
that	O
ORF7a	O
expression	O
may	O
regulate	O
cell	B-PATH
cycle	I-PATH
progression	O
.	O

Analysis	O
by	O
flow	O
cytometry	O
demonstrated	O
that	O
ORF7a	O
expression	O
was	O
associated	O
with	O
blockage	O
of	O
cell	B-PATH
cycle	I-PATH
progression	O
at	O
G0	O
/	O
G1	O
phase	O
in	O
HEK	O
293	O
cells	O
after	O
24	O
to	O
60	O
h	O
post	O
-	O
transfection	O
.	O

Mutation	O
analysis	O
of	O
ORF7a	O
revealed	O
that	O
the	O
domain	O
spanning	O
aa	O
44	O
-	O
82	O
of	O
7a	O
protein	O
was	O
essential	O
for	O
its	O
cytoplasmic	O
localization	O
and	O
for	O
induction	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
arrest	O
.	O

After	O
analyzing	O
the	O
cellular	O
proteins	O
involving	O
in	O
regulation	O
of	O
cell	B-PATH
cycle	I-PATH
progression	O
,	O
we	O
demonstrated	O
that	O
ORF7a	O
expression	O
was	O
correlated	O
with	O
a	O
significant	O
reduction	O
of	O
cyclin	O
D3	O
level	O
of	O
mRNA	O
transcription	O
and	O
expression	O
,	O
and	O
phosphorylation	O
of	O
retinoblastoma	O
(	O
Rb	O
)	O
protein	O
at	O
ser795	O
and	O
ser809	O
/	O
811	O
,	O
not	O
with	O
the	O
expression	O
of	O
cyclin	O
D1	O
,	O
D2	O
,	O
cdk4	O
and	O
cdk6	O
in	O
HEK	O
293	O
cells	O
.	O

HIV	O
/	O
AIDS	O
,	O
malaria	B-PATH
,	O
tuberculosis	B-PATH
,	O
influenza	O
,	O
SARS	O
,	O
West	O
Nile	O
virus	O
,	O
Marburg	O
virus	O
,	O
and	O
bioterrorism	O
are	O
examples	O
of	O
some	O
of	O
the	O
emerging	O
and	O
reemerging	O
threats	O
.	O

In	O
quantitative	O
suspension	O
tests	O
,	O
with	O
and	O
without	O
protein	O
load	O
,	O
this	O
formulation	O
reduced	O
the	O
infectivity	O
titre	O
of	O
seven	O
enveloped	O
(	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
herpes	O
simplex	O
1	O
and	O
2	O
,	O
bovine	O
corona	O
,	O
respiratory	O
syncytial	O
,	O
vaccinia	O
,	O
hepatitis	O
B	O
,	O
bovine	O
viral	O
diarrhoea	O
)	O
and	O
four	O
non	O
-	O
enveloped	O
(	O
hepatitis	O
A	O
,	O
polio	O
,	O
rota	O
,	O
feline	O
calici	O
)	O
viruses	O
>	O
10	O
(	O
3	O
)-	O
fold	O
within	O
30s	O
.	O

TITLE	O
:	O
[	O
Caveolar	O
endocytosis	B-PATH
and	O
virus	O
entry	O
].	O

However	O
,	O
a	O
real	O
-	O
time	O
-	O
imaging	O
analysis	O
of	O
Simian	O
virus	O
40	O
(	O
SV40	O
)	O
'	O
s	O
entry	O
in	O
cells	O
has	O
indicated	O
the	O
existence	O
of	O
caveolar	O
endocytosis	B-PATH
during	O
virus	O
entry	O
.	O

This	O
review	O
examines	O
the	O
involvement	O
of	O
caveolae	O
in	O
endocytosis	B-PATH
used	O
by	O
the	O
viral	O
entry	O
system	O
.	O

By	O
monitoring	O
apoptosis	B-PATH
indicators	O
including	O
chromatin	O
condensation	O
,	O
cellular	O
DNA	O
fragmentation	O
and	O
cell	O
membrane	O
asymmetry	O
,	O
we	O
demonstrated	O
that	O
the	O
adenovirus	O
-	O
mediated	O
over	O
-	O
expression	O
of	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
and	O
its	O
C	O
-	O
terminal	O
domain	O
(	O
S2	O
)	O
induce	O
apoptosis	B-PATH
in	O
Vero	O
E6	O
cells	O
in	O
a	O
time	O
-	O
and	O
dosage	O
-	O
dependent	O
manner	O
,	O
whereas	O
the	O
expression	O
of	O
its	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
)	O
and	O
other	O
structural	O
proteins	O
,	O
including	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
do	O
not	O
.	O

These	O
findings	O
suggest	O
a	O
possible	O
role	O
of	O
S	O
and	O
S2	O
protein	O
in	O
SARS	O
-	O
CoV	O
induced	O
apoptosis	B-PATH
and	O
the	O
molecular	O
pathogenesis	O
of	O
SARS	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
influenza	B-PATH
A	I-PATH
community	O
-	O
acquired	O
pneumonia	O
in	O
an	O
elderly	O
subject	O
hospitalised	O
in	O
intensive	O
care	O
unit	O
].	O

An	O
ultra	O
-	O
rapid	O
microchip	O
electrophoresis	O
method	O
was	O
established	O
for	O
simultaneous	O
determination	O
intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
related	O
to	O
apoptosis	B-PATH
and	O
oxidative	O
stress	O
.	O

The	O
presence	O
of	O
the	O
YxxPhi	O
and	O
diacidic	O
motifs	O
,	O
located	O
within	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
3a	O
protein	O
,	O
was	O
not	O
required	O
for	O
its	O
efficient	O
release	B-PATH
.	O

ABSTRACT	O
:	O
A	O
previous	O
study	O
demonstrated	O
that	O
infection	O
of	O
rat	O
oligodendrocytes	O
by	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
apoptosis	B-PATH
,	O
which	O
is	O
caspase	O
dependent	O
(	O
Y	O
.	O
Liu	O
,	O
Y	O
.	O
Cai	O
,	O
and	O
X	O
.	O
Zhang	O
,	O
J	O
.	O
Virol	O
.	O

Here	O
we	O
determined	O
the	O
involvement	O
of	O
the	O
mitochondrial	O
pathway	O
in	O
MHV	O
-	O
induced	O
oligodendrocyte	O
apoptosis	B-PATH
.	O

Stable	O
overexpression	O
of	O
the	O
two	O
antiapoptotic	O
proteins	O
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
significantly	O
,	O
though	O
only	O
partially	O
,	O
blocked	O
apoptosis	B-PATH
,	O
suggesting	O
that	O
activation	O
of	O
the	O
mitochondrial	O
pathway	O
is	O
partially	O
responsible	O
for	O
the	O
apoptosis	B-PATH
.	O

However	O
,	O
treatment	O
with	O
a	O
caspase	O
-	O
8	O
inhibitor	O
only	O
slightly	O
blocked	O
cytochrome	O
c	O
release	B-PATH
from	O
the	O
mitochondria	O
.	O

TITLE	O
:	O
Shrinking	O
lung	O
syndrome	O
in	O
a	O
14	O
-	O
year	O
-	O
old	O
boy	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
.	O

ABSTRACT	O
:	O
Pulmonary	O
complications	O
occur	O
frequently	O
in	O
people	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
.	O

Shrinking	O
lung	O
syndrome	O
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
dyspnea	O
in	O
both	O
children	O
and	O
adults	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
.	O

Furthermore	O
,	O
EM	O
forms	O
a	O
vital	O
part	O
of	O
the	O
national	O
emergency	O
response	O
programme	O
of	O
many	O
countries	O
and	O
will	O
provide	O
a	O
frontline	O
diagnostic	O
service	O
in	O
the	O
event	O
of	O
a	O
bioterrorism	O
incident	O
,	O
particularly	O
in	O
the	O
scenario	O
of	O
a	O
deliberate	O
release	B-PATH
of	O
smallpox	O
virus	O
.	O

Reviews	O
on	O
Helicobacter	O
and	O
gastric	O
neoplasia	O
,	O
innate	O
defences	O
against	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
infection	O
,	O
and	O
the	O
function	O
of	O
granulomas	O
in	O
tuberculosis	B-PATH
also	O
address	O
aspects	O
of	O
tissue	O
responses	O
to	O
bacterial	O
infection	O
.	O

The	O
inhibition	O
of	O
translation	O
and	O
other	O
cellular	O
processes	O
of	O
gene	O
expression	O
have	O
been	O
associated	O
with	O
the	O
induction	O
of	O
a	O
stress	B-PATH
response	I-PATH
in	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
induction	O
of	O
apoptosis	B-PATH
by	O
the	O
7a	O
protein	O
may	O
be	O
related	O
to	O
its	O
ability	O
to	O
inhibit	O
cellular	O
translation	O
and	O
activate	O
p38	O
MAPK	O
.	O

ABSTRACT	O
:	O
Enveloped	O
animal	O
viruses	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
hepatitis	O
B	O
virus	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
human	O
papillomavirus	O
,	O
Marburg	O
,	O
and	O
influenza	O
are	O
major	O
public	O
health	O
concerns	O
around	O
the	O
world	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
vivax	O
malaria	B-PATH
:	O
case	O
report	O
and	O
literature	O
review	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
43	O
-	O
year	O
-	O
old	O
Brazilian	O
woman	O
living	O
in	O
a	O
malaria	B-PATH
-	O
endemic	O
area	O
,	O
who	O
presented	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
caused	O
by	O
P	O
.	O
vivax	O
before	O
starting	O
anti	O
-	O
malarial	O
treatment	O
.	O

A	O
negative	O
rapid	O
immunochromatographic	O
assay	O
,	O
based	O
on	O
the	O
detection	O
of	O
Histidine	O
Rich	O
Protein	O
-	O
2	O
(	O
HRP	O
-	O
2	O
)	O
of	O
P	O
.	O
falciparum	O
,	O
indicated	O
that	O
falciparum	O
malaria	B-PATH
was	O
unlikely	O
.	O

Past	O
medical	O
history	O
was	O
significant	O
for	O
hepatitis	B-PATH
C	I-PATH
and	O
bipolar	O
disorder	O
.	O

Cytokine	O
ELISA	O
analysis	O
revealed	O
that	O
co	O
-	O
injection	O
of	O
M	O
could	O
enhance	O
the	O
levels	O
of	O
IFN	O
-	O
gamma	O
,	O
IL	O
-	O
2	O
release	B-PATH
induced	O
by	O
N	O
antigen	O
.	O

Our	O
recent	O
study	O
demonstrated	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
(	O
CoV	O
)	O
infection	O
of	O
monkey	O
kidney	O
Vero	O
E6	O
cells	O
induces	O
phosphorylation	O
and	O
dephosphorylation	O
of	O
signaling	O
pathways	O
,	O
resulting	O
in	O
apoptosis	B-PATH
.	O

Preferential	O
infection	O
of	O
mature	O
DCs	O
was	O
not	O
due	O
to	O
differential	O
expression	O
of	O
the	O
MHV	O
-	O
JHM	O
receptor	O
CEACAM	O
-	O
1a	O
on	O
mature	O
or	O
immature	O
cells	O
or	O
to	O
differences	O
in	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Characteristics	O
and	O
outcome	O
of	O
patients	O
with	O
active	O
pulmonary	O
tuberculosis	B-PATH
requiring	O
intensive	O
care	O
.	O

ABSTRACT	O
:	O
Severe	O
tuberculosis	B-PATH
(	O
TB	O
)	O
requiring	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
care	O
is	O
rare	O
but	O
commonly	O
known	O
to	O
be	O
of	O
markedly	O
bad	O
prognosis	O
.	O

These	O
data	O
indicate	O
a	O
high	O
mortality	O
of	O
patients	O
with	O
tuberculosis	B-PATH
requiring	O
intensive	O
care	O
unit	O
care	O
and	O
identifies	O
new	O
independently	O
associated	O
risk	O
factors	O
.	O

We	O
compared	O
the	O
cytokine	O
profile	O
in	O
Caco2	O
cells	O
after	O
infection	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
with	O
other	O
respiratory	O
viruses	O
including	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
FluAV	O
),	O
and	O
human	O
parainfluenza	O
virus	O
type	O
2	O
(	O
hPIV2	O
).	O

As	O
shown	O
in	O
our	O
previous	O
studies	O
,	O
apoptosis	B-PATH
occurred	O
in	O
virus	O
-	O
infected	O
cells	O
within	O
18	O
h	O
postinfection	O
.	O

Cellular	O
mRNA	O
transcription	O
,	O
which	O
was	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Caco	O
-	O
2	O
cells	O
,	O
was	O
not	O
up	O
-	O
regulated	O
in	O
virus	O
-	O
infected	O
Vero	O
E6	O
cells	O
,	O
partially	O
as	O
a	O
result	O
of	O
apoptosis	B-PATH
.	O

These	O
results	O
suggested	O
that	O
inhibition	O
of	O
cell	O
proliferation	O
is	O
regulated	O
by	O
both	O
the	O
phosphatidylinositol	O
3	O
'-	O
kinase	O
/	O
Akt	O
signaling	O
pathway	O
and	O
by	O
apoptosis	B-PATH
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

ABSTRACT	O
:	O
Side	O
effects	O
of	O
interferon	O
-	O
ribavirin	O
combination	O
therapy	O
limit	O
the	O
sustained	O
viral	O
response	O
achievable	O
in	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
patients	O
.	O

An	O
increased	O
concentration	O
of	O
NO	O
in	O
exhaled	O
air	O
has	O
been	O
reported	O
in	O
airway	O
diseases	O
,	O
characterized	O
by	O
airway	O
inflammation	O
,	O
such	O
as	O
bronchial	O
asthma	B-PATH
,	O
where	O
its	O
concentration	O
is	O
related	O
to	O
bronchial	O
hyperresponsiveness	O
and	O
sputum	O
eosinophilia	O
.	O

Exhaled	O
NO	O
concentration	O
in	O
asthma	B-PATH
is	O
a	O
sensitive	O
marker	O
of	O
airway	O
inflammation	O
that	O
reacts	O
rapidly	O
in	O
response	O
to	O
treatment	O
or	O
exacerbation	O
of	O
disease	O
.	O

Clinical	O
application	O
of	O
exhaled	O
NO	O
measurement	O
include	O
monitoring	O
compliance	O
and	O
response	O
to	O
treatment	O
,	O
disease	O
activity	O
,	O
diagnosis	O
of	O
asthma	B-PATH
,	O
and	O
the	O
prediction	O
of	O
acute	O
exacerbations	O
.	O

The	O
results	O
of	O
these	O
analyses	O
highlight	O
different	O
aspects	O
of	O
each	O
system	O
,	O
suggesting	O
in	O
general	O
that	O
(	O
1	O
)	O
differences	O
can	O
be	O
due	O
to	O
the	O
assay	O
systems	O
themselves	O
;	O
(	O
2	O
)	O
phylogenetic	O
differences	O
in	O
ribosome	B-PATH
structure	O
can	O
affect	O
frameshifting	O
efficiency	O
;	O
and	O
(	O
3	O
)	O
care	O
must	O
be	O
taken	O
to	O
employ	O
the	O
closest	O
phylogenetic	O
match	O
between	O
a	O
specific	O
-	O
1	O
PRF	O
signal	O
and	O
the	O
choice	O
of	O
translational	O
assay	O
system	O
.	O

It	O
has	O
also	O
helped	O
to	O
define	O
the	O
impact	O
of	O
previously	O
described	O
ones	O
such	O
as	O
human	O
metapneumovirus	O
and	O
rhinoviruses	O
,	O
which	O
account	O
for	O
the	O
majority	O
of	O
asthma	B-PATH
exacerbations	O
and	O
frequent	O
lower	O
respiratory	O
tract	O
illnesses	O
.	O

Neurons	O
were	O
the	O
target	O
cells	O
,	O
undergoing	O
degeneration	O
during	O
infection	O
,	O
in	O
part	O
due	O
to	O
apoptosis	B-PATH
.	O

Intracerebral	O
inoculation	O
of	O
HCoV	O
-	O
OC43	O
into	O
BALB	O
/	O
c	O
mice	O
led	O
to	O
an	O
acute	O
encephalitis	O
with	O
neuronal	O
cell	O
death	O
by	O
necrosis	O
and	O
apoptosis	B-PATH
.	O

Important	O
developments	O
in	O
the	O
identification	O
,	O
characterization	O
and	O
clinical	O
utility	O
of	O
inhibitors	O
of	O
human	O
immunodeficiency	O
virus	O
;	O
the	O
hepatitis	O
viruses	O
,	O
hepatitis	O
B	O
,	O
hepatitis	B-PATH
C	I-PATH
;	O
the	O
herpes	O
family	O
of	O
viruses	O
,	O
herpes	O
simplex	O
viruses	O
1	O
and	O
2	O
,	O
varicella	O
zoster	O
virus	O
,	O
Epstein	O
-	O
Barr	O
virus	O
and	O
human	O
cytomegalovirus	O
;	O
the	O
respiratory	O
viruses	O
,	O
influenza	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
picornaviruses	O
,	O
measles	B-PATH
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
;	O
human	O
papilloma	O
virus	O
;	O
rotavirus	O
;	O
Ebola	O
virus	O
and	O
West	O
Nile	O
virus	O
,	O
are	O
reviewed	O
.	O

Virus	O
entry	O
into	O
cells	O
was	O
inhibited	O
by	O
acidotropic	O
bases	O
and	O
by	O
other	O
inhibitors	O
of	O
pH	O
-	O
dependent	O
endocytosis	B-PATH
.	O

ABSTRACT	O
:	O
A	O
67	O
-	O
year	O
-	O
old	O
patient	O
with	O
newly	O
diagnosed	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
developed	O
acute	O
respiratory	O
failure	O
with	O
high	O
-	O
grade	O
fever	O
and	O
bilateral	O
pulmonary	O
infiltrates	O
.	O

Recently	O
,	O
SARS	O
-	O
CoV	O
has	O
been	O
demonstrated	O
to	O
induce	O
cell	O
apoptosis	B-PATH
in	O
Vero	O
-	O
E6	O
cells	O
.	O

Growth	O
arrest	O
and	O
apoptosis	B-PATH
via	O
caspase	O
-	O
3	O
and	O
caspase	O
-	O
9	O
activities	O
were	O
demonstrated	O
in	O
SARS	O
-	O
CoV	O
3CLpro	O
-	O
expressing	O
human	O
promonocyte	O
cells	O
.	O

An	O
additional	O
73	O
pathogens	O
were	O
detected	O
by	O
NAT	O
in	O
65	O
samples	O
including	O
30	O
pathogens	O
that	O
were	O
missed	O
by	O
conventional	O
methods	O
(	O
19	O
adenovirus	O
,	O
6	O
respiratory	O
syncytial	O
virus	O
,	O
3	O
parainfluenza	O
virus	O
1	O
-	O
4	O
,	O
2	O
influenza	B-PATH
A	I-PATH
),	O
41	O
pathogens	O
not	O
routinely	O
identified	O
by	O
conventional	O
methods	O
in	O
most	O
laboratories	O
(	O
23	O
rhinovirus	O
,	O
8	O
human	O
coronavirus	O
OC43	O
,	O
5	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
2	O
human	O
coronavirus	O
229E	O
,	O
2	O
human	O
coronavirus	O
NL63	O
,	O
1	O
Chlamydophila	O
pneumoniae	O
)	O
and	O
2	O
pathogens	O
from	O
samples	O
where	O
no	O
respiratory	O
virus	O
testing	O
was	O
requested	O
(	O
1	O
influenza	B-PATH
A	I-PATH
,	O
1	O
parainfluenza	O
virus	O
).	O

specificity	O
of	O
98	O
%	O
and	O
100	O
%	O
for	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
respectively	O
in	O
224	O
specimens	O
.	O

The	O
Binax	O
test	O
showed	O
specificity	O
of	O
99	O
%	O
and	O
100	O
%,	O
respectively	O
for	O
influenza	B-PATH
A	I-PATH
and	O
B	O
.	O
Sensitivity	O
results	O
were	O
identical	O
for	O
both	O
rapid	O
detection	O
kits	O
(	O
80	O
%	O
and	O
47	O
%	O
for	O
Flu	O
A	O
and	O
B	O
,	O
respectively	O
).	O

Flu	O
A	O
and	O
B	O
Plus	O
test	O
detecting	O
influenza	B-PATH
A	I-PATH
and	O
B	O
with	O
sharp	O
and	O
easy	O
to	O
read	O
results	O
.	O

Specific	O
treatment	O
for	O
acute	O
pancreatitis	O
currently	O
does	O
not	O
exist	O
and	O
management	O
is	O
still	O
supportive	O
,	O
with	O
therapy	O
aimed	O
at	O
reducing	O
pancreatic	B-PATH
secretion	I-PATH
,	O
replacing	O
fluid	O
and	O
electrolytes	O
losses	O
and	O
analgesia	O
.	O

Most	O
of	O
these	O
conditions	O
are	O
uncommon	O
or	O
rare	O
,	O
although	O
three	O
of	O
them	O
--	O
Wegener	O
'	O
s	O
granulomatosis	O
,	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
,	O
and	O
Goodpasture	O
'	O
s	O
syndrome	O
--	O
are	O
not	O
infrequently	O
encountered	O
by	O
respiratory	O
care	O
clinicians	O
.	O

TITLE	O
:	O
The	O
comparative	O
pathology	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
avian	O
influenza	B-PATH
A	I-PATH
subtype	O
H5N1	O
--	O
a	O
review	O
.	O

LXA	O
(	O
4	O
)	O
is	O
generated	O
in	O
vivo	O
during	O
acute	O
lung	O
injury	O
,	O
and	O
we	O
observed	O
that	O
nanomolar	O
quantities	O
increased	O
basal	O
epithelial	O
cell	O
proliferation	O
and	O
potently	O
blocked	O
acid	O
-	O
triggered	O
interleukin	O
-	O
6	O
release	B-PATH
and	O
neutrophil	O
transmigration	O
across	O
well	O
-	O
differentiated	O
normal	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

TITLE	O
:	O
Cell	B-PATH
cycle	I-PATH
perturbations	O
induced	O
by	O
infection	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
and	O
their	O
effect	O
on	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
In	O
eukaryotic	O
cells	O
,	O
cell	O
growth	O
and	O
division	O
occur	O
in	O
a	O
stepwise	O
,	O
orderly	O
fashion	O
described	O
by	O
a	O
process	O
known	O
as	O
the	O
cell	B-PATH
cycle	I-PATH
.	O

The	O
relationship	O
between	O
positive	O
-	O
strand	O
RNA	O
viruses	O
and	O
the	O
cell	B-PATH
cycle	I-PATH
and	O
the	O
concomitant	O
effects	O
on	O
virus	O
replication	O
are	O
not	O
clearly	O
understood	O
.	O

We	O
have	O
shown	O
that	O
infection	O
of	O
asynchronously	O
replicating	O
and	O
synchronized	O
replicating	O
cells	O
with	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
a	O
positive	O
-	O
strand	O
RNA	O
virus	O
,	O
resulted	O
in	O
the	O
accumulation	O
of	O
infected	O
cells	O
in	O
the	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
.	O

Analysis	O
of	O
various	O
cell	B-PATH
cycle	I-PATH
-	O
regulatory	O
proteins	O
and	O
cellular	O
morphology	O
indicated	O
that	O
there	O
was	O
a	O
down	O
-	O
regulation	O
of	O
cyclins	O
D1	O
and	O
D2	O
(	O
G1	O
regulatory	O
cyclins	O
)	O
and	O
that	O
a	O
proportion	O
of	O
virus	O
-	O
infected	O
cells	O
underwent	O
aberrant	O
cytokinesis	O
,	O
in	O
which	O
the	O
cells	O
underwent	O
nuclear	O
,	O
but	O
not	O
cytoplasmic	O
,	O
division	O
.	O

We	O
assessed	O
the	O
impact	O
of	O
the	O
perturbations	O
on	O
the	O
cell	B-PATH
cycle	I-PATH
for	O
virus	O
-	O
infected	O
cells	O
and	O
found	O
that	O
IBV	O
-	O
infected	O
G2	O
/	O
M	O
-	O
phase	O
-	O
synchronized	O
cells	O
exhibited	O
increased	O
viral	O
protein	O
production	O
when	O
released	O
from	O
the	O
block	O
when	O
compared	O
to	O
cells	O
synchronized	O
in	O
the	O
G0	O
phase	O
or	O
asynchronously	O
replicating	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
)	O
plays	O
a	O
key	O
role	O
in	O
maintaining	O
blood	O
pressure	O
homeostasis	O
,	O
as	O
well	O
as	O
fluid	O
and	O
salt	O
balance	O
.	O

Targets	O
for	O
the	O
prophylactic	O
or	O
therapeutic	O
interventions	O
include	O
interaction	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
(	O
S1	O
domain	O
)	O
with	O
the	O
host	O
cell	O
receptor	O
,	O
fusion	O
of	O
the	O
S2	O
domain	O
with	O
the	O
host	O
cell	O
membrane	O
,	O
processing	O
of	O
the	O
replicase	O
polyproteins	O
by	O
the	O
virus	O
-	O
encoded	O
proteases	O
(	O
3C	O
-	O
like	O
cysteine	O
protease	O
[	O
3CLpro	O
]	O
and	O
papain	O
-	O
like	O
cysteine	O
protease	O
)	O
and	O
other	O
virus	O
-	O
encoded	O
enzymes	O
such	O
as	O
the	O
NTPase	O
/	O
helicase	O
and	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

ABSTRACT	O
:	O
Albuterol	O
,	O
due	O
to	O
its	O
bronchodilatory	O
and	O
anti	O
-	O
inflammatory	O
effects	O
,	O
is	O
given	O
via	O
continuous	O
nebulization	O
in	O
children	O
with	O
severe	O
asthma	B-PATH
.	O

The	O
helicase	O
inhibitors	O
discussed	O
here	O
influence	O
rates	O
of	O
helicase	O
-	O
catalyzed	O
DNA	O
(	O
or	O
RNA	O
)	O
unwinding	O
by	O
preventing	O
ATP	O
hydrolysis	O
,	O
nucleic	O
acid	O
binding	O
,	O
nucleic	O
acid	O
release	B-PATH
,	O
or	O
by	O
disrupting	O
the	O
interaction	O
of	O
a	O
helicase	O
with	O
a	O
required	O
cofactor	O
.	O

ABSTRACT	O
:	O
Beginning	O
in	O
late	O
2003	O
,	O
a	O
substantial	O
outbreak	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
spread	O
among	O
poultry	O
in	O
Thailand	O
.	O

HRV	O
-	O
induced	O
colds	O
are	O
the	O
important	O
predisposing	O
factors	O
to	O
acute	O
otitis	O
media	O
,	O
sinusitis	O
,	O
and	O
are	O
the	O
major	O
factors	O
in	O
the	O
induction	O
of	O
exacerbations	O
of	O
asthma	B-PATH
in	O
adults	O
and	O
children	O
.	O

Association	O
of	O
rhinovirus	O
infections	O
with	O
asthma	B-PATH
.	O

In	O
addition	O
,	O
we	O
assessed	O
the	O
inherent	O
release	B-PATH
capacity	O
of	O
each	O
emulsion	O
variant	O
in	O
vitro	O
.	O

However	O
,	O
in	O
programmed	O
-	O
1	O
ribosomal	O
frameshifting	O
,	O
a	O
specific	O
subversion	O
of	O
frame	O
maintenance	O
takes	O
place	O
,	O
wherein	O
the	O
ribosome	B-PATH
is	O
forced	O
to	O
shift	O
one	O
nucleotide	O
backwards	O
into	O
an	O
overlapping	O
reading	O
frame	O
and	O
to	O
translate	O
an	O
entirely	O
new	O
sequence	O
of	O
amino	O
acids	O
.	O

How	O
these	O
components	O
operate	O
together	O
to	O
manipulate	O
the	O
ribosome	B-PATH
is	O
unknown	O
.	O

Here	O
we	O
describe	O
the	O
observation	O
of	O
a	O
ribosome	B-PATH
-	O
mRNA	O
pseudoknot	O
complex	O
that	O
is	O
stalled	O
in	O
the	O
process	O
of	O
-	O
1	O
frameshifting	O
.	O

From	O
this	O
it	O
can	O
be	O
seen	O
how	O
the	O
pseudoknot	O
interacts	O
with	O
the	O
ribosome	B-PATH
to	O
block	O
the	O
mRNA	O
entrance	O
channel	O
,	O
compromising	O
the	O
translocation	O
process	O
and	O
leading	O
to	O
a	O
spring	O
-	O
like	O
deformation	O
of	O
the	O
P	O
-	O
site	O
transfer	O
RNA	O
.	O

Together	O
,	O
the	O
structural	O
changes	O
provide	O
a	O
mechanical	O
explanation	O
of	O
how	O
the	O
pseudoknot	O
manipulates	O
the	O
ribosome	B-PATH
into	O
a	O
different	O
reading	O
frame	O
.	O

Leptospirosis	O
,	O
toxoplasmosis	B-PATH
and	O
chlamydiosis	O
have	O
been	O
diagnosed	O
as	O
the	O
major	O
causes	O
of	O
abortion	O
in	O
llamas	O
and	O
alpacas	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
responsible	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
contains	O
a	O
small	O
envelope	O
protein	O
,	O
E	O
,	O
with	O
putative	O
involvement	O
in	O
host	O
apoptosis	B-PATH
and	O
virus	O
morphogenesis	O
.	O

Similar	O
changes	O
have	O
been	O
documented	O
in	O
diabetes	O
,	O
sepsis	O
,	O
children	O
with	O
vasculitis	O
,	O
allograft	B-PATH
rejection	I-PATH
,	O
disseminated	O
intravascular	O
coagulation	O
,	O
patients	O
with	O
recurrent	O
pregnancy	O
losses	O
,	O
hereditary	O
angioedema	O
,	O
adult	O
respiratory	O
distress	O
syndrome	O
and	O
coronary	O
artery	O
disease	O
.	O

TITLE	O
:	O
[	O
Tuberculosis	B-PATH
miliar	O
in	O
a	O
patient	O
treated	O
with	O
intravesical	O
instillations	O
of	O
bacillus	O
Calmette	O
-	O
GuÃ©rin	O
].	O

ABSTRACT	O
:	O
Tuberculosis	B-PATH
miliar	O
is	O
a	O
very	O
rare	O
complication	O
of	O
bacillus	O
Calmette	O
-	O
GuÃ©rin	O
(	O
BCG	O
)	O
immunotherapy	O
that	O
is	O
associated	O
to	O
high	O
mortality	O
.	O

In	O
addition	O
,	O
a	O
LacZ	O
reporter	O
gene	O
was	O
introduced	O
into	O
the	O
universal	O
transfer	O
vector	O
named	O
pUGS	O
-	O
LacZ	O
.	O
Subsequently	O
,	O
a	O
PRV	O
genome	O
-	O
based	O
virus	O
live	O
vector	O
was	O
generated	O
via	O
homologous	B-PATH
recombination	I-PATH
.	O

These	O
compounds	O
were	O
also	O
evaluated	O
for	O
their	O
antiviral	O
activity	O
for	O
West	O
Nile	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
SARS	O
-	O
coronavirus	O
,	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
.	O

1	O
-[(	O
2	O
-	O
Hydroxy	O
-	O
1	O
-(	O
hydroxymethyl	O
)	O
ethoxy	O
)	O
methyl	O
]-	O
5	O
-	O
fluorocytosine	O
(	O
34	O
)	O
showed	O
some	O
inhibitory	O
activity	O
against	O
hepatitis	B-PATH
C	I-PATH
virus	O
.	O

Later	O
,	O
after	O
having	O
established	O
a	O
productive	O
infection	O
,	O
a	O
chemokine	O
response	O
is	O
induced	O
together	O
with	O
other	O
cellular	O
changes	O
associated	O
with	O
RNA	O
and	O
protein	O
metabolism	O
,	O
cell	B-PATH
cycle	I-PATH
and	O
apoptosis	B-PATH
.	O

Laboratory	O
testing	O
identified	O
influenza	B-PATH
A	I-PATH
for	O
44	O
%;	O
sequence	O
analysis	O
demonstrated	O
that	O
these	O
were	O
Fujian	O
-	O
like	O
influenza	O
strains	O
,	O
which	O
represented	O
the	O
predominant	O
strain	O
found	O
globally	O
in	O
2003	O
/	O
2004	O
.	O

In	O
addition	O
,	O
we	O
determined	O
how	O
many	O
of	O
the	O
EDs	O
would	O
isolate	O
patients	O
with	O
suspected	O
cases	O
of	O
chickenpox	O
,	O
tuberculosis	B-PATH
(	O
TB	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
other	O
suspicious	O
infections	O
.	O

TITLE	O
:	O
Comparative	O
stigma	O
of	O
HIV	O
/	O
AIDS	O
,	O
SARS	O
,	O
and	O
tuberculosis	B-PATH
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
This	O
study	O
compares	O
public	O
stigma	O
towards	O
three	O
types	O
of	O
infectious	O
diseases	O
-	O
human	O
immunodeficiency	O
virus	O
/	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
HIV	O
/	O
AIDS	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
tuberculosis	B-PATH
(	O
TB	O
)-	O
tests	O
an	O
attribution	O
model	O
of	O
stigma	O
,	O
and	O
explores	O
the	O
relationships	O
between	O
stigma	O
and	O
public	O
attitudes	O
towards	O
government	O
policies	O
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
Accelerated	O
induction	O
of	O
apoptosis	B-PATH
in	O
insect	O
cells	O
by	O
baculovirus	O
-	O
expressed	O
SARS	O
-	O
CoV	O
membrane	O
protein	O
.	O

Upon	O
expression	O
of	O
SARS	O
-	O
CoV	O
M	O
protein	O
using	O
the	O
baculovirus	O
/	O
insect	O
cell	O
expression	O
system	O
,	O
however	O
,	O
we	O
found	O
that	O
the	O
expressed	O
M	O
protein	O
triggered	O
accelerated	O
apoptosis	B-PATH
in	O
insect	O
cells	O
,	O
as	O
characterized	O
by	O
rapid	O
cell	O
death	O
,	O
elevated	O
cytotoxicity	O
,	O
cell	O
shrinkage	O
,	O
nuclear	O
condensation	O
and	O
DNA	O
fragmentation	O
.	O

Conversely	O
,	O
the	O
M	O
protein	O
expressed	O
in	O
mammalian	O
cells	O
did	O
not	O
induce	O
apoptosis	B-PATH
.	O

This	O
is	O
the	O
first	O
report	O
describing	O
the	O
induction	O
of	O
apoptosis	B-PATH
by	O
SARS	O
-	O
CoV	O
M	O
protein	O
in	O
animal	O
cells	O
and	O
possible	O
implications	O
are	O
discussed	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
which	O
signaling	O
pathways	O
play	O
important	O
roles	O
in	O
escape	O
from	O
apoptosis	B-PATH
in	O
cells	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
In	O
persistently	O
infected	O
cells	O
at	O
50h	O
.	O
p	O
.	O
i	O
.,	O
PI3K	O
/	O
Akt	O
,	O
JNK	O
,	O
p38	O
MAPK	O
and	O
Bcl	O
-	O
2	O
were	O
phosphorylated	O
and	O
the	O
protein	O
levels	O
of	O
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
were	O
increased	O
.	O

TITLE	O
:	O
Identification	O
and	O
structure	O
-	O
based	O
optimization	O
of	O
novel	O
dihydropyrones	O
as	O
potent	O
HCV	O
RNA	B-PATH
polymerase	I-PATH
inhibitors	O
.	O

Herein	O
we	O
report	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
this	O
novel	O
class	O
of	O
dihydropyrone	O
-	O
containing	O
compounds	O
that	O
show	O
potent	O
inhibitory	O
activities	O
against	O
the	O
HCV	O
RNA	B-PATH
polymerase	I-PATH
in	O
biochemical	O
assays	O
.	O

Cardiovascular	O
symptoms	O
,	O
including	O
hypotension	O
,	O
cardiac	O
arrhythmia	O
and	O
chest	O
pain	O
,	O
are	O
presumably	O
linked	O
to	O
cardiac	O
mast	O
cell	O
mediator	O
release	B-PATH
.	O

Even	O
if	O
SARS	O
does	O
not	O
reemerge	O
,	O
the	O
experience	O
gained	O
from	O
such	O
planning	O
is	O
valuable	O
in	O
preparing	O
for	O
threats	O
of	O
bioterrorism	O
or	O
a	O
global	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
pandemic	O
.	O

The	O
levels	O
of	O
inactivation	O
expressed	O
as	O
log	O
-	O
reduction	O
were	O
as	O
follows	O
:	O
cell	O
-	O
free	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
),	O
greater	O
than	O
6	O
.	O
8	O
;	O
cell	O
-	O
associated	O
HIV	O
-	O
1	O
,	O
greater	O
than	O
6	O
.	O
4	O
;	O
human	O
T	O
-	O
lymphotropic	O
virus	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
),	O
4	O
.	O
5	O
;	O
HTLV	O
-	O
II	O
,	O
greater	O
than	O
5	O
.	O
7	O
;	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
greater	O
than	O
4	O
.	O
5	O
;	O
duck	O
HBV	O
,	O
4	O
.	O
4	O
to	O
4	O
.	O
5	O
;	O
bovine	O
viral	O
diarrhea	O
virus	O
,	O
6	O
.	O
0	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
5	O
.	O
5	O
;	O
West	O
Nile	O
virus	O
,	O
6	O
.	O
8	O
;	O
bluetongue	O
virus	O
,	O
5	O
.	O
1	O
;	O
human	O
adenovirus	O
5	O
,	O
6	O
.	O
8	O
;	O
Klebsiella	O
pneumoniae	O
,	O
greater	O
than	O
7	O
.	O
4	O
;	O
Staphylococcus	O
epidermidis	O
and	O
Yersinia	O
enterocolitica	O
,	O
greater	O
than	O
7	O
.	O
3	O
;	O
Treponema	O
pallidum	O
,	O
greater	O
than	O
5	O
.	O
9	O
;	O
Borrelia	O
burgdorferi	O
,	O
greater	O
than	O
10	O
.	O
6	O
;	O
Plasmodium	O
falciparum	O
,	O
6	O
.	O
9	O
;	O
Trypanosoma	O
cruzi	O
,	O
greater	O
than	O
5	O
.	O
0	O
;	O
and	O
Babesia	O
microti	O
,	O
greater	O
than	O
5	O
.	O
3	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
inactivation	O
expressed	O
as	O
log	O
-	O
reduction	O
were	O
as	O
follows	O
:	O
cell	O
-	O
free	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
),	O
greater	O
than	O
6	O
.	O
8	O
;	O
cell	O
-	O
associated	O
HIV	O
-	O
1	O
,	O
greater	O
than	O
6	O
.	O
4	O
;	O
human	O
T	O
-	O
lymphotropic	O
virus	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
),	O
4	O
.	O
5	O
;	O
HTLV	O
-	O
II	O
,	O
greater	O
than	O
5	O
.	O
7	O
;	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
greater	O
than	O
4	O
.	O
5	O
;	O
duck	O
HBV	O
,	O
4	O
.	O
4	O
to	O
4	O
.	O
5	O
;	O
bovine	O
viral	O
diarrhea	O
virus	O
,	O
6	O
.	O
0	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
5	O
.	O
5	O
;	O
West	O
Nile	O
virus	O
,	O
6	O
.	O
8	O
;	O
bluetongue	O
virus	O
,	O
5	O
.	O
1	O
;	O
human	O
adenovirus	O
5	O
,	O
6	O
.	O
8	O
;	O
Klebsiella	O
pneumoniae	O
,	O
greater	O
than	O
7	O
.	O
4	O
;	O
Staphylococcus	O
epidermidis	O
and	O
Yersinia	O
enterocolitica	O
,	O
greater	O
than	O
7	O
.	O
3	O
;	O
Treponema	O
pallidum	O
,	O
greater	O
than	O
5	O
.	O
9	O
;	O
Borrelia	O
burgdorferi	O
,	O
greater	O
than	O
10	O
.	O
6	O
;	O
Plasmodium	O
falciparum	O
,	O
6	O
.	O
9	O
;	O
Trypanosoma	O
cruzi	O
,	O
greater	O
than	O
5	O
.	O
0	O
;	O
and	O
Babesia	O
microti	O
,	O
greater	O
than	O
5	O
.	O
3	O
.	O

In	O
expressing	O
cells	O
,	O
7a	O
protein	O
exhibits	O
a	O
variety	O
of	O
biological	O
activities	O
,	O
including	O
induction	O
of	O
apoptosis	B-PATH
,	O
activation	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathway	O
,	O
inhibition	O
of	O
host	O
protein	O
translation	O
,	O
and	O
suppression	O
of	O
cell	O
growth	O
progression	O
.	O

Phylogenetic	O
analyses	O
of	O
the	O
spike	O
,	O
envelope	O
,	O
membrane	O
,	O
and	O
nucleoprotein	O
structural	O
proteins	O
and	O
the	O
two	O
conserved	O
replicase	O
domains	O
,	O
putative	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
and	O
RNA	O
helicase	O
,	O
revealed	O
that	O
bat	O
coronaviruses	O
cluster	O
in	O
three	O
different	O
groups	O
:	O
group	O
1	O
,	O
another	O
group	O
that	O
includes	O
all	O
SARS	O
and	O
SARS	O
-	O
like	O
coronaviruses	O
(	O
putative	O
group	O
4	O
),	O
and	O
an	O
independent	O
bat	O
coronavirus	O
group	O
(	O
putative	O
group	O
5	O
).	O

The	O
samples	O
represented	O
virus	O
-	O
producing	O
cell	O
cultures	O
(	O
such	O
as	O
SARS	O
-	O
coronavirus	O
,	O
West	O
Nile	O
virus	O
,	O
Orthopox	O
virus	O
),	O
bacteria	O
suspensions	O
(	O
cultures	O
of	O
Escherichia	O
coli	O
and	O
genetically	O
knockout	O
apathogenic	O
Bacillus	O
anthracis	O
),	O
suspensions	O
of	O
parasites	O
(	O
malaria	B-PATH
Plasmodium	O
falciparum	O
,	O
Leishmania	O
major	O
,	O
Microsporidia	O
cuniculi	O
,	O
Caenorhabditis	O
elegans	O
),	O
and	O
whole	O
Drosophila	O
melanogaster	O
flies	O
infected	O
with	O
microsporidia	O
.	O

siVirus	O
will	O
be	O
a	O
useful	O
tool	O
for	O
designing	O
optimal	O
siRNAs	O
targeting	O
highly	O
divergent	O
pathogens	O
,	O
including	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
influenza	O
virus	O
and	O
SARS	O
coronavirus	O
,	O
all	O
of	O
which	O
pose	O
enormous	O
threats	O
to	O
global	O
human	O
health	O
.	O

To	O
determine	O
whether	O
the	O
structural	O
proteins	O
M	O
and	O
N	O
of	O
SARS	O
-	O
CoV	O
induce	O
apoptosis	B-PATH
.	O

The	O
results	O
show	O
that	O
M	O
and	O
N	O
proteins	O
of	O
SARS	O
-	O
CoV	O
can	O
induce	O
apoptosis	B-PATH
of	O
HPF	O
cells	O
.	O

Co	O
-	O
transfection	O
of	O
M	O
and	O
N	O
enhances	O
the	O
induction	O
of	O
apoptosis	B-PATH
by	O
M	O
or	O
N	O
alone	O
,	O
which	O
also	O
suggests	O
that	O
the	O
structural	O
proteins	O
of	O
SARS	O
-	O
CoV	O
may	O
play	O
an	O
important	O
role	O
not	O
only	O
in	O
the	O
process	O
of	O
invasion	O
but	O
also	O
in	O
the	O
pathogenetic	O
process	O
in	O
cells	O
.	O

Finally	O
,	O
we	O
survey	O
the	O
recent	O
use	O
of	O
R0	O
in	O
assessing	O
emerging	O
diseases	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
avian	O
influenza	O
,	O
a	O
number	O
of	O
recent	O
livestock	O
diseases	O
,	O
and	O
vector	O
-	O
borne	O
diseases	O
malaria	B-PATH
,	O
dengue	O
and	O
West	O
Nile	O
virus	O
.	O

Coronavirus	O
replication	O
entails	O
ribosome	B-PATH
frameshifting	O
during	O
genome	O
translation	O
,	O
the	O
synthesis	O
of	O
both	O
genomic	O
and	O
multiple	O
subgenomic	O
RNA	O
species	O
,	O
and	O
the	O
assembly	O
of	O
progeny	O
virions	O
by	O
a	O
pathway	O
that	O
is	O
unique	O
among	O
enveloped	O
RNA	O
viruses	O
.	O

In	O
the	O
context	O
of	O
studying	O
influenza	B-PATH
infection	I-PATH
and	O
vaccine	O
development	O
,	O
serial	O
bronchoscopic	O
procedures	O
,	O
including	O
bronchial	O
brush	O
biopsies	O
and	O
bronchoalveolar	O
lavage	O
,	O
were	O
performed	O
in	O
pigtailed	O
macaques	O
(	O
Macaca	O
nemestrina	O
).	O

Bronchiolitis	O
was	O
frequently	O
diagnosed	O
in	O
patients	O
who	O
tested	O
positive	O
for	O
RSV	O
,	O
PIV	O
-	O
3	O
,	O
or	O
rhinovirus	O
,	O
whereas	O
influenza	B-PATH
A	I-PATH
,	O
PIV	O
-	O
1	O
,	O
and	O
HCoV	O
-	O
NL63	O
were	O
commonly	O
found	O
in	O
patients	O
with	O
croup	O
.	O

Both	O
major	O
camps	O
in	O
the	O
argument	O
presume	O
that	O
humans	O
are	O
normally	O
free	O
of	O
such	O
viruses	O
and	O
assume	O
that	O
once	O
the	O
simian	O
virus	O
was	O
transmitted	O
,	O
it	O
immediately	O
infected	O
some	O
T	O
-	O
cells	O
and	O
caused	O
the	O
release	B-PATH
of	O
toxic	O
agents	O
that	O
killed	O
off	O
bystander	O
(	O
uninfected	O
)	O
T	O
-	O
cells	O
resulting	O
in	O
AIDS	O
.	O

Med	O
Hypotheses	O
2004	O
;	O
62	O
(	O
3	O
):	O
354	O
-	O
7	O
]	O
in	O
which	O
it	O
is	O
presumed	O
that	O
in	O
hyper	O
-	O
endemic	O
areas	O
of	O
malaria	B-PATH
(	O
central	O
Africa	O
),	O
all	O
primates	O
(	O
humans	O
and	O
non	O
-	O
human	O
primates	O
)	O
have	O
shared	O
a	O
retrovirus	O
that	O
augments	O
their	O
T	O
-	O
cell	O
response	O
to	O
the	O
malaria	B-PATH
parasite	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
3a	O
protein	O
forms	O
an	O
ion	O
channel	O
and	O
modulates	O
virus	O
release	B-PATH
.	O

Our	O
observation	O
suggests	O
that	O
SARS	O
-	O
CoV	O
ORF	O
3a	O
functions	O
as	O
an	O
ion	O
channel	O
that	O
may	O
promote	O
virus	O
release	B-PATH
.	O

ABSTRACT	O
:	O
Small	O
nucleolar	O
RNAs	O
(	O
snoRNAs	O
)	O
play	O
a	O
key	O
role	O
in	O
eukaryotic	O
ribosome	B-PATH
biogenesis	O
.	O

Despite	O
evidence	O
of	O
the	O
multiple	O
cytokine	O
-	O
release	B-PATH
syndrome	O
,	O
all	O
six	O
patients	O
survived	O
.	O

A	O
few	O
others	O
,	O
such	O
as	O
Bordetella	O
pertussis	B-PATH
,	O
Haemophilus	O
influenzae	O
,	O
Proteus	O
vulgaris	O
,	O
or	O
Vibrio	O
cholerae	O
,	O
however	O
,	O
persist	O
only	O
for	O
days	O
.	O

Mycobacteria	O
,	O
including	O
Mycobacterium	O
tuberculosis	B-PATH
,	O
and	O
spore	O
-	O
forming	O
bacteria	O
,	O
including	O
Clostridium	O
difficile	O
,	O
can	O
also	O
survive	O
for	O
months	O
on	O
surfaces	O
.	O

With	O
other	O
infections	O
such	O
as	O
tuberculosis	B-PATH
,	O
measles	B-PATH
and	O
chickenpox	O
,	O
the	O
concept	O
of	O
aerosol	O
transmission	O
is	O
so	O
well	O
accepted	O
that	O
isolation	O
of	O
such	O
patients	O
is	O
the	O
norm	O
.	O

Specific	O
modalities	O
reviewed	O
include	O
low	O
-	O
tidal	O
volume	O
ventilation	O
,	O
permissive	O
hypercapnia	O
,	O
the	O
open	O
lung	O
approach	O
,	O
recruitment	O
maneuvers	O
,	O
airway	O
pressure	O
release	B-PATH
ventilation	O
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
prone	O
positioning	O
,	O
and	O
extracorporeal	O
life	O
support	O
.	O

The	O
transmission	O
of	O
tuberculosis	B-PATH
,	O
hepatitis	O
B	O
,	O
and	O
measles	B-PATH
from	O
adopted	O
children	O
to	O
family	O
members	O
has	O
been	O
documented	O
.	O

Furthermore	O
,	O
infectious	O
organisms	O
(	O
e	O
.	O
g	O
.,	O
intestinal	O
parasites	O
),	O
bacterial	O
pathogens	O
(	O
e	O
.	O
g	O
.,	O
Bordetella	O
pertussis	B-PATH
and	O
Treponema	O
pallidum	O
),	O
and	O
viruses	O
(	O
e	O
.	O
g	O
.,	O
human	O
immunodeficiency	O
virus	O
and	O
hepatitis	O
viruses	O
)	O
may	O
cause	O
clinically	O
significant	O
morbidity	O
and	O
mortality	O
among	O
infected	O
children	O
.	O

TITLE	O
:	O
Over	O
-	O
expression	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3b	O
protein	O
induces	O
both	O
apoptosis	B-PATH
and	O
necrosis	O
in	O
Vero	O
E6	O
cells	O
.	O

Here	O
,	O
a	O
detailed	O
time	O
-	O
course	O
study	O
was	O
performed	O
to	O
compare	O
the	O
apoptosis	B-PATH
and	O
necrosis	O
profiles	O
induced	O
by	O
full	O
-	O
length	O
3b	O
,	O
a	O
3b	O
mutant	O
that	O
was	O
deleted	O
by	O
30	O
amino	O
acids	O
from	O
the	O
C	O
terminus	O
(	O
3bDelta124	O
-	O
154	O
)	O
and	O
the	O
classical	O
apoptosis	B-PATH
inducer	O
,	O
Bax	O
.	O

Our	O
results	O
showed	O
that	O
Vero	O
E6	O
cells	O
transfected	O
with	O
a	O
construct	O
for	O
expressing	O
3b	O
underwent	O
necrosis	O
as	O
early	O
as	O
6h	O
after	O
transfection	O
and	O
underwent	O
simultaneous	O
necrosis	O
and	O
apoptosis	B-PATH
at	O
later	O
time	O
-	O
points	O
.	O

At	O
all	O
the	O
time	O
-	O
points	O
analysed	O
,	O
the	O
apoptosis	B-PATH
induced	O
by	O
the	O
expression	O
of	O
3b	O
was	O
less	O
than	O
the	O
level	O
induced	O
by	O
Bax	O
but	O
the	O
level	O
of	O
necrosis	O
was	O
comparable	O
.	O

These	O
diseases	O
include	O
influenza	O
,	O
tuberculosis	B-PATH
,	O
and	O
measles	B-PATH
,	O
together	O
accounting	O
for	O
25	O
%	O
of	O
infectious	O
causes	O
of	O
death	O
worldwide	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
second	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
),	O
regulates	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
by	O
counterbalancing	O
ACE	O
activity	O
.	O

The	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUPT	O
nick	O
end	O
-	O
labeling	O
assay	O
demonstrated	O
many	O
cells	O
undergoing	O
apoptosis	B-PATH
.	O

Apoptosis	B-PATH
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
SARS	O
associated	O
coronavirus	O
infection	O
in	O
the	O
thyroid	O
gland	O
.	O

Molecular	O
simulation	O
indicates	O
that	O
the	O
MOL376	O
(	O
a	O
compound	O
derived	O
from	O
a	O
Chinese	O
medicine	O
herb	O
with	O
the	O
therapeutic	O
efficacy	O
on	O
the	O
human	O
body	O
such	O
as	O
relieving	O
cough	O
,	O
removing	O
the	O
phlegm	O
,	O
and	O
relieving	O
asthma	B-PATH
)	O
has	O
not	O
only	O
the	O
highest	O
binding	O
energy	O
with	O
the	O
receptor	O
but	O
also	O
the	O
good	O
match	O
in	O
geometric	O
conformation	O
.	O

TITLE	O
:	O
A	O
second	O
,	O
non	O
-	O
canonical	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
in	O
SARS	O
coronavirus	O
.	O

Its	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	B-PATH
)	O
activity	O
appears	O
to	O
be	O
supplied	O
by	O
non	O
-	O
structural	O
protein	O
12	O
(	O
nsp12	O
)	O
that	O
includes	O
an	O
RdRp	B-PATH
domain	O
conserved	O
in	O
all	O
RNA	O
viruses	O
.	O

Thin	O
-	O
section	O
electron	O
microscope	O
shows	O
increased	O
lysosome	B-PATH
-	O
like	O
granule	O
and	O
mitochondria	O
in	O
PBMC	O
of	O
patients	O
.	O

Our	O
clinical	O
evidence	O
obtained	O
with	O
the	O
aid	O
of	O
polymerase	O
chain	O
reaction	O
featured	O
genomes	O
of	O
adenoviruses	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
respiratory	O
-	O
scintillating	O
virus	O
and	O
coronaviruses	O
.	O

On	O
the	O
whole	O
,	O
respiratory	O
viral	O
infections	O
were	O
detected	O
in	O
27	O
(	O
52	O
.	O
9	O
%)	O
patients	O
:	O
adenoviruses	O
--	O
23	O
.	O
5	O
%,	O
coronaviruses	O
--	O
13	O
.	O
7	O
%,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
--	O
5	O
.	O
9	O
%	O
and	O
respiratory	O
-	O
scintillating	O
virus	O
--	O
3	O
.	O
9	O
%.	O

TITLE	O
:	O
The	O
changing	O
spectrum	O
of	O
severe	O
falciparum	O
malaria	B-PATH
:	O
a	O
clinical	O
study	O
from	O
Bikaner	O
(	O
northwest	O
India	O
).	O

In	O
a	O
prospective	O
study	O
in	O
1994	O
the	O
spectrum	O
of	O
complication	O
was	O
dominated	O
by	O
cerebral	O
malaria	B-PATH
(	O
25	O
.	O
75	O
%)	O
followed	O
by	O
jaundice	O
(	O
11	O
.	O
47	O
%),	O
bleeding	O
tendencies	O
(	O
9	O
.	O
59	O
%),	O
severe	O
anaemia	O
(	O
5	O
.	O
83	O
%),	O
shock	O
(	O
5	O
.	O
26	O
%),	O
Acute	O
respiratory	O
distress	O
syndrome	O
-	O
ARDS	O
(	O
3	O
.	O
01	O
%),	O
renal	O
failure	O
(	O
2	O
.	O
07	O
%)	O
and	O
hypoglycemia	O
(	O
2	O
.	O
07	O
%)	O
whereas	O
in	O
2001	O
it	O
was	O
dominated	O
by	O
jaundice	O
(	O
58	O
.	O
85	O
%)	O
followed	O
by	O
severe	O
anaemia	O
(	O
26	O
.	O
04	O
%),	O
bleeding	O
tendencies	O
(	O
25	O
.	O
52	O
%),	O
shock	O
(	O
10	O
.	O
94	O
%),	O
cerebral	O
malaria	B-PATH
(	O
10	O
.	O
94	O
%),	O
renal	O
failure	O
(	O
6	O
.	O
25	O
%),	O
ARDS	O
(	O
2	O
.	O
08	O
%)	O
and	O
hypoglycemia	O
(	O
1	O
.	O
56	O
%).	O

Similarly	O
,	O
the	O
important	O
cause	O
of	O
mortality	O
in	O
2001	O
was	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
71	O
.	O
10	O
%)	O
with	O
predominant	O
presentation	O
of	O
jaundice	O
and	O
renal	O
failure	O
,	O
whereas	O
in	O
1994	O
,	O
it	O
was	O
cerebral	O
malaria	B-PATH
(	O
77	O
.	O
96	O
%).	O

RESULTS	O
:	O
In	O
a	O
prospective	O
study	O
in	O
1994	O
the	O
spectrum	O
of	O
complication	O
was	O
dominated	O
by	O
cerebral	O
malaria	B-PATH
(	O
25	O
.	O
75	O
%)	O
followed	O
by	O
jaundice	O
(	O
11	O
.	O
47	O
%),	O
bleeding	O
tendencies	O
(	O
9	O
.	O
59	O
%),	O
severe	O
anaemia	O
(	O
5	O
.	O
83	O
%),	O
shock	O
(	O
5	O
.	O
26	O
%),	O
Acute	O
respiratory	O
distress	O
syndrome	O
-	O
ARDS	O
(	O
3	O
.	O
01	O
%),	O
renal	O
failure	O
(	O
2	O
.	O
07	O
%)	O
and	O
hypoglycemia	O
(	O
2	O
.	O
07	O
%)	O
whereas	O
in	O
2001	O
it	O
was	O
dominated	O
by	O
jaundice	O
(	O
58	O
.	O
85	O
%)	O
followed	O
by	O
severe	O
anaemia	O
(	O
26	O
.	O
04	O
%),	O
bleeding	O
tendencies	O
(	O
25	O
.	O
52	O
%),	O
shock	O
(	O
10	O
.	O
94	O
%),	O
cerebral	O
malaria	B-PATH
(	O
10	O
.	O
94	O
%),	O
renal	O
failure	O
(	O
6	O
.	O
25	O
%),	O
ARDS	O
(	O
2	O
.	O
08	O
%)	O
and	O
hypoglycemia	O
(	O
1	O
.	O
56	O
%).	O

Similarly	O
,	O
the	O
important	O
cause	O
of	O
mortality	O
in	O
2001	O
was	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
71	O
.	O
10	O
%)	O
with	O
predominant	O
presentation	O
of	O
jaundice	O
and	O
renal	O
failure	O
,	O
whereas	O
in	O
1994	O
,	O
it	O
was	O
cerebral	O
malaria	B-PATH
(	O
77	O
.	O
96	O
%).	O

Between	O
normal	O
and	O
uremic	O
neutrophils	O
,	O
there	O
were	O
no	O
differences	O
in	O
apoptosis	B-PATH
or	O
superoxide	O
production	O
.	O

These	O
include	O
other	O
acute	O
emerging	O
or	O
re	O
-	O
emerging	O
viral	O
diseases	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
West	O
-	O
Nile	O
virus	O
,	O
Ebola	O
virus	O
,	O
monkeypox	O
,	O
as	O
well	O
as	O
the	O
more	O
inapparent	O
insidious	O
slow	O
viral	O
and	O
prion	B-PATH
diseases	I-PATH
.	O

TITLE	O
:	O
A	O
""""	O
possible	O
""""	O
involvement	O
of	O
TNF	O
-	O
alpha	O
in	O
apoptosis	B-PATH
induction	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
.	O

In	O
addition	O
,	O
TNF	O
-	O
alpha	O
released	O
from	O
macrophages	O
and	O
TNF	O
-	O
receptor	O
(	O
TNFR	O
)	O
1	O
and	O
TNFR2	O
mRNA	O
expression	O
in	O
lymphocytes	O
were	O
closely	O
involved	O
in	O
this	O
apoptosis	B-PATH
induction	O
.	O

In	O
particular	O
,	O
in	O
CD8	O
+	O
cells	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
PEC	O
culture	O
supernatant	O
,	O
the	O
expression	O
levels	O
of	O
TNFR1	O
and	O
TNFR2	O
mRNA	O
were	O
increased	O
,	O
indicating	O
that	O
CD8	O
+	O
cells	O
are	O
more	O
susceptible	O
to	O
apoptosis	B-PATH
induction	O
by	O
TNF	O
-	O
alpha	O
than	O
other	O
lymphocyte	O
subsets	O
,	O
particularly	O
B	O
cells	O
(	O
CD21	O
+	O
cells	O
).	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
genetic	O
interactions	O
of	O
telomeres	O
and	O
DNA	O
-	O
PKcs	O
,	O
a	O
protein	O
involved	O
in	O
non	B-PATH
-	I-PATH
homologous	I-PATH
end	I-PATH
-	I-PATH
joining	I-PATH
(	O
NHEJ	O
)	O
and	O
immune	O
responses	O
,	O
in	O
the	O
context	O
of	O
a	O
key	O
aspect	O
of	O
aging	O
and	O
lifespan	O
--	O
the	O
capacity	O
to	O
mount	O
an	O
acute	O
and	O
appropriate	O
immune	O
-	O
mediated	O
stress	B-PATH
response	I-PATH
.	O

The	O
translation	O
of	O
ORF7b	O
appears	O
to	O
be	O
mediated	O
by	O
ribosome	B-PATH
leaky	O
scanning	O
,	O
and	O
the	O
protein	O
has	O
biochemical	O
properties	O
consistent	O
with	O
that	O
of	O
an	O
integral	O
membrane	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
H	O
-	O
2Db	O
-	O
restricted	O
CD8	O
T	O
cell	O
immune	O
response	O
to	O
influenza	B-PATH
A	I-PATH
is	O
directed	O
at	O
two	O
well	O
-	O
described	O
epitopes	O
,	O
nucleoprotein	O
366	O
(	O
NP366	O
)	O
and	O
acid	O
polymerase	O
224	O
(	O
PA224	O
).	O

We	O
examine	O
mathematically	O
the	O
impact	O
of	O
engineering	O
control	O
measures	O
such	O
as	O
enhanced	O
air	O
exchange	O
and	O
air	O
filtration	O
rates	O
with	O
personal	O
masking	O
combined	O
with	O
public	O
health	O
interventions	O
such	O
as	O
vaccination	O
,	O
isolation	O
,	O
and	O
contact	O
tracing	O
in	O
containing	O
the	O
spread	O
of	O
indoor	O
airborne	O
infections	O
including	O
influenza	O
,	O
chickenpox	O
,	O
measles	B-PATH
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

If	O
enhanced	O
engineering	O
controls	O
could	O
reduce	O
the	O
basic	O
reproductive	O
number	O
(	O
R0	O
)	O
below	O
1	O
.	O
60	O
for	O
chickenpox	O
and	O
3	O
for	O
measles	B-PATH
,	O
our	O
simulations	O
show	O
that	O
in	O
such	O
a	O
prepared	O
response	O
with	O
public	O
health	O
interventions	O
would	O
have	O
a	O
high	O
probability	O
of	O
containing	O
the	O
indoor	O
airborne	O
infections	O
.	O

TITLE	O
:	O
Virus	O
associated	O
hemophagocytic	O
syndrome	O
accompanied	O
by	O
acute	O
respiratory	O
failure	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
).	O

TITLE	O
:	O
Avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
infection	O
in	O
a	O
child	O
.	O

Throat	O
swab	O
RT	O
-	O
PCR	O
and	O
viral	O
culture	O
for	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
were	O
positive	O
.	O

The	O
preferentially	O
type	O
2	O
cell	O
expressed	O
genes	O
involved	O
in	O
critical	O
functions	O
(	O
such	O
as	O
ATP	O
-	O
binding	O
cassette	O
transporter	O
,	O
ABCA3	O
),	O
those	O
involved	O
in	O
susceptibility	O
to	O
acute	O
lung	O
damage	O
,	O
and	O
those	O
with	O
known	O
susceptibility	O
to	O
other	O
severe	O
lung	O
diseases	O
(	O
such	O
as	O
G	O
protein	O
-	O
coupled	O
receptor	O
for	O
asthma	B-PATH
susceptibility	O
,	O
GPR154	O
alias	O
GPRA	O
)	O
will	O
possibly	O
serve	O
as	O
candidate	O
genes	O
in	O
future	O
studies	O
.	O

132	O
patients	O
with	O
mild	O
to	O
moderate	O
asthma	B-PATH
who	O
were	O
allergic	O
to	O
HDM	O
,	O
recruited	O
from	O
three	O
hospitals	O
of	O
China	O
(	O
The	O
First	O
Affiliated	O
Hospital	O
of	O
Guangzhou	O
Medical	O
College	O
,	O
Shenyang	O
General	O
Military	O
Hospital	O
,	O
Suzhou	O
Children	O
'	O
s	O
Hospital	O
),	O
were	O
randomly	O
allocated	O
to	O
the	O
active	O
group	O
(	O
n	O
=	O
66	O
)	O
or	O
the	O
control	O
group	O
(	O
n	O
=	O
66	O
)	O
respectively	O
.	O

The	O
role	O
of	O
circulating	O
trypsin	O
,	O
phospholipase	O
A2	O
,	O
platelet	O
activating	O
factor	O
,	O
release	B-PATH
of	O
free	O
fatty	O
acids	O
,	O
chemoattractants	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
fMet	O
-	O
leu	O
-	O
phe	O
(	O
a	O
bacterial	O
wall	O
product	O
),	O
nitric	O
oxide	O
,	O
substance	O
P	O
,	O
and	O
macrophage	O
inhibitor	O
factor	O
is	O
currently	O
studied	O
.	O

During	O
April	O
2004	O
-	O
April	O
2006	O
,	O
nasopharyngeal	O
specimens	O
from	O
children	O
hospitalized	O
with	O
acute	O
respiratory	O
disease	O
were	O
tested	O
for	O
common	O
respiratory	O
viruses	O
,	O
including	O
RSV	O
,	O
influenza	B-PATH
A	I-PATH
,	O
influenza	O
B	O
,	O
parainfluenza	O
viruses	O
,	O
and	O
adenovirus	O
by	O
IFA	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
viral	O
respiratory	O
tract	O
infections	O
in	O
children	O
with	O
asthma	B-PATH
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
support	O
a	O
strong	O
association	O
between	O
viral	O
respiratory	O
tract	O
infections	O
and	O
asthma	B-PATH
exacerbations	O
.	O

The	O
effect	O
of	O
newly	O
discovered	O
viruses	O
on	O
asthma	B-PATH
control	O
is	O
less	O
well	O
defined	O
.	O

Respiratory	O
specimens	O
from	O
children	O
aged	O
2	O
to	O
17	O
years	O
with	O
asthma	B-PATH
exacerbations	O
(	O
case	O
patients	O
,	O
n	O
=	O
65	O
)	O
and	O
with	O
well	O
-	O
controlled	O
asthma	B-PATH
(	O
control	O
subjects	O
,	O
n	O
=	O
77	O
),	O
frequency	O
matched	O
by	O
age	O
and	O
season	O
of	O
enrollment	O
,	O
were	O
tested	O
for	O
rhinoviruses	O
,	O
enteroviruses	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
coronaviruses	O
229E	O
and	O
OC43	O
,	O
parainfluenza	O
viruses	O
1	O
to	O
3	O
,	O
influenza	O
viruses	O
,	O
adenoviruses	O
,	O
and	O
human	O
bocavirus	O
.	O

Infection	O
with	O
respiratory	O
viruses	O
was	O
associated	O
with	O
asthma	B-PATH
exacerbations	O
(	O
63	O
.	O
1	O
%	O
in	O
case	O
patients	O
vs	O
23	O
.	O
4	O
%	O
in	O
control	O
subjects	O
;	O
odds	O
ratio	O
,	O
5	O
.	O
6	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
7	O
-	O
11	O
.	O
6	O
).	O

Other	O
viruses	O
detected	O
included	O
human	O
metapneumovirus	O
(	O
4	O
.	O
6	O
%	O
in	O
patients	O
with	O
acute	O
asthma	B-PATH
vs	O
2	O
.	O
6	O
%	O
in	O
control	O
subjects	O
),	O
enteroviruses	O
(	O
4	O
.	O
6	O
%	O
vs	O
0	O
%),	O
coronavirus	O
229E	O
(	O
0	O
%	O
vs	O
1	O
.	O
3	O
%),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
1	O
.	O
5	O
%	O
vs	O
0	O
%).	O

Symptomatic	O
rhinovirus	O
infections	O
are	O
an	O
important	O
contributor	O
to	O
asthma	B-PATH
exacerbations	O
in	O
children	O
.	O

These	O
results	O
support	O
the	O
need	O
for	O
therapies	O
effective	O
against	O
rhinovirus	O
as	O
a	O
means	O
to	O
decrease	O
asthma	B-PATH
exacerbations	O
.	O

RESULTS	O
:	O
Infection	O
with	O
respiratory	O
viruses	O
was	O
associated	O
with	O
asthma	B-PATH
exacerbations	O
(	O
63	O
.	O
1	O
%	O
in	O
case	O
patients	O
vs	O
23	O
.	O
4	O
%	O
in	O
control	O
subjects	O
;	O
odds	O
ratio	O
,	O
5	O
.	O
6	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
7	O
-	O
11	O
.	O
6	O
).	O

Other	O
viruses	O
detected	O
included	O
human	O
metapneumovirus	O
(	O
4	O
.	O
6	O
%	O
in	O
patients	O
with	O
acute	O
asthma	B-PATH
vs	O
2	O
.	O
6	O
%	O
in	O
control	O
subjects	O
),	O
enteroviruses	O
(	O
4	O
.	O
6	O
%	O
vs	O
0	O
%),	O
coronavirus	O
229E	O
(	O
0	O
%	O
vs	O
1	O
.	O
3	O
%),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
1	O
.	O
5	O
%	O
vs	O
0	O
%).	O

TITLE	O
:	O
Pulmonary	O
manifestations	O
of	O
malaria	B-PATH
:	O
recognition	O
and	O
management	O
.	O

ABSTRACT	O
:	O
Lung	O
involvement	O
in	O
malaria	B-PATH
has	O
been	O
recognized	O
for	O
more	O
than	O
200	O
hundred	O
years	O
,	O
yet	O
our	O
knowledge	O
of	O
its	O
pathogenesis	O
and	O
management	O
is	O
limited	O
.	O

This	O
defines	O
malaria	B-PATH
as	O
another	O
cause	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O
Pulmonary	O
edema	O
has	O
been	O
described	O
most	O
often	O
in	O
non	O
-	O
immune	O
individuals	O
with	O
Plasmodium	O
falciparum	O
infections	O
as	O
part	O
of	O
a	O
severe	O
systemic	O
illness	O
or	O
as	O
the	O
main	O
feature	O
of	O
acute	O
malaria	B-PATH
.	O

Optimal	O
management	O
of	O
malaria	B-PATH
-	O
induced	O
ALI	O
/	O
ARDS	O
includes	O
early	O
recognition	O
and	O
diagnosis	O
.	O

Malaria	B-PATH
must	O
always	O
be	O
suspected	O
in	O
a	O
returning	O
traveler	O
or	O
a	O
visitor	O
from	O
a	O
malaria	B-PATH
-	O
endemic	O
country	O
with	O
an	O
acute	O
febrile	O
illness	O
.	O

Malaria	B-PATH
must	O
be	O
treated	O
with	O
effective	O
drugs	O
,	O
but	O
current	O
choices	O
are	O
few	O
:	O
e	O
.	O
g	O
.	O
parenteral	O
artemisinins	O
,	O
intravenous	O
quinine	O
or	O
quinidine	O
(	O
in	O
the	O
US	O
only	O
).	O

Patients	O
should	O
be	O
managed	O
in	O
an	O
intensive	O
care	O
unit	O
and	O
particular	O
attention	O
should	O
be	O
paid	O
to	O
the	O
energetic	O
management	O
of	O
other	O
severe	O
malaria	B-PATH
complications	O
,	O
notably	O
coma	O
and	O
acute	O
renal	O
failure	O
.	O

Despite	O
optimal	O
management	O
,	O
the	O
prognosis	O
of	O
severe	O
malaria	B-PATH
with	O
ARDS	O
is	O
poor	O
.	O

ALI	O
/	O
ARDS	O
in	O
pediatric	O
malaria	B-PATH
appears	O
to	O
be	O
rare	O
.	O

However	O
,	O
falciparum	O
malaria	B-PATH
with	O
severe	O
metabolic	O
acidosis	O
or	O
acute	O
pulmonary	O
edema	O
may	O
present	O
with	O
a	O
clinical	O
picture	O
of	O
pneumonia	O
,	O
i	O
.	O
e	O
.	O
with	O
tachypnea	O
,	O
intercostal	O
recession	O
,	O
wheeze	O
or	O
inspiratory	O
crepitations	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
-	O
induced	O
oligodendrocyte	O
apoptosis	B-PATH
is	O
mediated	O
through	O
the	O
activation	O
of	O
the	O
Fas	O
signaling	O
pathway	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
showed	O
that	O
infection	O
of	O
rat	O
oligodendrocytes	O
by	O
ultraviolet	O
light	O
-	O
inactivated	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
apoptosis	B-PATH
,	O
suggesting	O
that	O
the	O
apoptosis	B-PATH
is	O
triggered	O
during	O
cell	O
entry	O
.	O

Both	O
treatments	O
blocked	O
virus	O
infection	O
and	O
apoptosis	B-PATH
,	O
indicating	O
that	O
virus	O
-	O
receptor	O
binding	O
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
the	O
apoptosis	B-PATH
induction	O
.	O

Treatment	O
with	O
a	O
Fas	O
/	O
Fc	O
chimera	O
,	O
which	O
blocks	O
Fas	O
-	O
Fas	O
ligand	O
-	O
mediated	O
apoptosis	B-PATH
,	O
inhibited	O
the	O
formation	O
of	O
the	O
complexes	O
and	O
blocked	O
the	O
activation	O
of	O
caspase	O
-	O
8	O
and	O
apoptosis	B-PATH
in	O
MHV	O
-	O
infected	O
cells	O
.	O

It	O
also	O
inhibited	O
the	O
release	B-PATH
of	O
cytochrome	O
c	O
from	O
mitochondria	O
and	O
the	O
activation	O
of	O
caspase	O
-	O
9	O
.	O

A	O
5	O
x	O
5	O
oligonucleotide	O
microarray	O
for	O
detecting	O
4	O
respiratory	O
tract	O
viruses	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
influenza	O
B	O
virus	O
,	O
and	O
enterovirus	O
)	O
with	O
inner	O
controls	O
was	O
arranged	O
on	O
the	O
inner	O
surface	O
of	O
a	O
specially	O
designed	O
Eppendorf	O
cap	O
with	O
a	O
flat	O
,	O
optically	O
transparent	O
window	O
.	O

N	O
gene	O
expression	O
prevents	O
cellular	O
RNA	B-PATH
degradation	I-PATH
and	O
partially	O
rescues	O
the	O
dramatic	O
translation	O
shutoff	O
characteristic	O
of	O
the	O
VVDeltaE3L	O
virus	O
.	O

This	O
inhibition	O
was	O
prevented	O
by	O
addition	O
of	O
cholesterol	O
to	O
the	O
culture	O
medium	O
,	O
indicating	O
that	O
the	O
reduction	O
of	O
virus	O
particle	O
release	B-PATH
was	O
caused	O
by	O
the	O
loss	O
of	O
cholesterol	O
in	O
the	O
cell	O
membrane	O
.	O

TITLE	O
:	O
[	O
Imported	O
severe	O
malaria	B-PATH
in	O
adults	O
:	O
a	O
retrospective	O
study	O
of	O
ten	O
cases	O
admitted	O
to	O
intensive	O
care	O
units	O
in	O
Casablanca	O
].	O

All	O
patients	O
over	O
14	O
years	O
of	O
age	O
with	O
falciparum	O
malaria	B-PATH
,	O
who	O
were	O
admitted	O
to	O
ICUs	O
between	O
1996	O
and	O
2001	O
,	O
were	O
included	O
.	O

Ten	O
patients	O
were	O
included	O
for	O
severe	O
imported	O
malaria	B-PATH
.	O

The	O
lethality	O
of	O
severe	O
imported	O
malaria	B-PATH
is	O
still	O
high	O
despite	O
optimal	O
management	O
in	O
ICUs	O
.	O

RESULTS	O
:	O
Ten	O
patients	O
were	O
included	O
for	O
severe	O
imported	O
malaria	B-PATH
.	O

CONCLUSIONS	O
:	O
The	O
lethality	O
of	O
severe	O
imported	O
malaria	B-PATH
is	O
still	O
high	O
despite	O
optimal	O
management	O
in	O
ICUs	O
.	O

The	O
SARS	O
-	O
CoV	O
nsp1	O
protein	O
increases	O
cellular	O
RNA	B-PATH
degradation	I-PATH
and	O
thus	O
might	O
facilitate	O
SARS	O
-	O
CoV	O
replication	O
or	O
block	O
immune	O
responses	O
.	O

TITLE	O
:	O
The	O
intracellular	O
sites	O
of	O
early	O
replication	O
and	O
budding	B-PATH
of	O
SARS	O
-	O
coronavirus	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
replication	O
and	O
budding	B-PATH
sites	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
at	O
early	O
time	O
points	O
of	O
infection	O
.	O

Immuno	O
-	O
EM	O
revealed	O
that	O
budding	B-PATH
occurred	O
at	O
membranes	O
of	O
the	O
ERGIC	O
(	O
ER	O
-	O
Golgi	O
intermediate	O
compartment	O
)	O
and	O
the	O
Golgi	O
region	O
as	O
early	O
as	O
3	O
h	O
post	O
infection	O
,	O
demonstrating	O
that	O
SARS	O
-	O
CoV	O
replicates	O
surprisingly	O
fast	O
.	O

TITLE	O
:	O
UK	O
malaria	B-PATH
treatment	O
guidelines	O
.	O

Approximately	O
three	O
-	O
quarters	O
of	O
reported	O
malaria	B-PATH
cases	O
in	O
the	O
UK	O
are	O
caused	O
by	O
Plasmodium	O
falciparum	O
,	O
which	O
is	O
capable	O
of	O
invading	O
a	O
high	O
proportion	O
of	O
red	O
blood	O
cells	O
and	O
rapidly	O
leading	O
to	O
severe	O
or	O
life	O
-	O
threatening	O
multi	O
-	O
organ	O
disease	O
.	O

Most	O
non	O
-	O
falciparum	O
malaria	B-PATH
cases	O
are	O
caused	O
by	O
Plasmodium	O
vivax	O
;	O
a	O
few	O
cases	O
are	O
caused	O
by	O
the	O
other	O
two	O
species	O
of	O
Plasmodium	O
:	O
Plasmodium	O
ovale	O
or	O
Plasmodium	O
malariae	O
.	O

Mixed	O
infections	O
with	O
more	O
than	O
1	O
species	O
of	O
parasite	O
can	O
occur	O
;	O
they	O
commonly	O
involve	O
P	O
.	O
falciparum	O
with	O
the	O
attendant	O
risks	O
of	O
severe	O
malaria	B-PATH
.	O

Management	O
of	O
malaria	B-PATH
depends	O
on	O
awareness	O
of	O
the	O
diagnosis	O
and	O
on	O
performing	O
the	O
correct	O
diagnostic	O
tests	O
:	O
the	O
diagnosis	O
cannot	O
be	O
excluded	O
until	O
3	O
blood	O
specimens	O
have	O
been	O
examined	O
by	O
an	O
experienced	O
microscopist	O
.	O

There	O
are	O
no	O
typical	O
clinical	O
features	O
of	O
malaria	B-PATH
,	O
even	O
fever	O
is	O
not	O
invariably	O
present	O
.	O

The	O
optimum	O
diagnostic	O
procedure	O
is	O
examination	O
of	O
thick	O
and	O
thin	O
blood	O
films	O
by	O
an	O
expert	O
to	O
detect	O
and	O
speciate	O
the	O
malarial	O
parasites	O
;	O
P	O
.	O
falciparum	O
malaria	B-PATH
can	O
be	O
diagnosed	O
almost	O
as	O
accurately	O
using	O
rapid	O
diagnostic	O
tests	O
(	O
RDTs	O
)	O
which	O
detect	O
plasmodial	O
antigens	O
or	O
enzymes	O
,	O
although	O
RDTs	O
for	O
other	O
Plasmodium	O
species	O
are	O
not	O
as	O
reliable	O
.	O

The	O
treatment	O
of	O
choice	O
for	O
non	O
-	O
falciparum	O
malaria	B-PATH
is	O
a	O
3	O
-	O
day	O
course	O
of	O
oral	O
chloroquine	O
,	O
to	O
which	O
only	O
a	O
limited	O
proportion	O
of	O
P	O
.	O
vivax	O
strains	O
have	O
gained	O
resistance	O
.	O

Uncomplicated	O
P	O
.	O
falciparum	O
malaria	B-PATH
can	O
be	O
treated	O
orally	O
with	O
quinine	O
,	O
atovaquone	O
plus	O
proguanil	O
(	O
Malarone	O
)	O
or	O
co	O
-	O
artemether	O
(	O
Riamet	O
);	O
quinine	O
is	O
highly	O
effective	O
but	O
poorly	O
tolerated	O
in	O
prolonged	O
dosage	O
and	O
is	O
always	O
supplemented	O
by	O
additional	O
treatment	O
,	O
usually	O
with	O
oral	O
doxycycline	O
.	O

ALL	O
patients	O
treated	O
for	O
P	O
.	O
falciparum	O
malaria	B-PATH
should	O
be	O
admitted	O
to	O
hospital	O
for	O
at	O
least	O
24	O
h	O
,	O
since	O
patients	O
can	O
deteriorate	O
suddenly	O
,	O
especially	O
early	O
in	O
the	O
course	O
of	O
treatment	O
.	O

In	O
the	O
UK	O
,	O
the	O
treatment	O
of	O
choice	O
for	O
severe	O
or	O
complicated	O
malaria	B-PATH
is	O
currently	O
an	O
infusion	O
of	O
intravenous	O
quinine	O
.	O

This	O
may	O
exacerbate	O
hypoglycaemia	O
that	O
can	O
occur	O
in	O
malaria	B-PATH
;	O
patients	O
treated	O
with	O
intravenous	O
quinine	O
therefore	O
require	O
careful	O
monitoring	O
.	O

Intravenous	O
artesunate	O
reduces	O
high	O
parasite	O
loads	O
more	O
rapidly	O
than	O
quinine	O
and	O
is	O
more	O
effective	O
in	O
treating	O
severe	O
malaria	B-PATH
in	O
selected	O
situations	O
.	O

Patients	O
with	O
severe	O
or	O
complicated	O
malaria	B-PATH
should	O
be	O
managed	O
in	O
a	O
high	O
dependency	O
or	O
intensive	O
care	O
environment	O
.	O

The	O
treatment	O
of	O
choice	O
for	O
falciparum	O
malaria	B-PATH
in	O
pregnancy	O
is	O
quinine	O
;	O
doxycycline	O
is	O
contraindicated	O
in	O
pregnancy	O
but	O
clindamycin	O
can	O
be	O
substituted	O
for	O
it	O
,	O
and	O
is	O
equally	O
effective	O
.	O

Children	O
are	O
over	O
-	O
represented	O
in	O
the	O
incidence	O
of	O
malaria	B-PATH
in	O
the	O
UK	O
,	O
probably	O
because	O
completely	O
susceptible	O
UK	O
-	O
born	O
children	O
accompany	O
their	O
overseas	O
-	O
born	O
parents	O
on	O
visits	O
to	O
family	O
and	O
friends	O
in	O
endemic	O
areas	O
.	O

Malaria	B-PATH
in	O
children	O
(	O
and	O
sometimes	O
in	O
adults	O
)	O
may	O
present	O
with	O
misleading	O
symptoms	O
such	O
as	O
gastrointestinal	O
features	O
,	O
sore	O
throat	O
or	O
lower	O
respiratory	O
complaints	O
;	O
the	O
diagnosis	O
must	O
always	O
be	O
sought	O
in	O
a	O
feverish	O
or	O
very	O
sick	O
child	O
who	O
has	O
visited	O
malaria	B-PATH
-	O
endemic	O
areas	O
.	O

Generation	O
of	O
viruses	O
with	O
restored	O
wild	O
-	O
type	O
helical	O
pitch	O
resulted	O
in	O
increased	O
virus	O
production	O
,	O
but	O
some	O
exhibited	O
decreased	O
virus	O
release	B-PATH
.	O

ABSTRACT	O
:	O
Airborne	O
infection	O
isolation	O
rooms	O
(	O
AIIRs	O
)	O
house	O
patients	O
with	O
tuberculosis	B-PATH
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
many	O
other	O
airborne	O
infectious	O
diseases	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
cleavage	O
of	O
signal	O
peptide	O
at	O
the	O
C	O
-	O
terminus	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
core	O
protein	O
by	O
signal	O
peptide	O
peptidase	O
.	O

The	O
avian	O
influenza	B-PATH
A	I-PATH
-	O
H5N1	O
-	O
virus	O
of	O
high	O
pathogenicity	O
has	O
crossed	O
in	O
multiple	O
instances	O
the	O
species	O
barriers	O
between	O
humans	O
,	O
mammals	O
,	O
and	O
birds	O
posing	O
a	O
serious	O
pandemic	O
threat	O
.	O

The	O
application	O
of	O
the	O
so	O
far	O
learnt	O
and	O
the	O
continued	O
development	O
of	O
preventive	O
strategies	O
,	O
efficient	O
vaccines	O
,	O
and	O
antiviral	O
substances	O
are	O
besides	O
worldwide	O
surveillance	O
decisive	O
to	O
rapidly	O
detect	O
the	O
repeated	O
,	O
enforced	O
,	O
or	O
new	O
appearance	O
of	O
viruses	O
like	O
the	O
SARS	O
-	O
CoV	O
,	O
influenza	B-PATH
A	I-PATH
-	O
H5N1	O
virus	O
,	O
or	O
of	O
new	O
viruses	O
,	O
to	O
contain	O
their	O
spread	O
,	O
and	O
to	O
defeat	O
them	O
.	O

Morphologic	O
and	O
biochemical	O
features	O
of	O
apoptosis	B-PATH
,	O
such	O
as	O
blebbing	O
of	O
the	O
plasma	O
membrane	O
,	O
translocation	O
of	O
phosphatidilserine	O
to	O
cell	O
surface	O
and	O
annexin	O
V	O
positive	O
staining	O
,	O
nuclear	O
fragmentation	O
,	O
apoptotic	O
bodies	O
formation	O
and	O
DNA	O
laddering	O
,	O
were	O
detected	O
in	O
CCoV	O
-	O
infected	O
cells	O
.	O

A	O
4	O
years	O
-	O
old	O
girl	O
with	O
chronic	O
respiratory	O
syndrome	O
chronically	O
treated	O
with	O
anti	O
-	O
asthma	B-PATH
drugs	O
was	O
admitted	O
to	O
hospital	O
in	O
November	O
2005	O
with	O
acute	O
respiratory	O
syndrome	O
and	O
atelectasis	O
.	O

Human	O
metapneumovirus	O
contributes	O
as	O
an	O
etiological	O
agent	O
of	O
acute	O
lower	O
and	O
upper	O
respiratory	O
tract	O
infection	O
especially	O
in	O
winter	O
season	O
in	O
children	O
with	O
bronchiolitis	O
,	O
pneumonia	O
or	O
episodes	O
of	O
asthma	B-PATH
exacerbation	O
in	O
Hungary	O
,	O
too	O
.	O

RESULTS	O
:	O
A	O
4	O
years	O
-	O
old	O
girl	O
with	O
chronic	O
respiratory	O
syndrome	O
chronically	O
treated	O
with	O
anti	O
-	O
asthma	B-PATH
drugs	O
was	O
admitted	O
to	O
hospital	O
in	O
November	O
2005	O
with	O
acute	O
respiratory	O
syndrome	O
and	O
atelectasis	O
.	O

There	O
is	O
strong	O
and	O
sufficient	O
evidence	O
to	O
demonstrate	O
the	O
association	O
between	O
ventilation	O
,	O
air	O
movements	O
in	O
buildings	O
and	O
the	O
transmission	O
/	O
spread	O
of	O
infectious	O
diseases	O
such	O
as	O
measles	B-PATH
,	O
tuberculosis	B-PATH
,	O
chickenpox	O
,	O
influenza	O
,	O
smallpox	O
and	O
SARS	O
.	O

Most	O
commercial	O
mAbs	O
studied	O
as	O
antiviral	O
agents	O
in	O
the	O
clinic	O
have	O
either	O
directly	O
or	O
indirectly	O
targeted	O
human	O
immunodeficiency	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
or	O
hepatitis	B-PATH
C	I-PATH
virus	O
infections	O
.	O

Apoptosis	B-PATH
was	O
induced	O
easily	O
in	O
M	O
.	O
fermentans	O
-	O
infected	O
cells	O
,	O
indicating	O
that	O
they	O
were	O
primed	O
for	O
apoptosis	B-PATH
.	O

These	O
results	O
indicated	O
that	O
M	O
.	O
fermentans	O
enhances	O
apoptosis	B-PATH
in	O
surviving	O
cells	O
that	O
have	O
escaped	O
from	O
SARS	O
-	O
CoV	O
-	O
induced	O
apoptosis	B-PATH
.	O

In	O
contrast	O
to	O
human	O
influenza	B-PATH
A	I-PATH
H1NI	O
viruses	O
,	O
the	O
H5N1	O
viruses	O
hyper	O
-	O
induce	O
cytokines	O
(	O
tumour	O
necrosis	O
factor	O
[	O
TNF	O
]	O
alpha	O
,	O
interferon	O
beta	O
)	O
and	O
chemokines	O
(	O
IP10	O
,	O
MIP1alpha	O
,	O
MCP	O
)	O
in	O
in	O
vitro	O
cultures	O
of	O
primary	O
human	O
macrophages	O
.	O

In	O
vitro	O
experiments	O
of	O
chromatin	O
condensation	O
and	O
DNA	O
fragmentation	O
suggest	O
that	O
the	O
3a	O
protein	O
may	O
trigger	O
apoptosis	B-PATH
.	O

Our	O
data	O
show	O
that	O
over	O
-	O
expression	O
of	O
a	O
single	O
SARS	O
-	O
CoV	O
protein	O
can	O
induce	O
apoptosis	B-PATH
in	O
vitro	O
.	O

To	O
exploit	O
the	O
possibility	O
of	O
using	O
RNA	O
interference	O
(	O
RNAi	O
)	O
as	O
a	O
strategy	O
against	O
TGEV	O
infection	O
,	O
two	O
shRNA	O
-	O
expressing	O
plasmids	O
(	O
pEGFP	O
-	O
U6	O
/	O
P1	O
and	O
pEGFP	O
-	O
U6	O
/	O
P2	O
)	O
targeting	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
of	O
TGEV	O
were	O
constructed	O
and	O
transfected	O
into	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	O
.	O

The	O
model	O
reproduces	O
all	O
clinical	O
signs	O
of	O
measles	B-PATH
,	O
but	O
the	O
lack	O
of	O
ferret	O
-	O
specific	O
reagents	O
has	O
limited	O
the	O
characterization	O
of	O
the	O
cellular	O
immune	O
response	O
.	O

We	O
further	O
showed	O
that	O
M	O
protein	O
-	O
induced	O
apoptosis	B-PATH
involved	O
mitochondrial	O
release	B-PATH
of	O
cytochrome	O
c	O
protein	O
,	O
and	O
could	O
be	O
suppressed	O
by	O
caspase	O
inhibitors	O
.	O

Altogether	O
,	O
our	O
data	O
show	O
that	O
SARS	O
-	O
CoV	O
M	O
protein	O
induces	O
apoptosis	B-PATH
through	O
the	O
modulation	O
of	O
the	O
cellular	O
Akt	O
pro	O
-	O
survival	O
pathway	O
and	O
mitochondrial	O
cytochrome	O
c	O
release	B-PATH
.	O

Two	O
hundred	O
twenty	O
-	O
seven	O
children	O
were	O
enrolled	O
in	O
the	O
study	O
with	O
a	O
diagnosis	O
of	O
asthma	B-PATH
,	O
bronchiolitis	O
,	O
bronchopneumonia	O
,	O
or	O
laringo	O
-	O
tracheo	O
bronchitis	O
.	O

TITLE	O
:	O
Severe	O
malaria	B-PATH
--	O
analysis	O
of	O
prognostic	O
symptoms	O
and	O
signs	O
in	O
169	O
patients	O
treated	O
in	O
Gdynia	O
in	O
1991	O
-	O
2005	O
.	O

Moreover	O
,	O
meningoencephalitis	O
was	O
diagnosed	O
in	O
two	O
patients	O
--	O
in	O
one	O
of	O
them	O
concurrently	O
with	O
symptoms	O
and	O
signs	O
of	O
malaria	B-PATH
,	O
while	O
in	O
the	O
other	O
one	O
-	O
3	O
weeks	O
after	O
the	O
symptoms	O
subsided	O
.	O

The	O
cause	O
of	O
death	O
was	O
multi	O
-	O
organ	O
failure	O
,	O
with	O
the	O
first	O
sign	O
of	O
poor	O
prognosis	O
being	O
rapidly	O
progressing	O
renal	O
failure	O
resistant	O
to	O
treatment	O
in	O
three	O
men	O
;	O
in	O
one	O
case	O
death	O
resulted	O
from	O
cerebral	O
malaria	B-PATH
.	O

In	O
cases	O
of	O
suspected	O
malaria	B-PATH
,	O
relapsing	O
malaria	B-PATH
or	O
in	O
mixed	O
infections	O
,	O
molecular	O
testing	O
was	O
a	O
valuable	O
complementary	O
tool	O
of	O
diagnosis	O
,	O
which	O
helped	O
in	O
beginning	O
the	O
appropriate	O
treatment	O
.	O

TITLE	O
:	O
Progress	O
in	O
tuberculosis	B-PATH
control	O
and	O
the	O
evolving	O
public	O
-	O
health	O
system	O
in	O
China	O
.	O

These	O
signs	O
of	O
inadequate	O
tuberculosis	B-PATH
control	O
can	O
be	O
linked	O
to	O
a	O
malfunctioning	O
health	O
system	O
.	O

These	O
measures	O
contributed	O
to	O
acceleration	O
in	O
efforts	O
to	O
control	O
tuberculosis	B-PATH
.	O

By	O
2005	O
,	O
the	O
detection	O
of	O
cases	O
of	O
tuberculosis	B-PATH
had	O
increased	O
to	O
80	O
%	O
of	O
the	O
estimated	O
total	O
new	O
cases	O
,	O
permitting	O
China	O
to	O
achieve	O
the	O
2005	O
global	O
tuberculosis	B-PATH
control	O
targets	O
.	O

At	O
the	O
same	O
time	O
,	O
specific	O
efforts	O
to	O
improve	O
tuberculosis	B-PATH
control	O
also	O
contributed	O
to	O
strengthening	O
of	O
the	O
public	O
-	O
health	O
system	O
.	O

Preclinical	O
investigations	O
conducted	O
by	O
Alfacell	O
showed	O
synergistic	O
antitumour	O
effects	O
between	O
ranpirnase	O
and	O
proteasome	B-PATH
inhibitors	O
.	O

If	O
this	O
concept	O
can	O
be	O
proven	O
in	O
in	O
vivo	O
,	O
low	O
-	O
molecular	O
-	O
weight	O
non	O
-	O
peptidic	O
CBAs	O
such	O
as	O
Pradimycin	O
A	O
may	O
become	O
the	O
cornerstone	O
for	O
the	O
efficient	O
treatment	O
of	O
infections	O
of	O
those	O
viruses	O
that	O
require	O
a	O
glycosylated	O
envelope	O
(	O
that	O
is	O
,	O
HIV	O
,	O
but	O
also	O
hepatitis	B-PATH
C	I-PATH
virus	O
)	O
for	O
entry	O
into	O
its	O
target	O
cells	O
.	O

At	O
the	O
time	O
G3139	O
was	O
conceived	O
as	O
an	O
anti	O
-	O
cancer	O
drug	O
candidate	O
,	O
it	O
was	O
viewed	O
optimistically	O
because	O
Bcl	O
-	O
2	O
was	O
widely	O
believed	O
to	O
be	O
the	O
most	O
important	O
protein	O
blocking	O
p53	O
-	O
dependent	O
apoptosis	B-PATH
caused	O
by	O
internal	O
stress	O
.	O

Since	O
that	O
time	O
,	O
we	O
have	O
learnt	O
that	O
Bcl	O
-	O
2	O
is	O
not	O
the	O
only	O
protein	O
that	O
inhibits	O
apoptosis	B-PATH
and	O
that	O
p53	O
itself	O
is	O
frequently	O
malfunctioning	O
in	O
tumors	O
.	O

Moreover	O
,	O
Bcl	O
-	O
2	O
has	O
a	O
role	O
in	O
halting	O
the	O
cell	B-PATH
cycle	I-PATH
(	O
though	O
p27	O
),	O
which	O
may	O
slow	O
down	O
tumor	O
growth	O
;	O
and	O
Bcl	O
-	O
2	O
even	O
has	O
pro	O
-	O
apoptotic	O
roles	O
in	O
the	O
execution	O
of	O
apoptosis	B-PATH
initiated	O
by	O
external	O
death	O
signals	O
(	O
via	O
Fas	O
/	O
CD95	O
and	O
caspase	O
3	O
).	O

Specifically	O
,	O
the	O
unmethylated	O
CpG	O
ODN	O
(	O
and	O
/	O
or	O
the	O
phosphorothioate	O
group	O
)	O
activates	O
the	O
immune	O
system	O
,	O
but	O
this	O
potentially	O
important	O
anti	O
-	O
cancer	O
effect	O
is	O
lost	O
when	O
the	O
immune	O
cells	O
undergo	O
premature	O
apoptosis	B-PATH
apparently	O
because	O
their	O
Bcl	O
-	O
2	O
levels	O
have	O
been	O
lowered	O
by	O
the	O
antisense	O
effect	O
of	O
G3139	O
.	O

Risks	O
related	O
to	O
naloxone	O
use	O
in	O
opioid	O
-	O
dependent	O
patients	O
are	O
:	O
i	O
)	O
the	O
induction	O
of	O
an	O
acute	O
withdrawal	O
syndrome	O
(	O
the	O
occurrence	O
of	O
vomiting	O
and	O
aspiration	O
is	O
potentially	O
life	O
threatening	O
);	O
ii	O
)	O
the	O
effect	O
of	O
naloxone	O
may	O
wear	O
off	O
prematurely	O
when	O
used	O
for	O
treatment	O
of	O
opioid	O
-	O
induced	O
respiratory	O
depression	O
;	O
and	O
iii	O
)	O
in	O
patients	O
treated	O
for	O
severe	O
pain	O
with	O
an	O
opioid	O
,	O
high	O
-	O
dose	O
naloxone	O
and	O
/	O
or	O
rapidly	O
infused	O
naloxone	O
may	O
cause	O
catecholamine	O
release	B-PATH
and	O
consequently	O
pulmonary	O
edema	O
and	O
cardiac	O
arrhythmias	O
.	O

TITLE	O
:	O
Early	O
tumor	O
regression	O
following	O
severe	O
lung	O
injury	O
after	O
allogeneic	O
stem	O
cell	O
transplantation	O
in	O
a	O
patient	O
with	O
renal	B-PATH
cell	I-PATH
carcinoma	I-PATH
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
65	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
repeated	O
lung	O
injuries	O
after	O
reduced	O
-	O
intensity	O
allogeneic	O
stem	O
cell	O
transplantation	O
(	O
RIST	O
)	O
for	O
renal	B-PATH
cell	I-PATH
carcinoma	I-PATH
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
TNF	O
-	O
alpha	O
production	O
was	O
increased	O
with	O
viral	O
replication	O
in	O
macrophages	O
inoculated	O
with	O
a	O
mixture	O
of	O
FIPV	O
and	O
anti	O
-	O
S	O
antibody	O
,	O
and	O
demonstrated	O
that	O
this	O
culture	O
supernatant	O
had	O
feline	O
PBMC	O
apoptosis	B-PATH
-	O
inducing	O
activity	O
.	O

ABSTRACT	O
:	O
New	O
emerging	O
infectious	O
diseases	O
include	O
""""	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
""""	O
(	O
SARS	O
)	O
and	O
avian	O
influenza	B-PATH
A	I-PATH
H5N1	O
.	O

Avian	O
influenza	B-PATH
A	I-PATH
H5N1	O
is	O
another	O
emerging	O
infectious	O
disease	O
transmitted	O
from	O
avian	O
species	O
to	O
humans	O
,	O
without	O
clear	O
evidence	O
of	O
transmission	O
from	O
human	O
to	O
human	O
.	O

Immunohistochemical	O
examination	O
revealed	O
that	O
AE2	O
cells	O
as	O
well	O
as	O
alveolar	O
macrophages	O
were	O
deleted	O
via	O
apoptosis	B-PATH
in	O
the	O
mice	O
treated	O
with	O
DT	O
.	O

Previously	O
,	O
SARS	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
has	O
been	O
demonstrated	O
to	O
induce	O
apoptosis	B-PATH
via	O
the	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
caspase	O
-	O
9	O
(	O
Lin	O
,	O
C	O
.	O
W	O
.,	O
Lin	O
,	O
K	O
.	O
H	O
.,	O
Hsieh	O
,	O
T	O
.	O
H	O
.,	O
Shiu	O
,	O
S	O
.	O
Y	O
.	O
et	O
al	O
.,	O
FEMS	O
Immunol	O
.	O

Functional	O
classification	O
of	O
identified	O
up	O
-	O
regulated	O
proteins	O
indicated	O
that	O
protein	O
metabolism	O
and	O
modification	O
,	O
particularly	O
in	O
the	O
ubiquitin	O
proteasome	B-PATH
pathway	O
,	O
was	O
the	O
main	O
biological	O
process	O
occurring	O
in	O
SARS	O
CoV	O
3CLpro	O
-	O
expressing	O
cells	O
.	O

Thirty	O
-	O
six	O
percent	O
of	O
identified	O
up	O
-	O
regulated	O
proteins	O
were	O
located	O
in	O
the	O
mitochondria	O
,	O
including	O
apoptosis	B-PATH
-	O
inducing	O
factor	O
,	O
ATP	O
synthase	O
beta	O
chain	O
and	O
cytochrome	O
c	O
oxidase	O
.	O

TITLE	O
:	O
G1	O
phase	O
cell	B-PATH
cycle	I-PATH
arrest	O
induced	O
by	O
SARS	O
-	O
CoV	O
3a	O
protein	O
via	O
the	O
cyclin	O
D3	O
/	O
pRb	O
pathway	O
.	O

Here	O
we	O
observed	O
that	O
transient	O
expression	O
of	O
3a	O
inhibited	O
cell	O
growth	O
and	O
prevented	O
5	O
-	O
bromodeoxyuridine	O
incorporation	O
,	O
suggesting	O
that	O
3a	O
deregulated	O
cell	B-PATH
cycle	I-PATH
progression	O
.	O

Cell	B-PATH
cycle	I-PATH
analysis	O
demonstrated	O
that	O
3a	O
expression	O
was	O
associated	O
with	O
blockage	O
of	O
cell	B-PATH
cycle	I-PATH
progression	O
at	O
G1	O
phase	O
in	O
HEK	O
293	O
,	O
COS	O
-	O
7	O
,	O
and	O
Vero	O
cells	O
24	O
-	O
60	O
h	O
after	O
transfection	O
.	O

Mutation	O
analysis	O
of	O
3a	O
revealed	O
that	O
C	O
-	O
terminal	O
region	O
(	O
176	O
aa	O
approximately	O
274	O
aa	O
),	O
including	O
a	O
potential	O
calcium	O
ATPase	O
motif	O
,	O
was	O
essential	O
for	O
induction	O
of	O
cell	B-PATH
cycle	I-PATH
arrest	O
.	O

Analyzing	O
the	O
cellular	O
proteins	O
involving	O
in	O
regulation	O
of	O
cell	B-PATH
cycle	I-PATH
progression	O
,	O
we	O
demonstrated	O
that	O
3a	O
expression	O
was	O
correlated	O
with	O
a	O
significant	O
reduction	O
of	O
cyclin	O
D3	O
level	O
and	O
phosphorylation	O
of	O
retinoblastoma	O
(	O
Rb	O
)	O
protein	O
at	O
Ser	O
-	O
795	O
and	O
Ser	O
-	O
809	O
/	O
811	O
,	O
not	O
with	O
the	O
expression	O
of	O
cyclin	O
D1	O
,	O
D2	O
,	O
cdk4	O
,	O
and	O
cdk6	O
in	O
293	O
cells	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
,	O
seen	O
in	O
severe	O
falciparum	O
malaria	B-PATH
,	O
has	O
also	O
been	O
observed	O
in	O
vivax	O
malaria	B-PATH
.	O

A	O
study	O
has	O
demonstrated	O
the	O
return	O
of	O
chloroquine	O
-	O
sensitive	O
falciparum	O
malaria	B-PATH
several	O
years	O
after	O
chloroquine	O
treatment	O
was	O
discontinued	O
.	O

Studies	O
are	O
in	O
progress	O
to	O
develop	O
vaccines	O
against	O
amoebiasis	B-PATH
,	O
malaria	B-PATH
and	O
hookworm	O
infections	O
.	O

TITLE	O
:	O
Cell	B-PATH
cycle	I-PATH
dependent	O
nucleolar	O
localization	O
of	O
the	O
coronavirus	O
nucleocapsid	O
protein	O
.	O

Viral	O
proteins	O
can	O
localise	O
to	O
the	O
nucleolus	O
and	O
using	O
the	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
as	O
a	O
model	O
,	O
the	O
cell	B-PATH
cycle	I-PATH
dependent	O
trafficking	O
of	O
viral	O
proteins	O
to	O
the	O
nucleolus	O
was	O
investigated	O
.	O

Cell	O
synchronisation	O
studies	O
coupled	O
to	O
live	O
cell	O
confocal	O
microscopy	O
indicated	O
that	O
nucleolar	O
localisation	O
of	O
N	O
protein	O
was	O
greater	O
in	O
the	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
than	O
at	O
other	O
stages	O
.	O

This	O
result	O
was	O
reinforced	O
when	O
FRAP	O
and	O
FLIP	O
analysis	O
indicated	O
that	O
N	O
protein	O
was	O
more	O
mobile	O
within	O
the	O
nucleoplasm	O
and	O
nucleolus	O
in	O
the	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
.	O

The	O
data	O
suggested	O
that	O
viral	O
nucleolar	O
proteins	O
can	O
also	O
localise	O
to	O
the	O
nucleolus	O
in	O
a	O
cell	B-PATH
cycle	I-PATH
dependent	O
manner	O
and	O
this	O
may	O
be	O
related	O
to	O
dynamic	O
trafficking	O
.	O

Specimens	O
from	O
a	O
nasopharyngeal	O
swab	O
or	O
bronchial	O
washing	O
were	O
analyzed	O
for	O
influenza	B-PATH
A	I-PATH
,	O
B	O
,	O
parainfluenza	O
,	O
adenovirus	O
,	O
respiratory	O
syncytial	O
virus	O
and	O
avian	O
flu	O
and	O
SARS	O
by	O
using	O
technique	O
of	O
PCR	O
and	O
immunofluorescence	O
by	O
the	O
Department	O
of	O
Medical	O
Sciences	O
.	O

A	O
good	O
correlation	O
between	O
the	O
abilities	O
of	O
7a	O
deletion	O
mutants	O
to	O
induce	O
apoptosis	B-PATH
and	O
to	O
interact	O
with	O
Bcl	O
-	O
XL	O
was	O
observed	O
,	O
suggesting	O
that	O
7a	O
triggers	O
apoptosis	B-PATH
by	O
interfering	O
directly	O
with	O
the	O
prosurvival	O
function	O
of	O
Bcl	O
-	O
XL	O
.	O

Neutrophils	O
activated	O
by	O
TNF	O
release	B-PATH
a	O
huge	O
amount	O
of	O
neutrophil	O
elastase	O
that	O
is	O
capable	O
of	O
decreasing	O
endothelial	O
prostaglandin	O
production	O
.	O

ABSTRACT	O
:	O
The	O
genitourinary	O
tract	O
is	O
the	O
most	O
common	O
site	O
for	O
extrapulmonary	O
tuberculosis	B-PATH
(	O
TB	O
).	O

In	O
support	O
of	O
the	O
hACE2	O
localization	O
data	O
,	O
the	O
most	O
productive	O
route	O
of	O
inoculation	O
and	O
progeny	O
virion	O
egress	O
in	O
both	O
polarized	O
Calu	O
-	O
3	O
and	O
ciliated	O
cells	O
of	O
HAE	O
was	O
the	O
apical	O
surface	O
suggesting	O
mechanisms	O
to	O
release	B-PATH
large	O
quantities	O
of	O
virus	O
into	O
the	O
lumen	O
of	O
the	O
human	O
lung	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
induced	O
apoptosis	B-PATH
of	O
COS	O
-	O
1	O
mediated	O
by	O
the	O
mitochondrial	O
pathway	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
apoptosis	B-PATH
effect	O
of	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	O
on	O
cultured	O
cell	O
lines	O
and	O
to	O
explore	O
the	O
possible	O
pathway	O
of	O
apoptosis	B-PATH
.	O

Apoptosis	B-PATH
induced	O
by	O
SARS	O
coronavirus	O
N	O
protein	O
under	O
starvation	O
of	O
serum	O
of	O
COS	O
-	O
1	O
cells	O
was	O
monitored	O
by	O
Annexin	O
V	O
and	O
electron	O
microscopy	O
assays	O
.	O

After	O
removal	O
of	O
serum	O
in	O
COS	O
-	O
1	O
cells	O
,	O
we	O
observed	O
the	O
loss	O
of	O
DeltaPsim	O
,	O
the	O
increase	O
of	O
ROS	O
and	O
cytochrome	O
C	O
release	B-PATH
into	O
cytosol	O
and	O
subsequent	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
PARP	O
cleavage	O
.	O

SARS	O
coronavirus	O
M	O
,	O
S	O
protein	O
can	O
not	O
induce	O
apoptosis	B-PATH
in	O
COS	O
-	O
1	O
,	O
HepG2	O
and	O
Huh	O
-	O
7	O
and	O
SARS	O
coronavirus	O
N	O
protein	O
can	O
not	O
induce	O
apoptosis	B-PATH
in	O
HepG2	O
and	O
Huh	O
-	O
7	O
by	O
methods	O
used	O
in	O
this	O
study	O
.	O

Patients	O
who	O
are	O
infants	O
or	O
elderly	O
,	O
have	O
asthma	B-PATH
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
),	O
or	O
are	O
immunosuppressed	O
have	O
increased	O
frequency	O
of	O
rhinovirus	O
-	O
related	O
respiratory	O
complications	O
.	O

These	O
results	O
indicate	O
that	O
MHV	O
infection	O
causes	O
an	O
inhibition	B-PATH
of	I-PATH
IFN	I-PATH
-	I-PATH
beta	I-PATH
production	O
at	O
a	O
posttranscriptional	O
level	O
,	O
without	O
altering	O
RNA	O
or	O
protein	O
stability	O
.	O

Phylogenetic	O
analyses	O
revealed	O
that	O
the	O
envelope	O
,	O
membrane	O
,	O
and	O
nucleoprotein	O
structural	O
proteins	O
and	O
the	O
two	O
conserved	O
replicase	O
domains	O
,	O
putative	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
and	O
RNA	O
helicase	O
,	O
of	O
these	O
novel	O
coronaviruses	O
were	O
most	O
closely	O
related	O
to	O
those	O
of	O
group	O
3	O
coronaviruses	O
identified	O
from	O
birds	O
,	O
while	O
the	O
spike	O
protein	O
gene	O
was	O
most	O
closely	O
related	O
to	O
that	O
of	O
group	O
1	O
coronaviruses	O
from	O
mammals	O
.	O

Only	O
one	O
of	O
the	O
73	O
red	O
pandas	O
had	O
a	O
weak	O
positive	O
influenza	B-PATH
A	I-PATH
titer	O
.	O

Two	O
conflicting	O
cellular	O
programs	O
,	O
apoptosis	B-PATH
to	O
eliminate	O
virus	O
-	O
infected	O
cells	O
and	O
survival	O
to	O
delay	O
apoptosis	B-PATH
by	O
producing	O
antiviral	O
cytokines	O
,	O
occur	O
in	O
SARS	O
patients	O
.	O

We	O
demonstrate	O
the	O
approach	O
with	O
examples	O
of	O
optimal	O
control	O
measures	O
to	O
prioritize	O
respiratory	O
infections	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
influenza	O
,	O
measles	B-PATH
,	O
and	O
chickenpox	O
.	O

Recent	O
studies	O
suggest	O
that	O
the	O
3a	O
protein	O
may	O
function	O
as	O
an	O
ion	O
channel	O
and	O
may	O
promote	O
virus	O
release	B-PATH
.	O

We	O
propose	O
that	O
MHV	O
replication	O
induces	O
host	O
translational	O
shutoff	O
by	O
triggering	O
an	O
integrated	O
stress	B-PATH
response	I-PATH
.	O

TITLE	O
:	O
Cell	B-PATH
cycle	I-PATH
arrest	O
and	O
apoptosis	B-PATH
induced	O
by	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
in	O
the	O
absence	O
of	O
p53	O
.	O

In	O
cells	O
infected	O
with	O
coronaviruses	O
,	O
cell	B-PATH
cycle	I-PATH
perturbation	O
and	O
apoptosis	B-PATH
were	O
observed	O
in	O
several	O
reports	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
infection	O
with	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
imposed	O
a	O
growth	O
-	O
inhibitory	O
effect	O
on	O
cultured	O
cells	O
by	O
inducing	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
S	O
and	O
G	O
(	O
2	O
)/	O
M	O
phases	O
in	O
both	O
p53	O
-	O
null	O
cell	O
line	O
H1299	O
and	O
Vero	O
cells	O
.	O

This	O
cell	B-PATH
cycle	I-PATH
arrest	O
was	O
catalyzed	O
by	O
the	O
modulation	O
of	O
various	O
cell	B-PATH
cycle	I-PATH
regulatory	O
genes	O
and	O
the	O
accumulation	O
of	O
hypophosphorylated	O
RB	O
,	O
but	O
was	O
independent	O
of	O
p53	O
.	O

Proteasome	B-PATH
inhibitors	O
,	O
such	O
as	O
lactacystin	O
and	O
NLVS	O
,	O
could	O
bypass	O
the	O
IBV	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
by	O
restoring	O
the	O
expression	O
of	O
corresponding	O
cyclin	O
/	O
Cdk	O
complexes	O
.	O

Our	O
data	O
also	O
showed	O
that	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
both	O
S	O
-	O
and	O
G	O
(	O
2	O
)/	O
M	O
-	O
phases	O
was	O
manipulated	O
by	O
IBV	O
for	O
the	O
enhancement	O
of	O
viral	O
replication	O
.	O

In	O
addition	O
,	O
apoptosis	B-PATH
induced	O
by	O
IBV	O
at	O
late	O
stages	O
of	O
the	O
infection	O
cycle	O
in	O
cultured	O
cells	O
was	O
shown	O
to	O
be	O
p53	O
-	O
independent	O
.	O

ABSTRACT	O
:	O
The	O
implication	O
of	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
)	O
in	O
the	O
regulation	O
of	O
the	O
cardiovascular	O
system	O
has	O
been	O
well	O
known	O
for	O
many	O
years	O
.	O

ABSTRACT	O
:	O
The	O
penetration	O
of	O
various	O
viruses	O
into	O
host	O
cells	O
is	O
accomplished	O
by	O
hijacking	O
the	O
host	O
endocytosis	B-PATH
machinery	O
.	O

Here	O
we	O
demonstrate	O
that	O
SARS	O
-	O
CoV	O
mainly	O
utilizes	O
the	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
pathway	O
for	O
its	O
entry	O
to	O
target	O
cells	O
by	O
using	O
infectious	O
SARS	O
-	O
CoV	O
,	O
as	O
well	O
as	O
a	O
SARS	O
-	O
CoV	O
pseudovirus	O
packaged	O
in	O
the	O
SARS	O
-	O
CoV	O
envelope	O
.	O

The	O
SARS	O
-	O
CoV	O
entered	O
caveolin	O
-	O
1	O
-	O
negative	O
HepG2	O
cells	O
,	O
and	O
the	O
entry	O
was	O
significantly	O
inhibited	O
by	O
treatment	O
with	O
chlorpromazine	O
,	O
an	O
inhibitor	O
for	O
clathrin	O
-	O
dependent	O
endocytosis	B-PATH
,	O
and	O
by	O
small	O
interfering	O
RNA	O
-	O
mediated	O
gene	O
silencing	O
for	O
the	O
clathrin	O
heavy	O
chain	O
.	O

TITLE	O
:	O
De	O
novo	O
initiation	O
of	O
RNA	O
synthesis	O
by	O
the	O
arterivirus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

The	O
role	O
and	O
regulation	O
of	O
the	O
neprilysin	O
(	O
NEP	O
)	O
family	O
of	O
metalloproteinases	O
is	O
highlighted	O
in	O
particular	O
in	O
the	O
context	O
of	O
proteolytic	O
events	O
underlying	O
the	O
pathology	O
of	O
Alzheimer	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
.	O

Pulmonary	O
-	O
renal	O
syndromes	O
are	O
not	O
a	O
single	O
entity	O
,	O
but	O
are	O
caused	O
by	O
a	O
wide	O
variety	O
of	O
diseases	O
,	O
including	O
various	O
forms	O
of	O
primary	O
systemic	O
vasculitis	O
(	O
especially	O
Wegener	O
'	O
s	O
granulomatosis	O
and	O
microscopic	O
polyangiitis	O
),	O
Goodpasture	O
'	O
s	O
syndrome	O
(	O
associated	O
with	O
autoantibodies	O
to	O
the	O
alveolar	O
and	O
glomerular	O
basement	O
membrane	O
)	O
and	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
.	O

The	O
E	O
.	O
coli	O
-	O
mycobacterium	O
expression	O
shuttle	O
plasmid	O
pR	O
-	O
alpha	O
-	O
S1	O
was	O
constructed	O
by	O
inserting	O
the	O
S1	O
gene	O
to	O
the	O
pRR3	O
with	O
human	O
mycobacterium	O
tuberculosis	B-PATH
HSP70	O
promoter	O
and	O
a	O
signal	O
peptide	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
NS3	O
/	O
4A	O
and	O
secreted	O
alkaline	O
phosphatase	O
to	O
quantitate	O
cell	O
-	O
cell	O
membrane	O
fusion	O
mediated	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
S	O
protein	O
and	O
the	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

This	O
system	O
was	O
applied	O
to	O
develop	O
a	O
quantitative	O
measurement	O
of	O
cell	O
-	O
cell	O
fusion	O
using	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
NS3	O
/	O
4A	O
protease	O
and	O
a	O
secretion	O
-	O
blocked	O
EGFP	O
-	O
4A	O
/	O
4B	O
-	O
SEAP	O
(	O
EGFP	O
:	O
enhanced	O
green	O
fluorescent	O
protein	O
;	O
4A	O
/	O
4B	O
:	O
a	O
decapeptide	O
substrate	O
of	O
NS3	O
/	O
4A	O
protease	O
;	O
SEAP	O
:	O
secreted	O
alkaline	O
phosphatase	O
)	O
fusion	O
gene	O
.	O

In	O
addition	O
,	O
AM	O
significantly	O
suppressed	O
apoptosis	B-PATH
of	O
alveolar	O
wall	O
cells	O
as	O
indicated	O
by	O
cleaved	O
caspase	O
-	O
3	O
staining	O
.	O

This	O
beneficial	O
effect	O
of	O
AM	O
on	O
acute	O
lung	O
injury	O
may	O
be	O
mediated	O
by	O
inhibition	O
of	O
inflammation	O
,	O
hyperpermeability	O
,	O
and	O
alveolar	O
wall	O
cell	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
and	O
ACE2	O
are	O
highly	O
homologous	O
metalloproteases	O
that	O
provide	O
essential	O
catalytic	O
functions	O
in	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
).	O

ABSTRACT	O
:	O
The	O
syndrome	O
of	O
preschool	O
wheeze	O
commonly	O
regresses	O
completely	O
in	O
the	O
preschool	O
years	O
,	O
but	O
it	O
may	O
lead	O
to	O
prolonged	O
symptoms	O
and	O
established	O
asthma	B-PATH
.	O

The	O
in	O
vitro	O
reconstruction	O
of	O
a	O
step	O
in	O
mitotic	O
regulation	O
shows	O
how	O
this	O
expression	O
system	O
can	O
be	O
successfully	O
applied	O
to	O
the	O
detailed	O
analysis	O
of	O
complex	O
metabolic	B-PATH
pathways	I-PATH
.	O

The	O
viruses	O
identified	O
were	O
influenza	B-PATH
A	I-PATH
(	O
7	O
.	O
3	O
%),	O
coronavirus	O
OC43	O
(	O
4	O
.	O
6	O
%),	O
rhinovirus	O
(	O
3	O
.	O
1	O
%),	O
influenza	O
B	O
(	O
2	O
.	O
7	O
%),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
2	O
.	O
3	O
%).	O

Viral	O
infection	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
subsequent	O
readmissions	O
or	O
mortality	O
rate	O
over	O
a	O
study	O
period	O
of	O
1	O
year	O
Influenza	B-PATH
A	I-PATH
and	O
two	O
less	O
-	O
attended	O
viruses	O
,	O
coronavirus	O
OC43	O
and	O
rhinovirus	O
,	O
were	O
the	O
common	O
etiologic	O
agents	O
in	O
patients	O
hospitalized	O
with	O
AECOPD	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCoV	O
)	O
M	O
protein	O
plays	O
a	O
key	O
role	O
in	O
viral	O
assembly	O
and	O
budding	B-PATH
.	O

ABSTRACT	O
:	O
An	O
incident	O
involving	O
the	O
release	B-PATH
of	O
chlorine	O
gas	O
from	O
the	O
pump	O
room	O
at	O
a	O
local	O
swimming	O
pool	O
resulted	O
in	O
54	O
patients	O
seeking	O
treatment	O
in	O
the	O
emergency	O
departments	O
(	O
EDs	O
)	O
of	O
two	O
local	O
,	O
tertiary	O
-	O
level	O
hospitals	O
in	O
Singapore	O
.	O

The	O
assay	O
detected	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
;	O
influenza	B-PATH
A	I-PATH
virus	O
subtypes	O
H1	O
,	O
H3	O
,	O
and	O
H5	O
(	O
including	O
subtype	O
H5N1	O
of	O
the	O
Asian	O
lineage	O
);	O
parainfluenza	O
virus	O
types	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
;	O
respiratory	O
syncytial	O
virus	O
types	O
A	O
and	O
B	O
;	O
adenovirus	O
;	O
metapneumovirus	O
;	O
rhinovirus	O
;	O
enterovirus	O
;	O
and	O
coronaviruses	O
OC43	O
,	O
229E	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
NL63	O
,	O
and	O
HKU1	O
.	O

TITLE	O
:	O
Open	O
reading	O
frame	O
8a	O
of	O
the	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
not	O
only	O
promotes	O
viral	O
replication	O
but	O
also	O
induces	O
apoptosis	B-PATH
.	O

ORF8a	O
was	O
found	O
to	O
be	O
localized	O
in	O
mitochondria	O
,	O
and	O
overexpression	O
resulted	O
in	O
increases	O
in	O
mitochondrial	O
transmembrane	O
potential	O
,	O
reactive	O
oxygen	O
species	O
production	O
,	O
caspase	O
3	O
activity	O
,	O
and	O
cellular	O
apoptosis	B-PATH
.	O

ORF8a	O
not	O
only	O
enhances	O
viral	O
replication	O
but	O
also	O
induces	O
apoptosis	B-PATH
through	O
a	O
mitochondria	O
-	O
dependent	O
pathway	O
.	O

ORF8a	O
was	O
found	O
to	O
be	O
localized	O
in	O
mitochondria	O
,	O
and	O
overexpression	O
resulted	O
in	O
increases	O
in	O
mitochondrial	O
transmembrane	O
potential	O
,	O
reactive	O
oxygen	O
species	O
production	O
,	O
caspase	O
3	O
activity	O
,	O
and	O
cellular	O
apoptosis	B-PATH
.	O

Activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
with	O
the	O
production	O
of	O
cortisol	O
is	O
a	O
fundamental	O
component	O
of	O
the	O
stress	B-PATH
response	I-PATH
and	O
is	O
essential	O
for	O
survival	O
of	O
the	O
host	O
.	O

Drugs	O
for	O
the	O
treatment	O
of	O
HIV	B-PATH
infection	I-PATH
are	O
expensive	O
and	O
not	O
widely	O
available	O
in	O
the	O
developing	O
world	O
where	O
they	O
are	O
most	O
needed	O
.	O

TITLE	O
:	O
Role	O
of	O
endocytosis	B-PATH
and	O
low	O
pH	O
in	O
murine	O
hepatitis	O
virus	O
strain	O
A59	O
cell	O
entry	O
.	O

Infection	O
of	O
cells	O
assessed	O
by	O
plaque	O
reduction	O
assay	O
was	O
strongly	O
inhibited	O
by	O
lysosomotropic	O
compounds	O
and	O
substances	O
that	O
interfere	O
with	O
clathrin	O
-	O
dependent	O
endocytosis	B-PATH
,	O
suggesting	O
that	O
MHV	O
-	O
A59	O
is	O
taken	O
up	O
via	O
endocytosis	B-PATH
and	O
delivered	O
to	O
acidic	O
endosomal	O
compartments	O
.	O

Fluorescence	O
confocal	O
microscopy	O
of	O
labeled	O
MHV	O
-	O
A59	O
confirmed	O
that	O
virus	O
is	O
taken	O
up	O
via	O
endocytosis	B-PATH
.	O

The	O
results	O
imply	O
that	O
endocytosis	B-PATH
plays	O
a	O
major	O
role	O
in	O
MHV	O
-	O
A59	O
infection	O
and	O
the	O
acidic	O
pH	O
of	O
the	O
endosomal	O
compartment	O
triggers	O
a	O
conformational	O
change	O
of	O
the	O
S	O
protein	O
mediating	O
fusion	O
.	O

A	O
10	O
-	O
yr	O
-	O
old	O
girl	O
was	O
referred	O
to	O
our	O
hospital	O
for	O
the	O
treatment	O
of	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
.	O

ABSTRACT	O
:	O
Several	O
chronic	O
viral	O
infections	O
(	O
such	O
as	O
HIV	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
)	O
are	O
highly	O
prevalent	O
and	O
are	O
a	O
serious	O
health	O
risk	O
.	O

In	O
the	O
absence	O
of	O
the	O
8a	O
region	O
,	O
protein	O
8b	O
undergoes	O
rapid	O
degradation	O
by	O
proteasomes	O
,	O
and	O
addition	O
of	O
proteasome	B-PATH
inhibitors	O
inhibits	O
the	O
degradation	O
of	O
protein	O
8b	O
as	O
well	O
as	O
the	O
protein	O
8b	O
-	O
induced	O
rapid	O
degradation	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
E	O
protein	O
.	O

It	O
has	O
been	O
used	O
to	O
discover	O
serum	O
or	O
tissue	O
protein	O
signatures	O
and	O
biomarkers	O
for	O
infectious	O
diseases	O
in	O
the	O
fields	O
of	O
virology	O
(	O
hepatitis	O
B	O
and	O
C	O
viruses	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
HIV	O
-	O
1	O
,	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
-	O
1	O
and	O
BK	O
virus	O
),	O
parasitology	O
(	O
trypanosomiasis	O
)	O
and	O
bacteriology	O
(	O
intra	O
-	O
amniotic	O
inflammation	O
,	O
tuberculosis	B-PATH
and	O
bacterial	O
endocarditis	O
).	O

The	O
authors	O
report	O
on	O
a	O
case	O
of	O
pseudomembranous	O
necrotizing	O
form	O
of	O
histologically	O
proven	O
tracheobronchitis	O
,	O
caused	O
by	O
Aspergillus	O
spp	O
in	O
the	O
time	O
of	O
induction	O
chemotherapy	O
in	O
a	O
patient	O
with	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
.	O

Despite	O
significant	O
increases	O
in	O
levels	O
of	O
Cxcl2	O
mRNA	O
and	O
functional	O
nucleus	O
-	O
to	O
-	O
cytoplasm	O
RNA	B-PATH
transport	I-PATH
,	O
no	O
CXCL2	O
protein	O
was	O
released	O
into	O
the	O
medium	O
from	O
MHV	O
-	O
infected	O
cells	O
.	O

It	O
begins	O
with	O
the	O
release	B-PATH
of	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	O
-	O
6	O
and	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
from	O
inflammatory	O
cells	O
.	O

These	O
cytokines	O
induce	O
fever	O
,	O
leucocytosis	O
and	O
release	B-PATH
of	O
serum	O
acute	O
phase	O
proteins	O
(	O
APPs	O
).	O

In	O
cats	O
with	O
inflammatory	O
conditions	O
,	O
fever	O
is	O
a	O
common	O
finding	O
,	O
with	O
leucocytosis	O
due	O
to	O
the	O
release	B-PATH
of	O
cells	O
from	O
the	O
marginal	O
pool	O
,	O
followed	O
by	O
activation	O
of	O
myelopoiesis	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
gene	O
7	O
products	O
contribute	O
to	O
virus	O
-	O
induced	O
apoptosis	B-PATH
.	O

However	O
,	O
viruses	O
with	O
gene	O
7	O
disruptions	O
were	O
not	O
as	O
efficient	O
as	O
wild	O
-	O
type	O
virus	O
in	O
inducing	O
DNA	O
fragmentation	O
,	O
as	O
judged	O
by	O
terminal	O
deoxynucleotidyltransferase	O
-	O
mediated	O
dUTP	O
-	O
biotin	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
staining	O
,	O
indicating	O
that	O
the	O
gene	O
7	O
products	O
do	O
contribute	O
to	O
virus	O
-	O
induced	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
Pulmonary	O
complication	O
in	O
severe	O
Plasmodium	O
falciparum	O
malaria	B-PATH
is	O
manifested	O
as	O
a	O
prolonged	O
impairment	O
of	O
gas	O
transfer	O
or	O
the	O
more	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
Macroautophagy	O
(	O
herein	O
autophagy	O
)	O
is	O
a	O
cellular	O
process	O
,	O
requiring	O
ATG5	O
,	O
by	O
which	O
cells	O
deliver	O
double	O
membrane	O
-	O
bound	O
packets	O
containing	O
cytoplasm	O
or	O
cytoplasmic	O
organelles	O
to	O
the	O
lysosome	B-PATH
.	O

We	O
conclude	O
that	O
neither	O
ATG5	O
nor	O
an	O
intact	O
autophagic	O
pathway	O
re	O
required	O
for	O
MHV	O
replication	O
or	O
release	B-PATH
.	O

TITLE	O
:	O
Pan	O
-	O
viral	O
screening	O
of	O
respiratory	O
tract	O
infections	O
in	O
adults	O
with	O
and	O
without	O
asthma	B-PATH
reveals	O
unexpected	O
human	O
coronavirus	O
and	O
human	O
rhinovirus	O
diversity	O
.	O

Given	O
the	O
diversity	O
detected	O
here	O
,	O
larger	O
-	O
scale	O
studies	O
will	O
be	O
necessary	O
to	O
determine	O
whether	O
particular	O
substrains	O
of	O
viruses	O
confer	O
an	O
elevated	O
risk	O
of	O
asthma	B-PATH
exacerbation	O
.	O

ABSTRACT	O
:	O
Both	O
apoptosis	B-PATH
and	O
necrosis	O
have	O
been	O
observed	O
in	O
cells	O
infected	O
by	O
various	O
coronaviruses	O
,	O
suggesting	O
that	O
the	O
regulation	O
of	O
cell	O
death	O
is	O
important	O
for	O
viral	O
replication	O
and	O
/	O
or	O
pathogenesis	O
.	O

Viral	O
proteins	O
that	O
can	O
regulate	O
apoptosis	B-PATH
have	O
been	O
identified	O
,	O
and	O
many	O
of	O
these	O
also	O
have	O
the	O
abilities	O
to	O
interfere	O
with	O
cellular	O
functions	O
.	O

Weaker	O
evidence	O
supports	O
consideration	O
of	O
noninvasive	O
ventilation	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
patients	O
with	O
postoperative	O
or	O
postextubation	O
respiratory	O
failure	O
;	O
patients	O
with	O
acute	O
respiratory	O
failure	O
due	O
to	O
asthma	B-PATH
exacerbations	O
,	O
pneumonia	O
,	O
acute	O
lung	O
injury	O
,	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
during	O
bronchoscopy	O
;	O
or	O
as	O
a	O
means	O
of	O
preoxygenation	O
before	O
intubation	O
in	O
critically	O
ill	O
patients	O
with	O
severe	O
hypoxemia	O
.	O

The	O
peak	O
occurrence	O
of	O
cases	O
and	O
deaths	O
coincided	O
with	O
the	O
replacement	O
of	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	B-PATH
)	O
Panama	O
strain	O
,	O
which	O
had	O
been	O
circulating	O
in	O
Colombia	O
since	O
1999	O
,	O
by	O
three	O
new	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	B-PATH
)	O
strains	O
(	O
Korea	O
,	O
Fujian	O
,	O
and	O
Wyoming	O
).	O

The	O
peak	O
occurrence	O
of	O
cases	O
and	O
deaths	O
coincided	O
with	O
the	O
replacement	O
of	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	B-PATH
)	O
Panama	O
strain	O
,	O
which	O
had	O
been	O
circulating	O
in	O
Colombia	O
since	O
1999	O
,	O
by	O
three	O
new	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	B-PATH
)	O
strains	O
(	O
Korea	O
,	O
Fujian	O
,	O
and	O
Wyoming	O
).	O

TITLE	O
:	O
[	O
Acute	O
severe	O
asthma	B-PATH
in	O
infants	O
.	O

ABSTRACT	O
:	O
Acute	O
severe	O
asthma	B-PATH
is	O
the	O
most	O
severe	O
acute	O
complication	O
of	O
infant	O
asthma	B-PATH
.	O

The	O
acute	O
severe	O
asthma	B-PATH
was	O
induced	O
by	O
a	O
respiratory	O
viral	O
infection	O
in	O
80	O
%	O
of	O
cases	O
.	O

Acute	O
severe	O
asthma	B-PATH
forces	O
a	O
correct	O
evaluation	O
of	O
the	O
severity	O
of	O
the	O
asthmatic	O
disease	O
in	O
order	O
to	O
adapt	O
the	O
long	O
-	O
term	O
therapy	O
.	O

The	O
combination	O
of	O
the	O
surgical	O
approach	O
,	O
pre	O
-	O
existing	O
pulmonary	O
disorders	O
,	O
poor	O
nutritional	O
status	O
and	O
the	O
release	B-PATH
of	O
pro	O
-	O
inflammatory	O
cytokines	O
may	O
be	O
contributing	O
factors	O
.	O

We	O
found	O
that	O
a	O
history	O
of	O
breastfeeding	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
risk	O
of	O
acute	O
otitis	O
media	O
,	O
non	O
-	O
specific	O
gastroenteritis	O
,	O
severe	O
lower	O
respiratory	O
tract	O
infections	O
,	O
atopic	O
dermatitis	O
,	O
asthma	B-PATH
(	O
young	O
children	O
),	O
obesity	O
,	O
type	O
1	O
and	O
2	O
diabetes	O
,	O
childhood	O
leukemia	O
,	O
sudden	O
infant	O
death	O
syndrome	O
(	O
SIDS	O
),	O
and	O
necrotizing	O
enterocolitis	O
.	O

ABSTRACT	O
:	O
On	O
the	O
basis	O
of	O
our	O
previous	O
study	O
on	O
antiviral	O
agents	O
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
,	O
a	O
series	O
of	O
nucleoside	O
analogues	O
whose	O
5	O
'-	O
hydroxyl	O
groups	O
are	O
masked	O
by	O
various	O
protective	O
groups	O
such	O
as	O
carboxylate	O
,	O
sulfonate	O
,	O
and	O
ether	O
were	O
synthesized	O
and	O
evaluated	O
to	O
develop	O
novel	O
anti	O
-	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
agents	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
responsible	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
contains	O
a	O
small	O
envelope	O
protein	O
,	O
E	O
,	O
with	O
putative	O
involvement	O
in	O
host	O
cell	O
apoptosis	B-PATH
and	O
virus	O
morphogenesis	O
.	O

This	O
study	O
developed	O
and	O
evaluated	O
five	O
groups	O
of	O
multiplex	O
nested	O
PCR	O
assays	O
that	O
could	O
simultaneously	O
detect	O
21	O
different	O
respiratory	O
pathogens	O
:	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H1N1	O
,	O
H3N2	O
,	O
and	O
H5N1	O
);	O
influenza	O
B	O
virus	O
;	O
parainfluenza	O
virus	O
types	O
1	O
,	O
2	O
,	O
3	O
,	O
4a	O
,	O
and	O
4b	O
;	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
;	O
human	O
rhinoviruses	O
;	O
human	O
enteroviruses	O
;	O
human	O
coronaviruses	O
OC43	O
and	O
229E	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
;	O
human	O
metapneumoviruses	O
;	O
Mycoplasma	O
pneumoniae	O
;	O
Chlamydophila	O
pneumoniae	O
;	O
Legionella	O
pneumophila	O
;	O
and	O
adenoviruses	O
(	O
A	O
to	O
F	O
).	O

TITLE	O
:	O
A	O
pseudoknot	O
improves	O
selection	O
efficiency	O
in	O
ribosome	B-PATH
display	O
.	O

ABSTRACT	O
:	O
The	O
size	O
and	O
diversity	O
of	O
ribosome	B-PATH
display	O
libraries	O
depends	O
upon	O
stability	O
of	O
the	O
complex	O
formed	O
between	O
the	O
ribosome	B-PATH
,	O
mRNA	O
and	O
translated	O
protein	O
.	O

Complexes	O
containing	O
the	O
mRNA	O
pseudoknot	O
exhibited	O
a	O
higher	O
efficiency	O
of	O
affinity	O
selection	O
than	O
that	O
those	O
without	O
,	O
indicating	O
that	O
the	O
pseudoknot	O
improves	O
stability	O
of	O
the	O
mRNA	O
-	O
ribosome	B-PATH
-	O
antibody	O
complex	O
in	O
a	O
eukaryotic	O
translation	O
system	O
.	O

Thus	O
,	O
in	O
order	O
to	O
improve	O
the	O
efficiency	O
of	O
selection	O
,	O
this	O
relatively	O
short	O
pseudoknot	O
sequence	O
could	O
be	O
incorporated	O
into	O
ribosome	B-PATH
display	O
.	O

There	O
was	O
no	O
influenza	B-PATH
A	I-PATH
DNA	O
detected	O
in	O
any	O
of	O
the	O
specimens	O
.	O

The	O
community	O
epidemiology	O
and	O
burden	O
of	O
human	O
metapneumovirus	O
and	O
other	O
respiratory	O
viruses	O
(	O
influenza	B-PATH
A	I-PATH
,	O
influenza	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
parainfluenza	O
viruses	O
,	O
adenoviruses	O
,	O
and	O
picornaviruses	O
)	O
were	O
examined	O
in	O
a	O
cohort	O
of	O
234	O
preschool	O
-	O
aged	O
children	O
from	O
Melbourne	O
,	O
Australia	O
,	O
over	O
a	O
12	O
-	O
month	O
period	O
by	O
using	O
polymerase	O
chain	O
reaction	O
testing	O
.	O

Randomized	O
controlled	O
trials	O
confirmed	O
that	O
the	O
Glycyrrhiza	O
glabra	O
derived	O
compound	O
glycyrrhizin	O
and	O
its	O
derivatives	O
reduced	O
hepatocellular	O
damage	O
in	O
chronic	O
hepatitis	O
B	O
and	O
C	O
.	O
In	O
hepatitis	B-PATH
C	I-PATH
virus	O
-	O
induced	O
cirrhosis	O
the	O
risk	O
of	O
hepatocellular	O
carcinoma	O
was	O
reduced	O
.	O

Animal	O
studies	O
demonstrated	O
a	O
reduction	O
of	O
mortality	O
and	O
viral	O
activity	O
in	O
herpes	O
simplex	O
virus	O
encephalitis	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
pneumonia	O
.	O

The	O
assay	O
was	O
developed	O
to	O
detect	O
four	O
bacterial	O
pathogens	O
(	O
Bordetella	O
pertussis	B-PATH
,	O
Streptococcus	O
pyogenes	O
,	O
Chlamydia	O
pneumoniae	O
and	O
Mycoplasma	O
pneumoniae	O
)	O
and	O
9	O
viral	O
pathogens	O
(	O
adenovirus	O
4	O
,	O
coronavirus	O
OC43	O
,	O
229E	O
and	O
HK	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
parainfluenza	O
types	O
1	O
,	O
2	O
,	O
and	O
3	O
and	O
respiratory	O
syncytial	O
virus	O
.	O

The	O
8a	O
polypeptide	O
is	O
likely	O
to	O
remain	O
in	O
the	O
cytoplasm	O
,	O
as	O
it	O
is	O
too	O
small	O
for	O
its	O
signal	O
sequence	O
to	O
function	O
and	O
will	O
therefore	O
be	O
directly	O
released	O
from	O
the	O
ribosome	B-PATH
.	O

ABSTRACT	O
:	O
Rhabdomyolysis	O
is	O
a	O
clinical	O
syndrome	O
characterized	O
by	O
the	O
breakdown	O
and	O
later	O
necrosis	O
of	O
skeletal	O
muscle	O
,	O
leading	O
to	O
the	O
release	B-PATH
of	O
various	O
intracellular	O
components	O
into	O
the	O
blood	O
stream	O
.	O

TITLE	O
:	O
Transcriptional	O
profiling	O
of	O
Vero	O
E6	O
cells	O
over	O
-	O
expressing	O
SARS	O
-	O
CoV	O
S2	O
subunit	O
:	O
insights	O
on	O
viral	O
regulation	O
of	O
apoptosis	B-PATH
and	O
proliferation	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
demonstrated	O
that	O
over	O
-	O
expression	O
of	O
spike	O
protein	O
(	O
S	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
or	O
its	O
C	O
-	O
terminal	O
subunit	O
(	O
S2	O
)	O
is	O
sufficient	O
to	O
induce	O
apoptosis	B-PATH
in	O
vitro	O
.	O

Inhibition	O
of	O
Bcl	O
-	O
2	O
-	O
related	O
anti	O
-	O
apoptotic	O
pathway	O
was	O
further	O
supported	O
by	O
the	O
diminution	O
of	O
S2	O
-	O
induced	O
apoptosis	B-PATH
in	O
Vero	O
E6	O
cells	O
over	O
-	O
expressing	O
Bcl	O
-	O
xL	O
.	O
In	O
addition	O
,	O
modulation	O
of	O
CCN	O
E2	O
and	O
CDKN	O
1A	O
implied	O
the	O
possible	O
control	O
of	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
G1	O
/	O
S	O
phase	O
.	O

ABSTRACT	O
:	O
The	O
contribution	O
of	O
DRAK2	O
[	O
death	O
-	O
associated	O
protein	O
kinase	O
(	O
DAPK	O
)-	O
related	O
apoptosis	B-PATH
-	O
inducing	O
kinase	O
2	O
]	O
to	O
anti	O
-	O
viral	O
memory	O
T	O
cell	O
responses	O
following	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
was	O
examined	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
decrease	O
of	O
Na	O
,	O
K	O
-	O
ATPase	O
function	O
seen	O
during	O
lung	O
injury	O
is	O
due	O
to	O
its	O
endocytosis	B-PATH
from	O
the	O
cell	O
plasma	O
membrane	O
into	O
intracellular	O
pools	O
.	O

This	O
process	O
promotes	O
the	O
alpha1	O
-	O
subunit	O
recognition	O
by	O
the	O
mu2	O
subunit	O
of	O
the	O
adaptor	O
protein	O
-	O
2	O
and	O
its	O
endocytosis	B-PATH
trough	O
a	O
clathrin	O
dependent	O
mechanism	O
.	O

Finally	O
,	O
the	O
ubiquitinated	O
Na	O
,	O
K	O
-	O
ATPase	O
undergoes	O
degradation	O
via	O
a	O
lysosome	B-PATH
/	O
proteasome	B-PATH
dependent	O
mechanism	O
.	O

A	O
putative	O
role	O
of	O
SUD	O
in	O
virus	O
-	O
induced	O
apoptosis	B-PATH
or	O
survival	O
of	O
host	O
cells	O
is	O
discussed	O
.	O

(	O
14	O
/	O
312	O
:	O
4	O
.	O
5	O
%),	O
human	O
metapneumovirus	O
(	O
8	O
/	O
326	O
:	O
2	O
.	O
5	O
%),	O
human	O
coronavirus	O
NL63	O
(	O
4	O
/	O
325	O
:	O
1	O
.	O
2	O
%),	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
2	O
/	O
323	O
:	O
0	O
.	O
6	O
%).	O

More	O
HIV	O
-	O
infected	O
patients	O
survive	O
ICU	O
admission	O
and	O
are	O
less	O
likely	O
to	O
be	O
admitted	O
to	O
the	O
ICU	O
for	O
related	O
infections	O
;	O
in	O
most	O
cases	O
,	O
they	O
need	O
critical	O
care	O
for	O
problems	O
unrelated	O
to	O
HIV	B-PATH
infection	I-PATH
or	O
for	O
conditions	O
related	O
to	O
HAART	O
toxicity	O
.	O

As	O
acid	O
-	O
fast	O
bacilli	O
were	O
positive	O
in	O
urine	O
(	O
Gaffky	O
8	O
)	O
and	O
sputum	O
(	O
Gaffky	O
1	O
),	O
we	O
diagnosed	O
as	O
miliary	O
tuberculosis	B-PATH
and	O
pulmonary	O
tuberculosis	B-PATH
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
potentiates	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)-	O
induced	O
expression	O
of	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
but	O
attenuates	O
Smad3	O
/	O
Smad4	O
-	O
mediated	O
apoptosis	B-PATH
of	O
human	O
peripheral	O
lung	O
epithelial	O
HPL1	O
cells	O
.	O

These	O
findings	O
provide	O
evidence	O
of	O
a	O
novel	O
mechanism	O
whereby	O
N	O
protein	O
modulates	O
TGF	O
-	O
beta	O
signaling	O
to	O
block	O
apoptosis	B-PATH
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
host	O
cells	O
and	O
meanwhile	O
promote	O
tissue	O
fibrosis	O
.	O

It	O
was	O
suggested	O
that	O
AHFC	O
can	O
balance	O
the	O
immune	O
state	O
of	O
mouse	O
model	O
of	O
acute	O
hepatic	O
failure	O
infected	O
with	O
MHV	O
-	O
3	O
virus	O
mainly	O
through	O
regulating	O
the	O
expression	O
of	O
immune	O
related	O
genes	O
,	O
decrease	O
the	O
immune	O
damage	O
and	O
inhibit	O
liver	O
cell	O
apoptosis	B-PATH
of	O
mouse	O
acute	O
hepatic	O
failure	O
model	O
obviously	O
so	O
as	O
to	O
increase	O
the	O
survival	O
rate	O
of	O
mouse	O
models	O
of	O
acute	O
hepatic	O
failure	O
.	O

Previously	O
proposed	O
mechanisms	O
of	O
IMS	O
include	O
different	O
susceptibility	O
of	O
various	O
cholinergic	O
receptors	O
,	O
muscle	O
necrosis	O
,	O
prolonged	O
acetylcholinesterase	O
inhibition	O
,	O
inadequate	O
oxime	O
therapy	O
,	O
downregulation	O
or	O
desensitization	O
of	O
postsynaptic	O
acetylcholine	O
receptors	O
,	O
failure	O
of	O
postsynaptic	O
acetylcholine	O
release	B-PATH
,	O
and	O
oxidative	O
stress	O
-	O
related	O
myopathy	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
regulatory	O
protein	O
of	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
)	O
and	O
a	O
receptor	O
for	O
the	O
causative	O
agent	O
of	O
severe	O
-	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
the	O
SARS	O
-	O
coronavirus	O
.	O

Prevention	O
includes	O
epidemiological	O
control	O
of	O
donor	O
populations	O
;	O
checks	O
on	O
each	O
donor	O
'	O
s	O
health	O
condition	O
;	O
analysis	O
of	O
each	O
donation	O
for	O
the	O
main	O
pathogens	O
using	O
serological	O
methods	O
;	O
additional	O
analysis	O
of	O
all	O
plasma	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
hepatitis	O
A	O
virus	O
(	O
HAV	O
)	O
and	O
the	O
B19	O
virus	O
,	O
using	O
nucleic	O
acid	O
amplification	O
techniques	O
(	O
NAT	O
).	O

Local	O
release	B-PATH
of	O
IFN	O
-	O
gamma	O
was	O
evident	O
by	O
up	O
-	O
regulation	O
of	O
class	O
II	O
molecules	O
on	O
microglia	O
in	O
recipients	O
of	O
IFN	O
-	O
gamma	O
producing	O
CD4	O
(+)	O
T	O
cells	O
.	O

Conversely	O
,	O
the	O
promitogenic	O
effects	O
of	O
mid	O
-	O
range	O
concentrations	O
of	O
PGE2	O
were	O
mimicked	O
by	O
the	O
EP3	O
-	O
selective	O
agent	O
,	O
sulprostone	O
,	O
by	O
cAMP	O
reduction	O
,	O
and	O
lost	O
upon	O
inhibition	O
of	O
Gi	O
-	O
mediated	O
signaling	O
with	O
pertussis	B-PATH
toxin	O
.	O

TITLE	O
:	O
Peripheral	O
cell	O
wall	O
lipids	O
of	O
Mycobacterium	O
tuberculosis	B-PATH
are	O
inhibitory	O
to	O
surfactant	O
function	O
.	O

ABSTRACT	O
:	O
The	O
transmission	O
of	O
Mycobacterium	O
tuberculosis	B-PATH
(	O
TB	O
)	O
requires	O
extensive	O
damage	O
to	O
the	O
lungs	O
to	O
facilitate	O
bacterial	O
release	B-PATH
into	O
the	O
airways	O
,	O
and	O
it	O
is	O
therefore	O
likely	O
that	O
the	O
microorganism	O
has	O
evolved	O
mechanisms	O
to	O
exacerbate	O
its	O
local	O
pathology	O
.	O

In	O
this	O
study	O
,	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
targeting	O
of	O
the	O
RNAs	O
of	O
influenza	B-PATH
A	I-PATH
and	O
influenza	O
B	O
viruses	O
and	O
SARS	O
coronavirus	O
was	O
performed	O
,	O
and	O
the	O
resulting	O
products	O
were	O
spliced	O
into	O
a	O
fragment	O
which	O
was	O
packaged	O
into	O
armored	O
RNA	O
for	O
use	O
as	O
a	O
noninfectious	O
,	O
quantifiable	O
synthetic	O
substitute	O
.	O

ABSTRACT	O
:	O
Gemcitabine	O
is	O
a	O
new	O
important	O
drug	O
used	O
to	O
treat	O
solid	O
tumors	O
including	O
non	B-PATH
-	I-PATH
small	I-PATH
cell	I-PATH
lung	I-PATH
cancer	I-PATH
,	O
pancreatic	O
,	O
bladder	O
and	O
breast	O
cancers	O
.	O

Severe	O
pneumonitis	O
and	O
potentially	O
fatal	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
have	O
been	O
described	O
in	O
patients	O
treated	O
for	O
a	O
non	B-PATH
-	I-PATH
small	I-PATH
cell	I-PATH
lung	I-PATH
cancer	I-PATH
.	O

We	O
report	O
a	O
case	O
of	O
gemcitabine	O
-	O
induced	O
ARDS	O
in	O
a	O
72	O
-	O
year	O
old	O
patient	O
treated	O
with	O
gemcitabine	O
and	O
cisplatin	O
for	O
a	O
bladder	B-PATH
cancer	I-PATH
without	O
lung	O
metastasis	O
.	O

Concern	O
about	O
contracting	O
avian	O
influenza	O
was	O
a	O
predictor	O
of	O
the	O
vaccination	O
rate	O
in	O
2006	O
but	O
not	O
in	O
2007	O
(	O
OR	O
,	O
1	O
.	O
47	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
03	O
-	O
2	O
.	O
09	O
];	O
P	O
<.	O
05	O
),	O
as	O
was	O
the	O
perceived	O
lack	O
of	O
control	O
over	O
avian	O
influenza	B-PATH
infection	I-PATH
(	O
OR	O
,	O
1	O
.	O
52	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
-	O
2	O
.	O
18	O
];	O
P	O
<.	O
05	O
).	O

Concern	O
about	O
contracting	O
avian	O
influenza	O
was	O
a	O
predictor	O
of	O
the	O
vaccination	O
rate	O
in	O
2006	O
but	O
not	O
in	O
2007	O
(	O
OR	O
,	O
1	O
.	O
47	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
03	O
-	O
2	O
.	O
09	O
];	O
P	O
<.	O
05	O
),	O
as	O
was	O
the	O
perceived	O
lack	O
of	O
control	O
over	O
avian	O
influenza	B-PATH
infection	I-PATH
(	O
OR	O
,	O
1	O
.	O
52	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
-	O
2	O
.	O
18	O
];	O
P	O
<.	O
05	O
).	O

ABSTRACT	O
:	O
While	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
initially	O
thought	O
to	O
enter	O
cells	O
through	O
direct	O
fusion	O
with	O
the	O
plasma	O
membrane	O
,	O
more	O
recent	O
evidence	O
suggests	O
that	O
virus	O
entry	O
may	O
also	O
involve	O
endocytosis	B-PATH
.	O

We	O
have	O
found	O
that	O
SARS	O
-	O
CoV	O
enters	O
cells	O
via	O
pH	O
-	O
and	O
receptor	O
-	O
dependent	O
endocytosis	B-PATH
.	O

Taken	O
together	O
,	O
the	O
data	O
are	O
consistent	O
with	O
a	O
3CLpro	O
mechanism	O
that	O
utilizes	O
an	O
""""	O
electrostatic	O
""""	O
trigger	O
to	O
initiate	O
the	O
acylation	O
reaction	O
,	O
a	O
cysteine	O
-	O
histidine	O
catalytic	O
dyad	O
ion	O
pair	O
,	O
an	O
enzyme	O
-	O
facilitated	O
release	B-PATH
of	O
P1	O
,	O
and	O
a	O
general	O
base	O
-	O
catalyzed	O
deacylation	O
reaction	O
.	O

TITLE	O
:	O
Equine	O
coronavirus	O
induces	O
apoptosis	B-PATH
in	O
cultured	O
cells	O
.	O

Although	O
the	O
pathological	O
characteristics	O
of	O
ECoV	O
are	O
largely	O
unknown	O
,	O
apoptosis	B-PATH
may	O
be	O
the	O
pathological	O
basis	O
of	O
lesions	O
of	O
the	O
digestive	O
system	O
in	O
ECoV	O
infection	O
.	O

Twenty	O
-	O
three	O
patients	O
(	O
40	O
%)	O
had	O
underlying	O
diagnoses	O
of	O
acute	O
lymphoblastic	O
leukemia	O
,	O
11	O
(	O
19	O
%)	O
had	O
solid	O
tumors	O
,	O
and	O
24	O
(	O
41	O
%)	O
were	O
hematopoietic	O
stem	O
cell	O
transplant	O
recipients	O
,	O
had	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
,	O
or	O
had	O
severe	O
combined	O
immunodeficiency	O
syndrome	O
.	O

The	O
frequency	O
of	O
lower	O
respiratory	O
tract	O
infections	O
was	O
highest	O
in	O
patients	O
with	O
hematopoietic	O
stem	O
cell	O
transplants	O
,	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
,	O
or	O
severe	O
combined	O
immunodeficiency	O
syndrome	O
(	O
42	O
%).	O

All	O
deaths	O
occurred	O
in	O
patients	O
with	O
lower	O
respiratory	O
tract	O
infections	O
who	O
were	O
before	O
or	O
after	O
hematopoietic	O
stem	O
cell	O
transplants	O
or	O
were	O
<	O
2	O
years	O
of	O
age	O
and	O
receiving	O
treatment	O
for	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
.	O

TITLE	O
:	O
Detecting	O
human	O
-	O
to	O
-	O
human	O
transmission	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
).	O

ABSTRACT	O
:	O
Highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
HPAI	O
)	O
subtype	O
H5N1	O
has	O
caused	O
family	O
case	O
clusters	O
,	O
mostly	O
in	O
Southeast	O
Asia	O
,	O
that	O
could	O
be	O
due	O
to	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

Moreover	O
,	O
it	O
strongly	O
stimulates	O
pro	O
-	O
inflammatory	O
activation	O
of	O
the	O
macrophages	O
and	O
the	O
release	B-PATH
of	O
vasoactive	O
substances	O
,	O
such	O
as	O
prostaglandins	O
and	O
thromboxanes	O
.	O

The	O
inflammatory	O
response	O
is	O
triggered	O
by	O
cascade	O
systems	O
(	O
such	O
as	O
the	O
complement	O
,	O
coagulation	O
,	O
kinins	O
,	O
fibrinolysis	O
),	O
cell	O
elements	O
(	O
endothelium	O
,	O
leukocytes	O
,	O
macrophages	O
,	O
monocytes	O
,	O
mast	O
cells	O
)	O
and	O
the	O
release	B-PATH
of	O
mediators	O
(	O
cytokines	O
,	O
proteolytic	O
enzymes	O
,	O
histamine	O
,	O
etc	O
.)	O
and	O
others	O
interacting	O
factors	O
.	O

Compared	O
to	O
the	O
cell	O
culture	O
results	O
,	O
the	O
RespiFinder	O
assay	O
showed	O
specificities	O
and	O
sensitivities	O
of	O
98	O
.	O
2	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
adenovirus	O
;	O
96	O
.	O
4	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
human	O
metapneumovirus	O
;	O
98	O
.	O
2	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
InfA	O
);	O
99	O
.	O
1	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
parainfluenza	O
virus	O
type	O
1	O
(	O
PIV	O
-	O
1	O
);	O
99	O
.	O
1	O
%	O
and	O
80	O
%,	O
respectively	O
,	O
for	O
PIV	O
-	O
3	O
;	O
90	O
.	O
1	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
rhinovirus	O
;	O
and	O
94	O
.	O
6	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
for	O
RSV	O
.	O

We	O
examined	O
the	O
evolutionary	O
relationships	O
between	O
bat	O
CoVs	O
and	O
their	O
hosts	O
by	O
using	O
sequence	O
data	O
of	O
the	O
virus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
and	O
the	O
bat	O
cytochrome	O
b	O
gene	O
.	O

In	O
patients	O
with	O
severe	O
asthma	B-PATH
or	O
exacerbation	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
iLA	O
might	O
represent	O
an	O
attractive	O
rescue	O
therapy	O
in	O
the	O
future	O
.	O

A	O
3V	O
armored	O
L	O
-	O
RNA	O
of	O
2	O
,	O
248	O
bases	O
containing	O
six	O
gene	O
fragments	O
-	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV1	O
,	O
SARS	O
-	O
CoV2	O
,	O
and	O
SARS	O
-	O
CoV3	O
),	O
avian	O
influenza	O
virus	O
matrix	O
gene	O
(	O
M300	O
),	O
and	O
H5N1	O
avian	O
influenza	O
virus	O
(	O
HA300	O
)-	O
was	O
successfully	O
expressed	O
by	O
the	O
two	O
-	O
plasmid	O
coexpression	O
system	O
and	O
was	O
demonstrated	O
to	O
have	O
all	O
of	O
the	O
characteristics	O
of	O
armored	O
RNA	O
.	O

ABSTRACT	O
:	O
In	O
the	O
past	O
few	O
years	O
,	O
the	O
classical	O
concept	O
of	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
)	O
has	O
experienced	O
substantial	O
conceptual	O
changes	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
results	O
in	O
a	O
severe	O
inflammatory	O
response	O
,	O
which	O
leads	O
to	O
priming	O
and	O
activation	O
of	O
leucocytes	O
,	O
release	B-PATH
of	O
reactive	O
oxygen	O
and	O
reactive	O
nitrogen	O
species	O
,	O
destruction	O
of	O
pulmonary	O
endothelium	O
,	O
extravasation	O
of	O
protein	O
-	O
rich	O
fluid	O
into	O
the	O
interstitium	O
and	O
formation	O
of	O
oedema	O
.	O

ABSTRACT	O
:	O
The	O
significance	O
of	O
endotoxemia	O
in	O
man	O
is	O
controversial	O
,	O
induces	O
cytokine	O
release	B-PATH
and	O
stimulates	O
the	O
immune	O
system	O
.	O

Exaggerated	O
cytokine	O
release	B-PATH
of	O
mononuclear	O
cells	O
was	O
observed	O
in	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
).	O

These	O
results	O
indicate	O
that	O
viral	O
permissivity	O
of	O
KC	O
and	O
LSEC	O
is	O
involved	O
in	O
the	O
decrease	O
of	O
IL	O
-	O
10	O
and	O
PGE2	O
,	O
while	O
KC	O
may	O
play	O
an	O
additional	O
role	O
in	O
the	O
apoptosis	B-PATH
of	O
NK	O
and	O
NK	O
T	O
cells	O
during	O
acute	O
viral	O
hepatitis	O
.	O

Chronic	O
alcohol	O
abuse	O
increases	O
alveolar	O
epithelial	O
permeability	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
part	O
due	O
to	O
altered	O
tight	B-PATH
junction	I-PATH
formation	O
.	O

The	O
present	O
study	O
describes	O
the	O
spectrum	O
of	O
histopathological	O
changes	O
in	O
the	O
lung	O
,	O
spleen	O
,	O
lymph	O
node	O
,	O
liver	O
,	O
small	O
intestine	O
,	O
kidney	O
and	O
cerebrum	O
of	O
civets	O
infected	O
experimentally	O
with	O
SARS	O
-	O
CoV	O
.	O
In	O
-	O
situ	O
hybridization	O
(	O
ISH	O
)	O
with	O
probes	O
specific	O
for	O
the	O
RNA	B-PATH
polymerase	I-PATH
gene	O
demonstrated	O
viral	O
RNA	O
in	O
the	O
lung	O
,	O
small	O
intestine	O
and	O
cerebrum	O
only	O
.	O

TITLE	O
:	O
Induction	O
of	O
neutralising	O
antibodies	O
and	O
cellular	O
immune	O
responses	O
against	O
SARS	O
coronavirus	O
by	O
recombinant	O
measles	B-PATH
viruses	O
.	O

ABSTRACT	O
:	O
Live	O
attenuated	O
recombinant	O
measles	B-PATH
viruses	O
(	O
rMV	O
)	O
expressing	O
a	O
codon	O
-	O
optimised	O
spike	O
glycoprotein	O
(	O
S	O
)	O
or	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
generated	O
(	O
rMV	O
-	O
S	O
and	O
rMV	O
-	O
N	O
).	O

Both	O
recombinant	O
viruses	O
stably	O
expressed	O
the	O
corresponding	O
SARS	O
-	O
CoV	O
proteins	O
,	O
grew	O
to	O
similar	O
end	O
titres	O
as	O
the	O
parental	O
strain	O
and	O
induced	O
high	O
antibody	O
titres	O
against	O
MV	O
and	O
the	O
vectored	O
SARS	O
-	O
CoV	O
antigens	O
(	O
S	O
and	O
N	O
)	O
in	O
transgenic	O
mice	O
susceptible	O
to	O
measles	B-PATH
infection	O
.	O

Coronavirus	O
OC43	O
was	O
identified	O
in	O
three	O
cases	O
(	O
27	O
.	O
3	O
%)	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
in	O
two	O
(	O
18	O
.	O
2	O
%).	O

Nasopharyngeal	O
swabs	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
for	O
rhinovirus	O
and	O
enterovirus	O
,	O
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
virus	O
(	O
PIV	O
),	O
influenza	B-PATH
A	I-PATH
and	O
B	O
virus	O
,	O
human	O
bocavirus	O
,	O
human	O
metapneumovirus	O
,	O
adenovirus	O
,	O
and	O
Mycoplasma	O
pneumoniae	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
or	O
human	O
bocavirus	O
.	O

The	O
concerted	O
protein	O
-	O
protein	O
interactions	O
among	O
the	O
HR	O
helices	O
are	O
responsible	O
for	O
the	O
fusion	O
event	O
that	O
leads	O
to	O
the	O
release	B-PATH
of	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
into	O
the	O
target	O
host	O
-	O
cell	O
.	O

Nevertheless	O
,	O
in	O
the	O
absence	O
of	O
E	O
protein	O
,	O
release	B-PATH
of	O
virus	O
particles	O
efficacy	O
was	O
reduced	O
.	O

Clinical	O
diagnoses	O
included	O
9	O
pneumonia	O
,	O
6	O
bronchiolitis	O
,	O
2	O
cold	O
,	O
1	O
asthma	B-PATH
exacerbation	O
for	O
rhinovirus	O
;	O
10	O
pneumonia	O
,	O
4	O
bronchiolitis	O
,	O
and	O
1	O
clinical	O
sepsis	O
for	O
hPMV	O
;	O
and	O
1	O
pneumonia	O
,	O
2	O
croup	O
,	O
and	O
1	O
cold	O
for	O
coronavirus	O
.	O

We	O
were	O
the	O
third	O
group	O
in	O
the	O
world	O
to	O
release	B-PATH
the	O
complete	O
SARS	O
-	O
CoV	O
genome	O
sequence	O
(	O
isolate	O
CUHK	O
-	O
W1	O
)	O
on	O
the	O
world	O
-	O
wide	O
web	O
.	O

Presently	O
a	O
number	O
of	O
viral	O
diseases	O
have	O
disappeared	O
or	O
are	O
disappearing	O
from	O
our	O
country	O
,	O
as	O
smallpox	O
,	O
poliomyelitis	O
,	O
rabies	O
,	O
measles	B-PATH
or	O
rubella	O
.	O

ABSTRACT	O
:	O
Although	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
common	O
complication	O
of	O
severe	O
malaria	B-PATH
,	O
little	O
is	O
known	O
about	O
the	O
underlying	O
molecular	O
basis	O
of	O
lung	O
dysfunction	O
.	O

Animal	O
models	O
have	O
provided	O
powerful	O
insights	O
into	O
the	O
pathogenesis	O
of	O
severe	O
malaria	B-PATH
syndromes	O
such	O
as	O
cerebral	O
malaria	B-PATH
(	O
CM	O
);	O
however	O
,	O
no	O
model	O
of	O
malaria	B-PATH
-	O
induced	O
lung	O
injury	O
has	O
been	O
definitively	O
established	O
.	O

Severity	O
of	O
malaria	B-PATH
-	O
induced	O
ALI	O
varied	O
in	O
a	O
panel	O
of	O
inbred	O
mouse	O
strains	O
,	O
and	O
development	O
of	O
ALI	O
correlated	O
with	O
peripheral	O
parasite	O
burden	O
but	O
not	O
CM	O
susceptibility	O
.	O

In	O
summary	O
,	O
parasite	O
burden	O
and	O
CD36	O
-	O
mediated	O
sequestration	O
in	O
the	O
lung	O
are	O
primary	O
determinants	O
of	O
ALI	O
in	O
experimental	O
murine	O
malaria	B-PATH
.	O

Furthermore	O
,	O
differential	O
susceptibility	O
of	O
mouse	O
strains	O
to	O
malaria	B-PATH
-	O
induced	O
ALI	O
and	O
CM	O
suggests	O
that	O
distinct	O
genetic	O
determinants	O
may	O
regulate	O
susceptibility	O
to	O
these	O
two	O
important	O
causes	O
of	O
malaria	B-PATH
-	O
associated	O
morbidity	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
The	O
most	O
important	O
political	O
and	O
organizational	O
events	O
considerably	O
affecting	O
the	O
strategy	O
and	O
tactics	O
of	O
prevention	O
of	O
infectious	O
diseases	O
may	O
be	O
called	O
at	O
the	O
Summit	O
of	O
Eight	O
(	O
Saint	O
Petersburg	O
)	O
that	O
has	O
considered	O
the	O
problem	O
of	O
consolidation	O
of	O
the	O
world	O
community	O
'	O
s	O
efforts	O
in	O
counteracting	O
the	O
prevalence	O
of	O
infectious	O
diseases	O
,	O
as	O
well	O
as	O
the	O
adopted	O
specific	O
decisions	O
on	O
this	O
matter	O
;	O
development	O
of	O
a	O
concept	O
of	O
financial	O
provision	O
of	O
Russian	O
initiatives	O
in	O
the	O
control	O
of	O
infectious	O
diseases	O
and	O
its	O
realization	O
by	O
the	O
Government	O
of	O
the	O
Russian	O
Federation	O
;	O
implementation	O
of	O
the	O
national	O
priority	O
health	O
project	O
on	O
the	O
additional	O
mass	O
immunization	O
against	O
rubella	O
,	O
influenza	O
,	O
poliomyelitis	O
,	O
prevention	O
and	O
treatment	O
of	O
HIV	O
/	O
AIDS	O
and	O
viral	O
hepatitis	O
B	O
and	O
C	O
;	O
implementation	O
of	O
regional	O
and	O
federal	O
programs	O
on	O
the	O
population	O
'	O
s	O
sanitary	O
-	O
and	O
-	O
epidemiological	O
well	O
-	O
being	O
;	O
further	O
improvement	O
and	O
development	O
of	O
a	O
legal	O
and	O
standard	O
basis	O
in	O
the	O
control	O
of	O
infectious	O
diseases	O
;	O
reorganization	O
of	O
a	O
state	O
sanitary	O
-	O
and	O
-	O
epidemiological	O
service	O
on	O
a	O
large	O
scale	O
;	O
conferment	O
of	O
the	O
status	O
of	O
a	O
poliomyelitis	O
-	O
free	O
country	O
and	O
a	O
WHO	O
certificate	O
to	O
the	O
Russian	O
Federation	O
;	O
development	O
and	O
implementation	O
of	O
the	O
national	O
action	O
plan	O
to	O
maintain	O
the	O
achieved	O
results	O
;	O
implementation	O
of	O
the	O
national	O
program	O
in	O
eradicating	O
measles	B-PATH
in	O
the	O
Russian	O
Federation	O
;	O
implementation	O
of	O
complex	O
measures	O
against	O
the	O
importation	O
and	O
spread	O
of	O
revived	O
particularly	O
dangerous	O
infections	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
avian	O
influenza	O
and	O
preparation	O
of	O
the	O
population	O
for	O
a	O
possible	O
influenza	O
pandemic	O
;	O
establishment	O
of	O
an	O
executive	O
headquarters	O
to	O
coordinate	O
activities	O
against	O
the	O
prevalence	O
of	O
avian	O
influenza	O
in	O
the	O
Russian	O
Federation	O
;	O
making	O
decisions	O
,	O
with	O
the	O
results	O
of	O
a	O
meeting	O
of	O
the	O
Russian	O
Federation	O
'	O
s	O
State	O
Council	O
being	O
kept	O
in	O
mind	O
,	O
on	O
the	O
intensification	O
and	O
coordination	O
of	O
activities	O
aimed	O
at	O
counteracting	O
the	O
epidemic	O
of	O
HIV	O
/	O
AIDS	O
in	O
the	O
Russian	O
Federation	O
,	O
by	O
setting	O
up	O
a	O
governmental	O
commission	O
;	O
involvement	O
in	O
the	O
solution	O
of	O
biological	O
safety	O
problems	O
in	O
accordance	O
with	O
the	O
""""	O
Foundations	O
of	O
public	O
chemical	O
and	O
biological	O
safety	O
policy	O
of	O
the	O
Russian	O
Federation	O
for	O
the	O
period	O
till	O
2000	O
and	O
further	O
prospects	O
""""	O
approved	O
by	O
the	O
President	O
of	O
the	O
Russian	O
Federation	O
;	O
implementation	O
of	O
measures	O
for	O
sanitary	O
area	O
control	O
within	O
the	O
framework	O
of	O
the	O
goal	O
-	O
oriented	O
federal	O
program	O
""""	O
The	O
State	O
Boundary	O
of	O
the	O
Russian	O
Federation	O
""""	O
(	O
2003	O
-	O
2010	O
).	O

A	O
programmed	O
-	O
1	O
ribosomal	O
frameshift	O
is	O
required	O
by	O
coronaviruses	O
for	O
the	O
production	O
of	O
the	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
which	O
in	O
turn	O
is	O
essential	O
for	O
viral	O
replication	O
.	O

About	O
85	O
%	O
of	O
RSV	O
,	O
influenza	B-PATH
A	I-PATH
and	O
adenovirus	O
detections	O
were	O
associated	O
with	O
a	O
CFLI	O
,	O
whereas	O
less	O
than	O
62	O
%	O
of	O
other	O
virus	O
detections	O
were	O
associated	O
with	O
CFLI	O
.	O

All	O
but	O
1	O
pig	O
belonging	O
to	O
group	O
V	O
could	O
be	O
extubated	O
compared	O
with	O
none	O
in	O
groups	O
III	O
and	O
IV	O
(	O
P	O
<	O
.	O
01	O
),	O
and	O
only	O
their	O
lungs	O
normalized	O
cytokine	O
release	B-PATH
(	O
P	O
<	O
.	O
001	O
)	O
and	O
surfactant	O
(	O
P	O
<	O
.	O
03	O
)	O
and	O
displayed	O
fewer	O
parenchymal	O
lesions	O
(	O
P	O
<	O
.	O
05	O
).	O

Malaria	B-PATH
was	O
the	O
most	O
frequent	O
diagnosis	O
(	O
49	O
.	O
1	O
%),	O
which	O
was	O
especially	O
encountered	O
in	O
patients	O
returning	O
from	O
sub	O
-	O
Saharan	O
Africa	O
(	O
95	O
.	O
6	O
%),	O
without	O
adequate	O
chemoprophylaxis	O
(	O
78	O
.	O
2	O
%).	O

Imported	O
diseases	O
at	O
risk	O
of	O
secondary	O
transmission	O
were	O
also	O
diagnosed	O
,	O
including	O
pulmonary	O
tuberculosis	B-PATH
(	O
n	O
=	O
8	O
),	O
viral	O
hepatitis	O
(	O
n	O
=	O
8	O
),	O
typhoid	O
fever	O
(	O
n	O
=	O
6	O
),	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
(	O
six	O
new	O
diagnosis	O
),	O
non	O
-	O
typhoid	O
salmonellosis	O
(	O
n	O
=	O
5	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
and	O
Crimean	O
-	O
Congo	O
hemorrhagic	O
fever	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
high	O
frequency	O
oscillatory	O
ventilation	O
combined	O
with	O
exogenous	O
pulmonary	O
surfactant	O
on	O
apoptosis	B-PATH
of	O
lung	O
tissue	O
in	O
rabbit	O
with	O
acute	O
respiratory	O
failure	O
induced	O
by	O
steam	O
inhalation	O
injury	O
].	O

CONCLUSIONS	O
:	O
Compared	O
with	O
CMV	O
or	O
CMV	O
+	O
PS	O
,	O
HFOV	O
or	O
HFOV	O
+	O
PS	O
can	O
decrease	O
the	O
concentration	O
of	O
caspase	O
-	O
3	O
and	O
p73	O
,	O
reduce	O
the	O
mRNA	O
expression	O
of	O
caspase	O
-	O
3	O
and	O
p73	O
in	O
the	O
lung	O
homogenates	O
,	O
as	O
a	O
result	O
lung	O
tissue	O
apoptosis	B-PATH
in	O
inhalation	O
injury	O
may	O
be	O
suppressed	O
.	O

ABSTRACT	O
:	O
It	O
has	O
recently	O
been	O
shown	O
that	O
cell	O
entry	O
of	O
mouse	O
hepatitis	O
virus	O
type	O
2	O
(	O
MHV	O
-	O
2	O
)	O
is	O
mediated	O
through	O
endocytosis	B-PATH
(	O
Z	O
.	O
Qiu	O
et	O
al	O
.,	O
J	O
.	O
Virol	O
.	O

TITLE	O
:	O
Endocytosis	B-PATH
of	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
together	O
with	O
virus	O
receptor	O
ACE2	O
.	O

Viral	O
antibody	O
titers	O
to	O
eight	O
respiratory	O
viruses	O
(	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
virus	O
serotype	O
three	O
(	O
PIV	O
-	O
3	O
),	O
PIV	O
-	O
2	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
and	O
coronaviruses	O
229E	O
and	O
OC43	O
)	O
were	O
measured	O
using	O
enzyme	O
immunoassay	O
at	O
baseline	O
and	O
53	O
weeks	O
.	O

The	O
results	O
suggest	O
that	O
the	O
domain	O
conferring	O
the	O
ability	O
to	O
direct	O
VLP	O
assembly	O
and	O
release	B-PATH
in	O
SARS	O
-	O
CoV	O
N	O
is	O
largely	O
contained	O
between	O
residues	O
168	O
and	O
421	O
.	O

TITLE	O
:	O
Renal	O
failure	O
in	O
malaria	B-PATH
.	O

Malarial	O
ARF	O
is	O
commonly	O
found	O
in	O
non	O
-	O
immune	O
adults	O
and	O
older	O
children	O
with	O
falciparum	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
Acute	O
akinesia	O
(	O
AA	O
)	O
is	O
a	O
rare	O
but	O
serious	O
complication	O
of	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
Disease	I-PATH
(	O
PD	B-PATH
)	O
0	O
,	O
3	O
%	O
of	O
all	O
patients	O
with	O
PD	B-PATH
).	O

ABSTRACT	O
:	O
Programmed	O
ribosomal	O
frameshifting	O
(	O
PRF	O
)	O
is	O
one	O
of	O
the	O
multiple	O
translational	O
recoding	O
processes	O
that	O
fundamentally	O
alters	O
triplet	O
decoding	O
of	O
the	O
messenger	O
RNA	O
by	O
the	O
elongating	O
ribosome	B-PATH
.	O

-	O
1	O
PRF	O
is	O
programmed	O
by	O
a	O
bipartite	O
signal	O
embedded	O
in	O
the	O
mRNA	O
and	O
includes	O
a	O
heptanucleotide	O
""""	O
slip	O
site	O
""""	O
over	O
which	O
the	O
paused	O
ribosome	B-PATH
""""	O
backs	O
up	O
""""	O
by	O
one	O
nucleotide	O
,	O
and	O
a	O
downstream	O
stimulatory	O
element	O
,	O
either	O
an	O
RNA	O
pseudoknot	O
or	O
a	O
very	O
stable	O
RNA	O
stem	O
-	O
loop	O
.	O

The	O
precise	O
mechanism	O
by	O
which	O
the	O
downstream	O
RNA	O
stimulates	O
-	O
1	O
PRF	O
by	O
the	O
translocating	O
ribosome	B-PATH
remains	O
unclear	O
.	O

Support	O
for	O
the	O
hypothesis	O
that	O
the	O
downstream	O
stimulatory	O
element	O
provides	O
a	O
kinetic	O
barrier	O
to	O
the	O
ribosome	B-PATH
-	O
mediated	O
unfolding	O
is	O
discussed	O
.	O

Neither	O
influenza	B-PATH
A	I-PATH
virus	O
nor	O
canine	O
bocavirus	O
(	O
minute	O
virus	O
of	O
canines	O
)	O
was	O
found	O
in	O
any	O
dogs	O
examined	O
.	O

Virus	O
infection	O
and	O
some	O
individual	O
viral	O
proteins	O
,	O
including	O
the	O
3a	O
protein	O
,	O
induce	O
apoptosis	B-PATH
.	O

In	O
the	O
intrinsic	O
pathway	O
,	O
there	O
was	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
cytochrome	O
c	O
release	B-PATH
from	O
the	O
mitochondria	O
.	O

For	O
p38	O
activation	O
and	O
apoptosis	B-PATH
induction	O
,	O
the	O
3a	O
cytoplasmic	O
domain	O
was	O
sufficient	O
.	O

These	O
results	O
have	O
been	O
used	O
to	O
present	O
a	O
model	O
of	O
3a	O
-	O
mediated	O
apoptosis	B-PATH
.	O

Gene	O
expression	O
profiling	O
identified	O
induction	O
of	O
ALI	O
-	O
and	O
VILI	O
-	O
associated	O
gene	O
modules	O
(	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
leukocyte	O
extravasation	O
,	O
apoptosis	B-PATH
,	O
Toll	O
receptor	O
pathways	O
).	O

Previous	O
reports	O
show	O
that	O
overexpression	O
of	O
ORF	O
-	O
3a	O
,	O
ORF	O
-	O
3b	O
and	O
ORF	O
-	O
7a	O
induce	O
apoptosis	B-PATH
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
overexpression	O
of	O
ORF	O
-	O
6	O
also	O
induces	O
apoptosis	B-PATH
and	O
that	O
Caspase	O
-	O
3	O
inhibitor	O
and	O
JNK	O
inhibitor	O
block	O
ORF	O
-	O
6	O
induced	O
apoptosis	B-PATH
.	O

All	O
these	O
data	O
suggest	O
that	O
ORF	O
-	O
6	O
induces	O
apoptosis	B-PATH
via	O
Caspase	O
-	O
3	O
mediated	O
,	O
ER	O
stress	O
and	O
JNK	O
-	O
dependent	O
pathways	O
.	O

TITLE	O
:	O
Association	O
between	O
common	O
genetic	O
variation	O
in	O
Cockayne	O
syndrome	O
A	O
and	O
B	O
genes	O
and	O
nucleotide	B-PATH
excision	I-PATH
repair	I-PATH
capacity	O
among	O
smokers	O
.	O

Bulky	O
BPDE	O
-	O
DNA	O
adducts	O
are	O
repaired	O
via	O
either	O
transcription	O
-	O
coupled	O
repair	O
or	O
global	O
genome	O
nucleotide	B-PATH
excision	I-PATH
repair	I-PATH
depending	O
on	O
the	O
location	O
of	O
lesions	O
.	O

Cockayne	O
syndrome	O
A	O
(	O
CSA	O
)	O
and	O
B	O
(	O
CSB	O
)	O
play	O
essential	O
roles	O
in	O
integrating	O
the	O
recognition	O
of	O
damage	O
,	O
chromatin	O
remodeling	O
,	O
and	O
the	O
core	O
nucleotide	B-PATH
excision	I-PATH
repair	I-PATH
proteins	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
and	O
apoptosis	B-PATH
.	O

Such	O
apoptosis	B-PATH
in	O
Vero	O
E6	O
cells	O
is	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
.	O

The	O
adenovirus	O
-	O
mediated	O
overexpression	O
of	O
SARS	O
-	O
CoV	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
)	O
and	O
other	O
structural	O
proteins	O
,	O
including	O
E	O
,	O
M	O
and	O
N	O
protein	O
,	O
do	O
not	O
induce	O
apoptosis	B-PATH
.	O

Challenge	O
of	O
lymphocytes	O
and	O
monocytes	O
with	O
infectious	O
SARS	O
-	O
CoV	O
,	O
inactivated	O
virions	O
,	O
and	O
receptor	O
-	O
binding	O
fragment	O
of	O
spike	O
protein	O
does	O
not	O
trigger	O
apoptosis	B-PATH
.	O

This	O
was	O
supported	O
by	O
in	O
vitro	O
binding	O
studies	O
that	O
demonstrated	O
homozygous	O
L	O
-	O
SIGN	O
,	O
compared	O
to	O
heterozygous	O
,	O
had	O
higher	O
binding	O
capacity	O
for	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
with	O
higher	O
proteasome	B-PATH
-	O
dependent	O
viral	O
degradation	O
.	O

Raf	O
/	O
MEK	O
/	O
ERK	O
signaling	O
leads	O
to	O
stimulus	O
-	O
specific	O
changes	O
in	O
gene	O
expression	O
,	O
alterations	O
in	O
cell	O
metabolism	O
or	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
apoptosis	B-PATH
),	O
and	O
thus	O
controls	O
cell	O
differentiation	O
and	O
proliferation	O
.	O

This	O
important	O
control	O
center	O
of	O
cellular	O
responses	O
is	O
differently	O
employed	O
to	O
support	O
the	O
replication	O
of	O
several	O
important	O
human	O
pathogenic	O
RNA	O
viruses	O
including	O
influenza	O
,	O
Ebola	O
,	O
hepatitis	B-PATH
C	I-PATH
and	O
SARS	O
corona	O
viruses	O
.	O

A	O
64	O
-	O
yr	O
-	O
old	O
Caucasian	O
male	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
the	O
course	O
of	O
severe	O
falciparum	O
malaria	B-PATH
.	O

Finally	O
,	O
convergent	O
observations	O
indicate	O
that	O
the	O
molecules	O
encoded	O
by	O
the	O
2	O
'-	O
5	O
'	O
OAS	O
cluster	O
might	O
be	O
involved	O
in	O
other	O
fundamental	O
cellular	O
functions	O
such	O
as	O
cell	O
growth	O
and	O
differentiation	O
,	O
gene	O
regulation	O
,	O
and	O
apoptosis	B-PATH
.	O

Here	O
we	O
show	O
that	O
both	O
E	O
and	O
N	O
proteins	O
must	O
be	O
coexpressed	O
with	O
M	O
protein	O
for	O
the	O
efficient	O
production	O
and	O
release	B-PATH
of	O
VLPs	O
by	O
transfected	O
Vero	O
E6	O
cells	O
.	O

Patients	O
with	O
recurrent	O
wheeze	O
and	O
risk	O
factors	O
for	O
asthma	B-PATH
,	O
age	O
2	O
months	O
to	O
3	O
years	O
,	O
hospitalized	O
with	O
bronchial	O
obstruction	O
were	O
included	O
.	O

Infants	O
and	O
young	O
children	O
with	O
recurrent	O
wheeze	O
and	O
risk	O
factors	O
for	O
asthma	B-PATH
hospitalized	O
for	O
bronchial	O
obstruction	O
present	O
a	O
high	O
prevalence	O
of	O
respiratory	O
viruses	O
.	O

ABSTRACT	O
:	O
Mathematical	O
models	O
that	O
describe	O
the	O
global	O
spread	O
of	O
infectious	O
diseases	O
such	O
as	O
influenza	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
tuberculosis	B-PATH
(	O
TB	O
)	O
often	O
consider	O
a	O
sample	O
of	O
international	O
airports	O
as	O
a	O
network	O
supporting	O
disease	O
spread	O
.	O

TITLE	O
:	O
Acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
an	O
important	O
treatable	O
cause	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
the	O
tropics	O
and	O
in	O
the	O
returning	O
traveller	O
in	O
the	O
non	O
-	O
endemic	O
areas	O
.	O

ARDS	O
is	O
an	O
important	O
complication	O
in	O
severe	O
,	O
complicated	O
falciparum	O
malaria	B-PATH
and	O
has	O
been	O
described	O
in	O
P	O
.	O
vivax	O
and	O
P	O
.	O
ovale	O
malaria	B-PATH
also	O
.	O

In	O
malaria	B-PATH
,	O
ARDS	O
can	O
develop	O
either	O
at	O
initial	O
presentation	O
or	O
after	O
initiation	O
of	O
treatment	O
when	O
the	O
parasitaemia	O
is	O
falling	O
and	O
the	O
patient	O
is	O
improving	O
.	O

The	O
diagnosis	O
of	O
malaria	B-PATH
is	O
confirmed	O
by	O
slide	O
microscopy	O
supported	O
by	O
the	O
use	O
of	O
rapid	O
antigen	O
tests	O
.	O

Currently	O
,	O
specific	O
treatment	O
choices	O
for	O
malaria	B-PATH
include	O
parenteral	O
artemisinins	O
or	O
intravenous	O
quinine	O
along	O
with	O
doxycycline	O
.	O

ARDS	O
in	O
malaria	B-PATH
is	O
a	O
disease	O
with	O
a	O
high	O
mortality	O
.	O

TITLE	O
:	O
Hepatitis	B-PATH
C	I-PATH
is	O
a	O
predictor	O
of	O
acute	O
liver	O
injury	O
among	O
hospitalizations	O
for	O
acetaminophen	O
overdose	O
in	O
the	O
United	O
States	O
:	O
a	O
nationwide	O
analysis	O
.	O

ABSTRACT	O
:	O
Single	O
nucleotide	O
polymorphisms	O
in	O
the	O
myosin	O
light	O
chain	O
kinase	O
(	O
MYLK	O
)	O
gene	O
have	O
been	O
implicated	O
in	O
the	O
risk	O
of	O
sepsis	O
-	O
related	O
acute	O
lung	O
injury	O
and	O
asthma	B-PATH
.	O

MYLK	O
encodes	O
protein	O
isoforms	O
involved	O
in	O
multiple	O
components	O
of	O
the	O
inflammatory	O
response	O
,	O
including	O
apoptosis	B-PATH
,	O
vascular	O
permeability	O
,	O
and	O
leukocyte	O
diapedesis	O
.	O

Three	O
MYLK	O
coding	O
single	O
nucleotide	O
polymorphisms	O
previously	O
associated	O
with	O
sepsis	O
-	O
induced	O
acute	O
lung	O
injury	O
and	O
severe	O
asthma	B-PATH
in	O
African	O
Americans	O
were	O
associated	O
with	O
acute	O
lung	O
injury	O
development	O
after	O
trauma	O
in	O
African	O
Americans	O
,	O
although	O
effect	O
directions	O
differed	O
.	O

ABSTRACT	O
:	O
Acute	O
rhabdomyolysis	O
is	O
a	O
syndrome	O
characterized	O
by	O
the	O
lesion	O
of	O
skeletal	O
muscle	O
resulting	O
in	O
subsequent	O
release	B-PATH
of	O
intracellular	O
contents	O
into	O
the	O
circulatory	O
system	O
,	O
which	O
can	O
cause	O
potentially	O
lethal	O
complications	O
.	O

Cleavage	O
of	O
S	O
and	O
release	B-PATH
of	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
were	O
inhibited	O
by	O
furin	O
or	O
furin	O
-	O
like	O
enzyme	O
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
A	O
/	O
H5N1	O
)	O
virus	O
has	O
attracted	O
the	O
attention	O
of	O
governments	O
and	O
health	O
organizations	O
throughout	O
the	O
world	O
because	O
of	O
its	O
pandemic	O
potential	O
.	O

Asian	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	O
differ	O
from	O
their	O
Western	O
counterparts	O
in	O
microbiological	O
aetiology	O
,	O
in	O
particular	O
the	O
prominence	O
of	O
Gram	O
-	O
negative	O
organisms	O
,	O
Mycobacterium	O
tuberculosis	B-PATH
,	O
Burkholderia	O
pseudomallei	O
and	O
Staphylococcus	O
aureus	O
.	O

The	O
importance	O
of	O
emerging	O
infectious	O
diseases	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
avian	O
influenza	B-PATH
infection	I-PATH
remain	O
as	O
close	O
concerns	O
for	O
practising	O
respirologists	O
in	O
Asia	O
.	O

Specific	O
infections	O
such	O
as	O
melioidosis	O
,	O
dengue	O
haemorrhagic	O
fever	O
,	O
scrub	O
typhus	O
,	O
leptospirosis	O
,	O
salmonellosis	O
,	O
penicilliosis	O
marneffei	O
,	O
malaria	B-PATH
,	O
amoebiasis	B-PATH
,	O
paragonimiasis	O
,	O
strongyloidiasis	O
,	O
gnathostomiasis	O
,	O
trinchinellosis	O
,	O
schistosomiasis	O
and	O
echinococcosis	O
occur	O
commonly	O
in	O
Asia	O
and	O
manifest	O
with	O
a	O
prominent	O
respiratory	O
component	O
.	O

The	O
incidence	O
of	O
tuberculosis	B-PATH
and	O
the	O
proportion	O
of	O
disseminated	O
disease	O
increase	O
with	O
more	O
severe	O
immuno	O
-	O
suppression	O
.	O

Septic	O
shock	O
is	O
an	O
infrequent	O
complication	O
of	O
disseminated	O
tuberculosis	B-PATH
.	O

This	O
article	O
discusses	O
effects	O
of	O
lymphocytic	O
choriomeningitis	O
virus	O
,	O
West	O
Nile	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
avian	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
viral	O
hemorrhagic	O
fevers	O
,	O
spirochetal	O
illnesses	O
,	O
and	O
Chagas	O
'	O
disease	O
.	O

In	O
phylogenetic	O
trees	O
constructed	O
using	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)),	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
Pol	O
),	O
helicase	O
,	O
spike	O
,	O
and	O
nucleocapsid	O
proteins	O
,	O
BuCoV	O
HKU11	O
,	O
ThCoV	O
HKU12	O
,	O
and	O
MuCoV	O
HKU13	O
formed	O
a	O
cluster	O
distantly	O
related	O
to	O
infectious	O
bronchitis	O
virus	O
and	O
turkey	O
CoV	O
(	O
group	O
3a	O
CoVs	O
).	O

Unlike	O
SARS	O
,	O
a	O
person	O
with	O
influenza	B-PATH
infection	I-PATH
is	O
contagious	O
before	O
the	O
onset	O
of	O
case	O
-	O
defining	O
symptoms	O
which	O
limits	O
the	O
effectiveness	O
of	O
case	O
isolation	O
as	O
a	O
control	O
strategy	O
.	O

Influenza	B-PATH
A	I-PATH
,	O
parainfluenza	O
and	O
RSV	O
accounted	O
for	O
51	O
%,	O
and	O
non	O
-	O
cultivable	O
viruses	O
accounted	O
for	O
30	O
%	O
of	O
positive	O
cases	O
.	O

Influenza	B-PATH
A	I-PATH
peaked	O
at	O
March	O
and	O
June	O
.	O

In	O
general	O
,	O
children	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
,	O
adenovirus	O
and	O
mixed	O
viruses	O
had	O
higher	O
temperatures	O
.	O

This	O
article	O
reviews	O
some	O
of	O
the	O
emerging	O
and	O
reemerging	O
viral	O
pathogens	O
infecting	O
solid	O
organ	O
and	O
hematopoietic	O
stem	O
-	O
cell	O
recipients	O
,	O
including	O
adenovirus	O
,	O
bocavirus	O
,	O
coronavirus	O
,	O
human	O
herpesvirus	O
-	O
6	O
,	O
lymphocytic	O
choriomeningitis	O
virus	O
,	O
measles	B-PATH
,	O
mumps	O
,	O
metapneumovirus	O
,	O
parainfluenza	O
,	O
rotavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
West	O
Nile	O
virus	O
.	O

This	O
community	O
release	B-PATH
of	O
chlorine	O
gas	O
caused	O
widespread	O
exposure	O
and	O
resulted	O
in	O
significant	O
acute	O
health	O
effects	O
and	O
substantial	O
health	O
care	O
requirements	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
and	O
helicase	O
confirmed	O
them	O
as	O
group	O
1	O
coronaviruses	O
.	O

Several	O
such	O
compounds	O
exhibited	O
significant	O
activity	O
specifically	O
against	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
cell	O
culture	O
but	O
had	O
no	O
effect	O
on	O
the	O
replication	O
of	O
another	O
RNA	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
.	O

IBV	O
E	O
,	O
a	O
viral	O
envelope	O
protein	O
,	O
plays	O
a	O
role	O
in	O
virus	O
budding	B-PATH
,	O
possibly	O
by	O
altering	O
membrane	O
morphology	O
at	O
the	O
virus	O
assembly	O
site	O
.	O

Similar	O
malnutrition	O
-	O
attributable	O
fractions	O
were	O
seen	O
for	O
the	O
major	O
causes	O
of	O
severe	O
disease	O
(	O
severe	O
malaria	B-PATH
,	O
gastroenteritis	O
,	O
lower	O
respiratory	O
tract	O
infection	O
,	O
HIV	O
,	O
and	O
invasive	O
bacterial	O
disease	O
).	O

Similar	O
malnutrition	O
-	O
attributable	O
fractions	O
were	O
seen	O
for	O
the	O
major	O
causes	O
of	O
severe	O
disease	O
(	O
severe	O
malaria	B-PATH
,	O
gastroenteritis	O
,	O
lower	O
respiratory	O
tract	O
infection	O
,	O
HIV	O
,	O
and	O
invasive	O
bacterial	O
disease	O
).	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
triggers	O
apoptosis	B-PATH
via	O
protein	O
kinase	O
R	O
but	O
is	O
resistant	O
to	O
its	O
antiviral	O
activity	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
infection	O
of	O
293	O
/	O
ACE2	O
cells	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
activated	O
several	O
apoptosis	B-PATH
-	O
associated	O
events	O
,	O
namely	O
,	O
cleavage	O
of	O
caspase	O
-	O
3	O
,	O
caspase	O
-	O
8	O
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
1	O
(	O
PARP	O
),	O
and	O
chromatin	O
condensation	O
and	O
the	O
phosphorylation	O
and	O
hence	O
inactivation	O
of	O
the	O
eukaryotic	O
translation	O
initiation	O
factor	O
2alpha	O
(	O
eIF2alpha	O
).	O

Furthermore	O
,	O
our	O
data	O
suggest	O
that	O
viral	O
activation	O
of	O
PKR	O
can	O
lead	O
to	O
apoptosis	B-PATH
via	O
a	O
pathway	O
that	O
is	O
independent	O
of	O
eIF2alpha	O
phosphorylation	O
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
membranous	O
oxygenation	O
in	O
severe	O
infant	O
pertussis	B-PATH
:	O
a	O
case	O
report	O
].	O

ABSTRACT	O
:	O
Pertussis	B-PATH
is	O
a	O
leading	O
cause	O
of	O
death	O
from	O
community	O
infections	O
in	O
infant	O
.	O

Life	O
-	O
threatening	O
clinical	O
presentations	O
of	O
pertussis	B-PATH
can	O
associate	O
multiple	O
organ	O
system	O
failure	O
with	O
respiratory	O
distress	O
.	O

The	O
question	O
of	O
the	O
optimal	O
management	O
of	O
these	O
severe	O
forms	O
of	O
pertussis	B-PATH
,	O
in	O
order	O
to	O
reduce	O
the	O
high	O
mortality	O
rate	O
,	O
is	O
raised	O
by	O
the	O
clinicians	O
caring	O
for	O
such	O
patients	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
1	O
month	O
infant	O
who	O
was	O
admitted	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
for	O
a	O
severe	O
pertussis	B-PATH
.	O

While	O
the	O
analysis	O
of	O
the	O
literature	O
,	O
through	O
limited	O
experiences	O
on	O
the	O
use	O
of	O
ECMO	O
in	O
children	O
with	O
severe	O
pertussis	B-PATH
does	O
not	O
allow	O
concluding	O
definitively	O
on	O
the	O
utility	O
of	O
ECMO	O
in	O
this	O
situation	O
,	O
the	O
contribution	O
of	O
ECMO	O
in	O
the	O
favourable	O
outcome	O
for	O
our	O
patient	O
was	O
considerable	O
.	O

S	O
and	O
E	O
proteins	O
decreased	O
the	O
rate	O
of	O
ENaC	O
exocytosis	O
and	O
either	O
had	O
no	O
effect	O
(	O
S	O
)	O
or	O
decreased	O
(	O
E	O
)	O
rates	O
of	O
endocytosis	B-PATH
.	O

TITLE	O
:	O
Induction	O
of	O
proinflammatory	O
cytokines	O
in	O
primary	O
human	O
macrophages	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H5N1	O
)	O
is	O
selectively	O
regulated	O
by	O
IFN	O
regulatory	O
factor	O
3	O
and	O
p38	O
MAPK	O
.	O

The	O
OM	O
coincidence	O
rates	O
were	O
62	O
of	O
144	O
(	O
44	O
%)	O
for	O
rhinovirus	O
,	O
15	O
of	O
27	O
(	O
56	O
%)	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
8	O
of	O
11	O
(	O
73	O
%)	O
and	O
1	O
of	O
5	O
(	O
20	O
%)	O
for	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
respectively	O
,	O
6	O
of	O
12	O
(	O
50	O
%)	O
for	O
adenovirus	O
,	O
7	O
of	O
18	O
(	O
39	O
%)	O
for	O
coronavirus	O
,	O
and	O
4	O
of	O
11	O
(	O
36	O
%)	O
for	O
parainfluenza	O
virus	O
detections	O
(	O
P	O
=	O
.	O
37	O
).	O

Both	O
trifluoperazine	O
(	O
25	O
micromol	O
/	O
liter	O
)	O
and	O
calmidazolium	O
,	O
(	O
25	O
micromol	O
/	O
liter	O
)	O
significantly	O
increased	O
the	O
release	B-PATH
of	O
ACE2	O
into	O
the	O
medium	O
(	O
44	O
.	O
1	O
+/-	O

Other	O
important	O
results	O
come	O
from	O
the	O
clinical	O
application	O
of	O
interventional	O
lung	O
assist	O
,	O
a	O
pumpless	O
arteriovenous	O
extracorporeal	O
technique	O
,	O
in	O
different	O
clinical	O
conditions	O
(	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
bridge	O
to	O
transplantation	O
,	O
asthma	B-PATH
,	O
and	O
trauma	O
).	O

Underlying	O
CVDs	O
included	O
rheumatoid	B-PATH
arthritis	I-PATH
(	O
RA	O
)	O
(	O
n	O
=	O
5	O
;	O
overall	O
incidence	O
,	O
20	O
.	O
0	O
%)	O
and	O
primary	O
SjÃ¶gren	O
syndrome	O
(	O
n	O
=	O
1	O
;	O
overall	O
incidence	O
,	O
5	O
.	O
9	O
%).	O

ABSTRACT	O
:	O
Epidemiologic	O
studies	O
and	O
clinical	O
description	O
of	O
severe	O
Plasmodium	O
vivax	O
malaria	B-PATH
in	O
adults	O
living	O
in	O
malaria	B-PATH
-	O
endemic	O
areas	O
are	O
rare	O
and	O
more	O
attention	O
is	O
needed	O
to	O
understand	O
the	O
dynamics	O
and	O
its	O
interaction	O
with	O
the	O
immune	O
system	O
.	O

The	O
diagnosis	O
of	O
P	O
.	O
vivax	O
malaria	B-PATH
was	O
established	O
by	O
peripheral	O
blood	O
film	O
(	O
PBF	O
),	O
rapid	O
diagnostic	O
test	O
(	O
RDT	O
),	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
),	O
and	O
severe	O
malaria	B-PATH
was	O
categorized	O
as	O
per	O
World	O
Health	O
Organization	O
guidelines	O
.	O

A	O
68	O
-	O
year	O
-	O
old	O
female	O
presented	O
with	O
a	O
clinical	O
picture	O
of	O
community	O
-	O
acquired	O
pneumonia	O
and	O
exacerbation	O
of	O
asthma	B-PATH
that	O
was	O
supported	O
by	O
radiological	O
evidence	O
of	O
a	O
large	O
left	O
-	O
sided	O
pleural	O
effusion	O
.	O

P	O
.	O
jirovecii	O
was	O
detected	O
in	O
26	O
/	O
128	O
,	O
bacteria	O
in	O
10	O
,	O
fungi	O
in	O
four	O
,	O
Influenza	B-PATH
A	I-PATH
in	O
two	O
patients	O
.	O

RESULTS	O
:	O
P	O
.	O
jirovecii	O
was	O
detected	O
in	O
26	O
/	O
128	O
,	O
bacteria	O
in	O
10	O
,	O
fungi	O
in	O
four	O
,	O
Influenza	B-PATH
A	I-PATH
in	O
two	O
patients	O
.	O

Phosphate	O
release	B-PATH
assay	O
and	O
FRET	O
-	O
based	O
assay	O
of	O
the	O
ADK	O
analogues	O
showed	O
that	O
the	O
ADKs	O
selectively	O
inhibit	O
the	O
duplex	O
DNA	O
-	O
unwinding	O
activity	O
without	O
significant	O
impact	O
on	O
the	O
helicase	O
ATPase	O
activity	O
.	O

Currently	O
the	O
blood	O
supply	O
is	O
much	O
safer	O
because	O
of	O
very	O
sensitive	O
testing	O
for	O
HIV	O
as	O
well	O
as	O
hepatitis	B-PATH
C	I-PATH
.	O
However	O
,	O
new	O
infectious	O
agents	O
emerge	O
constantly	O
and	O
pose	O
a	O
threat	O
to	O
our	O
blood	O
supply	O
.	O

TITLE	O
:	O
Interaction	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
membrane	O
protein	O
with	O
beta	O
-	O
actin	O
and	O
its	O
implication	O
in	O
virion	O
assembly	O
and	O
budding	B-PATH
.	O

Disruption	O
of	O
actin	O
filaments	O
with	O
cell	O
-	O
permeable	O
agent	O
cytochalasin	O
D	O
at	O
early	O
stages	O
of	O
the	O
infection	O
cycle	O
led	O
to	O
the	O
detection	O
of	O
viral	O
protein	O
synthesis	O
in	O
infected	O
cells	O
but	O
not	O
release	B-PATH
of	O
virus	O
particles	O
to	O
the	O
cultured	O
media	O
.	O

However	O
,	O
the	O
same	O
treatment	O
at	O
late	O
stages	O
of	O
the	O
infection	O
cycle	O
did	O
not	O
affect	O
the	O
release	B-PATH
of	O
virus	O
particles	O
to	O
the	O
media	O
,	O
suggesting	O
that	O
disruption	O
of	O
the	O
actin	O
filaments	O
might	O
block	O
virion	O
assembly	O
and	O
budding	B-PATH
,	O
but	O
not	O
release	B-PATH
of	O
the	O
virus	O
particles	O
.	O

Nidovirus	O
RNA	O
synthesis	O
is	O
mediated	O
by	O
a	O
cytoplasmic	O
membrane	O
-	O
associated	O
replication	O
/	O
transcription	O
complex	O
that	O
includes	O
up	O
to	O
16	O
viral	O
nonstructural	O
proteins	O
(	O
nsps	O
),	O
which	O
carry	O
common	O
enzymatic	O
activities	O
,	O
like	O
the	O
viral	O
RNA	B-PATH
polymerase	I-PATH
,	O
but	O
also	O
unusual	O
and	O
poorly	O
understood	O
RNA	O
-	O
processing	O
functions	O
.	O

Neutrophil	O
adhesion	O
to	O
,	O
surface	O
expression	O
of	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
on	O
,	O
and	O
release	B-PATH
of	O
IL	O
-	O
8	O
and	O
G	O
-	O
CSF	O
from	O
A549	O
cells	O
were	O
measured	O
by	O
ELISA	O
after	O
stimulation	O
with	O
IL	O
-	O
1	O
beta	O
or	O
TNFalpha	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
miliary	O
tuberculosis	B-PATH
presenting	O
with	O
acute	O
resiratory	O
distress	O
syndrome	O
].	O

Roentgenogram	O
and	O
computed	O
tomographic	O
scan	O
of	O
the	O
chest	O
shows	O
bilateral	O
infiltration	O
and	O
diffuse	O
ground	O
glass	O
opacity	O
,	O
indicating	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
but	O
disseminated	O
nodules	O
,	O
indicating	O
miliary	O
tuberculosis	B-PATH
,	O
were	O
not	O
found	O
.	O

A	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
test	O
detected	O
Mycobacterium	O
tuberculosis	B-PATH
.	O

Therefore	O
,	O
we	O
diagnosed	O
miliary	O
tuberculosis	B-PATH
and	O
transferred	O
the	O
patient	O
to	O
an	O
infectious	O
disease	O
hospital	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
tactics	O
of	O
mechanical	O
ventilation	O
in	O
a	O
human	O
severe	O
case	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
data	O
of	O
the	O
patient	O
infected	O
by	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
admitted	O
to	O
People	O
'	O
s	O
Hospital	O
of	O
Guizhou	O
Province	O
on	O
January	O
15	O
,	O
2009	O
,	O
were	O
analyzed	O
and	O
summarized	O
.	O

This	O
article	O
reviews	O
the	O
clinical	O
signs	O
,	O
pathophysiology	O
,	O
diagnosis	O
,	O
treatment	O
and	O
prognosis	O
of	O
four	O
important	O
systemic	O
diseases	O
with	O
neurological	O
consequences	O
:	O
feline	O
infectious	O
peritonitis	O
,	O
toxoplasmosis	B-PATH
,	O
hypertension	O
and	O
hepatic	O
encephalopathy	O
.	O

Talpha	O
(	O
1	O
)	O
is	O
also	O
in	O
late	O
-	O
stage	O
clinical	O
testing	O
in	O
the	O
United	O
States	O
and	O
Europe	O
for	O
hepatitis	B-PATH
C	I-PATH
and	O
stage	O
IV	O
melanoma	B-PATH
.	O

We	O
fitted	O
a	O
log	O
-	O
normal	O
distribution	O
to	O
pooled	O
data	O
and	O
found	O
the	O
median	O
incubation	O
period	O
to	O
be	O
5	O
.	O
6	O
days	O
(	O
95	O
%	O
CI	O
4	O
.	O
8	O
-	O
6	O
.	O
3	O
)	O
for	O
adenovirus	O
,	O
3	O
.	O
2	O
days	O
(	O
95	O
%	O
CI	O
2	O
.	O
8	O
-	O
3	O
.	O
7	O
)	O
for	O
human	O
coronavirus	O
,	O
4	O
.	O
0	O
days	O
(	O
95	O
%	O
CI	O
3	O
.	O
6	O
-	O
4	O
.	O
4	O
)	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
1	O
.	O
4	O
days	O
(	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
1	O
.	O
5	O
)	O
for	O
influenza	B-PATH
A	I-PATH
,	O
0	O
.	O
6	O
days	O
(	O
95	O
%	O
CI	O
0	O
.	O
5	O
-	O
0	O
.	O
6	O
)	O
for	O
influenza	O
B	O
,	O
12	O
.	O
5	O
days	O
(	O
95	O
%	O
CI	O
11	O
.	O
8	O
-	O
13	O
.	O
3	O
)	O
for	O
measles	B-PATH
,	O
2	O
.	O
6	O
days	O
(	O
95	O
%	O
CI	O
2	O
.	O
1	O
-	O
3	O
.	O
1	O
)	O
for	O
parainfluenza	O
,	O
4	O
.	O
4	O
days	O
(	O
95	O
%	O
CI	O
3	O
.	O
9	O
-	O
4	O
.	O
9	O
)	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
1	O
.	O
9	O
days	O
(	O
95	O
%	O
CI	O
1	O
.	O
4	O
-	O
2	O
.	O
4	O
)	O
for	O
rhinovirus	O
.	O

We	O
further	O
demonstrated	O
that	O
the	O
blockade	O
of	O
3a	O
'	O
s	O
potassium	O
channel	O
activity	O
abolished	O
caspase	O
-	O
dependent	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
Viruses	O
such	O
as	O
hepatitis	B-PATH
C	I-PATH
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
encode	O
proteins	O
that	O
are	O
distributed	O
between	O
mitochondria	O
and	O
the	O
nucleus	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
factors	O
that	O
control	O
partitioning	O
between	O
these	O
sites	O
.	O

We	O
show	O
that	O
MAVS	O
causes	O
apoptosis	B-PATH
independent	O
of	O
its	O
function	O
in	O
initiating	O
IFN	O
-	O
I	O
production	O
.	O

MAVS	O
-	O
induced	O
cell	O
death	O
requires	O
mitochondrial	O
localization	O
,	O
is	O
caspase	O
dependent	O
,	O
and	O
displays	O
hallmarks	O
of	O
apoptosis	B-PATH
.	O

Furthermore	O
,	O
MAVS	O
(-/-)	O
fibroblasts	O
are	O
resistant	O
to	O
Sendai	O
virus	O
-	O
induced	O
apoptosis	B-PATH
.	O

A	O
functional	O
screen	O
identifies	O
the	O
hepatitis	B-PATH
C	I-PATH
virus	O
NS3	O
/	O
4A	O
and	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nonstructural	O
protein	O
(	O
NSP15	O
)	O
as	O
inhibitors	O
of	O
MAVS	O
-	O
induced	O
apoptosis	B-PATH
,	O
possibly	O
as	O
a	O
method	O
of	O
immune	O
evasion	O
.	O

This	O
study	O
describes	O
a	O
novel	O
role	O
for	O
MAVS	O
in	O
controlling	O
viral	O
infections	O
through	O
the	O
induction	O
of	O
apoptosis	B-PATH
,	O
and	O
identifies	O
viral	O
proteins	O
which	O
inhibit	O
this	O
host	O
response	O
.	O

The	O
regulation	O
of	O
ACE2	O
release	B-PATH
was	O
investigated	O
in	O
polarized	O
human	O
airway	O
epithelia	O
.	O

To	O
reveal	O
structural	O
determinants	O
underlying	O
ACE2	O
release	B-PATH
,	O
several	O
mutant	O
and	O
chimeric	O
ACE2	O
proteins	O
were	O
engineered	O
.	O

Neither	O
the	O
juxtamembrane	O
stalk	O
region	O
,	O
transmembrane	O
domain	O
,	O
nor	O
the	O
cytosolic	O
domain	O
was	O
needed	O
for	O
constitutive	O
ACE2	O
release	B-PATH
.	O

The	O
resultant	O
ACE2	O
-	O
L584A	O
mutant	O
trafficked	O
to	O
the	O
cell	O
membrane	O
and	O
facilitated	O
SARS	O
-	O
CoV	O
entry	O
into	O
target	O
cells	O
,	O
suggesting	O
that	O
the	O
ACE2	O
ectodomain	O
regulates	O
its	O
release	B-PATH
and	O
that	O
residue	O
L584	O
might	O
be	O
part	O
of	O
a	O
putative	O
sheddase	O
""""	O
recognition	O
motif	O
.	O

Bacterial	O
and	O
viral	O
infections	O
can	O
directly	O
promote	O
pulmonary	O
endothelial	O
hyperpermeability	O
and	O
indirectly	O
decrease	O
the	O
function	O
and	O
/	O
or	O
expression	O
of	O
ion	O
transporters	O
regulating	O
ALC	O
in	O
type	O
II	O
alveolar	O
epithelial	O
cells	O
,	O
by	O
means	O
of	O
inducing	O
a	O
strong	O
inflammatory	O
and	O
oxidative	O
stress	B-PATH
response	I-PATH
in	O
the	O
infected	O
lungs	O
.	O

We	O
also	O
sought	O
to	O
determine	O
whether	O
they	O
could	O
interfere	O
with	O
the	O
clathrin	O
-	O
dependent	O
endocytosis	B-PATH
pathway	O
using	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
as	O
an	O
indicator	O
.	O

Infection	O
of	O
malignant	O
human	O
glioblastoma	O
U87DeltaEGFR	O
cells	O
gave	O
rise	O
to	O
release	B-PATH
of	O
progeny	O
virus	O
and	O
efficient	O
cell	O
killing	O
in	O
vitro	O
.	O

Standard	O
shell	O
vial	O
culture	O
and	O
immunofluoresence	O
was	O
used	O
to	O
detect	O
the	O
common	O
respiratory	O
viruses	O
including	O
RSV	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
parainfluenza	O
viruses	O
1	O
,	O
2	O
,	O
3	O
,	O
adenovirus	O
and	O
CMV	O
.	O

Infection	O
with	O
equine	O
influenza	B-PATH
A	I-PATH
(	O
H3N8	O
)	O
or	O
a	O
highly	O
related	O
influenza	O
virus	O
can	O
cause	O
severe	O
respiratory	O
disease	O
and	O
mortality	O
in	O
greyhounds	O
and	O
other	O
dogs	O
.	O

Infection	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
can	O
cause	O
disease	O
and	O
mortality	O
in	O
cats	O
and	O
is	O
mostly	O
subclinical	O
in	O
dogs	O
.	O

In	O
addition	O
,	O
apoptosis	B-PATH
of	O
infected	O
cells	O
was	O
positively	O
related	O
with	O
cytopathic	O
effect	O
and	O
could	O
be	O
inhibited	O
by	O
effective	O
drug	O
treatment	O
.	O

Lung	O
metastases	O
and	O
tuberculosis	B-PATH
were	O
excluded	O
and	O
fungal	O
infection	O
suspected	O
.	O

ABSTRACT	O
:	O
Rhabdomyolysis	O
is	O
a	O
skeletal	O
muscle	O
injury	O
with	O
cell	O
components	O
'	O
release	B-PATH
to	O
plasma	O
.	O

Significant	O
cell	O
-	O
mediated	O
immune	O
responses	O
were	O
characterized	O
by	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
51	O
)	O
Cr	O
release	B-PATH
assay	O
and	O
interferon	O
-	O
gamma	O
secretion	O
ELISPOT	O
assay	O
against	O
RMA	O
-	O
S	O
target	O
cells	O
presenting	O
predicted	O
MHC	O
class	O
I	O
H2	O
-	O
Kb	O
epitopes	O
,	O
including	O
those	O
spanning	O
residues	O
884	O
-	O
891	O
and	O
1116	O
-	O
1123	O
within	O
the	O
S2	O
subunit	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
.	O

TITLE	O
:	O
How	O
benign	O
is	O
benign	O
tertian	O
malaria	B-PATH
?	O

The	O
peak	O
incidence	O
of	O
malaria	B-PATH
was	O
seen	O
in	O
September	O
2005	O
and	O
August	O
2006	O
.	O

CONCLUSIONS	O
:	O
This	O
paper	O
is	O
presented	O
to	O
highlight	O
that	O
P	O
.	O
vivax	O
malaria	B-PATH
though	O
considered	O
to	O
be	O
a	O
benign	O
entity	O
can	O
also	O
have	O
a	O
severe	O
and	O
complicated	O
course	O
which	O
is	O
usually	O
associated	O
with	O
P	O
.	O
falciparum	O
malaria	B-PATH
.	O

The	O
upregulation	O
of	O
chemokines	O
and	O
CCRs	O
may	O
facilitate	O
DC	O
migration	O
from	O
the	O
infection	O
site	O
to	O
the	O
lymph	O
nodes	O
,	O
whereas	O
the	O
increase	O
of	O
TRAIL	O
may	O
induce	O
lymphocyte	O
apoptosis	B-PATH
.	O

CONCLUSIONS	O
:	O
The	O
upregulation	O
of	O
chemokines	O
and	O
CCRs	O
may	O
facilitate	O
DC	O
migration	O
from	O
the	O
infection	O
site	O
to	O
the	O
lymph	O
nodes	O
,	O
whereas	O
the	O
increase	O
of	O
TRAIL	O
may	O
induce	O
lymphocyte	O
apoptosis	B-PATH
.	O

In	O
this	O
report	O
we	O
evaluate	O
the	O
ability	O
of	O
a	O
multiplex	O
PCR	O
test	O
(	O
xTAG	O
RVP	O
)	O
to	O
detect	O
new	O
,	O
""""	O
non	O
-	O
seasonal	O
""""	O
influenza	O
viruses	O
including	O
the	O
H1N1	O
swine	O
influenza	B-PATH
A	I-PATH
/	O
swine	O
/	O
California	O
/	O
04	O
/	O
2009	O
.	O

In	O
addition	O
to	O
detecting	O
the	O
current	O
swine	O
flu	O
the	O
xTAG	O
RVP	O
test	O
detected	O
the	O
H5N1	O
A	O
/	O
Vietnam	O
/	O
1203	O
/	O
2004	O
high	O
pathogenicity	O
avian	O
influenza	O
virus	O
that	O
circulated	O
in	O
South	O
East	O
Asia	O
in	O
2003	O
as	O
well	O
as	O
17	O
out	O
of	O
17	O
influenza	B-PATH
A	I-PATH
viruses	O
representing	O
11	O
HA	O
subtypes	O
isolated	O
from	O
birds	O
,	O
swine	O
and	O
horses	O
not	O
yet	O
seen	O
in	O
the	O
human	O
population	O
.	O

In	O
addition	O
to	O
detecting	O
the	O
current	O
swine	O
flu	O
the	O
xTAG	O
RVP	O
test	O
detected	O
the	O
H5N1	O
A	O
/	O
Vietnam	O
/	O
1203	O
/	O
2004	O
high	O
pathogenicity	O
avian	O
influenza	O
virus	O
that	O
circulated	O
in	O
South	O
East	O
Asia	O
in	O
2003	O
as	O
well	O
as	O
17	O
out	O
of	O
17	O
influenza	B-PATH
A	I-PATH
viruses	O
representing	O
11	O
HA	O
subtypes	O
isolated	O
from	O
birds	O
,	O
swine	O
and	O
horses	O
not	O
yet	O
seen	O
in	O
the	O
human	O
population	O
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
these	O
results	O
we	O
believe	O
that	O
this	O
molecular	O
test	O
can	O
perform	O
an	O
important	O
role	O
as	O
a	O
sentinel	O
test	O
to	O
detect	O
novel	O
non	O
-	O
seasonal	O
influenza	B-PATH
A	I-PATH
viruses	O
in	O
patients	O
presenting	O
with	O
influenza	O
-	O
like	O
illness	O
(	O
ILI	O
)	O
and	O
therefore	O
act	O
as	O
an	O
early	O
warning	O
system	O
for	O
the	O
detection	O
of	O
future	O
pandemic	O
influenza	O
threats	O
.	O

ABSTRACT	O
:	O
The	O
glycosylated	O
membrane	O
protein	O
M	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
main	O
structural	O
component	O
of	O
the	O
virion	O
and	O
mediates	O
assembly	O
and	O
budding	B-PATH
of	O
viral	O
particles	O
.	O

Further	O
functional	O
analysis	O
of	O
truncated	O
M	O
proteins	O
showed	O
that	O
the	O
N	O
-	O
terminal	O
134	O
amino	O
acids	O
comprising	O
the	O
three	O
transmembrane	O
domains	O
are	O
sufficient	O
to	O
mediate	O
accumulation	O
of	O
M	O
in	O
the	O
Golgi	O
complex	O
and	O
to	O
enforce	O
recruitment	O
of	O
the	O
viral	O
spike	O
protein	O
S	O
to	O
the	O
sites	O
of	O
virus	O
assembly	O
and	O
budding	B-PATH
in	O
the	O
ERGIC	O
.	O

ABSTRACT	O
:	O
Childhood	O
asthma	B-PATH
in	O
the	O
Caribbean	O
is	O
advancing	O
in	O
prevalence	O
and	O
morbidity	O
.	O

Viral	O
-	O
induced	O
exacerbations	O
of	O
asthma	B-PATH
are	O
independent	O
of	O
seasons	O
in	O
this	O
tropical	O
climate	O
.	O

ABSTRACT	O
:	O
In	O
late	O
March	O
2009	O
,	O
an	O
outbreak	O
of	O
a	O
respiratory	O
illness	O
later	O
proved	O
to	O
be	O
caused	O
by	O
novel	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
(	O
S	O
-	O
OIV	O
)	O
was	O
identified	O
in	O
Mexico	O
.	O

ABSTRACT	O
:	O
A	O
clinical	O
picture	O
of	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
induced	O
by	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
has	O
been	O
reported	O
.	O

In	O
animal	O
models	O
,	O
vagal	O
-	O
mediated	O
innate	O
immune	O
responses	O
have	O
been	O
shown	O
to	O
modulate	O
proinflammatory	O
cytokine	O
release	B-PATH
in	O
response	O
to	O
trauma	O
or	O
sepsis	O
.	O

Common	O
causes	O
of	O
non	O
-	O
malarial	O
fever	O
include	O
from	O
Africa	O
rickettsial	O
diseases	O
,	O
amoebic	O
liver	O
abscess	O
and	O
Katayama	O
syndrome	O
;	O
from	O
South	O
and	O
South	O
East	O
Asia	O
,	O
enteric	O
fever	O
and	O
arboviral	O
infection	O
;	O
from	O
the	O
Middle	O
East	O
,	O
brucellosis	O
and	O
from	O
the	O
Horn	O
of	O
Africa	O
visceral	O
leishmaniasis	B-PATH
.	O

TITLE	O
:	O
Intensive	O
-	O
care	O
patients	O
with	O
severe	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
-	O
Michigan	O
,	O
June	O
2009	O
.	O

As	O
of	O
July	O
6	O
,	O
a	O
total	O
of	O
122	O
countries	O
had	O
reported	O
94	O
,	O
512	O
cases	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
,	O
429	O
of	O
which	O
were	O
fatal	O
;	O
in	O
the	O
United	O
States	O
,	O
a	O
total	O
of	O
33	O
,	O
902	O
cases	O
were	O
reported	O
,	O
170	O
of	O
which	O
were	O
fatal	O
.	O

Cases	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
have	O
included	O
rapidly	O
progressive	O
lower	O
respiratory	O
tract	O
disease	O
resulting	O
in	O
respiratory	O
failure	O
,	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
prolonged	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
.	O

Since	O
April	O
26	O
,	O
communitywide	O
transmission	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
has	O
occurred	O
in	O
Michigan	O
,	O
with	O
655	O
probable	O
and	O
confirmed	O
cases	O
reported	O
as	O
of	O
June	O
18	O
(	O
Michigan	O
Department	O
of	O
Community	O
Health	O
[	O
MDCH	O
],	O
unpublished	O
data	O
,	O
2009	O
).	O

This	O
report	O
summarizes	O
the	O
clinical	O
characteristics	O
of	O
a	O
series	O
of	O
10	O
patients	O
with	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
and	O
ARDS	O
at	O
a	O
tertiary	O
-	O
care	O
ICU	O
in	O
Michigan	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
severe	O
complications	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
,	O
particularly	O
in	O
extremely	O
obese	O
patients	O
.	O

We	O
performed	O
real	O
-	O
time	O
quantitative	O
PCR	O
analysis	O
of	O
107	O
genes	O
with	O
functional	O
roles	O
in	O
inflammation	O
,	O
coagulation	O
,	O
fibrosis	O
and	O
apoptosis	B-PATH
;	O
some	O
key	O
genes	O
were	O
confirmed	O
at	O
a	O
protein	O
expression	O
level	O
by	O
immunohistochemistry	O
and	O
correlated	O
to	O
the	O
degree	O
of	O
morphological	O
severity	O
present	O
in	O
the	O
individual	O
samples	O
analyzed	O
.	O

Eleven	O
different	O
viruses	O
were	O
identified	O
in	O
91	O
nasopharyngeal	O
swabs	O
of	O
children	O
with	O
acute	O
respiratory	O
infection	O
,	O
influenza	B-PATH
A	I-PATH
(	O
IAV	O
)	O
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
rhinovirus	O
(	O
hRhV	O
),	O
human	O
echovirus	O
,	O
parainfluenza	O
viruses	O
(	O
PIV	O
)	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
and	O
human	O
coronavirus	O
NL63	O
.	O

ABSTRACT	O
:	O
Two	O
rapid	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
,	O
specific	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
were	O
evaluated	O
for	O
the	O
detection	O
of	O
these	O
viruses	O
in	O
clinical	O
respiratory	O
samples	O
.	O

ABSTRACT	O
:	O
The	O
threat	O
of	O
outbreak	O
of	O
infectious	O
disease	O
such	O
as	O
non	O
-	O
seasonal	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
),	O
commonly	O
referred	O
to	O
as	O
Swine	O
Flu	O
,	O
can	O
provoke	O
the	O
implementation	O
of	O
public	O
health	O
control	O
measures	O
such	O
as	O
quarantine	O
.	O

They	O
are	O
crucial	O
host	O
factors	O
for	O
the	O
replication	O
of	O
several	O
viral	O
pathogens	O
,	O
including	O
poliovirus	O
,	O
coxsackievirus	O
,	O
mouse	O
hepatitis	O
coronavirus	O
,	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
.	O

TITLE	O
:	O
Safety	O
and	O
tolerability	O
of	O
ribosome	B-PATH
-	O
component	O
immune	O
modulator	O
in	O
adults	O
and	O
children	O
.	O

To	O
study	O
the	O
role	O
of	O
ORF	O
7b	O
in	O
the	O
context	O
of	O
virus	O
replication	O
,	O
we	O
cloned	O
a	O
full	O
genome	O
cDNA	O
copy	O
of	O
Frankfurt	O
-	O
1	O
in	O
a	O
bacterial	O
artificial	O
chromosome	O
downstream	O
of	O
a	O
T7	O
RNA	B-PATH
polymerase	I-PATH
promoter	O
.	O

TITLE	O
:	O
Population	O
context	O
determines	O
cell	O
-	O
to	O
-	O
cell	O
variability	O
in	O
endocytosis	B-PATH
and	O
virus	O
infection	O
.	O

Here	O
we	O
analyse	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
heterogeneous	O
patterns	O
of	O
related	O
cellular	O
activities	O
,	O
namely	O
virus	O
infection	O
,	O
endocytosis	B-PATH
and	O
membrane	O
lipid	O
composition	O
in	O
adherent	O
human	O
cells	O
.	O

Finally	O
,	O
we	O
reveal	O
that	O
synergy	O
between	O
two	O
molecular	O
components	O
,	O
focal	B-PATH
adhesion	I-PATH
kinase	O
and	O
the	O
sphingolipid	O
GM1	O
,	O
enhances	O
the	O
population	O
-	O
determined	O
pattern	O
of	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
infection	O
.	O

We	O
first	O
examine	O
the	O
approach	O
by	O
analyzing	O
an	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
Hong	O
Kong	O
(	O
2003	O
)	O
with	O
known	O
unbiased	O
cCFR	O
estimate	O
,	O
and	O
then	O
investigate	O
published	O
epidemiological	O
datasets	O
of	O
novel	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
in	O
the	O
USA	O
and	O
Canada	O
(	O
2009	O
).	O

TITLE	O
:	O
Immune	O
responses	O
to	O
T	O
-	O
cell	O
epitopes	O
of	O
SARS	O
CoV	O
-	O
N	O
protein	O
are	O
enhanced	O
by	O
N	O
immunization	O
with	O
a	O
chimera	O
of	O
lysosome	B-PATH
-	O
associated	O
membrane	O
protein	O
.	O

With	O
new	O
information	O
surfacing	O
from	O
public	O
health	O
investigations	O
of	O
recent	O
cases	O
of	O
swine	O
influenza	O
in	O
the	O
United	O
States	O
,	O
here	O
we	O
discuss	O
putative	O
links	O
between	O
the	O
outbreak	O
of	O
SRI	O
in	O
Mexico	O
and	O
the	O
emergence	O
of	O
a	O
novel	O
swine	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
strain	O
in	O
several	O
southwestern	O
U	O
.	O
S	O
.	O
states	O
.	O

The	O
two	O
diagnostic	O
categories	O
acute	O
respiratory	O
failure	O
and	O
asthma	B-PATH
compared	O
to	O
ARDS	O
were	O
associated	O
with	O
decreased	O
odds	O
of	O
mortality	O
as	O
was	O
venovenous	O
compared	O
to	O
venoarterial	O
mode	O
.	O

ABSTRACT	O
:	O
The	O
preparation	O
and	O
medical	O
care	O
during	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
outbreak	O
(	O
June	O
2009	O
)	O
in	O
a	O
high	O
complexity	O
level	O
,	O
public	O
,	O
general	O
hospital	O
with	O
laboratory	O
diagnosis	O
,	O
general	O
and	O
intensive	O
care	O
(	O
ICU	O
)	O
hospitalization	O
is	O
described	O
.	O

TITLE	O
:	O
Bid	O
cleavage	O
,	O
cytochrome	O
c	O
release	B-PATH
and	O
caspase	O
activation	O
in	O
canine	O
coronavirus	O
-	O
induced	O
apoptosis	B-PATH
.	O

We	O
found	O
that	O
CCoV	O
-	O
II	O
triggers	O
apoptosis	B-PATH
in	O
A	O
-	O
72	O
cells	O
by	O
activating	O
initiator	O
(	O
caspase	O
-	O
8	O
and	O
-	O
9	O
)	O
and	O
executioner	O
(	O
caspase	O
-	O
3	O
and	O
-	O
6	O
)	O
caspases	O
.	O

Furthermore	O
,	O
CCoV	O
-	O
II	O
infection	O
resulted	O
in	O
truncated	O
bid	O
(	O
tbid	O
)	O
translocation	O
from	O
the	O
cytosolic	O
to	O
the	O
mitochondrial	O
fraction	O
,	O
the	O
cytochrome	O
c	O
release	B-PATH
from	O
mitochondria	O
,	O
and	O
alterations	O
in	O
the	O
pro	O
-	O
and	O
anti	O
-	O
apoptotic	O
proteins	O
of	O
bcl	O
-	O
2	O
family	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
inhibition	O
of	O
apoptosis	B-PATH
by	O
caspase	O
inhibitors	O
did	O
not	O
affect	O
CCoV	O
replication	O
,	O
suggesting	O
that	O
apoptosis	B-PATH
does	O
not	O
play	O
a	O
role	O
in	O
facilitating	O
viral	O
release	B-PATH
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
rapid	O
aggravation	O
of	O
rheumatoid	B-PATH
arthritis	I-PATH
.	O

ABSTRACT	O
:	O
A	O
76	O
-	O
year	O
-	O
old	O
woman	O
with	O
seropositive	O
rheumatoid	B-PATH
arthritis	I-PATH
(	O
RA	O
)	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
following	O
an	O
appearance	O
of	O
severe	O
inflammatory	O
symptoms	O
in	O
multiple	O
synovial	O
joints	O
.	O

However	O
,	O
PCD	O
therapy	O
used	O
in	O
a	O
timely	O
manner	O
for	O
drainage	O
may	O
decrease	O
mortality	O
in	O
patients	O
with	O
SAP	O
,	O
decrease	O
inflammatory	O
mediator	O
release	B-PATH
,	O
and	O
avoid	O
incidence	O
of	O
severe	O
sepsis	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
emergency	O
surgery	O
.	O

TITLE	O
:	O
Airway	O
pressure	O
-	O
release	B-PATH
ventilation	O
in	O
pregnant	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
novel	O
strategy	O
.	O

ABSTRACT	O
:	O
Airway	O
pressure	O
-	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
is	O
a	O
novel	O
mode	O
of	O
positive	O
-	O
pressure	O
ventilation	O
that	O
has	O
several	O
advantages	O
over	O
low	O
-	O
tidal	O
-	O
volume	O
,	O
assist	O
-	O
control	O
ventilation	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
specifically	O
,	O
lower	O
airway	O
pressures	O
,	O
lower	O
minute	O
ventilation	O
,	O
minimal	O
effects	O
on	O
cardio	O
-	O
circulatory	O
function	O
,	O
ability	O
to	O
spontaneously	O
breathe	O
throughout	O
the	O
entire	O
ventilatory	O
cycle	O
,	O
and	O
decreased	O
sedation	O
requirements	O
.	O

TITLE	O
:	O
Design	O
and	O
efficient	O
synthesis	O
of	O
novel	O
arylthiourea	O
derivatives	O
as	O
potent	O
hepatitis	B-PATH
C	I-PATH
virus	O
inhibitors	O
.	O

The	O
role	O
of	O
RNase	O
L	O
in	O
viral	O
encephalomyelitis	O
was	O
explored	O
based	O
on	O
its	O
functions	O
in	O
inhibiting	O
translation	O
,	O
inducing	O
apoptosis	B-PATH
,	O
and	O
propagating	O
the	O
IFN	O
-	O
alpha	O
/	O
beta	O
pathway	O
through	O
RNA	B-PATH
degradation	I-PATH
intermediates	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
clinical	O
features	O
and	O
treatment	O
strategy	O
of	O
human	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
infection	O
.	O

Main	O
outcome	O
measurements	O
were	O
age	O
,	O
breastfeeding	O
history	O
,	O
family	O
smoking	O
habits	O
,	O
family	O
history	O
for	O
asthma	B-PATH
and	O
atopy	O
,	O
blood	O
eosinophil	O
count	O
,	O
chest	O
radiological	O
findings	O
,	O
clinical	O
severity	O
score	O
and	O
number	O
of	O
days	O
of	O
hospitalisation	O
.	O

ABSTRACT	O
:	O
In	O
March	O
2009	O
,	O
novel	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
first	O
reported	O
in	O
the	O
southwestern	O
United	O
States	O
and	O
Mexico	O
.	O

To	O
describe	O
baseline	O
characteristics	O
,	O
treatment	O
,	O
and	O
outcomes	O
of	O
consecutive	O
critically	O
ill	O
patients	O
in	O
Mexico	O
hospitals	O
that	O
treated	O
the	O
majority	O
of	O
such	O
patients	O
with	O
confirmed	O
,	O
probable	O
,	O
or	O
suspected	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

Critical	O
illness	O
from	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Mexico	O
occurred	O
in	O
young	O
individuals	O
,	O
was	O
associated	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
shock	O
,	O
and	O
had	O
a	O
high	O
case	O
-	O
fatality	O
rate	O
.	O

CONCLUSIONS	O
:	O
Critical	O
illness	O
from	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Mexico	O
occurred	O
in	O
young	O
individuals	O
,	O
was	O
associated	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
shock	O
,	O
and	O
had	O
a	O
high	O
case	O
-	O
fatality	O
rate	O
.	O

TITLE	O
:	O
Critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
in	O
Canada	O
.	O

To	O
describe	O
characteristics	O
,	O
treatment	O
,	O
and	O
outcomes	O
of	O
critically	O
ill	O
patients	O
in	O
Canada	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

A	O
prospective	O
observational	O
study	O
of	O
168	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
in	O
38	O
adult	O
and	O
pediatric	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
in	O
Canada	O
between	O
April	O
16	O
and	O
August	O
12	O
,	O
2009	O
.	O

Critical	O
illness	O
occurred	O
in	O
215	O
patients	O
with	O
confirmed	O
(	O
n	O
=	O
162	O
),	O
probable	O
(	O
n	O
=	O
6	O
),	O
or	O
suspected	O
(	O
n	O
=	O
47	O
)	O
community	O
-	O
acquired	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

Critical	O
illness	O
due	O
to	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Canada	O
occurred	O
rapidly	O
after	O
hospital	O
admission	O
,	O
often	O
in	O
young	O
adults	O
,	O
and	O
was	O
associated	O
with	O
severe	O
hypoxemia	O
,	O
multisystem	O
organ	O
failure	O
,	O
a	O
requirement	O
for	O
prolonged	O
mechanical	O
ventilation	O
,	O
and	O
the	O
frequent	O
use	O
of	O
rescue	O
therapies	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
affected	O
Australia	O
and	O
New	O
Zealand	O
during	O
the	O
2009	O
southern	O
hemisphere	O
winter	O
.	O

An	O
observational	O
study	O
of	O
all	O
patients	O
(	O
n	O
=	O
68	O
)	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
associated	O
ARDS	O
treated	O
with	O
ECMO	O
in	O
15	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
in	O
Australia	O
and	O
New	O
Zealand	O
between	O
June	O
1	O
and	O
August	O
31	O
,	O
2009	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
eight	O
patients	O
with	O
severe	O
influenza	O
-	O
associated	O
ARDS	O
were	O
treated	O
with	O
ECMO	O
,	O
of	O
whom	O
61	O
had	O
either	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
(	O
n	O
=	O
53	O
)	O
or	O
influenza	B-PATH
A	I-PATH
not	O
subtyped	O
(	O
n	O
=	O
8	O
),	O
representing	O
an	O
incidence	O
rate	O
of	O
2	O
.	O
6	O
ECMO	O
cases	O
per	O
million	O
population	O
.	O

A	O
history	O
of	O
breastfeeding	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
risk	O
of	O
acute	O
otitis	O
media	O
,	O
nonspecific	O
gastroenteritis	O
,	O
severe	O
lower	O
respiratory	O
tract	O
infections	O
,	O
atopic	O
dermatitis	O
,	O
asthma	B-PATH
(	O
young	O
children	O
),	O
obesity	O
,	O
type	O
1	O
and	O
2	O
diabetes	O
,	O
childhood	O
leukemia	O
,	O
and	O
sudden	O
infant	O
death	O
syndrome	O
.	O

ABSTRACT	O
:	O
Type	O
II	O
mixed	O
cryoglobulin	O
syndrome	O
is	O
a	O
systematic	O
vasculitis	O
mainly	O
linked	O
to	O
immune	O
complex	O
deposition	O
in	O
several	O
organs	O
and	O
to	O
hepatitis	B-PATH
C	I-PATH
virus	O
infection	O
.	O

Therapeutic	O
strategies	O
can	O
target	O
either	O
the	O
viral	O
trigger	O
hepatitis	B-PATH
C	I-PATH
virus	O
if	O
present	O
,	O
or	O
pathogenic	O
events	O
downstream	O
the	O
triggering	O
infection	O
,	O
e	O
.	O
g	O
,	O
the	O
proliferation	O
B	O
-	O
cells	O
directly	O
.	O

We	O
report	O
on	O
a	O
75	O
-	O
year	O
-	O
old	O
patient	O
with	O
long	O
-	O
lasting	O
hepatitis	B-PATH
C	I-PATH
virus	O
infection	O
[	O
18	O
years	O
],	O
a	O
long	O
-	O
lasting	O
cryoglobulinemia	O
[	O
7	O
years	O
]	O
resistant	O
to	O
common	O
antiviral	O
therapy	O
,	O
diabetes	O
mellitus	O
and	O
deep	O
skin	O
ulcers	O
,	O
successfully	O
treated	O
with	O
the	O
combination	O
therapy	O
of	O
Rituximab	O
and	O
plasma	O
exchange	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
benign	O
acute	O
childhood	O
myositis	O
associated	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
.	O

We	O
describe	O
the	O
first	O
case	O
of	O
BACM	O
in	O
association	O
with	O
the	O
new	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
in	O
an	O
11	O
-	O
year	O
-	O
old	O
boy	O
from	O
Cyprus	O
.	O

Furthermore	O
,	O
the	O
nsp1	O
-	O
40S	O
ribosome	B-PATH
complex	O
induced	O
the	O
modification	O
of	O
the	O
5	O
'	O
region	O
of	O
capped	O
mRNA	O
template	O
and	O
rendered	O
the	O
template	O
RNA	O
translationally	O
incompetent	O
.	O

We	O
speculate	O
that	O
the	O
mRNAs	O
that	O
underwent	O
the	O
nsp1	O
-	O
mediated	O
modification	O
are	O
marked	O
for	O
rapid	O
turnover	O
by	O
the	O
host	O
RNA	B-PATH
degradation	I-PATH
machinery	O
.	O

Plasma	O
membrane	O
budding	B-PATH
was	O
occasionally	O
observed	O
.	O

TITLE	O
:	O
[	O
Pneumonia	O
and	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
].	O

We	O
present	O
a	O
case	O
of	O
ARDS	O
secondary	O
to	O
infection	O
with	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

The	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
caused	O
a	O
global	O
pandemia	O
91	O
years	O
ago	O
,	O
with	O
sporadic	O
outbreaks	O
afterward	O
.	O

The	O
new	O
influenza	B-PATH
A	I-PATH
pandemia	O
was	O
transmitted	O
from	O
swine	O
to	O
humans	O
.	O

Infection	O
by	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
can	O
cause	O
severe	O
respiratory	O
illness	O
,	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
secondary	O
infections	O
among	O
healthcare	O
workers	O
.	O

ABSTRACT	O
:	O
Acute	O
renal	O
failure	O
,	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
hypoglycemia	O
,	O
coma	O
,	O
or	O
epileptic	O
seizures	O
are	O
manifestations	O
of	O
severe	O
Plasmodium	O
falciparum	O
malaria	B-PATH
.	O

On	O
the	O
other	O
hand	O
,	O
Plasmodium	O
vivax	O
malaria	B-PATH
seldom	O
results	O
in	O
pulmonary	O
damage	O
,	O
and	O
pulmonary	O
complications	O
are	O
exceedingly	O
rare	O
.	O

A	O
diagnosis	O
of	O
Plasmodium	O
vivax	O
malaria	B-PATH
was	O
established	O
by	O
a	O
positive	O
Plasmodium	O
LDH	O
immunochromatographic	O
assay	O
while	O
a	O
negative	O
PfHRP2	O
based	O
assay	O
ruled	O
out	O
P	O
.	O
falciparum	O
malaria	B-PATH
.	O

Although	O
previous	O
investigations	O
focused	O
mainly	O
on	O
viruses	O
such	O
as	O
hepatitis	B-PATH
C	I-PATH
and	O
HIV	O
,	O
it	O
is	O
now	O
becoming	O
clear	O
that	O
other	O
microbes	O
associate	O
with	O
tetraspanins	O
,	O
using	O
TEMs	O
as	O
a	O
'	O
gateway	O
'	O
to	O
infection	O
.	O

TITLE	O
:	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
-	O
associated	O
acute	O
lung	O
injury	O
:	O
response	O
to	O
combination	O
oseltamivir	O
and	O
prolonged	O
corticosteroid	O
treatment	O
.	O

TITLE	O
:	O
[	O
Fulminant	O
,	O
life	O
-	O
threatening	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
virus	O
infection	O
].	O

The	O
following	O
day	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
-	O
test	O
was	O
confirmed	O
.	O

ABSTRACT	O
:	O
Acute	O
tumor	O
lysis	O
syndrome	O
(	O
TLS	O
)	O
is	O
characterized	O
by	O
the	O
triad	O
of	O
hyperuricemia	O
,	O
hyperkalemia	O
,	O
and	O
hyperphosphatemia	O
and	O
is	O
caused	O
by	O
the	O
death	O
of	O
tumor	O
cells	O
and	O
release	B-PATH
of	O
intracellular	O
contents	O
into	O
the	O
circulation	O
.	O

More	O
HIV	O
-	O
infected	O
patients	O
surviving	O
ICU	O
admission	O
are	O
more	O
likely	O
to	O
need	O
critical	O
care	O
for	O
problems	O
unrelated	O
to	O
HIV	B-PATH
infection	I-PATH
or	O
for	O
conditions	O
related	O
to	O
HAART	O
toxicity	O
.	O

Due	O
to	O
their	O
antimicrobial	O
properties	O
and	O
immunostimulatory	O
activity	O
,	O
beta	O
-	O
defensins	B-PATH
are	O
potential	O
tools	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
respiratory	O
disease	O
.	O

This	O
study	O
aimed	O
to	O
assess	O
the	O
presence	O
of	O
four	O
beta	O
-	O
defensins	B-PATH
in	O
the	O
canine	O
respiratory	O
tract	O
and	O
to	O
use	O
quantitative	O
real	O
-	O
time	O
PCR	O
to	O
determine	O
mRNA	O
levels	O
following	O
microbial	O
challenge	O
.	O

Three	O
beta	O
-	O
defensins	B-PATH
,	O
CBD1	O
,	O
CBD103	O
and	O
CBD108	O
,	O
were	O
detected	O
in	O
respiratory	O
cells	O
.	O

Recent	O
epidemics	O
of	O
measles	B-PATH
,	O
avian	O
flu	O
,	O
and	O
SARS	O
demonstrated	O
how	O
an	O
organism	O
can	O
rapidly	O
spread	O
worldwide	O
because	O
of	O
airline	O
travel	O
.	O

ABSTRACT	O
:	O
During	O
the	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
,	O
some	O
patients	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
or	O
severe	O
cardiopulmonary	O
failure	O
despite	O
the	O
use	O
of	O
conventional	O
management	O
.	O

TITLE	O
:	O
Clinical	O
findings	O
and	O
demographic	O
factors	O
associated	O
with	O
ICU	O
admission	O
in	O
Utah	O
due	O
to	O
novel	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

ABSTRACT	O
:	O
Novel	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
has	O
significantly	O
affected	O
ICUs	O
.	O

Up	O
to	O
104	O
cDNA	O
clones	O
of	O
eight	O
viruses	O
were	O
obtained	O
by	O
reverse	O
transcription	O
PCR	O
with	O
different	O
pairs	O
of	O
primers	O
designed	O
for	O
each	O
virus	O
and	O
a	O
pair	O
of	O
universal	O
primers	O
designed	O
for	O
the	O
RNA	B-PATH
polymerase	I-PATH
gene	O
of	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
influenza	B-PATH
A	I-PATH
pandemic	O
(	O
H1N1	O
)	O
2009	O
prompted	O
many	O
countries	O
in	O
Asia	O
,	O
previously	O
strongly	O
affected	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
to	O
respond	O
with	O
stringent	O
measures	O
,	O
particularly	O
in	O
preventing	O
outbreaks	O
in	O
hospitals	O
.	O

Our	O
data	O
show	O
a	O
remarkable	O
resemblance	O
to	O
results	O
obtained	O
recently	O
by	O
others	O
with	O
hepatitis	B-PATH
C	I-PATH
virus	O
.	O

TITLE	O
:	O
Measles	B-PATH
-	O
induced	O
respiratory	O
distress	O
,	O
air	O
-	O
leak	O
and	O
ARDS	O
.	O

ABSTRACT	O
:	O
Young	O
infants	O
with	O
measles	B-PATH
requiring	O
respiratory	O
support	O
have	O
a	O
significant	O
risk	O
for	O
death	O
and	O
long	O
-	O
term	O
complications	O
.	O

TITLE	O
:	O
Critical	O
care	O
aspects	O
of	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
remains	O
a	O
major	O
health	O
problem	O
in	O
much	O
of	O
Asia	O
and	O
Africa	O
.	O

Critical	O
care	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
complications	O
and	O
management	O
of	O
severe	O
malaria	B-PATH
.	O

Effective	O
management	O
of	O
severe	O
malaria	B-PATH
includes	O
early	O
suspicion	O
,	O
prompt	O
diagnosis	O
,	O
early	O
institution	O
of	O
appropriate	O
antimalarial	O
chemotherapy	O
,	O
and	O
supportive	O
care	O
,	O
preferably	O
in	O
an	O
intensive	O
care	O
unit	O
.	O

ABSTRACT	O
:	O
The	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
reported	O
to	O
cause	O
apoptosis	B-PATH
of	O
infected	O
cells	O
and	O
several	O
of	O
its	O
proteins	O
including	O
the	O
3a	O
accessory	O
protein	O
,	O
are	O
pro	O
-	O
apoptotic	O
.	O

TITLE	O
:	O
Clinical	O
management	O
of	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

ABSTRACT	O
:	O
Antiviral	O
therapy	O
and	O
vaccination	O
are	O
important	O
strategies	O
for	O
controlling	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
but	O
efficacy	O
depends	O
on	O
the	O
timing	O
of	O
administration	O
and	O
is	O
often	O
limited	O
by	O
supply	O
shortage	O
.	O

However	O
,	O
the	O
possibility	O
of	O
within	O
-	O
flight	O
transmission	O
of	O
H1N1	O
has	O
not	O
been	O
evaluated	O
;	O
although	O
it	O
is	O
known	O
that	O
smallpox	O
,	O
measles	B-PATH
,	O
tuberculosis	B-PATH
,	O
SARS	O
and	O
seasonal	O
influenza	O
can	O
be	O
transmitted	O
during	O
commercial	O
flights	O
.	O

Paradoxically	O
,	O
prolonged	O
administration	O
of	O
immunosuppressive	O
agents	O
because	O
of	O
acute	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
had	O
a	O
protective	O
effect	O
on	O
the	O
development	O
of	O
allo	O
-	O
LS	O
(	O
P	O
=	O
.	O
004	O
).	O

ABSTRACT	O
:	O
In	O
late	O
May	O
2009	O
,	O
an	O
outbreak	O
of	O
the	O
novel	O
swine	O
-	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H1N1	O
)	O
was	O
identified	O
in	O
the	O
Southern	O
hemisphere	O
.	O

The	O
protein	O
was	O
detected	O
within	O
the	O
endoplasmatic	O
reticulum	O
/	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
)	O
where	O
coronavirus	O
assembly	O
and	O
budding	B-PATH
takes	O
place	O
.	O

Previously	O
,	O
we	O
have	O
identified	O
two	O
shRNA	O
-	O
expressing	O
plasmids	O
pEGFP	O
-	O
U6	O
/	O
P1	O
and	O
pEGFP	O
-	O
U6	O
/	O
P2	O
that	O
target	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRP	O
)	O
gene	O
of	O
TGEV	O
with	O
more	O
than	O
95	O
%	O
of	O
virus	O
inhibition	O
in	O
vitro	O
.	O

TITLE	O
:	O
Extracorporeal	O
lung	O
support	O
for	O
patients	O
who	O
had	O
severe	O
respiratory	O
failure	O
secondary	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
infection	O
in	O
Canada	O
.	O

ABSTRACT	O
:	O
From	O
March	O
to	O
July	O
2009	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	B-PATH
)	O
2009	O
(	O
H1N1	B-PATH
-	O
2009	O
)	O
virus	O
emerged	O
as	O
a	O
major	O
cause	O
of	O
respiratory	O
failure	O
that	O
required	O
mechanical	O
ventilation	O
.	O

FcgammaRs	O
regulate	O
phagocytosis	O
and	O
cell	O
-	O
mediated	O
cytotoxicity	O
,	O
and	O
initiate	O
the	O
release	B-PATH
of	O
inflammatory	O
mediators	O
.	O

Immunohistochemically	O
,	O
influenza	B-PATH
A	I-PATH
viral	O
protein	O
was	O
confirmed	O
in	O
the	O
damaged	O
type	O
II	O
pneumocytes	O
and	O
also	O
in	O
the	O
infiltrated	O
macrophages	O
.	O

TITLE	O
:	O
Severe	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H1N1	O
)	O
infection	O
in	O
pregnancy	O
.	O

A	O
variable	O
increase	O
(	O
of	O
up	O
to	O
50	O
%)	O
on	O
the	O
release	B-PATH
of	O
NO	O
(-)	O
and	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
(	O
ROS	O
)	O
was	O
obtained	O
when	O
LAB	O
strains	O
were	O
co	O
-	O
incubated	O
with	O
the	O
cell	O
lines	O
,	O
but	O
the	O
results	O
were	O
found	O
to	O
be	O
LAB	O
strain	O
and	O
cell	O
line	O
specific	O
,	O
apart	O
from	O
a	O
small	O
number	O
of	O
strains	O
which	O
were	O
able	O
to	O
induce	O
strong	O
ROS	O
release	B-PATH
in	O
more	O
than	O
one	O
cell	O
line	O
.	O

TITLE	O
:	O
[	O
Acute	O
respiratory	O
distress	O
due	O
to	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
S	O
-	O
OIV	O
and	O
extracorporeal	O
oxygenation	O
:	O
the	O
benefit	O
of	O
a	O
multidisciplinary	O
care	O
network	O
].	O

ABSTRACT	O
:	O
Between	O
August	O
and	O
September	O
2009	O
,	O
on	O
Reunion	O
Island	O
,	O
our	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
treated	O
several	O
severe	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
S	O
-	O
OIV	O
cases	O
.	O

ABSTRACT	O
:	O
Novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
at	O
the	O
origin	O
of	O
the	O
2009	O
pandemic	O
flu	O
developed	O
mainly	O
in	O
subjects	O
of	O
less	O
than	O
65	O
years	O
contrary	O
to	O
the	O
seasonal	O
influenza	O
,	O
which	O
usually	O
developed	O
in	O
elderly	O
patients	O
of	O
more	O
than	O
65	O
years	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
can	O
arise	O
in	O
serious	O
forms	O
within	O
60	O
to	O
80	O
%	O
of	O
cases	O
a	O
fulminant	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
""""	O
malignant	O
and	O
fulminant	O
influenza	O
""""	O
in	O
subjects	O
without	O
any	O
comorbidity	O
,	O
which	O
makes	O
the	O
gravity	O
and	O
the	O
fear	O
of	O
this	O
influenza	O
.	O

The	O
first	O
publications	O
of	O
patients	O
admitted	O
in	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
for	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
often	O
associated	O
to	O
an	O
ARDS	O
reported	O
a	O
mortality	O
rate	O
from	O
15	O
to	O
40	O
%.	O

TITLE	O
:	O
[	O
Intensive	O
care	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
in	O
Iceland	O
2009	O
].	O

(	O
1	O
)	O
The	O
incidence	O
of	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
that	O
leads	O
to	O
ICU	O
admission	O
appears	O
to	O
be	O
high	O
in	O
Iceland	O
.	O

Key	O
words	O
:	O
influenza	B-PATH
A	I-PATH
,	O
pneumonia	O
,	O
multiple	O
organ	O
failure	O
,	O
death	O
rate	O
,	O
intensive	O
care	O
,	O
ventilator	O
therapy	O
,	O
ECMO	O
.	O

TITLE	O
:	O
Efficacy	O
and	O
safety	O
of	O
quinine	O
-	O
artesunate	O
in	O
an	O
HIV	O
-	O
positive	O
patient	O
with	O
severe	O
falciparum	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
Severe	O
falciparum	O
malaria	B-PATH
is	O
a	O
medical	O
emergency	O
that	O
is	O
associated	O
with	O
a	O
high	O
rate	O
of	O
mortality	O
,	O
even	O
when	O
treated	O
in	O
an	O
Intensive	O
Care	O
Unit	O
.	O

This	O
article	O
describes	O
the	O
case	O
of	O
an	O
HIV	O
-	O
positive	O
patient	O
,	O
who	O
returned	O
from	O
Africa	O
and	O
presented	O
with	O
10	O
%	O
parasitemia	O
and	O
clinical	O
signs	O
of	O
severe	O
falciparum	O
malaria	B-PATH
;	O
this	O
individual	O
was	O
successfully	O
treated	O
with	O
a	O
combination	O
of	O
artesunate	O
and	O
quinine	O
.	O

TITLE	O
:	O
Effect	O
on	O
tuberculosis	B-PATH
outcomes	O
of	O
educational	O
outreach	O
to	O
South	O
African	O
clinics	O
during	O
two	O
randomised	O
trials	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
first	O
homolog	O
of	O
ACE	O
,	O
regulates	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
by	O
counterbalancing	O
ACE	O
activity	O
.	O

Reactive	O
hemophagocytosis	O
,	O
thrombotic	O
phenomena	O
,	O
lymphoid	O
atrophy	O
,	O
diffuse	O
alveolar	O
damage	O
,	O
and	O
multiorgan	O
dysfunction	O
similar	O
to	O
fatal	O
avian	O
influenza	B-PATH
A	I-PATH
H5N1	O
infection	O
were	O
found	O
at	O
postmortem	O
examinations	O
.	O

Reactive	O
hemophagocytosis	O
,	O
thrombotic	O
phenomena	O
,	O
lymphoid	O
atrophy	O
,	O
diffuse	O
alveolar	O
damage	O
,	O
and	O
multiorgan	O
dysfunction	O
similar	O
to	O
fatal	O
avian	O
influenza	B-PATH
A	I-PATH
H5N1	O
infection	O
were	O
found	O
at	O
postmortem	O
examinations	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
viral	O
respiratory	O
pathogens	O
with	O
pandemic	O
potential	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
influenza	B-PATH
A	I-PATH
H5N1	O
,	O
urges	O
the	O
need	O
for	O
deciphering	O
their	O
pathogenesis	O
to	O
develop	O
new	O
intervention	O
strategies	O
.	O

TITLE	O
:	O
Hexokinase	O
II	O
gene	O
transfer	O
protects	O
against	O
neurodegeneration	O
in	O
the	O
rotenone	O
and	O
MPTP	O
mouse	O
models	O
of	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
.	O

ABSTRACT	O
:	O
A	O
typical	O
feature	O
of	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
is	O
the	O
progressive	O
loss	O
of	O
dopaminergic	O
neurons	O
in	O
the	O
substantia	O
nigra	O
,	O
in	O
which	O
inhibition	O
of	O
mitochondrial	O
complex	O
I	O
activity	O
may	O
play	O
an	O
important	O
role	O
.	O

Rotenone	O
or	O
1	O
-	O
methyl	O
-	O
4	O
-	O
phenyl	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
6	O
-	O
tetrahydropyridine	O
(	O
MPTP	O
)	O
inhibit	O
the	O
mitochondrial	O
complex	O
I	O
and	O
they	O
cause	O
the	O
death	O
of	O
substantia	O
nigra	O
dopaminergic	O
neurons	O
,	O
thereby	O
providing	O
acute	O
murine	O
models	O
of	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
.	O

Ap4A	O
-	O
hydrolase	O
is	O
responsible	O
for	O
metabolizing	O
the	O
""""	O
allarmone	O
""""	O
nucleotide	O
Ap4A	O
and	O
therefore	O
likely	O
involved	O
in	O
regulation	O
of	O
cell	O
proliferation	O
,	O
DNA	B-PATH
replication	I-PATH
,	O
RNA	O
processing	O
,	O
apoptosis	B-PATH
and	O
DNA	O
repair	O
.	O

Blocking	O
M	O
glycosylation	O
does	O
not	O
appear	O
to	O
significantly	O
affect	O
M	O
plasma	O
membrane	O
labeling	O
intensity	O
,	O
M	O
-	O
containing	O
vesicle	O
release	B-PATH
,	O
or	O
VLP	O
formation	O
.	O

Whereas	O
numerous	O
mammalian	O
protease	O
inhibitors	O
have	O
no	O
effect	O
on	O
MLK3	O
proteolysis	O
,	O
blockade	O
of	O
the	O
proteasome	B-PATH
through	O
epoxomicin	O
or	O
MG132	O
abolishes	O
PMA	O
-	O
induced	O
production	O
of	O
the	O
CTF	O
of	O
MLK3	O
.	O

TITLE	O
:	O
Mathematical	O
modeling	O
of	O
the	O
effectiveness	O
of	O
facemasks	O
in	O
reducing	O
the	O
spread	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

The	O
results	O
show	O
that	O
if	O
N95	O
respirators	O
are	O
only	O
20	O
%	O
effective	O
in	O
reducing	O
susceptibility	O
and	O
infectivity	O
,	O
only	O
10	O
%	O
of	O
the	O
population	O
would	O
have	O
to	O
wear	O
them	O
to	O
reduce	O
the	O
number	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
cases	O
by	O
20	O
%.	O

Our	O
findings	O
indicate	O
that	O
alveolar	O
epithelium	O
apoptosis	B-PATH
seems	O
to	O
be	O
less	O
important	O
during	O
the	O
early	O
phases	O
of	O
Adult	O
Respiratory	O
Distress	O
Syndrome	O
.	O

Despite	O
the	O
use	O
of	O
multimodal	O
therapy	O
to	O
include	O
empiric	O
antibiotics	O
,	O
intravenous	O
paralytics	O
,	O
intravenous	O
concentrated	O
albumin	O
,	O
high	O
-	O
dose	O
corticosteroids	O
as	O
well	O
as	O
sustained	O
high	O
mean	O
airway	O
pressure	O
mechanical	O
ventilation	O
by	O
airway	O
pressure	O
release	B-PATH
and	O
high	O
-	O
frequency	O
percussive	O
ventilation	O
(	O
HFPV	O
)	O
modes	O
,	O
the	O
patient	O
demonstrated	O
an	O
unchanging	O
arterial	O
oxygen	O
tension	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
ratio	O
of	O
only	O
57	O
mm	O
Hg	O
.	O

TITLE	O
:	O
Delayed	O
onset	O
of	O
severe	O
neonatal	O
toxoplasmosis	B-PATH
.	O

Clinicians	O
facing	O
an	O
unexplained	O
life	O
-	O
threatening	O
condition	O
in	O
the	O
first	O
week	O
of	O
life	O
should	O
take	O
into	O
consideration	O
the	O
possibility	O
of	O
neonatal	O
toxoplasmosis	B-PATH
.	O

TITLE	O
:	O
Pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
in	O
Argentina	O
:	O
a	O
study	O
of	O
337	O
patients	O
on	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
The	O
rapid	O
spread	O
of	O
the	O
2009	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
around	O
the	O
world	O
underscores	O
the	O
need	O
for	O
a	O
better	O
knowledge	O
of	O
epidemiology	O
,	O
clinical	O
features	O
,	O
outcomes	O
,	O
and	O
mortality	O
predictors	O
,	O
especially	O
in	O
the	O
most	O
severe	O
presentations	O
.	O

Patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
requiring	O
mechanical	O
ventilation	O
were	O
mostly	O
middle	O
-	O
aged	O
adults	O
,	O
often	O
with	O
comorbidities	O
,	O
and	O
frequently	O
developed	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
multiorgan	O
failure	O
requiring	O
advanced	O
organ	O
support	O
.	O

In	O
addition	O
,	O
other	O
diseases	O
such	O
as	O
malaria	B-PATH
,	O
tuberculosis	B-PATH
,	O
and	O
bacterial	O
pneumonia	O
are	O
increasingly	O
resistant	O
to	O
antimicrobial	O
treatment	O
.	O

Cow	O
'	O
s	O
milk	O
allergy	O
should	O
be	O
suspected	O
in	O
children	O
who	O
have	O
immediate	O
symptoms	O
such	O
as	O
acute	O
urticaria	O
/	O
angioedema	O
,	O
wheezing	O
,	O
rhinitis	O
,	O
dry	O
cough	O
,	O
vomiting	O
,	O
laryngeal	O
edema	O
,	O
acute	O
asthma	B-PATH
with	O
severe	O
respiratory	O
distress	O
,	O
anaphylaxis	O
.	O

We	O
show	O
that	O
Tregs	O
dampen	O
the	O
inflammatory	O
response	O
mediated	O
by	O
transferred	O
JHMV	O
-	O
immune	O
splenocytes	O
in	O
infected	O
RAG1	O
(-/-)	O
mice	O
by	O
decreasing	O
T	O
cell	O
proliferation	O
,	O
dendritic	O
cell	O
activation	O
,	O
and	O
proinflammatory	O
cytokine	O
/	O
chemokine	O
production	O
,	O
without	O
inducing	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
Our	O
studies	O
and	O
those	O
of	O
many	O
others	O
have	O
implicated	O
hepatocyte	O
necrosis	O
and	O
apoptosis	B-PATH
mediated	O
by	O
fibrinogen	O
-	O
like	O
protein	O
-	O
2	O
(	O
fgl2	O
)	O
prothrombinase	O
and	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
in	O
the	O
development	O
of	O
fulminant	O
viral	O
hepatitis	O
,	O
a	O
disease	O
with	O
a	O
mortality	O
rate	O
greater	O
than	O
80	O
%	O
in	O
cases	O
lacking	O
immediate	O
organ	O
transplantation	O
.	O

In	O
vivo	O
hydrodynamic	O
delivery	O
of	O
dual	O
-	O
interference	O
shRNA	O
plasmids	O
for	O
mfgl2	O
and	O
mTNFR1	O
significantly	O
decreased	O
mfgl2	O
and	O
mTNFR1	O
expression	O
;	O
markedly	O
ameliorated	O
fibrin	O
deposition	O
,	O
hepatocyte	O
necrosis	O
,	O
and	O
apoptosis	B-PATH
;	O
and	O
prolonged	O
survival	O
against	O
fulminant	O
viral	O
hepatitis	O
induced	O
by	O
MHV	O
-	O
3	O
in	O
BALB	O
/	O
cJ	O
mice	O
compared	O
with	O
mfgl2	O
or	O
TNFR1	O
single	O
-	O
gene	O
interference	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
affected	O
South	O
Africa	O
late	O
during	O
the	O
2009	O
Southern	O
hemisphere	O
winter	O
and	O
placed	O
an	O
extra	O
burden	O
on	O
a	O
health	O
care	O
system	O
already	O
dealing	O
with	O
a	O
high	O
prevalence	O
of	O
chronic	O
lung	O
diseases	O
and	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
epidemiological	O
characteristics	O
,	O
clinical	O
features	O
,	O
management	O
and	O
outcomes	O
of	O
patients	O
with	O
confirmed	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
complicated	O
by	O
respiratory	O
failure	O
.	O

We	O
included	O
all	O
adult	O
patients	O
with	O
confirmed	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
that	O
were	O
referred	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
of	O
a	O
large	O
academic	O
hospital	O
in	O
Cape	O
Town	O
for	O
ventilatory	O
support	O
in	O
this	O
prospective	O
observational	O
study	O
.	O

The	O
majority	O
of	O
patients	O
with	O
respiratory	O
failure	O
secondary	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
were	O
young	O
females	O
and	O
had	O
an	O
underlying	O
risk	O
factor	O
for	O
severe	O
disease	O
.	O

The	O
method	O
was	O
evaluated	O
using	O
the	O
data	O
available	O
at	O
the	O
early	O
stage	O
of	O
some	O
recent	O
outbreaks	O
of	O
infectious	O
diseases	O
,	O
including	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
in	O
2009	O
,	O
and	O
the	O
evaluation	O
supports	O
the	O
design	O
idea	O
.	O

RESULTS	O
:	O
The	O
method	O
was	O
evaluated	O
using	O
the	O
data	O
available	O
at	O
the	O
early	O
stage	O
of	O
some	O
recent	O
outbreaks	O
of	O
infectious	O
diseases	O
,	O
including	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
in	O
2009	O
,	O
and	O
the	O
evaluation	O
supports	O
the	O
design	O
idea	O
.	O

TITLE	O
:	O
Acute	O
kidney	O
injury	O
in	O
critically	O
ill	O
patients	O
infected	O
with	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
):	O
report	O
from	O
a	O
Canadian	O
Province	O
.	O

ABSTRACT	O
:	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
has	O
led	O
to	O
a	O
global	O
increase	O
in	O
severe	O
respiratory	O
illness	O
.	O

Viroporins	O
E	O
from	O
mouse	O
hepatitis	O
virus	O
,	O
6K	O
from	O
Sindbis	O
virus	O
and	O
NS4A	O
protein	O
from	O
hepatitis	B-PATH
C	I-PATH
virus	O
were	O
also	O
able	O
to	O
permeabilize	O
neighbouring	O
cells	O
to	O
different	O
extents	O
.	O

Using	O
mice	O
lacking	O
functional	O
receptors	O
for	O
type	O
I	O
IFN	O
,	O
type	O
III	O
IFN	O
,	O
or	O
both	O
,	O
we	O
found	O
that	O
IFN	O
-	O
lambda	O
plays	O
an	O
important	O
role	O
in	O
the	O
defense	O
against	O
several	O
human	O
pathogens	O
that	O
infect	O
the	O
respiratory	O
tract	O
,	O
such	O
as	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
influenza	O
B	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
.	O

TITLE	O
:	O
Practical	O
use	O
of	O
airway	O
pressure	O
release	B-PATH
ventilation	O
for	O
severe	O
ARDS	O
--	O
a	O
preliminary	O
report	O
in	O
comparison	O
with	O
a	O
conventional	O
ventilatory	O
support	O
.	O

ABSTRACT	O
:	O
Airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
is	O
a	O
ventilatory	O
mode	O
that	O
allows	O
unsupported	O
spontaneous	O
breathing	O
at	O
any	O
phase	O
of	O
the	O
ventilatory	O
cycle	O
with	O
high	O
mean	O
airway	O
pressures	O
.	O

Viral	O
RNA	O
was	O
detected	O
in	O
serum	O
samples	O
from	O
6	O
of	O
66	O
patients	O
:	O
4	O
of	O
41	O
with	O
RSV	O
pneumonia	O
,	O
1	O
with	O
influenza	O
B	O
,	O
and	O
1	O
with	O
MPV	O
/	O
influenza	B-PATH
A	I-PATH
virus	O
/	O
CoV	O
coinfection	O
(	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
MPV	O
RNA	O
detected	O
).	O

ABSTRACT	O
:	O
In	O
this	O
article	O
I	O
demonstrate	O
the	O
knowledge	O
perceptions	O
of	O
and	O
the	O
preventive	O
health	O
behaviors	O
toward	O
the	O
influenza	B-PATH
A	I-PATH
H1N1	O
pandemic	O
,	O
or	O
""""	O
human	O
swine	O
flu	O
","""	O
among	O
the	O
chronic	O
renal	O
disease	O
patients	O
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
[	O
Eighteen	O
cases	O
of	O
2009	O
influenza	B-PATH
A	I-PATH
H1N1	O
associated	O
with	O
respiratory	O
failure	O
in	O
adults	O
].	O

Respiratory	O
failure	O
occurred	O
in	O
18	O
patients	O
with	O
confirmed	O
(	O
n	O
=	O
9	O
)	O
or	O
probable	O
(	O
n	O
=	O
9	O
)	O
2009	O
influenza	B-PATH
A	I-PATH
H1N1	O
.	O

Seventeen	O
patients	O
had	O
primary	O
viral	O
pneumonia	O
and	O
1	O
patient	O
had	O
an	O
asthma	B-PATH
exacerbation	O
and	O
3	O
patients	O
experienced	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
).	O

Severe	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
the	O
most	O
common	O
manifestation	O
in	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
H1N1	O
infection	O
in	O
adult	O
.	O

RESULTS	O
:	O
Respiratory	O
failure	O
occurred	O
in	O
18	O
patients	O
with	O
confirmed	O
(	O
n	O
=	O
9	O
)	O
or	O
probable	O
(	O
n	O
=	O
9	O
)	O
2009	O
influenza	B-PATH
A	I-PATH
H1N1	O
.	O

CONCLUSIONS	O
:	O
Severe	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
the	O
most	O
common	O
manifestation	O
in	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
H1N1	O
infection	O
in	O
adult	O
.	O

TITLE	O
:	O
[	O
Clinical	O
analysis	O
of	O
75	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
H1N1	O
in	O
Qinghai	O
Province	O
].	O

ABSTRACT	O
:	O
To	O
observe	O
clinical	O
features	O
of	O
severe	O
influenza	B-PATH
A	I-PATH
H1N1	O
in	O
Qinghai	O
Province	O
.	O

RESULTS	O
:	O
The	O
first	O
case	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
H1N1	O
was	O
diagnosed	O
on	O
October	O
14	O
,	O
and	O
up	O
to	O
75	O
patients	O
(	O
47	O
.	O
78	O
%)	O
on	O
December	O
31	O
.	O

TITLE	O
:	O
Computational	O
approaches	O
for	O
the	O
discovery	O
of	O
cysteine	O
protease	O
inhibitors	O
against	O
malaria	B-PATH
and	O
SARS	O
.	O

Cynomolgus	O
macaques	O
(	O
Macaca	O
fascicularis	O
)	O
infected	O
with	O
a	O
human	O
highly	O
pathogenic	O
avian	O
influenza	O
(	O
HPAI	O
)	O
H5N1	O
virus	O
isolate	O
(	O
A	O
/	O
Vietnam	O
/	O
1203	O
/	O
2004	O
)	O
or	O
reassortants	O
of	O
human	O
influenza	O
virus	O
A	O
/	O
Texas	O
/	O
36	O
/	O
91	O
(	O
H1N1	O
)	O
containing	O
genes	O
from	O
the	O
1918	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
developed	O
severe	O
pneumonia	O
within	O
24	O
h	O
postinfection	O
.	O

ABSTRACT	O
:	O
In	O
the	O
last	O
decade	O
,	O
descriptions	O
of	O
outbreaks	O
of	O
extensively	O
drug	O
-	O
resistant	O
strains	O
of	O
tuberculosis	B-PATH
(	O
TB	B-PATH
)	O
have	O
increased	O
concern	O
about	O
the	O
nosocomial	O
transmission	O
of	O
TB	B-PATH
-	O
a	O
potentially	O
life	O
-	O
threatening	O
occupational	O
respiratory	O
infection	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pneumonia	O
in	O
an	O
immunossupressed	O
patient	O
after	O
heart	O
transplantation	O
.	O

This	O
suggests	O
that	O
type	O
I	O
,	O
II	O
and	O
III	O
interferon	B-PATH
signaling	I-PATH
play	O
minor	O
roles	O
in	O
regulating	O
SARS	O
pathogenesis	O
in	O
mouse	O
models	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
severe	O
pulmonary	O
tuberculosis	B-PATH
with	O
septic	O
shock	O
and	O
ARDS	O
].	O

A	O
diagnosis	O
of	O
pulmonary	O
tuberculosis	B-PATH
was	O
given	O
because	O
of	O
multiple	O
nodular	O
shadows	O
and	O
consolidation	O
on	O
chest	O
radiography	O
and	O
positive	O
testing	O
for	O
acid	O
-	O
fast	O
bacilli	O
in	O
his	O
sputum	O
;	O
he	O
was	O
then	O
referred	O
to	O
our	O
hospital	O
for	O
treatment	O
.	O

We	O
diagnosed	O
pulmonary	O
tuberculosis	B-PATH
complicated	O
with	O
septic	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
disseminated	O
intravascular	O
coagulation	O
based	O
on	O
his	O
clinical	O
course	O
and	O
laboratory	O
data	O
.	O

ABSTRACT	O
:	O
4	O
-[(	O
1	O
,	O
2	O
-	O
dihydro	O
-	O
2	O
-	O
oxo	O
-	O
3H	O
-	O
indol	O
-	O
3	O
-	O
ylidene	O
)	O
amino	O
]-	O
N	O
(	O
4	O
,	O
6	O
-	O
dimethyl	O
-	O
2	O
-	O
pyrimidiny	O
)	O
benzene	O
sulphonamide	O
and	O
its	O
derivatives	O
were	O
evaluated	O
for	O
antiviral	O
activity	O
against	O
Pathogenic	O
viruses	O
such	O
as	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
and	O
SARS	O
-	O
CoV	O
in	O
Vero	O
and	O
Huh	O
5	O
-	O
2	O
cells	O
,	O
respectively	O
.	O

BAG3	O
is	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
cellular	O
processes	O
,	O
including	O
cell	O
survival	O
,	O
cellular	O
stress	B-PATH
response	I-PATH
,	O
proliferation	O
,	O
migration	O
,	O
and	O
apoptosis	B-PATH
.	O

The	O
virus	O
surface	O
glycoprotein	O
hemagglutinin	O
-	O
esterase	O
(	O
HE	O
)	O
is	O
responsible	O
for	O
both	O
viral	O
attachment	O
and	O
release	B-PATH
.	O

The	O
three	O
amino	O
acid	O
differences	O
between	O
the	O
high	O
and	O
low	O
virulent	O
variants	O
,	O
of	O
which	O
two	O
localized	O
to	O
the	O
putative	O
receptor	O
-	O
binding	O
domain	O
and	O
one	O
in	O
the	O
esterase	O
domain	O
,	O
had	O
no	O
impact	O
on	O
receptor	O
-	O
binding	O
or	O
-	O
release	B-PATH
activities	O
.	O

Our	O
study	O
suggests	O
that	O
unlike	O
PRRSV	O
which	O
induces	O
apoptosis	B-PATH
in	O
AMs	O
,	O
respiratory	O
CoVs	O
such	O
as	O
PRCV	O
that	O
infect	O
pulmonary	O
epithelial	O
cells	O
and	O
cause	O
cytolysis	O
,	O
induce	O
NO	O
production	O
in	O
the	O
respiratory	O
tract	O
.	O

TITLE	O
:	O
Fatalities	O
associated	O
with	O
the	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
New	O
York	O
city	O
.	O

When	O
the	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
emerged	O
in	O
the	O
United	O
States	O
,	O
epidemiologic	O
and	O
clinical	O
information	O
about	O
severe	O
and	O
fatal	O
cases	O
was	O
limited	O
.	O

The	O
New	O
York	O
City	O
Department	O
of	O
Health	O
and	O
Mental	O
Hygiene	O
conducted	O
enhanced	O
surveillance	O
for	O
hospitalizations	O
and	O
deaths	O
associated	O
with	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

With	O
community	O
-	O
wide	O
transmission	O
of	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
timely	O
medical	O
care	O
and	O
antiviral	O
therapy	O
should	O
be	O
considered	O
for	O
patients	O
with	O
severe	O
influenza	O
-	O
like	O
illness	O
or	O
with	O
underlying	O
risk	O
conditions	O
for	O
complications	O
from	O
influenza	O
.	O

Knockdown	O
of	O
another	O
cytoplasmic	O
receptor	O
,	O
the	O
melanoma	B-PATH
-	O
differentiation	O
-	O
associated	O
gene	O
5	O
(	O
MDA5	O
),	O
by	O
small	O
interfering	O
RNAs	O
also	O
blocked	O
IFN	O
-	O
beta	O
induction	O
.	O

Severe	O
malaria	B-PATH
cases	O
are	O
reported	O
throughout	O
the	O
year	O
,	O
but	O
they	O
are	O
more	O
common	O
during	O
the	O
high	O
transmission	O
season	O
.	O

All	O
patients	O
with	O
severe	O
falciparum	O
malaria	B-PATH
above	O
the	O
age	O
of	O
14	O
years	O
admitted	O
to	O
the	O
ICU	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
clinical	O
spectrum	O
of	O
severe	O
falciparum	O
malaria	B-PATH
in	O
a	O
tertiary	O
care	O
level	O
III	O
ICU	O
was	O
analysed	O
from	O
December	O
1998	O
to	O
June	O
2008	O
.	O

Jaundice	O
with	O
acute	O
renal	O
failure	O
(	O
ARF	O
)	O
was	O
the	O
most	O
common	O
presentation	O
(	O
13	O
.	O
28	O
percent	O
),	O
followed	O
by	O
cerebral	O
malaria	B-PATH
with	O
jaundice	O
and	O
ARF	O
(	O
6	O
.	O
37	O
percent	O
),	O
and	O
jaundice	O
,	O
ARF	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
(	O
5	O
.	O
31	O
percent	O
).	O

Severe	O
falciparum	O
malaria	B-PATH
is	O
a	O
common	O
cause	O
of	O
multi	O
-	O
organ	O
failure	O
in	O
the	O
ICUs	O
in	O
eastern	O
India	O
.	O

CONCLUSIONS	O
:	O
Severe	O
falciparum	O
malaria	B-PATH
is	O
a	O
common	O
cause	O
of	O
multi	O
-	O
organ	O
failure	O
in	O
the	O
ICUs	O
in	O
eastern	O
India	O
.	O

TITLE	O
:	O
Acute	O
motor	O
axonal	O
neuropathy	O
associated	O
with	O
pandemic	O
H1N1	O
influenza	B-PATH
A	I-PATH
infection	O
.	O

Patient	O
with	O
AMAN	O
variant	O
of	O
GBS	O
after	O
severe	O
bilateral	O
pneumonia	O
and	O
ARDS	O
due	O
to	O
the	O
novel	O
pandemic	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
is	O
presented	O
.	O

We	O
report	O
a	O
case	O
of	O
AMAN	O
variant	O
of	O
GBS	O
associated	O
with	O
proven	O
H1N1	O
influenza	B-PATH
A	I-PATH
infection	O
.	O

There	O
is	O
also	O
the	O
risk	O
of	O
well	O
-	O
known	O
and	O
preventable	O
zoonotic	O
diseases	O
,	O
such	O
as	O
rabies	O
,	O
brucellosis	O
,	O
leishmaniasis	B-PATH
,	O
and	O
echinococcosis	O
/	O
hydatidosis	O
,	O
in	O
certain	O
countries	O
;	O
these	O
diseases	O
have	O
a	O
high	O
morbidity	O
with	O
the	O
potential	O
for	O
a	O
very	O
high	O
mortality	O
.	O

The	O
author	O
also	O
shows	O
that	O
even	O
for	O
the	O
larger	O
outbreaks	O
,	O
the	O
direct	O
impact	O
on	O
public	O
health	O
measured	O
by	O
the	O
morbidity	O
and	O
mortality	O
of	O
zoonoses	O
is	O
largely	O
inferior	O
to	O
that	O
of	O
major	O
communicable	O
diseases	O
that	O
affect	O
only	O
humans	O
,	O
particularly	O
human	O
tuberculosis	B-PATH
,	O
malaria	B-PATH
,	O
HIV	O
/	O
AIDS	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
pH1N1	O
)	O
infection	O
in	O
children	O
admitted	O
to	O
a	O
pediatric	O
intensive	O
care	O
unit	O
:	O
differences	O
with	O
other	O
respiratory	O
viruses	O
.	O

Patients	O
aged	O
>	O
1	O
month	O
with	O
acute	O
viral	O
LRTI	O
admitted	O
to	O
the	O
PICU	O
who	O
met	O
the	O
following	O
criteria	O
:	O
1	O
)	O
influenza	B-PATH
A	I-PATH
pH1N1	O
virus	O
infection	O
detected	O
between	O
June	O
1	O
,	O
2009	O
and	O
July	O
16	O
,	O
2009	O
;	O
and	O
2	O
)	O
patients	O
with	O
LRTI	O
due	O
to	O
other	O
viral	O
pathogens	O
infection	O
detected	O
in	O
the	O
same	O
period	O
of	O
the	O
year	O
2008	O
plus	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
non	O
-	O
pH1N1	O
infection	O
.	O

We	O
identified	O
30	O
patients	O
with	O
acute	O
LRTI	O
due	O
to	O
influenza	B-PATH
A	I-PATH
pH1N1	O
virus	O
(	O
group	O
1	O
)	O
and	O
62	O
patients	O
with	O
LRTI	O
due	O
to	O
other	O
viral	O
pathogens	O
(	O
group	O
2	O
).	O

When	O
both	O
groups	O
were	O
compared	O
,	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
pH1N1	O
infection	O
were	O
older	O
;	O
pneumonia	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
shock	O
were	O
more	O
frequently	O
seen	O
at	O
the	O
time	O
of	O
PICU	O
admission	O
,	O
although	O
length	O
of	O
stay	O
and	O
mortality	O
were	O
similar	O
.	O

Patients	O
with	O
influenza	B-PATH
A	I-PATH
pH1N1	O
respiratory	O
virus	O
infection	O
presented	O
with	O
more	O
severe	O
illness	O
.	O

During	O
AECOPD	O
,	O
upper	O
-	O
respiratory	O
viral	O
infections	O
were	O
detected	O
in	O
44	O
(	O
51	O
%)	O
patients	O
:	O
picornavirus	O
in	O
22	O
,	O
metapneumovirus	O
in	O
seven	O
,	O
coronavirus	O
in	O
eight	O
,	O
influenza	B-PATH
A	I-PATH
/	O
B	O
in	O
two	O
,	O
parainfluenza	O
in	O
two	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
in	O
three	O
.	O

ABSTRACT	O
:	O
Acute	O
pneumonitis	O
with	O
acute	O
lung	O
injury	O
is	O
a	O
cause	O
of	O
significant	O
mortality	O
related	O
to	O
the	O
2009	O
pH1N1	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

Also	O
,	O
many	O
of	O
these	O
patients	O
present	O
with	O
significant	O
hemodynamic	O
compromise	O
suggesting	O
systemic	O
cytokine	O
release	B-PATH
.	O

ABSTRACT	O
:	O
A	O
survey	O
of	O
infectious	O
and	O
parasitic	O
diseases	O
of	O
stray	O
cats	O
was	O
carried	O
out	O
using	O
biological	O
samples	O
collected	O
from	O
animals	O
captured	O
during	O
a	O
catch	O
-	O
neuter	O
-	O
release	B-PATH
programme	O
in	O
four	O
counties	O
of	O
the	O
Lisbon	O
Metropolitan	O
Area	O
.	O

Anti	O
-	O
neutrophil	O
cytoplasmic	O
antibody	O
(	O
ANCA	O
)	O
associated	O
vasculitis	O
""""	O
and	O
glomerular	O
basement	O
membrane	O
"("""	O
Goodpasture	O
'	O
s	O
""")"	O
disease	O
are	O
the	O
commonest	O
causes	O
but	O
other	O
pathologies	O
including	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
and	O
the	O
anti	O
-	O
phospholipid	O
syndrome	O
are	O
also	O
implicated	O
.	O

By	O
the	O
end	O
of	O
September	O
2009	O
,	O
it	O
was	O
estimated	O
that	O
at	O
least	O
270	O
,	O
000	O
persons	O
had	O
been	O
infected	O
by	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Singapore	O
.	O

For	O
hospitalised	O
children	O
,	O
the	O
most	O
common	O
risk	O
factors	O
were	O
being	O
under	O
5	O
years	O
of	O
age	O
and	O
asthma	B-PATH
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
-	O
2009	O
)	O
pandemic	O
in	O
Singapore	O
--	O
public	O
health	O
control	O
measures	O
implemented	O
and	O
lessons	O
learnt	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
the	O
public	O
health	O
control	O
measures	O
implemented	O
in	O
Singapore	O
to	O
limit	O
the	O
spread	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
-	O
2009	O
)	O
and	O
mitigate	O
its	O
social	O
effects	O
.	O

When	O
one	O
couples	O
these	O
grim	O
estimates	O
with	O
the	O
well	O
-	O
recognized	O
association	O
between	O
alcohol	O
abuse	O
and	O
severe	O
lung	O
infections	O
,	O
such	O
as	O
bacterial	O
pneumonia	O
and	O
tuberculosis	B-PATH
,	O
it	O
is	O
apparent	O
that	O
alcohol	O
-	O
related	O
lung	O
diseases	O
are	O
a	O
major	O
public	O
health	O
problem	O
.	O

TITLE	O
:	O
Interactions	O
of	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	O
with	O
the	O
host	O
cell	O
proteasome	B-PATH
subunit	O
p42	O
.	O

Using	O
surface	O
plasmon	O
resonance	O
biomolecular	O
interaction	O
analysis	O
(	O
SPR	O
/	O
BIA	O
)	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
of	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
mass	O
spectrometry	O
,	O
we	O
found	O
that	O
only	O
the	O
proteasome	B-PATH
subunit	O
p42	O
from	O
human	O
fetal	O
lung	O
diploid	O
fibroblast	O
(	O
2BS	O
)	O
cells	O
bound	O
to	O
SARS	O
-	O
CoV	O
NP	O
.	O

The	O
co	O
-	O
localization	O
signal	O
of	O
SARS	O
-	O
CoV	O
NP	O
and	O
proteasome	B-PATH
subunit	O
p42	O
in	O
2BS	O
cells	O
was	O
detected	O
using	O
indirect	O
immunofluorescence	O
and	O
confocal	O
microscopy	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
SARS	O
-	O
CoV	O
NP	O
interacts	O
with	O
the	O
proteasome	B-PATH
subunit	O
p42	O
within	O
host	O
cells	O
.	O

p42	O
is	O
a	O
subunit	O
of	O
the	O
26S	O
proteasome	B-PATH
;	O
this	O
large	O
,	O
multi	O
-	O
protein	O
complex	O
is	O
a	O
component	O
of	O
the	O
ubiquitin	O
-	O
proteasome	B-PATH
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	O
processes	O
and	O
inflammatory	O
responses	O
.	O

Two	O
of	O
52	O
R	O
.	O
ferrumequinum	O
captured	O
from	O
different	O
Italian	O
areas	O
tested	O
positive	O
by	O
reverse	O
transcription	O
-	O
PCR	O
for	O
a	O
fragment	O
of	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
of	O
viruses	O
related	O
to	O
Coronavirus	O
.	O

ABSTRACT	O
:	O
Viral	O
ion	O
channels	O
are	O
short	O
membrane	O
proteins	O
with	O
50	O
-	O
120	O
amino	O
acids	O
and	O
play	O
an	O
important	O
role	O
either	O
in	O
regulating	O
virus	O
replication	O
,	O
such	O
as	O
virus	O
entry	O
,	O
assembly	O
and	O
release	B-PATH
or	O
modulating	O
the	O
electrochemical	O
balance	O
in	O
the	O
subcellular	O
compartments	O
of	O
host	O
cells	O
.	O

Exposure	O
of	O
NSCLC	O
cells	O
to	O
TSL	O
-	O
1	O
caused	O
cell	O
-	O
cycle	O
arrest	O
in	O
subG1	O
phase	O
and	O
caused	O
apoptosis	B-PATH
.	O

Thus	O
,	O
the	O
TSL	O
-	O
1	O
-	O
induced	O
apoptosis	B-PATH
was	O
further	O
confirmed	O
by	O
cell	O
morphology	O
,	O
subG1	O
peak	O
accumulation	O
,	O
poly	O
(	O
adenosine	O
diphosphate	O
[	O
ADP	O
]-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
cleavage	O
,	O
propidium	O
iodide	O
(	O
PI	O
)-	O
Annexin	O
-	O
V	O
double	O
staining	O
,	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
end	O
-	O
labeling	O
(	O
TUNEL	O
)	O
assay	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-PATH
system	O
(	O
UPS	O
)	O
is	O
a	O
key	O
player	O
in	O
regulating	O
the	O
intracellular	O
sorting	O
and	O
degradation	O
of	O
proteins	O
.	O

Inhibition	O
of	O
the	O
proteasome	B-PATH
by	O
different	O
chemical	O
compounds	O
(	O
i	O
.	O
e	O
.,	O
MG132	O
,	O
epoxomicin	O
,	O
and	O
Velcade	O
)	O
appeared	O
to	O
not	O
only	O
impair	O
entry	O
but	O
also	O
RNA	O
synthesis	O
and	O
subsequent	O
protein	O
expression	O
of	O
different	O
CoVs	O
(	O
i	O
.	O
e	O
.,	O
mouse	O
hepatitis	O
virus	O
[	O
MHV	O
],	O
feline	O
infectious	O
peritonitis	O
virus	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
).	O

The	O
inhibitory	O
effect	O
on	O
CoV	O
protein	O
expression	O
did	O
not	O
appear	O
to	O
result	O
from	O
a	O
general	O
inhibition	O
of	O
translation	O
due	O
to	O
induction	O
of	O
a	O
cellular	O
stress	B-PATH
response	I-PATH
by	O
the	O
inhibitors	O
.	O

Stress	O
-	O
induced	O
phosphorylation	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
2alpha	O
(	O
eIF2alpha	O
)	O
generally	O
results	O
in	O
impaired	O
initiation	O
of	O
protein	O
synthesis	O
,	O
but	O
the	O
sensitivity	O
of	O
MHV	O
infection	O
to	O
proteasome	B-PATH
inhibitors	O
was	O
unchanged	O
in	O
cells	O
lacking	O
a	O
phosphorylatable	O
eIF2alpha	O
.	O

MHV	O
infection	O
was	O
affected	O
not	O
only	O
by	O
inhibition	O
of	O
the	O
proteasome	B-PATH
but	O
also	O
by	O
interfering	O
with	O
protein	O
ubiquitination	O
.	O

TITLE	O
:	O
The	O
proteasome	B-PATH
inhibitor	O
Velcade	O
enhances	O
rather	O
than	O
reduces	O
disease	O
in	O
mouse	O
hepatitis	O
coronavirus	O
-	O
infected	O
mice	O
.	O

Hence	O
,	O
the	O
proteasome	B-PATH
inhibitor	O
Velcade	O
(	O
bortezomib	O
),	O
a	O
clinically	O
approved	O
anticancer	O
drug	O
,	O
shown	O
in	O
an	O
accompanying	O
study	O
(	O
M	O
.	O
Raaben	O
et	O
al	O
.,	O
J	O
.	O
Virol	O
.	O

Rather	O
,	O
inhibition	O
of	O
the	O
proteasome	B-PATH
caused	O
enhanced	O
infection	O
with	O
lethal	O
outcome	O
,	O
calling	O
for	O
caution	O
when	O
using	O
this	O
type	O
of	O
drug	O
during	O
infection	O
.	O

TITLE	O
:	O
Ultrastructural	O
and	O
biochemical	O
analyses	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
-	O
associated	O
host	O
cell	O
membranes	O
.	O

ABSTRACT	O
:	O
Like	O
most	O
other	O
positive	O
-	O
strand	O
RNA	O
viruses	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
induces	O
changes	O
in	O
the	O
host	O
cell	O
'	O
s	O
membranes	O
,	O
resulting	O
in	O
a	O
membranous	O
web	O
.	O

Test	O
PCR	O
for	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
was	O
the	O
basis	O
in	O
diagnostics	O
procedures	O
of	O
the	O
new	O
pandemic	O
influenza	O
confirmation	O
.	O

TITLE	O
:	O
[	O
Influence	O
of	O
concomitant	O
illness	O
on	O
clinical	O
manifestations	O
and	O
severity	O
of	O
A	O
/	O
H1N1	O
influenza	B-PATH
infection	I-PATH
among	O
patients	O
hospitalized	O
in	O
the	O
Hospital	O
of	O
Infectious	O
Diseases	O
in	O
Warsaw	O
--	O
clinical	O
cases	O
].	O

Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
were	O
observed	O
in	O
10	O
pregnant	O
women	O
,	O
without	O
co	O
-	O
morbidities	O
.	O

TITLE	O
:	O
VEGF	O
promotes	O
malaria	B-PATH
-	O
associated	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
spectrum	O
of	O
the	O
clinical	O
presentation	O
and	O
severity	O
of	O
malaria	B-PATH
infections	O
is	O
broad	O
,	O
ranging	O
from	O
uncomplicated	O
febrile	O
illness	O
to	O
severe	O
forms	O
of	O
disease	O
such	O
as	O
cerebral	O
malaria	B-PATH
(	O
CM	O
),	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
pregnancy	O
-	O
associated	O
malaria	B-PATH
(	O
PAM	O
)	O
or	O
severe	O
anemia	O
(	O
SA	O
).	O

The	O
similarities	O
between	O
the	O
physiopathological	O
lesions	O
described	O
here	O
and	O
the	O
ones	O
occurring	O
in	O
humans	O
,	O
as	O
well	O
as	O
the	O
demonstration	O
that	O
VEGF	O
is	O
a	O
critical	O
host	O
factor	O
in	O
the	O
onset	O
of	O
malaria	B-PATH
-	O
associated	O
ALI	O
in	O
mice	O
,	O
not	O
only	O
offers	O
important	O
mechanistic	O
insights	O
into	O
the	O
processes	O
underlying	O
the	O
pathology	O
related	O
with	O
malaria	B-PATH
but	O
may	O
also	O
pave	O
the	O
way	O
for	O
interventional	O
studies	O
.	O

ABSTRACT	O
:	O
The	O
natural	O
history	O
and	O
consequences	O
of	O
severe	O
H1N1	O
influenza	B-PATH
infection	I-PATH
among	O
cancer	O
patients	O
are	O
not	O
yet	O
fully	O
characterized	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
infection	I-PATH
can	O
affect	O
cardiac	O
function	O
.	O

The	O
recent	O
pandemic	O
of	O
H1N1	O
influenza	B-PATH
A	I-PATH
provided	O
an	O
opportunity	O
to	O
study	O
echocardiographic	O
findings	O
in	O
critically	O
ill	O
infected	O
patients	O
.	O

The	O
recent	O
outbreaks	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
provide	O
evidence	O
of	O
the	O
benefits	O
of	O
the	O
new	O
global	O
monitoring	O
and	O
of	O
the	O
importance	O
of	O
the	O
World	O
Health	O
Organization	O
in	O
its	O
coordinating	O
role	O
in	O
the	O
multilateral	O
response	O
of	O
the	O
global	O
public	O
health	O
community	O
.	O

The	O
number	O
of	O
stories	O
published	O
in	O
10	O
newspapers	O
containing	O
the	O
words	O
,	O
'	O
SARS	O
,'	O
'	O
Bovine	O
Spongiform	O
Encephalopathy	O
,'	O
'	O
Avian	O
Influenza	O
,'	O
and	O
'	B-PATH
Influenza	I-PATH
A	I-PATH
virus	O
'	O
was	O
compared	O
with	O
the	O
number	O
of	O
stories	O
on	O
chronic	O
or	O
well	O
-	O
known	O
diseases	O
.	O

We	O
also	O
counted	O
the	O
annual	O
number	O
of	O
stories	O
,	O
published	O
in	O
a	O
12	O
-	O
year	O
period	O
,	O
containing	O
following	O
terms	O
:	O
'	O
cancer	O
,'	O
'	O
diabetes	O
,'	O
'	O
hypertension	O
,'	O
'	O
pneumonia	O
,'	O
and	O
'	B-PATH
tuberculosis	I-PATH
.'	O

Also	O
,	O
media	O
coverage	O
of	O
'	O
pneumonia	O
'	O
and	O
'	B-PATH
tuberculosis	I-PATH
'	O
did	O
not	O
vary	O
in	O
accordance	O
with	O
changes	O
in	O
the	O
mortality	O
of	O
each	O
disease	O
.	O

The	O
news	O
media	O
reduced	O
the	O
relative	O
level	O
of	O
attention	O
given	O
to	O
pneumonia	O
and	O
tuberculosis	B-PATH
.	O

TITLE	O
:	O
[	O
Acute	O
respiratory	O
distress	O
syndrome	O
during	O
the	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
pandemic	O
in	O
Ecuador	O
].	O

ABSTRACT	O
:	O
Among	O
the	O
most	O
severe	O
complications	O
caused	O
by	O
the	O
influenza	B-PATH
A	I-PATH
virus	O
H1N1	O
pandemic	O
is	O
the	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
).	O

Furthermore	O
,	O
when	O
the	O
transfected	O
sgmRNA	O
contains	O
an	O
internally	O
placed	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
template	O
-	O
switching	O
donor	O
signal	O
,	O
discontinuous	O
transcription	O
occurs	O
at	O
this	O
site	O
,	O
and	O
a	O
shorter	O
,	O
3	O
'	O
terminally	O
nested	O
leader	O
-	O
containing	O
sgmRNA	O
is	O
made	O
,	O
as	O
evidenced	O
by	O
its	O
leader	O
-	O
body	O
junction	O
and	O
by	O
the	O
expression	O
of	O
a	O
GFP	O
gene	O
.	O

TITLE	O
:	O
Malaria	B-PATH
in	O
pregnancy	O
:	O
update	O
on	O
emergency	O
management	O
.	O

ABSTRACT	O
:	O
Pregnancy	O
complicates	O
the	O
diagnosis	O
,	O
treatment	O
,	O
and	O
clinical	O
course	O
of	O
malaria	B-PATH
.	O

She	O
had	O
not	O
taken	O
malaria	B-PATH
prophylaxis	O
.	O

This	O
case	O
illustrates	O
the	O
serious	O
nature	O
of	O
malaria	B-PATH
in	O
the	O
pregnant	O
patient	O
.	O

If	O
the	O
risks	O
of	O
hospital	O
and	O
community	O
infection	O
are	O
equal	O
,	O
95	O
%	O
of	O
patients	O
who	O
develop	O
symptoms	O
of	O
adenovirus	O
infection	O
within	O
5	O
days	O
of	O
hospital	O
admission	O
will	O
have	O
been	O
infected	O
in	O
the	O
community	O
,	O
as	O
will	O
95	O
%	O
of	O
patients	O
who	O
develop	O
symptoms	O
within	O
3	O
days	O
for	O
human	O
-	O
coronavirus	O
infection	O
,	O
2	O
.	O
5	O
days	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
1	O
day	O
for	O
influenza	B-PATH
A	I-PATH
,	O
0	O
.	O
5	O
day	O
for	O
influenza	O
B	O
,	O
12	O
days	O
for	O
measles	B-PATH
,	O
2	O
days	O
for	O
parainfluenza	O
,	O
4	O
days	O
for	O
respiratory	O
syncytial	O
virus	O
infection	O
,	O
and	O
1	O
.	O
5	O
days	O
for	O
rhinovirus	O
infection	O
.	O

RESULTS	O
:	O
If	O
the	O
risks	O
of	O
hospital	O
and	O
community	O
infection	O
are	O
equal	O
,	O
95	O
%	O
of	O
patients	O
who	O
develop	O
symptoms	O
of	O
adenovirus	O
infection	O
within	O
5	O
days	O
of	O
hospital	O
admission	O
will	O
have	O
been	O
infected	O
in	O
the	O
community	O
,	O
as	O
will	O
95	O
%	O
of	O
patients	O
who	O
develop	O
symptoms	O
within	O
3	O
days	O
for	O
human	O
-	O
coronavirus	O
infection	O
,	O
2	O
.	O
5	O
days	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
1	O
day	O
for	O
influenza	B-PATH
A	I-PATH
,	O
0	O
.	O
5	O
day	O
for	O
influenza	O
B	O
,	O
12	O
days	O
for	O
measles	B-PATH
,	O
2	O
days	O
for	O
parainfluenza	O
,	O
4	O
days	O
for	O
respiratory	O
syncytial	O
virus	O
infection	O
,	O
and	O
1	O
.	O
5	O
days	O
for	O
rhinovirus	O
infection	O
.	O

TITLE	O
:	O
Genome	O
informatics	O
of	O
influenza	B-PATH
A	I-PATH
:	O
from	O
data	O
sharing	O
to	O
shared	O
analytical	O
capabilities	O
.	O

Further	O
analysis	O
revealed	O
that	O
vaccine	O
-	O
matched	O
circulating	O
influenza	B-PATH
A	I-PATH
viruses	O
were	O
significantly	O
associated	O
with	O
lower	O
excess	O
P	O
&	O
I	O
mortality	O
during	O
post	O
-	O
SARS	O
winters	O
(	O
i	O
.	O
e	O
.,	O
2005	O
-	O
2007	O
)	O
than	O
during	O
pre	O
-	O
SARS	O
winters	O
[	O
0	O
.	O
03	O
+/-	O
0	O
.	O
06	O
vs	O
.	O
1	O
.	O
57	O
+/-	O
1	O
.	O
27	O
,	O
p	O
=	O
0	O
.	O
01	O
].	O

Inclusion	O
of	O
CXCL1	O
within	O
JHMV	O
infected	O
cultures	O
restricted	O
caspase	O
3	O
cleavage	O
and	O
increased	O
Bcl	O
-	O
2	O
expression	O
that	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
decrease	O
in	O
apoptosis	B-PATH
.	O

These	O
findings	O
highlight	O
a	O
previously	O
unappreciated	O
role	O
for	O
CXCR2	O
signaling	O
in	O
protecting	O
oligodendrocyte	O
lineage	O
cells	O
from	O
apoptosis	B-PATH
during	O
inflammatory	O
demyelination	O
initiated	O
by	O
viral	O
infection	O
of	O
the	O
CNS	O
.	O

TITLE	O
:	O
Trilogy	O
of	O
ACE2	O
:	O
a	O
peptidase	O
in	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
,	O
a	O
SARS	O
receptor	O
,	O
and	O
a	O
partner	O
for	O
amino	O
acid	O
transporters	O
.	O

It	O
is	O
quite	O
possible	O
that	O
mass	O
casualties	O
from	O
a	O
terrorist	O
incident	O
or	O
major	O
industrial	O
accident	O
involving	O
the	O
release	B-PATH
of	O
large	O
quantities	O
of	O
inhaled	O
TICs	O
would	O
place	O
a	O
severe	O
burden	O
on	O
already	O
scarce	O
intensive	O
care	O
facilities	O
.	O

Advanced	O
modes	O
of	O
respiratory	O
support	O
such	O
as	O
high	O
-	O
frequency	O
ventilation	O
,	O
airway	O
pressure	O
release	B-PATH
ventilation	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
were	O
required	O
in	O
a	O
majority	O
of	O
the	O
cohort	O
(	O
6	O
of	O
8	O
patients	O
).	O

ABSTRACT	O
:	O
Young	O
adults	O
,	O
especially	O
pregnant	O
woman	O
and	O
patients	O
with	O
pre	O
-	O
existing	O
medical	O
conditions	O
,	O
appear	O
to	O
be	O
at	O
risk	O
for	O
the	O
development	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
from	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
,	O
leading	O
to	O
critical	O
hypoxemia	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
caused	O
by	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

ABSTRACT	O
:	O
In	O
view	O
of	O
the	O
pandemic	O
caused	O
by	O
a	O
new	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
),	O
we	O
report	O
the	O
case	O
of	O
a	O
56	O
-	O
year	O
-	O
old	O
patient	O
without	O
relevant	O
risk	O
factors	O
and	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
resulting	O
from	O
infection	O
with	O
this	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
management	O
of	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
an	O
emerging	O
challenge	O
,	O
especially	O
during	O
the	O
2009	O
pandemic	O
.	O

TITLE	O
:	O
Microcirculatory	O
abnormalities	O
in	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
degree	O
of	O
microcirculatory	O
abnormalities	O
in	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

We	O
assessed	O
the	O
sublingual	O
microcirculation	O
in	O
seven	O
consecutive	O
patients	O
with	O
acute	O
lung	O
injury	O
related	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

The	O
microcirculation	O
as	O
assessed	O
by	O
SDF	O
imaging	O
and	O
NIRS	O
techniques	O
was	O
compromised	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

A	O
coronavirus	O
(	O
CoV	O
)	O
was	O
detected	O
in	O
archived	O
tissues	O
from	O
1	O
of	O
the	O
5	O
seals	O
via	O
a	O
degenerate	O
PCR	O
for	O
nidoviral	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
and	O
was	O
subsequently	O
confirmed	O
via	O
specific	O
PCR	O
.	O

Appearing	O
in	O
1997	O
and	O
becoming	O
epidemic	O
in	O
2003	O
,	O
influenza	B-PATH
A	I-PATH
/	O
H5N1	O
provoked	O
many	O
deadly	O
enzootics	O
in	O
poultry	O
batteries	O
(	O
highly	O
pathogenic	O
avian	O
influenza	O
of	O
HPAI	O
).	O

In	O
recent	O
years	O
,	O
the	O
threat	O
of	O
a	O
possible	O
influenza	O
pandemic	O
arising	O
from	O
the	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
has	O
prompted	O
the	O
development	O
of	O
comprehensive	O
pandemic	O
preparedness	O
programs	O
in	O
many	O
countries	O
.	O

The	O
recent	O
emergence	O
of	O
the	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
virus	O
from	O
the	O
Americas	O
in	O
early	O
2009	O
,	O
although	O
surprising	O
in	O
its	O
geographic	O
and	O
zoonotic	O
origins	O
,	O
has	O
tested	O
these	O
preparedness	O
programs	O
and	O
revealed	O
areas	O
in	O
which	O
further	O
work	O
is	O
necessary	O
.	O

ABSTRACT	O
:	O
Occupational	O
pulmonary	O
infectious	O
diseases	O
include	O
tuberculosis	B-PATH
(	O
TB	O
)	O
and	O
many	O
viral	O
pathogens	O
,	O
including	O
influenza	O
,	O
coronavirus	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
or	O
SARS	O
),	O
varicella	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
hantavirus	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
showed	O
that	O
groups	O
1	O
and	O
2	O
CoVs	O
were	O
similar	O
to	O
Bat	O
-	O
CoV	O
/	O
China	O
/	O
A515	O
/	O
2005	O
(	O
95	O
%	O
nt	O
sequence	O
identity	O
)	O
and	O
Bat	O
-	O
CoV	O
/	O
HKU9	O
-	O
1	O
/	O
China	O
/	O
2007	O
(	O
83	O
%	O
identity	O
),	O
respectively	O
.	O

TITLE	O
:	O
Genomic	O
characterization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
related	O
coronavirus	O
in	O
European	O
bats	O
and	O
classification	O
of	O
coronaviruses	O
based	O
on	O
partial	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
sequences	O
.	O

Among	O
10	O
bats	O
with	O
complete	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
spike	O
(	O
S	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
sequenced	O
,	O
three	O
and	O
two	O
sequence	O
clades	O
for	O
all	O
three	O
genes	O
were	O
codetected	O
in	O
two	O
and	O
five	O
bats	O
,	O
respectively	O
,	O
suggesting	O
the	O
coexistence	O
of	O
two	O
or	O
three	O
distinct	O
genotypes	O
of	O
Ro	O
-	O
BatCoV	O
HKU9	O
in	O
the	O
same	O
bat	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
H1N1	O
2009	O
influenza	B-PATH
A	I-PATH
,	O
in	O
a	O
previously	O
fit	O
woman	O
at	O
24	O
weeks	O
of	O
gestation	O
,	O
who	O
presented	O
atypically	O
with	O
abdominal	O
pain	O
.	O

ABSTRACT	O
:	O
Mannose	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
is	O
an	O
important	O
constituent	O
of	O
the	O
human	O
innate	O
immune	O
system	O
,	O
and	O
can	O
bind	O
to	O
a	O
wide	O
range	O
of	O
pathogens	O
,	O
including	O
viruses	O
such	O
as	O
influenza	B-PATH
A	I-PATH
,	O
HIV	O
,	O
herpes	O
simplex	O
2	O
,	O
and	O
SARS	O
-	O
CoV	O
.	O
MBL	O
deficiency	O
results	O
from	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
exon	O
1	O
,	O
and	O
the	O
promoter	O
region	O
of	O
the	O
human	O
MBL2	O
gene	O
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
susceptibility	O
to	O
a	O
number	O
of	O
infections	O
.	O

The	O
3	O
most	O
commonly	O
detected	O
viruses	O
were	O
parainfluenza	O
virus	O
type	O
1	O
(	O
PIV1	O
)	O
in	O
44	O
(	O
24	O
.	O
2	O
%)	O
patients	O
,	O
HCoV	O
-	O
NL63	O
in	O
30	O
(	O
16	O
.	O
5	O
%)	O
patients	O
,	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
25	O
(	O
13	O
.	O
7	O
%)	O
patients	O
.	O

Patients	O
with	O
HCoV	O
-	O
NL63	O
infection	O
were	O
younger	O
than	O
those	O
who	O
were	O
positive	O
for	O
PIV1	O
(	O
median	O
age	O
13	O
months	O
versus	O
21	O
months	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
and	O
had	O
shorter	O
fever	O
duration	O
than	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
(	O
median	O
1	O
.	O
5	O
days	O
versus	O
4	O
days	O
,	O
P	O
=	O
0	O
.	O
000	O
).	O

Patients	O
with	O
HCoV	O
-	O
NL63	O
infection	O
were	O
younger	O
than	O
those	O
who	O
were	O
positive	O
for	O
PIV1	O
(	O
median	O
age	O
13	O
months	O
versus	O
21	O
months	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
and	O
had	O
shorter	O
fever	O
duration	O
than	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
(	O
median	O
1	O
.	O
5	O
days	O
versus	O
4	O
days	O
,	O
P	O
=	O
0	O
.	O
000	O
).	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
prospective	O
observational	O
comparative	O
study	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
characteristics	O
,	O
clinical	O
evolution	O
and	O
outcome	O
in	O
adult	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
treated	O
with	O
or	O
without	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

A	O
prospective	O
observational	O
study	O
of	O
patients	O
treated	O
in	O
Marseille	O
South	O
Hospital	O
from	O
October	O
2009	O
to	O
January	O
2010	O
for	O
confirmed	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
related	O
ARDS	O
.	O

ECMO	O
may	O
be	O
an	O
effective	O
salvage	O
treatment	O
for	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
related	O
ARDS	O
presenting	O
rapid	O
refractory	O
respiratory	O
failure	O
,	O
particularly	O
when	O
provided	O
by	O
a	O
mobile	O
team	O
allowing	O
early	O
cannulation	O
prior	O
to	O
transfer	O
to	O
a	O
reference	O
centre	O
.	O

Furthermore	O
,	O
the	O
potent	O
tylophorine	O
compounds	O
exerted	O
profound	O
anti	O
-	O
TGEV	O
replication	O
activity	O
and	O
thereby	O
blocked	O
the	O
TGEV	O
-	O
induced	O
apoptosis	B-PATH
and	O
subsequent	O
cytopathic	O
effect	O
in	O
ST	O
cells	O
.	O

TITLE	O
:	O
[	O
Experience	O
in	O
treating	O
severe	O
viral	O
respiratory	O
infection	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)].	O

ABSTRACT	O
:	O
The	O
authors	O
present	O
their	O
experience	O
in	O
treating	O
142	O
patients	O
with	O
severe	O
viral	O
respiratory	O
infection	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
),	O
describe	O
its	O
clinical	O
picture	O
,	O
and	O
identify	O
major	O
syndromes	O
observed	O
in	O
the	O
treatment	O
of	O
these	O
patients	O
at	O
an	O
intensive	O
care	O
unit	O
.	O

ABSTRACT	O
:	O
We	O
prospectively	O
tested	O
95	O
nasal	O
swabs	O
or	O
nasopharyngeal	O
aspirates	O
taken	O
from	O
56	O
adults	O
and	O
39	O
children	O
visiting	O
the	O
Reims	O
University	O
Medical	O
Centre	O
(	O
northern	O
France	O
)	O
for	O
influenza	O
-	O
like	O
illnesses	O
(	O
ILI	O
)	O
during	O
the	O
early	O
stage	O
of	O
the	O
French	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
pandemic	O
(	O
October	O
2009	O
).	O

Respiratory	O
samples	O
were	O
tested	O
using	O
a	O
combination	O
of	O
two	O
commercially	O
available	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
DNA	O
microarray	O
systems	O
allowing	O
rapid	O
detection	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
strains	O
,	O
including	O
the	O
new	O
A	O
/	O
H1N1v	O
strain	O
as	O
well	O
as	O
20	O
other	O
common	O
or	O
newly	O
discovered	O
respiratory	O
viruses	O
.	O

Of	O
the	O
95	O
respiratory	O
samples	O
tested	O
,	O
30	O
(	O
31	O
%)	O
were	O
positive	O
for	O
the	O
detection	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
virus	O
infection	O
by	O
both	O
RT	O
-	O
PCR	O
DNA	O
microarray	O
and	O
classical	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
detection	O
assays	O
.	O

We	O
present	O
a	O
17	O
-	O
year	O
-	O
old	O
patient	O
who	O
developed	O
rhabdomyalysis	O
following	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
/	O
09	O
)	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
nucleolus	O
is	O
a	O
dynamic	O
subnuclear	O
compartment	O
involved	O
in	O
ribosome	B-PATH
subunit	O
biogenesis	O
,	O
regulation	O
of	O
cell	O
stress	O
and	O
modulation	O
of	O
cellular	O
growth	O
and	O
the	O
cell	B-PATH
cycle	I-PATH
,	O
among	O
other	O
functions	O
.	O

Influenza	B-PATH
A	I-PATH
virus	O
,	O
parainfluenza	O
virus	O
4	O
and	O
SARS	O
-	O
coronavirus	O
were	O
not	O
detected	O
during	O
the	O
study	O
period	O
.	O

TITLE	O
:	O
Spontaneous	O
pnemomedastinum	O
in	O
acute	O
severe	O
asthma	B-PATH
.	O

ABSTRACT	O
:	O
Spontaneous	O
medastinal	O
emphysema	O
,	O
as	O
a	O
complication	O
of	O
acute	O
severe	O
asthma	B-PATH
,	O
is	O
an	O
uncommon	O
entity	O
.	O

This	O
case	O
is	O
being	O
presented	O
to	O
emphasize	O
its	O
recognition	O
in	O
the	O
differential	O
diagnosis	O
of	O
complications	O
arising	O
from	O
acute	O
severe	O
asthma	B-PATH
and	O
to	O
present	O
its	O
management	O
strategy	O
in	O
detail	O
.	O

TITLE	O
:	O
Proteasome	B-PATH
inhibition	O
in	O
vivo	O
promotes	O
survival	O
in	O
a	O
lethal	O
murine	O
model	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

To	O
explore	O
the	O
link	O
between	O
coronavirus	O
infection	O
and	O
the	O
ubiquitin	O
system	O
,	O
we	O
asked	O
whether	O
protein	O
degradation	O
by	O
the	O
26S	O
proteasome	B-PATH
plays	O
a	O
role	O
in	O
severe	O
coronavirus	O
infections	O
using	O
a	O
murine	O
model	O
of	O
SARS	O
-	O
like	O
pneumonitis	O
induced	O
by	O
murine	O
hepatitis	O
virus	O
strain	O
1	O
(	O
MHV	O
-	O
1	O
).	O

In	O
vitro	O
,	O
the	O
pretreatment	O
of	O
peritoneal	O
macrophages	O
with	O
inhibitors	O
of	O
the	O
proteasome	B-PATH
(	O
pyrrolidine	O
dithiocarbamate	O
[	O
PDTC	O
],	O
MG132	O
,	O
and	O
PS	O
-	O
341	O
)	O
markedly	O
inhibited	O
MHV	O
-	O
1	O
replication	O
at	O
an	O
early	O
step	O
in	O
its	O
replication	O
cycle	O
,	O
as	O
evidenced	O
by	O
inhibition	O
of	O
viral	O
RNA	O
production	O
.	O

Proteasome	B-PATH
inhibition	O
also	O
blocked	O
viral	O
cytotoxicity	O
in	O
macrophages	O
,	O
as	O
well	O
as	O
the	O
induction	O
of	O
inflammatory	O
mediators	O
such	O
as	O
IP	O
-	O
10	O
,	O
gamma	O
interferon	O
(	O
IFN	O
-	O
Î³	O
),	O
and	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP	O
-	O
1	O
).	O

These	O
data	O
demonstrate	O
that	O
inhibition	O
of	O
the	O
cellular	O
proteasome	B-PATH
attenuates	O
pneumonitis	O
and	O
cytokine	O
gene	O
expression	O
in	O
vivo	O
by	O
reducing	O
MHV	O
-	O
1	O
replication	O
and	O
the	O
resulting	O
inflammatory	O
response	O
.	O

The	O
results	O
further	O
suggest	O
that	O
targeting	O
the	O
proteasome	B-PATH
may	O
be	O
an	O
effective	O
new	O
treatment	O
for	O
severe	O
coronavirus	O
infections	O
.	O

TITLE	O
:	O
The	O
SARS	O
coronavirus	O
E	O
protein	O
interacts	O
with	O
PALS1	O
and	O
alters	O
tight	B-PATH
junction	I-PATH
formation	O
and	O
epithelial	O
morphogenesis	O
.	O

PALS1	O
,	O
a	O
tight	B-PATH
junction	I-PATH
-	O
associated	O
protein	O
,	O
is	O
a	O
member	O
of	O
the	O
CRUMBS3	O
-	O
PALS1	O
-	O
PATJ	O
polarity	O
complex	O
,	O
which	O
is	O
crucial	O
for	O
the	O
establishment	O
and	O
maintenance	O
of	O
epithelial	O
polarity	O
in	O
mammals	O
.	O

A	O
total	O
of	O
398	O
AFI	O
patients	O
were	O
diagnosed	O
with	O
:	O
scrub	O
typhus	O
(	O
47	O
.	O
5	O
%);	O
malaria	B-PATH
(	O
17	O
.	O
1	O
%);	O
enteric	O
fever	O
(	O
8	O
.	O
0	O
%);	O
dengue	O
(	O
7	O
.	O
0	O
%);	O
leptospirosis	O
(	O
3	O
.	O
0	O
%);	O
spotted	O
fever	O
rickettsiosis	O
(	O
1	O
.	O
8	O
%);	O
Hantavirus	O
(	O
0	O
.	O
3	O
%);	O
alternate	O
diagnosis	O
(	O
7	O
.	O
3	O
%);	O
and	O
unclear	O
diagnoses	O
(	O
8	O
.	O
0	O
%).	O

Normal	O
leukocyte	O
counts	O
,	O
moderate	O
to	O
severe	O
thrombocytopenia	O
,	O
renal	O
failure	O
,	O
splenomegaly	O
and	O
hyperbilirubinaemia	O
with	O
mildly	O
elevated	O
serum	O
transaminases	O
were	O
associated	O
with	O
malaria	B-PATH
.	O

RESULTS	O
:	O
18	O
influenza	O
(	O
influenza	B-PATH
A	I-PATH
=	O
13	O
and	O
influenza	O
B	O
=	O
5	O
)	O
and	O
17	O
parainfluenza	O
admissions	O
were	O
identified	O
over	O
the	O
7	O
-	O
year	O
period	O
.	O

This	O
review	O
aims	O
to	O
summarize	O
current	O
respiratory	O
health	O
issues	O
in	O
the	O
region	O
including	O
smoking	O
-	O
related	O
diseases	O
especially	O
COPD	O
,	O
lung	O
cancer	O
and	O
infectious	O
problems	O
such	O
as	O
pandemic	O
influenza	O
,	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
bacterial	O
pneumonia	O
and	O
tuberculosis	B-PATH
,	O
as	O
well	O
as	O
the	O
contribution	O
of	O
air	O
pollution	O
to	O
respiratory	O
disease	O
.	O

TITLE	O
:	O
[	O
Severe	O
respiratory	O
disease	O
in	O
an	O
intensive	O
care	O
unit	O
during	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
pandemia	O
].	O

ABSTRACT	O
:	O
We	O
describe	O
characteristics	O
of	O
patients	O
admitted	O
to	O
our	O
intensive	O
care	O
unit	O
with	O
severe	O
acute	O
respiratory	O
illness	O
and	O
influenza	O
-	O
like	O
syndrome	O
during	O
the	O
first	O
months	O
of	O
the	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
in	O
Argentina	O
.	O

Respondents	O
reported	O
use	O
of	O
noninvasive	O
positive	O
-	O
pressure	O
ventilation	O
for	O
acute	O
respiratory	O
failure	O
in	O
lower	O
airway	O
disease	O
(	O
70	O
%),	O
asthma	B-PATH
(	O
51	O
%),	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
43	O
%),	O
and	O
upper	O
airway	O
obstruction	O
(	O
31	O
%).	O

Results	O
indicate	O
that	O
TMPRSS2	O
needs	O
to	O
be	O
expressed	O
in	O
the	O
opposing	O
(	O
target	O
)	O
cell	O
membrane	O
to	O
activate	O
S	O
protein	O
rather	O
than	O
in	O
the	O
producer	O
cell	O
,	O
as	O
found	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
metapneumoviruses	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
impact	O
of	O
community	O
-	O
acquired	O
respiratory	O
coinfection	O
in	O
patients	O
with	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
Plasmodium	O
(	O
P	O
.)	O
vivax	O
malaria	B-PATH
is	O
rarely	O
associated	O
with	O
severe	O
complications	O
like	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
report	O
three	O
cases	O
of	O
ARDS	O
,	O
which	O
occurred	O
as	O
a	O
complication	O
of	O
vivax	O
malaria	B-PATH
,	O
from	O
the	O
city	O
of	O
Kolkata	O
.	O

In	O
all	O
cases	O
,	O
vivax	O
malaria	B-PATH
was	O
diagnosed	O
by	O
peripheral	O
blood	O
film	O
(	O
PBF	O
)	O
examination	O
.	O

Associated	O
falciparum	O
infection	O
was	O
excluded	O
by	O
repeated	O
PBF	O
examination	O
,	O
and	O
by	O
negative	O
P	O
.	O
falciparum	O
malaria	B-PATH
antigen	O
tests	O
.	O

In	O
this	O
Review	O
we	O
survey	O
the	O
research	O
on	O
the	O
host	O
jumps	O
of	O
influenza	B-PATH
A	I-PATH
,	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
,	O
canine	O
parvovirus	O
and	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
to	O
illustrate	O
the	O
insights	O
that	O
can	O
arise	O
from	O
combining	O
genetic	O
surveillance	O
with	O
microbiological	O
experimentation	O
in	O
the	O
context	O
of	O
epidemiological	O
data	O
.	O

ABSTRACT	O
:	O
Previous	O
study	O
on	O
TNFR1	O
-	O
mediated	O
hepatocyte	O
apoptosis	B-PATH
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
fulminant	O
viral	O
hepatitis	O
.	O

ABSTRACT	O
:	O
In	O
late	O
March	O
2009	O
,	O
an	O
outbreak	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
was	O
detected	O
in	O
Mexico	O
with	O
subsequent	O
cases	O
observed	O
in	O
many	O
other	O
countries	O
.	O

Until	O
February	O
1	O
,	O
2010	O
,	O
a	O
total	O
of	O
47	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
(	O
Inf	O
A	O
)	O
were	O
recorded	O
by	O
the	O
Spanish	O
Society	O
of	O
Nephrology	O
in	O
kidney	O
transplant	O
recipients	O
.	O

TITLE	O
:	O
Transfusion	O
-	O
related	O
Plasmodium	O
ovale	O
malaria	B-PATH
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
a	O
non	O
-	O
endemic	O
country	O
.	O

Malaria	B-PATH
smear	O
was	O
positive	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
secondary	O
to	O
blood	O
transfusion	O
related	O
P	O
.	O
ovale	O
malaria	B-PATH
infection	O
in	O
a	O
non	O
-	O
endemic	O
country	O
.	O

TITLE	O
:	O
[	O
Clinical	O
features	O
of	O
severe	O
new	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
pregnant	O
women	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
characteristics	O
of	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
pregnant	O
women	O
.	O

Sixteen	O
patients	O
with	O
severe	O
pneumonia	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
were	O
included	O
in	O
this	O
study	O
from	O
November	O
26	O
to	O
December	O
20	O
,	O
2009	O
.	O

Pregnant	O
women	O
with	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
appear	O
to	O
have	O
an	O
increased	O
risk	O
of	O
severe	O
disease	O
characterized	O
by	O
severe	O
pneumonia	O
and	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
[	O
The	O
changes	O
of	O
chest	O
imaging	O
and	O
clinical	O
features	O
in	O
patients	O
with	O
severe	O
infection	O
of	O
new	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)].	O

ABSTRACT	O
:	O
To	O
study	O
the	O
clinical	O
features	O
and	O
the	O
pulmonary	O
imaging	O
changes	O
of	O
severe	O
cases	O
of	O
new	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

This	O
study	O
included	O
10	O
severe	O
cases	O
with	O
new	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
in	O
the	O
Forth	O
People	O
'	O
s	O
Hospital	O
of	O
Taiyuan	O
from	O
20	O
Oct	O
.	O
2009	O
to	O
22	O
Nov	O
2009	O
.	O
Six	O
patients	O
were	O
males	O
and	O
4	O
were	O
females	O
,	O
with	O
an	O
average	O
age	O
of	O
19	O
.	O
3	O
years	O
(	O
range	O
5	O
-	O
41	O
years	O
).	O

Influenza	B-PATH
A	I-PATH
,	O
B	O
and	O
coronavirus	O
antibody	O
titers	O
were	O
measured	O
in	O
257	O
subjects	O
with	O
recurrent	O
unipolar	O
and	O
bipolar	O
disorder	O
and	O
healthy	O
controls	O
,	O
by	O
SCID	O
.	O

RESULTS	O
:	O
Seropositivity	O
for	O
influenza	B-PATH
A	I-PATH
(	O
p	O
=	O
0	O
.	O
004	O
),	O
B	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
coronaviruses	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
were	O
associated	O
with	O
history	O
of	O
mood	O
disorders	O
but	O
not	O
with	O
the	O
specific	O
diagnosis	O
of	O
unipolar	O
or	O
bipolar	O
depression	O
.	O

In	O
vivo	O
experiments	O
revealed	O
that	O
IFN	O
-	O
Î±2b	O
causes	O
STAT1	O
phosphorylation	O
and	O
upregulation	O
of	O
abundant	O
IFN	O
response	O
genes	O
(	O
IRGs	O
),	O
chemokine	O
receptors	O
,	O
and	O
other	O
genes	O
that	O
participate	O
in	O
phagocytosis	O
and	O
leukocyte	B-PATH
transendothelial	I-PATH
migration	I-PATH
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
8b	O
reduces	O
viral	O
replication	O
by	O
down	O
-	O
regulating	O
E	O
via	O
an	O
ubiquitin	O
-	O
independent	O
proteasome	B-PATH
pathway	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
8b	O
protein	O
,	O
which	O
is	O
not	O
expressed	O
by	O
other	O
known	O
coronaviruses	O
,	O
can	O
down	O
-	O
regulate	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
via	O
a	O
proteasome	B-PATH
-	O
dependent	O
pathway	O
.	O

Here	O
,	O
we	O
showed	O
that	O
the	O
down	O
-	O
regulation	O
of	O
E	O
is	O
not	O
dependent	O
on	O
the	O
lysine	O
residues	O
on	O
8b	O
and	O
the	O
reduction	O
of	O
polyubiquitination	O
of	O
E	O
mutants	O
is	O
not	O
correlated	O
with	O
their	O
down	O
-	O
regulation	O
by	O
8b	O
,	O
suggesting	O
an	O
ubiquitin	O
-	O
independent	O
proteasome	B-PATH
pathway	O
is	O
involved	O
.	O

ISG20	O
inhibited	O
infections	O
by	O
cell	O
culture	O
-	O
derived	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
and	O
a	O
pestivirus	O
,	O
bovine	O
viral	O
diarrhea	O
virus	O
and	O
a	O
picornavirus	O
,	O
hepatitis	O
A	O
virus	O
.	O

Determination	O
of	O
virus	O
-	O
induced	O
cytopathogenic	O
effects	O
and	O
virus	O
titres	O
revealed	O
that	O
EPs	O
Â®	O
7630	O
at	O
concentrations	O
up	O
to	O
100	O
Î¼g	O
/	O
ml	O
interfered	O
with	O
replication	O
of	O
seasonal	O
influenza	B-PATH
A	I-PATH
virus	O
strains	O
(	O
H1N1	O
,	O
H3N2	O
),	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
coronavirus	O
,	O
parainfluenza	O
virus	O
,	O
and	O
coxsackie	O
virus	O
but	O
did	O
not	O
affect	O
replication	O
of	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H5N1	O
),	O
adenovirus	O
,	O
or	O
rhinovirus	O
.	O

TITLE	O
:	O
Clinical	O
features	O
of	O
children	O
hospitalized	O
with	O
malaria	B-PATH
--	O
a	O
study	O
from	O
Bikaner	O
,	O
northwest	O
India	O
.	O

ABSTRACT	O
:	O
Severe	O
Plasmodium	O
vivax	O
malaria	B-PATH
in	O
adults	O
has	O
been	O
reported	O
from	O
Bikaner	O
(	O
northwestern	O
India	O
)	O
but	O
the	O
reports	O
on	O
children	O
are	O
scanty	O
.	O

This	O
prospective	O
study	O
was	O
done	O
on	O
303	O
admitted	O
children	O
of	O
malaria	B-PATH
.	O

Severe	O
disease	O
was	O
present	O
in	O
49	O
.	O
5	O
%	O
(	O
150	O
/	O
303	O
)	O
children	O
with	O
malaria	B-PATH
,	O
with	O
the	O
risk	O
greatest	O
among	O
P	O
.	O
vivax	O
monoinfection	O
(	O
63	O
.	O
1	O
%	O
[	O
65	O
/	O
103	O
])	O
compared	O
with	O
P	O
.	O
falciparum	O
,	O
either	O
alone	O
(	O
42	O
.	O
7	O
%	O
[	O
79	O
/	O
185	O
];	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2	O
.	O
3	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
40	O
-	O
3	O
.	O
76	O
],	O
P	O
=	O
0	O
.	O
001	O
)	O
or	O
mixed	O
infections	O
(	O
40	O
%	O
[	O
6	O
/	O
15	O
];	O
OR	O
=	O
2	O
.	O
57	O
[	O
95	O
%	O
CI	O
=	O
0	O
.	O
88	O
-	O
7	O
.	O
48	O
]).	O

In	O
children	O
<	O
5	O
years	O
of	O
age	O
,	O
the	O
proportion	O
of	O
severe	O
malaria	B-PATH
attributable	O
to	O
P	O
.	O
vivax	O
rose	O
to	O
67	O
.	O
4	O
%	O
(	O
31	O
/	O
46	O
)	O
compared	O
with	O
30	O
.	O
4	O
%	O
(	O
14	O
/	O
46	O
)	O
of	O
P	O
.	O
falciparum	O
(	O
OR	O
=	O
4	O
.	O
7	O
[	O
95	O
%	O
CI	O
=	O
2	O
.	O
6	O
-	O
8	O
.	O
6	O
],	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
2	O
.	O
2	O
%	O
(	O
1	O
/	O
46	O
)	O
of	O
mixed	O
infection	O
(	O
OR	O
=	O
92	O
[	O
95	O
%	O
CI	O
=	O
24	O
.	O
6	O
-	O
339	O
.	O
9	O
],	O
P	O
<	O
0	O
.	O
0001	O
).	O

The	O
proportion	O
of	O
patients	O
having	O
severe	O
manifestations	O
,	O
which	O
included	O
severe	O
anemia	O
,	O
thrombocytopenia	O
,	O
cerebral	O
malaria	B-PATH
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
hepatic	O
dysfunction	O
,	O
renal	O
dysfunction	O
,	O
abnormal	O
bleeding	O
was	O
significantly	O
high	O
in	O
association	O
with	O
P	O
.	O
vivax	O
monoinfection	O
in	O
0	O
-	O
5	O
year	O
age	O
group	O
,	O
while	O
the	O
same	O
was	O
significantly	O
high	O
in	O
association	O
with	O
P	O
.	O
falciparum	O
monoinfection	O
in	O
5	O
-	O
10	O
year	O
age	O
group	O
.	O

Plasmodium	O
vivax	O
monoinfection	O
was	O
almost	O
equally	O
serious	O
to	O
cause	O
significant	O
mortality	O
in	O
comparison	O
to	O
P	O
.	O
falciparum	O
(	O
case	O
fatality	O
rate	O
of	O
severe	O
P	O
.	O
vivax	O
was	O
3	O
.	O
9	O
%	O
versus	O
3	O
.	O
2	O
%	O
of	O
severe	O
P	O
.	O
falciparum	O
malaria	B-PATH
;	O
P	O
=	O
1	O
.	O
0	O
).	O

This	O
study	O
reaffirms	O
the	O
evidence	O
of	O
severe	O
P	O
.	O
vivax	O
malaria	B-PATH
in	O
children	O
in	O
Bikaner	O
.	O

The	O
mutant	O
virus	O
,	O
IBV	O
-	O
EG3	O
,	O
was	O
defective	O
in	O
release	B-PATH
of	O
infectious	O
virus	O
particles	O
.	O

TITLE	O
:	O
[	O
Clinical	O
analysis	O
of	O
children	O
with	O
lymphoma	O
complicated	O
with	O
severe	O
pneumonia	O
due	O
to	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
].	O

The	O
clinical	O
manifestations	O
,	O
radiologic	O
features	O
,	O
reasons	O
of	O
misdiagnosis	O
,	O
experiences	O
in	O
treatment	O
and	O
prognosis	O
of	O
4	O
children	O
with	O
lymphoma	O
complicated	O
with	O
pneumonia	O
due	O
to	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
during	O
chemotherapy	O
were	O
analyzed	O
retrospectively	O
.	O

The	O
children	O
with	O
lymphoma	O
who	O
undergo	O
chemotherapy	O
are	O
prone	O
to	O
develop	O
severe	O
pneumonia	O
during	O
epidemics	O
of	O
influenza	B-PATH
A	I-PATH
H1N1	O
.	O

METHODS	O
:	O
The	O
clinical	O
manifestations	O
,	O
radiologic	O
features	O
,	O
reasons	O
of	O
misdiagnosis	O
,	O
experiences	O
in	O
treatment	O
and	O
prognosis	O
of	O
4	O
children	O
with	O
lymphoma	O
complicated	O
with	O
pneumonia	O
due	O
to	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
during	O
chemotherapy	O
were	O
analyzed	O
retrospectively	O
.	O

CONCLUSIONS	O
:	O
The	O
children	O
with	O
lymphoma	O
who	O
undergo	O
chemotherapy	O
are	O
prone	O
to	O
develop	O
severe	O
pneumonia	O
during	O
epidemics	O
of	O
influenza	B-PATH
A	I-PATH
H1N1	O
.	O

TITLE	O
:	O
Clinical	O
aspects	O
and	O
cytokine	O
response	O
in	O
severe	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
.	O

In	O
our	O
critically	O
ill	O
patients	O
with	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
,	O
the	O
hallmarks	O
of	O
the	O
severity	O
of	O
disease	O
were	O
IL	O
-	O
6	O
,	O
IL	O
-	O
15	O
,	O
IL	O
-	O
8	O
and	O
TNFÎ±	O
.	O

For	O
a	O
10	O
-	O
year	O
period	O
between	O
1998	O
and	O
2007	O
we	O
studied	O
the	O
trend	O
,	O
epidemiological	O
characteristics	O
,	O
proportion	O
of	O
imported	O
versus	O
local	O
transmission	O
of	O
malaria	B-PATH
,	O
viral	O
hepatitis	O
(	O
hepatitis	O
A	O
and	O
E	O
),	O
enteric	O
fevers	O
(	O
typhoid	O
and	O
paratyphoid	O
),	O
cholera	O
,	O
chikungunya	O
and	O
SARS	O
.	O

This	O
study	O
underlines	O
that	O
diseases	O
such	O
as	O
malaria	B-PATH
,	O
viral	O
hepatitis	O
and	O
enteric	O
fever	O
occur	O
in	O
Singapore	O
mainly	O
because	O
of	O
importation	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
underlines	O
that	O
diseases	O
such	O
as	O
malaria	B-PATH
,	O
viral	O
hepatitis	O
and	O
enteric	O
fever	O
occur	O
in	O
Singapore	O
mainly	O
because	O
of	O
importation	O
.	O

Taken	O
together	O
,	O
this	O
treatment	O
strategy	O
is	O
not	O
a	O
single	O
mediator	O
approach	O
,	O
but	O
it	O
rather	O
provides	O
protection	O
by	O
modulating	O
multiple	O
levels	O
of	O
early	O
signaling	O
pathways	O
involved	O
in	O
apoptosis	B-PATH
,	O
inflammation	O
,	O
and	O
peroxidation	O
,	O
potentially	O
restoring	O
overall	O
homeostasis	O
.	O

ABSTRACT	O
:	O
The	O
appearance	O
of	O
eight	O
new	O
respiratory	O
viruses	O
in	O
the	O
human	O
population	O
in	O
the	O
past	O
9	O
years	O
,	O
including	O
two	O
new	O
pandemics	O
(	O
SARS	O
coronavirus	O
in	O
2003	O
and	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
in	O
2009	O
),	O
has	O
tested	O
the	O
ability	O
of	O
virology	O
laboratories	O
to	O
develop	O
diagnostic	O
tests	O
to	O
identify	O
these	O
viruses	O
.	O

TITLE	O
:	O
Zn	O
(	O
2	O
+)	O
inhibits	O
coronavirus	O
and	O
arterivirus	O
RNA	B-PATH
polymerase	I-PATH
activity	O
in	O
vitro	O
and	O
zinc	O
ionophores	O
block	O
the	O
replication	O
of	O
these	O
viruses	O
in	O
cell	O
culture	O
.	O

It	O
is	O
caused	O
due	O
to	O
release	B-PATH
of	O
nitrogen	O
gas	O
bubbles	O
that	O
impinge	O
the	O
blood	O
vessels	O
of	O
the	O
spinal	O
cord	O
and	O
brain	O
and	O
result	O
in	O
severe	O
neurodeficit	O
.	O

The	O
blood	O
test	O
for	O
toxoplasmosis	B-PATH
,	O
syphilis	O
,	O
varicella	O
-	O
zoster	O
,	O
rubella	O
,	O
cytomegalovirus	O
,	O
and	O
herpes	O
simplex	O
virus	O
(	O
TORCH	O
)	O
complex	O
and	O
various	O
metabolic	O
tests	O
of	O
blood	O
and	O
urine	O
specimens	O
yielded	O
unremarkable	O
results	O
.	O

Cav	O
-	O
1	O
regulates	O
critical	O
cell	O
functions	O
including	O
proliferation	O
,	O
apoptosis	B-PATH
,	O
cell	O
differentiation	O
,	O
and	O
transcytosis	O
via	O
diverse	O
signaling	O
pathways	O
.	O

TITLE	O
:	O
Use	O
of	O
early	O
corticosteroid	O
therapy	O
on	O
ICU	O
admission	O
in	O
patients	O
affected	O
by	O
severe	O
pandemic	O
(	O
H1N1	O
)	O
v	O
influenza	B-PATH
A	I-PATH
infection	O
.	O

ABSTRACT	O
:	O
Early	O
use	O
of	O
corticosteroids	O
in	O
patients	O
affected	O
by	O
pandemic	O
(	O
H1N1	O
)	O
v	O
influenza	B-PATH
A	I-PATH
infection	O
,	O
although	O
relatively	O
common	O
,	O
remains	O
controversial	O
.	O

Early	O
use	O
of	O
corticosteroids	O
in	O
patients	O
affected	O
by	O
pandemic	O
(	O
H1N1	O
)	O
v	O
influenza	B-PATH
A	I-PATH
infection	O
did	O
not	O
result	O
in	O
better	O
outcomes	O
and	O
was	O
associated	O
with	O
increased	O
risk	O
of	O
superinfections	O
.	O

ABSTRACT	O
:	O
We	O
developed	O
a	O
two	O
-	O
layer	O
,	O
four	O
-	O
channel	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)-	O
capillary	O
electrophoresis	O
microdevice	O
that	O
integrates	O
nucleic	O
acid	O
amplification	O
,	O
sample	O
cleanup	O
and	O
concentration	O
,	O
capillary	O
electrophoretic	O
separation	O
,	O
and	O
detection	O
for	O
multiplex	O
analysis	O
of	O
four	O
human	O
respiratory	O
viral	O
pathogens	O
,	O
influenza	B-PATH
A	I-PATH
,	O
influenza	O
B	O
,	O
coronavirus	O
OC43	O
,	O
and	O
human	O
metapneumovirus	O
.	O

TITLE	O
:	O
Engaging	O
hospitals	O
to	O
meet	O
tuberculosis	B-PATH
control	O
targets	O
in	O
China	O
:	O
using	O
the	O
Internet	O
as	O
a	O
tool	O
to	O
put	O
policy	O
into	O
practice	O
.	O

ABSTRACT	O
:	O
Tuberculosis	B-PATH
(	O
TB	B-PATH
)	O
services	O
in	O
China	O
are	O
provided	O
through	O
a	O
large	O
network	O
of	O
TB	B-PATH
dispensaries	O
.	O

We	O
hypothesize	O
that	O
the	O
mechanism	O
underlying	O
the	O
rare	O
association	O
of	O
takotsubo	O
cardiomyopathy	O
with	O
myasthenic	O
crisis	O
involves	O
excessive	O
endogenous	O
glucocorticoid	O
release	B-PATH
,	O
a	O
high	O
-	O
catecholamine	O
state	O
,	O
or	O
a	O
combination	O
of	O
both	O
.	O

Two	O
children	O
received	O
treatment	O
with	O
oseltamivir	O
(	O
one	O
boy	O
with	O
congenital	O
heart	O
defect	O
and	O
Down	O
'	O
s	O
syndrome	O
and	O
another	O
with	O
severe	O
bronchial	O
asthma	B-PATH
).	O

No	O
patients	O
required	O
hospitalization	O
either	O
due	O
to	O
primary	O
influenza	B-PATH
infection	I-PATH
or	O
secondary	O
complications	O
.	O

The	O
etiologic	O
agent	O
was	O
then	O
identified	O
as	O
a	O
novel	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
which	O
subsequent	O
spread	O
rapidly	O
throughout	O
the	O
globe	O
.	O

TITLE	O
:	O
[	O
Two	O
adult	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
virus	O
pneumonia	O
hospitalized	O
in	O
the	O
Intensive	O
Care	O
Unit	O
of	O
the	O
Reims	O
University	O
Medical	O
Centre	O
].	O

The	O
etiological	O
diagnosis	O
of	O
S	O
-	O
OIV	O
infection	O
was	O
performed	O
by	O
use	O
of	O
a	O
real	O
time	O
RT	O
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
assay	O
allowing	O
the	O
detection	O
of	O
all	O
the	O
known	O
human	O
influenza	B-PATH
A	I-PATH
viruses	O
(	O
rRT	O
-	O
PCR	O
targeting	O
the	O
influenza	O
gene	O
M	O
)	O
and	O
of	O
the	O
new	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pandemic	O
strain	O
.	O

The	O
CTL	O
-	O
based	O
liposomal	O
technique	O
might	O
be	O
applicable	O
for	O
developing	O
vaccines	O
against	O
influenza	O
and	O
other	O
viruses	O
,	O
such	O
as	O
hepatitis	B-PATH
C	I-PATH
,	O
HIV	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
corona	O
virus	O
,	O
which	O
frequently	O
change	O
their	O
surface	O
antigenic	O
molecules	O
.	O

TITLE	O
:	O
Hospitalized	O
children	O
with	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
):	O
comparison	O
to	O
seasonal	O
influenza	O
and	O
risk	O
factors	O
for	O
admission	O
to	O
the	O
ICU	O
.	O

We	O
conducted	O
a	O
retrospective	O
chart	O
review	O
of	O
all	O
hospitalized	O
children	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
2008	O
-	O
09	O
seasonal	O
influenza	O
at	O
The	O
Children	O
'	O
s	O
Hospital	O
,	O
Denver	O
,	O
Colorado	O
.	O

We	O
further	O
show	O
that	O
IFN	O
-	O
Î³	O
facilitates	O
antigen	O
-	O
induced	O
apoptosis	B-PATH
of	O
Th17	O
cells	O
and	O
adoptive	O
transferred	O
IFN	O
-	O
Î³R	O
(-/-),	O
but	O
not	O
IFN	O
-	O
Î³R	O
(+/+);	O
CD4	O
(+)	O
T	O
cells	O
promotes	O
an	O
enhanced	O
liver	O
damage	O
in	O
wild	O
-	O
type	O
mice	O
.	O

However	O
,	O
the	O
auto	O
-	O
processing	O
mechanism	O
of	O
M	O
(	O
pro	O
),	O
i	O
.	O
e	O
.	O
its	O
own	O
release	B-PATH
from	O
the	O
polyproteins	O
through	O
autocleavage	O
,	O
remains	O
unclear	O
.	O

In	O
conclusion	O
,	O
an	O
auto	O
-	O
release	B-PATH
model	O
of	O
M	O
(	O
pro	O
)	O
from	O
the	O
polyproteins	O
is	O
proposed	O
,	O
which	O
will	O
help	O
understand	O
the	O
auto	O
-	O
processing	O
mechanism	O
and	O
the	O
difference	O
between	O
the	O
autocleavage	O
and	O
trans	O
-	O
cleavage	O
proteolytic	O
activities	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
).	O

TITLE	O
:	O
Sudden	O
death	O
of	O
an	O
immunocompetent	O
young	O
adult	O
caused	O
by	O
novel	O
(	O
swine	O
origin	O
)	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
-	O
associated	O
myocarditis	O
.	O

ABSTRACT	O
:	O
The	O
main	O
cause	O
of	O
death	O
from	O
novel	O
(	O
swine	O
origin	O
)	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
is	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Here	O
,	O
we	O
report	O
a	O
fatal	O
case	O
of	O
acute	O
interstitial	O
myocarditis	O
associated	O
with	O
novel	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
in	O
an	O
immunocompetent	O
young	O
woman	O
.	O

In	O
conclusion	O
,	O
sudden	O
death	O
by	O
myocarditis	O
may	O
be	O
a	O
rare	O
complication	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
in	O
otherwise	O
healthy	O
individuals	O
,	O
even	O
in	O
the	O
absence	O
of	O
significant	O
respiratory	O
tract	O
infection	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
and	O
severe	O
cardiac	O
dysfunction	O
in	O
adults	O
:	O
A	O
case	O
series	O
.	O

ABSTRACT	O
:	O
While	O
viral	B-PATH
myocarditis	I-PATH
and	O
heart	O
failure	O
are	O
recognized	O
and	O
feared	O
complications	O
of	O
seasonal	O
influenza	B-PATH
A	I-PATH
infection	O
,	O
only	O
limited	O
information	O
is	O
available	O
for	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
induced	O
heart	O
failure	O
.	O

This	O
case	O
series	O
summarizes	O
the	O
disease	O
course	O
of	O
four	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
who	O
were	O
treated	O
at	O
our	O
institution	O
from	O
November	O
2009	O
until	O
September	O
2010	O
.	O

Except	O
for	O
one	O
patient	O
who	O
died	O
before	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
had	O
been	O
diagnosed	O
,	O
all	O
patients	O
received	O
antiviral	O
therapy	O
with	O
oseltamivir	O
and	O
supportive	O
critical	O
care	O
.	O

An	O
RT	O
-	O
PCR	O
/	O
ESI	O
-	O
MS	O
respiratory	O
virus	O
surveillance	O
kit	O
designed	O
to	O
detect	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
parainfluenza	O
types	O
1	O
-	O
4	O
,	O
Adenoviridae	O
types	O
A	O
-	O
F	O
,	O
Coronaviridae	O
,	O
human	O
bocavirus	O
,	O
and	O
human	O
metapneumovirus	O
was	O
evaluated	O
using	O
both	O
mock	O
-	O
ups	O
and	O
frozen	O
archived	O
NPA	O
(	O
N	O
=	O
280	O
),	O
95	O
of	O
which	O
were	O
positive	O
by	O
clinical	O
virology	O
methods	O
.	O

TITLE	O
:	O
Distinct	O
patterns	O
of	O
IFITM	O
-	O
mediated	O
restriction	O
of	O
filoviruses	O
,	O
SARS	O
coronavirus	O
,	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

The	O
cause	O
of	O
death	O
was	O
primary	O
pandemic	O
influenza	B-PATH
infection	I-PATH
in	O
16	O
(	O
64	O
%),	O
nosocomial	O
infection	O
in	O
four	O
(	O
16	O
%),	O
and	O
primary	O
disease	O
progression	O
in	O
five	O
(	O
20	O
%)	O
patients	O
.	O

Influenza	B-PATH
A	I-PATH
H5N1	O
has	O
had	O
a	O
profound	O
effect	O
on	O
the	O
poultry	O
industry	O
.	O

Poly	O
-	O
ubiquitination	O
of	O
ERK1	O
showed	O
a	O
relationship	O
between	O
ERK1	O
and	O
ubiquitin	O
proteasome	B-PATH
signalling	O
pathways	O
associated	O
with	O
IFN	O
antagonism	O
by	O
PLpro	O
.	O

Virus	O
diversity	O
included	O
environmentally	O
transmitted	O
agents	O
such	O
as	O
parechovirus	O
,	O
coronavirus	O
,	O
adenovirus	O
and	O
aichi	O
virus	O
,	O
as	O
well	O
as	O
viruses	O
associated	O
with	O
chronic	O
human	O
infections	O
such	O
as	O
human	O
herpes	O
and	O
hepatitis	B-PATH
C	I-PATH
viruses	O
.	O

Patients	O
are	O
sometimes	O
admitted	O
to	O
ICUs	O
for	O
hypercapnic	O
respiratory	O
failure	O
or	O
cor	O
pulmonale	O
,	O
but	O
more	O
often	O
,	O
they	O
are	O
admitted	O
for	O
pneumonia	O
,	O
excessive	O
daytime	O
sleepiness	O
,	O
heart	O
failure	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
),	O
asthma	B-PATH
attacks	O
or	O
pulmonary	O
embolism	O
,	O
and	O
hypercapnic	O
respiratory	O
failure	O
is	O
coincidentally	O
noticed	O
during	O
this	O
period	O
.	O

We	O
discuss	O
the	O
role	O
of	O
computational	O
chemistry	O
in	O
the	O
development	O
of	O
small	O
molecules	O
as	O
agents	O
against	O
HIV	O
integrase	O
,	O
HIV	O
-	O
1	O
protease	O
,	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
,	O
the	O
influenza	O
virus	O
M2	O
channel	O
protein	O
,	O
influenza	O
virus	O
neuraminidase	O
,	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	O
and	O
spike	O
protein	O
,	O
thymidine	O
kinases	O
of	O
herpes	O
viruses	O
,	O
hepatitis	B-PATH
c	I-PATH
virus	O
proteins	O
and	O
other	O
flaviviruses	O
as	O
well	O
as	O
human	O
rhinovirus	O
coat	O
protein	O
and	O
proteases	O
,	O
and	O
other	O
picornaviridae	O
.	O

ABSTRACT	O
:	O
Pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
a	O
serious	O
health	O
problem	O
during	O
the	O
winter	O
of	O
2009	O
-	O
2010	O
in	O
Turkey	O
.	O

ABSTRACT	O
:	O
Nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
a	O
major	O
pathological	O
determinant	O
in	O
the	O
host	O
that	O
may	O
cause	O
host	O
cell	O
apoptosis	B-PATH
,	O
upregulate	O
the	O
proinflammatory	O
cytokine	O
production	O
,	O
and	O
block	O
innate	O
immune	O
responses	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
successfully	O
treated	O
acute	O
respiratory	O
distress	O
syndrome	O
complicating	O
Plasmodium	O
falciparum	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
While	O
endemic	O
malaria	B-PATH
has	O
been	O
eliminated	O
in	O
the	O
United	O
States	O
,	O
approximately	O
1200	O
mostly	O
imported	O
cases	O
are	O
reported	O
annually	O
in	O
the	O
country	O
,	O
with	O
fewer	O
than	O
20	O
recorded	O
deaths	O
.	O

In	O
a	O
review	O
of	O
all	O
malaria	B-PATH
deaths	O
in	O
the	O
United	O
States	O
from	O
1963	O
to	O
2001	O
,	O
failure	O
to	O
diagnose	O
malaria	B-PATH
on	O
initial	O
presentation	O
,	O
promptly	O
initiate	O
treatment	O
,	O
and	O
/	O
or	O
prescribe	O
appropriate	O
antimalarial	O
drugs	O
were	O
identified	O
as	O
contributing	O
factors	O
to	O
death	O
.	O

Plasmodium	O
falciparum	O
can	O
lead	O
to	O
a	O
particularly	O
severe	O
type	O
of	O
malaria	B-PATH
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
physicians	O
must	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
this	O
diagnosis	O
in	O
immigrants	O
and	O
returning	O
travelers	O
.	O

We	O
report	O
a	O
case	O
of	O
successfully	O
treated	O
acute	O
respiratory	O
distress	O
syndrome	O
complicating	O
imported	O
P	O
falciparum	O
malaria	B-PATH
at	O
a	O
large	O
teaching	O
hospital	O
in	O
Washington	O
,	O
DC	O
.	O

ABSTRACT	O
:	O
Airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
and	O
bi	O
-	O
level	O
positive	O
airway	O
pressure	O
(	O
BIPAP	O
)	O
are	O
proposed	O
to	O
reduce	O
patient	O
work	O
of	O
breathing	O
(	O
WOB	O
)	O
sufficiently	O
and	O
to	O
obviate	O
issues	O
related	O
to	O
patient	O
-	O
ventilator	O
synchrony	O
,	O
so	O
that	O
spontaneous	O
breathing	O
can	O
be	O
maintained	O
throughout	O
the	O
course	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

TITLE	O
:	O
A	O
spontaneous	O
intercostal	O
artery	O
hemorrhage	O
in	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
.	O

ABSTRACT	O
:	O
Systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
(	O
SLE	O
)	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
that	O
can	O
lead	O
to	O
damage	O
to	O
several	O
vital	O
organs	O
.	O

Apart	O
from	O
being	O
cytotoxic	O
,	O
these	O
cells	O
are	O
also	O
involved	O
in	O
maintaining	O
inflammatory	O
reactions	O
by	O
the	O
release	B-PATH
of	O
cytokines	O
and	O
bioactive	O
lipids	O
such	O
as	O
platelet	O
-	O
activating	O
factor	O
and	O
arachidonic	O
acid	O
metabolites	O
.	O

Entry	O
and	O
release	B-PATH
of	O
canine	O
coronavirus	O
from	O
polarized	O
epithelial	O
cells	O
.	O

In	O
order	O
to	O
establish	O
the	O
polarity	O
of	O
entry	O
and	O
release	B-PATH
of	O
CCoV	O
from	O
epithelial	O
cells	O
,	O
the	O
interactions	O
of	O
the	O
virus	O
with	O
A72	O
and	O
CrFK	O
cells	O
grown	O
on	O
permeable	O
supports	O
was	O
evaluated	O
,	O
and	O
the	O
amount	O
of	O
infective	O
virus	O
in	O
the	O
apical	O
and	O
in	O
the	O
basolateral	O
media	O
was	O
determined	O
and	O
compared	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
refractory	O
respiratory	O
failure	O
secondary	O
to	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
.	O
ABSTRACT	O
:	O
Respiratory	O
failure	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
H1N1	O
influenza	B-PATH
infection	I-PATH
is	O
a	O
source	O
of	O
substantial	O
morbidity	O
and	O
mortality	O
,	O
having	O
caused	O
over	O
265	O
,	O
000	O
hospitalizations	O
in	O
the	O
United	O
States	O
in	O
2009	O
.	O

This	O
series	O
suggests	O
that	O
ECMO	O
is	O
a	O
viable	O
treatment	O
for	O
refractory	O
hypoxemia	O
secondary	O
to	O
H1N1	O
influenza	B-PATH
infection	I-PATH
in	O
both	O
pediatric	O
and	O
adult	O
patients	O
.	O

Drugs	O
that	O
inhibit	O
the	O
ion	O
channel	O
formed	O
by	O
the	O
3a	O
protein	O
can	O
be	O
expected	O
to	O
inhibit	O
virus	O
release	B-PATH
,	O
and	O
would	O
be	O
a	O
source	O
for	O
the	O
development	O
of	O
novel	O
therapeutic	O
agents	O
.	O

Here	O
we	O
demonstrate	O
that	O
emodin	O
can	O
inhibit	O
the	O
3a	O
ion	O
channel	O
of	O
coronavirus	O
SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
OC43	O
as	O
well	O
as	O
virus	O
release	B-PATH
from	O
HCoV	O
-	O
OC43	O
with	O
a	O
K1	O
/	O
2	O
value	O
of	O
about	O
20	O
Î¼M	O
.	O
We	O
suggest	O
that	O
viral	O
ion	O
channels	O
,	O
in	O
general	O
,	O
may	O
be	O
a	O
good	O
target	O
for	O
the	O
development	O
of	O
antiviral	O
agents	O
.	O

However	O
,	O
infections	O
with	O
unrelated	O
pathogens	O
,	O
as	O
may	O
occur	O
in	O
areas	O
endemic	O
to	O
malaria	B-PATH
,	O
can	O
dramatically	O
decrease	O
pre	O
-	O
existing	O
memory	O
CD8	O
T	O
cells	O
.	O

However	O
,	O
and	O
of	O
relevance	O
to	O
deployment	O
of	O
Plasmodium	O
vaccines	O
in	O
areas	O
endemic	O
to	O
malaria	B-PATH
,	O
attrition	O
of	O
memory	O
CD8	O
T	O
cells	O
was	O
reversed	O
by	O
booster	O
immunization	O
,	O
which	O
restored	O
protection	O
.	O

TITLE	O
:	O
PLP2	O
of	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
targets	O
TBK1	O
to	O
negatively	O
regulate	O
cellular	O
type	O
I	O
interferon	B-PATH
signaling	I-PATH
pathway	O
.	O

TITLE	O
:	O
Virus	O
-	O
associated	O
hemophagocytic	O
syndrome	O
as	O
a	O
major	O
contributor	O
to	O
death	O
in	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

VAHS	O
developed	O
in	O
9	O
(	O
36	O
%)	O
of	O
25	O
critically	O
ill	O
patients	O
with	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
,	O
and	O
8	O
(	O
89	O
%)	O
of	O
them	O
died	O
.	O

The	O
findings	O
of	O
this	O
study	O
raise	O
the	O
possibility	O
that	O
VAHS	O
may	O
be	O
a	O
frequent	O
complication	O
of	O
severe	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
and	O
represents	O
an	O
important	O
contributor	O
to	O
multiorgan	O
failure	O
and	O
death	O
.	O

RESULTS	O
:	O
VAHS	O
developed	O
in	O
9	O
(	O
36	O
%)	O
of	O
25	O
critically	O
ill	O
patients	O
with	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
,	O
and	O
8	O
(	O
89	O
%)	O
of	O
them	O
died	O
.	O

The	O
study	O
enrolled	O
24	O
patients	O
,	O
including	O
8	O
males	O
and	O
16	O
females	O
(	O
10	O
of	O
whom	O
were	O
pregnant	O
),	O
aged	O
17	O
to	O
58	O
years	O
,	O
with	O
a	O
laboratorily	O
verified	O
diagnosis	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
/	O
2009	O
,	O
treated	O
at	O
the	O
intensive	O
care	O
unit	O
for	O
the	O
significant	O
symptoms	O
of	O
acute	O
respiratory	O
failure	O
(	O
RF	O
).	O

CONCLUSIONS	O
:	O
The	O
severity	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
/	O
2009	O
was	O
determined	O
by	O
massive	O
bilateral	O
pneumonia	O
,	O
interstitial	O
(	O
alveolar	O
)	O
pulmonary	O
edema	O
,	O
formation	O
of	O
diffuse	O
bilateral	O
lung	O
fibrosis	O
at	O
the	O
outcome	O
of	O
severe	O
virus	O
pneumonia	O
(	O
acute	O
respiratory	O
distress	O
syndrome	O
)	O
with	O
a	O
decrease	O
in	O
vital	O
and	O
diffusing	O
capacities	O
,	O
thereby	O
generating	O
a	O
need	O
to	O
follow	O
up	O
this	O
patient	O
category	O
and	O
,	O
possibly	O
,	O
to	O
elaborate	O
special	O
rehabilitation	O
programs	O
.	O

These	O
proteins	O
mostly	O
related	O
to	O
the	O
cytoskeleton	O
,	O
binding	O
of	O
calcium	O
ions	O
,	O
the	O
stress	B-PATH
response	I-PATH
,	O
anti	O
-	O
oxidative	O
,	O
and	O
macromolecular	O
metabolism	O
.	O

ABSTRACT	O
:	O
Swine	O
origin	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
(	O
H1N1	O
)	O
emerged	O
in	O
early	O
2009	O
and	O
rapidly	O
spread	O
to	O
humans	O
.	O

ABSTRACT	O
:	O
Conditions	O
characterized	O
by	O
immunosuppression	O
have	O
been	O
recently	O
reported	O
as	O
risk	O
factors	O
for	O
severe	O
novel	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
(	O
S	O
-	O
OIV	O
)	O
infection	O
during	O
the	O
current	O
2009	O
pandemic	O
.	O

A	O
small	O
number	O
of	O
samples	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
respiratory	O
syncytial	O
virus	O
B	O
,	O
human	O
metapneumovirus	O
,	O
and	O
parainfluenza	O
virus	O
type	O
1	O
were	O
not	O
detected	O
by	O
the	O
RVP	O
Classic	O
assay	O
and	O
in	O
general	O
had	O
low	O
viral	O
loads	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
human	O
rhinovirus	O
were	O
the	O
major	O
pathogens	O
responsible	O
for	O
respiratory	O
disease	O
.	O

ABSTRACT	O
:	O
The	O
worldwide	O
outbreak	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
influenza	O
)	O
infection	O
in	O
2009	O
caused	O
numerous	O
hospitalizations	O
and	O
deaths	O
resulting	O
from	O
severe	O
complications	O
such	O
as	O
pneumonia	O
,	O
sepsis	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Is	O
respiratory	O
viral	O
infection	O
really	O
an	O
important	O
trigger	O
of	O
asthma	B-PATH
exacerbations	O
in	O
children	O
?	O

ABSTRACT	O
:	O
We	O
performed	O
a	O
prospective	O
cohort	O
study	O
from	O
September	O
2003	O
to	O
December	O
2004	O
to	O
delineate	O
attributing	O
the	O
effect	O
of	O
different	O
respiratory	O
viral	O
infections	O
including	O
newly	O
discovered	O
ones	O
to	O
asthma	B-PATH
exacerbations	O
in	O
children	O
in	O
Hong	O
Kong	O
.	O

Nasal	O
specimens	O
were	O
available	O
in	O
166	O
episodes	O
,	O
92	O
of	O
which	O
were	O
diagnosed	O
as	O
asthma	B-PATH
exacerbations	O
,	O
and	O
74	O
non	O
-	O
asthma	B-PATH
related	O
episodes	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
virus	O
detection	O
rate	O
between	O
asthma	B-PATH
exacerbations	O
(	O
32	O
out	O
of	O
97	O
episodes	O
,	O
34	O
.	O
8	O
%)	O
and	O
non	O
-	O
asthma	B-PATH
respiratory	O
illnesses	O
(	O
29	O
out	O
of	O
79	O
episodes	O
,	O
39	O
.	O
2	O
%).	O

We	O
conclude	O
that	O
not	O
all	O
viral	O
infections	O
in	O
children	O
with	O
asthma	B-PATH
lead	O
to	O
an	O
asthma	B-PATH
exacerbation	O
and	O
the	O
attributing	O
effect	O
of	O
different	O
triggers	O
of	O
asthma	B-PATH
exacerbations	O
in	O
children	O
vary	O
across	O
different	O
time	O
periods	O
and	O
across	O
different	O
localities	O
.	O

CONCLUSIONS	O
:	O
Complications	O
related	O
to	O
influenza	B-PATH
infection	I-PATH
can	O
be	O
life	O
threatening	O
,	O
particularly	O
in	O
immunocompromised	O
patients	O
.	O

Then	O
genome	O
RNA	O
was	O
synthesized	O
in	O
vitro	O
by	O
T7	O
RNA	B-PATH
polymerase	I-PATH
and	O
transfected	O
into	O
BHK	O
-	O
21	O
cells	O
.	O

TITLE	O
:	O
Early	O
corticosteroids	O
in	O
severe	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

To	O
analyze	O
the	O
impact	O
of	O
corticosteroid	O
therapy	O
on	O
outcomes	O
of	O
patients	O
having	O
ARDS	O
associated	O
with	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pneumonia	O
.	O

Patients	O
from	O
the	O
French	O
registry	O
of	O
critically	O
ill	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
2009	O
infection	O
were	O
selected	O
if	O
fulfilling	O
criteria	O
for	O
ARDS	O
,	O
excluding	O
patients	O
having	O
other	O
indication	O
for	O
corticosteroids	O
,	O
or	O
decompensated	O
underlying	O
disease	O
as	O
the	O
primary	O
cause	O
for	O
intensive	O
care	O
unit	O
admission	O
.	O

TITLE	O
:	O
Overview	O
of	O
the	O
winter	O
wave	O
of	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
v	O
in	O
Vojvodina	O
,	O
Serbia	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
epidemiological	O
data	O
for	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
v	O
in	O
the	O
Autonomous	O
Province	O
of	O
Vojvodina	O
,	O
Serbia	O
,	O
during	O
the	O
season	O
of	O
2009	O
/	O
2010	O
and	O
to	O
assess	O
whether	O
including	O
severe	O
acute	O
respiratory	O
illness	O
(	O
SARI	O
)	O
hospitalization	O
data	O
to	O
the	O
surveillance	O
system	O
gives	O
a	O
more	O
complete	O
picture	O
of	O
the	O
impact	O
of	O
influenza	O
during	O
the	O
pandemic	O
.	O

Among	O
blood	O
-	O
borne	O
virus	O
infections	O
there	O
were	O
six	O
cases	O
of	O
particular	O
note	O
:	O
three	O
cases	O
of	O
acute	O
hepatitis	O
following	O
hepatitis	B-PATH
C	I-PATH
virus	O
infection	O
with	O
a	O
short	O
period	O
of	O
incubation	O
,	O
one	O
laboratory	O
case	O
of	O
human	O
immunodeficiency	O
virus	O
infection	O
through	O
aerosol	O
inhalation	O
,	O
one	O
case	O
of	O
hepatitis	O
following	O
hepatitis	O
G	O
virus	O
infection	O
,	O
and	O
one	O
case	O
of	O
fulminant	O
hepatitis	O
with	O
hepatitis	O
B	O
virus	O
infection	O
following	O
exposure	O
of	O
the	O
worker	O
'	O
s	O
conjunctiva	O
to	O
hepatitis	O
B	O
virus	O
e	O
antigen	O
-	O
negative	O
patient	O
saliva	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
the	O
S	O
gene	O
revealed	O
that	O
the	O
newly	O
detected	O
viruses	O
form	O
a	O
sublineage	O
genetically	O
related	O
with	O
,	O
but	O
significantly	O
different	O
from	O
,	O
NA	O
TCoV	O
.	O
Additionally	O
,	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
and	O
the	O
N	O
gene	O
,	O
located	O
on	O
the	O
5	O
'	O
and	O
3	O
'	O
sides	O
of	O
the	O
S	O
gene	O
in	O
the	O
coronavirus	O
genome	O
,	O
were	O
partially	O
sequenced	O
.	O

TITLE	O
:	O
Repeated	O
virus	O
identification	O
in	O
the	O
airways	O
of	O
patients	O
with	O
mild	O
and	O
severe	O
asthma	B-PATH
during	O
prospective	O
follow	O
-	O
up	O
.	O

We	O
hypothesized	O
that	O
patients	O
with	O
clinically	O
stable	O
,	O
severe	O
asthma	B-PATH
exhibit	O
increased	O
and	O
more	O
prolonged	O
viral	O
presence	O
in	O
the	O
airways	O
as	O
compared	O
to	O
mild	O
asthmatics	O
and	O
healthy	O
controls	O
.	O

Thirty	O
-	O
five	O
subjects	O
(	O
no	O
cold	O
symptoms	O
>	O
4	O
weeks	O
)	O
entered	O
a	O
12	O
-	O
week	O
prospective	O
study	O
using	O
three	O
groups	O
:	O
clinically	O
stable	O
mild	O
asthma	B-PATH
(	O
GINA	O
2	O
)	O
(	O
n	O
=	O
12	O
,	O
age	O
34	O
.	O
1	O
Â±	O
13	O
.	O
4	O
year	O
),	O
severe	O
asthma	B-PATH
(	O
GINA	O
4	O
)	O
(	O
n	O
=	O
12	O
,	O
age	O
49	O
.	O
3	O
Â±	O
14	O
.	O
8	O
year	O
)	O
and	O
healthy	O
controls	O
(	O
n	O
=	O
11	O
,	O
age	O
37	O
.	O
9	O
Â±	O
14	O
.	O
2	O
year	O
).	O

Patients	O
with	O
clinically	O
stable	O
asthma	B-PATH
and	O
healthy	O
controls	O
have	O
similar	O
detection	O
rates	O
of	O
respiratory	O
viruses	O
in	O
samples	O
from	O
nasopharynx	O
,	O
sputum	O
and	O
exhaled	O
air	O
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
clinically	O
stable	O
asthma	B-PATH
and	O
healthy	O
controls	O
have	O
similar	O
detection	O
rates	O
of	O
respiratory	O
viruses	O
in	O
samples	O
from	O
nasopharynx	O
,	O
sputum	O
and	O
exhaled	O
air	O
.	O

A	O
key	O
enzyme	O
of	O
this	O
replication	O
complex	O
is	O
the	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
).	O

ABSTRACT	O
:	O
The	O
clinical	O
severity	O
of	O
human	O
infection	O
with	O
the	O
novel	O
influenza	O
virus	O
A	O
/	O
H1N1v	O
has	O
not	O
been	O
completely	O
defined	O
,	O
especially	O
in	O
HIV	O
/	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
infected	O
patients	O
.	O

Examples	O
include	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
or	O
influenza	B-PATH
A	I-PATH
virus	O
H3N2	O
.	O

TITLE	O
:	O
Clinical	O
manifestations	O
,	O
therapy	O
and	O
outcome	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
in	O
hospitalized	O
patients	O
.	O

There	O
were	O
74	O
(	O
75	O
.	O
5	O
%)	O
patients	O
with	O
suspected	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
,	O
10	O
(	O
10	O
.	O
2	O
%)	O
with	O
the	O
likelihood	O
and	O
14	O
(	O
14	O
.	O
3	O
%)	O
with	O
the	O
confirmed	O
influenza	O
.	O

The	O
average	O
time	O
from	O
the	O
beginning	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
to	O
the	O
admission	O
in	O
hospital	O
was	O
3	O
days	O
(	O
0	O
-	O
16	O
days	O
)	O
and	O
from	O
the	O
moment	O
of	O
hospitalization	O
to	O
the	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
admission	O
was	O
2	O
days	O
(	O
0	O
-	O
5	O
days	O
).	O

Novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
is	O
most	O
commonly	O
manifested	O
as	O
a	O
mild	O
acute	O
respiratory	O
disease	O
,	O
which	O
usually	O
affects	O
young	O
healthy	O
adults	O
.	O

RESULTS	O
:	O
The	O
average	O
time	O
from	O
the	O
beginning	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
to	O
the	O
admission	O
in	O
hospital	O
was	O
3	O
days	O
(	O
0	O
-	O
16	O
days	O
)	O
and	O
from	O
the	O
moment	O
of	O
hospitalization	O
to	O
the	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
admission	O
was	O
2	O
days	O
(	O
0	O
-	O
5	O
days	O
).	O

Children	O
with	O
a	O
higher	O
severity	O
score	O
had	O
greater	O
chance	O
to	O
develop	O
asthma	B-PATH
in	O
the	O
next	O
2	O
years	O
(	O
p	O
=	O
0	O
.	O
042	O
).	O

This	O
case	O
report	O
reveals	O
a	O
patient	O
with	O
ARDS	O
secondary	O
to	O
influenza	B-PATH
A	I-PATH
with	O
deteriorating	O
clinical	O
status	O
,	O
who	O
improved	O
tremendously	O
after	O
intravenous	O
immunoglobulin	O
G	O
(	O
IV	O
IgG	O
).	O

TITLE	O
:	O
[	O
Mechanical	O
ventilation	O
in	O
patients	O
with	O
most	O
severe	O
forms	O
of	O
influenza	B-PATH
A	I-PATH
H1N1	O
].	O

The	O
systematic	O
review	O
covered	O
over	O
3	O
,	O
700	O
peer	O
-	O
reviewed	O
articles	O
and	O
grey	O
literature	O
for	O
the	O
following	O
diseases	O
:	O
tuberculosis	B-PATH
,	O
influenza	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
invasive	O
meningococcal	O
disease	O
,	O
measles	B-PATH
,	O
rubella	O
,	O
diphtheria	O
,	O
Ebola	O
and	O
Marburg	O
haemorrhagic	O
fevers	O
,	O
Lassa	O
fever	O
,	O
smallpox	O
and	O
anthrax	O
.	O

Disease	O
-	O
specific	O
guidance	O
documents	O
on	O
tuberculosis	B-PATH
,	O
SARS	O
,	O
meningococcal	O
infections	O
,	O
measles	B-PATH
,	O
rubella	O
,	O
Ebola	O
and	O
Marburg	O
haemorrhagic	O
fevers	O
,	O
Lassa	O
fever	O
,	O
smallpox	O
and	O
anthrax	O
were	O
the	O
result	O
of	O
consultations	O
of	O
disease	O
-	O
specific	O
expert	O
panels	O
.	O

Four	O
air	O
-	O
handling	O
units	O
were	O
selected	O
from	O
each	O
building	O
,	O
and	O
a	O
total	O
of	O
64	O
prefilters	O
and	O
final	O
filters	O
were	O
tested	O
for	O
the	O
presence	O
of	O
influenza	B-PATH
A	I-PATH
,	O
influenza	O
B	O
,	O
respiratory	O
syncytial	O
,	O
corona	O
,	O
parainfluenza	O
1	O
-	O
3	O
,	O
adeno	O
,	O
orthopox	O
,	O
entero	O
,	O
Ebola	O
,	O
Marburg	O
,	O
Lassa	O
fever	O
,	O
Machupo	O
,	O
eastern	O
equine	O
encephalitis	O
,	O
western	O
equine	O
encephalitis	O
,	O
and	O
Venezuelan	O
equine	O
encephalitis	O
viruses	O
.	O

Nine	O
of	O
the	O
64	O
filters	O
tested	O
were	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
2	O
filters	O
were	O
positive	O
for	O
influenza	O
B	O
virus	O
,	O
and	O
1	O
filter	O
was	O
positive	O
for	O
parainfluenza	O
virus	O
1	O
.	O

Nine	O
of	O
the	O
64	O
filters	O
tested	O
were	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
2	O
filters	O
were	O
positive	O
for	O
influenza	O
B	O
virus	O
,	O
and	O
1	O
filter	O
was	O
positive	O
for	O
parainfluenza	O
virus	O
1	O
.	O

The	O
Virochip	O
has	O
also	O
been	O
used	O
to	O
identify	O
novel	O
viruses	O
,	O
including	O
the	O
SARS	O
coronavirus	O
,	O
a	O
novel	O
rhinovirus	O
clade	O
,	O
XMRV	O
(	O
a	O
retrovirus	O
linked	O
to	O
prostate	B-PATH
cancer	I-PATH
),	O
avian	O
bornavirus	O
(	O
the	O
cause	O
of	O
a	O
wasting	O
disease	O
in	O
parrots	O
),	O
and	O
a	O
novel	O
cardiovirus	O
in	O
children	O
with	O
respiratory	O
and	O
diarrheal	O
illness	O
.	O

Pulmonologists	O
are	O
also	O
faced	O
with	O
the	O
consequences	O
of	O
modernization	O
,	O
including	O
large	O
immigrant	O
population	O
and	O
associated	O
social	O
and	O
health	O
issues	O
,	O
rising	O
incidence	O
of	O
obesity	O
and	O
sleep	O
apnoea	O
,	O
and	O
drug	O
-	O
resistant	O
tuberculosis	B-PATH
.	O

Moreover	O
,	O
immunofluorescence	O
(	O
IF	O
)	O
and	O
flow	O
cytometry	O
analyses	O
based	O
on	O
staining	O
of	O
Annexin	O
V	O
and	O
propidium	O
iodide	O
staining	O
of	O
nuclei	O
indicated	O
that	O
early	O
and	O
late	O
cell	O
apoptosis	B-PATH
induced	O
by	O
TGEV	O
was	O
inhibited	O
efficiently	O
.	O

TITLE	O
:	O
Exogenous	O
surfactant	O
as	O
a	O
component	O
of	O
complex	O
non	O
-	O
ECMO	O
therapy	O
of	O
ARDS	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
2009	O
H1N1	O
).	O

ABSTRACT	O
:	O
During	O
the	O
pandemy	O
caused	O
by	O
novel	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
subgroup	O
H1N1	O
),	O
a	O
significant	O
number	O
of	O
patients	O
became	O
critically	O
ill	O
from	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Clinical	O
course	O
of	O
ICU	O
patients	O
with	O
severe	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pneumonia	O
:	O
single	O
center	O
experience	O
with	O
proning	O
and	O
pressure	O
release	B-PATH
ventilation	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
different	O
modalities	O
have	O
been	O
employed	O
in	O
addition	O
to	O
conventional	O
ventilation	O
to	O
improve	O
oxygenation	O
in	O
patients	O
with	O
severe	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pneumonia	O
.	O

A	O
single	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
experience	O
with	O
management	O
of	O
laboratory	O
-	O
confirmed	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
ARDS	O
with	O
a	O
combination	O
of	O
proning	O
and	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
is	O
described	O
.	O

Fourteen	O
ICU	O
patients	O
were	O
managed	O
with	O
invasive	O
ventilation	O
for	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
related	O
ARDS	O
.	O

RESULTS	O
:	O
Fourteen	O
ICU	O
patients	O
were	O
managed	O
with	O
invasive	O
ventilation	O
for	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
related	O
ARDS	O
.	O

Unexpectedly	O
,	O
it	O
was	O
found	O
that	O
allopurinol	O
and	O
ethyl	O
pyruvate	O
inhibited	O
the	O
release	B-PATH
of	O
both	O
uric	O
acid	O
and	O
HMGB1	O
.	O

TITLE	O
:	O
Role	O
of	O
proteases	O
in	O
the	O
release	B-PATH
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
from	O
infected	O
cells	O
.	O

We	O
found	O
that	O
PEDV	O
infection	O
was	O
enhanced	O
,	O
and	O
viruses	O
were	O
efficiently	O
released	O
into	O
the	O
culture	O
fluid	O
,	O
from	O
Vero	O
cells	O
infected	O
in	O
the	O
presence	O
of	O
protease	O
,	O
while	O
in	O
cells	O
without	O
protease	O
,	O
the	O
virus	O
grew	O
,	O
but	O
its	O
release	B-PATH
into	O
the	O
culture	O
fluid	O
was	O
strongly	O
hampered	O
.	O

Thus	O
,	O
the	O
present	O
study	O
indicates	O
that	O
proteases	O
play	O
an	O
important	O
role	O
in	O
the	O
release	B-PATH
of	O
PEDV	O
virions	O
clustered	O
on	O
cells	O
after	O
replication	O
occurs	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
tuberculosis	B-PATH
can	O
lead	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
which	O
is	O
associated	O
with	O
high	O
mortality	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
pulmonary	O
tuberculosis	B-PATH
and	O
severe	O
ARDS	O
(	O
PaO2	O
/	O
FiO2	O
<	O
100	O
mmHg	O
)	O
who	O
was	O
initially	O
managed	O
with	O
advanced	O
up	O
-	O
to	O
-	O
date	O
treatments	O
(	O
protective	O
ventilation	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
ECMO	O
)	O
but	O
failed	O
to	O
improve	O
.	O

TITLE	O
:	O
Virucidal	O
activity	O
of	O
a	O
scorpion	O
venom	O
peptide	O
variant	O
mucroporin	O
-	O
M1	O
against	O
measles	B-PATH
,	O
SARS	O
-	O
CoV	O
and	O
influenza	O
H5N1	O
viruses	O
.	O

ABSTRACT	O
:	O
Outbreaks	O
of	O
SARS	O
-	O
CoV	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
,	O
H1N1	O
)	O
and	O
measles	B-PATH
viruses	O
in	O
recent	O
years	O
have	O
raised	O
serious	O
concerns	O
about	O
the	O
measures	O
available	O
to	O
control	O
emerging	O
and	O
re	O
-	O
emerging	O
infectious	O
viral	O
diseases	O
.	O

Effective	O
antiviral	O
agents	O
are	O
lacking	O
that	O
specifically	O
target	O
RNA	O
viruses	O
such	O
as	O
measles	B-PATH
,	O
SARS	O
-	O
CoV	O
and	O
influenza	O
H5N1	O
viruses	O
,	O
and	O
available	O
vaccinations	O
have	O
demonstrated	O
variable	O
efficacy	O
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
the	O
antiviral	O
activities	O
of	O
mucroporin	O
-	O
M1	O
against	O
measles	B-PATH
,	O
SARS	O
-	O
CoV	O
and	O
influenza	O
H5N1	O
viruses	O
were	O
notably	O
increased	O
with	O
an	O
ECââ	O
of	O
7	O
.	O
15	O
Î¼g	O
/	O
ml	O
(	O
3	O
.	O
52	O
Î¼M	O
)	O
and	O
a	O
CCââ	O
of	O
70	O
.	O
46	O
Î¼g	O
/	O
ml	O
(	O
34	O
.	O
70	O
Î¼M	O
)	O
against	O
measles	B-PATH
virus	O
,	O
an	O
ECââ	O
of	O
14	O
.	O
46	O
Î¼g	O
/	O
ml	O
(	O
7	O
.	O
12	O
Î¼M	O
)	O
against	O
SARS	O
-	O
CoV	O
and	O
an	O
ECââ	O
of	O
2	O
.	O
10	O
Î¼g	O
/	O
ml	O
(	O
1	O
.	O
03	O
Î¼M	O
)	O
against	O
H5N1	O
,	O
while	O
the	O
original	O
peptide	O
mucroporin	O
showed	O
no	O
antiviral	O
activity	O
against	O
any	O
of	O
these	O
three	O
viruses	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
9b	O
protein	O
diffuses	O
into	O
nucleus	O
,	O
undergoes	O
active	O
Crm1	O
mediated	O
nucleocytoplasmic	O
export	O
and	O
triggers	O
apoptosis	B-PATH
when	O
retained	O
in	O
the	O
nucleus	O
.	O

Here	O
,	O
we	O
showed	O
that	O
nuclear	O
shuttling	O
of	O
9b	O
and	O
its	O
interaction	O
with	O
Crm1	O
are	O
essential	O
for	O
the	O
proper	O
degradation	O
of	O
9b	O
and	O
blocking	O
the	O
nuclear	O
export	O
of	O
this	O
protein	O
induces	O
apoptosis	B-PATH
.	O

Intranasal	O
inoculation	O
of	O
ferrets	O
with	O
influenza	B-PATH
A	I-PATH
/	O
H5N1	O
virus	O
causes	O
lesions	O
in	O
both	O
the	O
respiratory	O
tract	O
and	O
extrarespiratory	O
organs	O
(	O
primarily	O
brain	O
).	O

These	O
findings	O
indicate	O
that	O
influenza	B-PATH
A	I-PATH
/	O
H5N1	O
virus	O
spread	O
directly	O
from	O
nasal	O
cavity	O
to	O
brain	O
,	O
and	O
that	O
CNS	O
lesions	O
contributed	O
more	O
than	O
pulmonary	O
lesions	O
to	O
the	O
pathogenicity	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H5N1	O
virus	O
infection	O
in	O
ferrets	O
.	O

TITLE	O
:	O
Clinical	O
features	O
,	O
complications	O
and	O
mortality	O
in	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Sfax	O
,	O
Tunisia	O
.	O

ABSTRACT	O
:	O
Africa	O
,	O
as	O
the	O
rest	O
of	O
the	O
world	O
,	O
was	O
touched	O
by	O
the	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

We	O
prospectively	O
describe	O
baseline	O
characteristics	O
,	O
treatment	O
and	O
outcomes	O
of	O
consecutive	O
critically	O
ill	O
patients	O
with	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
Sfax	O
hospital	O
.	O

From	O
29	O
November	O
2009	O
through	O
21	O
January	O
2010	O
,	O
32	O
patients	O
with	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
were	O
admitted	O
to	O
our	O
ICU	O
.	O

CONCLUSIONS	O
:	O
Critical	O
illness	O
from	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Sfax	O
occurred	O
in	O
young	O
individuals	O
and	O
was	O
associated	O
with	O
severe	O
acute	O
respiratory	O
and	O
additional	O
organ	O
system	O
failure	O
.	O

Trypsin	O
treatment	O
during	O
the	O
budding	B-PATH
stage	O
of	O
virus	O
infection	O
induces	O
an	O
obvious	O
cytopathic	O
effect	O
in	O
infected	O
cells	O
.	O

Asthma	B-PATH
and	O
wheezing	O
may	O
represent	O
more	O
significant	O
risk	O
factors	O
for	O
the	O
development	O
of	O
ACS	O
in	O
children	O
with	O
hemoglobin	O
SC	O
disease	O
.	O

Most	O
cases	O
with	O
adenovirus	O
,	O
influenza	B-PATH
A	I-PATH
,	O
hMPV	O
,	O
hBoV	O
,	O
coronaviruses	O
,	O
and	O
WU	O
virus	O
occurred	O
as	O
co	O
-	O
infections	O
while	O
RSV	O
,	O
PIV	O
-	O
3	O
,	O
and	O
rhinovirus	O
were	O
identified	O
most	O
frequently	O
as	O
the	O
only	O
respiratory	O
pathogen	O
.	O

Macromolecular	O
synthesis	O
analysis	O
showed	O
that	O
rTGEV	O
-	O
Î7	O
virus	O
infection	O
led	O
to	O
host	O
translational	O
shut	O
-	O
off	O
and	O
increased	O
cellular	O
RNA	B-PATH
degradation	I-PATH
compared	O
with	O
rTGEV	O
-	O
wt	O
infection	O
.	O

Moreover	O
,	O
the	O
interaction	O
between	O
protein	O
7	O
and	O
PP1	O
was	O
required	O
,	O
during	O
the	O
infection	O
,	O
for	O
eIF2Î±	O
dephosphorylation	O
and	O
inhibition	O
of	O
cell	O
RNA	B-PATH
degradation	I-PATH
.	O

The	O
specificity	O
of	O
the	O
primers	O
and	O
probe	O
was	O
confirmed	O
with	O
the	O
closely	O
related	O
Nairoviruses	O
CCHFV	O
and	O
Hazara	O
virus	O
,	O
and	O
on	O
the	O
non	O
-	O
related	O
viruses	O
Coronavirus	O
and	O
Influenza	B-PATH
A	I-PATH
virus	O
.	O

TITLE	O
:	O
Comparison	O
of	O
airway	O
pressure	O
release	B-PATH
ventilation	O
to	O
conventional	O
mechanical	O
ventilation	O
in	O
the	O
early	O
management	O
of	O
smoke	O
inhalation	O
injury	O
in	O
swine	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
airway	O
pressure	O
release	B-PATH
ventilation	O
in	O
the	O
management	O
of	O
early	O
smoke	O
inhalation	O
injury	O
has	O
not	O
been	O
studied	O
.	O

PaO2	O
/	O
Fio2	O
ratio	O
was	O
lower	O
in	O
airway	O
pressure	O
release	B-PATH
ventilation	O
vs	O
.	O
conventional	O
mechanical	O
ventilation	O
pigs	O
at	O
12	O
,	O
18	O
,	O
and	O
24	O
hrs	O
(	O
p	O
<	O
.	O
05	O
)	O
but	O
not	O
at	O
48	O
hrs	O
.	O

Respiratory	O
rates	O
were	O
lower	O
in	O
airway	O
pressure	O
release	B-PATH
ventilation	O
at	O
24	O
,	O
42	O
,	O
and	O
48	O
hrs	O
(	O
p	O
<	O
.	O
05	O
).	O

Mean	O
airway	O
pressures	O
were	O
higher	O
in	O
airway	O
pressure	O
release	B-PATH
ventilation	O
animals	O
between	O
6	O
and	O
48	O
hrs	O
(	O
p	O
<	O
.	O
05	O
).	O

In	O
this	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
severe	O
smoke	O
inhalation	O
in	O
swine	O
,	O
airway	O
pressure	O
release	B-PATH
ventilation	O
-	O
treated	O
animals	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
faster	O
than	O
conventional	O
mechanical	O
ventilation	O
-	O
treated	O
animals	O
,	O
showing	O
a	O
lower	O
PaO2	O
/	O
Fio2	O
ratio	O
at	O
12	O
,	O
18	O
,	O
and	O
24	O
hrs	O
after	O
injury	O
.	O

At	O
other	O
time	O
points	O
,	O
PaO2	O
/	O
Fio2	O
ratio	O
was	O
not	O
different	O
between	O
conventional	O
mechanical	O
ventilation	O
and	O
airway	O
pressure	O
release	B-PATH
ventilation	O
.	O

Specifically	O
,	O
we	O
review	O
the	O
effects	O
of	O
hypercapnia	O
and	O
acidosis	O
on	O
the	O
attenuation	O
of	O
pulmonary	O
inflammation	O
,	O
reduction	O
of	O
apoptosis	B-PATH
in	O
alveolar	O
epithelial	O
cells	O
,	O
improvement	O
in	O
sepsis	O
-	O
induced	O
ALI	O
and	O
the	O
therapeutic	O
effects	O
on	O
other	O
organ	O
systems	O
,	O
as	O
well	O
as	O
the	O
potentially	O
harmful	O
effects	O
of	O
these	O
strategies	O
.	O

TITLE	O
:	O
Inbreeding	O
depression	O
increases	O
susceptibility	O
to	O
bovine	O
tuberculosis	B-PATH
in	O
lions	O
:	O
an	O
experimental	O
test	O
using	O
an	O
inbred	O
-	O
outbred	O
contrast	O
through	O
translocation	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
susceptibility	O
to	O
bovine	O
tuberculosis	B-PATH
(	O
bTB	O
),	O
and	O
the	O
prevalence	O
of	O
antibody	O
to	O
feline	O
viruses	O
of	O
native	O
lions	O
,	O
and	O
compared	O
the	O
findings	O
with	O
those	O
from	O
translocated	O
outbred	O
lions	O
and	O
their	O
offspring	O
.	O

Bovine	O
tuberculosis	B-PATH
posed	O
a	O
major	O
threat	O
to	O
the	O
inbred	O
native	O
lion	O
population	O
,	O
but	O
not	O
to	O
translocated	O
lions	O
and	O
their	O
offspring	O
.	O

TITLE	O
:	O
The	O
Italian	O
ECMO	O
network	O
experience	O
during	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
:	O
preparation	O
for	O
severe	O
respiratory	O
emergency	O
outbreaks	O
.	O

ABSTRACT	O
:	O
In	O
view	O
of	O
the	O
expected	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
,	O
the	O
Italian	O
Health	O
Authorities	O
set	O
up	O
a	O
national	O
referral	O
network	O
of	O
selected	O
intensive	O
care	O
units	O
(	O
ICU	O
)	O
able	O
to	O
provide	O
advanced	O
respiratory	O
care	O
up	O
to	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
Retroviruses	O
assemble	O
new	O
virus	O
particles	O
that	O
are	O
released	O
by	O
budding	B-PATH
from	O
the	O
plasma	O
membranes	O
of	O
infected	O
cells	O
.	O

We	O
propose	O
that	O
association	O
of	O
the	O
viral	O
RNA	O
induces	O
a	O
conformational	O
change	O
in	O
Gag	O
that	O
reveals	O
its	O
nuclear	O
export	O
signal	O
(	O
NES	O
)	O
and	O
prepares	O
that	O
complex	O
for	O
its	O
journey	O
to	O
the	O
plasma	O
membrane	O
for	O
budding	B-PATH
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
is	O
only	O
a	O
handful	O
of	O
reported	O
cases	O
of	O
post	O
-	O
infection	O
glomerulonephritis	O
with	O
a	O
nephrotic	O
syndrome	O
in	O
a	O
patient	O
with	O
legionellosis	B-PATH
.	O

CONCLUSIONS	O
:	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
is	O
only	O
a	O
handful	O
of	O
reported	O
cases	O
of	O
post	O
-	O
infection	O
glomerulonephritis	O
with	O
a	O
nephrotic	O
syndrome	O
in	O
a	O
patient	O
with	O
legionellosis	B-PATH
.	O

The	O
reason	O
for	O
this	O
emerging	O
debate	O
is	O
twofold	O
:	O
the	O
recent	O
occurrence	O
of	O
pandemic	O
viruses	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
H1N1	O
,	O
and	O
the	O
emergence	O
of	O
highly	O
resistant	O
strains	O
of	O
infectious	O
pathogens	O
such	O
as	O
multi	O
and	O
extensively	O
drug	O
-	O
resistant	O
tuberculosis	B-PATH
(	O
TB	O
).	O

TITLE	O
:	O
Sixty	O
-	O
two	O
severe	O
and	O
critical	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Shanghai	O
,	O
China	O
.	O

ABSTRACT	O
:	O
Pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
emerged	O
rapidly	O
in	O
China	O
in	O
May	O
2009	O
.	O

Sixty	O
-	O
two	O
severe	O
or	O
critically	O
ill	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
with	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

Severe	O
illness	O
from	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
in	O
Shanghai	O
occurred	O
among	O
young	O
individuals	O
.	O

He	O
was	O
diagnosed	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
,	O
severe	O
type	O
),	O
severe	O
pneumonia	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
Evans	O
syndrome	O
and	O
multiple	O
organ	O
failure	O
.	O

This	O
is	O
the	O
first	O
case	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
Evans	O
syndrome	O
.	O

ABSTRACT	O
:	O
A	O
38	O
-	O
year	O
-	O
old	O
female	O
patient	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
presented	O
with	O
pulmonary	O
infiltrates	O
and	O
hypoxemia	O
for	O
several	O
months	O
following	O
immunodepleting	O
autologous	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
review	O
data	O
from	O
studies	O
of	O
the	O
past	O
decade	O
that	O
implicate	O
AngII	O
and	O
functional	O
polymorphisms	O
of	O
the	O
ACE	O
gene	O
that	O
increase	O
ACE	O
activity	O
with	O
increased	O
susceptibility	O
for	O
asthma	B-PATH
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
for	O
pulmonary	O
hypertension	O
.	O

Since	O
1997	O
,	O
several	O
new	O
respiratory	O
viruses	O
and	O
their	O
subgroups	O
have	O
been	O
discovered	O
:	O
influenza	B-PATH
A	I-PATH
viruses	O
H5N1	O
and	O
H1N1	O
,	O
human	O
metapneumovirus	O
,	O
coronaviruses	O
SARS	O
,	O
NL63	O
and	O
HKU1	O
,	O
human	O
bocavirus	O
,	O
human	O
rhinoviruses	O
C	O
and	O
D	O
and	O
potential	O
respiratory	O
pathogens	O
,	O
the	O
KI	O
and	O
WU	O
polyomaviruses	O
and	O
the	O
torque	O
teno	O
virus	O
.	O

The	O
new	O
viruses	O
cause	O
respiratory	O
symptoms	O
like	O
the	O
common	O
cold	O
,	O
cough	O
,	O
bronchitis	O
,	O
bronchiolitis	O
,	O
exacerbations	O
of	O
asthma	B-PATH
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
pneumonia	O
.	O

TITLE	O
:	O
Severe	O
Plasmodium	O
knowlesi	O
malaria	B-PATH
in	O
a	O
tertiary	O
care	O
hospital	O
,	O
Sabah	O
,	O
Malaysia	O
.	O

ABSTRACT	O
:	O
The	O
simian	O
parasite	O
Plasmodium	O
knowlesi	O
causes	O
severe	O
human	O
malaria	B-PATH
;	O
the	O
optimal	O
treatment	O
remains	O
unknown	O
.	O

We	O
describe	O
the	O
clinical	O
features	O
,	O
disease	O
spectrum	O
,	O
and	O
response	O
to	O
antimalarial	O
chemotherapy	O
,	O
including	O
artemether	O
-	O
lumefantrine	O
and	O
artesunate	O
,	O
in	O
patients	O
with	O
P	O
.	O
knowlesi	O
malaria	B-PATH
diagnosed	O
by	O
PCR	O
during	O
December	O
2007	O
-	O
November	O
2009	O
at	O
a	O
tertiary	O
care	O
hospital	O
in	O
Sabah	O
,	O
Malaysia	O
.	O

Twenty	O
-	O
two	O
(	O
39	O
%)	O
had	O
severe	O
malaria	B-PATH
;	O
of	O
these	O
,	O
6	O
(	O
27	O
%)	O
died	O
.	O

P	O
.	O
knowlesi	O
is	O
a	O
major	O
cause	O
of	O
severe	O
and	O
fatal	O
malaria	B-PATH
in	O
Sabah	O
.	O

Artemisinin	O
derivatives	O
rapidly	O
clear	O
parasitemia	O
and	O
are	O
efficacious	O
in	O
treating	O
uncomplicated	O
and	O
severe	O
knowlesi	O
malaria	B-PATH
.	O

In	O
addition	O
,	O
cellular	O
PDZ	O
protein	O
targets	O
of	O
viral	O
PBMs	O
commonly	O
control	O
tight	B-PATH
junction	I-PATH
formation	O
,	O
cell	O
polarity	O
establishment	O
,	O
and	O
apoptosis	B-PATH
.	O

From	O
the	O
simulated	O
aerosol	O
release	B-PATH
to	O
the	O
detection	O
,	O
we	O
observed	O
a	O
time	O
scale	O
of	O
1	O
-	O
2	O
min	O
.	O

TITLE	O
:	O
Cytokine	O
levels	O
in	O
bronchoalveolar	O
lavage	O
and	O
serum	O
in	O
3	O
patients	O
with	O
2009	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
v	O
severe	O
pneumonia	O
.	O

ABSTRACT	O
:	O
Pandemic	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
v	O
pneumonia	O
has	O
led	O
to	O
a	O
notable	O
increase	O
of	O
admissions	O
to	O
intensive	O
care	O
units	O
.	O

However	O
,	O
few	O
studies	O
have	O
focused	O
on	O
the	O
role	O
of	O
these	O
inflammatory	O
mediators	O
in	O
infections	O
caused	O
by	O
the	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
v	O
.	O

In	O
this	O
study	O
,	O
we	O
assess	O
the	O
inflammatory	O
response	O
mediated	O
by	O
cytokines	O
at	O
the	O
local	O
and	O
systemic	O
levels	O
in	O
three	O
cases	O
of	O
severe	O
pneumonia	O
caused	O
by	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

Serum	O
and	O
bronchoalveolar	O
lavage	O
samples	O
were	O
obtained	O
from	O
three	O
mechanically	O
ventilated	O
patients	O
diagnosed	O
with	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
pneumonia	O
by	O
bronchoscopic	O
bronchoalveolar	O
lavage	O
.	O

Title	O
compounds	O
were	O
investigated	O
for	O
cytotoxicity	O
and	O
antiviral	O
activity	O
against	O
herpes	O
simplex	O
virus	O
-	O
1	O
(	O
KOS	O
),	O
herpes	O
simplex	O
virus	O
-	O
2	O
(	O
G	O
),	O
vaccinia	O
virus	O
,	O
vesicular	O
stomatitis	O
virus	O
,	O
herpes	O
simplex	O
virus	O
-	O
1	O
TK	O
-	O
KOS	O
ACVr	O
,	O
para	O
influenza	O
-	O
3	O
virus	O
,	O
reovirus	O
-	O
1	O
,	O
Sindbis	O
virus	O
,	O
Coxsackie	O
virus	O
B4	O
,	O
Punta	O
Toro	O
virus	O
,	O
feline	O
corona	O
virus	O
(	O
FIPV	O
),	O
feline	O
herpes	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
H1	O
N1	O
subtype	O
,	O
influenza	B-PATH
A	I-PATH
H3N2	O
subtype	O
,	O
influenza	O
B	O
and	O
vesicular	O
stomatitis	O
virus	O
.	O

ABSTRACT	O
:	O
Prior	O
studies	O
of	O
asthma	B-PATH
in	O
children	O
with	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
were	O
based	O
on	O
reports	O
of	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-PATH
with	O
limited	O
description	O
of	O
asthma	B-PATH
features	O
.	O

Objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
if	O
asthma	B-PATH
characteristics	O
are	O
present	O
in	O
adults	O
with	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-PATH
and	O
/	O
or	O
wheezing	O
,	O
and	O
to	O
examine	O
the	O
relationship	O
between	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-PATH
,	O
wheezing	O
and	O
SCD	O
morbidity	O
.	O

Adults	O
reporting	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-PATH
(	O
N	O
=	O
34	O
)	O
were	O
more	O
likely	O
to	O
have	O
features	O
of	O
asthma	B-PATH
including	O
wheeze	O
,	O
eczema	O
,	O
family	O
history	O
of	O
asthma	B-PATH
,	O
and	O
an	O
elevated	O
IgE	O
level	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
pain	O
or	O
ACS	O
rate	O
,	O
lung	O
function	O
,	O
or	O
risk	O
of	O
death	O
between	O
adults	O
with	O
and	O
without	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-PATH
.	O

In	O
contrast	O
,	O
adults	O
who	O
reported	O
recurrent	O
,	O
severe	O
episodes	O
of	O
wheezing	O
(	O
N	O
=	O
34	O
),	O
regardless	O
of	O
asthma	B-PATH
,	O
had	O
twice	O
the	O
rates	O
of	O
pain	O
and	O
ACS	O
,	O
decreased	O
lung	O
function	O
and	O
increased	O
risk	O
of	O
death	O
compared	O
with	O
adults	O
without	O
recurrent	O
,	O
severe	O
wheezing	O
.	O

Asthma	B-PATH
features	O
were	O
not	O
associated	O
with	O
recurrent	O
,	O
severe	O
wheezing	O
.	O

Our	O
data	O
suggest	O
that	O
wheezing	O
in	O
SCD	O
may	O
occur	O
independently	O
of	O
asthma	B-PATH
and	O
is	O
a	O
marker	O
of	O
disease	O
severity	O
.	O

TITLE	O
:	O
Difficulties	O
with	O
neurological	O
prognostication	O
in	O
a	O
young	O
woman	O
with	O
delayed	O
-	O
onset	O
generalised	O
status	O
myoclonus	O
after	O
cardiac	O
arrest	O
due	O
to	O
acute	O
severe	O
asthma	B-PATH
.	O

The	O
prevalence	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
was	O
3	O
.	O
2	O
%	O
(	O
95	O
%	O
CI	O
:	O
0	O
-	O
6	O
.	O
6	O
)	O
with	O
a	O
1	O
.	O
7	O
%	O
(	O
95	O
%	O
CI	O
:	O
0	O
-	O
3	O
.	O
2	O
)	O
prevalence	O
of	O
H5N1	O
being	O
detected	O
.	O

Moreover	O
,	O
the	O
effect	O
of	O
HC	O
on	O
cell	O
apoptosis	B-PATH
induced	O
by	O
IBV	O
was	O
investigated	O
.	O

TITLE	O
:	O
Lung	O
function	O
and	O
organ	O
dysfunctions	O
in	O
178	O
patients	O
requiring	O
mechanical	O
ventilation	O
during	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
.	O

ABSTRACT	O
:	O
Most	O
cases	O
of	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
are	O
self	O
-	O
limited	O
,	O
but	O
occasionally	O
the	O
disease	O
evolves	O
to	O
a	O
severe	O
condition	O
needing	O
hospitalization	O
.	O

Here	O
we	O
describe	O
the	O
evolution	O
of	O
the	O
respiratory	O
compromise	O
,	O
ventilatory	O
management	O
and	O
laboratory	O
variables	O
of	O
patients	O
with	O
diffuse	O
viral	O
pneumonitis	O
caused	O
by	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
admitted	O
to	O
the	O
ICU	O
.	O

This	O
was	O
a	O
multicenter	O
,	O
prospective	O
inception	O
cohort	O
study	O
including	O
adult	O
patients	O
with	O
acute	O
respiratory	O
failure	O
requiring	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
admitted	O
to	O
20	O
ICUs	O
in	O
Argentina	O
between	O
June	O
and	O
September	O
of	O
2009	O
during	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
prospective	O
inception	O
cohort	O
study	O
including	O
adult	O
patients	O
with	O
acute	O
respiratory	O
failure	O
requiring	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
admitted	O
to	O
20	O
ICUs	O
in	O
Argentina	O
between	O
June	O
and	O
September	O
of	O
2009	O
during	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
.	O

Twenty	O
-	O
nine	O
HCoV	O
-	O
OC43	O
strains	O
from	O
nasopharyngeal	O
aspirates	O
,	O
collected	O
from	O
2004	O
to	O
2011	O
,	O
were	O
subjected	O
to	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
spike	O
,	O
and	O
nucleocapsid	O
gene	O
analysis	O
.	O

The	O
consensus	O
-	O
degenerated	O
hybrid	O
oligonucleotide	O
primer	O
(	O
CODEHOP	O
)	O
strategy	O
was	O
modified	O
to	O
design	O
primers	O
targeting	O
the	O
most	O
conserved	O
motifs	O
in	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
locus	O
.	O

Seven	O
thousand	O
eight	O
hundred	O
and	O
fifty	O
-	O
three	O
nasopharyngeal	O
samples	O
from	O
7220	O
patients	O
(	O
age	O
range	O
0	O
-	O
98	O
y	O
,	O
median	O
22	O
y	O
)	O
obtained	O
during	O
36	O
consecutive	O
months	O
(	O
November	O
2006	O
-	O
October	O
2009	O
),	O
were	O
analyzed	O
with	O
a	O
multiplex	O
PCR	O
panel	O
including	O
influenza	B-PATH
A	I-PATH
(	O
IfA	O
)	O
and	O
B	O
(	O
IfB	O
)	O
virus	O
,	O
parainfluenza	O
virus	O
(	O
PIV	O
)	O
1	O
-	O
3	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
human	O
coronavirus	O
(	O
CoV	O
)	O
OC43	O
,	O
NL63	O
,	O
and	O
229E	O
,	O
human	O
metapneumovirus	O
(	O
HMPV	O
),	O
adenovirus	O
(	O
AdV	O
),	O
enterovirus	O
(	O
EV	O
),	O
and	O
2	O
bacteria	O
--	O
Mycoplasma	O
pneumoniae	O
and	O
Chlamydophila	O
pneumoniae	O
.	O

ABSTRACT	O
:	O
Caspase	O
-	O
8	O
(	O
casp8	O
)	O
is	O
required	O
for	O
extrinsic	O
apoptosis	B-PATH
,	O
and	O
mice	O
deficient	O
in	O
casp8	O
fail	O
to	O
develop	O
and	O
die	O
in	O
utero	O
while	O
ultimately	O
failing	O
to	O
maintain	O
the	O
proliferation	O
of	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
a	O
host	O
of	O
other	O
cell	O
types	O
.	O

Two	O
primer	O
sets	O
were	O
used	O
for	O
the	O
detection	O
of	O
BtCoV	O
:	O
one	O
was	O
for	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
region	O
and	O
the	O
other	O
was	O
for	O
the	O
spike	O
(	O
S	O
)	O
protein	O
region	O
.	O

Such	O
increased	O
ammonia	O
levels	O
are	O
suggested	O
to	O
alter	O
neurotransmission	O
signals	O
and	O
impair	O
cerebral	O
energy	B-PATH
metabolism	I-PATH
due	O
to	O
mitochondrial	O
dysfunctions	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
role	O
of	O
cerebral	O
electron	O
transport	O
chain	O
complexes	O
,	O
including	O
complex	O
I	O
,	O
II	O
,	O
III	O
IV	O
,	O
and	O
pyruvate	B-PATH
dehydrogenase	I-PATH
in	O
the	O
non	O
-	O
synaptic	O
mitochondria	O
isolated	O
from	O
the	O
cortex	O
of	O
the	O
thioacetamide	O
-	O
induced	O
FHF	O
rats	O
.	O

Further	O
the	O
activity	O
of	O
pyruvate	B-PATH
dehydrogenase	I-PATH
at	O
18	O
and	O
24	O
h	O
after	O
the	O
induction	O
of	O
FHF	O
was	O
inhibited	O
by	O
29	O
and	O
43	O
%,	O
respectively	O
.	O

HRSV	O
and	O
influenza	B-PATH
A	I-PATH
were	O
consistently	O
one	O
of	O
the	O
greatest	O
causes	O
of	O
disease	O
regardless	O
of	O
sampled	O
population	O
.	O

In	O
fact	O
,	O
EFL	O
(	O
T	O
)	O
occurs	O
commonly	O
in	O
COPD	O
patients	O
(	O
mainly	O
in	O
Global	O
Initiative	O
for	O
Chronic	O
Obstructive	O
Lung	O
Disease	O
III	O
and	O
IV	O
stage	O
),	O
in	O
whom	O
the	O
latter	O
symptoms	O
are	O
common	O
,	O
but	O
is	O
not	O
exclusive	O
to	O
COPD	O
,	O
since	O
it	O
can	O
also	O
be	O
detected	O
in	O
other	O
pulmonary	O
and	O
nonpulmonary	O
diseases	O
like	O
asthma	B-PATH
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
heart	O
failure	O
and	O
obesity	O
,	O
etc	O
.	O

TITLE	O
:	O
Drastic	O
changes	O
in	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
secreted	O
phospholipases	B-PATH
A2	O
in	O
chicken	O
pulmonary	O
disease	O
.	O

Because	O
secreted	O
phospholipases	B-PATH
A2	O
(	O
sPLA2	O
)	O
are	O
involved	O
in	O
inflammatory	O
processes	O
,	O
the	O
gene	O
expressions	O
of	O
sPLA2s	O
were	O
investigated	O
in	O
both	O
healthy	O
chickens	O
and	O
chickens	O
with	O
infectious	O
bronchitis	O
and	O
lung	O
inflammation	O
.	O

Quantitation	O
by	O
qPCR	O
of	O
the	O
transcript	O
levels	O
of	O
ChPLA2	O
-	O
IB	O
,	O
-	O
IIA	O
,	O
-	O
IIE	O
,	O
-	O
V	O
and	O
-	O
X	O
in	O
several	O
tissues	O
from	O
healthy	O
chicken	O
indicated	O
that	O
the	O
expression	O
patterns	O
and	O
mRNA	O
levels	O
diverged	O
among	O
the	O
phospholipases	B-PATH
tested	O
.	O

Additionally	O
,	O
postnatal	O
ETS	O
exposure	O
causes	O
acute	O
respiratory	O
infections	O
,	O
ear	O
problems	O
,	O
respiratory	O
symptoms	O
,	O
more	O
severe	O
asthma	B-PATH
,	O
and	O
it	O
slows	O
lung	O
growth	O
.	O

TITLE	O
:	O
Coronavirus	O
infection	O
induces	O
DNA	B-PATH
replication	I-PATH
stress	O
partly	O
through	O
interaction	O
of	O
its	O
nonstructural	O
protein	O
13	O
with	O
the	O
p125	O
subunit	O
of	O
DNA	O
polymerase	O
Î´	O
.	O

IBV	O
infection	O
was	O
shown	O
to	O
induce	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
both	O
S	O
and	O
G	O
(	O
2	O
)/	O
M	O
phases	O
for	O
the	O
enhancement	O
of	O
viral	O
replication	O
and	O
progeny	O
production	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
activation	O
of	O
cellular	O
DNA	B-PATH
damage	I-PATH
response	I-PATH
is	O
one	O
of	O
the	O
mechanisms	O
exploited	O
by	O
Coronavirus	O
to	O
induce	O
cell	B-PATH
cycle	I-PATH
arrest	O
.	O

An	O
ATR	O
-	O
dependent	O
cellular	O
DNA	B-PATH
damage	I-PATH
response	I-PATH
was	O
shown	O
to	O
be	O
activated	O
by	O
IBV	O
infection	O
.	O

Furthermore	O
,	O
yeast	O
two	O
-	O
hybrid	O
screens	O
and	O
subsequent	O
biochemical	O
and	O
functional	O
studies	O
demonstrated	O
that	O
interaction	O
between	O
Coronavirus	O
nsp13	O
and	O
DNA	O
polymerase	O
Î´	O
induced	O
DNA	B-PATH
replication	I-PATH
stress	O
in	O
IBV	O
-	O
infected	O
cells	O
.	O

We	O
included	O
patients	O
with	O
severe	O
acute	O
respiratory	O
infection	O
in	O
whom	O
a	O
nasopharyngeal	O
swab	O
was	O
positive	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
for	O
2009	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
virus	O
and	O
negative	O
for	O
seasonal	O
influenza	B-PATH
A	I-PATH
H1	O
and	O
H3	O
.	O

From	O
26	O
April	O
2009	O
to	O
11	O
January	O
2010	O
,	O
confirmed	O
cases	O
of	O
pandemic	O
2009	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
reached	O
806	O
.	O

The	O
2009	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
outbreak	O
affected	O
mainly	O
the	O
pediatric	O
population	O
,	O
had	O
a	O
low	O
case	O
fatality	O
rate	O
,	O
and	O
was	O
the	O
predominant	O
virus	O
circulating	O
in	O
Panama	O
during	O
the	O
2009	O
/	O
2010	O
flu	O
season	O
.	O

RESULTS	O
:	O
From	O
26	O
April	O
2009	O
to	O
11	O
January	O
2010	O
,	O
confirmed	O
cases	O
of	O
pandemic	O
2009	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
reached	O
806	O
.	O

CS	O
have	O
proven	O
beneficial	O
roles	O
in	O
the	O
treatment	O
of	O
asthma	B-PATH
,	O
croup	O
,	O
allergic	O
bronchopulmonary	O
aspergillosis	O
,	O
and	O
subglottic	O
hemangioma	O
.	O

In	O
other	O
conditions	O
,	O
such	O
as	O
tuberculosis	B-PATH
,	O
interstitial	O
lung	O
disease	O
,	O
acute	O
lung	O
aspiration	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
CS	O
are	O
often	O
used	O
empirically	O
despite	O
the	O
lack	O
of	O
clear	O
evidence	O
of	O
their	O
benefit	O
.	O

New	O
drug	O
regimens	O
,	O
including	O
the	O
more	O
flexible	O
use	O
of	O
inhaled	O
corticosteroids	O
and	O
long	O
-	O
acting	O
Î²	O
-	O
agonists	O
in	O
asthma	B-PATH
,	O
the	O
lack	O
of	O
efficacy	O
of	O
oral	O
corticosteroids	O
in	O
preschool	O
children	O
with	O
acute	O
wheeze	O
,	O
the	O
severe	O
complications	O
of	O
systemic	O
dexamethasone	O
used	O
to	O
prevent	O
bronchopulmonary	O
dysplasia	O
and	O
thus	O
more	O
restricted	O
use	O
,	O
and	O
the	O
beneficial	O
effect	O
of	O
pulse	O
high	O
-	O
dose	O
intravenous	O
methylprednisolone	O
in	O
patients	O
with	O
allergic	O
bronchopulmonary	O
aspergillosis	O
or	O
cystic	O
fibrosis	O
are	O
among	O
the	O
major	O
recent	O
developments	O
.	O

TITLE	O
:	O
2	O
,	O
6	O
-	O
Bis	O
-	O
arylmethyloxy	O
-	O
5	O
-	O
hydroxychromones	O
with	O
antiviral	O
activity	O
against	O
both	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
and	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCV	O
).	O

TITLE	O
:	O
Distinguishing	O
characteristics	O
between	O
pandemic	O
2009	O
-	O
2010	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
other	O
viruses	O
in	O
patients	O
hospitalized	O
with	O
respiratory	O
illness	O
.	O

ABSTRACT	O
:	O
Differences	O
in	O
clinical	O
presentation	O
and	O
outcomes	O
among	O
patients	O
infected	O
with	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
H1N1	O
(	O
pH1N1	O
)	O
compared	O
to	O
other	O
respiratory	O
viruses	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

No	O
seasonal	O
influenza	B-PATH
A	I-PATH
or	O
B	O
was	O
detected	O
.	O

During	O
the	O
peak	O
pandemic	O
2009	O
-	O
2010	O
influenza	O
season	O
in	O
Rhode	O
Island	O
,	O
nearly	O
half	O
of	O
patients	O
admitted	O
with	O
influenza	O
-	O
like	O
symptoms	O
had	O
respiratory	O
viruses	O
other	O
than	O
influenza	B-PATH
A	I-PATH
.	O
A	O
high	O
proportion	O
of	O
patients	O
were	O
treated	O
with	O
antibiotics	O
and	O
pH1N1	O
infection	O
had	O
higher	O
mortality	O
compared	O
to	O
other	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Referral	O
to	O
an	O
extracorporeal	O
membrane	O
oxygenation	O
center	O
and	O
mortality	O
among	O
patients	O
with	O
severe	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

ECMO	O
was	O
used	O
to	O
treat	O
patients	O
with	O
ARDS	O
during	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
NL	O
-	O
63	O
infection	O
in	O
a	O
Brazilian	O
patient	O
suspected	O
of	O
H1N1	O
2009	O
influenza	B-PATH
infection	I-PATH
:	O
description	O
of	O
a	O
fatal	O
case	O
.	O

Among	O
viruses	O
detectable	O
by	O
both	O
commercial	O
assays	O
(	O
adenovirus	O
,	O
human	O
metapneumovirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
influenza	O
B	O
virus	O
,	O
parainfluenza	O
viruses	O
1	O
to	O
3	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
),	O
the	O
FilmArray	O
and	O
Prodesse	O
assays	O
showed	O
good	O
overall	O
agreement	O
(	O
181	O
/	O
192	O
[	O
94	O
.	O
3	O
%];	O
kappa	O
=	O
0	O
.	O
87	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
79	O
to	O
0	O
.	O
94	O
).	O

The	O
FDA	O
-	O
cleared	O
version	O
includes	O
the	O
following	O
targets	O
:	O
adenovirus	O
,	O
coronaviruses	O
HKU1	O
and	O
NL63	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
to	O
type	O
level	O
only	O
),	O
influenza	B-PATH
A	I-PATH
H1	O
seasonal	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
H3	O
seasonal	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
H1	O
-	O
2009	O
,	O
influenza	O
B	O
virus	O
,	O
parainfluenza	O
viruses	O
1	O
to	O
4	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
and	O
RV	O
/	O
EV	O
(	O
no	O
differentiation	O
).	O

TITLE	O
:	O
Guillain	O
-	O
BarrÃ©	O
syndrome	O
associated	O
with	O
the	O
D222E	O
variant	O
of	O
the	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

However	O
,	O
GBS	O
has	O
rarely	O
reported	O
to	O
be	O
a	O
neurological	O
complication	O
of	O
the	O
recent	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
virus	O
infections	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	O
regulates	O
cell	O
stress	B-PATH
response	I-PATH
and	O
apoptosis	B-PATH
.	O

Twenty	O
-	O
five	O
stress	B-PATH
response	I-PATH
genes	O
were	O
preferentially	O
upregulated	O
during	O
infection	O
in	O
the	O
absence	O
of	O
the	O
E	O
gene	O
.	O

In	O
addition	O
,	O
genes	O
involved	O
in	O
signal	O
transduction	O
,	O
transcription	O
,	O
cell	O
metabolism	O
,	O
immunoregulation	O
,	O
inflammation	O
,	O
apoptosis	B-PATH
and	O
cell	B-PATH
cycle	I-PATH
and	O
differentiation	O
were	O
differentially	O
regulated	O
in	O
cells	O
infected	O
with	O
rSARS	O
-	O
CoV	O
with	O
or	O
without	O
the	O
E	O
gene	O
.	O

Overall	O
,	O
the	O
activation	O
of	O
the	O
IRE	O
-	O
1	O
pathway	O
was	O
not	O
able	O
to	O
restore	O
cell	O
homeostasis	O
,	O
and	O
apoptosis	B-PATH
was	O
induced	O
probably	O
as	O
a	O
measure	O
to	O
protect	O
the	O
host	O
by	O
limiting	O
virus	O
production	O
and	O
dissemination	O
.	O

Fourteen	O
patients	O
had	O
active	O
chronic	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
(	O
cGvHD	O
)	O
at	O
the	O
time	O
of	O
vaccination	O
/	O
infection	O
and	O
seven	O
patients	O
had	O
cGvHD	O
in	O
remission	O
;	O
11	O
patients	O
had	O
no	O
immunosuppressive	O
therapy	O
,	O
and	O
27	O
patients	O
were	O
on	O
immunosuppressive	O
therapy	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
coronavirus	O
nsp7	O
+	O
nsp8	O
complex	O
is	O
a	O
unique	O
multimeric	O
RNA	B-PATH
polymerase	I-PATH
capable	O
of	O
both	O
de	O
novo	O
initiation	O
and	O
primer	O
extension	O
.	O

ABSTRACT	O
:	O
Uniquely	O
among	O
RNA	O
viruses	O
,	O
replication	O
of	O
the	O
~	O
30	O
-	O
kb	O
SARS	O
-	O
coronavirus	O
genome	O
is	O
believed	O
to	O
involve	O
two	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
activities	O
.	O

To	O
observe	O
the	O
clinical	O
manifestations	O
of	O
the	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
the	O
epidemic	O
waves	O
of	O
hospitalized	O
children	O
for	O
a	O
period	O
of	O
one	O
year	O
.	O

The	O
correct	O
provisional	O
diagnosis	O
of	O
pandemic	O
influenza	B-PATH
infection	I-PATH
are	O
39	O
.	O
5	O
%,	O
the	O
other	O
initial	O
diagnosis	O
are	O
pneumonia	O
,	O
bronchiolitis	O
,	O
tonsillitis	O
,	O
encephalitis	O
,	O
and	O
dengue	O
infection	O
.	O

Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
the	O
antiviral	O
activity	O
of	O
three	O
new	O
classes	O
of	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
inhibitors	O
.	O

Inhibition	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
replication	O
.	O

Conditions	O
such	O
as	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
toxoplasmosis	B-PATH
are	O
of	O
global	O
significance	O
.	O

Some	O
,	O
such	O
as	O
FIP	O
,	O
are	O
more	O
common	O
in	O
pedigree	O
households	O
,	O
whereas	O
others	O
such	O
as	O
toxoplasmosis	B-PATH
,	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
)	O
or	O
feline	O
leukaemia	O
virus	O
(	O
FeLV	O
)	O
infections	O
,	O
are	O
more	O
likely	O
to	O
affect	O
a	O
single	O
cat	O
with	O
an	O
outdoor	O
lifestyle	O
.	O

This	O
likely	O
stems	O
from	O
the	O
ability	O
of	O
Staphylococcal	O
enterotoxins	O
to	O
elicit	O
powerful	O
episodes	O
of	O
T	O
cell	O
stimulation	O
resulting	O
in	O
release	B-PATH
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

The	O
mortality	O
rate	O
for	O
patients	O
with	O
severe	O
malaria	B-PATH
lies	O
around	O
10	O
%.	O

Malaria	B-PATH
must	O
be	O
given	O
priority	O
in	O
the	O
differential	O
diagnosis	O
of	O
travelers	O
returning	O
febrile	O
from	O
endemic	O
areas	O
.	O

Treatment	O
requires	O
prompt	O
administration	O
of	O
safe	O
and	O
fast	O
-	O
acting	O
antimalarials	O
,	O
which	O
in	O
severe	O
malaria	B-PATH
is	O
treatment	O
with	O
quinine	O
or	O
artesunate	O
.	O

Hospitals	O
must	O
be	O
prepared	O
to	O
diagnose	O
and	O
treat	O
malaria	B-PATH
patients	O
-	O
or	O
have	O
a	O
standard	O
operating	O
procedure	O
for	O
transferring	O
the	O
patient	O
to	O
a	O
specialized	O
center	O
.	O

The	O
clinical	O
course	O
of	O
severe	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
-	O
infection	O
is	O
markedly	O
different	O
from	O
the	O
disease	O
pattern	O
seen	O
during	O
epidemics	O
of	O
seasonal	O
influenza	O
.	O

TITLE	O
:	O
Involvement	O
of	O
FOXO	O
transcription	O
factors	O
,	O
TRAIL	O
-	O
FasL	O
/	O
Fas	O
,	O
and	O
sirtuin	O
proteins	O
family	O
in	O
canine	O
coronavirus	O
type	O
II	O
-	O
induced	O
apoptosis	B-PATH
.	O

In	O
addition	O
,	O
CCoV	O
-	O
II	O
induces	O
a	O
remarkable	O
increase	O
in	O
the	O
expression	O
of	O
TNF	O
-	O
related	O
apoptosis	B-PATH
-	O
inducing	O
ligand	O
(	O
TRAIL	O
),	O
while	O
we	O
observed	O
a	O
slight	O
up	O
-	O
regulation	O
of	O
FasL	O
/	O
Fas	O
at	O
36	O
p	O
.	O
i	O
.	O

These	O
data	O
suggest	O
that	O
FOXO	O
transcription	O
factors	O
mediate	O
pro	O
-	O
apoptotic	O
effects	O
of	O
CCoV	O
-	O
II	O
,	O
in	O
part	O
due	O
to	O
activation	O
of	O
extrinsic	O
apoptosis	B-PATH
pathway	O
,	O
while	O
some	O
Sirtuin	O
family	O
members	O
(	O
such	O
as	O
SIRT3	O
and	O
SIRT4	O
)	O
may	O
be	O
involved	O
in	O
intrinsic	O
apoptotic	O
pathway	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
and	O
nonstructural	O
proteins	O
2	O
,	O
3	O
,	O
and	O
8	O
are	O
incorporated	O
into	O
viral	O
particles	O
.	O

ABSTRACT	O
:	O
Pandemic	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
arrived	O
at	O
Isfahan	O
in	O
August	O
2009	O
.	O

We	O
evaluated	O
the	O
thoracic	O
CT	O
findings	O
in	O
patients	O
with	O
2009	O
H1N1	O
virus	O
infection	O
to	O
describe	O
findings	O
compared	O
to	O
previously	O
reported	O
findings	O
,	O
and	O
to	O
suggest	O
patterns	O
that	O
may	O
be	O
suggestive	O
for	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
an	O
appropriate	O
clinical	O
setting	O
.	O

Out	O
of	O
216	O
patients	O
with	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
,	O
26	O
cases	O
with	O
abnormal	O
CT	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

While	O
these	O
findings	O
can	O
be	O
associated	O
with	O
other	O
infections	O
;	O
they	O
may	O
be	O
suggestive	O
to	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
the	O
appropriate	O
clinical	O
setting	O
.	O

The	O
overall	O
distribution	O
of	O
positive	O
results	O
was	O
influenza	B-PATH
A	I-PATH
42	O
.	O
0	O
%,	O
influenza	O
B	O
38	O
.	O
7	O
%,	O
adenovirus	O
1	O
.	O
5	O
%,	O
bocavirus	O
0	O
.	O
5	O
%,	O
coronavirus	O
3	O
.	O
3	O
%,	O
enterovirus	O
5	O
.	O
6	O
%,	O
metapneumovirus	O
1	O
.	O
0	O
%,	O
parainfluenza	O
virus	O
0	O
.	O
8	O
%,	O
rhinovirus	O
4	O
.	O
1	O
%,	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
2	O
.	O
5	O
%.	O

MassTag	O
polymerase	O
chain	O
reaction	O
for	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
groups	O
A	O
and	O
B	O
,	O
human	O
coronavirus	O
-	O
229E	O
and	O
human	O
coronavirus	O
-	O
OC43	O
,	O
human	O
metapneumovirus	O
,	O
enterovirus	O
,	O
human	O
parainfluenza	O
viruses	O
2	O
,	O
3	O
,	O
and	O
4a	O
,	O
human	O
adenovirus	O
,	O
Haemophilus	O
influenzae	O
,	O
Neisseria	O
meningitidis	O
,	O
Streptococcus	O
pneumoniae	O
,	O
Legionella	O
pneumonia	O
,	O
and	O
Mycoplasma	O
pneumonia	O
was	O
done	O
on	O
respiratory	O
specimens	O
.	O

TITLE	O
:	O
Novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
-	O
induced	O
hemophagocytosis	O
:	O
first	O
case	O
reported	O
in	O
Saudi	O
Arabia	O
.	O

ABSTRACT	O
:	O
H1N1	O
is	O
a	O
novel	O
subtype	O
of	O
the	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

The	O
pathophysiology	O
of	O
MAS	O
is	O
multifactorial	O
and	O
includes	O
acute	O
airway	O
obstruction	O
,	O
surfactant	O
dysfunction	O
or	O
inactivation	O
,	O
chemical	O
pneumonitis	O
with	O
release	B-PATH
of	O
vasoconstrictive	O
and	O
inflammatory	O
mediators	O
,	O
and	O
persistent	O
pulmonary	O
hypertension	O
of	O
newborn	O
(	O
PPHN	O
).	O

Experiments	O
using	O
dicistronic	O
mRNAs	O
carrying	O
different	O
IRESes	O
showed	O
that	O
nsp1	O
induced	O
endonucleolytic	O
RNA	O
cleavage	O
within	O
the	O
ribosome	B-PATH
loading	O
region	O
of	O
type	O
I	O
and	O
type	O
II	O
picornavirus	O
IRES	O
elements	O
,	O
but	O
not	O
that	O
of	O
classical	O
swine	O
fever	O
virus	O
IRES	O
,	O
which	O
is	O
characterized	O
as	O
a	O
hepatitis	B-PATH
C	I-PATH
virus	O
-	O
like	O
IRES	O
.	O

The	O
sample	O
of	O
throat	O
and	O
pharyngeal	O
swab	O
were	O
collected	O
from	O
each	O
patient	O
.	O
11	O
types	O
of	O
virus	O
including	O
influenza	B-PATH
A	I-PATH
(	O
FluA	O
),	O
influenza	O
B	O
(	O
FluB	O
),	O
adenovirus	O
(	O
ADV	O
),	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
virus	O
type	O
1	O
,	O
type	O
2	O
,	O
type	O
3	O
(	O
HPIV1	O
,	O
HPIV2	O
,	O
HPIV3	O
),	O
human	O
metapneumovirus	O
(	O
MPV	O
)	O
and	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
type	O
229E	O
,	O
type	O
OC43	O
were	O
detected	O
by	O
Fluorescence	O
Quota	O
PCR	O
method	O
.	O

ABSTRACT	O
:	O
Positive	O
-	O
sense	O
RNA	O
((+)	O
RNA	O
)	O
viruses	O
such	O
as	O
hepatitis	B-PATH
C	I-PATH
virus	O
exploit	O
host	O
cells	O
by	O
subverting	O
host	O
proteins	O
,	O
remodelling	O
subcellular	O
membranes	O
,	O
co	O
-	O
opting	O
and	O
modulating	O
protein	O
and	O
ribonucleoprotein	O
complexes	O
,	O
and	O
altering	O
cellular	O
metabolic	B-PATH
pathways	I-PATH
during	O
infection	O
.	O

From	O
a	O
compendium	O
of	O
12	O
studies	O
that	O
included	O
responses	O
to	O
influenza	B-PATH
A	I-PATH
subtype	O
H5N1	O
,	O
reconstructed	O
1918	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
and	O
SARS	O
coronavirus	O
,	O
we	O
used	O
meta	O
-	O
analysis	O
to	O
derive	O
multiple	O
gene	O
expression	O
signatures	O
.	O

RESULTS	O
:	O
From	O
a	O
compendium	O
of	O
12	O
studies	O
that	O
included	O
responses	O
to	O
influenza	B-PATH
A	I-PATH
subtype	O
H5N1	O
,	O
reconstructed	O
1918	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
and	O
SARS	O
coronavirus	O
,	O
we	O
used	O
meta	O
-	O
analysis	O
to	O
derive	O
multiple	O
gene	O
expression	O
signatures	O
.	O

TITLE	O
:	O
The	O
prevalance	O
of	O
respiratory	O
viruses	O
among	O
healthcare	O
workers	O
serving	O
pilgrims	O
in	O
Makkah	O
during	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
different	O
respiratory	O
viruses	O
among	O
healthcare	O
workers	O
who	O
treated	O
pilgrims	O
during	O
Hajj	O
2009	O
,	O
the	O
year	O
of	O
the	O
influenza	B-PATH
A	I-PATH
H1N1	O
pandemic	O
.	O

Before	O
the	O
Hajj	O
,	O
rates	O
of	O
seasonal	O
influenza	O
vaccination	O
were	O
higher	O
(	O
51	O
%)	O
than	O
rates	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
H1N1	O
vaccination	O
(	O
22	O
%).	O

Influenza	B-PATH
A	I-PATH
(	O
including	O
H1N1	O
),	O
influenza	O
B	O
.	O
respiratory	O
syncytial	O
virus	O
,	O
other	O
coronaviruses	O
,	O
parainfluenza	O
viruses	O
,	O
human	O
metapneumovirus	O
,	O
adenovirus	O
,	O
and	O
human	O
bocavirus	O
were	O
not	O
detected	O
.	O

None	O
of	O
the	O
participants	O
had	O
influenza	B-PATH
A	I-PATH
H1N1	O
2009	O
,	O
possibly	O
because	O
it	O
was	O
also	O
infrequent	O
among	O
the	O
2009	O
pilgrims	O
.	O

The	O
application	O
of	O
new	O
methods	O
and	O
strategies	O
such	O
as	O
dendritic	O
cell	O
targeting	O
in	O
cancer	O
therapy	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
tuberculosis	B-PATH
,	O
human	O
immune	O
deficiency	O
virus	O
,	O
and	O
malaria	B-PATH
might	O
play	O
an	O
important	O
role	O
.	O

Nevertheless	O
,	O
the	O
absence	O
of	O
CNS	O
CD4	O
T	O
cells	O
was	O
associated	O
with	O
reduced	O
gamma	O
interferon	O
(	O
IFN	O
-	O
Î³	O
)	O
and	O
granzyme	O
B	O
expression	O
by	O
infiltrating	O
CD8	O
T	O
cells	O
,	O
increased	O
CD8	O
T	O
cell	O
apoptosis	B-PATH
,	O
and	O
impaired	O
control	O
of	O
infectious	O
virus	O
.	O

TITLE	O
:	O
Development	O
of	O
common	O
variable	O
immunodeficiency	O
in	O
IgA	O
-	O
and	O
IgG2	O
-	O
deficient	O
patients	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
.	O

There	O
have	O
been	O
few	O
reports	O
on	O
children	O
who	O
developed	O
common	O
variable	O
immunodeficiency	O
(	O
CVID	O
)	O
in	O
association	O
with	O
immunoglobulin	O
A	O
(	O
IgA	O
)	O
and	O
IgG2	O
deficiencies	O
and	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
(	O
SLE	O
).	O

Our	O
patient	O
experienced	O
nephrotic	O
syndrome	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
virus	O
infection	O
at	O
5	O
years	O
of	O
age	O
.	O

The	O
differentiation	O
of	O
leukemic	O
blasts	O
and	O
promyelocytes	O
induced	O
by	O
ATRA	O
and	O
/	O
or	O
ATO	O
may	O
lead	O
to	O
cellular	O
migration	O
,	O
endothelial	O
activation	O
,	O
and	O
release	B-PATH
of	O
interleukins	O
and	O
vascular	O
factors	O
responsible	O
of	O
tissue	O
damage	O
.	O

TITLE	O
:	O
Understanding	O
the	O
clinical	O
spectrum	O
of	O
complicated	O
Plasmodium	O
vivax	O
malaria	B-PATH
:	O
a	O
systematic	O
review	O
on	O
the	O
contributions	O
of	O
the	O
Brazilian	O
literature	O
.	O

It	O
is	O
the	O
most	O
geographically	O
widespread	O
parasite	O
causing	O
human	O
malaria	B-PATH
,	O
with	O
around	O
2	O
.	O
85	O
billion	O
people	O
living	O
under	O
risk	O
of	O
infection	O
.	O

The	O
Brazilian	O
Amazon	O
region	O
reports	O
more	O
than	O
50	O
%	O
of	O
the	O
malaria	B-PATH
cases	O
in	O
Latin	O
America	O
and	O
since	O
1990	O
there	O
is	O
a	O
marked	O
predominance	O
of	O
this	O
species	O
,	O
responsible	O
for	O
85	O
%	O
of	O
cases	O
in	O
2009	O
.	O

A	O
systematic	O
review	O
of	O
the	O
Brazilian	O
indexed	O
and	O
non	O
-	O
indexed	O
literature	O
on	O
complicated	O
cases	O
of	O
vivax	O
malaria	B-PATH
was	O
performed	O
including	O
published	O
articles	O
,	O
masters	O
'	O
dissertations	O
,	O
doctoral	O
theses	O
and	O
national	O
congresses	O
'	O
abstracts	O
.	O

Clinical	O
atypical	O
cases	O
of	O
malaria	B-PATH
are	O
more	O
frequent	O
than	O
published	O
in	O
the	O
indexed	O
literature	O
,	O
probably	O
due	O
to	O
a	O
publication	O
bias	O
.	O

TITLE	O
:	O
[	O
Recommendations	O
of	O
the	O
Infectious	O
Diseases	O
Work	O
Group	O
(	O
GTEI	O
)	O
of	O
the	O
Spanish	O
Society	O
of	O
Intensive	O
and	O
Critical	O
Care	O
Medicine	O
and	O
Coronary	O
Units	O
(	O
SEMICYUC	O
)	O
and	O
the	O
Infections	O
in	O
Critically	O
Ill	O
Patients	O
Study	O
Group	O
(	O
GEIPC	O
)	O
of	O
the	O
Spanish	O
Society	O
of	O
Infectious	O
Diseases	O
and	O
Clinical	O
Microbiology	O
(	O
SEIMC	O
)	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
in	O
seriously	O
ill	O
adults	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
].	O

Patients	O
with	O
a	O
high	O
suspicion	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
must	O
continue	O
with	O
antiviral	O
treatment	O
,	O
regardless	O
of	O
the	O
negative	O
results	O
of	O
initial	O
tests	O
,	O
unless	O
an	O
alternative	O
diagnosis	O
can	O
be	O
established	O
or	O
clinical	O
criteria	O
suggest	O
a	O
low	O
probability	O
of	O
influenza	O
.	O

Although	O
the	O
use	O
of	O
moderate	O
-	O
or	O
low	O
-	O
dose	O
corticosteroids	O
has	O
been	O
proposed	O
for	O
the	O
treatment	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pneumonia	O
,	O
the	O
existing	O
scientific	O
evidence	O
is	O
not	O
sufficient	O
to	O
recommend	O
the	O
use	O
of	O
corticosteroids	O
in	O
these	O
patients	O
.	O

Extracorporeal	O
membrane	O
oxygenation	O
is	O
a	O
rescue	O
technique	O
in	O
refractory	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
.	O

The	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
)	O
through	O
Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)-	O
generated	O
Angiotensin	O
II	O
contributes	O
to	O
lung	O
injury	O
.	O

TITLE	O
:	O
Case	O
report	O
:	O
Increased	O
viral	O
receptor	O
expression	O
associated	O
with	O
high	O
viral	O
load	O
and	O
severe	O
pneumonia	O
in	O
a	O
young	O
patient	O
infected	O
with	O
2009	O
H1N1	O
influenza	B-PATH
a	I-PATH
with	O
no	O
pre	O
-	O
existing	O
conditions	O
.	O

Almost	O
all	O
virus	O
particles	O
in	O
the	O
cytoplasm	O
of	O
satellite	O
cells	O
were	O
contained	O
in	O
groups	O
within	O
vesicles	O
and	O
lysosome	B-PATH
-	O
like	O
structures	O
,	O
suggesting	O
that	O
these	O
glial	O
cells	O
may	O
restrict	O
the	O
local	O
diffusion	O
of	O
HEV	O
.	O

ABSTRACT	O
:	O
The	O
pandemic	O
of	O
the	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
S	O
-	O
OIV	O
)	O
in	O
2009	O
demonstrated	O
severe	O
viral	O
pneumonia	O
followed	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Up	O
-	O
regulation	O
of	O
Mcl	O
-	O
1	O
and	O
Bak	O
by	O
coronavirus	O
infection	O
of	O
human	O
,	O
avian	O
and	O
animal	O
cells	O
modulates	O
apoptosis	B-PATH
and	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
Virus	O
-	O
induced	O
apoptosis	B-PATH
and	O
viral	O
mechanisms	O
that	O
regulate	O
this	O
cell	O
death	O
program	O
are	O
key	O
issues	O
in	O
understanding	O
virus	O
-	O
host	O
interactions	O
and	O
viral	O
pathogenesis	O
.	O

Like	O
many	O
other	O
human	O
and	O
animal	O
viruses	O
,	O
coronavirus	O
infection	O
of	O
mammalian	O
cells	O
induces	O
apoptosis	B-PATH
.	O

IBV	O
progeny	O
production	O
and	O
release	B-PATH
were	O
increased	O
in	O
infected	O
Mcl	O
-	O
1	O
knockdown	O
cells	O
compared	O
to	O
similarly	O
infected	O
control	O
cells	O
,	O
while	O
the	O
contrary	O
was	O
observed	O
in	O
infected	O
Bak	O
knockdown	O
cells	O
.	O

Inhibition	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
/	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
MEK	O
/	O
ERK	O
)	O
and	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
/	O
Akt	O
)	O
signaling	O
pathways	O
by	O
chemical	O
inhibitors	O
and	O
knockdown	O
of	O
GADD153	O
by	O
siRNA	O
demonstrated	O
the	O
involvement	O
of	O
ER	O
-	O
stress	B-PATH
response	I-PATH
in	O
regulation	O
of	O
IBV	O
-	O
induced	O
Mcl	O
-	O
1	O
expression	O
.	O

These	O
results	O
illustrate	O
the	O
sophisticated	O
regulatory	O
strategies	O
evolved	O
by	O
a	O
coronavirus	O
to	O
modulate	O
both	O
virus	O
-	O
induced	O
apoptosis	B-PATH
and	O
viral	O
replication	O
during	O
its	O
replication	O
cycle	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
with	O
miliary	O
tuberculosis	B-PATH
.	O

Based	O
upon	O
the	O
clinical	O
suspicion	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
miliary	O
tuberculosis	B-PATH
(	O
TB	O
),	O
empiric	O
treatment	O
with	O
antituberculosis	O
and	O
systemic	O
steroids	O
was	O
started	O
.	O

There	O
is	O
clear	O
overlap	O
between	O
the	O
pathogenesis	O
of	O
CRS	O
and	O
asthma	B-PATH
.	O

Infections	O
with	O
respiratory	O
viruses	O
in	O
childhood	O
increase	O
the	O
risk	O
of	O
subsequently	O
developing	O
asthma	B-PATH
.	O

PCR	O
was	O
used	O
to	O
look	O
for	O
common	O
respiratory	O
viruses	O
(	O
parainfluenza	O
1	O
,	O
2	O
,	O
and	O
3	O
;	O
respiratory	O
syncytial	O
virus	O
[	O
RSV	O
];	O
human	O
metapneumovirus	O
[	O
hMPV	O
];	O
adenovirus	O
[	O
ADV	O
];	O
rhinovirus	O
;	O
coronavirus	O
;	O
bocavirus	O
[	O
BoV	O
];	O
cytomegalovirus	O
[	O
CMV	O
];	O
and	O
influenza	B-PATH
A	I-PATH
and	O
B	O
).	O

TITLE	O
:	O
A	O
study	O
on	O
pulmonary	O
manifestations	O
in	O
patients	O
with	O
malaria	B-PATH
from	O
northwestern	O
India	O
(	O
Bikaner	O
).	O

ABSTRACT	O
:	O
Plasmodium	O
falciparum	O
(	O
Pf	O
)	O
and	O
Plasmodium	O
vivax	O
(	O
Pv	O
)	O
are	O
responsible	O
for	O
most	O
of	O
the	O
global	O
burden	O
of	O
malaria	B-PATH
.	O

With	O
changing	O
spectrum	O
of	O
clinical	O
presentation	O
in	O
malaria	B-PATH
,	O
pulmonary	O
system	O
involvement	O
has	O
always	O
been	O
under	O
diagnosed	O
.	O

STUDY	O
DESIGN	O
&	O
DESCRIPTION	O
OF	O
THE	O
PATIENTS	O
:	O
Our	O
study	O
was	O
conducted	O
during	O
2007	O
to	O
2009	O
in	O
200	O
cases	O
of	O
severe	O
malaria	B-PATH
[	O
Pf	O
,	O
Pv	O
,	O
and	O
mixed	O
(	O
Pf	O
+	O
Pv	O
)]	O
with	O
pulmonary	O
involvement	O
.	O

Pulmonary	O
involvement	O
was	O
observed	O
in	O
30	O
%	O
(	O
60	O
/	O
200	O
)	O
patients	O
among	O
which	O
cough	O
in	O
24	O
%	O
,	O
dyspnea	O
in	O
12	O
%,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
7	O
%	O
,	O
bronchitis	O
in	O
3	O
%	O
and	O
pneumonia	O
in	O
1	O
.	O
5	O
%	O
were	O
the	O
major	O
clinical	O
manifestations	O
of	O
malaria	B-PATH
.	O

Therefore	O
,	O
early	O
diagnosis	O
of	O
malaria	B-PATH
induced	O
ARDS	O
can	O
significantly	O
affect	O
the	O
outcome	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
antiviral	O
evaluation	O
of	O
7	O
-	O
O	O
-	O
arylmethylquercetin	O
derivatives	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCV	O
)	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
).	O

In	O
this	O
study	O
,	O
we	O
prepared	O
a	O
series	O
of	O
the	O
7	O
-	O
O	O
-	O
arylmethylquercetin	O
derivatives	O
with	O
various	O
aromatic	O
substituents	O
and	O
evaluated	O
their	O
antiviral	O
activity	O
against	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
,	O
SCV	O
)	O
as	O
well	O
as	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
).	O

Expression	O
of	O
the	O
sNsp15	O
in	O
cells	O
resulted	O
in	O
an	O
increased	O
abundance	O
of	O
pRb	O
in	O
the	O
cytoplasm	O
,	O
decreased	O
overall	O
levels	O
of	O
pRb	O
,	O
an	O
increased	O
proportion	O
of	O
cells	O
in	O
the	O
S	O
phase	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
,	O
and	O
an	O
enhanced	O
expression	O
from	O
a	O
promoter	O
normally	O
repressed	O
by	O
pRb	O
.	O

Use	O
of	O
a	O
selective	O
inhibitor	O
of	O
CXCR2	O
,	O
SB265610	O
,	O
demonstrated	O
that	O
CXCR2	O
signaling	O
was	O
required	O
for	O
RCoV	O
-	O
AT1	O
-	O
mediated	O
inhibition	O
of	O
PMN	O
apoptosis	B-PATH
.	O

These	O
data	O
suggest	O
that	O
CXC	O
chemokines	O
produced	O
by	O
RCoV	O
-	O
infected	O
AT1	O
-	O
like	O
cells	O
inhibit	O
PMN	O
apoptosis	B-PATH
during	O
infection	O
.	O

ABSTRACT	O
:	O
Passengers	O
in	O
an	O
aircraft	O
cabin	O
can	O
have	O
different	O
risks	O
of	O
infection	O
from	O
airborne	O
infectious	O
diseases	O
such	O
as	O
influenza	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
tuberculosis	B-PATH
(	O
TB	O
)	O
because	O
of	O
the	O
non	O
-	O
uniform	O
airflow	O
in	O
an	O
aircraft	O
cabin	O
.	O

Of	O
6	O
cases	O
,	O
2	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pneumonia	O
finally	O
died	O
of	O
shock	O
;	O
1	O
patient	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pneumonia	O
and	O
1	O
patient	O
with	O
Klebsiella	O
pneumoniae	O
pneumonia	O
were	O
withdrawn	O
from	O
ECMO	O
treatment	O
because	O
of	O
deterioration	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
Nonstructural	O
proteins	O
7	O
and	O
8	O
of	O
feline	O
coronavirus	O
form	O
a	O
2	O
:	O
1	O
heterotrimer	O
that	O
exhibits	O
primer	O
-	O
independent	O
RNA	B-PATH
polymerase	I-PATH
activity	O
.	O

Upon	O
addition	O
of	O
Nsp7	O
,	O
the	O
RNA	B-PATH
polymerase	I-PATH
activity	O
is	O
further	O
enhanced	O
so	O
that	O
RNA	O
up	O
to	O
template	O
length	O
(	O
67	O
nucleotides	O
)	O
can	O
be	O
synthesized	O
.	O

These	O
results	O
indicate	O
that	O
in	O
case	O
of	O
FCoV	O
as	O
well	O
as	O
of	O
HCoV	O
229E	O
,	O
the	O
formation	O
of	O
a	O
hexadecameric	O
Nsp7	O
:	O
Nsp8	O
complex	O
is	O
not	O
necessary	O
for	O
RNA	B-PATH
polymerase	I-PATH
activity	O
.	O

Further	O
,	O
the	O
FCoV	O
Nsp7	O
:	O
Nsp8	O
complex	O
functions	O
as	O
a	O
noncanonical	O
RNA	B-PATH
polymerase	I-PATH
capable	O
of	O
synthesizing	O
RNA	O
of	O
up	O
to	O
template	O
length	O
.	O

The	O
antiviral	O
and	O
anti	O
-	O
tuberculosis	B-PATH
activity	O
data	O
of	O
some	O
compounds	O
are	O
presented	O
.	O

ABSTRACT	O
:	O
Ultraviolet	O
germicidal	O
irradiation	O
(	O
UVGI	O
),	O
254	O
nm	O
UV	O
-	O
C	O
,	O
is	O
increasingly	O
used	O
as	O
an	O
infection	O
control	O
strategy	O
to	O
reduce	O
the	O
spread	O
of	O
airborne	O
pathogens	O
such	O
as	O
tuberculosis	B-PATH
(	O
TB	O
),	O
influenza	O
viruses	O
,	O
and	O
measles	B-PATH
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
novel	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
].	O

ABSTRACT	O
:	O
To	O
summarize	O
the	O
clinical	O
experiences	O
and	O
indications	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
ARDS	O
caused	O
by	O
novel	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

All	O
ECMO	O
cases	O
with	O
severe	O
ARDS	O
associated	O
with	O
novel	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
were	O
analyzed	O
in	O
5	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
from	O
5	O
different	O
hospitals	O
in	O
Beijing	O
and	O
Tianjin	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
infection	O
induces	O
apoptosis	B-PATH
through	O
FasL	O
-	O
and	O
mitochondria	O
-	O
mediated	O
pathways	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
has	O
been	O
reported	O
to	O
induce	O
apoptosis	B-PATH
in	O
swine	O
testis	O
(	O
ST	O
)	O
cells	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
TGEV	O
-	O
induced	O
apoptosis	B-PATH
are	O
still	O
unclear	O
.	O

Both	O
extrinsic	O
and	O
intrinsic	O
pathways	O
activated	O
downstream	O
effector	O
caspase	O
-	O
3	O
,	O
followed	O
by	O
the	O
cleavage	O
of	O
PARP	O
,	O
resulting	O
in	O
cell	O
apoptosis	B-PATH
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrates	O
that	O
TGEV	O
-	O
induced	O
apoptosis	B-PATH
is	O
dependent	O
on	O
viral	O
replication	O
in	O
PK	O
-	O
15	O
cells	O
and	O
occurs	O
through	O
activation	O
of	O
FasL	O
-	O
and	O
mitochondria	O
-	O
mediated	O
apoptotic	O
pathways	O
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
lung	O
support	O
in	O
patients	O
with	O
severe	O
respiratory	O
failure	O
secondary	O
to	O
the	O
2010	O
-	O
2011	O
winter	O
seasonal	O
outbreak	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Spain	O
].	O

The	O
use	O
of	O
ECMO	O
in	O
refractory	O
respiratory	O
failure	O
in	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
is	O
rare	O
in	O
Spain	O
.	O

ABSTRACT	O
:	O
Increasing	O
concerns	O
about	O
the	O
spread	O
of	O
airborne	O
pathogens	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
novel	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
have	O
attracted	O
public	O
attention	O
to	O
bioaerosols	O
and	O
protection	O
against	O
them	O
.	O

ABSTRACT	O
:	O
Î¸	O
-	O
Defensins	B-PATH
are	O
cyclic	O
octadecapeptides	O
found	O
in	O
nonhuman	O
primates	O
whose	O
broad	O
antiviral	O
spectrum	O
includes	O
HIV	O
-	O
1	O
,	O
HSV	O
-	O
1	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
).	O

Seventy	O
-	O
two	O
hapivirin	O
or	O
diprovirin	O
peptides	O
are	O
described	O
in	O
this	O
work	O
,	O
including	O
several	O
whose	O
anti	O
-	O
IAV	O
activity	O
equals	O
or	O
exceeds	O
that	O
of	O
normal	O
Î±	O
-	O
or	O
Î¸	O
-	O
defensins	B-PATH
.	O

We	O
then	O
started	O
mechanical	O
ventilation	O
with	O
airway	O
pressure	O
release	B-PATH
ventilation	O
and	O
treated	O
him	O
with	O
antibiotics	O
,	O
peramivir	O
,	O
and	O
corticosteroids	O
,	O
despite	O
negative	O
results	O
for	O
a	O
rapid	O
antigen	O
test	O
for	O
influenza	O
.	O

We	O
believed	O
that	O
this	O
clinical	O
exacerbation	O
might	O
have	O
occurred	O
due	O
to	O
the	O
re	O
-	O
exacerbation	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pneumonia	O
due	O
to	O
the	O
cessation	O
of	O
corticosteroids	O
.	O

Currently	O
,	O
the	O
use	O
of	O
corticosteroid	O
therapy	O
for	O
severe	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pneumonia	O
is	O
controversial	O
,	O
but	O
even	O
the	O
late	O
administration	O
of	O
corticosteroid	O
therapy	O
may	O
be	O
effective	O
.	O

ABSTRACT	O
:	O
The	O
neuraminidase	O
inhibitor	O
oseltamivir	O
is	O
a	O
recommended	O
treatment	O
for	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

Tuberculosis	B-PATH
,	O
as	O
a	O
bacterial	O
infection	O
,	O
has	O
re	O
-	O
emerged	O
since	O
the	O
1990s	O
and	O
has	O
become	O
prevalent	O
in	O
the	O
country	O
.	O

The	O
new	O
viruses	O
cause	O
respiratory	O
illnesses	O
such	O
as	O
common	O
cold	O
,	O
bronchitis	O
,	O
bronchiolitis	O
,	O
exacerbations	O
of	O
asthma	B-PATH
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
pneumonia	O
.	O

TITLE	O
:	O
Acute	O
renal	O
failure	O
in	O
falciparum	O
malaria	B-PATH
:	O
clinical	O
characteristics	O
,	O
demonstration	O
of	O
oxidative	O
stress	O
,	O
and	O
prognostication	O
.	O

ABSTRACT	O
:	O
In	O
this	O
prospective	O
study	O
,	O
we	O
aimed	O
to	O
assess	O
the	O
clinical	O
characteristics	O
of	O
acute	O
renal	O
failure	O
(	O
ARF	O
),	O
determine	O
oxidative	O
stress	O
,	O
as	O
well	O
as	O
to	O
predict	O
the	O
outcome	O
in	O
patients	O
with	O
severe	O
falciparum	O
malaria	B-PATH
(	O
FM	O
).	O

Molecular	O
clock	O
analysis	O
using	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
genes	O
dated	O
the	O
most	O
recent	O
common	O
ancestor	O
of	O
RbCoV	O
HKU14	O
to	O
around	O
2002	O
,	O
suggesting	O
that	O
this	O
virus	O
has	O
emerged	O
relatively	O
recently	O
.	O

ABSTRACT	O
:	O
In	O
2009	O
,	O
during	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
epidemic	O
,	O
there	O
were	O
many	O
reported	O
cases	O
of	O
pulmonary	O
infection	O
with	O
severe	O
hypoxemia	O
that	O
was	O
refractory	O
to	O
the	O
ventilatory	O
strategies	O
and	O
rescue	O
therapies	O
commonly	O
used	O
to	O
treat	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
find	O
new	O
molecules	O
for	O
antiviral	O
drug	O
design	O
,	O
we	O
screened	O
102	O
ethyl	O
acetate	O
extracts	O
from	O
New	O
-	O
Caledonian	O
flora	O
for	O
antiviral	O
activity	O
against	O
the	O
dengue	O
2	O
virus	O
RNA	O
-	O
dependant	O
RNA	B-PATH
polymerase	I-PATH
(	O
DV	O
-	O
NS5	O
RdRp	O
).	O

BALB	O
/	O
c	O
mice	O
were	O
infected	O
with	O
a	O
sublethal	O
dose	O
of	O
mouse	O
-	O
adapted	O
virulent	O
influenza	B-PATH
A	I-PATH
/	O
Aichi	O
/	O
2	O
/	O
68	O
(	O
H3N2	O
)	O
virus	O
,	O
and	O
administered	O
daily	O
with	O
20mg	O
/	O
kg	O
or	O
60	O
mg	O
/	O
kg	O
DOX	O
orally	O
.	O

TITLE	O
:	O
Is	O
benign	O
tertian	O
malaria	B-PATH
actually	O
benign	O
?	O

ABSTRACT	O
:	O
This	O
retrospective	O
study	O
was	O
conducted	O
in	O
order	O
to	O
determine	O
the	O
incidence	O
of	O
various	O
complications	O
of	O
Plasmodium	O
vivax	O
malaria	B-PATH
based	O
on	O
a	O
review	O
of	O
case	O
records	O
in	O
a	O
tertiary	O
care	O
hospital	O
in	O
New	O
Delhi	O
,	O
India	O
.	O

This	O
paper	O
highlights	O
the	O
fact	O
that	O
P	O
.	O
vivax	O
malaria	B-PATH
,	O
although	O
considered	O
to	O
be	O
a	O
benign	O
entity	O
,	O
can	O
have	O
a	O
severe	O
and	O
complicated	O
course	O
,	O
which	O
is	O
usually	O
associated	O
with	O
P	O
.	O
falciparum	O
malaria	B-PATH
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
large	O
-	O
scale	O
analysis	O
of	O
microarray	O
datasets	O
involving	O
host	O
response	O
to	O
infections	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
rhinovirus	O
,	O
SARS	O
-	O
coronavirus	O
,	O
metapneumonia	O
virus	O
,	O
coxsackievirus	O
and	O
cytomegalovirus	O
.	O

Pathway	O
enrichment	O
analysis	O
also	O
identified	O
a	O
potential	O
novel	O
host	O
response	O
,	O
the	O
Parkin	O
-	O
Ubiquitin	O
Proteasomal	O
System	O
(	O
Parkin	O
-	O
UPS	O
)	O
pathway	O
,	O
which	O
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
progression	O
of	O
neurodegenerative	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
.	O

TITLE	O
:	O
Influenza	O
-	O
associated	O
pneumonia	O
among	O
hospitalized	O
patients	O
with	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
--	O
United	O
States	O
,	O
2009	O
.	O

However	O
,	O
foci	O
of	O
nascent	O
RNAs	O
were	O
always	O
found	O
to	O
colocalize	O
with	O
the	O
nsp12	O
-	O
encoded	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

Clinical	O
usefulness	O
of	O
ECMO	O
was	O
documented	O
in	O
many	O
cases	O
of	O
severe	O
ARDS	O
secondary	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
infection	O
.	O

Results	O
demonstrated	O
that	O
some	O
proteins	O
which	O
had	O
functions	O
in	O
cytoskeleton	O
organization	O
,	O
anti	O
-	O
oxidative	O
stress	O
,	O
and	O
stress	B-PATH
response	I-PATH
,	O
showed	O
different	O
change	O
patterns	O
in	O
abundance	O
from	O
chicken	O
infected	O
with	O
the	O
highly	O
virulent	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
P5	O
strain	O
and	O
those	O
given	O
the	O
embryo	O
-	O
passaged	O
,	O
attenuated	O
P115	O
stain	O
.	O

Among	O
the	O
tested	O
compounds	O
,	O
six	O
compounds	O
(	O
2e	O
-	O
2h	O
,	O
2l	O
,	O
2r	O
)	O
exhibited	O
significantly	O
inhibitory	O
activity	O
against	O
HBV	O
DNA	B-PATH
replication	I-PATH
with	O
IC	O
(	O
50	O
)	O
values	O
in	O
the	O
range	O
of	O
2	O
.	O
82	O
-	O
7	O
.	O
48	O
Î¼M	O
.	O
Interestingly	O
,	O
two	O
compounds	O
(	O
2e	O
,	O
2f	O
)	O
had	O
potent	O
activity	O
inhibiting	O
not	O
only	O
the	O
secretion	O
of	O
HBsAg	O
(	O
IC	O
(	O
50	O
)=	O
18	O
.	O
68	O
Î¼M	O
,	O
21	O
.	O
71	O
Î¼M	O
),	O
HBeAg	O
(	O
IC	O
(	O
50	O
)=	O
13	O
.	O
16	O
Î¼M	O
,	O
33	O
.	O
73	O
Î¼M	O
),	O
but	O
also	O
HBV	O
DNA	B-PATH
replication	I-PATH
(	O
IC	O
(	O
50	O
)=	O
7	O
.	O
48	O
Î¼M	O
,	O
3	O
.	O
63	O
Î¼M	O
).	O

TITLE	O
:	O
Heme	O
mediated	O
STAT3	O
activation	O
in	O
severe	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
The	O
mortality	O
of	O
severe	O
malaria	B-PATH
[	O
cerebral	O
malaria	B-PATH
(	O
CM	O
),	O
severe	O
malaria	B-PATH
anemia	O
(	O
SMA	O
),	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)]	O
remains	O
high	O
despite	O
the	O
availability	O
associated	O
with	O
adequate	O
treatments	O
.	O

We	O
first	O
clarified	O
the	O
roles	O
of	O
Heme	O
/	O
HO	O
-	O
1	O
,	O
CXCL10	O
/	O
CXCR3	O
and	O
STAT3	O
in	O
CM	O
pathogenesis	O
utilizing	O
a	O
well	O
established	O
experimental	O
cerebral	O
malaria	B-PATH
mouse	O
(	O
ECM	O
,	O
P	O
.	O
berghei	O
ANKA	O
)	O
model	O
.	O

Our	O
data	O
indicate	O
that	O
Heme	O
/	O
HO	O
-	O
1	O
,	O
CXCL10	O
/	O
CXCR3	O
and	O
STAT3	O
molecules	O
as	O
well	O
as	O
related	O
signaling	O
pathways	O
play	O
very	O
important	O
roles	O
in	O
the	O
pathogenesis	O
of	O
severe	O
malaria	B-PATH
.	O

Our	O
ultimate	O
goal	O
is	O
to	O
develop	O
novel	O
therapies	O
targeting	O
Heme	O
or	O
CXCL10	O
-	O
related	O
biological	O
signaling	O
molecules	O
associated	O
with	O
development	O
of	O
fatal	O
malaria	B-PATH
.	O

TITLE	O
:	O
Two	O
years	O
after	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
2009	O
/	O
H1N1	O
:	O
what	O
have	O
we	O
learned	O
?	O

The	O
pandemic	O
influenza	B-PATH
A	I-PATH
H1N1	O
2009	O
virus	O
(	O
A	O
/	O
2009	O
/	O
H1N1	O
)	O
finally	O
arrived	O
,	O
causing	O
the	O
first	O
pandemic	O
influenza	O
of	O
the	O
new	O
millennium	O
,	O
which	O
has	O
affected	O
over	O
214	O
countries	O
and	O
caused	O
over	O
18	O
,	O
449	O
deaths	O
.	O

TITLE	O
:	O
Plasmodium	O
vivax	O
malaria	B-PATH
-	O
associated	O
acute	O
kidney	O
injury	O
,	O
India	O
,	O
2010	O
-	O
2011	O
.	O

ABSTRACT	O
:	O
Plasmodium	O
vivax	O
is	O
causing	O
increasingly	O
more	O
cases	O
of	O
severe	O
malaria	B-PATH
worldwide	O
.	O

Among	O
25	O
cases	O
in	O
India	O
during	O
2010	O
-	O
2011	O
,	O
associated	O
conditions	O
were	O
renal	O
failure	O
,	O
thrombocytopenia	O
,	O
jaundice	O
,	O
severe	O
anemia	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
shock	O
,	O
cerebral	O
malaria	B-PATH
,	O
hypoglycemia	O
,	O
and	O
death	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
why	O
P	O
.	O
vivax	O
malaria	B-PATH
is	O
becoming	O
more	O
severe	O
.	O

Among	O
them	O
,	O
sixteen	O
compounds	O
showed	O
greater	O
anti	O
-	O
HBV	O
activity	O
than	O
GA	O
,	O
especially	O
,	O
compounds	O
29	O
,	O
32	O
,	O
35	O
,	O
41	O
exhibited	O
significantly	O
inhibitory	O
activities	O
against	O
HBV	O
DNA	B-PATH
replication	I-PATH
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
5	O
.	O
71	O
,	O
5	O
.	O
36	O
,	O
8	O
.	O
90	O
and	O
9	O
.	O
08	O
Î¼M	O
,	O
respectively	O
.	O

TITLE	O
:	O
Score	O
to	O
identify	O
the	O
severity	O
of	O
adult	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
virus	O
infection	O
at	O
hospital	O
admission	O
.	O

The	O
objective	O
of	O
this	O
paper	O
was	O
to	O
develop	O
a	O
prognostic	O
index	O
for	O
severe	O
complications	O
among	O
hospitalized	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
virus	O
infection	O
.	O

This	O
easy	O
-	O
to	O
-	O
score	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	B-PATH
)	O
2009	O
virus	O
infection	O
risk	O
index	O
accurately	O
stratifies	O
patients	O
hospitalized	O
for	O
H1N1	B-PATH
virus	O
infection	O
into	O
low	O
-,	O
intermediate	O
-,	O
and	O
high	O
-	O
risk	O
groups	O
for	O
SIHC	O
.	O

We	O
previously	O
identified	O
the	O
antiviral	O
activities	O
of	O
the	O
scorpion	O
-	O
venom	O
-	O
peptide	O
-	O
derived	O
mucroporin	O
-	O
M1	O
for	O
three	O
RNA	O
viruses	O
(	O
measles	B-PATH
viruses	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
H5N1	O
).	O

It	O
has	O
also	O
been	O
implicated	O
in	O
the	O
release	B-PATH
of	O
infectious	O
particles	O
after	O
budding	B-PATH
.	O

We	O
previously	O
showed	O
that	O
the	O
HD	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
E	O
protein	O
is	O
required	O
for	O
the	O
efficient	O
release	B-PATH
of	O
infectious	O
virus	O
,	O
an	O
activity	O
that	O
correlated	O
with	O
disruption	O
of	O
the	O
secretory	O
pathway	O
.	O

However	O
,	O
there	O
are	O
no	O
natural	O
or	O
synthetic	O
compounds	O
currently	O
available	O
that	O
can	O
inhibit	O
SARS	O
-	O
CoV	O
.	O
We	O
examined	O
the	O
inhibitory	O
effects	O
of	O
64	O
purified	O
natural	O
compounds	O
against	O
the	O
activity	O
of	O
SARS	O
helicase	O
,	O
nsP13	O
,	O
and	O
the	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
helicase	O
,	O
NS3h	O
,	O
by	O
conducting	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)-	O
based	O
double	O
-	O
strand	O
(	O
ds	O
)	O
DNA	O
unwinding	O
assay	O
or	O
by	O
using	O
a	O
colorimetry	O
-	O
based	O
ATP	O
hydrolysis	O
assay	O
.	O

Recent	O
studies	O
have	O
indicated	O
that	O
the	O
E	O
protein	O
has	O
functions	O
during	O
infection	O
beyond	O
assembly	O
,	O
including	O
in	O
virus	O
egress	O
and	O
in	O
the	O
host	O
stress	B-PATH
response	I-PATH
.	O

We	O
therefore	O
hypothesize	O
that	O
CD200R	O
ligation	O
suppresses	O
TLR7	O
responses	O
and	O
that	O
release	B-PATH
of	O
this	O
inhibition	O
enlarges	O
sex	O
differences	O
in	O
TLR7	O
signaling	O
.	O

In	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
we	O
show	O
that	O
viral	O
clearance	O
is	O
determined	O
by	O
sex	O
but	O
not	O
by	O
CD200R	O
signaling	O
.	O

However	O
,	O
absence	O
of	O
CD200R	O
in	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
results	O
in	O
enhanced	O
lung	O
neutrophil	O
influx	O
and	O
pathology	O
in	O
females	O
.	O

We	O
also	O
showed	O
that	O
nsp12	O
,	O
the	O
SARS	O
-	O
CoV	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
enhances	O
(	O
2	O
-	O
fold	O
)	O
the	O
catalytic	O
efficiency	O
of	O
nsp13	O
by	O
increasing	O
the	O
step	O
size	O
of	O
nucleic	O
acid	O
(	O
RNA	O
/	O
RNA	O
or	O
DNA	O
/	O
DNA	O
)	O
unwinding	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
not	O
associated	O
with	O
obesity	O
in	O
pregnant	O
women	O
living	O
in	O
Toluca	O
,	O
MÃ©xico	O
.	O

Five	O
women	O
suffering	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
attended	O
at	O
HMPMP	O
'	O
s	O
intensive	O
care	O
unit	O
during	O
2009	O
;	O
only	O
one	O
survived	O
.	O

No	O
new	O
case	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
found	O
after	O
the	O
first	O
eight	O
months	O
of	O
2010	O
.	O

The	O
key	O
to	O
better	O
survival	O
for	O
pregnant	O
women	O
hospitalized	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
seemed	O
to	O
be	O
early	O
treatment	O
with	O
oseltamivir	O
.	O

RESULTS	O
:	O
Five	O
women	O
suffering	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
attended	O
at	O
HMPMP	O
'	O
s	O
intensive	O
care	O
unit	O
during	O
2009	O
;	O
only	O
one	O
survived	O
.	O

No	O
new	O
case	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
found	O
after	O
the	O
first	O
eight	O
months	O
of	O
2010	O
.	O

The	O
nsp14	O
ExoN	O
activity	O
ensures	O
a	O
yet	O
-	O
uncharacterized	O
function	O
in	O
the	O
virus	O
life	O
cycle	O
and	O
must	O
be	O
regulated	O
to	O
avoid	O
nonspecific	O
RNA	B-PATH
degradation	I-PATH
.	O

In	O
addition	O
to	O
the	O
activation	O
of	O
nsp16	O
-	O
mediated	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
,	O
nsp10	O
also	O
activates	O
nsp14	O
in	O
an	O
RNA	O
processing	O
function	O
potentially	O
connected	O
to	O
a	O
replicative	O
mismatch	B-PATH
repair	I-PATH
mechanism	O
.	O

BTLA	O
-	O
deficient	O
(	O
BTLA	O
-/-)	O
mice	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
were	O
infected	O
with	O
murine	O
hepatitis	O
virus	O
strain	O
-	O
3	O
(	O
MHV	O
-	O
3	O
),	O
and	O
the	O
levels	O
of	O
tissue	O
damage	O
,	O
cell	O
apoptosis	B-PATH
,	O
serum	O
liver	O
enzymes	O
,	O
fibrinogen	O
-	O
like	O
protein	O
2	O
(	O
FGL2	O
)	O
and	O
cytokine	O
production	O
were	O
measured	O
and	O
compared	O
.	O

This	O
effect	O
is	O
due	O
to	O
rapid	O
,	O
TRAIL	O
(	O
TNF	O
-	O
related	O
apoptosis	B-PATH
-	O
inducing	O
ligand	O
)-	O
dependent	O
apoptosis	B-PATH
of	O
MHV	O
-	O
3	O
-	O
infected	O
macrophages	O
in	O
BTLA	O
-/-	O
mice	O
.	O

VIGOR	O
has	O
been	O
extended	O
to	O
predict	O
genes	O
for	O
12	O
viruses	O
:	O
measles	B-PATH
virus	O
,	O
mumps	O
virus	O
,	O
rubella	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
alphavirus	O
and	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
,	O
norovirus	O
,	O
metapneumovirus	O
,	O
yellow	O
fever	O
virus	O
,	O
Japanese	O
encephalitis	O
virus	O
,	O
parainfluenza	O
virus	O
and	O
Sendai	O
virus	O
.	O

Patients	O
with	O
ARDS	O
were	O
more	O
likely	O
to	O
be	O
morbidly	O
obese	O
(	O
36	O
%	O
versus	O
19	O
%,	O
P	O
=	O
0	O
.	O
04	O
)	O
and	O
patients	O
who	O
died	O
were	O
less	O
likely	O
to	O
have	O
asthma	B-PATH
(	O
11	O
%	O
versus	O
28	O
%,	O
P	O
=	O
0	O
.	O
05	O
).	O

Patients	O
with	O
asthma	B-PATH
had	O
less	O
severe	O
outcomes	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
initial	O
multidetector	O
computed	O
tomographic	O
(	O
MDCT	O
)	O
findings	O
of	O
novel	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
(	O
S	O
-	O
OIV	O
)	O
infection	O
in	O
immunocompromised	O
patients	O
and	O
to	O
evaluate	O
whether	O
or	O
not	O
identification	O
of	O
certain	O
abnormalities	O
can	O
help	O
predict	O
patients	O
who	O
are	O
at	O
risk	O
for	O
a	O
severe	O
clinical	O
course	O
.	O

BALB	O
/	O
cAnNCr	O
mice	O
(	O
8	O
-	O
12	O
wk	O
old	O
)	O
were	O
inoculated	O
intranasally	O
with	O
10	O
,	O
000	O
plaque	O
-	O
forming	O
units	O
/	O
mouse	O
influenza	B-PATH
A	I-PATH
/	O
WSN	O
/	O
33	O
(	O
H1N1	O
).	O

ABSTRACT	O
:	O
Î¸	O
-	O
Defensins	B-PATH
,	O
the	O
only	O
cyclic	O
peptides	O
of	O
animal	O
origin	O
,	O
have	O
been	O
isolated	O
from	O
the	O
leukocytes	O
of	O
rhesus	O
macaques	O
and	O
baboons	O
.	O

Synthetic	O
Î¸	O
-	O
defensins	B-PATH
with	O
sequences	O
that	O
correspond	O
to	O
those	O
encoded	O
within	O
the	O
human	O
pseudogenes	O
are	O
called	O
retrocyclins	O
.	O

The	O
small	O
size	O
,	O
unique	O
structure	O
,	O
and	O
multiple	O
host	O
defense	O
activities	O
of	O
Î¸	O
-	O
defensins	B-PATH
make	O
them	O
intriguing	O
potential	O
therapeutic	O
agents	O
.	O

TITLE	O
:	O
National	O
survey	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
-	O
associated	O
encephalopathy	O
in	O
Japanese	O
children	O
.	O

Washes	O
and	O
flocked	O
swabs	O
collected	O
from	O
children	O
<	O
3	O
years	O
old	O
hospitalized	O
with	O
a	O
lower	O
respiratory	O
tract	O
infection	O
were	O
tested	O
for	O
parainfluenza	O
virus	O
1	O
-	O
3	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
and	O
metapneumovirus	O
(	O
Group	O
1	O
)	O
and	O
adenovirus	O
,	O
rhinovirus	O
and	O
coronavirus	O
(	O
Group	O
2	O
)	O
using	O
real	O
-	O
time	O
reverse	O
transcriptase	O
PCR	O
(	O
rRT	O
-	O
PCR	O
).	O

ABSTRACT	O
:	O
From	O
early	O
May	O
2009	O
,	O
the	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
affected	O
mainland	O
China	O
.	O

From	O
November	O
2009	O
to	O
January	O
2010	O
,	O
all	O
patients	O
suffering	O
from	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
associated	O
ARDS	O
referred	O
to	O
Beijing	O
Anzhen	O
Hospital	O
for	O
treatment	O
with	O
ECMO	O
were	O
enrolled	O
.	O

Use	O
of	O
ECMO	O
for	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
related	O
ARDS	O
is	O
feasible	O
and	O
effective	O
.	O

Tracheal	O
aspirates	O
for	O
Pneumocystis	O
jiroveci	O
detection	O
,	O
bacterial	O
culture	O
,	O
tuberculosis	B-PATH
culture	O
,	O
and	O
viral	O
identification	O
were	O
performed	O
.	O

Only	O
7	O
.	O
9	O
%	O
of	O
infants	O
had	O
a	O
positive	O
tuberculosis	B-PATH
culture	O
.	O

TITLE	O
:	O
High	O
-	O
flow	O
nasal	O
therapy	O
in	O
adults	O
with	O
severe	O
acute	O
respiratory	O
infection	O
:	O
a	O
cohort	O
study	O
in	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
.	O

The	O
objective	O
was	O
to	O
assess	O
the	O
effectiveness	O
of	O
HFNC	O
oxygen	O
therapy	O
in	O
adult	O
patients	O
with	O
SARI	O
by	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
infection	O
(	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
testing	O
).	O

A	O
single	O
-	O
center	O
post	O
hoc	O
analysis	O
of	O
a	O
cohort	O
of	O
intensive	O
care	O
unit	O
patients	O
admitted	O
with	O
SARI	O
due	O
to	O
2009	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
was	O
done	O
.	O

We	O
describe	O
57	O
critically	O
ill	O
patients	O
treated	O
with	O
the	O
investigational	O
intravenous	O
neuraminidase	O
inhibitor	O
drug	O
peramivir	O
for	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
[	O
pH1N1	O
].	O

TITLE	O
:	O
Postmortem	O
characterization	O
of	O
patients	O
with	O
clinical	O
diagnosis	O
of	O
Plasmodium	O
vivax	O
malaria	B-PATH
:	O
to	O
what	O
extent	O
does	O
this	O
parasite	O
kill	O
?	O

Of	O
17	O
autopsies	O
,	O
13	O
revealed	O
that	O
death	O
could	O
be	O
attributed	O
to	O
P	O
.	O
vivax	O
infection	O
;	O
in	O
the	O
remaining	O
4	O
,	O
acute	O
diseases	O
other	O
than	O
malaria	B-PATH
were	O
found	O
to	O
be	O
the	O
cause	O
of	O
death	O
.	O

The	O
primary	O
complication	O
in	O
patients	O
in	O
which	O
malaria	B-PATH
contributed	O
to	O
death	O
was	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
pulmonary	O
edema	O
associated	O
with	O
the	O
accumulation	O
of	O
neutrophils	O
in	O
the	O
interalveolar	O
space	O
(	O
6	O
cases	O
).	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
is	O
severely	O
impaired	O
by	O
MG132	O
due	O
to	O
proteasome	B-PATH
-	O
independent	O
inhibition	O
of	O
M	O
-	O
calpain	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-PATH
system	O
(	O
UPS	O
)	O
is	O
involved	O
in	O
the	O
replication	O
of	O
a	O
broad	O
range	O
of	O
viruses	O
.	O

TITLE	O
:	O
Surveillance	O
of	O
hospitalised	O
severe	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
and	O
related	O
fatalities	O
in	O
nine	O
EU	O
countries	O
in	O
2010	O
-	O
2011	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
assess	O
the	O
association	O
between	O
patient	O
characteristics	O
,	O
in	O
particular	O
underlying	O
conditions	O
,	O
and	O
the	O
severity	O
level	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
during	O
the	O
2010	O
-	O
2011	O
season	O
.	O

Patient	O
age	O
,	O
the	O
presence	O
of	O
underlying	O
conditions	O
,	O
pneumonia	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
the	O
need	O
for	O
ventilation	O
were	O
significantly	O
associated	O
with	O
the	O
severity	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
biochemical	O
properties	O
of	O
a	O
full	O
-	O
length	O
recombinant	O
SARS	O
-	O
CoV	O
nsp12	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
capable	O
of	O
copying	O
viral	O
RNA	O
templates	O
.	O

TITLE	O
:	O
Mechanically	O
ventilated	O
children	O
with	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
:	O
results	O
from	O
the	O
National	O
Pediatric	O
Intensive	O
Care	O
Registry	O
in	O
Japan	O
.	O

ABSTRACT	O
:	O
To	O
outline	O
the	O
characteristics	O
,	O
clinical	O
course	O
,	O
and	O
outcome	O
of	O
pediatric	O
patients	O
requiring	O
mechanical	O
ventilation	O
with	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
in	O
Japan	O
.	O

Forty	O
-	O
one	O
patients	O
(	O
50	O
%)	O
had	O
at	O
least	O
one	O
underlying	O
chronic	O
condition	O
,	O
including	O
31	O
with	O
asthma	B-PATH
.	O

Associated	O
clinical	O
symptoms	O
and	O
diagnosis	O
were	O
as	O
follows	O
:	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
9	O
%),	O
asthma	B-PATH
or	O
bronchitis	O
(	O
37	O
%),	O
pneumonia	O
(	O
68	O
%)	O
with	O
8	O
(	O
14	O
%)	O
having	O
bacterial	O
pneumonia	O
,	O
neurological	O
symptoms	O
(	O
32	O
%),	O
myocarditis	O
(	O
2	O
%),	O
and	O
rhabdomyolysis	O
(	O
1	O
%).	O

ABSTRACT	O
:	O
Responding	O
to	O
Pandemic	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
alert	O
in	O
2009	O
,	O
Ministry	O
of	O
Health	O
(	O
MoH	O
),	O
Sultanate	O
Of	O
Oman	O
arranged	O
task	O
force	O
to	O
deal	O
with	O
the	O
emergency	O
.	O

These	O
interactions	O
may	O
be	O
directly	O
involved	O
in	O
viral	O
replication	O
or	O
lead	O
to	O
the	O
alteration	O
of	O
certain	O
signaling	O
pathways	O
,	O
such	O
as	O
cell	O
stress	B-PATH
response	I-PATH
and	O
innate	O
immunity	O
,	O
to	O
facilitate	O
viral	O
replication	O
and	O
pathogenesis	O
.	O

TITLE	O
:	O
Clinical	O
features	O
of	O
the	O
hospitalized	O
patients	O
with	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Santa	O
Fe	O
,	O
Argentina	O
.	O

Using	O
medical	O
charts	O
,	O
we	O
collected	O
data	O
on	O
242	O
patients	O
who	O
were	O
hospitalized	O
with	O
confirmed	O
laboratory	O
results	O
(	O
defined	O
as	O
positive	O
by	O
specific	O
PCR	O
for	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
H1N1	O
).	O

ABSTRACT	O
:	O
Shortly	O
after	O
the	O
advent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
the	O
avian	O
influenza	O
,	O
the	O
emergence	O
of	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
pandemic	O
caused	O
significant	O
vibrations	O
to	O
the	O
public	O
health	O
authorities	O
and	O
stressed	O
the	O
health	O
systems	O
worldwide	O
.	O

The	O
recent	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
pandemic	O
has	O
highlighted	O
our	O
weaknesses	O
relating	O
to	O
the	O
diagnosis	O
and	O
assessment	O
of	O
severity	O
of	O
SARI	O
,	O
compromising	O
early	O
treatment	O
and	O
ultimate	O
outcomes	O
;	O
further	O
research	O
based	O
on	O
this	O
experience	O
will	O
help	O
to	O
improve	O
prognosis	O
and	O
boost	O
our	O
future	O
preparedness	O
.	O

ABSTRACT	O
:	O
In	O
2010	O
,	O
there	O
was	O
an	O
increase	O
in	O
the	O
severity	O
of	O
malaria	B-PATH
admissions	O
to	O
Kalawati	O
Saran	O
Children	O
'	O
s	O
Hospital	O
,	O
New	O
Delhi	O
and	O
this	O
report	O
describes	O
the	O
morbidity	O
and	O
mortality	O
profile	O
.	O

There	O
were	O
91	O
(	O
58	O
.	O
3	O
%)	O
patients	O
with	O
severe	O
malaria	B-PATH
:	O
P	O
.	O
vivax	O
mono	O
-	O
infection	O
46	O
(	O
50	O
.	O
5	O
%),	O
P	O
.	O
falciparum	O
mono	O
-	O
infection	O
35	O
(	O
38	O
.	O
5	O
%)	O
and	O
mixed	O
10	O
(	O
11	O
%).	O

Complications	O
including	O
cerebral	O
malaria	B-PATH
,	O
acute	O
renal	O
failure	O
,	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
multiple	O
-	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Increased	O
morbidity	O
owing	O
to	O
P	O
.	O
vivax	O
malaria	B-PATH
was	O
observed	O
and	O
risk	O
of	O
mortality	O
was	O
highest	O
in	O
patients	O
with	O
ARDS	O
and	O
MODS	O
.	O

METHODS	O
:	O
A	O
retrospective	O
chart	O
review	O
of	O
patients	O
admitted	O
with	O
parasitologically	O
confirmed	O
malaria	B-PATH
between	O
January	O
and	O
December	O
2010	O
.	O

Risk	O
of	O
mortality	O
in	O
vivax	O
malaria	B-PATH
was	O
highest	O
in	O
patients	O
with	O
ARDS	O
followed	O
by	O
MODS	O
and	O
shock	O
.	O

ABSTRACT	O
:	O
Airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
is	O
an	O
alternative	O
approach	O
to	O
the	O
low	O
-	O
tidal	O
volume	O
""""	O
open	O
-	O
lung	O
""""	O
ventilation	O
strategy	O
.	O

The	O
epidemic	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
2003	O
,	O
re	O
-	O
emergence	O
of	O
a	O
panzootic	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
H5N1	O
in	O
2005	O
,	O
and	O
the	O
sudden	O
emergence	O
of	O
pandemic	O
H1N1	O
in	O
North	O
America	O
in	O
2009	O
all	O
highlighted	O
the	O
importance	O
of	O
shared	O
global	O
responsibility	O
for	O
surveillance	O
and	O
disease	O
control	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
partial	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
suggested	O
that	O
one	O
of	O
the	O
detected	O
BtCoVs	O
was	O
a	O
novel	O
alphacoronavirus	O
,	O
while	O
the	O
others	O
belonged	O
to	O
the	O
genus	O
Betacoronavirus	O
.	O

The	O
emergence	O
of	O
""""	O
old	O
""""	O
vaccine	O
-	O
preventable	O
diseases	O
-	O
pertussis	B-PATH
and	O
measles	B-PATH
-	O
is	O
also	O
discussed	O
.	O

However	O
,	O
effects	O
of	O
H1N1	O
influenza	B-PATH
infection	I-PATH
on	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
):	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
ratios	O
and	O
related	O
pathophysiologic	O
readouts	O
of	O
lung	O
function	O
have	O
not	O
been	O
reported	O
in	O
mice	O
.	O

Influenza	B-PATH
infection	I-PATH
of	O
mice	O
results	O
in	O
impairment	O
of	O
alveolar	O
gas	O
exchange	O
consistent	O
with	O
rapid	O
development	O
of	O
acute	O
lung	O
injury	O
and	O
progression	O
to	O
ARDS	O
.	O

ABSTRACT	O
:	O
Respiratory	O
distress	O
develops	O
in	O
up	O
to	O
25	O
%	O
of	O
adults	O
and	O
40	O
%	O
of	O
children	O
with	O
severe	O
falciparum	O
malaria	B-PATH
.	O

Patients	O
with	O
severe	O
falciparum	O
,	O
vivax	O
,	O
and	O
knowlesi	O
malaria	B-PATH
may	O
develop	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
ARDS	O
,	O
often	O
several	O
days	O
after	O
antimalarial	O
drug	O
treatment	O
.	O

TITLE	O
:	O
Detection	O
of	O
human	O
coronavirus	O
strain	O
HKU1	O
in	O
a	O
2	O
years	O
old	O
girl	O
with	O
asthma	B-PATH
exacerbation	O
caused	O
by	O
acute	O
pharyngitis	O
.	O

ABSTRACT	O
:	O
Respiratory	O
viral	O
infections	O
can	O
trigger	O
asthma	B-PATH
attack	O
which	O
may	O
lead	O
to	O
sever	O
morbidity	O
.	O

In	O
this	O
report	O
,	O
using	O
molecular	O
methods	O
,	O
we	O
show	O
the	O
chronological	O
association	O
between	O
human	O
coronavirus	O
--	O
HKU1	O
infection	O
and	O
asthma	B-PATH
exacerbation	O
in	O
a	O
two	O
years	O
and	O
seven	O
months	O
old	O
asthmatic	O
girl	O
who	O
was	O
not	O
under	O
treatment	O
and	O
was	O
otherwise	O
healthy	O
.	O

Analysis	O
of	O
immune	O
-	O
related	O
gene	O
expression	O
profiles	O
showed	O
that	O
at	O
24	O
h	O
after	O
SARS	O
-	O
CoV	O
infection	O
:	O
(	O
1	O
)	O
IFN	O
-	O
Î±	O
/	O
Î²	O
-	O
inducible	O
and	O
cathepsin	O
/	O
proteasome	B-PATH
genes	O
were	O
downregulated	O
;	O
(	O
2	O
)	O
hypoxia	O
/	O
hyperoxia	O
-	O
related	O
genes	O
were	O
upregulated	O
;	O
and	O
(	O
3	O
)	O
TLR	O
/	O
TLR	O
-	O
signaling	O
,	O
cytokine	O
/	O
cytokine	O
receptor	O
-	O
related	O
,	O
chemokine	O
/	O
chemokine	O
receptor	O
-	O
related	O
,	O
lysosome	B-PATH
-	O
related	O
,	O
MHC	O
/	O
chaperon	O
-	O
related	O
,	O
and	O
fibrosis	O
-	O
related	O
genes	O
were	O
differentially	O
regulated	O
.	O

BALB	O
/	O
c	O
mice	O
were	O
inoculated	O
with	O
several	O
viral	O
doses	O
of	O
influenza	B-PATH
A	I-PATH
/	O
Puerto	O
Rico	O
/	O
8	O
/	O
34	O
(	O
PR8	O
)	O
virus	O
(	O
H1N1	O
).	O

TITLE	O
:	O
[	O
Epidemiological	O
profile	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
cases	O
in	O
the	O
south	O
of	O
Santa	O
Catarina	O
state	O
,	O
Brazil	O
,	O
in	O
2009	O
].	O

During	O
the	O
pandemic	O
period	O
,	O
1	O
149	O
suspected	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
were	O
notified	O
,	O
of	O
which	O
560	O
(	O
48	O
.	O
6	O
%)	O
were	O
confirmed	O
.	O

Age	O
<	O
30	O
years	O
,	O
symptoms	O
of	O
fever	O
,	O
cough	O
and	O
dyspnea	O
,	O
and	O
death	O
were	O
independently	O
associated	O
with	O
influenza	B-PATH
A	I-PATH
infection	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
studied	O
sample	O
differed	O
from	O
the	O
national	O
profile	O
of	O
influenza	B-PATH
A	I-PATH
cases	O
in	O
Brazil	O
by	O
the	O
absence	O
of	O
associated	O
comorbidities	O
.	O

RESULTS	O
:	O
During	O
the	O
pandemic	O
period	O
,	O
1	O
149	O
suspected	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
were	O
notified	O
,	O
of	O
which	O
560	O
(	O
48	O
.	O
6	O
%)	O
were	O
confirmed	O
.	O

CONCLUSIONS	O
:	O
The	O
studied	O
sample	O
differed	O
from	O
the	O
national	O
profile	O
of	O
influenza	B-PATH
A	I-PATH
cases	O
in	O
Brazil	O
by	O
the	O
absence	O
of	O
associated	O
comorbidities	O
.	O

The	O
technique	O
has	O
also	O
been	O
successfully	O
used	O
as	O
a	O
rescue	O
therapy	O
for	O
the	O
most	O
severe	O
ARDS	O
cases	O
associated	O
with	O
the	O
recent	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
.	O

Observation	O
of	O
the	O
cytopathic	O
effect	O
and	O
apoptosis	B-PATH
,	O
as	O
well	O
as	O
a	O
cell	O
proliferation	O
assay	O
demonstrated	O
that	O
the	O
three	O
shRNAs	O
were	O
capable	O
of	O
protecting	O
ST	O
cells	O
against	O
TGEV	O
destruction	O
,	O
with	O
high	O
specificity	O
and	O
efficiency	O
.	O

Observation	O
of	O
the	O
cytopathic	O
effect	O
and	O
apoptosis	B-PATH
,	O
as	O
well	O
as	O
a	O
cell	O
proliferation	O
assay	O
demonstrated	O
that	O
the	O
three	O
shRNAs	O
were	O
capable	O
of	O
protecting	O
ST	O
cells	O
against	O
TGEV	O
destruction	O
,	O
with	O
high	O
specificity	O
and	O
efficiency	O
.	O

A	O
retrospective	O
review	O
was	O
conducted	O
that	O
included	O
patients	O
admitted	O
to	O
the	O
Cleveland	O
Clinic	O
MICU	O
with	O
ALI	O
/	O
ARDS	O
and	O
confirmed	O
influenza	B-PATH
A	I-PATH
infection	O
,	O
and	O
all	O
patients	O
admitted	O
with	O
ALI	O
/	O
ARDS	O
from	O
any	O
other	O
etiology	O
from	O
September	O
2009	O
to	O
March	O
2010	O
.	O

Results	O
point	O
to	O
SARS	O
-	O
CoV	O
PLpro	O
triggering	O
TGF	O
-	O
Î²1	O
production	O
via	O
ubiquitin	O
proteasome	B-PATH
,	O
p38	O
MAPK	O
,	O
and	O
ERK1	O
/	O
2	O
-	O
mediated	O
signaling	O
.	O

Historical	O
evidence	O
points	O
to	O
the	O
fact	O
that	O
pandemics	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
viruses	O
remain	O
a	O
major	O
zoonotic	O
threat	O
to	O
mankind	O
.	O

Although	O
swine	O
are	O
widely	O
recognized	O
as	O
a	O
potential	O
host	O
for	O
generating	O
novel	O
influenza	O
viruses	O
,	O
and	O
that	O
some	O
of	O
these	O
viruses	O
,	O
including	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
2009	O
,	O
have	O
been	O
shown	O
to	O
be	O
readily	O
transmissible	O
between	O
humans	O
and	O
swine	O
,	O
only	O
one	O
study	O
was	O
found	O
related	O
to	O
the	O
modelling	O
of	O
influenza	O
spread	O
at	O
the	O
swine	O
-	O
human	O
interface	O
.	O

Significant	O
gaps	O
in	O
the	O
knowledge	O
of	O
frequency	O
of	O
novel	O
viral	O
strains	O
evolution	O
in	O
pigs	O
,	O
farm	O
-	O
level	O
natural	O
history	O
of	O
influenza	B-PATH
infection	I-PATH
,	O
incidences	O
of	O
influenza	O
transmission	O
between	O
farms	O
and	O
between	O
swine	O
and	O
humans	O
are	O
clearly	O
evident	O
.	O

Leadership	O
'	O
s	O
support	O
of	O
the	O
program	O
evidenced	O
through	O
visible	O
leadership	O
presence	O
,	O
messaging	O
and	O
release	B-PATH
of	O
resources	O
is	O
the	O
key	O
factor	O
in	O
helping	O
to	O
make	O
the	O
program	O
a	O
true	O
success	O
.	O

Identified	O
viruses	O
included	O
37	O
of	O
human	O
rhinovirus	O
(	O
22	O
.	O
6	O
%	O
of	O
cases	O
),	O
32	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
19	O
.	O
5	O
%),	O
30	O
of	O
parainfluenzavirus	O
-	O
2	O
(	O
18	O
.	O
3	O
%),	O
23	O
of	O
parainfluenzavirus	O
-	O
3	O
(	O
14	O
.	O
0	O
%),	O
15	O
of	O
human	O
enterovirus	O
(	O
9	O
.	O
1	O
%),	O
14	O
each	O
of	O
parainfluenzavirus	O
-	O
1	O
,	O
respiratory	O
syncytial	O
virus	O
B	O
and	O
adenovirus	O
(	O
8	O
.	O
5	O
%),	O
8	O
of	O
coronavirus	O
229E	O
/	O
NL63	O
(	O
4	O
.	O
9	O
%),	O
6	O
of	O
human	O
bocavirus	O
(	O
3	O
.	O
7	O
%),	O
5	O
each	O
of	O
influenza	O
B	O
virus	O
and	O
respiratory	O
syncytial	O
virus	O
A	O
(	O
3	O
.	O
0	O
%),	O
3	O
of	O
parainfluenzavirus	O
-	O
4	O
(	O
1	O
.	O
8	O
%),	O
2	O
of	O
coronavirus	O
OC43	O
/	O
HKU1	O
(	O
1	O
.	O
2	O
%),	O
and	O
1	O
human	O
metapneumovirus	O
(	O
0	O
.	O
6	O
%).	O

Identified	O
viruses	O
included	O
37	O
of	O
human	O
rhinovirus	O
(	O
22	O
.	O
6	O
%	O
of	O
cases	O
),	O
32	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
19	O
.	O
5	O
%),	O
30	O
of	O
parainfluenzavirus	O
-	O
2	O
(	O
18	O
.	O
3	O
%),	O
23	O
of	O
parainfluenzavirus	O
-	O
3	O
(	O
14	O
.	O
0	O
%),	O
15	O
of	O
human	O
enterovirus	O
(	O
9	O
.	O
1	O
%),	O
14	O
each	O
of	O
parainfluenzavirus	O
-	O
1	O
,	O
respiratory	O
syncytial	O
virus	O
B	O
and	O
adenovirus	O
(	O
8	O
.	O
5	O
%),	O
8	O
of	O
coronavirus	O
229E	O
/	O
NL63	O
(	O
4	O
.	O
9	O
%),	O
6	O
of	O
human	O
bocavirus	O
(	O
3	O
.	O
7	O
%),	O
5	O
each	O
of	O
influenza	O
B	O
virus	O
and	O
respiratory	O
syncytial	O
virus	O
A	O
(	O
3	O
.	O
0	O
%),	O
3	O
of	O
parainfluenzavirus	O
-	O
4	O
(	O
1	O
.	O
8	O
%),	O
2	O
of	O
coronavirus	O
OC43	O
/	O
HKU1	O
(	O
1	O
.	O
2	O
%),	O
and	O
1	O
human	O
metapneumovirus	O
(	O
0	O
.	O
6	O
%).	O

TITLE	O
:	O
Prolonged	O
period	O
of	O
acute	O
bronchitis	O
with	O
late	O
progression	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
as	O
possible	O
result	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
utility	O
of	O
animal	O
models	O
for	O
studies	O
of	O
influenza	B-PATH
A	I-PATH
viruses	O
,	O
HIV	O
and	O
SARS	O
-	O
CoV	O
in	O
light	O
of	O
viral	O
emergence	O
,	O
assessment	O
of	O
infection	O
and	O
transmission	O
risks	O
,	O
and	O
regulatory	O
decision	O
making	O
.	O

Single	O
infections	O
were	O
detected	O
in	O
56	O
samples	O
,	O
50	O
of	O
those	O
were	O
caused	O
by	O
RNA	O
viruses	O
:	O
33	O
samples	O
tested	O
positive	O
for	O
rhinovirus	O
,	O
five	O
for	O
influenza	B-PATH
A	I-PATH
,	O
five	O
for	O
metapneumovirus	O
,	O
four	O
for	O
coronavirus	O
and	O
,	O
three	O
for	O
respiratory	O
syncytial	O
virus	O
.	O

TITLE	O
:	O
[	O
Peculiarities	O
of	O
present	O
-	O
day	O
morbidity	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
swl	O
)].	O

We	O
consider	O
the	O
epidemiological	O
situation	O
as	O
regards	O
respiratory	O
viral	O
diseases	O
during	O
recent	O
years	O
with	O
special	O
reference	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
swl	O
).	O

ABSTRACT	O
:	O
A	O
distinctive	O
feature	O
of	O
pneumonia	O
in	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
is	O
interstitial	O
infiltration	O
of	O
lung	O
tissues	O
and	O
high	O
frequency	O
of	O
pulmonary	O
lesions	O
leading	O
to	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
half	O
of	O
the	O
patients	O
.	O

Pulmonary	O
CT	O
is	O
believed	O
to	O
be	O
the	O
most	O
informative	O
method	O
for	O
diagnostics	O
of	O
pneumonia	O
and	O
its	O
complications	O
during	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

Tuberculosis	B-PATH
remains	O
a	O
serious	O
problem	O
in	O
China	O
,	O
with	O
a	O
high	O
prevalence	O
of	O
multidrug	O
-	O
resistant	O
and	O
extensively	O
drug	O
-	O
resistant	O
strains	O
.	O

We	O
have	O
shown	O
that	O
STAT1	O
plays	O
an	O
important	O
role	O
in	O
the	O
severity	O
of	O
SARS	O
-	O
CoV	O
pathogenesis	O
and	O
that	O
it	O
is	O
independent	O
of	O
the	O
role	O
of	O
STAT1	O
in	O
interferon	B-PATH
signaling	I-PATH
.	O

nsp1	O
inhibits	O
the	O
translation	O
of	O
cap	O
-	O
dependent	O
and	O
internal	O
ribosome	B-PATH
entry	O
site	O
(	O
IRES	O
)-	O
driven	O
mRNAs	O
,	O
including	O
SARS	O
coronavirus	O
mRNAs	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
and	O
cricket	O
paralysis	O
virus	O
(	O
CrPV	O
)	O
IRES	O
-	O
driven	O
mRNAs	O
that	O
are	O
resistant	O
to	O
nsp1	O
-	O
induced	O
RNA	O
cleavage	O
.	O

Otitis	O
media	O
,	O
sinusitis	O
,	O
bronchiolitis	O
,	O
pneumonia	O
,	O
and	O
asthma	B-PATH
exacerbation	O
are	O
commonly	O
accepted	O
as	O
complications	O
of	O
viral	O
upper	O
respiratory	O
tract	O
infections	O
.	O

The	O
frequency	O
order	O
of	O
the	O
viral	O
agents	O
detected	O
were	O
as	O
follows	O
;	O
rhinoviruses	O
14	O
.	O
7	O
%,	O
RSV	O
B	O
7	O
.	O
3	O
%,	O
influenza	B-PATH
A	I-PATH
6	O
.	O
4	O
%,	O
metapneumovirus	O
3	O
.	O
6	O
%,	O
adenovirus	O
3	O
.	O
6	O
%,	O
coronavirus	O
0	O
.	O
9	O
%,	O
parainfluenzavirus	O
type	O
3	O
,	O
0	O
.	O
9	O
%,	O
parainfluenzavirus	O
type	O
4	O
,	O
0	O
.	O
9	O
%	O
and	O
RSV	O
A	O
0	O
.	O
9	O
%.	O

Droplet	O
nuclei	O
are	O
responsible	O
for	O
the	O
airborne	O
transmission	O
of	O
infectious	O
diseases	O
such	O
as	O
tuberculosis	B-PATH
,	O
chicken	O
pox	O
(	O
varicella	O
),	O
measles	B-PATH
(	O
rubeola	O
),	O
and	O
dessiminated	O
herpes	O
zoster	O
,	O
whereas	O
close	O
contact	O
is	O
required	O
for	O
the	O
direct	O
transmission	O
of	O
infectious	O
diseases	O
transmitted	O
by	O
droplets	O
,	O
such	O
as	O
influenza	O
(	O
the	O
flu	O
)	O
and	O
SARS	O
.	O

Concomitantly	O
,	O
the	O
threat	O
of	O
epidemics	O
,	O
ranging	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
to	O
the	O
resurgence	O
of	O
vector	O
-	O
borne	O
diseases	O
as	O
well	O
as	O
the	O
rise	O
of	O
modern	O
lifestyle	O
-	O
related	O
outbreaks	O
,	O
have	O
worsened	O
difficulties	O
in	O
safeguarding	O
public	O
health	O
amidst	O
much	O
elusiveness	O
and	O
unpredictability	O
.	O

Positivity	O
only	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
OR	O
=	O
4	O
.	O
3	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
3	O
-	O
14	O
.	O
6	O
)	O
was	O
significantly	O
associated	O
with	O
fatal	O
outcome	O
.	O

TITLE	O
:	O
[	O
Epidemiological	O
and	O
clinical	O
characteristics	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
at	O
San	O
Felipe	O
,	O
Valparaiso	O
Region	O
,	O
Chile	O
:	O
June	O
-	O
August	O
2009	O
].	O

It	O
analyses	O
the	O
trends	O
in	O
consultations	O
for	O
respiratory	O
causes	O
in	O
three	O
primary	O
care	O
centers	O
and	O
hospital	O
discharges	O
by	O
comparing	O
data	O
from	O
years	O
2008	O
and	O
2009	O
until	O
epidemiological	O
week	O
37	O
.	O
It	O
also	O
includes	O
a	O
study	O
of	O
cases	O
of	O
ILI	O
/	O
SARI	O
(	O
influenza	O
like	O
disease	O
/	O
severe	O
acute	O
respiratory	O
disease	O
)	O
in	O
which	O
viruses	O
were	O
detected	O
by	O
direct	O
immunofluorescence	O
(	O
DIF	O
)	O
of	O
nasopharyngeal	O
aspirates	O
and	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
in	O
the	O
case	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
.	O

TITLE	O
:	O
Steroid	O
modulation	O
of	O
cytokine	O
release	B-PATH
and	O
desmosine	O
levels	O
in	O
bilateral	O
total	O
knee	O
replacement	O
:	O
a	O
prospective	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
controlled	O
trial	O
.	O

ABSTRACT	O
:	O
The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
two	O
new	O
influenza	B-PATH
A	I-PATH
subtypes	O
and	O
they	O
have	O
become	O
a	O
cause	O
of	O
concern	O
for	O
the	O
global	O
community	O
.	O

Many	O
clinical	O
experiences	O
of	O
the	O
extracorporeal	O
membrane	O
oxygenator	O
(	O
ECMO	O
)	O
treatment	O
for	O
adult	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
patients	O
,	O
which	O
is	O
caused	O
by	O
the	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
were	O
reported	O
.	O

A	O
wide	O
range	O
of	O
respiratory	O
viruses	O
,	O
including	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
parainfluenza	O
viruses	O
(	O
PIVs	O
),	O
adenovirus	O
,	O
rhinovirus	O
(	O
HRV	O
),	O
have	O
repeatedly	O
been	O
detected	O
in	O
acute	O
lower	O
respiratory	O
tract	O
infections	O
(	O
LRTI	O
)	O
in	O
children	O
in	O
the	O
past	O
decades	O
.	O

However	O
,	O
in	O
the	O
last	O
ten	O
years	O
thanks	O
to	O
progress	O
in	O
molecular	O
technologies	O
,	O
newly	O
discovered	O
viruses	O
have	O
been	O
identified	O
including	O
human	O
Metapneumovirus	O
(	O
hMPV	O
),	O
coronaviruses	O
NL63	O
(	O
HcoV	O
-	O
NL63	O
)	O
and	O
HKU1	O
(	O
HcoV	O
-	O
HKU1	O
),	O
human	O
Bocavirus	O
(	O
HBoV	O
),	O
new	O
enterovirus	O
(	O
HEV	O
),	O
parechovirus	O
(	O
HpeV	O
)	O
and	O
rhinovirus	O
(	O
HRV	O
)	O
strains	O
,	O
polyomaviruses	O
WU	O
(	O
WUPyV	O
)	O
and	O
KI	O
(	O
KIPyV	O
)	O
and	O
the	O
pandemic	O
H1N1v	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

TITLE	O
:	O
Natural	O
transmission	O
of	O
Plasmodium	O
berghei	O
exacerbates	O
chronic	O
tuberculosis	B-PATH
in	O
an	O
experimental	O
co	O
-	O
infection	O
model	O
.	O

Two	O
of	O
the	O
world	O
'	O
s	O
most	O
notorious	O
killers	O
,	O
malaria	B-PATH
and	O
tuberculosis	B-PATH
,	O
are	O
co	O
-	O
endemic	O
in	O
impoverished	O
populations	O
in	O
the	O
tropics	O
.	O

Both	O
pathogens	O
have	O
a	O
major	O
impact	O
on	O
the	O
lung	O
as	O
the	O
prime	O
target	O
organ	O
for	O
aerogenic	O
Mycobacterium	O
tuberculosis	B-PATH
and	O
the	O
site	O
for	O
one	O
of	O
the	O
main	O
complications	O
in	O
severe	O
malaria	B-PATH
,	O
malaria	B-PATH
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
MA	O
-	O
ARDS	O
).	O

Our	O
study	O
provides	O
evidence	O
that	O
malaria	B-PATH
-	O
induced	O
immune	O
responses	O
impair	O
host	O
resistance	O
to	O
Mycobacterium	O
tuberculosis	B-PATH
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
-	O
related	O
pneumonia	O
and	O
other	O
complications	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
infection	O
was	O
associated	O
with	O
significant	O
morbidity	O
,	O
mainly	O
among	O
children	O
and	O
young	O
adults	O
.	O

In	O
addition	O
to	O
respiratory	O
complications	O
,	O
several	O
complications	O
due	O
to	O
direct	O
and	O
indirect	O
effects	O
on	O
other	O
body	O
systems	O
were	O
associated	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
infection	O
.	O

The	O
main	O
complications	O
reported	O
in	O
hospitalized	O
adults	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
were	O
pneumonia	O
(	O
primary	O
influenza	O
pneumonia	O
and	O
concomitant	O
/	O
secondary	O
bacterial	O
pneumonia	O
),	O
exacerbations	O
of	O
chronic	O
pulmonary	O
diseases	O
(	O
mainly	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
asthma	B-PATH
),	O
the	O
need	O
for	O
intensive	O
unit	O
care	O
admission	O
(	O
including	O
mechanical	O
ventilation	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
septic	O
shock	O
),	O
nosocomial	O
infections	O
and	O
acute	O
cardiac	O
events	O
.	O

In	O
experimentally	O
infected	O
animals	O
,	O
the	O
level	O
of	O
pulmonary	O
replication	O
of	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
was	O
higher	O
than	O
that	O
of	O
seasonal	O
influenza	O
viruses	O
.	O

Pathological	O
studies	O
in	O
autopsy	O
specimens	O
indicated	O
that	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
mainly	O
targeted	O
the	O
lower	O
respiratory	O
tract	O
,	O
resulting	O
in	O
diffuse	O
alveolar	O
damage	O
(	O
edema	O
,	O
hyaline	O
membranes	O
,	O
inflammation	O
,	O
and	O
fibrosis	O
),	O
manifested	O
clinically	O
by	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
refractory	O
hypoxemia	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
-	O
related	O
pneumonia	O
and	O
other	O
complications	O
were	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
among	O
hospitalized	O
patients	O
.	O

TITLE	O
:	O
Mortality	O
,	O
severe	O
acute	O
respiratory	O
infection	O
,	O
and	O
influenza	O
-	O
like	O
illness	O
associated	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
in	O
Argentina	O
,	O
2009	O
.	O

ABSTRACT	O
:	O
While	O
there	O
is	O
much	O
information	O
about	O
the	O
burden	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
in	O
North	O
America	O
,	O
little	O
data	O
exist	O
on	O
its	O
burden	O
in	O
South	O
America	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
ILI	O
rates	O
per	O
100	O
py	O
ranged	O
between	O
1	O
.	O
6	O
among	O
children	O
aged	O
<	O
5	O
to	O
17	O
.	O
1	O
among	O
persons	O
aged	O
45	O
-	O
64	O
years	O
.	O

While	O
9	O
(	O
53	O
%)	O
of	O
17	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
decedents	O
with	O
available	O
data	O
had	O
obesity	O
and	O
7	O
(	O
17	O
%)	O
of	O
40	O
had	O
diabetes	O
,	O
less	O
than	O
4	O
%	O
of	O
surviving	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
case	O
-	O
patients	O
had	O
these	O
pre	O
-	O
existing	O
conditions	O
(	O
p	O
â¤	O
0	O
.	O
001	O
).	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
caused	O
a	O
similar	O
burden	O
of	O
disease	O
in	O
Argentina	O
as	O
in	O
other	O
countries	O
.	O

ABSTRACT	O
:	O
The	O
degradative	O
activity	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
reverse	O
transcriptase	O
(	O
RT	O
),	O
termed	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
),	O
which	O
hydrolyzes	O
the	O
RNA	O
component	O
of	O
the	O
heteroduplex	O
RNA	O
:	O
DNA	B-PATH
replication	I-PATH
intermediate	O
,	O
is	O
an	O
excellent	O
target	O
for	O
drug	O
discovery	O
.	O

Excision	O
biopsy	O
was	O
performed	O
because	O
of	O
a	O
suspected	O
pigmented	O
basal	B-PATH
cell	I-PATH
carcinoma	I-PATH
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
cohort	O
study	O
and	O
propensity	O
-	O
matched	O
analysis	O
.	O

Rhabdomyolysis	O
is	O
characterized	O
by	O
injury	O
of	O
skeletal	O
muscle	O
with	O
subsequent	O
release	B-PATH
of	O
intracellular	O
contents	O
,	O
such	O
as	O
myoglobin	O
,	O
potassium	O
and	O
creatine	O
phosphokinase	O
.	O

There	O
were	O
3	O
deaths	O
as	O
a	O
result	O
of	O
severe	O
malaria	B-PATH
.	O

Among	O
all	O
influenza	O
cases	O
,	O
54	O
(	O
95	O
%)	O
were	O
influenza	B-PATH
A	I-PATH
and	O
3	O
(	O
5	O
%)	O
were	O
influenza	O
B	O
.	O
Of	O
the	O
influenza	B-PATH
A	I-PATH
viruses	O
,	O
16	O
(	O
30	O
%)	O
were	O
A	O
(	O
H1N1	O
)	O
pdm09	O
,	O
29	O
(	O
54	O
%)	O
were	O
seasonal	O
A	O
(	O
H1N1	O
),	O
6	O
(	O
11	O
%)	O
were	O
A	O
(	O
H3N2	O
),	O
and	O
4	O
(	O
7	O
%)	O
were	O
unsubtyped	O
.	O

HCoV	O
-	O
EMC	O
/	O
2012	O
may	O
be	O
most	O
closely	O
related	O
to	O
a	O
coronavirus	O
detected	O
in	O
Pipistrellus	O
pipistrellus	O
in	O
The	O
Netherlands	O
,	O
but	O
because	O
only	O
a	O
short	O
sequence	O
from	O
the	O
most	O
conserved	O
part	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
-	O
encoding	O
region	O
of	O
the	O
genome	O
was	O
reported	O
for	O
this	O
bat	O
virus	O
,	O
its	O
genetic	O
distance	O
from	O
HCoV	O
-	O
EMC	O
remains	O
uncertain	O
.	O

TITLE	O
:	O
Pathogenesis	O
of	O
malaria	B-PATH
in	O
tissues	O
and	O
blood	O
.	O

In	O
addition	O
to	O
cerebral	O
malaria	B-PATH
or	O
severe	O
anaemia	O
,	O
which	O
are	O
quite	O
common	O
manifestation	O
of	O
severe	O
malaria	B-PATH
,	O
clinical	O
evidences	O
of	O
thrombocytopenia	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
liver	O
and	O
kidney	O
disease	O
,	O
are	O
reported	O
.	O

In	O
primigravidae	O
from	O
endemic	O
areas	O
,	O
life	O
threatening	O
placental	O
malaria	B-PATH
may	O
also	O
be	O
present	O
.	O

In	O
the	O
following	O
pages	O
,	O
some	O
of	O
the	O
pathogenetic	O
aspects	O
will	O
be	O
briefly	O
reviewed	O
and	O
then	O
data	O
on	O
selected	O
and	O
less	O
frequent	O
manifestation	O
of	O
severe	O
malaria	B-PATH
,	O
such	O
as	O
liver	O
or	O
renal	O
failure	O
or	O
ARDS	O
will	O
be	O
discussed	O
.	O

ABSTRACT	O
:	O
The	O
mechanisms	O
by	O
which	O
viruses	O
induce	O
asthma	B-PATH
exacerbations	O
are	O
not	O
well	O
understood	O
.	O

We	O
characterized	O
fluctuations	O
in	O
nasal	O
aspirate	O
cytokines	O
during	O
naturally	O
occurring	O
respiratory	O
viral	O
infections	O
in	O
children	O
with	O
asthma	B-PATH
.	O

ABSTRACT	O
:	O
:	O
The	O
data	O
on	O
human	O
rhinovirus	O
,	O
coronavirus	O
,	O
bocavirus	O
,	O
metapneumovirus	O
,	O
Chlamydophila	O
pneumoniae	O
,	O
Mycoplasma	O
pneumoniae	O
and	O
Bordetella	O
pertussis	B-PATH
infections	O
in	O
children	O
with	O
cancer	O
is	O
limited	O
.	O
:	O
We	O
sought	O
to	O
determine	O
prospectively	O
the	O
prevalence	O
of	O
respiratory	O
pathogens	O
in	O
these	O
children	O
,	O
using	O
multiplexed	O
-	O
polymerase	O
chain	O
reaction	O
.	O

CDC	O
relied	O
on	O
vertical	O
programs	O
,	O
some	O
of	O
them	O
successful	O
(	O
such	O
as	O
elimination	O
of	O
lymphatic	O
filariasis	O
and	O
child	O
immunisation	O
),	O
but	O
others	O
(	O
such	O
as	O
control	O
of	O
schistosomiasis	O
and	O
tuberculosis	B-PATH
)	O
demonstrating	O
only	O
intermittent	O
progress	O
due	O
to	O
failed	O
strategies	O
or	O
reliance	O
on	O
support	O
by	O
the	O
poorest	O
governments	O
and	O
health	O
workers	O
,	O
who	O
could	O
not	O
or	O
would	O
not	O
collaborate	O
.	O

TITLE	O
:	O
Clinical	O
preparedness	O
for	O
severe	O
pneumonia	O
with	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
):	O
experiences	O
with	O
cases	O
in	O
Vietnam	O
.	O

ABSTRACT	O
:	O
Avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
in	O
human	O
presents	O
a	O
global	O
pandemic	O
threat	O
,	O
and	O
preparedness	O
is	O
urgently	O
required	O
in	O
high	O
-	O
risk	O
countries	O
.	O

We	O
identified	O
103	O
patients	O
(	O
BOS	O
(	O
n	O
=	O
77	O
),	O
asthma	B-PATH
(	O
n	O
=	O
11	O
)	O
and	O
chronic	O
bronchitis	O
(	O
n	O
=	O
15	O
)).	O

TITLE	O
:	O
Characteristics	O
and	O
outcome	O
of	O
critically	O
ill	O
patients	O
with	O
2009	O
H1N1	O
influenza	B-PATH
infection	I-PATH
in	O
Syria	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
epidemiologic	O
characteristics	O
,	O
clinical	O
features	O
,	O
and	O
outcome	O
of	O
severe	O
cases	O
of	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
infections	O
who	O
were	O
admitted	O
to	O
the	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
in	O
Damascus	O
,	O
Syria	O
.	O

Retrospectively	O
,	O
we	O
collected	O
clinical	O
data	O
on	O
all	O
patients	O
who	O
were	O
admitted	O
to	O
the	O
ICU	O
with	O
confirmed	O
or	O
suspected	O
diagnosis	O
of	O
severe	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
with	O
respiratory	O
failure	O
at	O
4	O
major	O
tertiary	O
care	O
hospitals	O
in	O
Damascus	O
,	O
Syria	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
for	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
related	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
has	O
been	O
described	O
once	O
all	O
other	O
therapeutic	O
options	O
have	O
been	O
exhausted	O
.	O

It	O
is	O
related	O
with	O
emotional	O
and	O
physical	O
stress	O
,	O
and	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
an	O
acute	O
release	B-PATH
of	O
catecholamines	O
.	O

TITLE	O
:	O
Acute	O
asthma	B-PATH
exacerbations	O
in	O
childhood	O
:	O
risk	O
factors	O
,	O
prevention	O
and	O
treatment	O
.	O

ABSTRACT	O
:	O
Asthma	B-PATH
is	O
a	O
heterogeneous	O
disease	O
more	O
appropriately	O
seen	O
as	O
a	O
syndrome	O
rather	O
than	O
a	O
single	O
pathologic	O
entity	O
.	O

In	O
this	O
review	O
,	O
the	O
authors	O
focus	O
on	O
such	O
sudden	O
-	O
onset	O
events	O
,	O
emphasizing	O
on	O
their	O
diversity	O
on	O
the	O
basis	O
of	O
the	O
numerous	O
asthma	B-PATH
phenotypes	O
.	O

ABSTRACT	O
:	O
Amantadine	O
constitutes	O
an	O
interesting	O
,	O
diamond	O
crystal	O
lattice	O
-	O
shaped	O
,	O
antivirally	O
active	O
amine	O
with	O
an	O
inhibitory	O
effect	O
on	O
influenza	B-PATH
A	I-PATH
viruses	O
causing	O
common	O
'	O
flu	O
'	O
in	O
humans	O
.	O

One	O
N	O
-	O
phenacyl	O
amantadine	O
derivative	O
was	O
investigated	O
for	O
inhibiting	O
the	O
in	O
vitro	O
replication	O
of	O
respiratory	O
viruses	O
(	O
influenza	B-PATH
A	I-PATH
viruses	O
,	O
influenza	O
B	O
virus	O
,	O
human	O
parainfluenza	O
virus	O
type	O
3	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
).	O

An	O
amantadine	O
-	O
folate	O
conjugate	O
was	O
inhibitory	O
on	O
HIV	O
-	O
1	O
replication	O
in	O
primary	O
human	O
lymphocytes	O
,	O
and	O
one	O
N	O
-	O
phenacyl	O
amantadine	O
derivative	O
was	O
inhibitory	O
towards	O
low	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H5N1	O
)	O
replication	O
in	O
vitro	O
.	O

An	O
amantadine	O
-	O
folate	O
conjugate	O
was	O
inhibitory	O
on	O
HIV	O
-	O
1	O
replication	O
in	O
primary	O
human	O
lymphocytes	O
,	O
and	O
one	O
N	O
-	O
phenacyl	O
amantadine	O
derivative	O
was	O
inhibitory	O
towards	O
low	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H5N1	O
)	O
replication	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
a	O
public	O
health	O
problem	O
in	O
the	O
UrabÃ¡	O
region	O
recording	O
rates	O
of	O
infection	O
above	O
those	O
of	O
the	O
Antioquia	O
department	O
.	O

We	O
reviewed	O
the	O
medical	O
records	O
of	O
patients	O
with	O
vivax	O
malaria	B-PATH
hospitalized	O
in	O
the	O
Antonio	O
RoldÃ¡n	O
Betancur	O
hospital	O
from	O
2004	O
-	O
2007	O
.	O

Some	O
patients	O
met	O
several	O
criteria	O
for	O
complicated	O
malaria	B-PATH
simultaneously	O
,	O
including	O
one	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Only	O
4	O
.	O
82	O
%	O
(	O
4	O
/	O
83	O
)	O
of	O
patients	O
with	O
complicated	O
malaria	B-PATH
were	O
treated	O
with	O
intravenous	O
quinine	O
,	O
no	O
one	O
died	O
.	O

The	O
elevated	O
frequency	O
of	O
complicated	O
vivax	O
malaria	B-PATH
found	O
in	O
the	O
Uraba	O
region	O
in	O
this	O
study	O
is	O
noteworthy	O
,	O
particularly	O
in	O
children	O
under	O
5	O
years	O
.	O

The	O
results	O
highlight	O
the	O
need	O
to	O
strengthen	O
,	O
amongst	O
the	O
health	O
staff	O
,	O
the	O
knowledge	O
of	O
the	O
guidelines	O
for	O
the	O
clinical	O
care	O
of	O
malaria	B-PATH
patients	O
,	O
in	O
order	O
to	O
make	O
a	O
correct	O
clinical	O
diagnosis	O
and	O
provide	O
appropriate	O
treatment	O
.	O

In	O
case	O
of	O
the	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
a	O
member	O
of	O
the	O
family	O
Flaviviridae	O
,	O
infected	O
cells	O
contain	O
accumulations	O
of	O
vesicles	O
forming	O
a	O
membranous	O
web	O
(	O
MW	O
)	O
that	O
is	O
thought	O
to	O
be	O
the	O
site	O
of	O
viral	O
RNA	O
replication	O
.	O

Bootscan	O
analysis	O
revealed	O
that	O
NTU156	O
evolved	O
from	O
two	O
crossover	O
events	O
between	O
type	O
I	O
FCoV	O
and	O
canine	O
coronavirus	O
,	O
with	O
recombination	O
sites	O
located	O
in	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
and	O
M	O
genes	O
.	O

hMPV	O
can	O
cause	O
morbidity	O
in	O
hematopoietic	O
stem	O
cell	O
transplant	O
recipients	O
and	O
recent	O
research	O
has	O
demonstrated	O
that	O
it	O
is	O
an	O
important	O
virus	O
in	O
patients	O
admitted	O
to	O
hospital	O
with	O
respiratory	O
infections	O
and	O
suspected	O
of	O
having	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1pdm09	O
)	O
virus	O
.	O

In	O
nasopharyngeal	O
aspirates	O
the	O
following	O
viruses	O
were	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
:	O
cytomegalovirus	O
,	O
Epstein	O
-	O
Barr	O
virus	O
,	O
parvovirus	O
B19	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
parainfluenza	O
viruses	O
,	O
human	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
,	O
human	O
metapneumovirus	O
,	O
rhinovirus	O
,	O
enterovirus	O
,	O
adenovirus	O
,	O
human	O
coronavirus	O
OC43	O
,	O
229E	O
,	O
NL63	O
and	O
human	O
bocavirus	O
.	O

TITLE	O
:	O
Abdominal	O
obesity	O
and	O
prolonged	O
prone	O
positioning	O
increase	O
risk	O
of	O
developing	O
sclerosing	O
cholangitis	O
in	O
critically	O
ill	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
-	O
associated	O
ARDS	O
.	O

We	O
report	O
on	O
a	O
homogenous	O
cohort	O
of	O
critically	O
ill	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pneumonia	O
and	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
of	O
whom	O
a	O
subgroup	O
developed	O
sclerosing	O
cholangitis	O
,	O
allowing	O
for	O
probing	O
of	O
risk	O
factors	O
associated	O
with	O
SC	O
-	O
CIP	O
.	O

We	O
followed	O
97	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
or	O
influenza	O
B	O
who	O
received	O
care	O
at	O
the	O
emergency	O
department	O
(	O
ED	O
).	O

ABSTRACT	O
:	O
To	O
describe	O
characteristics	O
and	O
outcome	O
of	O
mechanically	O
ventilated	O
patients	O
admitted	O
to	O
three	O
newly	O
established	O
intensive	O
care	O
units	O
(	O
ICU	O
)	O
in	O
Bosnia	O
-	O
Herzegovina	O
and	O
Serbia	O
for	O
2009	O
H1N1	O
influenza	B-PATH
infection	I-PATH
.	O

The	O
retrospective	O
observational	O
study	O
included	O
all	O
mechanically	O
ventilated	O
adult	O
patients	O
of	O
three	O
university	O
-	O
affiliated	O
hospitals	O
between	O
November	O
1	O
,	O
2009	O
and	O
March	O
1	O
2010	O
who	O
had	O
2009	O
H1N1	O
influenza	B-PATH
infection	I-PATH
confirmed	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	O
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
swab	O
specimens	O
and	O
respiratory	O
secretions	O
.	O

They	O
are	O
essentially	O
represented	O
by	O
COPD	O
,	O
asthma	B-PATH
,	O
and	O
allergic	O
diseases	O
.	O

Smoking	O
prevention	O
and	O
standardized	O
management	O
programs	O
for	O
asthma	B-PATH
and	O
COPD	O
are	O
now	O
available	O
but	O
prompt	O
actions	O
are	O
needed	O
to	O
make	O
them	O
more	O
effective	O
in	O
this	O
region	O
and	O
thus	O
avoid	O
an	O
adverse	O
impact	O
on	O
national	O
economic	O
development	O
.	O

ABSTRACT	O
:	O
Most	O
betacoronaviruses	O
possess	O
an	O
hemagglutinin	O
-	O
esterase	O
(	O
HE	O
)	O
protein	O
,	O
which	O
appears	O
to	O
play	O
a	O
role	O
in	O
binding	O
to	O
or	O
release	B-PATH
from	O
the	O
target	O
cell	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
,	O
and	O
functions	O
as	O
the	O
key	O
SARS	O
coronavirus	O
receptor	O
and	O
stabilizer	O
of	O
neutral	O
amino	O
acid	O
transporters	O
.	O

The	O
subcellular	O
localization	O
and	O
function	O
of	O
PEDV	O
E	O
protein	O
were	O
investigated	O
by	O
examining	O
its	O
effects	O
on	O
cell	O
growth	O
,	O
cell	B-PATH
cycle	I-PATH
progression	O
,	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
expression	O
and	O
cell	O
survival	O
.	O

The	O
PEDV	O
E	O
protein	O
has	O
no	O
effect	O
on	O
the	O
intestinal	O
epithelial	O
cells	O
(	O
IEC	O
)	O
growth	O
,	O
cell	B-PATH
cycle	I-PATH
and	O
cyclin	O
A	O
expression	O
.	O

The	O
PEDV	O
E	O
protein	O
had	O
no	O
effect	O
on	O
the	O
IEC	O
growth	O
and	O
cell	B-PATH
cycle	I-PATH
.	O

For	O
one	O
,	O
our	O
study	O
demonstrates	O
the	O
advantages	O
of	O
biodegradable	O
IFNÎ±	O
-	O
coated	O
R	O
-	O
Chitosan	O
NPs	O
for	O
controlled	O
cytokine	O
release	B-PATH
,	O
and	O
thereby	O
improved	O
therapy	O
.	O

The	O
aims	O
of	O
this	O
paper	O
are	O
to	O
address	O
the	O
mechanisms	O
for	O
alcohol	O
-	O
induced	O
GSH	O
depletion	O
and	O
oxidation	O
and	O
the	O
subsequent	O
effects	O
in	O
alveolar	O
barrier	O
integrity	O
,	O
modulation	O
of	O
the	O
immune	O
response	O
,	O
and	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
miliary	O
tuberculosis	B-PATH
complicated	O
by	O
disseminated	O
intravascular	O
coagulation	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
successfully	O
treated	O
with	O
recombinant	O
human	O
soluble	O
thrombomodulin	O
].	O

Examination	O
of	O
sputum	O
and	O
urine	O
revealed	O
acid	O
-	O
fast	O
bacilli	O
,	O
which	O
were	O
later	O
confirmed	O
as	O
Mycobacterium	O
tuberculosis	B-PATH
sensitive	O
to	O
all	O
drugs	O
.	O

It	O
is	O
generally	O
thought	O
that	O
prognosis	O
of	O
miliary	O
tuberculosis	B-PATH
complicated	O
by	O
DIC	O
and	O
ARDS	O
is	O
very	O
poor	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
miliary	O
tuberculosis	B-PATH
complicated	O
by	O
DIC	O
and	O
ARDS	O
successfully	O
treated	O
with	O
rTM	O
.	O

TITLE	O
:	O
Release	B-PATH
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nuclear	O
import	O
block	O
enhances	O
host	O
transcription	O
in	O
human	O
lung	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
accessory	O
protein	O
ORF6	O
antagonizes	O
interferon	B-PATH
signaling	I-PATH
by	O
blocking	O
karyopherin	O
-	O
mediated	O
nuclear	O
import	O
processes	O
.	O

TITLE	O
:	O
Asthma	B-PATH
in	O
patients	O
hospitalized	O
with	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
infection	O
-	O
United	O
States	O
,	O
2009	O
.	O

ABSTRACT	O
:	O
Asthma	B-PATH
was	O
the	O
most	O
common	O
co	O
-	O
morbidity	O
among	O
patients	O
hospitalized	O
with	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
[	O
pH1N1	O
]	O
infection	O
.	O

The	O
objective	O
was	O
to	O
compare	O
characteristics	O
of	O
hospitalized	O
pH1N1	O
patients	O
with	O
and	O
without	O
asthma	B-PATH
and	O
assess	O
factors	O
associated	O
with	O
severity	O
among	O
asthma	B-PATH
patients	O
.	O

Asthma	B-PATH
status	O
was	O
determined	O
through	O
chart	O
review	O
.	O

Among	O
473	O
cases	O
,	O
29	O
%	O
had	O
asthma	B-PATH
.	O

Persons	O
with	O
asthma	B-PATH
were	O
more	O
likely	O
to	O
be	O
2	O
-	O
17	O
years	O
old	O
(	O
39	O
%	O
vs	O
.	O
30	O
%,	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
black	O
(	O
29	O
%	O
vs	O
.	O
18	O
%,	O
p	O
<	O
0	O
.	O
01	O
),	O
and	O
have	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
13	O
%	O
vs	O
.	O
9	O
%,	O
p	O
=	O
0	O
.	O
04	O
)	O
but	O
less	O
likely	O
to	O
have	O
pneumonia	O
(	O
37	O
%	O
vs	O
.	O
47	O
%,	O
p	O
=	O
0	O
.	O
05	O
),	O
need	O
mechanical	O
ventilation	O
(	O
13	O
%	O
vs	O
.	O
23	O
%,	O
p	O
=	O
0	O
.	O
02	O
),	O
and	O
die	O
(	O
4	O
%	O
vs	O
.	O
10	O
%,	O
p	O
=	O
0	O
.	O
04	O
)	O
than	O
those	O
without	O
asthma	B-PATH
.	O

Among	O
patients	O
with	O
asthma	B-PATH
,	O
those	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
or	O
who	O
died	O
(	O
n	O
=	O
38	O
)	O
compared	O
with	O
survivors	O
not	O
admitted	O
to	O
an	O
ICU	O
(	O
n	O
=	O
99	O
)	O
were	O
more	O
likely	O
to	O
have	O
pneumonia	O
on	O
admission	O
(	O
60	O
%	O
vs	O
.	O
27	O
%,	O
p	O
<	O
0	O
.	O
01	O
)	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
24	O
%	O
vs	O
.	O
0	O
%,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
less	O
likely	O
to	O
receive	O
influenza	O
antiviral	O
agents	O
â¤	O
2	O
days	O
of	O
admission	O
(	O
73	O
%	O
vs	O
.	O
92	O
%,	O
p	O
=	O
0	O
.	O
02	O
).	O

Influenza	O
antiviral	O
agents	O
should	O
be	O
started	O
early	O
in	O
hospitalized	O
patients	O
with	O
suspected	O
influenza	O
,	O
including	O
those	O
with	O
asthma	B-PATH
.	O

Among	O
patients	O
with	O
asthma	B-PATH
,	O
those	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
or	O
who	O
died	O
(	O
n	O
=	O
38	O
)	O
compared	O
with	O
survivors	O
not	O
admitted	O
to	O
an	O
ICU	O
(	O
n	O
=	O
99	O
)	O
were	O
more	O
likely	O
to	O
have	O
pneumonia	O
on	O
admission	O
(	O
60	O
%	O
vs	O
.	O
27	O
%,	O
p	O
<	O
0	O
.	O
01	O
)	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
24	O
%	O
vs	O
.	O
0	O
%,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
less	O
likely	O
to	O
receive	O
influenza	O
antiviral	O
agents	O
â¤	O
2	O
days	O
of	O
admission	O
(	O
73	O
%	O
vs	O
.	O
92	O
%,	O
p	O
=	O
0	O
.	O
02	O
).	O

When	O
compared	O
with	O
health	O
outcomes	O
among	O
formula	O
-	O
fed	O
children	O
,	O
the	O
health	O
advantages	O
associated	O
with	O
breastfeeding	O
include	O
a	O
lower	O
risk	O
of	O
acute	O
otitis	O
media	O
,	O
gastroenteritis	O
and	O
diarrhea	O
,	O
severe	O
lower	O
respiratory	O
infections	O
,	O
asthma	B-PATH
,	O
sudden	O
infant	O
death	O
syndrome	O
,	O
obesity	O
and	O
other	O
childhood	O
diseases	O
and	O
conditions	O
.	O

TITLE	O
:	O
Heparin	O
-	O
binding	O
protein	O
(	O
HBP	O
)	O
in	O
critically	O
ill	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

Severe	O
acute	O
respiratory	O
failure	O
with	O
ARDS	O
is	O
a	O
complication	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

Accordingly	O
,	O
we	O
studied	O
the	O
HBP	O
levels	O
in	O
critically	O
ill	O
patients	O
with	O
infection	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O
Critically	O
ill	O
patients	O
in	O
four	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
with	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
confirmed	O
infection	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
were	O
prospectively	O
evaluated	O
.	O

TITLE	O
:	O
Postpneumonectomy	O
-	O
like	O
syndrome	O
presenting	O
in	O
a	O
patient	O
with	O
treated	O
pulmonary	O
tuberculosis	B-PATH
:	O
a	O
case	O
report	O
.	O

We	O
present	O
a	O
rare	O
case	O
of	O
a	O
91	O
-	O
year	O
-	O
old	O
Puerto	O
Rican	O
man	O
presenting	O
with	O
progressively	O
worsening	O
dyspnea	O
with	O
a	O
history	O
of	O
pulmonary	O
tuberculosis	B-PATH
diagnosed	O
40	O
years	O
earlier	O
who	O
developed	O
severe	O
unilateral	O
lung	O
fibrosis	O
.	O

We	O
present	O
a	O
rare	O
case	O
of	O
postpneumonectomy	O
-	O
like	O
syndrome	O
as	O
sequelae	O
of	O
severe	O
pulmonary	O
parenchymal	O
tuberculosis	B-PATH
infection	O
along	O
with	O
a	O
review	O
of	O
literature	O
,	O
in	O
the	O
hopes	O
of	O
aiding	O
clinicians	O
to	O
include	O
the	O
differential	O
of	O
postpneumonectomy	O
-	O
like	O
syndrome	O
in	O
patients	O
presenting	O
with	O
worsening	O
dyspnea	O
without	O
a	O
history	O
of	O
surgical	O
lung	O
resection	O
.	O

CONCLUSIONS	O
:	O
We	O
present	O
a	O
rare	O
case	O
of	O
postpneumonectomy	O
-	O
like	O
syndrome	O
as	O
sequelae	O
of	O
severe	O
pulmonary	O
parenchymal	O
tuberculosis	B-PATH
infection	O
along	O
with	O
a	O
review	O
of	O
literature	O
,	O
in	O
the	O
hopes	O
of	O
aiding	O
clinicians	O
to	O
include	O
the	O
differential	O
of	O
postpneumonectomy	O
-	O
like	O
syndrome	O
in	O
patients	O
presenting	O
with	O
worsening	O
dyspnea	O
without	O
a	O
history	O
of	O
surgical	O
lung	O
resection	O
.	O

The	O
infection	O
rates	O
were	O
15	O
.	O
8	O
%	O
for	O
human	O
rhinovirus	O
,	O
14	O
.	O
4	O
&	O
percnt	O
;	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
A	O
,	O
9	O
.	O
7	O
%	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
B	O
,	O
10	O
.	O
1	O
%	O
for	O
human	O
adenovirus	O
,	O
5	O
.	O
4	O
%	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
1	O
.	O
7	O
%	O
for	O
influenza	O
B	O
virus	O
,	O
4	O
.	O
7	O
%	O
for	O
human	O
metapneumovirus	O
,	O
2	O
.	O
3	O
%	O
for	O
human	O
coronavirus	O
OC43	O
,	O
1	O
.	O
9	O
%	O
for	O
human	O
coronavirus	O
229E	O
/	O
NL63	O
,	O
3	O
.	O
7	O
%	O
for	O
human	O
parainfluenza	O
virus	O
(	O
HPIV	O
)-	O
1	O
,	O
1	O
.	O
1	O
%	O
for	O
HPIV	O
-	O
2	O
,	O
and	O
5	O
.	O
3	O
%	O
for	O
HPIV	O
-	O
3	O
.	O

New	O
Zealand	O
nurses	O
perceptions	O
of	O
caring	O
for	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

The	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
caused	O
a	O
global	O
pandemic	O
and	O
also	O
affected	O
New	O
Zealand	O
during	O
that	O
winter	O
.	O

TITLE	O
:	O
Plasmodium	O
vivax	O
malaria	B-PATH
complicated	O
by	O
acute	O
kidney	O
injury	O
:	O
experience	O
at	O
a	O
referral	O
hospital	O
in	O
Uttarakhand	O
,	O
India	O
.	O

ABSTRACT	O
:	O
Acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
is	O
a	O
serious	O
complication	O
of	O
Plasmodium	O
vivax	O
malaria	B-PATH
,	O
worsening	O
its	O
prognosis	O
.	O

This	O
prospective	O
study	O
assessed	O
the	O
incidence	O
,	O
clinical	O
spectrum	O
,	O
prognostic	O
factors	O
and	O
outcome	O
of	O
AKI	O
in	O
P	O
.	O
vivax	O
malaria	B-PATH
.	O

During	O
2010	O
-	O
2011	O
,	O
195	O
patients	O
with	O
vivax	O
malaria	B-PATH
diagnosed	O
by	O
positive	O
peripheral	O
blood	O
film	O
and	O
rapid	O
malaria	B-PATH
test	O
were	O
studied	O
for	O
AKI	O
using	O
RIFLE	O
criteria	O
.	O

AKI	O
is	O
now	O
common	O
in	O
vivax	O
malaria	B-PATH
and	O
has	O
significant	O
mortality	O
.	O

For	O
each	O
strain	O
,	O
we	O
analyzed	O
the	O
replication	O
kinetics	O
and	O
progeny	O
virus	O
release	B-PATH
on	O
HAE	O
cell	O
cultures	O
derived	O
from	O
different	O
donors	O
.	O

ABSTRACT	O
:	O
Molecular	O
typing	O
is	O
a	O
valuable	O
tool	O
for	O
gaining	O
insight	O
into	O
spread	O
of	O
Mycobacterium	O
tuberculosis	B-PATH
.	O

Observed	O
distributions	O
of	O
genotypic	O
cluster	O
sizes	O
of	O
tuberculosis	B-PATH
(	O
TB	O
)	O
are	O
highly	O
skewed	O
.	O

To	O
diagnose	O
sarcoidosis	O
,	O
other	O
infectious	O
granulomatous	O
lung	O
diseases	O
such	O
as	O
tuberculosis	B-PATH
,	O
atypical	O
mycobacterial	O
and	O
fungal	O
infection	O
have	O
to	O
be	O
ruled	O
out	O
.	O

Pulmonary	O
granuloma	O
also	O
evolve	O
in	O
the	O
context	O
of	O
autoimmune	O
diseases	O
such	O
as	O
rheumatoid	B-PATH
arthritis	I-PATH
,	O
granulomatosis	O
with	O
polyangiitis	O
(	O
GBA	O
,	O
Wegener	O
'	O
s	O
)	O
and	O
eosinophilic	O
granulomatosis	O
with	O
polyangiitis	O
(	O
EGPA	O
,	O
Churg	O
-	O
Strauss	O
syndrome	O
).	O

TITLE	O
:	O
Using	O
routine	O
surveillance	O
data	O
to	O
estimate	O
the	O
epidemic	O
potential	O
of	O
emerging	O
zoonoses	O
:	O
application	O
to	O
the	O
emergence	O
of	O
US	O
swine	O
origin	O
influenza	B-PATH
A	I-PATH
H3N2v	O
virus	O
.	O

We	O
apply	O
it	O
to	O
assess	O
the	O
transmissibility	O
of	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
H3N2v	O
-	O
M	O
virus	O
in	O
the	O
US	O
,	O
Nipah	O
virus	O
in	O
Malaysia	O
and	O
Bangladesh	O
,	O
and	O
also	O
present	O
a	O
non	O
-	O
zoonotic	O
example	O
(	O
cholera	O
in	O
the	O
Dominican	O
Republic	O
).	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
the	O
commonest	O
imported	O
infection	O
in	O
the	O
UK	O
.	O

Malaria	B-PATH
requiring	O
ICU	O
admission	O
has	O
a	O
reported	O
mortality	O
of	O
up	O
to	O
25	O
%.	O

The	O
relationship	O
between	O
ethnicity	O
,	O
immunity	O
,	O
and	O
risk	O
of	O
malaria	B-PATH
is	O
complex	O
.	O

Cerebral	O
malaria	B-PATH
and	O
acute	O
kidney	O
injury	O
occurred	O
earlier	O
(	O
median	O
day	O
1	O
)	O
than	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
median	O
day	O
3	O
).	O

Patients	O
who	O
died	O
succumbed	O
to	O
complications	O
associated	O
with	O
a	O
prolonged	O
stay	O
on	O
ICU	O
rather	O
than	O
malaria	B-PATH
per	O
se	O
.	O

ABSTRACT	O
:	O
Complicated	O
falciparum	O
malaria	B-PATH
remains	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

All	O
cases	O
of	O
falciparum	O
malaria	B-PATH
are	O
potentially	O
severe	O
and	O
life	O
threatening	O
,	O
especially	O
when	O
managed	O
inappropriately	O
.	O

Total	O
47	O
patients	O
fulfilling	O
criterion	O
of	O
complicated	O
malaria	B-PATH
due	O
to	O
P	O
.	O
falciparum	O
who	O
presented	O
with	O
fever	O
having	O
positive	O
trophozoites	O
of	O
P	O
.	O
falciparum	O
in	O
blood	O
smear	O
were	O
included	O
in	O
this	O
study	O
.	O

A	O
total	O
47	O
patients	O
had	O
smear	O
positive	O
complicated	O
P	O
.	O
falciparum	O
malaria	B-PATH
with	O
39	O
were	O
male	O
and	O
8	O
were	O
female	O
patients	O
.	O

Total	O
6	O
(	O
12	O
.	O
76	O
%)	O
had	O
cerebral	O
malaria	B-PATH
,	O
6	O
(	O
12	O
.	O
76	O
%)	O
had	O
acute	O
renal	O
failure	O
(	O
ARF	O
),	O
5	O
(	O
10	O
.	O
63	O
%)	O
had	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
1	O
(	O
2	O
.	O
12	O
%)	O
had	O
thrombocytopenia	O
.	O

Total	O
26	O
patients	O
had	O
single	O
complication	O
in	O
the	O
form	O
of	O
cerebral	O
malaria	B-PATH
6	O
(	O
12	O
.	O
76	O
%),	O
jaundice	O
9	O
(	O
19	O
.	O
14	O
%),	O
ARF	O
5	O
(	O
10	O
.	O
63	O
%),	O
ARDS	O
4	O
(	O
8	O
.	O
51	O
%)	O
and	O
anemia	O
2	O
(	O
4	O
.	O
25	O
%).	O

One	O
(	O
2	O
.	O
12	O
%)	O
patient	O
had	O
four	O
complications	O
in	O
the	O
form	O
of	O
cerebral	O
malaria	B-PATH
with	O
ARF	O
with	O
ARDS	O
with	O
thrombocytopenia	O
with	O
100	O
%	O
mortality	O
.	O

The	O
case	O
fatality	O
rate	O
for	O
isolated	O
ARDS	O
was	O
50	O
%	O
(	O
2	O
/	O
4	O
),	O
with	O
ARF	O
was	O
20	O
%	O
(	O
1	O
/	O
5	O
)	O
and	O
with	O
cerebral	O
malaria	B-PATH
it	O
was	O
16	O
.	O
66	O
%	O
(	O
1	O
/	O
6	O
).	O

Case	O
fatality	O
rate	O
was	O
highest	O
in	O
patients	O
with	O
ARDS	O
compared	O
to	O
ARF	O
and	O
cerebral	O
malaria	B-PATH
with	O
'	O
P	O
'	O
=	O
0	O
.	O
0221	O
.	O

Overall	O
case	O
fatality	O
rate	O
of	O
complicated	O
P	O
.	O
falciparum	O
malaria	B-PATH
was	O
10	O
.	O
63	O
%.	O

This	O
study	O
highlights	O
the	O
significant	O
burden	O
of	O
P	O
.	O
falciparum	O
complicated	O
malaria	B-PATH
with	O
isolated	O
complication	O
like	O
ARDS	O
with	O
high	O
mortality	O
rate	O
of	O
50	O
%	O
in	O
present	O
population	O
.	O

TITLE	O
:	O
[	O
Case	O
report	O
of	O
the	O
first	O
world	O
death	O
due	O
to	O
a	O
new	O
strain	O
of	O
human	O
influenza	B-PATH
A	I-PATH
H1N1	O
virus	O
and	O
behavior	O
of	O
human	O
influenzae	O
in	O
pregnant	O
women	O
].	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
H1N1	O
is	O
an	O
acute	O
respiratory	O
illness	O
caused	O
by	O
a	O
new	O
strain	O
of	O
H1N1	O
.	O

Due	O
to	O
the	O
clinical	O
presentation	O
of	O
the	O
case	O
,	O
the	O
doctors	O
sent	O
samples	O
to	O
the	O
Instituto	O
Nacional	O
de	O
DiagnÃ³stico	O
y	O
Referencia	O
EpidemiolÃ³gica	O
that	O
sent	O
an	O
aliquot	O
of	O
the	O
National	O
Center	O
for	O
Immunization	O
and	O
Respiratory	O
Diseases	O
of	O
theAgency	O
of	O
Public	O
Health	O
in	O
Canada	O
,	O
that	O
reported	O
positivity	O
to	O
influenza	O
virus	O
,	O
and	O
catalogued	O
it	O
as	O
a	O
new	O
global	O
strain	O
called	O
influenza	B-PATH
A	I-PATH
virus	O
H1N1	O
.	O

In	O
order	O
of	O
frequency	O
,	O
identified	O
pathogens	O
were	O
respiratory	O
syncytial	O
virus	O
(	O
32	O
.	O
0	O
%),	O
adenovirus	O
(	O
26	O
.	O
2	O
%),	O
parainfluenza	O
viruses	O
type	O
1	O
-	O
4	O
(	O
19	O
.	O
4	O
%),	O
rhinovirus	O
(	O
18	O
.	O
4	O
%),	O
influenza	B-PATH
A	I-PATH
and	O
B	O
(	O
12	O
.	O
6	O
%),	O
human	O
metapneumovirus	O
(	O
12	O
.	O
6	O
%),	O
coronavirus	O
(	O
2	O
.	O
9	O
%),	O
and	O
bocavirus	O
(	O
0	O
.	O
9	O
%).	O

In	O
this	O
series	O
,	O
seven	O
cases	O
of	O
AAC	O
from	O
a	O
cohort	O
of	O
42	O
adult	O
patients	O
with	O
severe	O
imported	O
falciparum	O
malaria	B-PATH
[	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
criteria	O
]	O
are	O
presented	O
.	O

The	O
aim	O
is	O
to	O
report	O
the	O
cases	O
and	O
look	O
for	O
malaria	B-PATH
conditions	O
that	O
may	O
affect	O
the	O
incidence	O
of	O
this	O
unusual	O
malaria	B-PATH
complication	O
.	O

Each	O
patient	O
presented	O
five	O
to	O
nine	O
WHO	O
severe	O
malaria	B-PATH
criteria	O
:	O
all	O
had	O
hyperparasitaemia	O
and	O
hyperbilirubinaemia	O
.	O

Patients	O
with	O
AAC	O
have	O
significantly	O
more	O
commonly	O
five	O
or	O
more	O
criteria	O
of	O
severe	O
malaria	B-PATH
:	O
renal	O
insufficiency	O
,	O
pulmonary	O
oedema	O
/	O
ARDS	O
,	O
parasitaemia	O
higher	O
than	O
30	O
%,	O
nosocomial	O
infection	O
and	O
a	O
prolonged	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
stay	O
.	O

Increased	O
awareness	O
for	O
this	O
unusual	O
and	O
potentially	O
severe	O
complication	O
of	O
malaria	B-PATH
is	O
needed	O
.	O

Transmission	O
electron	O
microscopy	O
showed	O
virions	O
within	O
the	O
cytoplasm	O
of	O
bronchial	O
epithelial	O
cells	O
and	O
budding	B-PATH
virions	O
from	O
alveolar	O
epithelial	O
cells	O
(	O
type	O
II	O
).	O

Thirty	O
-	O
four	O
patients	O
with	O
at	O
least	O
5	O
years	O
of	O
HIV	B-PATH
infection	I-PATH
and	O
27	O
healthy	O
controls	O
underwent	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
in	O
a	O
1	O
.	O
5	O
T	O
scanner	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
N	O
protein	O
prolongs	O
S	O
-	O
phase	O
cell	B-PATH
cycle	I-PATH
,	O
induces	O
endoplasmic	O
reticulum	O
stress	O
,	O
and	O
up	O
-	O
regulates	O
interleukin	O
-	O
8	O
expression	O
.	O

The	O
results	O
show	O
that	O
the	O
PEDV	O
N	O
protein	O
localizes	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
),	O
inhibits	O
the	O
IEC	O
growth	O
and	O
prolongs	O
S	O
-	O
phase	O
cell	B-PATH
cycle	I-PATH
.	O

This	O
is	O
the	O
first	O
report	O
to	O
demonstrate	O
that	O
PEDV	O
N	O
protein	O
can	O
induce	O
cell	B-PATH
cycle	I-PATH
prolongation	O
at	O
the	O
S	O
-	O
phase	O
,	O
ER	O
stress	O
and	O
up	O
-	O
regulation	O
interleukin	O
-	O
8	O
expression	O
.	O

TITLE	O
:	O
Human	O
infection	O
with	O
a	O
novel	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
.	O

In	O
March	O
2013	O
,	O
three	O
urban	O
residents	O
of	O
Shanghai	O
or	O
Anhui	O
,	O
China	O
,	O
presented	O
with	O
rapidly	O
progressing	O
lower	O
respiratory	O
tract	O
infections	O
and	O
were	O
found	O
to	O
be	O
infected	O
with	O
a	O
novel	O
reassortant	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
.	O

A	O
novel	O
reassortant	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	B-PATH
)	O
virus	O
was	O
isolated	O
from	O
respiratory	O
specimens	O
obtained	O
from	O
all	O
three	O
patients	O
and	O
was	O
identified	O
as	O
H7N9	B-PATH
.	O

RESULTS	O
:	O
A	O
novel	O
reassortant	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	B-PATH
)	O
virus	O
was	O
isolated	O
from	O
respiratory	O
specimens	O
obtained	O
from	O
all	O
three	O
patients	O
and	O
was	O
identified	O
as	O
H7N9	B-PATH
.	O

TGEV	O
membrane	O
(	O
M	O
)	O
protein	O
not	O
only	O
plays	O
a	O
vital	O
role	O
in	O
the	O
process	O
of	O
virus	O
assembly	O
and	O
budding	B-PATH
,	O
but	O
also	O
induces	O
the	O
production	O
of	O
interferon	O
-	O
Î±	O
during	O
infection	O
.	O

TITLE	O
:	O
Interstitial	O
lung	O
disease	O
and	O
profound	O
hypoxaemia	O
in	O
a	O
severely	O
-	O
malnourished	O
child	O
with	O
very	O
severe	O
pneumonia	O
and	O
potential	O
lymph	O
-	O
node	O
tuberculosis	B-PATH
:	O
an	O
uncommon	O
but	O
serious	O
co	O
-	O
morbidity	O
.	O

During	O
the	O
hospital	O
stay	O
,	O
hypoxaemia	O
was	O
persistent	O
with	O
very	O
little	O
improvement	O
of	O
pneumonia	O
;	O
a	O
number	O
of	O
differentials	O
,	O
such	O
as	O
pneumocystis	O
jirovecii	O
pneumonia	O
,	O
lymph	O
-	O
node	O
tuberculosis	B-PATH
,	O
were	O
added	O
to	O
the	O
problems	O
.	O

Following	O
infection	O
,	O
we	O
observed	O
rapidly	O
increasing	O
viral	O
RNA	O
synthesis	O
and	O
release	B-PATH
of	O
high	O
titres	O
of	O
infectious	O
progeny	O
,	O
followed	O
by	O
a	O
pronounced	O
cytopathology	O
.	O

Of	O
these	O
,	O
7	O
risk	O
factors	O
were	O
significantly	O
associated	O
with	O
severe	O
ALRI	O
in	O
a	O
consistent	O
manner	O
across	O
studies	O
,	O
with	O
the	O
following	O
meta	O
-	O
analysis	O
estimates	O
of	O
odds	O
ratios	O
(	O
with	O
95	O
%	O
confidence	O
intervals	O
):	O
low	O
birth	O
weight	O
3	O
.	O
18	O
(	O
1	O
.	O
02	O
-	O
9	O
.	O
90	O
),	O
lack	O
of	O
exclusive	O
breastfeeding	O
2	O
.	O
34	O
(	O
1	O
.	O
42	O
-	O
3	O
.	O
88	O
),	O
crowding	O
-	O
more	O
than	O
7	O
persons	O
per	O
household	O
1	O
.	O
96	O
(	O
1	O
.	O
53	O
-	O
2	O
.	O
52	O
),	O
exposure	O
to	O
indoor	O
air	O
pollution	O
1	O
.	O
57	O
(	O
1	O
.	O
06	O
-	O
2	O
.	O
31	O
),	O
incomplete	O
immunization	O
1	O
.	O
83	O
(	O
1	O
.	O
32	O
-	O
2	O
.	O
52	O
),	O
undernutrition	O
-	O
weight	O
-	O
for	O
-	O
age	O
less	O
than	O
2	O
standard	O
deviations	O
4	O
.	O
47	O
(	O
2	O
.	O
10	O
-	O
9	O
.	O
49	O
),	O
and	O
HIV	B-PATH
infection	I-PATH
4	O
.	O
15	O
(	O
2	O
.	O
57	O
-	O
9	O
.	O
74	O
).	O

Since	O
the	O
upstream	O
hairpin	O
is	O
unwound	O
(	O
by	O
a	O
marching	O
ribosome	B-PATH
)	O
before	O
the	O
downstream	O
stimulator	O
,	O
this	O
study	O
'	O
s	O
findings	O
suggest	O
a	O
new	O
mode	O
of	O
translational	O
regulation	O
that	O
is	O
mediated	O
by	O
the	O
reformed	O
stem	O
of	O
a	O
ribosomal	O
unwound	O
RNA	O
hairpin	O
during	O
elongation	O
.	O

TITLE	O
:	O
Emergence	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
causing	O
severe	O
human	O
illness	O
-	O
China	O
,	O
February	O
-	O
April	O
2013	O
.	O

ABSTRACT	O
:	O
On	O
March	O
29	O
,	O
2013	O
,	O
the	O
Chinese	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
completed	O
laboratory	O
confirmation	O
of	O
three	O
human	O
infections	O
with	O
an	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
not	O
previously	O
reported	O
in	O
humans	O
.	O

Clinicians	O
should	O
consider	O
the	O
diagnosis	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
infection	O
in	O
persons	O
with	O
acute	O
respiratory	O
illness	O
and	O
relevant	O
exposure	O
history	O
and	O
should	O
contact	O
their	O
state	O
health	O
departments	O
regarding	O
specimen	O
collection	O
and	O
facilitation	O
of	O
confirmatory	O
testing	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
infection	O
induces	O
cell	O
apoptosis	B-PATH
via	O
activation	O
of	O
p53	O
signalling	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
infection	O
induced	O
apoptosis	B-PATH
in	O
several	O
cell	O
lines	O
in	O
vitro	O
.	O

Our	O
previous	O
studies	O
demonstrated	O
that	O
TGEV	O
could	O
activate	O
FasL	O
-	O
and	O
mitochondria	O
-	O
mediated	O
pathways	O
to	O
induce	O
apoptosis	B-PATH
in	O
PK	O
-	O
15	O
cells	O
.	O

Blocking	O
of	O
p53	O
activation	O
significantly	O
inhibited	O
the	O
occurrence	O
of	O
apoptosis	B-PATH
through	O
suppressing	O
the	O
TGEV	O
-	O
induced	O
FasL	O
expression	O
,	O
Bcl	O
-	O
2	O
reduction	O
,	O
Bax	O
and	O
cytochrome	O
c	O
redistribution	O
,	O
while	O
inhibition	O
of	O
p38	O
activity	O
moderately	O
blocked	O
apoptosis	B-PATH
induction	O
and	O
partly	O
attenuated	O
the	O
accumulation	O
and	O
activation	O
of	O
p53	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
TGEV	O
infection	O
promoted	O
the	O
activation	O
of	O
p38	O
MAPK	O
and	O
p53	O
signalling	O
,	O
and	O
p53	O
signalling	O
might	O
play	O
a	O
dominant	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Cytokine	O
release	B-PATH
syndrome	O
after	O
blinatumomab	O
treatment	O
related	O
to	O
abnormal	O
macrophage	O
activation	O
and	O
ameliorated	O
with	O
cytokine	O
-	O
directed	O
therapy	O
.	O

We	O
hypothesized	O
that	O
patients	O
with	O
more	O
severe	O
toxicity	O
may	O
experience	O
abnormal	O
macrophage	O
activation	O
triggered	O
by	O
the	O
release	B-PATH
of	O
cytokines	O
by	O
T	O
-	O
cell	O
receptor	O
-	O
activated	O
cytotoxic	O
T	O
cells	O
engaged	O
by	O
BiTE	O
antibodies	O
and	O
leading	O
to	O
hemophagocytic	O
lymphohistiocytosis	O
(	O
HLH	O
).	O

TITLE	O
:	O
Upregulation	O
of	O
CHOP	O
/	O
GADD153	O
during	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
infection	O
modulates	O
apoptosis	B-PATH
by	O
restricting	O
activation	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
activation	O
of	O
the	O
protein	O
kinase	O
R	O
-	O
like	O
ER	O
kinase	O
(	O
PERK	O
)	O
pathway	O
of	O
UPR	O
in	O
cells	O
infected	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
its	O
relationship	O
with	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
.	O

Knockdown	O
of	O
PERK	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
suppressed	O
the	O
activation	O
of	O
GADD153	O
and	O
the	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
.	O

Interestingly	O
,	O
knockdown	O
of	O
protein	O
kinase	O
R	O
(	O
PKR	O
)	O
by	O
siRNA	O
and	O
inhibition	O
of	O
the	O
PKR	O
kinase	O
activity	O
by	O
2	O
-	O
aminopurine	O
(	O
2	O
-	O
AP	O
)	O
also	O
reduced	O
the	O
IBV	O
-	O
induced	O
upregulation	O
of	O
GADD153	O
and	O
apoptosis	B-PATH
induction	O
.	O

In	O
GADD153	O
-	O
knockdown	O
cells	O
,	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
was	O
suppressed	O
and	O
virus	O
replication	O
inhibited	O
,	O
revealing	O
a	O
key	O
role	O
of	O
GADD153	O
in	O
IBV	O
-	O
induced	O
cell	O
death	O
and	O
virus	O
replication	O
.	O

TITLE	O
:	O
[	O
The	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
malaria	B-PATH
:	O
is	O
it	O
always	O
the	O
prerogative	O
of	O
Plasmodium	O
falciparum	O
?].	O

We	O
report	O
the	O
case	O
of	O
a	O
young	O
Moroccan	O
soldier	O
who	O
died	O
in	O
an	O
array	O
of	O
ARDS	O
related	O
to	O
malaria	B-PATH
of	O
Plasmodium	O
ovale	O
7	O
months	O
after	O
his	O
return	O
from	O
an	O
endemic	O
country	O
.	O

Influenza	O
B	O
(	O
Flu	O
B	O
)	O
and	O
seasonal	O
influenza	B-PATH
A	I-PATH
H1N1	O
(	O
sH1N1	O
)	O
were	O
not	O
detected	O
.	O

TITLE	O
:	O
Treatment	O
of	O
cerebral	O
malaria	B-PATH
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
with	O
parenteral	O
artesunate	O
.	O

ABSTRACT	O
:	O
Infection	O
with	O
Plasmodium	O
Falciparum	O
can	O
cause	O
a	O
severe	O
form	O
of	O
malaria	B-PATH
with	O
multiorgan	O
involvement	O
.	O

Cerebrum	O
is	O
one	O
of	O
the	O
organs	O
involved	O
in	O
the	O
P	O
.	O
Falciparum	O
malaria	B-PATH
,	O
which	O
can	O
lead	O
to	O
coma	O
,	O
convulsions	O
,	O
and	O
other	O
neurological	O
sequel	O
.	O

Due	O
to	O
multi	O
-	O
organ	O
involvement	O
in	O
P	O
.	O
Falciparum	O
malaria	B-PATH
,	O
supportive	O
therapy	O
is	O
crucial	O
along	O
with	O
parenteral	O
antimalarial	O
to	O
improve	O
survival	O
.	O

We	O
retrospectively	O
reviewed	O
the	O
efficacy	O
and	O
safety	O
of	O
CART	O
in	O
three	O
patients	O
(	O
two	O
with	O
acute	O
myelogenous	O
leukemia	O
and	O
one	O
with	O
chronic	B-PATH
myeloid	I-PATH
leukemia	I-PATH
)	O
who	O
developed	O
SOS	O
after	O
allo	O
-	O
HSCT	O
.	O

The	O
surprisingly	O
low	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
who	O
were	O
treated	O
with	O
ECMO	O
in	O
the	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pandemic	O
of	O
2009	O
resurrected	O
interest	O
in	O
ECMO	O
in	O
many	O
intensive	O
care	O
units	O
around	O
the	O
world	O
.	O

TITLE	O
:	O
Clinical	O
findings	O
in	O
111	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
During	O
the	O
spring	O
of	O
2013	O
,	O
a	O
novel	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
emerged	O
and	O
spread	O
among	O
humans	O
in	O
China	O
.	O

Using	O
medical	O
charts	O
,	O
we	O
collected	O
data	O
on	O
111	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
infection	O
through	O
May	O
10	O
,	O
2013	O
.	O

Also	O
,	O
many	O
viruses	O
require	O
cyclophilins	O
for	O
replication	O
;	O
these	O
include	O
human	O
immunodeficiency	O
virus	O
,	O
vesicular	O
stomatitis	O
virus	O
,	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
membrane	O
(	O
M	O
)	O
proteins	O
are	O
capable	O
of	O
self	O
-	O
assembly	O
and	O
release	B-PATH
in	O
the	O
form	O
of	O
membrane	O
-	O
enveloped	O
vesicles	O
,	O
and	O
of	O
forming	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
when	O
coexpressed	O
with	O
SARS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
.	O

ABSTRACT	O
:	O
Apolipoprotein	O
D	O
(	O
ApoD	O
)	O
gene	O
expression	O
is	O
increased	O
in	O
several	O
neurological	O
disorders	O
such	O
as	O
Alzheimer	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
(	O
AD	O
)	O
and	O
multiple	O
sclerosis	O
.	O

TITLE	O
:	O
Fatal	O
disseminated	O
toxoplasmosis	B-PATH
in	O
an	O
immunocompetent	O
cat	O
.	O

Sequencing	O
of	O
their	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	B-PATH
),	O
spike	O
(	O
S	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
revealed	O
that	O
MERS	O
-	O
CoV	O
is	O
more	O
closely	O
related	O
to	O
Pi	O
-	O
BatCoV	O
HKU5	O
in	O
RdRp	B-PATH
(	O
92	O
.	O
1	O
%	O
to	O
92	O
.	O
3	O
%	O
amino	O
acid	O
[	O
aa	O
]	O
identity	O
)	O
but	O
is	O
more	O
closely	O
related	O
to	O
Ty	O
-	O
BatCoV	O
HKU4	O
in	O
S	O
(	O
66	O
.	O
8	O
%	O
to	O
67	O
.	O
4	O
%	O
aa	O
identity	O
)	O
and	O
N	O
(	O
71	O
.	O
9	O
%	O
to	O
72	O
.	O
3	O
%	O
aa	O
identity	O
).	O

The	O
public	O
health	O
community	O
'	O
s	O
response	O
to	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
pandemic	O
demonstrated	O
the	O
value	O
of	O
planning	O
and	O
provided	O
insights	O
into	O
improving	O
future	O
plans	O
and	O
response	O
efforts	O
.	O

TITLE	O
:	O
Pathogenesis	O
of	O
malaria	B-PATH
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
MA	O
-	O
ARDS	O
)	O
is	O
an	O
increasingly	O
reported	O
,	O
often	O
lethal	O
,	O
and	O
incompletely	O
understood	O
complication	O
of	O
malaria	B-PATH
.	O

In	O
patients	O
as	O
well	O
as	O
in	O
mice	O
,	O
severe	O
edema	O
and	O
impaired	O
gas	O
exchange	O
are	O
associated	O
with	O
abundant	O
inflammatory	O
infiltrates	O
consisting	O
of	O
mainly	O
mononuclear	O
cells	O
and	O
parasite	O
sequestration	O
,	O
and	O
the	O
pathogenesis	O
appears	O
different	O
from	O
cerebral	O
malaria	B-PATH
(	O
CM	O
).	O

Sensitivities	O
of	O
RV16	O
,	O
RV15	O
,	O
and	O
culture	O
for	O
virus	O
tested	O
were	O
as	O
follows	O
:	O
100	O
/	O
93	O
/	O
63	O
%	O
for	O
influenza	B-PATH
A	I-PATH
,	O
90	O
/	O
80	O
/	O
69	O
%	O
for	O
influenza	O
B	O
,	O
98	O
/	O
94	O
/	O
63	O
%	O
for	O
RSV	O
,	O
98	O
/	O
52	O
/	O
23	O
%	O
for	O
adenovirus	O
,	O
and	O
100	O
/	O
75	O
/	O
46	O
%	O
for	O
PIV	O
.	O

Based	O
on	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)-	O
based	O
grouping	O
units	O
(	O
RGUs	O
)	O
as	O
a	O
surrogate	O
for	O
CoV	O
species	O
identification	O
,	O
the	O
50	O
viruses	O
represented	O
five	O
different	O
alphacoronavirus	O
RGUs	O
and	O
two	O
betacoronavirus	O
RGUs	O
.	O

TITLE	O
:	O
Influenza	B-PATH
infection	I-PATH
screening	O
tools	O
fail	O
to	O
accurately	O
predict	O
influenza	O
status	O
for	O
patients	O
during	O
pandemic	O
H1N1	O
influenza	O
season	O
.	O

TITLE	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
induces	O
apoptosis	B-PATH
in	O
a	O
porcine	O
kidney	O
cell	O
line	O
via	O
caspase	O
-	O
dependent	O
pathways	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
PHEV	O
-	O
induced	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
was	O
caused	O
by	O
apoptosis	B-PATH
.	O

Moreover	O
,	O
the	O
tripeptide	O
pan	O
-	O
ICE	O
(	O
caspase	O
)	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
FMK	O
blocked	O
PHEV	O
-	O
induced	O
apoptosis	B-PATH
but	O
did	O
not	O
have	O
an	O
effect	O
on	O
virus	O
production	O
by	O
96h	O
post	O
-	O
infection	O
.	O

Although	O
the	O
pathological	O
characteristics	O
of	O
PHEV	O
are	O
largely	O
unknown	O
,	O
apoptosis	B-PATH
may	O
be	O
the	O
pathological	O
basis	O
of	O
the	O
lesions	O
resulting	O
from	O
PHEV	O
infection	O
.	O

Organ	O
failure	O
in	O
vivax	O
malaria	B-PATH
is	O
caused	O
by	O
mechanisms	O
of	O
inflammation	O
as	O
well	O
as	O
sequestration	O
.	O

2	O
)	O
To	O
compare	O
the	O
incidence	O
of	O
complications	O
in	O
vivax	O
,	O
falciparum	O
and	O
mixed	O
malaria	B-PATH
.	O

680	O
cases	O
of	O
malaria	B-PATH
were	O
included	O
in	O
the	O
study	O
.	O

31	O
%	O
cases	O
of	O
severe	O
malaria	B-PATH
had	O
vivax	O
monoinfection	O
.	O

Acute	O
renal	O
failure	O
,	O
cerebral	O
malaria	B-PATH
,	O
high	O
bilirubin	O
,	O
anaemia	O
,	O
metabolic	O
acidosis	O
and	O
death	O
were	O
also	O
found	O
in	O
vivax	O
malaria	B-PATH
but	O
less	O
frequently	O
than	O
in	O
falciparum	O
and	O
mixed	O
malaria	B-PATH
.	O

RESULTS	O
:	O
680	O
cases	O
of	O
malaria	B-PATH
were	O
included	O
in	O
the	O
study	O
.	O

The	O
complications	O
seen	O
in	O
vivax	O
malaria	B-PATH
were	O
:	O
thrombocytopenia	O
(	O
68	O
%),	O
leukopenia	O
(	O
19	O
%),	O
ARDS	O
(	O
3	O
%),	O
high	O
bilirubin	O
(	O
5	O
%),	O
acute	O
renal	O
failure	O
(	O
3	O
.	O
5	O
%),	O
anemia	O
(	O
3	O
%),	O
mucosal	O
bleeding	O
(	O
8	O
%),	O
cerebral	O
malaria	B-PATH
(	O
3	O
.	O
5	O
%),	O
hypotension	O
(	O
5	O
%),	O
metabolic	O
acidosis	O
(	O
4	O
%)	O
and	O
death	O
(	O
1	O
.	O
77	O
%).	O

The	O
evidence	O
for	O
the	O
role	O
of	O
vitamin	O
D	O
in	O
lung	O
disease	O
is	O
growing	O
-	O
deficiency	O
has	O
been	O
associated	O
with	O
impaired	O
pulmonary	O
function	O
,	O
increased	O
incidence	O
of	O
viral	O
and	O
bacterial	O
infections	O
and	O
inflammatory	O
disease	O
including	O
asthma	B-PATH
and	O
COPD	O
.	O

ABSTRACT	O
:	O
Severe	O
pulmonary	O
involvement	O
in	O
malaria	B-PATH
has	O
been	O
frequently	O
reported	O
in	O
cases	O
of	O
Plasmodium	O
falciparum	O
infection	O
but	O
rarely	O
in	O
vivax	O
malaria	B-PATH
.	O

We	O
look	O
at	O
a	O
case	O
of	O
a	O
38	O
-	O
year	O
-	O
old	O
man	O
living	O
in	O
a	O
malaria	B-PATH
endemic	O
area	O
who	O
presented	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
caused	O
by	O
P	O
.	O
vivax	O
.	O

TITLE	O
:	O
Clinical	O
presentation	O
of	O
patients	O
with	O
seasonal	O
influenza	O
and	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
-	O
2009	O
)	O
requiring	O
hospitalisation	O
.	O

ABSTRACT	O
:	O
A	O
sudden	O
increase	O
in	O
the	O
number	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
pH1N1	O
-	O
2009	O
)	O
infection	O
prompted	O
us	O
to	O
compare	O
the	O
clinical	O
presentation	O
and	O
outcomes	O
of	O
patients	O
infected	O
with	O
pH1N1	O
-	O
2009	O
and	O
seasonal	O
influenza	B-PATH
A	I-PATH
virus	O
during	O
the	O
post	O
-	O
pandemic	O
phase	O
.	O

Nineteen	O
(	O
17	O
.	O
9	O
%)	O
patients	O
were	O
tested	O
positive	O
for	O
pH1N1	O
-	O
2009	O
and	O
78	O
(	O
73	O
.	O
6	O
%)	O
were	O
tested	O
positive	O
for	O
seasonal	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

The	O
most	O
common	O
comorbidities	O
included	O
bronchial	O
asthma	B-PATH
/	O
bronchitis	O
/	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
in	O
4	O
(	O
21	O
%);	O
followed	O
by	O
hypertension	O
in	O
3	O
(	O
15	O
.	O
8	O
%)	O
and	O
diabetes	O
in	O
3	O
(	O
15	O
.	O
8	O
%)	O
patients	O
.	O

RESULTS	O
:	O
Nineteen	O
(	O
17	O
.	O
9	O
%)	O
patients	O
were	O
tested	O
positive	O
for	O
pH1N1	O
-	O
2009	O
and	O
78	O
(	O
73	O
.	O
6	O
%)	O
were	O
tested	O
positive	O
for	O
seasonal	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

TITLE	O
:	O
Exchange	O
transfusion	O
for	O
severe	O
malaria	B-PATH
:	O
evidence	O
base	O
and	O
literature	O
review	O
.	O

The	O
literature	O
review	O
used	O
search	O
terms	O
""""	O
severe	O
malaria	B-PATH
""""	O
and	O
""""	O
exchange	O
transfusion	O
.	O

Despite	O
rapid	O
parasite	O
clearance	O
times	O
resulting	O
from	O
ET	O
,	O
there	O
is	O
no	O
evidence	O
for	O
efficacy	O
of	O
ET	O
as	O
adjunctive	O
therapy	O
in	O
severe	O
malaria	B-PATH
.	O

As	O
an	O
example	O
of	O
the	O
latter	O
,	O
a	O
research	O
program	O
was	O
reported	O
that	O
identified	O
compounds	O
with	O
activity	O
against	O
HIV	O
-	O
1	O
and	O
-	O
2	O
,	O
herpes	O
virus	O
,	O
influenza	O
virus	O
and	O
Coxsackie	O
virus	O
(	O
Dejmek	O
,	O
M	O
.	O
et	O
al	O
.,	O
Abst	O
35	O
),	O
while	O
studies	O
with	O
Griffithsin	O
,	O
a	O
red	O
algae	O
-	O
derived	O
protein	O
with	O
potent	O
,	O
broad	O
antiviral	O
activity	O
against	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
coronavirus	O
and	O
Japanese	O
encephalitis	O
virus	O
,	O
among	O
others	O
,	O
showed	O
it	O
also	O
inhibited	O
HIV	O
,	O
although	O
only	O
when	O
the	O
tight	O
dimer	O
structure	O
is	O
respected	O
(	O
Xue	O
,	O
J	O
.	O
et	O
al	O
.,	O
Abst	O
104	O
).	O

TITLE	O
:	O
[	O
Fatal	O
course	O
of	O
virus	O
-	O
associated	O
pneumonia	O
in	O
patient	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)].	O

The	O
authors	O
gave	O
an	O
example	O
of	O
fatal	O
course	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
S	O
-	O
OIV	O
in	O
young	O
patient	O
with	O
severe	O
VA	O
-	O
pneumonia	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
disseminated	O
intravascular	O
coagulation	O
with	O
progressive	O
respiratory	O
distress	O
secondary	O
to	O
an	O
metabolic	O
syndrome	O
.	O

TITLE	O
:	O
Malaria	B-PATH
,	O
clinical	O
features	O
and	O
acute	O
crisis	O
in	O
children	O
suffering	O
from	O
sickle	O
cell	O
disease	O
in	O
resource	O
-	O
limited	O
settings	O
:	O
a	O
retrospective	O
description	O
of	O
90	O
cases	O
.	O

For	O
the	O
10	O
years	O
studied	O
,	O
108	O
children	O
with	O
SCD	O
were	O
reviewed	O
and	O
the	O
data	O
of	O
those	O
who	O
developed	O
malaria	B-PATH
during	O
admission	O
were	O
retrieved	O
and	O
analyzed	O
.	O

RESULTS	O
:	O
Of	O
the	O
90	O
homozygous	O
sickle	O
cell	O
children	O
with	O
malaria	B-PATH
,	O
fever	O
,	O
pallor	O
,	O
and	O
jaundice	O
were	O
the	O
commonly	O
-	O
found	O
symptoms	O
.	O

ABSTRACT	O
:	O
The	O
study	O
was	O
intended	O
to	O
document	O
the	O
clinical	O
profile	O
and	O
treatment	O
outcome	O
of	O
severe	O
malaria	B-PATH
caused	O
by	O
Plasmodium	O
vivax	O
(	O
P	O
.	O
vivax	O
)	O
in	O
children	O
hospitalized	O
in	O
a	O
tertiary	O
care	O
centre	O
of	O
northern	O
India	O
.	O

This	O
prospective	O
observational	O
study	O
was	O
performed	O
among	O
children	O
admitted	O
with	O
severe	O
malaria	B-PATH
at	O
a	O
tertiary	O
care	O
referral	O
hospital	O
of	O
northern	O
India	O
from	O
January	O
2012	O
to	O
December	O
2012	O
.	O

Presence	O
of	O
malarial	O
parasite	O
on	O
thick	O
and	O
thin	O
smears	O
and	O
/	O
or	O
positive	O
parasite	O
lactate	O
dehydrogenase	O
(	O
p	O
-	O
LDH	O
)	O
based	O
rapid	O
malaria	B-PATH
antigen	O
test	O
was	O
considered	O
diagnostic	O
of	O
'	B-PATH
malaria	I-PATH
'.	O

Thirty	O
-	O
five	O
children	O
with	O
a	O
diagnosis	O
of	O
severe	O
malaria	B-PATH
were	O
enrolled	O
[	O
18	O
(	O
51	O
Â·	O
4	O
%)	O
P	O
.	O
vivax	O
,	O
nine	O
(	O
25	O
Â·	O
7	O
%)	O
mixed	O
infection	O
,	O
eight	O
(	O
22	O
Â·	O
8	O
%)	O
P	O
.	O
falciparum	O
].	O

Clinical	O
features	O
of	O
severe	O
vivax	O
malaria	B-PATH
(	O
n	O
=	O
18	O
)	O
were	O
abnormal	O
sensorium	O
[	O
9	O
(	O
50	O
%)],	O
multiple	O
seizures	O
[	O
8	O
(	O
44	O
Â·	O
4	O
%)],	O
jaundice	O
[	O
5	O
(	O
27	O
Â·	O
8	O
%)],	O
severe	O
anaemia	O
[	O
5	O
(	O
27	O
Â·	O
8	O
%)],	O
and	O
shock	O
[	O
3	O
(	O
16	O
Â·	O
7	O
%)].	O

Two	O
children	O
[	O
2	O
/	O
18	O
(	O
11	O
Â·	O
1	O
%)]	O
infected	O
with	O
P	O
.	O
vivax	O
had	O
died	O
of	O
cerebral	O
malaria	B-PATH
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
shock	O
,	O
and	O
metabolic	O
acidosis	O
.	O

The	O
clinical	O
presentation	O
and	O
outcome	O
of	O
severe	O
vivax	O
malaria	B-PATH
was	O
found	O
to	O
be	O
similar	O
to	O
severe	O
malaria	B-PATH
caused	O
by	O
P	O
.	O
falciparum	O
and	O
mixed	O
infection	O
,	O
except	O
for	O
higher	O
chances	O
of	O
severe	O
anaemia	O
among	O
the	O
children	O
infected	O
with	O
P	O
.	O
falciparum	O
(	O
P	O
=	O
0	O
Â·	O
04	O
).	O

The	O
present	O
study	O
highlights	O
P	O
.	O
vivax	O
as	O
an	O
increasingly	O
recognized	O
causative	O
agent	O
for	O
severe	O
malaria	B-PATH
in	O
children	O
from	O
Rohtak	O
,	O
with	O
similar	O
clinical	O
presentation	O
and	O
outcome	O
to	O
that	O
caused	O
by	O
P	O
.	O
falciparum	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
five	O
children	O
with	O
a	O
diagnosis	O
of	O
severe	O
malaria	B-PATH
were	O
enrolled	O
[	O
18	O
(	O
51	O
Â·	O
4	O
%)	O
P	O
.	O
vivax	O
,	O
nine	O
(	O
25	O
Â·	O
7	O
%)	O
mixed	O
infection	O
,	O
eight	O
(	O
22	O
Â·	O
8	O
%)	O
P	O
.	O
falciparum	O
].	O

The	O
clinical	O
presentation	O
and	O
outcome	O
of	O
severe	O
vivax	O
malaria	B-PATH
was	O
found	O
to	O
be	O
similar	O
to	O
severe	O
malaria	B-PATH
caused	O
by	O
P	O
.	O
falciparum	O
and	O
mixed	O
infection	O
,	O
except	O
for	O
higher	O
chances	O
of	O
severe	O
anaemia	O
among	O
the	O
children	O
infected	O
with	O
P	O
.	O
falciparum	O
(	O
P	O
=	O
0	O
Â·	O
04	O
).	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
highlights	O
P	O
.	O
vivax	O
as	O
an	O
increasingly	O
recognized	O
causative	O
agent	O
for	O
severe	O
malaria	B-PATH
in	O
children	O
from	O
Rohtak	O
,	O
with	O
similar	O
clinical	O
presentation	O
and	O
outcome	O
to	O
that	O
caused	O
by	O
P	O
.	O
falciparum	O
.	O

TITLE	O
:	O
Biological	O
features	O
of	O
novel	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
.	O

Sixty	O
samples	O
were	O
concordant	O
influenza	B-PATH
A	I-PATH
virus	O
positive	O
,	O
and	O
8	O
samples	O
were	O
found	O
to	O
be	O
concordant	O
influenza	O
B	O
virus	O
positive	O
.	O

TITLE	O
:	O
Bilateral	O
entry	O
and	O
release	B-PATH
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
induces	O
profound	O
apoptosis	B-PATH
of	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Infection	O
results	O
in	O
profound	O
apoptosis	B-PATH
within	O
24	O
h	O
irrespective	O
of	O
its	O
production	O
of	O
titers	O
that	O
are	O
lower	O
than	O
those	O
of	O
SARS	O
-	O
CoV	O
.	O
Together	O
,	O
our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
dissemination	O
and	O
pathogenesis	O
of	O
MERS	O
-	O
CoV	O
and	O
may	O
indicate	O
that	O
the	O
virus	O
differs	O
markedly	O
from	O
SARS	O
-	O
CoV	O
.	O

Malaria	B-PATH
may	O
be	O
more	O
severe	O
in	O
the	O
pregnant	O
woman	O
,	O
and	O
carries	O
significant	O
risk	O
to	O
both	O
mother	O
and	O
fetus	O
.	O

TITLE	O
:	O
Pathogenesis	O
and	O
transmission	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
in	O
ferrets	O
and	O
mice	O
.	O

ABSTRACT	O
:	O
On	O
29	O
March	O
2013	O
,	O
the	O
Chinese	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
confirmed	O
the	O
first	O
reported	O
case	O
of	O
human	O
infection	O
with	O
an	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
phosphorylation	O
at	O
Thr378	O
and	O
Ser379	O
sites	O
is	O
dependent	O
on	O
the	O
ataxia	O
-	O
telangiectasia	O
mutated	O
(	O
ATM	B-PATH
)	O
and	O
Rad3	O
-	O
related	O
(	O
ATR	O
),	O
a	O
kinase	O
activated	O
during	O
IBV	O
replication	O
.	O

There	O
was	O
a	O
rapid	O
release	B-PATH
of	O
endothelial	O
progenitor	O
cells	O
from	O
bone	O
marrow	O
into	O
circulation	O
in	O
moderate	O
acute	O
lung	O
injury	O
,	O
and	O
endothelial	O
progenitor	O
cell	O
mobilization	O
was	O
impaired	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

These	O
receptor	O
-	O
destroying	O
enzymes	O
promote	O
virus	O
release	B-PATH
from	O
infected	O
cells	O
and	O
neutralize	O
sialic	O
acid	O
-	O
containing	O
soluble	O
proteins	O
interfering	O
with	O
cell	O
surface	O
binding	O
of	O
the	O
virus	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
this	O
locus	O
,	O
which	O
contains	O
the	O
gene	O
for	O
accessory	O
protein	O
3a	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
encodes	O
a	O
protein	O
that	O
forms	O
ion	O
channels	O
and	O
regulates	O
virus	O
release	B-PATH
.	O

RESULTS	O
:	O
Main	O
ARDS	O
etiologies	O
were	O
bacterial	O
(	O
45	O
%),	O
influenza	B-PATH
A	I-PATH
[	O
HâNâ	O
]	O
(	O
26	O
%)	O
and	O
post	O
-	O
operative	O
(	O
17	O
%)	O
pneumonias	O
.	O

ABSTRACT	O
:	O
Laboratory	O
capacity	O
is	O
needed	O
in	O
central	O
Viet	O
Nam	O
to	O
provide	O
early	O
warning	O
to	O
public	O
health	O
authorities	O
of	O
respiratory	O
outbreaks	O
of	O
importance	O
to	O
human	O
health	O
,	O
for	O
example	O
the	O
outbreak	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
in	O
2009	O
.	O

We	O
determined	O
the	O
incidence	O
and	O
clinical	O
impact	O
of	O
229E	O
and	O
OC43	O
CoV	O
in	O
this	O
population	O
during	O
4	O
consecutive	O
winters	O
,	O
and	O
compared	O
illnesses	O
to	O
influenza	B-PATH
A	I-PATH
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
human	O
metapneumovirus	O
.	O

TITLE	O
:	O
ACE2	O
-	O
from	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
to	O
gut	O
microbiota	O
and	O
malnutrition	O
.	O

ABSTRACT	O
:	O
The	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
)	O
is	O
a	O
complex	O
network	O
that	O
regulates	O
blood	O
pressure	O
,	O
electrolyte	O
and	O
fluid	O
homeostasis	O
,	O
as	O
well	O
as	O
the	O
function	O
of	O
several	O
organs	O
.	O

TITLE	O
:	O
Acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
in	O
a	O
38	O
-	O
year	O
-	O
old	O
hemodialyzed	O
patient	O
with	O
von	O
Hippel	O
-	O
Lindau	O
disease	O
.	O

Clinical	O
hallmarks	O
of	O
von	O
Hippel	O
-	O
Lindau	O
disease	O
are	O
the	O
development	O
of	O
central	O
nervous	O
system	O
hemangioblastomas	O
,	O
renal	B-PATH
cell	I-PATH
carcinoma	I-PATH
,	O
pheochromocytoma	O
,	O
neuroendocrine	O
tumors	O
and	O
endolymphatic	O
sac	O
tumors	O
.	O

In	O
this	O
paper	O
we	O
present	O
for	O
the	O
first	O
time	O
a	O
case	O
of	O
von	O
Hippel	O
-	O
Lindau	O
disease	O
associated	O
with	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
.	O

ABSTRACT	O
:	O
Ferrets	O
are	O
widely	O
used	O
as	O
a	O
small	O
animal	O
model	O
for	O
a	O
number	O
of	O
viral	O
infections	O
,	O
including	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
SARS	O
coronavirus	O
.	O

ABSTRACT	O
:	O
France	O
has	O
recently	O
witnessed	O
a	O
nationwide	O
outbreak	O
of	O
measles	B-PATH
.	O

We	O
performed	O
a	O
retrospective	O
analysis	O
of	O
a	O
cohort	O
of	O
36	O
adults	O
admitted	O
to	O
a	O
total	O
of	O
64	O
ICUs	O
throughout	O
France	O
for	O
complications	O
of	O
measles	B-PATH
from	O
January	O
1	O
,	O
2009	O
,	O
to	O
December	O
31	O
,	O
2011	O
.	O

All	O
cases	O
of	O
measles	B-PATH
were	O
confirmed	O
by	O
serologic	O
testing	O
and	O
/	O
or	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O

Among	O
the	O
26	O
patients	O
whose	O
measles	B-PATH
vaccination	O
status	O
was	O
documented	O
,	O
none	O
had	O
received	O
2	O
injections	O
.	O

Underlying	O
comorbid	O
conditions	O
included	O
chronic	O
respiratory	O
disease	O
in	O
9	O
patients	O
,	O
immunosuppression	O
in	O
7	O
patients	O
,	O
and	O
obesity	O
in	O
3	O
patients	O
,	O
while	O
measles	B-PATH
affected	O
5	O
pregnant	O
women	O
.	O

Respiratory	O
complications	O
induced	O
by	O
measles	B-PATH
infection	O
led	O
to	O
ICU	O
admission	O
in	O
32	O
cases	O
,	O
and	O
measles	B-PATH
-	O
related	O
neurologic	O
complications	O
led	O
to	O
ICU	O
admission	O
in	O
2	O
cases	O
.	O

Bacterial	O
superinfection	O
of	O
measles	B-PATH
-	O
related	O
airway	O
infection	O
was	O
suspected	O
in	O
28	O
patients	O
and	O
was	O
documented	O
in	O
8	O
.	O

On	O
follow	O
-	O
up	O
,	O
1	O
patient	O
had	O
severe	O
chronic	O
respiratory	O
failure	O
related	O
to	O
lung	O
fibrosis	O
,	O
and	O
2	O
patients	O
had	O
mild	O
lower	O
limb	O
paraparesis	O
along	O
with	O
bladder	O
dysfunction	O
,	O
both	O
of	O
which	O
were	O
ascribable	O
to	O
measles	B-PATH
-	O
induced	O
encephalitis	O
and	O
myelitis	O
.	O

Among	O
the	O
5	O
pregnant	O
patients	O
,	O
the	O
course	O
of	O
measles	B-PATH
infection	O
was	O
uneventful	O
,	O
albeit	O
1	O
patient	O
underwent	O
emergent	O
cesarean	O
delivery	O
because	O
of	O
fetal	O
growth	O
restriction	O
.	O

Measles	B-PATH
is	O
a	O
disease	O
with	O
protean	O
and	O
potentially	O
deceptive	O
clinical	O
manifestations	O
,	O
especially	O
in	O
the	O
immunocompromised	O
patient	O
.	O

In	O
contrast	O
with	O
the	O
usually	O
benign	O
course	O
of	O
the	O
disease	O
in	O
immunocompetent	O
patients	O
,	O
measles	B-PATH
occurring	O
in	O
immunocompromised	O
patients	O
gives	O
rise	O
to	O
lethal	O
complications	O
including	O
ARDS	O
,	O
with	O
or	O
without	O
bacterial	O
superinfection	O
.	O

Measles	B-PATH
pneumonitis	O
may	O
predispose	O
to	O
air	O
leak	O
disease	O
in	O
patients	O
using	O
mechanical	O
ventilation	O
.	O

To	O
date	O
,	O
vaccination	O
remains	O
the	O
most	O
potent	O
tool	O
to	O
control	O
measles	B-PATH
infection	O
.	O

ABSTRACT	O
:	O
Plasmodium	O
vivax	O
(	O
p	O
.	O
vivax	O
)	O
malaria	B-PATH
was	O
traditionally	O
considered	O
as	O
benign	O
tertian	O
malaria	B-PATH
,	O
however	O
,	O
recent	O
studies	O
have	O
pointed	O
out	O
that	O
p	O
.	O
vivax	O
have	O
potential	O
to	O
cause	O
all	O
severe	O
complications	O
previously	O
attributed	O
to	O
p	O
.	O
falciparum	O
infection	O
only	O
.	O

The	O
aim	O
of	O
this	O
report	O
is	O
to	O
study	O
the	O
incidence	O
of	O
various	O
clinical	O
and	O
biochemical	O
complications	O
associated	O
with	O
severe	O
p	O
.	O
vivax	O
malaria	B-PATH
.	O

A	O
retrospective	O
analysis	O
was	O
performed	O
on	O
all	O
patients	O
with	O
p	O
.	O
vivax	O
malaria	B-PATH
admitted	O
to	O
our	O
center	O
between	O
January	O
2009	O
and	O
December	O
2011	O
.	O

The	O
complications	O
observed	O
were	O
Hepatic	O
dysfunction	O
in	O
18	O
(	O
29	O
%),	O
renal	O
dysfunction	O
in	O
13	O
(	O
21	O
%),	O
cerebral	O
malaria	B-PATH
in	O
10	O
(	O
16	O
.	O
1	O
%),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
6	O
(	O
9	O
.	O
7	O
%),	O
shock	O
in	O
10	O
(	O
16	O
.	O
1	O
%),	O
severe	O
anemia	O
in	O
16	O
(	O
25	O
.	O
8	O
%),	O
thrombocytopenia	O
in	O
35	O
(	O
56	O
.	O
5	O
%),	O
and	O
hypoglycemia	O
in	O
3	O
(	O
4	O
.	O
8	O
%)	O
patients	O
.	O

P	O
.	O
vivax	O
has	O
immense	O
potential	O
to	O
cause	O
life	O
threatening	O
complications	O
and	O
even	O
death	O
,	O
more	O
research	O
is	O
required	O
to	O
understand	O
the	O
exact	O
pathogenesis	O
of	O
various	O
complications	O
encountered	O
in	O
vivax	O
malaria	B-PATH
.	O

RESULTS	O
:	O
Sixty	O
-	O
two	O
patients	O
met	O
the	O
criteria	O
for	O
severe	O
malaria	B-PATH
during	O
the	O
study	O
period	O
.	O

Moreover	O
,	O
Î³	O
-	O
PGA	O
(	O
2000	O
kDa	O
)	O
displayed	O
an	O
antiviral	O
activity	O
against	O
SARS	O
coronavirus	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
.	O

In	O
addition	O
,	O
LIMK1	O
or	O
SSH	O
-	O
1L	O
depletion	O
inhibited	O
RelA	O
/	O
p65	O
phosphorylation	O
at	O
Ser	O
(	O
536	O
),	O
a	O
critical	O
event	O
conferring	O
transcriptional	O
competency	O
to	O
the	O
bound	O
NF	O
-	O
ÎºB	O
.	O
However	O
,	O
unlike	O
SSH	O
-	O
1L	O
,	O
LIMK1	O
knockdown	O
also	O
impairs	O
the	O
release	B-PATH
of	O
RelA	O
/	O
p65	O
by	O
blocking	O
IKKÎ²	O
-	O
dependent	O
phosphorylation	O
/	O
degradation	O
of	O
IÎºBÎ±	O
.	O

Additionally	O
,	O
the	O
results	O
show	O
the	O
applicability	O
of	O
the	O
real	O
-	O
time	O
PCR	O
assay	O
in	O
laboratory	O
practice	O
for	O
the	O
identification	O
and	O
differentiation	O
of	O
Newcastle	O
disease	O
and	O
influenza	B-PATH
A	I-PATH
viruses	O
in	O
birds	O
.	O

LOH	O
is	O
frequently	O
associated	O
with	O
chronic	O
conditions	O
including	O
cardiovascular	O
diseases	O
(	O
CVD	O
),	O
obesity	O
,	O
osteoporosis	O
,	O
HIV	B-PATH
infection	I-PATH
,	O
renal	O
failure	O
,	O
and	O
obstructive	O
pulmonary	O
diseases	O
.	O

The	O
fear	O
of	O
prostate	B-PATH
cancer	I-PATH
and	O
the	O
risk	O
of	O
erythrocytosis	O
probably	O
represent	O
the	O
main	O
limitations	O
of	O
TRT	O
in	O
aging	O
men	O
.	O

Among	O
the	O
124	O
influenza	O
-	O
like	O
illness	O
cases	O
,	O
~	O
50	O
%	O
(	O
58	O
)	O
were	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
WHO	O
-	O
CDC	O
molecular	O
assay	O
,	O
including	O
subtyping	O
.	O

An	O
unexpected	O
high	O
contribution	O
of	O
influenza	B-PATH
A	I-PATH
was	O
confirmed	O
among	O
ILI	O
patients	O
,	O
as	O
well	O
as	O
a	O
very	O
limited	O
number	O
of	O
other	O
detected	O
viruses	O
,	O
indicate	O
that	O
the	O
2009	O
epidemic	O
in	O
western	O
Ukraine	O
was	O
strongly	O
related	O
to	O
novel	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
.	O

RESULTS	O
:	O
Among	O
the	O
124	O
influenza	O
-	O
like	O
illness	O
cases	O
,	O
~	O
50	O
%	O
(	O
58	O
)	O
were	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
WHO	O
-	O
CDC	O
molecular	O
assay	O
,	O
including	O
subtyping	O
.	O

MAb	O
2	O
-	O
4	O
exhibited	O
high	O
neutralizing	O
activity	O
against	O
natural	O
TNF	O
-	O
alpha	O
derived	O
from	O
FIPV	O
-	O
infected	O
macrophages	O
,	O
and	O
was	O
confirmed	O
to	O
inhibit	O
the	O
following	O
feline	O
TNF	O
-	O
alpha	O
-	O
induced	O
conditions	O
in	O
vitro	O
:	O
(	O
i	O
)	O
an	O
increase	O
in	O
the	O
survival	O
rate	O
of	O
neutrophils	O
from	O
cats	O
with	O
FIP	O
,	O
(	O
ii	O
)	O
aminopeptidase	O
N	O
(	O
APN	O
)	O
mRNA	O
expression	O
in	O
macrophages	O
,	O
and	O
(	O
iii	O
)	O
apoptosis	B-PATH
of	O
a	O
feline	O
T	O
-	O
lymphocyte	O
cell	O
line	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
infection	O
induces	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
S	O
and	O
G2	O
/	O
M	O
phases	O
via	O
p53	O
-	O
dependent	O
pathway	O
.	O

ABSTRACT	O
:	O
p53	B-PATH
signaling	I-PATH
pathway	I-PATH
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	B-PATH
cycle	I-PATH
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
TGEV	O
infection	O
on	O
the	O
cell	B-PATH
cycle	I-PATH
of	O
host	O
cells	O
and	O
the	O
roles	O
of	O
p53	O
activation	O
in	O
this	O
process	O
.	O

The	O
results	O
showed	O
that	O
TGEV	O
infection	O
induced	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
S	O
and	O
G2	O
/	O
M	O
phases	O
in	O
both	O
asynchronous	O
and	O
synchronized	O
PK	O
-	O
15	O
and	O
ST	O
cells	O
,	O
while	O
UV	O
-	O
inactivated	O
TGEV	O
lost	O
the	O
ability	O
of	O
induction	O
of	O
cell	B-PATH
cycle	I-PATH
arrest	O
.	O

We	O
used	O
small	O
compound	O
-	O
based	O
forward	O
chemical	O
genetics	O
to	O
screen	O
a	O
chemical	O
library	O
of	O
1280	O
known	O
drugs	O
against	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
Biosafety	O
Level	O
-	O
2	O
laboratory	O
.	O

TITLE	O
:	O
Virus	O
-	O
induced	O
exacerbations	O
in	O
asthma	B-PATH
and	O
COPD	O
.	O

Chronic	O
bronchitis	O
,	O
pulmonary	O
emphysema	O
,	O
and	O
bronchial	O
asthma	B-PATH
may	O
all	O
be	O
associated	O
with	O
airflow	O
limitation	O
;	O
therefore	O
,	O
exacerbation	O
of	O
asthma	B-PATH
may	O
be	O
associated	O
with	O
the	O
pathophysiology	O
of	O
COPD	O
.	O

Furthermore	O
,	O
recent	O
studies	O
have	O
suggested	O
that	O
the	O
exacerbation	O
of	O
asthma	B-PATH
,	O
namely	O
virus	O
-	O
induced	O
asthma	B-PATH
,	O
may	O
be	O
associated	O
with	O
a	O
wide	O
variety	O
of	O
respiratory	O
viruses	O
.	O

COPD	O
and	O
asthma	B-PATH
have	O
different	O
underlying	O
pathophysiological	O
processes	O
and	O
thus	O
require	O
individual	O
therapies	O
.	O

Exacerbation	O
of	O
both	O
COPD	O
and	O
asthma	B-PATH
,	O
which	O
are	O
basically	O
defined	O
and	O
diagnosed	O
by	O
clinical	O
symptoms	O
,	O
is	O
associated	O
with	O
a	O
rapid	O
decline	O
in	O
lung	O
function	O
and	O
increased	O
mortality	O
.	O

Similar	O
pathogens	O
,	O
including	O
human	O
rhinovirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
virus	O
,	O
parainfluenza	O
virus	O
,	O
and	O
coronavirus	O
,	O
are	O
also	O
frequently	O
detected	O
during	O
exacerbation	O
of	O
asthma	B-PATH
and	O
/	O
or	O
COPD	O
.	O

In	O
this	O
regard	O
,	O
it	O
is	O
crucial	O
to	O
recognize	O
and	O
understand	O
both	O
the	O
similarities	O
and	O
differences	O
of	O
clinical	O
features	O
in	O
patients	O
with	O
COPD	O
and	O
/	O
or	O
asthma	B-PATH
associated	O
with	O
respiratory	O
viral	O
infections	O
,	O
especially	O
in	O
the	O
exacerbative	O
stage	O
.	O

In	O
relation	O
to	O
definition	O
,	O
epidemiology	O
,	O
and	O
pathophysiology	O
,	O
this	O
review	O
aims	O
to	O
summarize	O
current	O
knowledge	O
concerning	O
exacerbation	O
of	O
both	O
COPD	O
and	O
asthma	B-PATH
by	O
focusing	O
on	O
the	O
clinical	O
significance	O
of	O
associated	O
respiratory	O
virus	O
infections	O
.	O

A	O
respiratory	O
virus	O
was	O
detected	O
successfully	O
in	O
102	O
(	O
51	O
%)	O
children	O
;	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
in	O
39	O
.	O
2	O
%,	O
influenza	O
B	O
in	O
23	O
.	O
5	O
%,	O
RSV	O
in	O
15	O
.	O
6	O
%,	O
rhinovirus	O
in	O
13	O
.	O
7	O
%,	O
bocavirus	O
in	O
2	O
.	O
9	O
%,	O
coronavirus	O
in	O
2	O
.	O
9	O
%,	O
and	O
metapneumovirus	O
in	O
0	O
.	O
9	O
%	O
of	O
patients	O
.	O

Only	O
one	O
patient	O
was	O
co	O
-	O
infected	O
with	O
bocavirus	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

ABSTRACT	O
:	O
Severe	O
malaria	B-PATH
may	O
be	O
complicated	O
by	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
which	O
is	O
associated	O
with	O
a	O
high	O
mortality	O
.	O

ECMO	O
referral	O
should	O
be	O
considered	O
early	O
in	O
malaria	B-PATH
complicated	O
by	O
severe	O
ARDS	O
refractory	O
to	O
conventional	O
treatment	O
.	O

ABSTRACT	O
:	O
Griffithsin	O
(	O
GRFT	O
)	O
is	O
a	O
red	O
-	O
alga	O
-	O
derived	O
lectin	O
that	O
binds	O
the	O
terminal	O
mannose	O
residues	O
of	O
N	O
-	O
linked	O
glycans	O
found	O
on	O
the	O
surface	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
),	O
HIV	O
-	O
2	O
,	O
and	O
other	O
enveloped	O
viruses	O
,	O
including	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
and	O
Ebola	O
virus	O
.	O

TITLE	O
:	O
The	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
coincides	O
with	O
changes	O
in	O
the	O
epidemiology	O
of	O
other	O
viral	O
pathogens	O
causing	O
acute	O
respiratory	O
tract	O
infections	O
in	O
children	O
.	O

ABSTRACT	O
:	O
In	O
Germany	O
,	O
the	O
outbreak	O
of	O
the	O
novel	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
A	O
(	O
H1N1	O
)	O
pdm09	O
caused	O
a	O
wave	O
of	O
high	O
activity	O
between	O
November	O
2009	O
and	O
January	O
2011	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
19	O
respiratory	O
pathogens	O
in	O
children	O
hospitalized	O
for	O
lower	O
respiratory	O
tract	O
infections	O
during	O
the	O
winter	O
influenza	O
seasons	O
of	O
2009	O
/	O
2010	O
and	O
2010	O
/	O
2011	O
and	O
to	O
observe	O
a	O
possible	O
impact	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
on	O
the	O
epidemiology	O
of	O
other	O
epidemic	O
viruses	O
.	O

The	O
specimens	O
were	O
subjected	O
to	O
a	O
previously	O
described	O
multiplex	O
reverse	O
transcription	O
PCR	O
assay	O
to	O
detect	O
the	O
following	O
microorganisms	O
:	O
enterovirus	O
,	O
influenza	O
virus	O
types	O
A	O
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenzavirus	O
types	O
1	O
-	O
4	O
,	O
adenovirus	O
,	O
Mycoplasma	O
pneumoniae	O
,	O
Chlamydophila	O
pneumoniae	O
,	O
rhinovirus	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
coronavirus	O
OC43	O
and	O
229E	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
,	O
Bordetella	O
pertussis	B-PATH
,	O
Bordetella	O
parapertussis	O
,	O
and	O
Legionella	O
pneumophila	O
.	O

An	O
epidemic	O
of	O
seasonal	O
influenza	B-PATH
A	I-PATH
or	O
B	O
was	O
not	O
observed	O
in	O
the	O
2009	O
/	O
2010	O
season	O
,	O
but	O
a	O
minor	O
epidemic	O
of	O
seasonal	O
influenza	O
B	O
was	O
observed	O
in	O
January	O
/	O
February	O
2011	O
.	O

The	O
emergence	O
of	O
the	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
may	O
have	O
been	O
influenced	O
the	O
epidemiology	O
of	O
other	O
epidemic	O
viruses	O
,	O
such	O
as	O
the	O
RSV	O
and	O
hMPV	O
.	O

TITLE	O
:	O
Bronchoscopy	O
with	O
N	O
-	O
acetylcysteine	O
lavage	O
in	O
severe	O
respiratory	O
failure	O
from	O
pertussis	B-PATH
infection	O
.	O

ABSTRACT	O
:	O
Pertussis	B-PATH
is	O
an	O
illness	O
that	O
causes	O
significant	O
morbidity	O
and	O
mortality	O
,	O
especially	O
in	O
infants	O
younger	O
than	O
3	O
months	O
old	O
.	O

However	O
,	O
the	O
mortality	O
of	O
ECMO	O
with	O
pertussis	B-PATH
is	O
higher	O
than	O
with	O
other	O
causes	O
of	O
pediatric	O
respiratory	O
failure	O
.	O

Although	O
pulmonary	O
hypertension	O
is	O
a	O
key	O
factor	O
in	O
most	O
cases	O
of	O
fatal	O
pertussis	B-PATH
,	O
the	O
adverse	O
effects	O
of	O
hyperinflation	O
and	O
air	O
leaks	O
were	O
more	O
important	O
in	O
this	O
patient	O
'	O
s	O
clinical	O
course	O
.	O

Because	O
bronchiolar	O
obstruction	O
from	O
inflammatory	O
,	O
mucous	O
,	O
and	O
airway	O
epithelial	O
debris	O
can	O
be	O
seen	O
in	O
severe	O
pertussis	B-PATH
,	O
a	O
regimen	O
of	O
repeated	O
therapeutic	O
bronchoscopy	O
was	O
initiated	O
,	O
and	O
thick	O
,	O
inspissated	O
secretions	O
were	O
retrieved	O
.	O

Gene	O
ontology	O
category	O
,	O
KEGG	O
pathway	O
,	O
and	O
gene	O
interaction	O
networks	O
(	O
STRING	O
analysis	O
)	O
were	O
analyzed	O
to	O
identify	O
relationships	O
among	O
differentially	O
expressed	O
genes	O
involved	O
in	O
signal	O
transduction	O
,	O
cell	O
adhesion	O
,	O
immune	O
responses	O
,	O
apoptosis	B-PATH
regulation	O
,	O
positive	O
regulation	O
of	O
the	O
I	O
-	O
kappaB	O
kinase	O
/	O
NF	O
-	O
kappaB	O
cascade	O
and	O
response	O
to	O
cytokine	O
stimulus	O
.	O

ABSTRACT	O
:	O
The	O
critical	O
asthma	B-PATH
syndrome	O
(	O
CAS	O
)	O
encompasses	O
the	O
most	O
severe	O
,	O
persistent	O
,	O
refractory	O
asthma	B-PATH
patients	O
for	O
the	O
clinician	O
to	O
manage	O
.	O

Personalized	O
pharmacotherapy	O
is	O
necessary	O
to	O
prevent	O
the	O
next	O
acute	O
severe	O
asthma	B-PATH
exacerbation	O
,	O
not	O
just	O
the	O
control	O
of	O
symptoms	O
.	O

The	O
2007	O
National	O
Asthma	B-PATH
Education	O
and	O
Prevention	O
Program	O
Expert	O
Panel	O
3	O
provides	O
guidelines	O
for	O
the	O
treatment	O
of	O
uncontrolled	O
asthma	B-PATH
.	O

The	O
patient	O
'	O
s	O
response	O
to	O
recommended	O
pharmacotherapy	O
is	O
highly	O
variable	O
which	O
risks	O
poor	O
asthma	B-PATH
control	O
leading	O
to	O
frequent	O
exacerbations	O
that	O
can	O
deteriorate	O
into	O
CAS	O
.	O

Controlling	O
asthma	B-PATH
symptoms	O
and	O
preventing	O
acute	O
exacerbations	O
may	O
be	O
two	O
separate	O
clinical	O
activities	O
with	O
their	O
own	O
unique	O
demands	O
.	O

Clinicians	O
must	O
be	O
prepared	O
to	O
use	O
the	O
entire	O
spectrum	O
of	O
asthma	B-PATH
medications	O
available	O
but	O
must	O
concurrently	O
be	O
aware	O
of	O
potential	O
drug	O
toxicities	O
some	O
of	O
which	O
can	O
paradoxically	O
worsen	O
asthma	B-PATH
control	O
.	O

Medications	O
normally	O
prescribed	O
for	O
COPD	O
can	O
potentially	O
be	O
useful	O
in	O
the	O
CAS	O
patient	O
,	O
particularly	O
those	O
with	O
asthma	B-PATH
-	O
COPD	O
overlap	O
syndrome	O
.	O

The	O
pharmacology	O
and	O
toxicities	O
of	O
the	O
agents	O
that	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
CAS	O
to	O
control	O
asthma	B-PATH
symptoms	O
and	O
prevent	O
severe	O
exacerbations	O
are	O
reviewed	O
.	O

TITLE	O
:	O
The	O
unusual	O
presentation	O
of	O
a	O
usual	O
organism	O
-	O
the	O
changing	O
spectrum	O
of	O
the	O
clinical	O
manifestations	O
of	O
Plasmodium	O
vivax	O
malaria	B-PATH
in	O
children	O
:	O
a	O
retrospective	O
study	O
.	O

A	O
majority	O
of	O
the	O
deaths	O
are	O
attributed	O
to	O
severe	O
malaria	B-PATH
which	O
is	O
caused	O
by	O
Plasmodium	O
falciparum	O
.	O

To	O
highlight	O
the	O
increasing	O
number	O
of	O
severe	O
manifestations	O
in	O
P	O
.	O
vivax	O
malaria	B-PATH
in	O
the	O
children	O
who	O
were	O
admitted	O
in	O
the	O
malaria	B-PATH
transmission	O
season	O
of	O
2011	O
,	O
at	O
a	O
tertiary	O
care	O
hospital	O
.	O

Children	O
with	O
an	O
acute	O
febrile	O
illness	O
of	O
a	O
duration	O
of	O
<	O
7	O
days	O
,	O
which	O
was	O
confirmed	O
as	O
Plasmodium	O
vivax	O
positive	O
malaria	B-PATH
by	O
testing	O
the	O
peripheral	O
smears	O
and	O
/	O
or	O
by	O
Rapid	O
Diagnostic	O
Testing	O
,	O
who	O
were	O
admitted	O
in	O
the	O
paediatric	O
ward	O
of	O
a	O
tertiary	O
care	O
hospital	O
in	O
New	O
Delhi	O
(	O
India	O
),	O
during	O
May	O
2011	O
to	O
October	O
2011	O
,	O
Case	O
records	O
of	O
context	O
cases	O
were	O
analysed	O
retrospectively	O
.	O

Plasmodium	O
vivax	O
is	O
emerging	O
as	O
a	O
cause	O
of	O
severe	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
Plasmodium	O
ovale	O
is	O
one	O
of	O
the	O
causative	O
agents	O
of	O
human	O
malaria	B-PATH
.	O

Due	O
to	O
its	O
lower	O
morbidity	O
,	O
P	O
.	O
ovale	O
receives	O
little	O
attention	O
in	O
malaria	B-PATH
research	O
.	O

The	O
other	O
patient	O
came	O
down	O
with	O
malaria	B-PATH
-	O
induced	O
respiratory	O
complication	O
during	O
the	O
course	O
of	O
treatment	O
.	O

Monitoring	O
of	O
respiratory	O
and	O
renal	O
function	O
of	O
malaria	B-PATH
patients	O
,	O
regardless	O
of	O
the	O
species	O
of	O
malaria	B-PATH
parasites	O
involved	O
is	O
crucial	O
during	O
the	O
course	O
of	O
hospital	O
admission	O
.	O

A	O
phylogenetic	O
analysis	O
of	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
sequence	O
fragments	O
aided	O
in	O
identifying	O
two	O
alphacoronaviruses	O
from	O
Kuhl	O
'	O
s	O
pipistrelle	O
(	O
Pipistrellus	O
kuhlii	O
),	O
three	O
clade	O
2b	O
betacoronaviruses	O
from	O
lesser	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
hipposideros	O
),	O
and	O
10	O
clade	O
2c	O
betacoronaviruses	O
from	O
Kuhl	O
'	O
s	O
pipistrelle	O
,	O
common	O
noctule	O
(	O
Nyctalus	O
noctula	O
),	O
and	O
Savi	O
'	O
s	O
pipistrelle	O
(	O
Hypsugo	O
savii	O
).	O

Three	O
major	O
infectious	O
diseases	O
,	O
namely	O
AIDS	O
,	O
malaria	B-PATH
,	O
and	O
tuberculosis	B-PATH
,	O
are	O
killing	O
around	O
8	O
million	O
people	O
in	O
the	O
world	O
annually	O
.	O

The	O
majority	O
of	O
the	O
genes	O
that	O
were	O
significantly	O
regulated	O
,	O
were	O
those	O
associated	O
with	O
monocytes	O
-	O
macrophage	O
and	O
Th1	O
cell	O
functions	O
,	O
and	O
the	O
regulation	O
of	O
apoptosis	B-PATH
.	O

Real	O
time	O
RT	O
-	O
qPCR	O
developed	O
focusing	O
on	O
2	O
up	O
-	O
regulated	O
genes	O
(	O
PD	O
-	O
L1	O
and	O
A3H	O
)	O
together	O
with	O
an	O
apoptosis	B-PATH
associated	O
gene	O
PD	O
-	O
1	O
expressions	O
in	O
FIPV	O
infected	O
CRFK	O
cells	O
and	O
in	O
PBMCs	O
from	O
healthy	O
and	O
FIP	O
diagnosed	O
cats	O
produced	O
concordant	O
results	O
with	O
transcriptome	O
data	O
.	O

Real	O
time	O
RT	O
-	O
qPCR	O
developed	O
focusing	O
on	O
2	O
up	O
-	O
regulated	O
genes	O
(	O
PD	O
-	O
L1	O
and	O
A3H	O
)	O
together	O
with	O
an	O
apoptosis	B-PATH
associated	O
gene	O
PD	O
-	O
1	O
expressions	O
in	O
FIPV	O
infected	O
CRFK	O
cells	O
and	O
in	O
PBMCs	O
from	O
healthy	O
and	O
FIP	O
diagnosed	O
cats	O
produced	O
concordant	O
results	O
with	O
transcriptome	O
data	O
.	O

TITLE	O
:	O
Definition	O
of	O
critical	O
asthma	B-PATH
syndromes	O
.	O

ABSTRACT	O
:	O
Urgent	O
visits	O
to	O
the	O
clinic	O
and	O
emergency	O
department	O
for	O
acute	O
severe	O
asthma	B-PATH
exacerbations	O
are	O
all	O
too	O
frequent	O
.	O

Existing	O
national	O
guidelines	O
do	O
not	O
present	O
consistent	O
or	O
specific	O
recommendations	O
for	O
the	O
evaluation	O
and	O
treatment	O
of	O
individual	O
asthma	B-PATH
patients	O
in	O
respiratory	O
distress	O
.	O

In	O
this	O
vein	O
,	O
we	O
propose	O
the	O
term	O
""""	O
critical	O
asthma	B-PATH
syndrome	O
""""	O
(	O
CAS	O
)	O
to	O
describe	O
any	O
child	O
or	O
adult	O
who	O
is	O
at	O
high	O
risk	O
for	O
fatal	O
asthma	B-PATH
.	O

Acute	O
severe	O
asthma	B-PATH
,	O
refractory	O
asthma	B-PATH
,	O
status	O
asthmaticus	O
,	O
and	O
near	O
-	O
fatal	O
asthma	B-PATH
all	O
describe	O
CAS	O
where	O
physical	O
exhaustion	O
from	O
the	O
overwhelming	O
work	O
of	O
breathing	O
leads	O
to	O
respiratory	O
arrest	O
and	O
death	O
from	O
hypoxia	O
or	O
related	O
complications	O
.	O

CAS	O
is	O
not	O
severe	O
persistent	O
asthma	B-PATH
where	O
control	O
of	O
symptoms	O
and	O
prevention	O
of	O
exacerbations	O
are	O
targets	O
of	O
chronic	O
disease	O
management	O
in	O
the	O
outpatient	O
setting	O
.	O

In	O
addition	O
,	O
gaps	O
in	O
knowledge	O
and	O
clinical	O
experience	O
in	O
regards	O
to	O
critical	O
asthma	B-PATH
are	O
highlighted	O
.	O

Knowledge	O
gaps	O
include	O
a	O
lack	O
of	O
understanding	O
of	O
how	O
to	O
recognize	O
CAS	O
,	O
how	O
to	O
coordinate	O
and	O
integrate	O
hospital	O
and	O
outpatient	O
resources	O
,	O
when	O
to	O
further	O
phenotype	O
patients	O
with	O
critical	O
asthma	B-PATH
in	O
order	O
to	O
facilitate	O
effective	O
treatment	O
,	O
and	O
how	O
to	O
prevent	O
future	O
acute	O
exacerbations	O
.	O

ABSTRACT	O
:	O
While	O
antiviral	O
therapy	O
is	O
an	O
important	O
component	O
of	O
care	O
in	O
patients	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
following	O
influenza	B-PATH
infection	I-PATH
,	O
it	O
is	O
not	O
sufficient	O
to	O
ensure	O
good	O
outcomes	O
,	O
and	O
additional	O
measures	O
are	O
usually	O
necessary	O
.	O

A	O
recent	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
comparing	O
hyperimmune	O
globulin	O
prepared	O
from	O
convalescent	O
plasma	O
against	O
normal	O
intravenous	O
gammaglobulin	O
(	O
IVIG	O
)	O
manufactured	O
before	O
2009	O
as	O
control	O
in	O
patients	O
with	O
severe	O
A	O
(	O
H1N1	B-PATH
)	O
pdm09	O
infection	O
on	O
standard	O
antiviral	O
treatment	O
has	O
shown	O
that	O
the	O
hyperimmune	O
globulin	O
group	O
who	O
received	O
treatment	O
within	O
5	O
days	O
of	O
symptom	O
onset	O
had	O
a	O
lower	O
viral	O
load	O
and	O
reduced	O
mortality	O
compared	O
with	O
the	O
controls	O
.	O

Furthermore	O
,	O
the	O
two	O
scavengers	O
significantly	O
inhibited	O
the	O
activation	O
of	O
p38	O
MAPK	O
and	O
p53	O
and	O
further	O
blocked	O
apoptosis	B-PATH
occurrence	O
through	O
suppressing	O
the	O
TGEV	O
-	O
induced	O
Bcl	O
-	O
2	O
reduction	O
,	O
Bax	O
redistribution	O
,	O
cytochrome	O
c	O
release	B-PATH
and	O
caspase	O
-	O
3	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
oxidative	O
stress	O
pathway	O
might	O
be	O
a	O
key	O
element	O
in	O
TGEV	O
-	O
induced	O
apoptosis	B-PATH
and	O
TGEV	O
pathogenesis	O
.	O

Here	O
,	O
we	O
review	O
the	O
up	O
-	O
to	O
-	O
date	O
knowledge	O
on	O
SARS	O
-	O
CoV	O
replicative	O
enzymes	O
encoded	O
in	O
the	O
ORF1b	O
,	O
i	O
.	O
e	O
.,	O
the	O
main	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
nsp12	O
),	O
the	O
helicase	O
/	O
triphosphatase	O
(	O
nsp13	O
),	O
two	O
unusual	O
ribonucleases	O
(	O
nsp14	O
,	O
nsp15	O
)	O
and	O
RNA	O
-	O
cap	O
methyltransferases	O
(	O
nsp14	O
,	O
nsp16	O
).	O

ABSTRACT	O
:	O
During	O
the	O
recent	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
,	O
due	O
to	O
severe	O
respiratory	O
failure	O
many	O
patients	O
required	O
treatment	O
with	O
alternative	O
ventilator	O
modalities	O
including	O
High	O
Frequency	O
Oscillatory	O
Ventilation	O
(	O
HFOV	O
).	O

Mechanistically	O
,	O
TNFR1	O
deficiency	O
directly	O
impeded	O
the	O
serum	O
and	O
tissue	O
levels	O
of	O
fibrinogen	O
-	O
like	O
protein	O
2	O
(	O
FGL2	O
),	O
a	O
virus	O
-	O
induced	O
procoagulant	O
molecule	O
that	O
promotes	O
cell	O
apoptosis	B-PATH
.	O

Additionally	O
,	O
the	O
expression	O
of	O
apoptosis	B-PATH
-	O
associated	O
molecules	O
,	O
Fas	O
and	O
Fas	O
ligand	O
(	O
FasL	O
)	O
in	O
the	O
infected	O
organs	O
from	O
TNFR1	O
(-/-)	O
mice	O
were	O
also	O
decreased	O
.	O

Many	O
viruses	O
such	O
as	O
poliovirus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
virus	O
inhibit	O
protein	O
import	O
into	O
the	O
nucleus	O
,	O
whereas	O
viruses	O
such	O
as	O
influenza	B-PATH
A	I-PATH
virus	O
target	O
and	O
disrupt	O
host	O
mRNA	O
nuclear	O
export	O
.	O

Although	O
the	O
incidence	O
of	O
tuberculosis	B-PATH
has	O
decreased	O
in	O
the	O
developed	O
world	O
,	O
it	O
is	O
still	O
a	O
significant	O
public	O
health	O
problem	O
in	O
the	O
rest	O
of	O
the	O
world	O
.	O

Even	O
with	O
the	O
development	O
of	O
new	O
pharmaceuticals	O
to	O
treat	O
tuberculosis	B-PATH
,	O
there	O
is	O
no	O
indication	O
that	O
the	O
disease	O
will	O
be	O
eradicated	O
.	O

Severe	O
asthma	B-PATH
presents	O
a	O
special	O
problem	O
,	O
but	O
the	O
question	O
is	O
whether	O
there	O
can	O
be	O
one	O
treatment	O
pathway	O
for	O
all	O
patients	O
with	O
severe	O
asthma	B-PATH
.	O

Severe	O
asthma	B-PATH
is	O
a	O
heterogeneous	O
disease	O
with	O
many	O
phenotypes	O
and	O
endotypes	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
vivax	O
malaria	B-PATH
complicated	O
by	O
adult	O
respiratory	O
distress	O
syndrome	O
and	O
successful	O
management	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

ABSTRACT	O
:	O
Complicated	O
malaria	B-PATH
is	O
mainly	O
caused	O
by	O
Plasmodium	O
falciparum	O
,	O
but	O
,	O
increasingly	O
,	O
Plasmodium	O
vivax	O
is	O
also	O
being	O
reported	O
as	O
a	O
cause	O
.	O

Herein	O
,	O
we	O
report	O
a	O
case	O
of	O
vivax	O
malaria	B-PATH
complicated	O
by	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
that	O
was	O
successfully	O
managed	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Genetic	O
variation	O
affecting	O
interferon	O
lambda	O
(	O
IFN	O
-	O
Î»	O
)	O
expression	O
is	O
now	O
known	O
to	O
influence	O
the	O
outcome	O
of	O
both	O
hepatitis	B-PATH
C	I-PATH
virus	O
and	O
herpes	O
simplex	O
virus	O
type	O
1	O
infection	O
in	O
humans	O
.	O

Interestingly	O
,	O
data	O
from	O
animal	O
models	O
show	O
that	O
IFN	O
-	O
Î»	O
contributes	O
to	O
host	O
control	O
of	O
viruses	O
infecting	O
these	O
sites	O
,	O
including	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
and	O
rotavirus	O
.	O

Furthermore	O
,	O
defective	O
IFN	O
-	O
Î»	O
production	O
by	O
humans	O
with	O
asthma	B-PATH
impairs	O
the	O
control	O
of	O
rhinovirus	O
infection	O
.	O

TITLE	O
:	O
Chinese	O
social	O
media	O
reaction	O
to	O
the	O
MERS	O
-	O
CoV	O
and	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
outbreaks	O
.	O

Capitalizing	O
on	O
the	O
wealth	O
of	O
public	O
opinion	O
data	O
contained	O
in	O
posts	O
on	O
Weibo	O
,	O
this	O
study	O
used	O
Weibo	O
as	O
a	O
measure	O
of	O
the	O
Chinese	O
people	O
'	O
s	O
reactions	O
to	O
two	O
different	O
outbreaks	O
:	O
the	O
2012	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
,	O
and	O
the	O
2013	O
outbreak	O
of	O
human	O
infection	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
in	O
China	O
.	O

These	O
findings	O
indicate	O
that	O
MERS	O
-	O
CoV	O
PLpro	O
acts	O
as	O
a	O
viral	O
DUB	O
and	O
suppresses	O
production	O
of	O
IFN	O
-	O
Î²	O
by	O
an	O
interfering	O
IRF3	O
-	O
mediated	O
signalling	O
pathway	O
,	O
in	O
addition	O
to	O
recognizing	O
and	O
processing	O
the	O
CS	O
at	O
the	O
N	O
terminus	O
of	O
replicase	O
polyprotein	O
to	O
release	B-PATH
the	O
non	O
-	O
structural	O
proteins	O
.	O

The	O
balance	O
between	O
inflammatory	O
mediators	O
is	O
key	O
for	O
the	O
outcome	O
of	O
the	O
pulmonary	O
infection	O
;	O
elimination	O
of	O
invading	O
pathogen	O
was	O
marked	O
by	O
the	O
release	B-PATH
of	O
cytokines	O
and	O
other	O
inflammatory	O
mediators	O
from	O
alveolar	O
macrophages	O
and	O
glucocorticoid	O
steroids	O
(	O
GCs	O
)	O
acting	O
on	O
the	O
inflammatory	O
component	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
the	O
course	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
infection	O
--	O
genetic	O
aspects	O
.	O

The	O
case	O
is	O
described	O
of	O
a	O
male	O
patient	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
the	O
course	O
of	O
influenza	B-PATH
A	I-PATH
/	O
N1H1v	O
infection	O
,	O
confirmed	O
by	O
virological	O
molecular	O
analysis	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
complicating	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
infection	O
--	O
a	O
clinical	O
approach	O
.	O

Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
development	O
of	O
extremely	O
severe	O
type	O
of	O
ARDS	O
with	O
poor	O
response	O
to	O
routine	O
treatment	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
caused	O
an	O
epidemic	O
of	O
critical	O
illness	O
,	O
and	O
some	O
patients	O
developed	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
or	O
severe	O
cardiopulmonary	O
failure	O
despite	O
the	O
use	O
of	O
conventional	O
management	O
.	O

ABSTRACT	O
:	O
Severe	O
bronchial	O
obstruction	O
due	O
to	O
one	O
of	O
the	O
major	O
pulmonary	O
diseases	O
:	O
asthma	B-PATH
,	O
COPD	O
,	O
or	O
emphysema	O
often	O
requires	O
mechanical	O
ventilation	O
support	O
.	O

ABSTRACT	O
:	O
Bone	O
marrow	O
stromal	O
antigen	O
2	O
(	O
BST2	O
),	O
an	O
interferon	O
-	O
inducible	O
antiviral	O
factor	O
,	O
has	O
been	O
shown	O
to	O
block	O
the	O
release	B-PATH
of	O
various	O
enveloped	O
viruses	O
from	O
cells	O
.	O

Here	O
we	O
report	O
our	O
findings	O
that	O
(	O
a	O
)	O
the	O
production	O
of	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
progeny	O
viruses	O
,	O
whose	O
budding	B-PATH
occurs	O
at	O
the	O
ER	O
-	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
),	O
markedly	O
decreases	O
in	O
the	O
presence	O
of	O
BST2	O
;	O
and	O
(	O
b	O
)	O
BST2	O
knockdown	O
expression	O
results	O
in	O
enhanced	O
HCoV	O
-	O
229E	O
virion	O
production	O
.	O

Our	O
results	O
suggest	O
that	O
BST2	O
exerts	O
a	O
broad	O
blocking	O
effect	O
against	O
enveloped	O
virus	O
release	B-PATH
,	O
regardless	O
of	O
whether	O
budding	B-PATH
occurs	O
at	O
the	O
plasma	O
membrane	O
or	O
intracellular	O
compartments	O
.	O

This	O
is	O
a	O
retrospective	O
cohort	O
study	O
of	O
14	O
patients	O
with	O
HMs	O
(	O
aggressive	O
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
n	O
=	O
5	O
;	O
highly	O
aggressive	O
NHL	O
,	O
that	O
is	O
acute	O
lymphoblastic	O
leukemia	O
or	O
Burkitt	O
lymphoma	O
,	O
n	O
=	O
5	O
;	O
Hodgkin	O
lymphoma	O
,	O
n	O
=	O
2	O
;	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
,	O
n	O
=	O
1	O
;	O
multiple	O
myeloma	O
,	O
n	O
=	O
1	O
)	O
receiving	O
ECMO	O
support	O
because	O
of	O
ARF	O
(	O
all	O
data	O
as	O
medians	O
and	O
interquartile	O
ranges	O
;	O
age	O
,	O
32	O
years	O
(	O
22	O
to	O
51	O
years	O
);	O
simplified	O
acute	O
physiology	O
score	O
II	O
(	O
SAPS	O
II	O
):	O
51	O
(	O
42	O
to	O
65	O
)).	O

TITLE	O
:	O
Mutant	O
murine	O
hepatitis	O
virus	O
-	O
induced	O
apoptosis	B-PATH
in	O
the	O
hippocampus	O
.	O

In	O
contrast	O
,	O
in	O
cl	O
-	O
2	O
infection	O
,	O
10	O
-	O
20	O
%	O
of	O
the	O
infected	O
mice	O
exhibited	O
apoptosis	B-PATH
in	O
the	O
hippocampus	O
,	O
which	O
was	O
primarily	O
observed	O
in	O
the	O
CA1	O
subregion	O
.	O

Apoptosis	B-PATH
also	O
occurred	O
in	O
the	O
pyramidal	O
neurons	O
and	O
CD11b	O
-	O
bearing	O
cells	O
.	O

These	O
data	O
indicated	O
that	O
apoptosis	B-PATH
observed	O
in	O
Mu	O
-	O
3	O
infection	O
could	O
be	O
induced	O
by	O
the	O
indirect	O
effects	O
of	O
infection	O
in	O
addition	O
to	O
direct	O
effects	O
of	O
the	O
infected	O
cells	O
occurring	O
in	O
a	O
cell	O
-	O
autonomous	O
manner	O
.	O

Their	O
action	O
is	O
essential	O
in	O
living	O
organisms	O
facilitating	O
electric	O
signaling	O
,	O
muscle	O
contraction	O
or	O
osmotic	O
stress	B-PATH
response	I-PATH
among	O
other	O
effects	O
.	O

The	O
activity	O
of	O
the	O
channel	O
is	O
involved	O
in	O
the	O
mechanism	O
of	O
virus	O
release	B-PATH
.	O

Drugs	O
that	O
inhibit	O
the	O
ion	O
channel	O
can	O
,	O
therefore	O
,	O
inhibit	O
virus	O
release	B-PATH
,	O
and	O
they	O
could	O
be	O
a	O
source	O
for	O
development	O
of	O
novel	O
therapeutic	O
antiviral	O
agents	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
decade	O
,	O
Vietnam	O
has	O
successfully	O
responded	O
to	O
global	O
health	O
security	O
(	O
GHS	O
)	O
challenges	O
,	O
including	O
domestic	O
elimination	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
rapid	O
public	O
health	O
responses	O
to	O
human	O
infections	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
.	O

Any	O
virus	O
was	O
detected	O
in	O
320	O
/	O
556	O
(	O
57	O
.	O
6	O
%)	O
ILI	O
episodes	O
:	O
influenza	B-PATH
A	I-PATH
(	O
104	O
/	O
556	O
,	O
18	O
.	O
7	O
%),	O
rhinovirus	O
/	O
enterovirus	O
(	O
82	O
/	O
556	O
,	O
14	O
.	O
7	O
%),	O
coronavirus	O
and	O
human	O
metapneumovirus	O
(	O
each	O
32	O
/	O
556	O
,	O
5	O
.	O
6	O
%).	O

The	O
nucleoside	O
analogue	O
2a	O
(	O
Ac	O
)	O
showed	O
good	O
anti	O
SARS	O
-	O
CoV	O
and	O
anti	O
influenza	B-PATH
A	I-PATH
(	O
HâNâ	O
)	O
activities	O
.	O

Other	O
viruses	O
have	O
developed	O
'	O
cap	O
-	O
mimicking	O
'	O
mechanisms	O
by	O
attaching	O
a	O
peptide	O
to	O
the	O
5	O
'	O
end	O
of	O
viral	O
RNA	O
(	O
e	O
.	O
g	O
.	O
picornavirus	O
and	O
calicivirus	O
)	O
or	O
by	O
having	O
a	O
complex	O
5	O
'	O
RNA	O
structure	O
(	O
internal	O
ribosome	B-PATH
entry	O
site	O
)	O
for	O
translation	O
initiation	O
(	O
e	O
.	O
g	O
.	O
picornavirus	O
,	O
pestivirus	O
and	O
hepacivirus	O
).	O

TITLE	O
:	O
Clinical	O
Manifestations	O
,	O
Treatment	O
,	O
and	O
Outcome	O
of	O
Hospitalized	O
Patients	O
with	O
Plasmodium	O
vivax	O
Malaria	B-PATH
in	O
Two	O
Indian	O
States	O
:	O
A	O
Retrospective	O
Study	O
.	O

As	O
per	O
WHO	O
criteria	O
for	O
severity	O
,	O
19	O
of	O
110	O
patients	O
had	O
severe	O
disease	O
-	O
six	O
patients	O
had	O
clinical	O
jaundice	O
with	O
hepatic	O
dysfunction	O
,	O
three	O
patients	O
had	O
severe	O
anemia	O
,	O
three	O
had	O
spontaneous	O
bleeding	O
,	O
two	O
had	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
one	O
had	O
cerebral	O
malaria	B-PATH
,	O
hyperparasitemia	O
,	O
renal	O
failure	O
,	O
circulatory	O
collapse	O
,	O
and	O
metabolic	O
acidosis	O
.	O

Plasmodium	O
vivax	O
malaria	B-PATH
can	O
no	O
longer	O
be	O
considered	O
a	O
benign	O
condition	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
forms	O
a	O
helical	O
ribonucleoprotein	O
with	O
the	O
viral	O
positive	O
-	O
strand	O
RNA	O
genome	O
and	O
binds	O
to	O
the	O
principal	O
constituent	O
of	O
the	O
virion	O
envelope	O
,	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
,	O
to	O
facilitate	O
assembly	O
and	O
budding	B-PATH
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	B-PATH
)	O
vs	O
non	O
-	O
H1N1	B-PATH
ARDS	O
:	O
analysis	O
of	O
clinical	O
course	O
.	O

TGEV	O
infection	O
induced	O
the	O
occurring	O
of	O
apoptosis	B-PATH
in	O
swine	O
testicle	O
(	O
ST	O
)	O
cells	O
,	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
,	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
Bax	O
,	O
altered	O
mitochondrial	O
membrane	O
potential	O
,	O
activated	O
p38	O
MAPK	O
signal	O
pathway	O
,	O
and	O
increased	O
expression	O
of	O
p53	O
as	O
evidenced	O
by	O
immunofluorescence	O
assays	O
,	O
real	O
-	O
time	O
PCR	O
,	O
flow	O
cytometry	O
and	O
Western	O
blot	O
.	O

ABSTRACT	O
:	O
Our	O
previous	O
studies	O
showed	O
that	O
TGEV	O
infection	O
could	O
induce	O
cell	B-PATH
cycle	I-PATH
arrest	O
and	O
apoptosis	B-PATH
via	O
activation	O
of	O
p53	O
signaling	O
in	O
cultured	O
host	O
cells	O
.	O

Characterization	O
of	O
various	O
cellular	O
proteins	O
that	O
are	O
involved	O
in	O
regulating	O
cell	B-PATH
cycle	I-PATH
progression	O
demonstrated	O
that	O
the	O
expression	O
of	O
N	O
gene	O
resulted	O
in	O
an	O
accumulation	O
of	O
p53	O
and	O
p21	O
,	O
which	O
suppressed	O
cyclin	O
B1	O
,	O
cdc2	O
and	O
cdk2	O
expression	O
.	O

Moreover	O
,	O
the	O
expression	O
of	O
TGEV	O
N	O
gene	O
promoted	O
translocation	O
of	O
Bax	O
to	O
mitochondria	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	B-PATH
of	O
cytochrome	O
c	O
,	O
followed	O
by	O
activation	O
of	O
caspase	O
-	O
3	O
,	O
resulting	O
in	O
cell	O
apoptosis	B-PATH
in	O
the	O
transfected	O
PK	O
-	O
15	O
cells	O
following	O
cell	B-PATH
cycle	I-PATH
arrest	O
.	O

Further	O
studies	O
showed	O
that	O
p53	O
inhibitor	O
attenuated	O
TGEV	O
N	O
protein	O
induced	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	B-PATH
through	O
reversing	O
the	O
expression	O
changes	O
of	O
cdc2	O
,	O
cdk2	O
and	O
cyclin	O
B1	O
and	O
the	O
translocation	O
changes	O
of	O
Bax	O
and	O
cytochrome	O
c	O
induced	O
by	O
TGEV	O
N	O
protein	O
.	O

We	O
demonstrate	O
that	O
MHV	O
S	O
proteins	O
are	O
indeed	O
cleaved	O
upon	O
virus	O
endocytosis	B-PATH
,	O
and	O
we	O
identify	O
a	O
novel	O
processing	O
product	O
S2	O
*	O
with	O
characteristics	O
of	O
a	O
fusion	O
-	O
active	O
subunit	O
.	O

Two	O
new	O
respiratory	O
viruses	O
,	O
Middle	O
East	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
avian	O
-	O
origin	O
Influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
have	O
been	O
reported	O
.	O

ABSTRACT	O
:	O
Community	O
-	O
acquired	O
pneumonia	O
continues	O
to	O
be	O
an	O
important	O
complication	O
of	O
HIV	B-PATH
infection	I-PATH
.	O

This	O
tripeptidic	O
acylsulfonamide	O
inhibitor	O
of	O
the	O
NS3	O
/	O
4A	O
enzyme	O
is	O
currently	O
in	O
phase	O
III	O
clinical	O
trials	O
for	O
the	O
treatment	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
infection	O
.	O

ABSTRACT	O
:	O
African	B-PATH
trypanosomiasis	I-PATH
is	O
a	O
parasitic	O
infection	O
sporadically	O
imported	O
to	O
Europe	O
by	O
tourists	O
or	O
immigrants	O
returning	O
from	O
endemic	O
areas	O
.	O

We	O
present	O
the	O
first	O
and	O
an	O
unusual	O
case	O
of	O
East	O
African	B-PATH
trypanosomiasis	I-PATH
imported	O
to	O
Poland	O
by	O
a	O
patient	O
returning	O
from	O
a	O
tourist	O
trip	O
to	O
Uganda	O
and	O
Rwanda	O
,	O
which	O
was	O
successfully	O
treated	O
with	O
pentamidine	O
.	O

The	O
other	O
internal	O
genes	O
NP	O
and	O
PA	O
genes	O
are	O
more	O
closely	O
related	O
to	O
those	O
of	O
non	O
-	O
A	O
(	O
H7N9	O
)	O
avian	O
influenza	B-PATH
A	I-PATH
viruses	O
.	O

Examples	O
are	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
novel	O
variants	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
such	O
as	O
H5N1	O
and	O
pandemic	O
H1N1	O
.	O

Sensitivities	O
of	O
culture	O
,	O
RV15	O
,	O
and	O
AdvanSure	O
for	O
each	O
virus	O
tested	O
were	O
as	O
follows	O
:	O
91	O
/	O
100	O
/	O
96	O
%	O
for	O
influenza	B-PATH
A	I-PATH
,	O
60	O
/	O
0	O
/	O
100	O
%	O
for	O
influenza	O
B	O
,	O
63	O
/	O
95	O
/	O
97	O
%	O
for	O
RSV	O
,	O
69	O
/	O
81	O
/	O
89	O
%	O
for	O
adenovirus	O
,	O
and	O
87	O
/	O
93	O
/	O
93	O
%	O
for	O
parainfluenza	O
virus	O
.	O

ABSTRACT	O
:	O
Proteolytic	O
cleavage	O
of	O
the	O
hemagglutinin	O
(	O
HA	O
)	O
protein	O
is	O
essential	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
to	O
acquire	O
infectivity	O
.	O

TITLE	O
:	O
Neuroleptic	O
malignant	O
-	O
like	O
syndrome	O
with	O
a	O
slight	O
elevation	O
of	O
creatine	O
-	O
kinase	O
levels	O
and	O
respiratory	O
failure	O
in	O
a	O
patient	O
with	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
.	O

The	O
patient	O
,	O
a	O
68	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
4	O
-	O
years	O
history	O
of	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
,	O
presented	O
with	O
hyperthermia	O
and	O
severe	O
muscular	O
rigidity	O
.	O

There	O
are	O
differences	O
in	O
both	O
the	O
epidemiology	O
of	O
imported	O
malaria	B-PATH
and	O
in	O
the	O
facilities	O
available	O
to	O
treat	O
travellers	O
with	O
severe	O
malaria	B-PATH
between	O
different	O
parts	O
of	O
the	O
world	O
.	O

There	O
are	O
limited	O
data	O
to	O
guide	O
clinicians	O
caring	O
for	O
adults	O
with	O
imported	O
malaria	B-PATH
in	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

PubMed	O
was	O
searched	O
for	O
studies	O
on	O
adults	O
with	O
imported	O
malaria	B-PATH
treated	O
in	O
an	O
ICU	O
.	O

Many	O
patients	O
who	O
require	O
admission	O
to	O
ICU	O
were	O
originally	O
from	O
malaria	B-PATH
-	O
endemic	O
countries	O
and	O
many	O
did	O
not	O
have	O
hyperparasitaemia	O
.	O

TITLE	O
:	O
A	O
lysine	O
-	O
methionine	O
exchange	O
in	O
a	O
coronavirus	O
surface	O
protein	O
transforms	O
a	O
retention	O
motif	O
into	O
an	O
endocytosis	B-PATH
signal	O
.	O

TITLE	O
:	O
Protection	O
from	O
SARS	O
coronavirus	O
conferred	O
by	O
live	O
measles	B-PATH
vaccine	O
expressing	O
the	O
spike	O
glycoprotein	O
.	O

To	O
this	O
aim	O
,	O
we	O
generated	O
live	O
attenuated	O
recombinant	O
measles	B-PATH
vaccine	O
(	O
MV	O
)	O
candidates	O
expressing	O
either	O
the	O
membrane	O
-	O
anchored	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
or	O
its	O
secreted	O
soluble	O
ectodomain	O
(	O
Ssol	O
).	O

Although	O
an	O
abundance	O
of	O
memory	O
CD4	O
(+)	O
T	O
cells	O
at	O
mucosal	O
sites	O
render	O
them	O
highly	O
susceptible	O
to	O
HIV	B-PATH
infection	I-PATH
,	O
the	O
gut	O
and	O
not	O
the	O
lung	O
experiences	O
severe	O
and	O
sustained	O
CD4	O
(+)	O
T	O
cell	O
depletion	O
and	O
tissue	O
disruption	O
.	O

LoFS	O
also	O
induced	O
muscle	O
peroxisome	B-PATH
proliferator	O
-	O
activated	O
receptor	O
-	O
Î³	O
and	O
peroxisome	B-PATH
proliferator	O
-	O
activated	O
receptor	O
-	O
Î±	O
coactivator	O
-	O
1	O
mRNA	O
.	O

Applying	O
our	O
method	O
to	O
data	O
from	O
the	O
three	O
largest	O
outbreaks	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H7N9	O
outbreak	O
in	O
China	O
in	O
2013	O
,	O
we	O
found	O
evidence	O
that	O
human	O
-	O
to	O
-	O
human	O
transmission	O
accounted	O
for	O
13	O
%	O
(	O
95	O
%	O
credible	O
interval	O
1	O
%-	O
32	O
%)	O
of	O
cases	O
overall	O
.	O

However	O
,	O
in	O
more	O
vulnerable	O
populations	O
,	O
such	O
as	O
newborns	O
,	O
infants	O
,	O
the	O
elderly	O
,	O
and	O
immune	O
-	O
compromised	O
individuals	O
,	O
they	O
can	O
also	O
affect	O
the	O
lower	O
respiratory	O
tract	O
,	O
leading	O
to	O
pneumonia	O
,	O
exacerbations	O
of	O
asthma	B-PATH
,	O
respiratory	O
distress	O
syndrome	O
,	O
or	O
even	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

TITLE	O
:	O
SARS	O
coronavirus	O
papain	O
-	O
like	O
protease	O
inhibits	O
the	O
type	O
I	O
interferon	B-PATH
signaling	I-PATH
pathway	O
through	O
interaction	O
with	O
the	O
STING	O
-	O
TRAF3	O
-	O
TBK1	O
complex	O
.	O

TITLE	O
:	O
Viral	O
lung	O
infections	O
:	O
epidemiology	O
,	O
virology	O
,	O
clinical	O
features	O
,	O
and	O
management	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
).	O

ABSTRACT	O
:	O
The	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
has	O
jumped	O
species	O
barrier	O
and	O
caused	O
severe	O
human	O
infections	O
.	O

ABSTRACT	O
:	O
Double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
PKR	O
)	O
regulates	O
antiviral	O
activity	O
,	O
immune	O
responses	O
,	O
apoptosis	B-PATH
and	O
neurotoxicity	O
.	O

TITLE	O
:	O
Kidney	O
transplantation	O
from	O
donors	O
with	O
hepatitis	B-PATH
C	I-PATH
infection	O
.	O

When	O
allocated	O
to	O
serology	O
-	O
matched	O
recipients	O
,	O
kidney	O
transplantation	O
from	O
donors	O
with	O
hepatitis	B-PATH
C	I-PATH
may	O
result	O
in	O
an	O
excellent	O
short	O
-	O
term	O
outcome	O
and	O
a	O
significant	O
reduction	O
of	O
time	O
on	O
the	O
waiting	O
list	O
.	O

Reovirus	O
pathogenicity	O
has	O
been	O
associated	O
with	O
virus	O
-	O
induced	O
apoptosis	B-PATH
in	O
cultured	O
cells	O
and	O
in	O
vivo	O
.	O

The	O
reovirus	O
outer	O
capsid	O
protein	O
Î¼1	O
is	O
recognized	O
as	O
the	O
primary	O
determinant	O
of	O
reovirus	O
-	O
induced	O
apoptosis	B-PATH
.	O

Under	O
electron	O
microscopy	O
,	O
BYD1	O
-	O
infected	O
cells	O
showed	O
characteristics	O
typical	O
of	O
apoptosis	B-PATH
.	O

Notably	O
,	O
ectopically	O
expressed	O
Î¼1	O
and	O
Ï1	O
induced	O
similar	O
pathological	O
apoptosis	B-PATH
,	O
independent	O
of	O
BYD1	O
infection	O
,	O
in	O
host	O
cells	O
in	O
which	O
they	O
were	O
expressed	O
,	O
which	O
suggests	O
that	O
Î¼1	O
and	O
Ï1	O
are	O
both	O
apoptotic	O
virulence	O
factors	O
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
BYD1	O
Î¼1	O
-	O
and	O
Ï1	O
-	O
induced	O
apoptosis	B-PATH
is	O
involved	O
in	O
the	O
multi	O
-	O
organ	O
lesions	O
in	O
a	O
suckling	O
mouse	O
BYD1	O
infection	O
model	O
.	O

However	O
,	O
in	O
the	O
Znhigh	O
group	O
,	O
we	O
found	O
a	O
prevention	O
of	O
villus	O
atrophy	O
and	O
decreased	O
caspase	O
-	O
3	O
-	O
mediated	O
apoptosis	B-PATH
of	O
jejunal	O
epithelium	O
.	O

TITLE	O
:	O
Anxiety	O
,	O
worry	O
and	O
cognitive	O
risk	O
estimate	O
in	O
relation	O
to	O
protective	O
behaviors	O
during	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pandemic	O
in	O
Hong	O
Kong	O
:	O
ten	O
cross	O
-	O
sectional	O
surveys	O
.	O

This	O
study	O
was	O
aimed	O
to	O
compare	O
the	O
strength	O
of	O
associations	O
between	O
different	O
cognitive	O
and	O
affective	O
measures	O
of	O
risk	O
and	O
self	O
-	O
reported	O
protective	O
behaviors	O
in	O
a	O
series	O
of	O
ten	O
cross	O
-	O
sectional	O
surveys	O
conducted	O
throughout	O
the	O
first	O
wave	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pandemic	O
.	O

Blast	O
crisis	O
with	O
transformation	O
into	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
occurs	O
in	O
one	O
third	O
of	O
patients	O
.	O

IMPORTANCE	O
The	O
viruses	O
that	O
cause	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
poliomyelitis	O
,	O
and	O
hepatitis	B-PATH
C	I-PATH
all	O
replicate	O
in	O
double	O
-	O
membrane	O
vesicles	O
(	O
DMVs	O
).	O

TITLE	O
:	O
Early	O
response	O
to	O
the	O
emergence	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
in	O
humans	O
in	O
China	O
:	O
the	O
central	O
role	O
of	O
prompt	O
information	O
sharing	O
and	O
public	O
communication	O
.	O

ABSTRACT	O
:	O
Human	O
disease	O
caused	O
by	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
HPAI	O
)	O
(	O
H5N1	O
)	O
is	O
associated	O
with	O
fulminant	O
viral	O
pneumonia	O
and	O
mortality	O
rates	O
in	O
excess	O
of	O
60	O
%.	O

In	O
this	O
study	O
,	O
the	O
antiviral	O
and	O
anti	O
-	O
inflammatory	O
effects	O
of	O
two	O
indirubin	O
derivatives	O
:	O
indirubin	O
-	O
3	O
'-	O
oxime	O
(	O
IM	O
)	O
and	O
E804	O
on	O
primary	O
human	O
peripherial	O
blood	O
-	O
derived	O
macrophages	O
and	O
type	O
-	O
I	O
like	O
pneumocytes	O
(	O
human	O
alveolar	O
epithelial	O
cells	O
)	O
during	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
infection	O
were	O
investigated	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
a	O
conserved	O
region	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
revealed	O
that	O
alphacoronaviruses	O
had	O
diversities	O
with	O
some	O
obvious	O
differences	O
from	O
those	O
reported	O
previously	O
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
who	O
had	O
rapidly	O
progressive	O
pneumonia	O
with	O
respiratory	O
distress	O
and	O
bilateral	O
exduation	O
and	O
consolidation	O
changes	O
on	O
chest	O
X	O
-	O
ray	O
and	O
computerized	O
tomography	O
(	O
CT	O
)	O
scan	O
that	O
did	O
not	O
respond	O
to	O
ordinary	O
antibiotics	O
was	O
diagnosed	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
infection	O
in	O
our	O
hospital	O
on	O
July	O
19	O
,	O
2013	O
.	O

The	O
testing	O
for	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
turned	O
negative	O
on	O
day	O
16	O
since	O
the	O
antivirus	O
therapy	O
.	O

ABSTRACT	O
:	O
Dehydroandrographolide	O
and	O
andrographolide	O
,	O
two	O
natural	O
diterpenoids	O
isolated	O
from	O
Andrographis	O
paniculata	O
possessed	O
activity	O
against	O
HBV	O
DNA	B-PATH
replication	I-PATH
with	O
IC50	O
values	O
of	O
22	O
.	O
58	O
and	O
54	O
.	O
07Î¼M	O
and	O
low	O
SI	O
values	O
of	O
8	O
.	O
7	O
and	O
3	O
.	O
7	O
in	O
our	O
random	O
assay	O
.	O

Consequently	O
,	O
48	O
derivatives	O
of	O
dehydroandrographolide	O
and	O
andrographolide	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HBV	O
properties	O
to	O
yield	O
a	O
series	O
of	O
active	O
derivatives	O
with	O
lower	O
cytotoxicity	O
,	O
including	O
14	O
derivatives	O
against	O
HBsAg	O
secretion	O
,	O
19	O
derivatives	O
against	O
HBeAg	O
secretion	O
and	O
38	O
derivatives	O
against	O
HBV	O
DNA	B-PATH
replication	I-PATH
.	O

TITLE	O
:	O
Coronavirus	O
entry	O
and	O
release	B-PATH
in	O
polarized	O
epithelial	O
cells	O
:	O
a	O
review	O
.	O

In	O
this	O
paper	O
,	O
we	O
review	O
the	O
knowledge	O
regarding	O
the	O
entry	O
and	O
release	B-PATH
of	O
coronaviruses	O
,	O
with	O
particular	O
emphasis	O
on	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
In	O
2011	O
,	O
autochthonous	O
Plasmodium	O
vivax	O
malaria	B-PATH
emerged	O
in	O
a	O
focal	O
geographical	O
area	O
in	O
Greece	O
after	O
importation	O
by	O
immigrants	O
from	O
the	O
Indian	O
subcontinent	O
.	O

We	O
discuss	O
the	O
risks	O
potentially	O
associated	O
with	O
the	O
reappearance	O
of	O
P	O
.	O
vivax	O
malaria	B-PATH
in	O
a	O
previously	O
malaria	B-PATH
-	O
free	O
area	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
3a	O
protein	O
functions	O
as	O
an	O
ion	O
channel	O
,	O
induces	O
apoptosis	B-PATH
and	O
is	O
important	O
for	O
viral	O
pathogenesis	O
.	O

Whether	O
E	O
can	O
release	B-PATH
from	O
cells	O
or	O
E	O
/	O
N	O
interaction	O
exists	O
so	O
as	O
to	O
contribute	O
to	O
enhanced	O
VLP	O
production	O
is	O
unknown	O
.	O

Changing	O
all	O
three	O
E	O
cysteine	O
residues	O
to	O
alanines	O
did	O
not	O
exert	O
negative	O
effects	O
on	O
E	O
release	B-PATH
,	O
E	O
association	O
with	O
N	O
,	O
or	O
E	O
enhancement	O
of	O
VLP	O
production	O
,	O
suggesting	O
that	O
E	O
palmitoylation	O
modification	O
or	O
disulfide	O
bond	O
formation	O
is	O
not	O
required	O
for	O
SARS	O
-	O
CoV	O
virus	O
assembly	O
.	O

We	O
found	O
that	O
removal	O
of	O
the	O
last	O
E	O
carboxyl	O
-	O
terminal	O
residue	O
markedly	O
affected	O
E	O
release	B-PATH
,	O
N	O
association	O
,	O
and	O
VLP	O
incorporation	O
,	O
but	O
did	O
not	O
significantly	O
compromise	O
the	O
contribution	O
of	O
E	O
to	O
efficient	O
VLP	O
production	O
.	O

We	O
found	O
that	O
removal	O
of	O
the	O
last	O
E	O
carboxyl	O
-	O
terminal	O
residue	O
markedly	O
affected	O
E	O
release	B-PATH
,	O
N	O
association	O
,	O
and	O
VLP	O
incorporation	O
,	O
but	O
did	O
not	O
significantly	O
compromise	O
the	O
contribution	O
of	O
E	O
to	O
efficient	O
VLP	O
production	O
.	O

TITLE	O
:	O
Is	O
abdomen	O
release	B-PATH
really	O
necessary	O
for	O
prone	O
ventilation	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
?	O

TITLE	O
:	O
[	O
Influenza	B-PATH
infection	I-PATH
in	O
intensive	O
cardiac	O
care	O
unit	O
patients	O
].	O

Influenza	B-PATH
A	I-PATH
virus	O
,	O
RSV	O
A	O
,	O
HRV	O
,	O
coronavirus	O
OC43	O
,	O
and	O
adenovirus	O
were	O
detected	O
more	O
frequently	O
in	O
sputum	O
samples	O
than	O
in	O
nasopharyngeal	O
swabs	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Importantly	O
,	O
12	O
of	O
44	O
(	O
27	O
%)	O
influenza	B-PATH
A	I-PATH
infections	O
and	O
11	O
of	O
27	O
(	O
41	O
%)	O
RSV	O
infections	O
were	O
positive	O
in	O
only	O
sputum	O
samples	O
.	O

TITLE	O
:	O
Plasmodium	O
falciparum	O
Malaria	B-PATH
Complicated	O
by	O
Symmetrical	O
Peripheral	O
Gangrene	O
,	O
Bowel	O
Ischemia	O
,	O
Repeated	O
Candidemia	O
,	O
and	O
Bacteraemia	O
.	O

Including	O
the	O
co	O
-	O
infections	O
,	O
RSV	O
was	O
the	O
most	O
commonly	O
identified	O
virus	O
(	O
n	O
=	O
21	O
;	O
33	O
.	O
9	O
%),	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
[	O
H1N1	O
]	O
(	O
n	O
=	O
18	O
;	O
29	O
%),	O
RV	O
(	O
n	O
=	O
18	O
;	O
29	O
%),	O
hMPV	O
(	O
n	O
=	O
13	O
;	O
21	O
%),	O
PIV	O
(	O
n	O
=	O
10	O
;	O
16	O
.	O
1	O
%),	O
AdV	O
(	O
n	O
=	O
5	O
;	O
8	O
%),	O
HBoV	O
(	O
n	O
=	O
3	O
;	O
4	O
.	O
8	O
%)	O
and	O
EV	O
(	O
n	O
=	O
1	O
;	O
1	O
.	O
6	O
%).	O

Including	O
the	O
co	O
-	O
infections	O
,	O
the	O
most	O
commonly	O
detected	O
virus	O
was	O
RV	O
(	O
n	O
=	O
10	O
;	O
30	O
.	O
3	O
%),	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
[	O
H1N1	O
]	O
(	O
n	O
=	O
6	O
;	O
18	O
.	O
1	O
%),	O
AdV	O
(	O
n	O
=	O
6	O
;	O
18	O
.	O
1	O
%),	O
RSV	O
(	O
n	O
=	O
4	O
;	O
12	O
.	O
1	O
%)	O
and	O
PIV	O
(	O
n	O
=	O
3	O
;	O
9	O
%),	O
however	O
HBoV	O
and	O
hMPV	O
were	O
not	O
detected	O
in	O
the	O
control	O
group	O
.	O

ABSTRACT	O
:	O
Respiratory	O
viral	O
infections	O
precipitate	O
exacerbations	O
of	O
chronic	O
respiratory	O
diseases	O
such	O
as	O
asthma	B-PATH
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
though	O
similar	O
data	O
in	O
non	O
-	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
bronchiectasis	O
are	O
missing	O
.	O

Respiratory	O
viruses	O
were	O
detected	O
during	O
37	O
(	O
48	O
%)	O
exacerbations	O
:	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
in	O
20	O
;	O
an	O
enterovirus	O
or	O
bocavirus	O
in	O
four	O
each	O
;	O
adenoviruses	O
,	O
metapneumovirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
parainfluenza	O
virus	O
3	O
or	O
4	O
in	O
two	O
each	O
;	O
coronavirus	O
or	O
parainfluenza	O
virus	O
1	O
and	O
2	O
in	O
one	O
each	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
viruses	O
recruit	O
components	O
of	O
the	O
nuclear	O
import	O
pathway	O
to	O
enter	O
the	O
host	O
cell	O
nucleus	O
and	O
promote	O
viral	O
replication	O
.	O

Importance	O
:	O
Influenza	B-PATH
A	I-PATH
viruses	O
are	O
respiratory	O
pathogens	O
that	O
may	O
cause	O
pneumonia	O
in	O
humans	O
.	O

Notably	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
NS1	O
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
this	O
histone	O
-	O
mediated	O
downregulation	O
in	O
highly	O
pathogenic	O
influenza	O
strains	O
.	O

Together	O
,	O
the	O
work	O
demonstrates	O
the	O
existence	O
of	O
unique	O
and	O
common	O
viral	O
strategies	O
for	O
controlling	O
the	O
global	O
ISG	O
response	O
and	O
provides	O
a	O
novel	O
avenue	O
for	O
viral	O
antagonism	O
via	O
altered	O
histone	B-PATH
modifications	I-PATH
.	O

Each	O
case	O
examines	O
a	O
significant	O
aspect	O
of	O
One	O
Health	O
operationalisation	O
,	O
framed	O
around	O
the	O
control	O
of	O
both	O
emerging	O
and	O
Neglected	O
Zoonotic	O
Diseases	O
including	O
HPAI	O
,	O
Human	O
African	B-PATH
Trypanosomiasis	I-PATH
and	O
rabies	O
.	O

We	O
then	O
used	O
reverse	O
-	O
transcription	O
PCR	O
to	O
look	O
for	O
the	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
in	O
fecal	O
samples	O
collected	O
from	O
27	O
little	O
Japanese	O
horseshoe	O
bats	O
and	O
found	O
eight	O
were	O
provisionally	O
positive	O
.	O

TITLE	O
:	O
A	O
highly	O
conserved	O
WDYPKCDRA	O
epitope	O
in	O
the	O
RNA	O
directed	O
RNA	B-PATH
polymerase	I-PATH
of	O
human	O
coronaviruses	O
can	O
be	O
used	O
as	O
epitope	O
-	O
based	O
universal	O
vaccine	O
design	O
.	O

We	O
found	O
that	O
conserved	O
region	O
is	O
present	O
only	O
in	O
the	O
RNA	O
directed	O
RNA	B-PATH
polymerase	I-PATH
protein	O
.	O

TITLE	O
:	O
Serum	O
activin	O
A	O
and	O
B	O
,	O
and	O
follistatin	O
in	O
critically	O
ill	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

ARDS	O
and	O
severe	O
respiratory	O
failure	O
are	O
complications	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

Interleukin	O
6	O
(	O
IL	O
-	O
6	O
),	O
which	O
in	O
experimental	O
studies	O
increases	O
after	O
activin	O
A	O
release	B-PATH
,	O
is	O
known	O
to	O
be	O
related	O
to	O
the	O
severity	O
of	O
H1N1	O
infection	O
.	O

TITLE	O
:	O
Uncomplicated	O
Plasmodium	O
vivax	O
malaria	B-PATH
in	O
pregnancy	O
associated	O
with	O
mortality	O
from	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
The	O
association	O
between	O
severe	O
malaria	B-PATH
and	O
Plasmodium	O
vivax	O
species	O
is	O
contentious	O
.	O

On	O
the	O
Thai	O
-	O
Myanmar	O
border	O
,	O
all	O
pregnant	O
women	O
are	O
followed	O
systematically	O
with	O
active	O
weekly	O
malaria	B-PATH
screening	O
.	O

Sensitive	O
detection	O
with	O
nested	O
PCR	O
confirmed	O
only	O
the	O
presence	O
of	O
P	O
.	O
vivax	O
species	O
and	O
concomitant	O
infections	O
such	O
as	O
tuberculosis	B-PATH
and	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
were	O
also	O
ruled	O
out	O
.	O

Furthermore	O
,	O
transplantation	O
of	O
differentiated	O
RAE	O
-	O
1	O
(-)	O
allogeneic	O
NPCs	O
into	O
JHMV	O
-	O
infected	O
BALB	O
/	O
c	O
mice	O
resulted	O
in	O
enhanced	O
survival	O
,	O
highlighting	O
a	O
role	O
for	O
the	O
NKG2D	O
/	O
RAE	O
-	O
1	O
signaling	O
axis	O
in	O
allograft	B-PATH
rejection	I-PATH
.	O

Gene	O
transcription	O
is	O
dynamic	O
and	O
condition	O
-	O
specific	O
;	O
therefore	O
,	O
to	O
better	O
understand	O
the	O
mouse	O
transcriptional	O
response	O
to	O
respiratory	O
virus	O
infection	O
,	O
we	O
infected	O
the	O
eight	O
founder	O
strains	O
of	O
the	O
Collaborative	O
Cross	O
with	O
either	O
influenza	B-PATH
A	I-PATH
virus	O
or	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
sequenced	O
lung	O
RNA	O
samples	O
at	O
2	O
and	O
4	O
days	O
after	O
infection	O
.	O

ABSTRACT	O
:	O
Glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
is	O
an	O
energy	B-PATH
metabolism	I-PATH
-	O
related	O
enzyme	O
in	O
the	O
glycolytic	O
pathway	O
.	O

Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
GAPDH	O
has	O
other	O
physiological	O
functions	O
,	O
such	O
as	O
apoptosis	B-PATH
,	O
DNA	O
repair	O
and	O
autophagy	O
.	O

Here	O
we	O
systematically	O
inferred	O
the	O
regulatory	O
functions	O
of	O
host	O
lncRNAs	O
in	O
response	O
to	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
based	O
on	O
their	O
similarity	O
in	O
expression	O
with	O
genes	O
of	O
known	O
function	O
.	O

However	O
,	O
the	O
care	O
of	O
patients	O
with	O
HIV	B-PATH
infection	I-PATH
has	O
advanced	O
since	O
the	O
introduction	O
of	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
),	O
with	O
increased	O
life	O
expectancy	O
and	O
decreased	O
mortality	O
.	O

Three	O
HIV	O
-	O
infected	O
patients	O
with	O
AIDS	O
were	O
admitted	O
to	O
ICU	O
and	O
were	O
treated	O
with	O
ECMO	O
:	O
a	O
21	O
years	O
old	O
Caucasian	O
female	O
with	O
congenital	O
HIV	B-PATH
infection	I-PATH
presented	O
with	O
Pneumocystis	O
jirovecii	O
pneumonia	O
(	O
PJP	O
);	O
a	O
38	O
years	O
old	O
Caucasian	O
female	O
with	O
HIV	O
-	O
HCV	O
infection	O
and	O
L	O
.	O
pneumophila	O
pneumonia	O
;	O
a	O
24	O
years	O
old	O
Caucasian	O
male	O
with	O
fever	O
,	O
cough	O
weight	O
loss	O
and	O
PJP	O
pneumonia	O
.	O

TITLE	O
:	O
Lung	O
ultrasound	O
imaging	O
in	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
respiratory	O
failure	O
.	O

We	O
describe	O
the	O
use	O
of	O
lung	O
ultrasound	O
imaging	O
and	O
findings	O
in	O
two	O
cases	O
of	O
severe	O
respiratory	O
failure	O
from	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
infection	O
.	O

Here	O
,	O
we	O
identified	O
the	O
steps	O
that	O
govern	O
-	O
1PRF	O
by	O
following	O
the	O
stepwise	O
movement	O
of	O
the	O
ribosome	B-PATH
through	O
the	O
frameshifting	O
site	O
of	O
a	O
model	O
mRNA	O
derived	O
from	O
the	O
IBV	O
1a	O
/	O
1b	O
gene	O
in	O
a	O
reconstituted	O
in	O
vitro	O
translation	O
system	O
from	O
Escherichia	O
coli	O
.	O

The	O
slippage	O
of	O
the	O
ribosome	B-PATH
into	O
the	O
-	O
1	O
frame	O
accelerates	O
the	O
completion	O
of	O
translocation	O
,	O
thereby	O
further	O
favoring	O
translation	O
in	O
the	O
new	O
reading	O
frame	O
.	O

ABSTRACT	O
:	O
Inherited	O
variability	O
in	O
host	O
immune	O
responses	O
influences	O
susceptibility	O
and	O
outcome	O
of	O
Influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
infection	O
,	O
but	O
these	O
factors	O
remain	O
largely	O
unknown	O
.	O

TITLE	O
:	O
Clinical	O
and	O
epidemiological	O
analysis	O
of	O
the	O
first	O
case	O
of	O
human	O
infection	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
in	O
Shenzhen	O
,	O
China	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
human	O
infection	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
in	O
Shenzhen	O
,	O
China	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
2	O
-	O
oxo	O
-	O
pyrazine	O
-	O
3	O
-	O
carboxamide	O
-	O
yl	O
nucleoside	O
analogues	O
and	O
their	O
epimers	O
as	O
inhibitors	O
of	O
influenza	B-PATH
A	I-PATH
viruses	O
.	O

ABSTRACT	O
:	O
Novel	O
2	O
-	O
oxo	O
-	O
pyrazine	O
-	O
3	O
-	O
carboxamide	O
-	O
yl	O
nucleoside	O
analogues	O
and	O
their	O
epimers	O
were	O
designed	O
,	O
synthesized	O
and	O
evaluated	O
for	O
their	O
activities	O
against	O
influenza	B-PATH
A	I-PATH
viruses	O
H1N1	O
and	O
H3N2	O
in	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
cells	O
.	O

One	O
of	O
the	O
epimers	O
,	O
4	O
-[(	O
1S	O
,	O
3R	O
,	O
4R	O
,	O
7R	O
)-	O
7	O
-	O
hydroxy	O
-	O
1	O
-(	O
hydroxymethyl	O
)-	O
2	O
,	O
5	O
-	O
dioxabicyclo	O
[	O
2	O
.	O
2	O
.	O
1	O
]	O
heptan	O
-	O
3	O
-	O
yl	O
]-	O
3	O
-	O
oxo	O
-	O
3	O
,	O
4	O
-	O
dihydropyrazine	O
-	O
2	O
-	O
carboxamide	O
8a	O
,	O
with	O
high	O
antiviral	O
activities	O
(	O
IC50	O
=	O
7	O
.	O
41	O
,	O
5	O
.	O
63	O
Î¼m	O
for	O
H3N2	O
and	O
H1N1	O
,	O
respectively	O
)	O
and	O
remarkable	O
low	O
cytotoxicity	O
(	O
TC50	O
>	O
200	O
Î¼m	O
),	O
has	O
great	O
potential	O
for	O
further	O
development	O
as	O
a	O
novel	O
anti	O
-	O
influenza	B-PATH
A	I-PATH
agent	O
.	O

Specimens	O
were	O
tested	O
by	O
real	O
time	O
RT	O
-	O
PCR	O
for	O
influenza	B-PATH
A	I-PATH
and	O
B	O
.	O
Influenza	B-PATH
A	I-PATH
-	O
positive	O
specimens	O
were	O
subtyped	O
for	O
H1	O
,	O
H3	O
,	O
H5	O
,	O
and	O
(	O
beginning	O
in	O
May	O
2009	O
)	O
A	O
(	O
H1N1	O
)	O
pdm09	O
.	O

Of	O
all	O
influenza	O
-	O
positive	O
specimens	O
,	O
78	O
%	O
were	O
influenza	B-PATH
A	I-PATH
,	O
21	O
%	O
were	O
influenza	O
B	O
,	O
and	O
1	O
%	O
were	O
influenza	B-PATH
A	I-PATH
/	O
B	O
coinfections	O
.	O

Indeed	O
,	O
functions	O
such	O
as	O
cap	B-PATH
-	I-PATH
independent	I-PATH
translation	I-PATH
initiation	I-PATH
mechanisms	O
are	O
,	O
in	O
some	O
cases	O
,	O
primarily	O
driven	O
by	O
RNA	O
structural	O
determinants	O
.	O

TITLE	O
:	O
Plasmodium	O
vivax	O
malaria	B-PATH
--	O
is	O
it	O
really	O
benign	O
?	O

All	O
patients	O
of	O
severe	O
and	O
complicated	O
P	O
vivax	O
malaria	B-PATH
were	O
admitted	O
and	O
treated	O
as	O
severe	O
P	O
falciparum	O
malaria	B-PATH
.	O

Severe	O
complications	O
like	O
significant	O
hepatomegaly	O
,	O
thrombocytopenia	O
,	O
acute	O
renal	O
failure	O
,	O
severe	O
anaemia	O
,	O
leucopoenia	O
,	O
electrolyte	O
disturbance	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
cerebral	O
malaria	B-PATH
,	O
multiorgan	O
dysfunction	O
,	O
hepatic	O
dysfunction	O
,	O
pancytopenia	O
,	O
and	O
death	O
seen	O
in	O
21	O
.	O
57	O
%,	O
18	O
.	O
63	O
%,	O
11	O
.	O
76	O
%,	O
8	O
.	O
82	O
%,	O
5	O
.	O
88	O
%,	O
5	O
.	O
88	O
%,	O
3	O
.	O
92	O
%,	O
2	O
.	O
94	O
%,	O
1	O
.	O
96	O
%,	O
1	O
.	O
96	O
%,	O
0	O
.	O
98	O
%,	O
1	O
.	O
96	O
%	O
patients	O
respectively	O
.	O

A	O
significant	O
proportion	O
of	O
morbidity	O
and	O
mortality	O
in	O
malaria	B-PATH
also	O
observed	O
in	O
P	O
vivax	O
infection	O
as	O
seen	O
in	O
P	O
falciparum	O
infection	O
and	O
require	O
hospitalisation	O
.	O

The	O
most	O
common	O
respiratory	O
virus	O
was	O
human	O
rhinovirus	O
,	O
detected	O
in	O
57	O
.	O
7	O
%	O
of	O
the	O
positive	O
samples	O
,	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
23	O
.	O
1	O
%)	O
and	O
human	O
coronaviruses	O
(	O
19	O
.	O
2	O
%).	O

TITLE	O
:	O
Infection	O
in	O
severe	O
asthma	B-PATH
exacerbations	O
and	O
critical	O
asthma	B-PATH
syndrome	O
.	O

ABSTRACT	O
:	O
In	O
chronic	O
persistent	O
asthma	B-PATH
and	O
severe	O
acute	O
exacerbations	O
of	O
bronchial	O
asthma	B-PATH
,	O
infectious	O
agents	O
are	O
the	O
predominant	O
triggers	O
that	O
drive	O
disease	O
and	O
airway	O
pathobiology	O
.	O

In	O
acute	O
exacerbations	O
of	O
bronchial	O
asthma	B-PATH
(	O
AEBA	O
)	O
including	O
near	O
fatal	O
and	O
fatal	O
asthma	B-PATH
,	O
viral	O
agents	O
,	O
particularly	O
human	O
rhinovirus	O
-	O
C	O
,	O
respiratory	O
syncytial	O
virus	O
and	O
influenza	B-PATH
A	I-PATH
appear	O
to	O
be	O
the	O
more	O
prevalent	O
and	O
recurring	O
threats	O
.	O

Both	O
viral	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
bacterial	O
agents	O
,	O
can	O
play	O
a	O
role	O
,	O
and	O
co	O
-	O
infection	O
may	O
also	O
be	O
present	O
and	O
worsen	O
prognosis	O
in	O
hospitalized	O
patients	O
,	O
placing	O
a	O
portion	O
at	O
risk	O
for	O
critical	O
asthma	B-PATH
syndrome	O
.	O

In	O
this	O
manuscript	O
we	O
will	O
outline	O
the	O
impact	O
of	O
the	O
major	O
viral	O
agents	O
on	O
severe	O
asthma	B-PATH
including	O
the	O
data	O
from	O
the	O
2009	O
H1N1	O
influenza	O
pandemic	O
.	O

The	O
role	O
of	O
bacterial	O
infections	O
in	O
acute	O
exacerbations	O
of	O
asthma	B-PATH
will	O
also	O
be	O
reviewed	O
as	O
well	O
as	O
the	O
benefit	O
of	O
empiric	O
antibiotics	O
and	O
the	O
role	O
of	O
macrolides	O
in	O
both	O
acute	O
and	O
chronic	O
asthma	B-PATH
.	O

Inflammasomes	B-PATH
contribute	O
to	O
both	O
the	O
clearance	O
of	O
the	O
pathogen	O
as	O
well	O
as	O
its	O
pathogenesis	O
-	O
depending	O
on	O
the	O
amount	O
of	O
inflammation	O
triggered	O
.	O

This	O
is	O
a	O
novel	O
mechanism	O
by	O
which	O
respiratory	O
viral	O
infection	O
activates	O
inflammasomes	B-PATH
,	O
and	O
identifies	O
sensing	O
of	O
disturbances	O
in	O
intracellular	O
ionic	O
concentrations	O
as	O
a	O
novel	O
pathogen	O
-	O
recognition	O
pathway	O
in	O
the	O
lung	O
.	O

This	O
study	O
aimed	O
to	O
assess	O
the	O
effectiveness	O
of	O
Peg	O
-	O
interferon	O
/	O
ribavirin	O
therapy	O
in	O
""""	O
real	O
world	O
""""	O
chronic	O
hepatitis	B-PATH
C	I-PATH
patients	O
in	O
Italy	O
.	O

The	O
difference	O
in	O
response	O
rates	O
was	O
more	O
pronounced	O
among	O
easy	O
-	O
to	O
-	O
treat	O
than	O
among	O
difficult	O
-	O
to	O
-	O
treat	O
hepatitis	B-PATH
C	I-PATH
virus	O
genotypes	O
.	O

TITLE	O
:	O
Coronavirus	O
infection	O
,	O
ER	O
stress	O
,	O
apoptosis	B-PATH
and	O
innate	O
immunity	O
.	O

Activation	O
of	O
the	O
three	O
branches	O
of	O
UPR	O
modulates	O
a	O
wide	O
variety	O
of	O
signaling	O
pathways	O
,	O
such	O
as	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
activation	O
,	O
autophagy	O
,	O
apoptosis	B-PATH
,	O
and	O
innate	O
immune	O
response	O
.	O

TITLE	O
:	O
Risk	O
factors	O
for	O
febrile	O
neutropenia	O
in	O
patients	O
receiving	O
docetaxel	O
chemotherapy	O
for	O
castration	O
-	O
resistant	O
prostate	B-PATH
cancer	I-PATH
.	O

ABSTRACT	O
:	O
Docetaxel	O
is	O
a	O
standard	O
therapy	O
for	O
patients	O
with	O
castration	O
-	O
resistant	O
prostate	B-PATH
cancer	I-PATH
(	O
CRPC	O
).	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
induces	O
caspase	O
-	O
independent	O
apoptosis	B-PATH
through	O
activation	O
of	O
mitochondrial	O
apoptosis	B-PATH
-	O
inducing	O
factor	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
sought	O
to	O
investigate	O
whether	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
induces	O
apoptosis	B-PATH
and	O
to	O
elucidate	O
the	O
mechanisms	O
associated	O
with	O
apoptotic	O
cell	O
death	O
after	O
PEDV	O
infection	O
.	O

PEDV	O
-	O
infected	O
cells	O
showed	O
evidence	O
of	O
apoptosis	B-PATH
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Interestingly	O
,	O
mitochondrial	O
apoptosis	B-PATH
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
was	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
during	O
PEDV	O
infection	O
,	O
and	O
AIF	O
relocalization	O
was	O
completely	O
abrogated	O
by	O
the	O
presence	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
),	O
an	O
inhibitor	O
of	O
cyclophilin	O
D	O
(	O
CypD	O
)	O
that	O
is	O
an	O
essential	O
component	O
of	O
the	O
mitochondrial	O
permeabilization	O
transition	O
pore	O
(	O
mPTP	O
)	O
complex	O
.	O

CsA	O
treatment	O
resulted	O
in	O
significant	O
inhibition	O
of	O
PEDV	O
-	O
triggered	O
apoptosis	B-PATH
and	O
suppressed	O
PEDV	O
replication	O
.	O

Altogether	O
,	O
our	O
results	O
indicate	O
that	O
a	O
caspase	O
-	O
independent	O
mitochondrial	O
AIF	O
-	O
mediated	O
pathway	O
plays	O
a	O
central	O
role	O
in	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
to	O
facilitate	O
viral	O
replication	O
and	O
pathogenesis	O
.	O

We	O
evaluated	O
the	O
proportion	O
of	O
SARI	O
/	O
ARDS	O
cases	O
and	O
deaths	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
and	O
the	O
impact	O
of	O
other	O
respiratory	O
viruses	O
during	O
pandemic	O
and	O
postpandemic	O
period	O
(	O
2009	O
-	O
2011	O
)	O
in	O
northern	O
Italy	O
;	O
additionally	O
we	O
searched	O
for	O
unknown	O
viruses	O
in	O
those	O
cases	O
for	O
which	O
diagnosis	O
remained	O
negative	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
was	O
detected	O
in	O
58	O
.	O
3	O
%	O
of	O
specimens	O
,	O
with	O
a	O
case	O
fatality	O
rate	O
of	O
11	O
.	O
3	O
%.	O

The	O
impact	O
of	O
other	O
respiratory	O
viruses	O
was	O
19	O
.	O
4	O
%,	O
and	O
the	O
most	O
commonly	O
detected	O
viruses	O
were	O
human	O
rhinovirus	O
/	O
enterovirus	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
).	O

Different	O
kinds	O
of	O
DNA	O
vaccines	O
are	O
investigated	O
to	O
provide	O
protection	O
against	O
respiratory	O
infectious	O
diseases	O
including	O
tuberculosis	B-PATH
,	O
coronavirus	O
,	O
influenza	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
etc	O
.	O

Major	O
advances	O
in	O
technology	O
and	O
the	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
that	O
characterized	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
have	O
stimulated	O
renewed	O
interest	O
in	O
the	O
use	O
of	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
and	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
to	O
support	O
the	O
respiratory	O
system	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
was	O
performed	O
on	O
""""	O
dunked	O
""""	O
sputum	O
and	O
NTS	O
samples	O
for	O
influenza	B-PATH
A	I-PATH
(	O
Flu	O
A	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
coronavirus	O
OC43	O
(	O
OC43	O
),	O
and	O
human	O
metapneumovirus	O
(	O
HMPV	O
).	O

We	O
found	O
that	O
higher	O
concentrations	O
of	O
anti	O
-	O
sera	O
against	O
SARS	O
-	O
CoV	O
neutralized	O
SARS	O
-	O
CoV	O
infection	O
,	O
while	O
highly	O
diluted	O
anti	O
-	O
sera	O
significantly	O
increased	O
SARS	O
-	O
CoV	O
infection	O
and	O
induced	O
higher	O
levels	O
of	O
apoptosis	B-PATH
.	O

The	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
region	O
from	O
four	O
highly	O
divergent	O
partial	O
viral	O
genomes	O
in	O
the	O
order	O
Picornavirales	O
were	O
sequenced	O
.	O

Our	O
data	O
confirmed	O
that	O
PEDV	O
entry	O
followed	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
independence	O
of	O
caveolae	O
-	O
coated	O
pit	O
assembly	O
.	O

Our	O
data	O
revealed	O
that	O
PEDV	O
entry	O
followed	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
and	O
was	O
dependent	O
on	O
a	O
low	O
pH	O
and	O
serine	O
proteolysis	O
for	O
successful	O
entry	O
into	O
cells	O
.	O

In	O
fact	O
,	O
after	O
infection	O
with	O
viruses	O
in	O
which	O
this	O
protein	O
has	O
been	O
deleted	O
,	O
increased	O
cellular	O
stress	O
and	O
unfolded	O
protein	O
responses	O
,	O
apoptosis	B-PATH
,	O
and	O
augmented	O
host	O
immune	O
responses	O
were	O
observed	O
.	O

Although	O
E	O
protein	O
is	O
not	O
essential	O
for	O
CoV	O
genome	O
replication	O
or	O
subgenomic	O
mRNA	O
synthesis	O
,	O
it	O
affects	O
virus	O
morphogenesis	O
,	O
budding	B-PATH
,	O
assembly	O
,	O
intracellular	O
trafficking	O
,	O
and	O
virulence	O
.	O

ABSTRACT	O
:	O
Viral	O
protease	O
inhibitors	O
are	O
remarkably	O
effective	O
at	O
blocking	O
the	O
replication	O
of	O
viruses	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
but	O
they	O
inevitably	O
lead	O
to	O
the	O
selection	O
of	O
inhibitor	O
-	O
resistant	O
mutants	O
,	O
which	O
may	O
contribute	O
to	O
ongoing	O
disease	O
.	O

TITLE	O
:	O
CD18	O
deficiency	O
evolving	O
to	O
megakaryocytic	O
(	O
M7	O
)	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
:	O
case	O
report	O
.	O

Here	O
,	O
a	O
20	O
year	O
-	O
old	O
female	O
presenting	O
a	O
partial	O
CD18	O
deficiency	O
that	O
developed	O
a	O
megakaryocytic	O
(	O
M7	O
)	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
is	O
described	O
for	O
the	O
first	O
time	O
.	O

TITLE	O
:	O
Severity	O
in	O
Plasmodium	O
vivax	O
malaria	B-PATH
claiming	O
global	O
vigilance	O
and	O
exploration	O
--	O
a	O
tertiary	O
care	O
centre	O
-	O
based	O
cohort	O
study	O
.	O

ABSTRACT	O
:	O
Mounting	O
reports	O
on	O
severe	O
Plasmodium	O
vivax	O
malaria	B-PATH
from	O
across	O
the	O
globe	O
have	O
raised	O
concerns	O
among	O
the	O
scientific	O
community	O
.	O

However	O
,	O
the	O
risk	O
of	O
P	O
.	O
vivax	O
resulting	O
in	O
complicated	O
malaria	B-PATH
and	O
mortality	O
is	O
not	O
as	O
firmly	O
established	O
as	O
it	O
is	O
with	O
Plasmodium	O
falciparum	O
.	O

Severe	O
malaria	B-PATH
was	O
defined	O
as	O
per	O
the	O
World	O
Health	O
Organization	O
'	O
s	O
guidelines	O
.	O

Of	O
922	O
malaria	B-PATH
cases	O
included	O
in	O
the	O
study	O
,	O
P	O
.	O
vivax	O
was	O
the	O
largest	O
(	O
63	O
.	O
4	O
%,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
60	O
.	O
3	O
-	O
66	O
.	O
5	O
%)	O
infecting	O
species	O
,	O
followed	O
by	O
P	O
.	O
falciparum	O
(	O
34	O
.	O
4	O
%,	O
95	O
%	O
CI	O
31	O
.	O
3	O
-	O
37	O
.	O
5	O
%)	O
and	O
their	O
mixed	O
infection	O
(	O
2	O
.	O
2	O
%,	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
3	O
.	O
2	O
%).	O

Mortality	O
in	O
vivax	O
and	O
falciparum	O
malaria	B-PATH
was	O
0	O
.	O
34	O
%	O
(	O
95	O
%	O
CI	O
-	O
0	O
.	O
13	O
-	O
0	O
.	O
81	O
%)	O
and	O
2	O
.	O
21	O
%	O
(	O
95	O
%	O
CI	O
0	O
.	O
59	O
-	O
3	O
.	O
83	O
%),	O
respectively	O
.	O

Except	O
hyperparasitaemia	O
and	O
shock	O
,	O
other	O
complications	O
were	O
associated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
mortality	O
in	O
falciparum	O
malaria	B-PATH
.	O

Pulmonary	O
oedema	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
was	O
associated	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
with	O
mortality	O
in	O
vivax	O
malaria	B-PATH
.	O

Plasmodium	O
vivax	O
does	O
cause	O
severe	O
malaria	B-PATH
and	O
mortality	O
in	O
substantial	O
proportion	O
but	O
results	O
in	O
much	O
lesser	O
amalgamations	O
of	O
multi	O
-	O
organ	O
involvements	O
than	O
P	O
.	O
falciparum	O
.	O

Nitazoxanide	O
inhibits	O
a	O
broad	O
range	O
of	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
including	O
influenza	B-PATH
A	I-PATH
(	O
pH1N1	O
)	O
and	O
the	O
avian	O
A	O
(	O
H7N9	O
)	O
as	O
well	O
as	O
viruses	O
that	O
are	O
resistant	O
to	O
neuraminidase	O
inhibitors	O
.	O

Clinical	O
trials	O
have	O
indicated	O
a	O
potential	O
role	O
for	O
thiazolides	O
in	O
treating	O
rotavirus	O
and	O
norovirus	O
gastroenteritis	O
and	O
chronic	O
hepatitis	O
B	O
and	O
chronic	O
hepatitis	B-PATH
C	I-PATH
.	O
Ongoing	O
and	O
future	O
clinical	O
development	O
is	O
focused	O
on	O
viral	O
respiratory	O
infections	O
,	O
viral	O
gastroenteritis	O
and	O
emerging	O
infections	O
such	O
as	O
dengue	O
fever	O
.	O

TITLE	O
:	O
DESC1	O
and	O
MSPL	O
activate	O
influenza	B-PATH
A	I-PATH
viruses	O
and	O
emerging	O
coronaviruses	O
for	O
host	O
cell	O
entry	O
.	O

Clusters	O
of	O
rapidly	O
-	O
evolving	O
microRNAs	O
were	O
identified	O
,	O
as	O
well	O
as	O
microRNAs	O
predicted	O
to	O
target	O
genes	O
involved	O
in	O
antiviral	O
immunity	O
,	O
the	O
DNA	B-PATH
damage	I-PATH
response	I-PATH
,	O
apoptosis	B-PATH
and	O
autophagy	O
.	O

MicroRNAs	O
are	O
likely	O
to	O
play	O
major	O
roles	O
in	O
regulating	O
virus	O
-	O
host	O
interaction	O
in	O
bats	O
,	O
via	O
dampening	O
of	O
inflammatory	O
responses	O
(	O
limiting	O
the	O
effects	O
of	O
immunopathology	O
),	O
and	O
directly	O
limiting	O
the	O
extent	O
of	O
viral	O
replication	O
,	O
either	O
through	O
restricting	O
the	O
availability	O
of	O
essential	O
factors	O
or	O
by	O
controlling	O
apoptosis	B-PATH
.	O

Conditioned	O
medium	O
at	O
15	O
%	O
significantly	O
increased	O
apoptosis	B-PATH
in	O
brain	O
cell	O
cultures	O
24	O
h	O
after	O
treatment	O
,	O
whereas	O
25	O
%	O
and	O
50	O
%	O
significantly	O
increased	O
both	O
necrosis	O
and	O
apoptosis	B-PATH
.	O

Our	O
findings	O
demonstrated	O
that	O
human	O
epithelial	O
pulmonary	O
cells	O
stimulated	O
with	O
bacterial	O
lipopolysaccharide	O
release	B-PATH
inflammatory	O
mediators	O
that	O
are	O
able	O
to	O
induce	O
a	O
translational	O
clinically	O
relevant	O
and	O
harmful	O
response	O
in	O
brain	O
cells	O
.	O

Under	O
prolonged	O
and	O
irremediable	O
ER	O
stress	O
,	O
however	O
,	O
the	O
UPR	O
can	O
also	O
trigger	O
apoptosis	B-PATH
.	O

Knockdown	O
and	O
overexpression	O
experiments	O
demonstrated	O
that	O
IRE1Î±	O
protects	O
infected	O
cells	O
from	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
,	O
which	O
required	O
both	O
its	O
kinase	O
and	O
RNase	O
activities	O
.	O

In	O
addition	O
,	O
they	O
also	O
could	O
affect	O
the	O
microfilaments	O
remodelling	O
of	O
IPEC	O
-	O
J2	O
cells	O
,	O
and	O
the	O
drug	O
-	O
interfered	O
microfilaments	O
could	O
inhibit	O
viral	O
replication	O
and	O
release	B-PATH
.	O

China	O
'	O
s	O
health	O
aid	O
deploys	O
medical	O
teams	O
,	O
constructs	O
facilities	O
,	O
donates	O
drugs	O
and	O
equipment	O
,	O
trains	O
personnel	O
,	O
and	O
supports	O
malaria	B-PATH
control	O
mainly	O
in	O
Africa	O
and	O
Asia	O
.	O

The	O
positive	O
results	O
from	O
the	O
CESAR	O
(	O
Conventional	O
ventilation	O
or	O
ECMO	O
for	O
Severe	O
Adult	O
Respiratory	O
failure	O
)	O
study	O
and	O
excellent	O
outcomes	O
in	O
patients	O
who	O
suffered	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
/	O
09	O
)	O
infection	O
have	O
established	O
ECMO	O
in	O
the	O
care	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Forty	O
-	O
seven	O
CAP	O
patients	O
were	O
infected	O
by	O
a	O
single	O
virus	O
(	O
24	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
5	O
influenza	O
B	O
,	O
10	O
parainfluenza	O
virus	O
type	O
3	O
[	O
PIV	O
-	O
3	O
],	O
2	O
PIV	O
-	O
1	O
,	O
2	O
adenovirus	O
,	O
2	O
human	O
rhinovirus	O
and	O
2	O
coronavirus	O
OC43	O
),	O
five	O
cases	O
by	O
two	O
or	O
three	O
viruses	O
co	O
-	O
infection	O
.	O

On	O
multivariate	O
analysis	O
,	O
myalgia	O
was	O
included	O
in	O
the	O
model	O
for	O
pneumonia	O
associated	O
with	O
influenza	B-PATH
infection	I-PATH
.	O

In	O
the	O
CURB	O
-	O
65	O
model	O
only	O
influenza	B-PATH
infection	I-PATH
was	O
found	O
independently	O
associated	O
with	O
severe	O
disease	O
(	O
CURB	O
-	O
65	O
score	O
â¥	O
3	O
)	O
out	O
of	O
variables	O
,	O
including	O
age	O
(	O
years	O
),	O
sex	O
,	O
current	O
smoking	O
status	O
,	O
sick	O
contact	O
with	O
febrile	O
patients	O
,	O
numbers	O
of	O
comorbidity	O
,	O
presence	O
of	O
influenza	B-PATH
infection	I-PATH
,	O
presence	O
of	O
PIV	O
infection	O
,	O
with	O
P	O
=	O
0	O
.	O
021	O
,	O
OR	O
7	O
.	O
86	O
(	O
95	O
%	O
CI	O
1	O
.	O
37	O
-	O
45	O
.	O
04	O
).	O

TITLE	O
:	O
Emergence	O
of	O
pathogenic	O
coronaviruses	O
in	O
cats	O
by	O
homologous	B-PATH
recombination	I-PATH
between	O
feline	O
and	O
canine	O
coronaviruses	O
.	O

The	O
results	O
showed	O
that	O
three	O
Japanese	O
type	O
II	O
FCoVs	O
,	O
M91	O
-	O
267	O
,	O
KUK	O
-	O
H	O
/	O
L	O
and	O
Tokyo	O
/	O
cat	O
/	O
130627	O
,	O
also	O
emerged	O
by	O
homologous	B-PATH
recombination	I-PATH
between	O
type	O
I	O
FCoV	O
and	O
type	O
II	O
CCoV	O
and	O
their	O
parent	O
viruses	O
were	O
genetically	O
different	O
from	O
one	O
another	O
.	O

Since	O
then	O
,	O
we	O
have	O
witnessed	O
the	O
emergence	O
of	O
several	O
other	O
viral	O
respiratory	O
pathogens	O
including	O
influenza	O
viruses	O
(	O
avian	O
influenza	O
H5N1	O
,	O
H7N9	O
,	O
and	O
H10N8	O
;	O
variant	O
influenza	B-PATH
A	I-PATH
H3N2	O
virus	O
),	O
human	O
adenovirus	O
-	O
14	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
The	O
past	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
several	O
novel	O
viruses	O
that	O
cause	O
respiratory	O
tract	O
infections	O
in	O
human	O
beings	O
,	O
including	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Saudi	O
Arabia	O
,	O
an	O
H7N9	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
eastern	O
China	O
,	O
a	O
swine	O
-	O
like	O
influenza	O
H3N2	O
variant	O
virus	O
in	O
the	O
USA	O
,	O
and	O
a	O
human	O
adenovirus	O
14p1	O
also	O
in	O
the	O
USA	O
.	O

The	O
pathogenesis	O
and	O
mode	O
of	O
transmission	O
of	O
MERS	O
-	O
CoV	O
and	O
H7N9	O
influenza	B-PATH
A	I-PATH
virus	O
are	O
poorly	O
understood	O
,	O
making	O
it	O
more	O
difficult	O
to	O
implement	O
intervention	O
and	O
preventive	O
measures	O
.	O

New	O
viral	O
respiratory	O
tract	O
infections	O
with	O
epidemic	O
potential	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
H1N1	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
,	O
require	O
development	O
of	O
new	O
antiviral	O
agents	O
.	O

The	O
substantial	O
rise	O
in	O
the	O
global	O
numbers	O
of	O
patients	O
with	O
respiratory	O
tract	O
infections	O
caused	O
by	O
pan	O
-	O
antibiotic	O
-	O
resistant	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
,	O
multidrug	O
-	O
resistant	O
Mycobacterium	O
tuberculosis	B-PATH
,	O
and	O
multiazole	O
-	O
resistant	O
fungi	O
has	O
focused	O
attention	O
on	O
investments	O
into	O
development	O
of	O
new	O
drugs	O
and	O
treatment	O
regimens	O
.	O

ABSTRACT	O
:	O
Celiac	O
and	O
splanchnic	O
plexus	O
blocks	O
are	O
considered	O
as	O
terminal	O
approaches	O
for	O
pain	O
control	O
in	O
end	O
stage	O
pancreatic	B-PATH
cancer	I-PATH
.	O

TITLE	O
:	O
One	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
protein	O
complex	O
integrates	O
processive	O
RNA	B-PATH
polymerase	I-PATH
and	O
exonuclease	O
activities	O
.	O

SARS	O
-	O
CoV	O
nsp12	O
,	O
the	O
canonical	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
exhibits	O
poorly	O
processive	O
RNA	O
synthesis	O
in	O
vitro	O
,	O
at	O
odds	O
with	O
the	O
efficient	O
replication	O
of	O
a	O
very	O
large	O
RNA	O
genome	O
in	O
vivo	O
.	O

This	O
protein	O
complex	O
is	O
a	O
fascinating	O
example	O
of	O
the	O
functional	O
integration	O
of	O
RNA	B-PATH
polymerase	I-PATH
,	O
capping	O
,	O
and	O
proofreading	O
activities	O
.	O

ABSTRACT	O
:	O
The	O
pregnant	O
patients	O
are	O
prone	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
,	O
which	O
may	O
rapidly	O
progress	O
to	O
lower	O
respiratory	O
tract	O
infection	O
and	O
subsequent	O
respiratory	O
failure	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
Acute	O
liver	O
failure	O
(	O
ALF	O
)	O
caused	O
by	O
viral	O
and	O
non	O
-	O
viral	O
hepatitis	O
is	O
often	O
accompanied	O
with	O
severe	O
metabolic	O
disorders	O
,	O
the	O
accumulation	O
of	O
toxic	O
substances	O
and	O
continuous	O
release	B-PATH
and	O
accumulation	O
of	O
a	O
large	O
number	O
of	O
endogenous	O
toxins	O
and	O
inflammatory	O
mediators	O
.	O

ABSTRACT	O
:	O
Apoptosis	B-PATH
of	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
plays	O
a	O
pathogenic	O
role	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
severe	O
type	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
investigated	O
the	O
effects	O
of	O
rat	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
BMSCs	O
)	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
apoptosis	B-PATH
in	O
AMs	O
using	O
transwell	O
experiments	O
,	O
and	O
examined	O
the	O
underlying	O
mechanisms	O
LPS	O
induced	O
AMs	O
apoptosis	B-PATH
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
fashion	O
,	O
whereas	O
BMSCs	O
reduced	O
AMs	O
apoptosis	B-PATH
when	O
co	O
-	O
cultured	O
at	O
appropriate	O
ratios	O
.	O

In	O
conclusion	O
,	O
BMSCs	O
can	O
attenuate	O
AM	O
apoptosis	B-PATH
partially	O
by	O
suppressing	O
the	O
Wnt	O
/	O
Î²	O
-	O
catenin	O
pathway	O
.	O

TITLE	O
:	O
Determinants	O
of	O
mortality	O
,	O
intensive	O
care	O
requirement	O
and	O
prolonged	O
hospitalization	O
in	O
malaria	B-PATH
-	O
a	O
tertiary	O
care	O
hospital	O
based	O
cohort	O
study	O
from	O
South	O
-	O
Western	O
India	O
.	O

A	O
tertiary	O
care	O
hospital	O
based	O
retrospective	O
study	O
was	O
conducted	O
from	O
the	O
year	O
2007	O
to	O
2011	O
among	O
microscopically	O
proven	O
adult	O
malaria	B-PATH
patients	O
.	O

Of	O
a	O
total	O
of	O
922	O
malaria	B-PATH
cases	O
studied	O
,	O
more	O
than	O
seven	O
days	O
of	O
hospitalization	O
was	O
the	O
most	O
frequent	O
outcome	O
(	O
21	O
.	O
8	O
%	O
(	O
201	O
),	O
95	O
%	O
CI	O
=	O
19	O
.	O
1	O
-	O
24	O
.	O
5	O
%)	O
followed	O
by	O
intensive	O
care	O
requirement	O
(	O
8	O
.	O
6	O
%	O
(	O
79	O
),	O
95	O
%	O
CI	O
=	O
6	O
.	O
8	O
-	O
10	O
.	O
4	O
%)	O
and	O
in	O
-	O
hospital	O
mortality	O
(	O
1	O
.	O
2	O
%	O
(	O
11	O
),	O
95	O
%	O
CI	O
=	O
0	O
.	O
5	O
-	O
1	O
.	O
9	O
%).	O

Odds	O
of	O
mortality	O
were	O
significantly	O
higher	O
with	O
cerebral	O
malaria	B-PATH
,	O
pulmonary	O
oedema	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PE	O
/	O
ARDS	O
),	O
liver	O
dysfunction	O
,	O
severe	O
anaemia	O
,	O
renal	O
failure	O
,	O
respiratory	O
distress	O
,	O
metabolic	O
acidosis	O
and	O
leucocytosis	O
.	O

More	O
than	O
three	O
days	O
of	O
history	O
of	O
fever	O
,	O
cerebral	O
malaria	B-PATH
,	O
PE	O
/	O
ARDS	O
,	O
renal	O
failure	O
,	O
metabolic	O
acidosis	O
,	O
hyperparasitaemia	O
,	O
leucocytosis	O
and	O
severe	O
thrombocytopaenia	O
were	O
independently	O
associated	O
factors	O
with	O
intensive	O
care	O
requirement	O
.	O

Leucocytosis	O
and	O
severe	O
thrombocytopaenia	O
should	O
be	O
identified	O
as	O
severity	O
determinant	O
in	O
malaria	B-PATH
.	O

RESULTS	O
:	O
Of	O
a	O
total	O
of	O
922	O
malaria	B-PATH
cases	O
studied	O
,	O
more	O
than	O
seven	O
days	O
of	O
hospitalization	O
was	O
the	O
most	O
frequent	O
outcome	O
(	O
21	O
.	O
8	O
%	O
(	O
201	O
),	O
95	O
%	O
CI	O
=	O
19	O
.	O
1	O
-	O
24	O
.	O
5	O
%)	O
followed	O
by	O
intensive	O
care	O
requirement	O
(	O
8	O
.	O
6	O
%	O
(	O
79	O
),	O
95	O
%	O
CI	O
=	O
6	O
.	O
8	O
-	O
10	O
.	O
4	O
%)	O
and	O
in	O
-	O
hospital	O
mortality	O
(	O
1	O
.	O
2	O
%	O
(	O
11	O
),	O
95	O
%	O
CI	O
=	O
0	O
.	O
5	O
-	O
1	O
.	O
9	O
%).	O

More	O
than	O
three	O
days	O
of	O
history	O
of	O
fever	O
,	O
cerebral	O
malaria	B-PATH
,	O
PE	O
/	O
ARDS	O
,	O
renal	O
failure	O
,	O
metabolic	O
acidosis	O
,	O
hyperparasitaemia	O
,	O
leucocytosis	O
and	O
severe	O
thrombocytopaenia	O
were	O
independently	O
associated	O
factors	O
with	O
intensive	O
care	O
requirement	O
.	O

The	O
release	B-PATH
of	O
RAGE	O
(	O
but	O
not	O
cytokeratin	O
18	O
)	O
isoforms	O
occurs	O
early	O
and	O
transiently	O
after	O
trauma	O
and	O
is	O
associated	O
with	O
the	O
extent	O
of	O
injury	O
and	O
inflammatory	O
response	O
.	O

CONCLUSIONS	O
:	O
The	O
release	B-PATH
of	O
RAGE	O
(	O
but	O
not	O
cytokeratin	O
18	O
)	O
isoforms	O
occurs	O
early	O
and	O
transiently	O
after	O
trauma	O
and	O
is	O
associated	O
with	O
the	O
extent	O
of	O
injury	O
and	O
inflammatory	O
response	O
.	O

TITLE	O
:	O
Ca2	O
+	O
influx	O
and	O
ATP	O
release	B-PATH
mediated	O
by	O
mechanical	O
stretch	O
in	O
human	O
lung	O
fibroblasts	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
mechanical	O
stretch	O
on	O
the	O
intracellular	O
Ca	O
(	O
2	O
+)	O
concentration	O
([	O
Ca	O
(	O
2	O
+)]	O
i	O
)	O
and	O
ATP	O
release	B-PATH
were	O
investigated	O
in	O
primary	O
human	O
lung	O
fibroblasts	O
.	O

TITLE	O
:	O
Acute	O
Respiratory	O
Distress	O
in	O
Children	O
:	O
Croup	O
and	O
Acute	O
Asthma	B-PATH
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
of	O
human	O
infection	O
with	O
a	O
novel	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H10N8	O
)	O
virus	O
.	O

ABSTRACT	O
:	O
Novel	O
influenza	B-PATH
A	I-PATH
viruses	O
of	O
avian	O
-	O
origin	O
may	O
be	O
the	O
precursors	O
of	O
pandemic	O
strains	O
.	O

Collecting	O
clinical	O
data	O
of	O
three	O
cases	O
of	O
human	O
infection	O
with	O
a	O
novel	O
reassortment	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H10N8	O
)	O
virus	O
in	O
Nanchang	O
,	O
Jiangxi	O
Province	O
,	O
China	O
.	O

Three	O
cases	O
of	O
human	O
infection	O
with	O
a	O
new	O
reassortment	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H10N8	O
)	O
virus	O
were	O
described	O
,	O
of	O
which	O
two	O
were	O
fatal	O
cases	O
,	O
and	O
one	O
was	O
severe	O
case	O
.	O

This	O
novel	O
reassortment	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H10N8	O
)	O
virus	O
in	O
China	O
resulted	O
in	O
fatal	O
human	O
infections	O
,	O
and	O
should	O
be	O
added	O
to	O
concerns	O
in	O
clinical	O
practice	O
.	O

RESULTS	O
:	O
Three	O
cases	O
of	O
human	O
infection	O
with	O
a	O
new	O
reassortment	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H10N8	O
)	O
virus	O
were	O
described	O
,	O
of	O
which	O
two	O
were	O
fatal	O
cases	O
,	O
and	O
one	O
was	O
severe	O
case	O
.	O

CONCLUSIONS	O
:	O
This	O
novel	O
reassortment	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H10N8	O
)	O
virus	O
in	O
China	O
resulted	O
in	O
fatal	O
human	O
infections	O
,	O
and	O
should	O
be	O
added	O
to	O
concerns	O
in	O
clinical	O
practice	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
coronavirus	O
membrane	O
protein	O
induces	O
apoptosis	B-PATH
via	O
interfering	O
with	O
PDK1	O
-	O
PKB	O
/	O
Akt	O
signalling	O
.	O

We	O
also	O
showed	O
that	O
overexpression	O
of	O
PDK1	O
(	O
3	O
-	O
phosphoinositide	O
-	O
dependent	O
protein	O
kinase	O
1	O
),	O
the	O
immediate	O
upstream	O
kinase	O
of	O
PKB	O
/	O
Akt	O
,	O
suppressed	O
M	O
-	O
induced	O
apoptosis	B-PATH
.	O

This	O
subsequently	O
reduced	O
the	O
level	O
of	O
the	O
phosphorylated	O
forkhead	O
transcription	O
factor	O
FKHRL1	O
and	O
ASK	O
(	O
apoptosis	B-PATH
signal	O
-	O
regulating	O
kinase	O
),	O
and	O
led	O
to	O
the	O
activation	O
of	O
caspases	O
8	O
and	O
9	O
.	O

However	O
,	O
in	O
more	O
vulnerable	O
populations	O
,	O
such	O
as	O
newborns	O
,	O
infants	O
,	O
the	O
elderly	O
and	O
immune	O
-	O
compromised	O
individuals	O
,	O
these	O
opportunistic	O
pathogens	O
can	O
also	O
affect	O
the	O
lower	O
respiratory	O
tract	O
,	O
leading	O
to	O
pneumonia	O
,	O
exacerbations	O
of	O
asthma	B-PATH
,	O
and	O
various	O
types	O
of	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
[	O
Value	O
of	O
routine	O
identification	O
of	O
respiratory	O
infectious	O
agents	O
in	O
children	O
hospitalized	O
with	O
an	O
acute	O
asthma	B-PATH
exacerbation	O
].	O

ABSTRACT	O
:	O
Asthma	B-PATH
is	O
the	O
most	O
common	O
chronic	O
disease	O
in	O
childhood	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	O
in	O
routine	O
care	O
was	O
to	O
evaluate	O
our	O
practices	O
concerning	O
microbiological	O
prescriptions	O
in	O
children	O
hospitalized	O
for	O
asthma	B-PATH
exacerbation	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
severity	O
of	O
asthma	B-PATH
exacerbation	O
and	O
the	O
microbiological	O
diagnosis	O
of	O
infection	O
.	O

This	O
value	O
of	O
the	O
serial	O
interval	O
for	O
pertussis	B-PATH
is	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
first	O
that	O
is	O
based	O
on	O
observations	O
.	O

RESULTS	O
:	O
Maximum	O
enrolled	O
children	O
were	O
of	O
viral	O
encephalitis	O
(	O
46	O
.	O
59	O
%)	O
and	O
rest	O
,	O
were	O
of	O
pyogenic	O
meningitis	O
,	O
tuberculosis	B-PATH
meningitis	O
and	O
cerebral	O
malaria	B-PATH
.	O

TITLE	O
:	O
Coronavirus	O
-	O
induced	O
ER	O
stress	B-PATH
response	I-PATH
and	O
its	O
involvement	O
in	O
regulation	O
of	O
coronavirus	O
-	O
host	O
interactions	O
.	O

UPR	O
is	O
closely	O
associated	O
with	O
a	O
number	O
of	O
major	O
signaling	O
pathways	O
,	O
including	O
autophagy	O
,	O
apoptosis	B-PATH
,	O
the	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
pathways	O
,	O
innate	O
immunity	O
and	O
pro	O
-	O
inflammatory	O
response	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
the	O
up	O
-	O
to	O
-	O
date	O
knowledge	O
on	O
coronavirus	O
-	O
induced	O
UPR	O
and	O
discuss	O
its	O
potential	O
involvement	O
in	O
regulation	O
of	O
innate	O
immunity	O
and	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
still	O
considered	O
a	O
major	O
global	O
health	O
problem	O
.	O

This	O
report	O
is	O
about	O
a	O
patient	O
with	O
a	O
case	O
of	O
severe	O
imported	O
malaria	B-PATH
.	O

During	O
his	O
stay	O
at	O
the	O
hospital	O
,	O
P	O
.	O
Falciparum	O
Malaria	B-PATH
was	O
diagnosed	O
through	O
the	O
thick	O
drop	O
test	O
.	O

And	O
,	O
even	O
with	O
the	O
adequate	O
anti	O
-	O
malaria	B-PATH
therapy	O
,	O
the	O
patient	O
Â	O
s	O
condition	O
evolved	O
to	O
an	O
acute	O
renal	O
failure	O
requiring	O
hemodialis	O
;	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
septic	O
shock	O
,	O
and	O
hematological	O
disorders	O
,	O
forming	O
a	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
).	O

From	O
the	O
criteria	O
described	O
in	O
medical	O
literature	O
to	O
define	O
critical	O
malaria	B-PATH
,	O
the	O
patient	O
fulfilled	O
the	O
following	O
:	O
acute	O
renal	O
failure	O
,	O
ARDS	O
,	O
metabolic	O
acidosis	O
,	O
altered	O
level	O
of	O
consciousness	O
,	O
macroscopic	O
hemoglobinuria	O
,	O
hyperparasitism	O
and	O
hyperbilirubinemia	O
,	O
related	O
to	O
a	O
lethality	O
rate	O
of	O
over	O
10	O
%,	O
depending	O
on	O
early	O
treatment	O
and	O
available	O
resources	O
.	O

The	O
use	O
of	O
multiplex	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
increased	O
the	O
viral	O
detection	O
by	O
33	O
.	O
9	O
%	O
and	O
revealed	O
a	O
larger	O
number	O
of	O
respiratory	O
viruses	O
implicated	O
in	O
ARI	O
cases	O
,	O
including	O
the	O
most	O
recently	O
described	O
respiratory	O
viruses	O
[	O
human	O
bocavirus	O
,	O
human	O
metapneumovirus	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
,	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
NL63	O
and	O
HCoV	O
HKU1	O
].	O

In	O
vitro	O
studies	O
examining	O
human	O
lung	O
EC	O
viability	O
and	O
HMGB1	O
release	B-PATH
following	O
exposure	O
to	O
allogenic	O
RBCs	O
were	O
conducted	O
under	O
static	O
conditions	O
and	O
using	O
a	O
microengineered	O
model	O
of	O
RBC	O
perfusion	O
.	O

A	O
murine	O
model	O
of	O
RBC	O
transfusion	O
followed	O
by	O
LPS	O
administration	O
was	O
used	O
to	O
determine	O
the	O
effects	O
of	O
RBC	O
transfusion	O
and	O
HMGB1	O
release	B-PATH
on	O
LPS	O
-	O
induced	O
lung	O
inflammation	O
.	O

RBC	O
transfusion	O
sensitized	O
mice	O
to	O
LPS	O
-	O
induced	O
lung	O
inflammation	O
through	O
release	B-PATH
of	O
the	O
danger	O
signal	O
HMGB1	O
.	O

RBC	O
transfusion	O
enhances	O
susceptibility	O
to	O
lung	O
inflammation	O
through	O
release	B-PATH
of	O
HMGB1	O
and	O
induces	O
necroptosis	O
of	O
lung	O
EC	O
.	O

Necroptosis	O
and	O
subsequent	O
danger	O
signal	O
release	B-PATH
is	O
a	O
novel	O
mechanism	O
of	O
injury	O
following	O
transfusion	O
that	O
may	O
account	O
for	O
the	O
increased	O
risk	O
of	O
ARDS	O
in	O
critically	O
ill	O
transfused	O
patients	O
.	O

Besides	O
symptoms	O
of	O
the	O
respiratory	O
tract	O
(	O
asthma	B-PATH
,	O
nasal	O
polyps	O
,	O
eosinophilic	O
lung	O
infiltrations	O
)	O
also	O
cardiovascular	O
symptoms	O
,	O
gastrointestinal	O
tract	O
symptoms	O
,	O
as	O
well	O
as	O
skin	O
lesions	O
and	O
kidneys	O
involvement	O
can	O
appear	O
.	O

We	O
present	O
a	O
patient	O
with	O
asthma	B-PATH
and	O
eosinophilia	O
in	O
whom	O
EGPA	O
was	O
diagnosed	O
in	O
the	O
course	O
of	O
acute	O
recurrent	O
substernal	O
chest	O
pain	O
,	O
with	O
subsequent	O
signs	O
of	O
cardiac	O
insufficiency	O
.	O

ABSTRACT	O
:	O
Because	O
of	O
technological	O
advancements	O
and	O
encouraging	O
experiences	O
during	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
epidemic	O
,	O
many	O
critical	O
care	O
clinicians	O
consider	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
a	O
reasonable	O
strategy	O
for	O
managing	O
patients	O
with	O
refractory	O
hypoxemia	O
when	O
standardized	O
therapies	O
have	O
failed	O
.	O

TITLE	O
:	O
Nebulized	O
perflubron	O
and	O
carbon	O
dioxide	O
rapidly	O
dilate	O
constricted	O
airways	O
in	O
an	O
ovine	O
model	O
of	O
allergic	O
asthma	B-PATH
.	O

The	O
formulation	O
has	O
potential	O
as	O
a	O
rescue	O
treatment	O
for	O
acute	O
severe	O
asthma	B-PATH
.	O

These	O
differentially	O
expressed	O
proteins	O
were	O
involved	O
in	O
the	O
cell	B-PATH
cycle	I-PATH
,	O
cellular	O
growth	O
and	O
proliferation	O
,	O
the	O
innate	O
immune	O
response	O
,	O
etc	O
.	O

Interestingly	O
,	O
many	O
upregulated	O
proteins	O
were	O
associated	O
with	O
interferon	B-PATH
signaling	I-PATH
,	O
especially	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
and	O
interferon	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
).	O

This	O
study	O
for	O
the	O
first	O
time	O
reveals	O
that	O
TGEV	O
induces	O
interferon	B-PATH
signaling	I-PATH
from	O
the	O
point	O
of	O
proteomic	O
analysis	O
.	O

TITLE	O
:	O
Novel	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
in	O
critically	O
ill	O
patients	O
in	O
China	O
*.	O
ABSTRACT	O
:	O
In	O
March	O
2013	O
,	O
human	O
infection	O
with	O
a	O
novel	O
avian	O
-	O
origin	O
reassortment	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
was	O
identified	O
in	O
China	O
.	O

Patients	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
from	O
March	O
20	O
,	O
2013	O
,	O
through	O
May	O
1	O
,	O
2013	O
,	O
in	O
Jiangsu	O
Province	O
were	O
included	O
.	O

Infection	O
with	O
novel	O
avian	O
-	O
origin	O
reassortment	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
is	O
characterized	O
by	O
high	O
fever	O
,	O
cough	O
,	O
and	O
severe	O
respiratory	O
failure	O
and	O
is	O
associated	O
with	O
a	O
high	O
mortality	O
.	O

Animals	O
(	O
n	O
=	O
7	O
per	O
group	O
)	O
were	O
randomly	O
assigned	O
to	O
6	O
h	O
of	O
MV	O
(	O
airway	O
pressure	O
release	B-PATH
ventilation	O
)	O
with	O
:	O
(	O
1	O
)	O
conventional	O
P	O
-	O
MV	O
with	O
VT	O
â	O
6	O
ml	O
/	O
kg	O
(	O
P	O
-	O
MVcontr	O
);	O
(	O
2	O
)	O
UP	O
-	O
MV	O
with	O
VT	O
â	O
3	O
ml	O
/	O
kg	O
(	O
UP	O
-	O
MVcontr	O
);	O
(	O
3	O
)	O
UP	O
-	O
MV	O
with	O
VT	O
â	O
3	O
ml	O
/	O
kg	O
and	O
SB	O
(	O
UP	O
-	O
MVspont	O
);	O
and	O
(	O
4	O
)	O
UP	O
-	O
MV	O
with	O
VT	O
â	O
3	O
ml	O
/	O
kg	O
and	O
pressure	O
supported	O
SB	O
(	O
UP	O
-	O
MVPS	O
).	O

Nevertheless	O
,	O
MHV	O
was	O
shown	O
to	O
be	O
less	O
sensitive	O
to	O
perturbation	O
of	O
endosomal	O
pH	O
than	O
vesicular	O
stomatitis	O
virus	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
which	O
fuse	O
in	O
early	O
and	O
late	O
endosomes	O
,	O
respectively	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
Severe	O
Pneumonia	O
:	O
Novel	O
Morphocytological	O
Findings	O
in	O
Bronchoalveolar	O
Lavage	O
.	O

For	O
each	O
syndrome	O
17	O
-	O
27	O
%	O
of	O
participants	O
had	O
etiologic	O
diagnoses	O
that	O
would	O
be	O
non	O
-	O
responsive	O
to	O
ceftriaxone	O
,	O
but	O
responsive	O
to	O
other	O
available	O
antimicrobial	O
regimens	O
including	O
amphotericin	O
for	O
cryptococcosis	O
and	O
histoplasmosis	O
;	O
anti	O
-	O
tuberculosis	B-PATH
therapy	O
for	O
bacteremic	O
disseminated	O
tuberculosis	B-PATH
;	O
or	O
tetracycline	O
therapy	O
for	O
rickettsioses	O
and	O
Q	O
fever	O
.	O

ABSTRACT	O
:	O
Since	O
March	O
2013	O
,	O
the	O
emergence	O
of	O
an	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
has	O
raised	O
concern	O
in	O
China	O
.	O

To	O
date	O
,	O
no	O
effective	O
drugs	O
that	O
improve	O
the	O
clinical	O
outcome	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
-	O
infected	O
patients	O
have	O
been	O
identified	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
report	O
that	O
ACE2	O
could	O
mediate	O
the	O
severe	O
acute	O
lung	O
injury	O
induced	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
infection	O
in	O
an	O
experimental	O
mouse	O
model	O
.	O

The	O
current	O
findings	O
demonstrate	O
that	O
ACE2	O
plays	O
a	O
critical	O
role	O
in	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	B-PATH
)	O
virus	O
-	O
induced	O
acute	O
lung	O
injury	O
,	O
and	O
suggest	O
that	O
might	O
be	O
a	O
useful	O
potential	O
therapeutic	O
target	O
for	O
future	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	B-PATH
)	O
outbreaks	O
.	O

Despite	O
release	B-PATH
of	O
ATF3	O
-	O
dependent	O
Nrf2	O
transcriptional	O
inhibition	O
,	O
mice	O
that	O
lacked	O
ATF3	O
expression	O
in	O
resident	O
cells	O
had	O
increased	O
Nrf2	O
protein	O
degradation	O
.	O

The	O
most	O
common	O
viruses	O
found	O
in	O
patients	O
experiencing	O
exacerbations	O
were	O
coronavirus	O
(	O
19	O
of	O
65	O
,	O
39	O
.	O
2	O
%),	O
rhinovirus	O
(	O
16	O
of	O
65	O
,	O
24	O
.	O
6	O
%),	O
and	O
influenza	B-PATH
A	I-PATH
/	O
B	O
viruses	O
(	O
16	O
of	O
65	O
,	O
24	O
.	O
6	O
%).	O

Forty	O
two	O
(	O
38	O
%)	O
pilgrims	O
had	O
laboratory	O
-	O
confirmed	O
viral	O
infections	O
;	O
28	O
(	O
25	O
%)	O
rhinovirus	O
,	O
5	O
(	O
4	O
%)	O
influenza	B-PATH
A	I-PATH
,	O
2	O
(	O
2	O
%)	O
adenovirus	O
,	O
2	O
(	O
2	O
%)	O
human	O
coronavirus	O
OC43	O
/	O
229E	O
,	O
2	O
(	O
2	O
%)	O
parainfluenza	O
virus	O
3	O
,	O
1	O
(	O
1	O
%)	O
parainfluenza	O
virus	O
1	O
,	O
and	O
2	O
(	O
2	O
%)	O
dual	O
infections	O
.	O

TITLE	O
:	O
Clinical	O
outcomes	O
of	O
children	O
with	O
acute	O
asthma	B-PATH
and	O
pneumonia	O
in	O
Mulago	O
hospital	O
,	O
Uganda	O
:	O
a	O
prospective	O
study	O
.	O

In	O
'	O
under	O
-	O
fives	O
',	O
acute	O
asthma	B-PATH
and	O
pneumonia	O
have	O
similar	O
clinical	O
presentation	O
and	O
most	O
children	O
with	O
acute	O
respiratory	O
symptoms	O
are	O
diagnosed	O
with	O
pneumonia	O
according	O
to	O
the	O
WHO	O
criteria	O
.	O

We	O
describe	O
the	O
immediate	O
clinical	O
outcomes	O
of	O
children	O
with	O
acute	O
asthma	B-PATH
and	O
pneumonia	O
and	O
document	O
the	O
factors	O
associated	O
with	O
prolonged	O
hospitalization	O
and	O
mortality	O
.	O

Children	O
with	O
asthma	B-PATH
and	O
bronchiolitis	O
were	O
collectively	O
referred	O
to	O
as	O
'	B-PATH
Asthma	I-PATH
syndrome	O
'.	O

Survival	O
analysis	O
was	O
done	O
to	O
compare	O
outcome	O
of	O
children	O
with	O
asthma	B-PATH
and	O
pneumonia	O
.	O

The	O
highest	O
case	O
fatality	O
was	O
due	O
to	O
pneumocystis	O
jirovecii	O
pneumonia	O
(	O
2	O
/	O
4	O
)	O
and	O
pulmonary	O
tuberculosis	B-PATH
(	O
2	O
/	O
7	O
).	O

None	O
of	O
the	O
children	O
with	O
asthma	B-PATH
syndrome	O
died	O
.	O

Children	O
with	O
'	B-PATH
asthma	I-PATH
syndrome	O
'	O
had	O
a	O
significantly	O
shorter	O
hospital	O
stay	O
compared	O
to	O
those	O
with	O
pneumonia	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Factors	O
independently	O
associated	O
with	O
prolonged	O
hospitalization	O
among	O
children	O
with	O
asthma	B-PATH
syndrome	O
included	O
age	O
less	O
than	O
12	O
months	O
(	O
RR	O
=	O
1	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
0	O
-	O
1	O
.	O
4	O
),	O
hypoxemia	O
(	O
RR	O
=	O
1	O
.	O
4	O
,	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
),	O
and	O
severe	O
malnutrition	O
(	O
RR	O
=	O
1	O
.	O
5	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
1	O
.	O
8	O
).	O

This	O
may	O
be	O
related	O
to	O
focus	O
on	O
and	O
treatment	O
of	O
asthma	B-PATH
in	O
this	O
study	O
,	O
and	O
will	O
be	O
analysed	O
in	O
a	O
later	O
study	O
.	O

The	O
keywords	O
selected	O
were	O
non	O
-	O
invasive	O
ventilation	O
pulmonary	O
infections	O
,	O
influenza	O
-	O
A	O
(	O
H1N1	O
),	O
SARS	O
and	O
tuberculosis	B-PATH
.	O

The	O
members	O
of	O
the	O
International	O
NIV	O
Network	O
examined	O
the	O
major	O
results	O
regarding	O
NIV	O
applications	O
and	O
SARS	O
,	O
H1N1	O
and	O
tuberculosis	B-PATH
.	O

Cross	O
-	O
referencing	O
with	O
tuberculosis	B-PATH
yielded	O
285	O
studies	O
,	O
of	O
which	O
15	O
involved	O
NIV	O
and	O
from	O
these	O
seven	O
were	O
selected	O
.	O

NIV	O
,	O
when	O
applied	O
early	O
in	O
selected	O
patients	O
with	O
SARS	O
,	O
H1N1	O
and	O
acute	O
pulmonary	O
tuberculosis	B-PATH
infections	O
,	O
can	O
reverse	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Temporal	O
dynamics	O
,	O
diversity	O
,	O
and	O
interplay	O
in	O
three	O
components	O
of	O
the	O
virodiversity	O
of	O
a	O
Mallard	O
population	O
:	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
avian	O
paramyxovirus	O
and	O
avian	O
coronavirus	O
.	O

For	O
example	O
,	O
screening	O
of	O
Mallards	O
for	O
influenza	B-PATH
A	I-PATH
viruses	O
(	O
IAV	O
)	O
have	O
repeatedly	O
revealed	O
high	O
prevalence	O
and	O
large	O
subtype	O
diversity	O
in	O
the	O
Northern	O
Hemisphere	O
.	O

The	O
initial	O
study	O
sample	O
was	O
positive	O
in	O
15	O
patients	O
with	O
the	O
following	O
respiratory	O
viruses	O
:	O
rhinovirus	O
(	O
6	O
),	O
metapneumovirus	O
(	O
1	O
),	O
coronavirus	O
(	O
2	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
2	O
),	O
parainfluenza	O
virus	O
(	O
2	O
),	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
2	O
).	O

RESULTS	O
:	O
The	O
initial	O
study	O
sample	O
was	O
positive	O
in	O
15	O
patients	O
with	O
the	O
following	O
respiratory	O
viruses	O
:	O
rhinovirus	O
(	O
6	O
),	O
metapneumovirus	O
(	O
1	O
),	O
coronavirus	O
(	O
2	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
2	O
),	O
parainfluenza	O
virus	O
(	O
2	O
),	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
2	O
).	O

TITLE	O
:	O
Pan	O
-	O
human	O
coronavirus	O
and	O
human	O
bocavirus	O
SYBR	O
Green	O
and	O
TaqMan	O
PCR	O
assays	O
;	O
use	O
in	O
studying	O
influenza	B-PATH
A	I-PATH
viruses	O
co	O
-	O
infection	O
and	O
risk	O
of	O
hospitalization	O
.	O

This	O
study	O
investigated	O
the	O
association	O
between	O
influenza	B-PATH
A	I-PATH
viruses	O
co	O
-	O
infection	O
with	O
hBoV	O
and	O
hCoV	O
and	O
severity	O
and	O
the	O
sensitivity	O
of	O
a	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
for	O
identification	O
of	O
15	O
coronaviruses	O
.	O

A	O
series	O
of	O
217	O
samples	O
from	O
patients	O
aged	O
37	O
.	O
7	O
(	O
SD	O
Â±	O
30	O
.	O
4	O
)]	O
with	O
seasonal	O
influenza	B-PATH
A	I-PATH
viruses	O
(	O
SeasFluA	O
)	O
identified	O
between	O
06	O
/	O
2011	O
and	O
06	O
/	O
2012	O
in	O
NW	O
England	O
were	O
tested	O
for	O
hCoV	O
and	O
hBoV	O
using	O
RT	O
-	O
PCR	O
.	O

A	O
total	O
of	O
12	O
hCoV	O
and	O
17	O
hBoV	O
were	O
identified	O
in	O
the	O
217	O
influenza	B-PATH
A	I-PATH
positive	O
samples	O
.	O

This	O
explains	O
their	O
participation	O
in	O
virtually	O
every	O
metabolic	O
process	O
that	O
involves	O
nucleic	O
acids	O
,	O
including	O
DNA	B-PATH
replication	I-PATH
,	O
recombination	O
and	O
repair	O
,	O
transcription	O
,	O
translation	O
,	O
as	O
well	O
as	O
RNA	O
processing	O
.	O

By	O
promoting	O
p53	O
degradation	O
,	O
PLP2	O
inhibits	O
the	O
p53	O
-	O
mediated	O
antiviral	O
response	O
and	O
apoptosis	B-PATH
to	O
ensure	O
viral	O
growth	O
in	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
characterize	O
the	O
2013	O
-	O
2014	O
epidemic	O
season	O
from	O
the	O
results	O
of	O
detection	O
of	O
influenza	B-PATH
infection	I-PATH
in	O
patients	O
;	O
to	O
provide	O
the	O
molecular	O
genetic	O
characteristics	O
of	O
the	O
strains	O
isolated	O
from	O
deceased	O
patients	O
.	O

Out	O
of	O
the	O
1203	O
examinees	O
,	O
284	O
(	O
23	O
.	O
6	O
%)	O
were	O
influenza	O
-	O
positive	O
:	O
221	O
(	O
77	O
.	O
8	O
%),	O
24	O
(	O
8	O
.	O
5	O
%),	O
and	O
39	O
(	O
13	O
.	O
7	O
%)	O
patients	O
had	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
),	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
,	O
and	O
influenza	O
B	O
,	O
respectively	O
.	O

TITLE	O
:	O
A	O
retrospective	O
study	O
of	O
the	O
clinical	O
benefit	O
from	O
acetylsalicylic	O
acid	O
desensitization	O
in	O
patients	O
with	O
nasal	O
polyposis	O
and	O
asthma	B-PATH
.	O

ABSTRACT	O
:	O
Aspirin	O
-	O
exacerbated	O
respiratory	O
disease	O
(	O
AERD	O
),	O
also	O
known	O
as	O
Samter	O
'	O
s	O
triad	O
,	O
is	O
a	O
clinical	O
syndrome	O
which	O
consists	O
of	O
aspirin	O
(	O
ASA	O
)	O
intolerance	O
,	O
chronic	O
rhinosinusitis	O
with	O
nasal	O
polyposis	O
,	O
and	O
intrinsic	O
bronchial	O
asthma	B-PATH
(	O
Press	O
Med	O
119	O
:	O
48	O
-	O
51	O
,	O
1922	O
).	O

ASA	O
challenge	O
is	O
the	O
gold	O
standard	O
for	O
diagnosing	O
AERD	O
(	O
Curr	O
Allergy	O
Asthma	B-PATH
9	O
:	O
155	O
-	O
163	O
,	O
2009	O
).	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
NLRP3	O
inflammasomes	B-PATH
in	O
mice	O
with	O
HALI	O
.	O

ABSTRACT	O
:	O
Mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
)	O
with	O
a	O
concomitant	O
enhancement	O
of	O
transaminases	O
and	O
release	B-PATH
of	O
alarmins	O
such	O
as	O
uric	O
acid	O
and	O
high	O
-	O
mobility	O
group	O
box	O
protein	O
1	O
(	O
HMGB1	O
).	O

Results	O
showed	O
that	O
MT	O
strongly	O
enhanced	O
the	O
hypergammaglobulinemia	O
induced	O
by	O
the	O
virus	O
,	O
as	O
well	O
as	O
anti	O
-	O
MHV	O
Ab	O
and	O
uric	O
acid	O
release	B-PATH
.	O

Among	O
them	O
,	O
compounds	O
Ib	O
and	O
If	O
possessed	O
antiviral	O
activities	O
against	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
A	O
/	O
Jinan	O
/	O
15	O
/	O
90	O
)	O
with	O
IC50	O
values	O
of	O
4	O
.	O
12	O
and	O
12	O
.	O
35	O
Î¼g	O
/	O
mL	O
,	O
respectively	O
.	O

These	O
activities	O
limit	O
infection	O
in	O
cultured	O
cells	O
by	O
many	O
viruses	O
,	O
including	O
dengue	O
virus	O
,	O
Ebola	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
and	O
West	O
Nile	O
virus	O
.	O

Murine	O
Ifitm3	O
controls	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
in	O
vivo	O
,	O
and	O
polymorphisms	O
in	O
human	O

Mast	O
cells	O
can	O
release	B-PATH
various	O
inflammatory	O
mediators	O
known	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
lung	O
edema	O
following	O
scorpion	O
venom	O
injection	O
.	O

These	O
differentially	O
expressed	O
proteins	O
were	O
involved	O
in	O
apoptosis	B-PATH
,	O
signal	O
transduction	O
,	O
and	O
stress	O
responses	O
.	O

Based	O
on	O
these	O
differentially	O
expressed	O
proteins	O
,	O
we	O
propose	O
that	O
PEDV	O
might	O
utilize	O
apoptosis	B-PATH
and	O
extracellular	O
signal	O
regulated	O
kinases	O
pathways	O
for	O
maximum	O
viral	O
replication	O
.	O

A	O
partial	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
sequence	O
was	O
detected	O
in	O
feces	O
and	O
tissues	O
samples	O
from	O
the	O
fruit	O
bats	O
,	O
and	O
the	O
region	O
between	O
the	O
RdRp	O
and	O
helicase	O
genes	O
could	O
also	O
be	O
amplified	O
from	O
fecal	O
samples	O
.	O

For	O
analysing	O
coronavirus	O
diversity	O
in	O
a	O
bat	O
species	O
-	O
rich	O
country	O
,	O
a	O
total	O
of	O
421	O
anal	O
swabs	O
/	O
faecal	O
samples	O
from	O
Costa	O
Rican	O
bats	O
were	O
screened	O
for	O
CoV	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
sequences	O
by	O
a	O
pancoronavirus	O
PCR	O
.	O

As	O
controls	O
,	O
the	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
were	O
included	O
.	O

There	O
are	O
many	O
studies	O
regarding	O
the	O
gender	O
difference	O
in	O
severe	O
falciparum	O
malaria	B-PATH
.	O

Subsequently	O
,	O
polarized	O
entry	O
into	O
and	O
release	B-PATH
from	O
both	O
Vero	O
E6	O
and	O
IECs	O
was	O
analyzed	O
.	O

Many	O
immigrants	O
and	O
refugees	O
are	O
exposed	O
to	O
communicable	O
diseases	O
not	O
routinely	O
encountered	O
in	O
the	O
United	O
States	O
These	O
include	O
helminthic	O
infections	O
,	O
tuberculosis	B-PATH
,	O
malaria	B-PATH
,	O
and	O
other	O
infections	O
.	O

Zoonotic	O
infections	O
,	O
such	O
as	O
influenza	B-PATH
A	I-PATH
,	O
and	O
novel	O
coronavirus	O
infections	O
also	O
are	O
of	O
increasing	O
concern	O
because	O
of	O
population	O
mobility	O
.	O

Furthermore	O
,	O
no	O
significant	O
alteration	O
in	O
cell	B-PATH
cycle	I-PATH
progression	O
in	O
cells	O
expressing	O
the	O
protein	O
was	O
observed	O
.	O

The	O
prevalence	O
of	O
viruses	O
and	O
bacteria	O
increased	O
,	O
from	O
7	O
.	O
4	O
%	O
and	O
15	O
.	O
4	O
%	O
before	O
the	O
Hajj	O
to	O
45	O
.	O
4	O
%	O
and	O
31	O
.	O
0	O
%	O
after	O
the	O
Hajj	O
,	O
respectively	O
,	O
due	O
to	O
the	O
acquisition	O
of	O
rhinovirus	O
,	O
coronaviruses	O
(	O
229E	O
,	O
HKU1	O
,	O
OC43	O
),	O
influenza	B-PATH
A	I-PATH
H1N1	O
,	O
Streptococcus	O
pneumoniae	O
,	O
Haemophilus	O
influenzae	O
and	O
Staphylococcus	O
aureus	O
.	O

The	O
most	O
frequent	O
organisms	O
were	O
influenza	B-PATH
A	I-PATH
/	O
B	O
virus	O
in	O
27	O
(	O
11	O
%),	O
rhinovirus	O
in	O
20	O
(	O
8	O
%),	O
coronavirus	O
in	O
seven	O
(	O
3	O
%),	O
respiratory	O
syncytial	O
virus	O
in	O
seven	O
(	O
3	O
%)	O
and	O
Mycoplasma	O
pneumoniae	O
in	O
eight	O
(	O
3	O
%)	O
of	O
254	O
patients	O
.	O

We	O
related	O
structures	O
of	O
influenza	B-PATH
A	I-PATH
N10	O
and	O
N11	O
proteins	O
that	O
have	O
no	O
established	O
function	O
to	O
structures	O
of	O
proteins	O
with	O
known	O
function	O
by	O
identifying	O
spatially	O
conserved	O
atoms	O
.	O

We	O
identified	O
atoms	O
with	O
common	O
distributed	O
spatial	O
occupancy	O
in	O
PDB	O
structures	O
of	O
N10	O
protein	O
,	O
N11	O
protein	O
,	O
an	O
influenza	B-PATH
A	I-PATH
neuraminidase	O
,	O
an	O
influenza	O
B	O
neuraminidase	O
,	O
and	O
a	O
bacterial	O
neuraminidase	O
.	O

The	O
presence	O
of	O
active	O
site	O
components	O
common	O
to	O
the	O
N6	O
,	O
influenza	O
B	O
,	O
and	O
S	O
.	O
pneumoniae	O
neuraminidases	O
in	O
the	O
N10	O
and	O
N11	O
proteins	O
,	O
combined	O
with	O
the	O
absence	O
of	O
apparent	O
neuraminidase	O
function	O
,	O
suggests	O
that	O
the	O
role	O
of	O
neuraminidases	O
in	O
H17N10	O
and	O
H18N11	O
emerging	O
influenza	B-PATH
A	I-PATH
viruses	O
may	O
have	O
changed	O
.	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	O
of	O
vaccinia	O
virus	O
DNA	O
,	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
,	O
into	O
cells	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

TITLE	O
:	O
Quantification	O
of	O
interferon	B-PATH
signaling	I-PATH
in	O
avian	O
cells	O
.	O

Compared	O
with	O
VicS	O
-	O
v	O
,	O
the	O
more	O
attenuated	O
VicS	O
-	O
del	O
strain	O
had	O
two	O
non	O
-	O
synonymous	O
changes	O
in	O
the	O
non	O
-	O
structural	O
protein	O
6	O
(	O
nsp6	O
),	O
a	O
transmembrane	O
(	O
TM	O
)	O
domain	O
that	O
may	O
participate	O
in	O
autocatalytic	O
release	B-PATH
of	O
the	O
3	O
-	O
chymotrypsin	O
-	O
like	O
protease	O
,	O
a	O
polymorphic	O
difference	O
at	O
the	O
end	O
of	O
the	O
S2	O
gene	O
,	O
which	O
coincided	O
with	O
the	O
body	O
transcription	O
-	O
regulating	O
sequence	O
(	O
B	O
-	O
TRS	O
)	O
of	O
mRNA	O
3	O
and	O
a	O
truncated	O
open	O
reading	O
frame	O
for	O
a	O
peptide	O
encoded	O
by	O
gene	O
4	O
(	O
4b	O
).	O

The	O
results	O
provide	O
strong	O
support	O
that	O
E	O
proteins	O
carry	O
out	O
their	O
function	O
(	O
s	O
)	O
at	O
the	O
site	O
of	O
budding	B-PATH
/	O
assembly	O
.	O

TITLE	O
:	O
[	O
Severe	O
pulmonary	O
tuberculosis	B-PATH
in	O
the	O
ICU	O
,	O
diagnosis	O
and	O
treatment	O
].	O

ABSTRACT	O
:	O
Pulmonary	O
tuberculosis	B-PATH
can	O
rarely	O
lead	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
anti	O
-	O
tuberculous	O
therapy	O
initiation	O
depends	O
on	O
this	O
difficult	O
diagnosis	O
in	O
ICU	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aim	O
was	O
to	O
investigate	O
an	O
outbreak	O
of	O
human	O
cases	O
of	O
unexplained	O
influenza	O
-	O
like	O
illness	O
and	O
fatal	O
acute	O
respiratory	O
infection	O
(	O
ARI	O
),	O
with	O
simultaneous	O
poultry	O
illness	O
and	O
high	O
mortality	O
raising	O
concerns	O
of	O
possible	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
),	O
virus	O
in	O
Cote	O
d	O
'	O
Ivoire	O
in	O
February	O
and	O
March	O
2007	O
.	O

The	O
investigation	O
quickly	O
ruled	O
out	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
),	O
virus	O
as	O
the	O
cause	O
and	O
found	O
laboratory	O
-	O
confirmed	O
cases	O
of	O
influenza	O
C	O
virus	O
and	O
human	O
Coronavirus	O
OC	O
43	O
for	O
the	O
first	O
time	O
in	O
both	O
CÃ´te	O
d	O
'	O
Ivoire	O
and	O
in	O
a	O
Sub	O
-	O
Saharan	O
African	O
country	O
.	O

TITLE	O
:	O
Severe	O
morbidity	O
and	O
mortality	O
risk	O
from	O
malaria	B-PATH
in	O
the	O
United	O
States	O
,	O
1985	O
-	O
2011	O
.	O

ABSTRACT	O
:	O
Recent	O
reports	O
of	O
Plasmodium	O
vivax	O
associated	O
with	O
severe	O
syndromes	O
and	O
mortality	O
from	O
malaria	B-PATH
endemic	O
areas	O
questions	O
the	O
""""	O
benign	O
""""	O
course	O
of	O
non	O
-	O
falciparum	O
malarias	O
.	O

Although	O
less	O
common	O
,	O
patients	O
presenting	O
with	O
non	O
-	O
falciparum	O
even	O
in	O
the	O
United	O
States	O
can	O
develop	O
severe	O
illness	O
,	O
and	O
severe	O
illness	O
in	O
patients	O
having	O
malaria	B-PATH
of	O
any	O
species	O
threatens	O
life	O
.	O

Subsequent	O
structural	O
modification	O
on	O
p	O
-	O
HAP	O
and	O
its	O
glycoside	O
led	O
to	O
the	O
synthesis	O
of	O
28	O
additional	O
derivatives	O
,	O
of	O
which	O
13	O
compounds	O
showed	O
activity	O
inhibiting	O
hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAg	O
)	O
secretion	O
;	O
and	O
18	O
compounds	O
possessed	O
inhibition	O
on	O
HBV	O
DNA	B-PATH
replication	I-PATH
.	O

Eight	O
compounds	O
1	O
,	O
2	O
,	O
5	O
,	O
8	O
,	O
9	O
,	O
1e	O
,	O
1k	O
,	O
and	O
1m	O
increased	O
activity	O
against	O
HBV	O
DNA	B-PATH
replication	I-PATH
with	O
the	O
SI	O
values	O
higher	O
than	O
11	O
.	O

In	O
particular	O
,	O
derivatives	O
1e	O
and	O
1k	O
exhibited	O
the	O
most	O
potent	O
inhibition	O
on	O
HBV	O
DNA	B-PATH
replication	I-PATH
with	O
the	O
IC50	O
values	O
of	O
0	O
.	O
026	O
mM	O
(	O
SI	O
>	O
70	O
.	O
8	O
)	O
and	O
0	O
.	O
045	O
mM	O
(	O
SI	O
>	O
36	O
.	O
0	O
),	O
respectively	O
.	O

The	O
diagnosis	O
of	O
ARDS	O
,	O
HIV	B-PATH
infection	I-PATH
and	O
MDR	O
bacterial	O
and	O
fungal	O
VAP	O
was	O
made	O
.	O

TITLE	O
:	O
Airway	O
pressure	O
release	B-PATH
ventilation	O
and	O
respiratory	O
failure	O
during	O
pregnancy	O
.	O

We	O
present	O
3	O
cases	O
of	O
respiratory	O
failure	O
and	O
severe	O
pulmonary	O
disease	O
managed	O
with	O
airway	O
pressure	O
release	B-PATH
ventilation	O
,	O
among	O
other	O
ventilatory	O
modes	O
,	O
with	O
improved	O
ventilation	O
.	O

Airway	O
pressure	O
release	B-PATH
ventilation	O
may	O
be	O
an	O
important	O
option	O
as	O
a	O
ventilatory	O
mode	O
for	O
management	O
of	O
maternal	O
respiratory	O
failure	O
during	O
pregnancy	O
.	O

At	O
the	O
cellular	O
level	O
,	O
the	O
effect	O
of	O
the	O
recombinant	O
human	O
interferon	O
alpha	O
2b	O
on	O
influenza	B-PATH
A	I-PATH
virus	O
was	O
detected	O
using	O
real	O
-	O
time	O
fluorescence	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Recombinant	O
human	O
interferon	O
alpha	O
2b	O
has	O
a	O
stronger	O
inhibitory	O
effect	O
on	O
different	O
influenza	B-PATH
A	I-PATH
virus	O
RNA	O
than	O
drug	O
control	O
.	O

However	O
,	O
an	O
exacerbated	O
innate	O
immune	O
response	O
,	O
mediated	O
by	O
the	O
melanoma	B-PATH
differentiation	O
-	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
pathway	O
,	O
was	O
observed	O
in	O
cells	O
infected	O
with	O
the	O
mutant	O
virus	O
compared	O
with	O
the	O
response	O
observed	O
in	O
cells	O
infected	O
with	O
the	O
parental	O
virus	O
.	O

ABSTRACT	O
:	O
Hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
NS5B	O
RNA	O
-	O
depended	O
-	O
RNA	O
-	O
polymerase	O
(	O
RdRp	O
)	O
is	O
an	O
essential	O
enzyme	O
in	O
HCV	O
viral	O
replication	O
and	O
has	O
no	O
functional	O
equivalent	O
in	O
mammalian	O
cells	O
.	O

The	O
emergence	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
and	O
the	O
avian	O
influenza	B-PATH
A	I-PATH
strain	O
H7N9	O
are	O
of	O
concern	O
but	O
still	O
these	O
are	O
infrequent	O
causes	O
of	O
CAP	O
.	O

However	O
,	O
the	O
blockade	O
of	O
apoptosis	B-PATH
in	O
the	O
lungs	O
may	O
also	O
have	O
deleterious	O
effects	O
by	O
hampering	O
viral	O
clearance	O
,	O
and	O
importantly	O
,	O
by	O
enhancing	O
or	O
prolonging	O
local	O
proinflammatory	O
responses	O
.	O

PVM	O
-	O
infected	O
mice	O
that	O
received	O
zVAD	O
had	O
a	O
strong	O
increase	O
in	O
neutrophil	O
numbers	O
in	O
the	O
lungs	O
,	O
which	O
was	O
associated	O
with	O
decreased	O
neutrophil	O
apoptosis	B-PATH
.	O

In	O
contrast	O
,	O
zVAD	O
did	O
not	O
reduce	O
apoptosis	B-PATH
of	O
lung	O
epithelial	O
cells	O
and	O
did	O
not	O
affect	O
the	O
degree	O
of	O
lung	O
injury	O
,	O
permeability	O
,	O
and	O
viral	O
titers	O
in	O
PVM	O
disease	O
.	O

Specifically	O
,	O
use	O
of	O
these	O
building	O
blocks	O
to	O
investigate	O
protein	O
folding	O
and	O
misfolding	O
has	O
been	O
of	O
particular	O
value	O
since	O
it	O
can	O
provide	O
tremendous	O
insights	O
into	O
peptide	O
aggregation	O
related	O
to	O
a	O
variety	O
of	O
protein	O
misfolding	O
diseases	O
,	O
or	O
amyloid	O
diseases	O
(	O
e	O
.	O
g	O
.,	O
Alzheimer	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
,	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
,	O
type	O
-	O
II	O
diabetes	O
).	O

In	O
this	O
paper	O
,	O
we	O
present	O
estimates	O
of	O
Râ	O
and	O
SI	O
from	O
the	O
2003	O
SARS	O
outbreak	O
in	O
Hong	O
Kong	O
and	O
Singapore	O
,	O
and	O
the	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
outbreak	O
in	O
South	O
Africa	O
using	O
methods	O
that	O
expand	O
upon	O
an	O
existing	O
Bayesian	O
framework	O
.	O

ABSTRACT	O
:	O
Despite	O
a	O
regional	O
decline	O
in	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
infections	O
during	O
2013	O
-	O
14	O
,	O
cases	O
at	O
a	O
Florida	O
hospital	O
were	O
more	O
severe	O
than	O
those	O
during	O
2009	O
-	O
10	O
.	O

TITLE	O
:	O
Age	O
and	O
gender	O
adjusted	O
comparison	O
of	O
clinical	O
features	O
between	O
severe	O
cases	O
infected	O
with	O
H7N9	O
and	O
H1N1pdm	O
influenza	B-PATH
A	I-PATH
in	O
Jiangsu	O
Province	O
,	O
China	O
.	O

Biological	O
plausibility	O
of	O
aerosol	O
transmission	O
is	O
evaluated	O
for	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
and	O
norovirus	O
and	O
discussed	O
for	O
Mycobacterium	O
tuberculosis	B-PATH
,	O
influenza	O
,	O
and	O
Ebola	O
virus	O
.	O

This	O
research	O
focuses	O
on	O
coronavirus	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
cell	O
entry	O
and	O
identifies	O
TEMs	O
as	O
sites	O
of	O
viral	O
proteolysis	O
,	O
thereby	O
defining	O
subcellular	O
locations	O
of	O
virus	O
priming	O
with	O
greater	O
precision	O
.	O

The	O
risk	O
of	O
skidding	O
and	O
epidemiological	O
complications	O
conditionally	O
designated	O
as	O
high	O
,	O
moderate	O
and	O
minimal	O
risk	O
importation	O
of	O
measles	B-PATH
virus	O
-	O
Rate	O
was	O
considered	O
as	O
high	O
.	O

Of	O
these	O
compounds	O
,	O
compound	O
4c	O
-	O
1	O
showed	O
the	O
most	O
potent	O
anti	O
-	O
HBV	O
activity	O
,	O
demonstrating	O
potent	O
inhibitory	O
effect	O
not	O
only	O
on	O
the	O
secretion	O
of	O
HBsAg	O
(	O
IC50	O
=	O
14	O
.	O
18	O
Î¼M	O
,	O
SI	O
=	O
17	O
.	O
85	O
)	O
and	O
HBeAg	O
(	O
IC50	O
=	O
6	O
.	O
20	O
Î¼M	O
,	O
SI	O
=	O
40	O
.	O
82	O
)	O
secretion	O
but	O
also	O
HBV	O
DNA	B-PATH
replication	I-PATH
(	O
IC50	O
=	O
23	O
.	O
43	O
Î¼M	O
,	O
SI	O
=	O
10	O
.	O
80	O
).	O

Samples	O
were	O
tested	O
by	O
multiplex	O
polymerase	O
chain	O
reaction	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
parainfluenza	O
viruses	O
1	O
-	O
4	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
human	O
metapneumovirus	O
,	O
adenovirus	O
,	O
and	O
human	O
rhinoviruses	O
,	O
coronaviruses	O
,	O
and	O
bocavirus	O
.	O

TITLE	O
:	O
An	O
isolated	O
outbreak	O
of	O
influenza	B-PATH
A	I-PATH
H1N1	O
in	O
a	O
haematological	O
department	O
during	O
post	O
-	O
pandemic	O
period	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
H1N1	O
virus	O
strain	O
was	O
associated	O
with	O
the	O
pandemic	O
outbreak	O
of	O
febrile	O
respiratory	O
infections	O
worldwide	O
in	O
2009	O
,	O
however	O
in	O
August	O
2010	O
,	O
the	O
WHO	O
announced	O
that	O
the	O
world	O
had	O
entered	O
the	O
postpandemic	O
period	O
.	O

Of	O
them	O
,	O
nine	O
tested	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
H1N1	O
in	O
a	O
screening	O
test	O
and	O
eight	O
in	O
confirmatory	O
polymerase	O
chain	O
reaction	O
.	O

nsp14	O
associates	O
with	O
the	O
CoV	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
nsp12	O
-	O
RdRp	O
),	O
and	O
nsp14	O
-	O
ExoN	O
activity	O
is	O
enhanced	O
by	O
binding	O
nsp10	O
,	O
a	O
small	O
nonenzymatic	O
protein	O
.	O

Excellent	O
delivery	O
vehicles	O
must	O
ensure	O
the	O
stability	O
of	O
the	O
cargo	O
,	O
maintain	O
the	O
cargo	O
'	O
s	O
solubility	O
,	O
and	O
promote	O
efficient	O
delivery	O
and	O
release	B-PATH
.	O

Applying	O
the	O
method	O
to	O
real	O
-	O
life	O
infections	O
,	O
we	O
obtained	O
accurate	O
estimates	O
for	O
the	O
degree	O
of	O
age	O
-	O
specific	O
immunity	O
against	O
monkeypox	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
and	O
A	O
(	O
H7N9	O
),	O
and	O
refined	O
existing	O
estimates	O
of	O
the	O
reproduction	O
number	O
.	O

TITLE	O
:	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
)	O
from	O
Endemic	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
:	O
Prehospital	O
Management	O
.	O

TITLE	O
:	O
[	O
Analysis	O
of	O
serious	O
respiratory	O
complications	O
in	O
PICU	O
in	O
children	O
with	O
measles	B-PATH
].	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
characteristics	O
of	O
the	O
serious	O
complications	O
of	O
17	O
cases	O
with	O
measles	B-PATH
in	O
ICU	O
.	O

Seventeen	O
cases	O
with	O
measles	B-PATH
with	O
serious	O
complications	O
in	O
ICU	O
in	O
Anhui	O
Provincial	O
Children	O
'	O
s	O
Hospital	O
were	O
recruited	O
from	O
May	O
2012	O
to	O
May	O
2013	O
.	O

Fourteen	O
cases	O
failed	O
to	O
inoculate	O
measles	B-PATH
vaccine	O
.	O

CoV	O
RNA	O
was	O
detected	O
in	O
47	O
specimens	O
(	O
7	O
.	O
6	O
%),	O
from	O
13	O
different	O
bat	O
species	O
,	O
using	O
broadly	O
reactive	O
consensus	O
PCR	O
primers	O
targeting	O
the	O
RNA	O
-	O
Dependent	O
RNA	B-PATH
Polymerase	I-PATH
gene	O
designed	O
to	O
detect	O
all	O
CoVs	O
.	O

Most	O
frequently	O
co	O
-	O
detected	O
viruses	O
were	O
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

We	O
analyzed	O
fecal	O
and	O
throat	O
swabs	O
to	O
detect	O
the	O
presence	O
of	O
virus	O
through	O
amplification	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
all	O
known	O
coronaviruses	O
.	O

Respiratory	O
viruses	O
were	O
detected	O
in	O
61	O
.	O
3	O
%	O
of	O
the	O
subjects	O
,	O
most	O
of	O
whom	O
had	O
ARI	O
(	O
90	O
.	O
8	O
%,	O
OR	O
=	O
11	O
.	O
39	O
),	O
were	O
hospitalized	O
(	O
96	O
.	O
9	O
%,	O
OR	O
=	O
22	O
.	O
31	O
),	O
had	O
asthma	B-PATH
exacerbation	O
(	O
90	O
.	O
9	O
%,	O
OR	O
=	O
8	O
.	O
67	O
),	O
and	O
/	O
or	O
had	O
pneumonia	O
(	O
80	O
%,	O
OR	O
=	O
4	O
.	O
0	O
).	O

Influenza	B-PATH
A	I-PATH
H3N2	O
,	O
human	O
metapneumovirus	O
(	O
HMPV	O
)	O
subtypes	O
A1	O
and	O
A2	O
,	O
the	O
influenza	O
B	O
virus	O
,	O
human	O
adenovirus	O
B	O
,	O
and	O
human	O
coronavirus	O
OC43	O
were	O
also	O
detected	O
.	O

Coinfections	O
of	O
the	O
influenza	B-PATH
A	I-PATH
H3N2	O
virus	O
with	O
TTV	O
,	O
HMPV	O
with	O
TTV	O
,	O
HRV	O
with	O
TTV	O
,	O
and	O
human	O
parainfluenza	O
virus	O
-	O
3	O
with	O
TTV	O
were	O
found	O
in	O
4	O
.	O
7	O
,	O
2	O
.	O
8	O
,	O
19	O
.	O
8	O
,	O
and	O
0	O
.	O
9	O
%	O
of	O
the	O
samples	O
,	O
respectively	O
.	O

This	O
study	O
highlights	O
the	O
need	O
to	O
perform	O
routine	O
detection	O
of	O
respiratory	O
viruses	O
in	O
adults	O
hospitalized	O
with	O
ARI	O
,	O
asthma	B-PATH
exacerbation	O
,	O
and	O
/	O
or	O
pneumonia	O
.	O

RESULTS	O
:	O
Respiratory	O
viruses	O
were	O
detected	O
in	O
61	O
.	O
3	O
%	O
of	O
the	O
subjects	O
,	O
most	O
of	O
whom	O
had	O
ARI	O
(	O
90	O
.	O
8	O
%,	O
OR	O
=	O
11	O
.	O
39	O
),	O
were	O
hospitalized	O
(	O
96	O
.	O
9	O
%,	O
OR	O
=	O
22	O
.	O
31	O
),	O
had	O
asthma	B-PATH
exacerbation	O
(	O
90	O
.	O
9	O
%,	O
OR	O
=	O
8	O
.	O
67	O
),	O
and	O
/	O
or	O
had	O
pneumonia	O
(	O
80	O
%,	O
OR	O
=	O
4	O
.	O
0	O
).	O

Coinfections	O
of	O
the	O
influenza	B-PATH
A	I-PATH
H3N2	O
virus	O
with	O
TTV	O
,	O
HMPV	O
with	O
TTV	O
,	O
HRV	O
with	O
TTV	O
,	O
and	O
human	O
parainfluenza	O
virus	O
-	O
3	O
with	O
TTV	O
were	O
found	O
in	O
4	O
.	O
7	O
,	O
2	O
.	O
8	O
,	O
19	O
.	O
8	O
,	O
and	O
0	O
.	O
9	O
%	O
of	O
the	O
samples	O
,	O
respectively	O
.	O

We	O
also	O
confirmed	O
that	O
sodium	O
chlorate	O
,	O
which	O
interferes	O
with	O
heparan	B-PATH
sulfate	I-PATH
biosynthesis	I-PATH
,	O
also	O
inhibited	O
PEDV	O
infection	O
.	O

Airway	O
pressure	O
release	B-PATH
ventilation	O
was	O
the	O
initial	O
choice	O
of	O
treatment	O
reported	O
by	O
most	O
when	O
conventional	O
mechanical	O
ventilation	O
strategy	O
failed	O
followed	O
by	O
inhaled	O
nitric	O
oxide	O
and	O
prone	O
positioning	O
.	O

Two	O
oropharyngeal	O
swab	O
specimens	O
were	O
collected	O
on	O
the	O
1st	O
and	O
2nd	O
day	O
of	O
patient	O
hospitalization	O
and	O
tested	O
using	O
two	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
assays	O
targeting	O
the	O
UpE	O
and	O
Orf	O
-	O
1a	O
regions	O
of	O
the	O
MERS	O
-	O
CoV	O
genome	O
and	O
RT	O
-	O
PCR	O
and	O
partial	O
sequencing	O
of	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
and	O
nucleocapsid	O
genes	O
.	O

We	O
provide	O
a	O
demonstration	O
of	O
the	O
features	O
of	O
plethy	O
using	O
a	O
dataset	O
assessing	O
the	O
respiratory	O
effects	O
over	O
time	O
of	O
SARS	O
and	O
Influenza	B-PATH
infection	I-PATH
in	O
mice	O
.	O

Our	O
package	O
is	O
implemented	O
in	O
R	O
and	O
is	O
freely	O
available	O
as	O
part	O
of	O
the	O
Bioconductor	O
project	O
http	O
://	O
www	O
.	O
bioconductor	O
.	O
org	O
/	O
packages	O
/	O
release	B-PATH
/	O
bioc	O
/	O
html	O
/	O
plethy	O
.	O
html	O
.	O

We	O
provide	O
a	O
demonstration	O
of	O
the	O
features	O
of	O
plethy	O
using	O
a	O
dataset	O
assessing	O
the	O
respiratory	O
effects	O
over	O
time	O
of	O
SARS	O
and	O
Influenza	B-PATH
infection	I-PATH
in	O
mice	O
.	O

When	O
compared	O
to	O
influenza	B-PATH
A	I-PATH
virus	O
NS1	O
protein	O
,	O
EBOV	O
VP35	O
showed	O
improved	O
inhibition	O
of	O
viral	O
dsRNA	O
-	O
based	O
IFN	O
-	O
Î²	O
induction	O
.	O

TITLE	O
:	O
Outbreak	O
of	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
a	O
Kidney	O
Transplant	O
Unit	O
-	O
Protective	O
Effect	O
of	O
Vaccination	O
.	O

We	O
characterize	O
an	O
outbreak	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
a	O
kidney	O
transplant	O
unit	O
.	O

After	O
the	O
first	O
positive	O
case	O
,	O
all	O
patients	O
were	O
tested	O
with	O
nasopharyngeal	O
swab	O
tests	O
and	O
7	O
patients	O
were	O
diagnosed	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

Five	O
of	O
six	O
unvaccinated	O
patients	O
were	O
diagnosed	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
);	O
3	O
/	O
5	O
suffered	O
from	O
severe	O
respiratory	O
failure	O
and	O
were	O
treated	O
with	O
ventilator	O
support	O
in	O
the	O
ICU	O
,	O
but	O
all	O
died	O
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
whereas	O
2	O
/	O
5	O
suffered	O
from	O
mild	O
viral	O
pneumonitis	O
and	O
recovered	O
fully	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
had	O
a	O
high	O
mortality	O
in	O
our	O
cohort	O
of	O
nonvaccinated	O
immunosuppressed	O
patients	O
early	O
after	O
kidney	O
transplantation	O
.	O

Focal	B-PATH
adhesion	I-PATH
kinase	O
(	O
FAK	O
)	O
activation	O
was	O
reduced	O
in	O
HS	O
group	O
as	O
well	O
as	O
neutrophil	O
infiltration	O
,	O
NOS2	O
expression	O
and	O
NO	O
content	O
.	O

TITLE	O
:	O
Serological	O
evidence	O
of	O
influenza	B-PATH
A	I-PATH
viruses	O
in	O
frugivorous	O
bats	O
from	O
Africa	O
.	O

The	O
identification	O
of	O
bats	O
as	O
possible	O
additional	O
reservoir	O
for	O
influenza	B-PATH
A	I-PATH
viruses	O
raises	O
questions	O
about	O
the	O
role	O
of	O
this	O
mammalian	O
taxon	O
in	O
influenza	B-PATH
A	I-PATH
virus	O
ecology	O
and	O
possible	O
public	O
health	O
relevance	O
.	O

This	O
study	O
aimed	O
at	O
screening	O
available	O
sera	O
from	O
100	O
free	O
-	O
ranging	O
,	O
frugivorous	O
bats	O
(	O
Eidolon	O
helvum	O
)	O
sampled	O
in	O
2009	O
/	O
10	O
in	O
Ghana	O
,	O
for	O
the	O
presence	O
of	O
antibodies	O
against	O
the	O
complete	O
panel	O
of	O
influenza	B-PATH
A	I-PATH
haemagglutinin	O
(	O
HA	O
)	O
types	O
ranging	O
from	O
H1	O
to	O
H18	O
by	O
means	O
of	O
a	O
protein	O
microarray	O
platform	O
.	O

This	O
condition	O
is	O
frequently	O
misdiagnosed	O
as	O
pulmonary	O
tuberculosis	B-PATH
,	O
lymphoma	O
,	O
schistosomiasis	O
,	O
Wegener	O
'	O
s	O
granuloma	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
or	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
.	O

Human	O
pathogens	O
in	O
the	O
Orthomyxoviridae	O
and	O
Coronaviridae	O
families	O
,	O
especially	O
pandemic	O
H1N1	O
and	O
avian	O
H5N1	O
influenza	B-PATH
A	I-PATH
viruses	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
were	O
investigated	O
.	O

When	O
purified	O
histones	O
were	O
delivered	O
to	O
lung	O
via	O
the	O
airways	O
,	O
intense	O
inflammatory	O
injury	O
ensued	O
and	O
type	O
II	O
cells	O
developed	O
large	O
blebs	O
indicating	O
cellular	O
damage	O
and	O
apoptosis	B-PATH
.	O

The	O
mechanistic	O
description	O
is	O
that	O
C5a	O
altered	O
the	O
alveolar	O
cytokine	O
milieu	O
and	O
caused	O
significant	O
release	B-PATH
of	O
CC	O
-	O
chemokines	O
.	O

RNA	O
/	O
DNA	O
of	O
influenza	B-PATH
A	I-PATH
,	O
B	O
,	O
parainfluenza	O
(	O
PI	O
);	O
adeno	O
-,	O
rhino	O
-,	O
RS	O
-	O
viruses	O
,	O
corona	O
-,	O
metapneumo	O
-	O
(	O
MPV	O
)	O
and	O
bocaviruses	O
were	O
detected	O
in	O
nasopharynx	O
smears	O
by	O
PCR	O
with	O
hybridization	O
-	O
fluorescent	O
detection	O
in	O
real	O
time	O
.	O

We	O
hypothesized	O
that	O
HGF	O
/	O
c	O
-	O
Met	O
and	O
TGF	O
-	O
Î±	O
/	O
EGFR	O
would	O
regulate	O
innate	O
immune	O
responses	O
to	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
in	O
human	O
AECs	O
.	O

Influenza	B-PATH
infection	I-PATH
stimulated	O
the	O
secretion	O
of	O
IL	O
-	O
8	O
and	O
GM	O
-	O
CSF	O
by	O
AECs	O
plated	O
on	O
rat	O
-	O
tail	O
collagen	O
through	O
EGFR	O
activation	O
likely	O
by	O
TGF	O
-	O
Î±	O
released	O
from	O
AECs	O
and	O
through	O
c	O
-	O
Met	O
activated	O
by	O
HGF	O
secreted	O
from	O
lung	O
fibroblasts	O
.	O

HGF	O
secretion	O
by	O
fibroblasts	O
was	O
stimulated	O
by	O
AEC	O
production	O
of	O
prostaglandin	O
E2	O
during	O
influenza	B-PATH
infection	I-PATH
.	O

Unregulated	O
complement	O
activation	O
is	O
likely	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
induced	O
by	O
highly	O
pathogenic	O
virus	O
including	O
influenza	B-PATH
A	I-PATH
viruses	O
H5N1	O
,	O
H7N9	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
elevated	O
level	O
of	O
endothelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
has	O
been	O
detected	O
in	O
the	O
bronchoalveolar	O
lavage	O
of	O
patients	O
with	O
severe	O
asthma	B-PATH
,	O
acute	O
lung	O
injury	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
sepsis	O
.	O

In	O
order	O
of	O
frequency	O
,	O
the	O
etiological	O
agents	O
identified	O
were	O
,	O
rhinovirus	O
/	O
enterovirus	O
(	O
24	O
.	O
6	O
%),	O
respiratory	O
syncytial	O
virus	O
(	O
13	O
.	O
8	O
%),	O
adenovirus	O
(	O
11	O
.	O
5	O
%),	O
parainfluenza	O
virus	O
(	O
9	O
.	O
2	O
%),	O
influenza	O
B	O
(	O
8	O
.	O
4	O
%),	O
influenza	B-PATH
A	I-PATH
(	O
5	O
.	O
4	O
%),	O
human	O
metapneumovirus	O
(	O
4	O
.	O
6	O
%),	O
human	O
coronavirus	O
(	O
2	O
%),	O
and	O
human	O
bocavirus	O
(	O
2	O
%).	O

ABSTRACT	O
:	O
A	O
72	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
diagnosed	O
with	O
type	O
B	O
influenza	B-PATH
infection	I-PATH
and	O
high	O
fever	O
4	O
days	O
previously	O
was	O
admitted	O
to	O
our	O
hospital	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
severe	O
respiratory	O
failure	O
after	O
type	O
B	O
influenza	B-PATH
infection	I-PATH
.	O

For	O
these	O
techniques	O
,	O
the	O
highest	O
Youden	O
'	O
s	O
index	O
(	O
YI	O
),	O
positive	O
predictive	O
(	O
PPV	O
)	O
and	O
specificity	O
(	O
Sp	O
)	O
values	O
were	O
observed	O
for	O
Core	O
tests	O
(	O
e	O
.	O
g	O
.,	O
influenza	B-PATH
A	I-PATH
[	O
YI	O
:	O
0	O
.	O
86	O
-	O
1	O
.	O
00	O
;	O
PPV	O
:	O
78	O
.	O
95	O
-	O
100	O
.	O
00	O
;	O
Sp	O
:	O
97	O
.	O
32	O
-	O
100	O
.	O
00	O
]	O
&	O
B	O
[	O
YI	O
:	O
0	O
.	O
44	O
-	O
1	O
.	O
00	O
;	O
PPV	O
:	O
100	O
.	O
00	O
;	O
Sp	O
:	O
100	O
.	O
00	O
],	O
hRSV	O
[	O
YI	O
:	O
0	O
.	O
50	O
-	O
0	O
.	O
99	O
;	O
PPV	O
:	O
85	O
.	O
71	O
-	O
100	O
.	O
00	O
;	O
Sp	O
:	O
99	O
.	O
38	O
-	O
100	O
.	O
00	O
],	O
hMPV	O
[	O
YI	O
:	O
0	O
.	O
71	O
-	O
1	O
.	O
00	O
;	O
PPV	O
:	O
83	O
.	O
33	O
-	O
100	O
.	O
00	O
;	O
Sp	O
:	O
99	O
.	O
37	O
-	O
100	O
.	O
00	O
],	O
EV	O
/	O
hRV	O
[	O
YI	O
:	O
0	O
.	O
62	O
-	O
0	O
.	O
82	O
;	O
PPV	O
:	O
93	O
.	O
33	O
-	O
100	O
.	O
00	O
;	O
Sp	O
:	O
94	O
.	O
48	O
-	O
100	O
.	O
00	O
],	O
AdV	O
[	O
YI	O
:	O
1	O
.	O
00	O
;	O
PPV	O
:	O
100	O
.	O
00	O
;	O
Sp	O
:	O
100	O
.	O
00	O
]	O
and	O
hBoV	O
[	O
YI	O
:	O
0	O
.	O
20	O
-	O
0	O
.	O
80	O
;	O
PPV	O
:	O
57	O
.	O
14	O
-	O
100	O
.	O
00	O
;	O
Sp	O
:	O
98	O
.	O
14	O
-	O
100	O
.	O
00	O
]).	O

Children	O
with	O
single	O
HRV	O
infections	O
presented	O
with	O
significantly	O
higher	O
rate	O
of	O
hypoxia	O
than	O
those	O
infected	O
with	O
respiratory	O
syncytial	O
virus	O
or	O
parainfluenza	O
virus	O
(	O
PIV	O
)-	O
3	O
(	O
12	O
Â·	O
4	O
%	O
vs	O
.	O
3	O
Â·	O
8	O
%	O
and	O
0	O
%,	O
respectively	O
,	O
P	O
<	O
0	O
Â·	O
05	O
),	O
higher	O
rate	O
of	O
chest	O
retraction	O
than	O
PIV	O
-	O
1	O
(	O
57	O
Â·	O
3	O
%	O
vs	O
.	O
34	O
Â·	O
5	O
%,	O
P	O
=	O
0	O
Â·	O
028	O
),	O
higher	O
rate	O
of	O
wheezing	O
than	O
influenza	B-PATH
A	I-PATH
(	O
63	O
Â·	O
2	O
%	O
vs	O
.	O
42	O
Â·	O
3	O
%,	O
P	O
=	O
0	O
Â·	O
038	O
).	O

This	O
methodology	O
closely	O
tracked	O
with	O
traditional	O
pathogenesis	O
metrics	O
,	O
distinguished	O
both	O
virus	O
-	O
and	O
dose	O
-	O
specific	O
responses	O
,	O
and	O
identified	O
long	O
-	O
term	O
respiratory	O
changes	O
following	O
both	O
SARS	O
-	O
CoV	O
and	O
Influenza	B-PATH
A	I-PATH
Virus	O
infection	O
.	O

TITLE	O
:	O
Methylene	O
blue	O
treatment	O
for	O
cytokine	O
release	B-PATH
syndrome	O
-	O
associated	O
vasoplegia	O
following	O
a	O
renal	O
transplant	O
with	O
rATG	O
infusion	O
:	O
A	O
case	O
report	O
and	O
literature	O
review	O
.	O

However	O
,	O
the	O
product	O
monograph	O
issued	O
by	O
the	O
manufacturer	O
(	O
Sanofi	O
Canada	O
)	O
reports	O
that	O
serious	O
immune	O
-	O
mediated	O
reactions	O
have	O
been	O
observed	O
following	O
the	O
use	O
of	O
rATG	O
,	O
consisting	O
of	O
anaphylaxis	O
or	O
severe	O
cytokine	O
release	B-PATH
syndrome	O
(	O
CRS	O
),	O
which	O
is	O
a	O
form	O
of	O
vasoplegic	O
syndrome	O
(	O
VS	O
),	O
in	O
which	O
distributive	O
shock	O
occurs	O
refractory	O
to	O
norepinephrine	O
(	O
NE	O
)	O
and	O
vasopressin	O
(	O
VP	O
).	O

Expression	O
of	O
avian	O
Î²	O
-	O
defensins	B-PATH
(	O
AvBDs	O
)	O
and	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
in	O
16	O
tissues	O
of	O
chicken	O
were	O
compared	O
at	O
7	O
days	O
PI	O
.	O

TITLE	O
:	O
Human	O
infection	O
with	O
a	O
novel	O
,	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N6	O
)	O
virus	O
:	O
Virological	O
and	O
clinical	O
findings	O
.	O

A	O
novel	O
reassortant	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H5N6	O
)	O
virus	O
was	O
isolated	O
from	O
the	O
throat	O
swab	O
or	O
trachea	O
aspirate	O
of	O
the	O
patient	O
.	O

microRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
novel	O
class	O
of	O
small	O
non	O
-	O
coding	O
RNAs	O
which	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
numerous	O
biological	O
processes	O
such	O
as	O
viral	O
infection	O
and	O
cell	O
apoptosis	B-PATH
.	O

Overall	O
,	O
the	O
replication	O
cycle	O
of	O
HAdV	O
-	O
B14p1	O
following	O
apical	O
infection	O
and	O
including	O
apical	O
release	B-PATH
of	O
infectious	O
virus	O
progeny	O
was	O
about	O
1000	O
-	O
fold	O
more	O
effective	O
compared	O
to	O
the	O
non	O
-	O
pneumotropic	O
HAdV	O
-	O
C5	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
Acute	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
and	O
bronchiolitis	O
obliterans	O
after	O
autologous	O
stem	O
cell	O
transplantation	O
in	O
a	O
patient	O
with	O
multiple	O
myeloma	O
.	O

He	O
was	O
diagnosed	O
with	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
and	O
bronchiolitis	O
obliterans	O
syndrome	O
.	O

TITLE	O
:	O
Pulmonary	O
Mucormycosis	O
in	O
a	O
Patient	O
with	O
Systemic	B-PATH
Lupus	I-PATH
Erythematosus	I-PATH
:	O

ABSTRACT	O
:	O
Pulmonary	O
mucormycosis	O
is	O
commonly	O
encountered	O
in	O
patients	O
with	O
diabetic	O
ketoacidosis	O
,	O
hematologic	O
malignancies	O
,	O
neutropenia	O
,	O
organ	O
or	O
hematopoietic	O
stem	O
cell	O
transplantation	O
,	O
and	O
malignancy	O
,	O
but	O
it	O
rarely	O
occurs	O
in	O
high	O
-	O
risk	O
patients	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
(	O
SLE	O
).	O

Activation	O
of	O
alveolar	O
macrophages	O
in	O
the	O
donor	O
lung	O
causes	O
the	O
release	B-PATH
of	O
pro	O
-	O
inflammatory	O
chemokines	O
and	O
cytokines	O
,	O
such	O
as	O
TNF	O
-	O
Î±	O
.	O

We	O
further	O
demonstrated	O
that	O
MERS	O
-	O
CoV	O
infection	O
induced	O
apoptosis	B-PATH
in	O
T	O
cells	O
,	O
which	O
involved	O
the	O
activation	O
of	O
both	O
the	O
extrinsic	O
and	O
intrinsic	O
apoptosis	B-PATH
pathways	O
.	O

We	O
report	O
a	O
38	O
years	O
old	O
female	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
treated	O
with	O
methylprednisolone	O
and	O
cyclophosphamide	O
.	O

TITLE	O
:	O
Structure	O
-	O
activity	O
relationship	O
studies	O
on	O
quinoxalin	O
-	O
2	O
(	O
1H	O
)-	O
one	O
derivatives	O
containing	O
thiazol	O
-	O
2	O
-	O
amine	O
against	O
hepatitis	B-PATH
C	I-PATH
virus	O
leading	O
to	O
the	O
discovery	O
of	O
BH6870	O
.	O

ABSTRACT	O
:	O
Chronic	O
hepatitis	B-PATH
C	I-PATH
virus	O
infection	O
represents	O
a	O
serious	O
global	O
public	O
health	O
problem	O
,	O
typically	O
resulting	O
in	O
fibrosis	O
,	O
cirrhosis	O
,	O
and	O
ultimately	O
hepatocellular	O
carcinoma	O
.	O

TITLE	O
:	O
Quantitative	O
Proteomics	O
Identifies	O
Serum	O
Response	O
Factor	O
Binding	O
Protein	O
1	O
as	O
a	O
Host	O
Factor	O
for	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
Entry	O
.	O

ABSTRACT	O
:	O
Hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
enters	O
human	O
hepatocytes	O
through	O
a	O
multistep	O
mechanism	O
involving	O
,	O
among	O
other	O
host	O
proteins	O
,	O
the	O
virus	O
receptor	O
CD81	O
.	O

TITLE	O
:	O
Retinal	O
Hemorrhages	O
in	O
Severe	O
Non	O
-	O
cerebral	O
Plasmodium	O
vivax	O
Malaria	B-PATH
in	O
an	O
Adult	O
.	O

It	O
causes	O
severe	O
malarial	O
disease	O
similar	O
to	O
those	O
as	O
Plasmodium	O
falciparum	O
including	O
cerebral	O
malaria	B-PATH
,	O
severe	O
anaemia	O
,	O
severe	O
thrombocytopenia	O
,	O
hepatic	O
dysfunction	O
,	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
acute	O
renal	O
failure	O
,	O
and	O
pulmonary	O
oedema	O
.	O

In	O
this	O
study	O
we	O
characterized	O
the	O
concentration	O
and	O
size	O
distribution	O
of	O
inhalable	O
particles	O
that	O
transport	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
),	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
and	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
generated	O
by	O
acutely	O
infected	O
pigs	O
and	O
assessed	O
virus	O
viability	O
for	O
each	O
particle	O
size	O
range	O
.	O

The	O
capacity	O
of	O
influenza	B-PATH
A	I-PATH
to	O
cross	O
species	O
barriers	O
presents	O
a	O
potential	O
threat	O
to	O
human	O
health	O
.	O

Influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
(	O
23	O
.	O
1	O
%)	O
and	O
rhinovirus	O
(	O
19	O
.	O
8	O
%)	O
were	O
the	O
most	O
common	O
pathogens	O
identified	O
among	O
these	O
travelers	O
.	O

TITLE	O
:	O
Discovery	O
of	O
an	O
essential	O
nucleotidylating	O
activity	O
associated	O
with	O
a	O
newly	O
delineated	O
conserved	O
domain	O
in	O
the	O
RNA	B-PATH
polymerase	I-PATH
-	O
containing	O
protein	O
of	O
all	O
nidoviruses	O
.	O

ABSTRACT	O
:	O
RNA	O
viruses	O
encode	O
an	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
that	O
catalyzes	O
the	O
synthesis	O
of	O
their	O
RNA	O
(	O
s	O
).	O

In	O
this	O
study	O
,	O
6	O
duplex	O
real	O
-	O
time	O
PCR	O
assays	O
,	O
using	O
EvaGreen	O
intercalating	O
dye	O
,	O
were	O
developed	O
to	O
detect	O
12	O
major	O
viruses	O
responsible	O
for	O
respiratory	O
diseases	O
:	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
enteroviruses	O
(	O
including	O
enterovirus	O
spp	O
,	O
and	O
rhinovirus	O
spp	O
),	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
coronaviruses	O
group	O
I	O
(	O
of	O
which	O
CoV	O
229E	O
and	O
CoV	O
NL63	O
are	O
part	O
)	O
and	O
II	O
(	O
including	O
CoV	O
OC43	O
and	O
CoV	O
HKU1	O
),	O
parainfluenza	O
viruses	O
type	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
,	O
human	O
adenoviruses	O
and	O
human	O
bocaviruses	O
.	O

In	O
adult	O
patients	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
was	O
the	O
most	O
frequently	O
detected	O
respiratory	O
virus	O
followed	O
by	O
rhinoviruses	O
.	O

In	O
contrast	O
,	O
respiratory	O
syncytial	O
virus	O
was	O
the	O
most	O
common	O
virus	O
in	O
children	O
,	O
followed	O
by	O
enteroviruses	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
coronavirus	O
NL63	O
.	O

The	O
pretravel	O
medical	O
consultation	O
includes	O
immunizations	O
,	O
malaria	B-PATH
chemoprophylaxis	O
,	O
self	O
-	O
treatment	O
for	O
traveler	O
'	O
s	O
diarrhea	O
,	O
and	O
advice	O
on	O
the	O
prevention	O
of	O
a	O
myriad	O
of	O
other	O
infectious	O
causes	O
including	O
dengue	O
,	O
chikungunya	O
,	O
rickettsiosis	O
,	O
leptospirosis	O
,	O
schistosomiasis	O
,	O
and	O
strongyloidiasis	O
.	O

Empiric	O
treatment	O
is	O
sometimes	O
necessary	O
when	O
suspicion	O
of	O
a	O
certain	O
diagnosis	O
is	O
strong	O
and	O
confirmatory	O
tests	O
are	O
delayed	O
or	O
lacking	O
,	O
particularly	O
for	O
infections	O
that	O
are	O
rapidly	O
progressive	O
(	O
for	O
example	O
,	O
malaria	B-PATH
)	O
or	O
for	O
which	O
timing	O
of	O
testing	O
is	O
prolonged	O
(	O
such	O
as	O
leptospirosis	O
).	O

Replication	O
-	O
competent	O
recombinant	O
measles	B-PATH
virus	O
(	O
MV	O
)	O
expressing	O
foreign	O
antigens	O
constitutes	O
a	O
promising	O
tool	O
to	O
induce	O
protective	O
immunity	O
against	O
corresponding	O
pathogens	O
.	O

The	O
quick	O
release	B-PATH
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
by	O
the	O
infected	O
macrophages	O
suggests	O
a	O
plausible	O
viral	O
initiation	O
of	O
NLRP3	O
inflammasome	O
activation	O
.	O

Between	O
2003	O
and	O
2012	O
,	O
influenza	O
B	O
,	O
RSV	O
,	O
and	O
coronavirus	O
showed	O
shifts	O
in	O
their	O
occurrence	O
when	O
influenza	B-PATH
A	I-PATH
epidemics	O
occurred	O
earlier	O
than	O
usual	O
(	O
before	O
week	O
1	O
).	O

When	O
influenza	B-PATH
A	I-PATH
epidemics	O
occured	O
early	O
,	O
timing	O
of	O
the	O
epidemics	O
of	O
several	O
respiratory	O
winter	O
viruses	O
usually	O
occurring	O
close	O
in	O
time	O
to	O
influenza	B-PATH
A	I-PATH
was	O
affected	O
,	O
while	O
trends	O
in	O
rhinoviruses	O
(	O
occurring	O
in	O
autumn	O
)	O
and	O
trends	O
in	O
enteral	O
viruses	O
were	O
not	O
.	O

RESULTS	O
:	O
Between	O
2003	O
and	O
2012	O
,	O
influenza	O
B	O
,	O
RSV	O
,	O
and	O
coronavirus	O
showed	O
shifts	O
in	O
their	O
occurrence	O
when	O
influenza	B-PATH
A	I-PATH
epidemics	O
occurred	O
earlier	O
than	O
usual	O
(	O
before	O
week	O
1	O
).	O

CONCLUSIONS	O
:	O
When	O
influenza	B-PATH
A	I-PATH
epidemics	O
occured	O
early	O
,	O
timing	O
of	O
the	O
epidemics	O
of	O
several	O
respiratory	O
winter	O
viruses	O
usually	O
occurring	O
close	O
in	O
time	O
to	O
influenza	B-PATH
A	I-PATH
was	O
affected	O
,	O
while	O
trends	O
in	O
rhinoviruses	O
(	O
occurring	O
in	O
autumn	O
)	O
and	O
trends	O
in	O
enteral	O
viruses	O
were	O
not	O
.	O

Bone	O
marrow	O
stromal	O
antigen	O
2	O
(	O
BST	O
-	O
2	O
;	O
also	O
known	O
as	O
CD317	O
or	O
tetherin	O
)	O
was	O
initially	O
identified	O
to	O
be	O
a	O
pre	O
-	O
B	O
-	O
cell	O
growth	O
promoter	O
,	O
but	O
it	O
also	O
inhibits	O
the	O
release	B-PATH
of	O
virions	O
of	O
the	O
retrovirus	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
by	O
tethering	O
budding	B-PATH
virions	O
to	O
the	O
host	O
cell	O
membrane	O
.	O

We	O
have	O
found	O
that	O
BST	O
-	O
2	O
is	O
capable	O
of	O
restricting	O
SARS	O
-	O
CoV	O
release	B-PATH
from	O
cells	O
;	O
however	O
,	O
we	O
also	O
identified	O
a	O
SARS	O
-	O
CoV	O
protein	O
that	O
inhibits	O
BST	O
-	O
2	O
function	O
.	O

TITLE	O
:	O
Apoptosis	B-PATH
transcriptional	O
mechanism	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Apoptosis	B-PATH
has	O
been	O
postulated	O
to	O
play	O
an	O
important	O
role	O
during	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
infection	O
;	O
however	O
,	O
its	O
mechanism	O
is	O
not	O
well	O
characterized	O
.	O

This	O
study	O
is	O
focused	O
on	O
apoptosis	B-PATH
and	O
transcriptional	O
profiling	O
of	O
FIPV	O
-	O
infected	O
cells	O
following	O
in	O
vitro	O
infection	O
of	O
CRFK	O
cells	O
with	O
FIPV	O
79	O
-	O
1146	O
WSU	O
.	O

FIPV	O
infected	O
cells	O
underwent	O
early	O
apoptosis	B-PATH
at	O
9	O
hpi	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
followed	O
by	O
late	O
apoptosis	B-PATH
at	O
12	O
hpi	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
necrosis	O
from	O
24	O
hpi	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
efficiency	O
of	O
the	O
treatment	O
policy	O
for	O
patients	O
with	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
(	O
AML	O
)	O
and	O
hyperleukocytosis	O
(	O
HL	O
),	O
which	O
is	O
aimed	O
at	O
preventing	O
rapid	O
hypercytolysis	O
and	O
massive	O
tumor	O
lysis	O
(	O
cytolysis	O
)	O
syndrome	O
and	O
/	O
or	O
at	O
reducing	O
the	O
degree	O
of	O
the	O
latter	O
at	O
the	O
start	O
of	O
induction	O
polychemotherapy	O
.	O

Ten	O
pathogens	O
in	O
the	O
highest	O
priority	O
group	O
(	O
Borrelia	O
,	O
calicivirus	O
,	O
Campylobacter	O
,	O
Echinococcus	O
multilocularis	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
HIV	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
SARS	O
-	O
and	O
MERS	O
coronavirus	O
,	O
tick	O
-	O
borne	O
encephalitis	O
virus	O
and	O
varicella	O
-	O
zoster	O
virus	O
)	O
did	O
not	O
have	O
any	O
surveillance	O
of	O
typing	O
results	O
.	O

TITLE	O
:	O
Airway	O
Pressure	O
Release	B-PATH
Ventilation	O
and	O
High	O
-	O
Frequency	O
Oscillatory	O
Ventilation	O
:	O
Potential	O
Strategies	O
to	O
Treat	O
Severe	O
Hypoxemia	O
and	O
Prevent	O
Ventilator	O
-	O
Induced	O
Lung	O
Injury	O
.	O

Of	O
the	O
18	O
pathogens	O
analyzed	O
,	O
four	O
were	O
detected	O
with	O
a	O
positive	O
detection	O
rate	O
(	O
PDR	O
)	O
>	O
5	O
%:	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
>	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
>	O
Mycoplasma	O
pneumoniae	O
(	O
MP	O
)	O
>	O
human	O
coronavirus	O
(	O
HCoV	O
).	O

ABSTRACT	O
:	O
Infection	O
with	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
activates	O
the	O
pattern	O
recognition	O
receptors	O
melanoma	B-PATH
differentiation	O
-	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
and	O
Toll	O
-	O
like	O
receptor	O
7	O
(	O
TLR7	O
)	O
to	O
induce	O
transcription	O
of	O
type	O
I	O
interferon	O
.	O

TITLE	O
:	O
Bioinformatics	O
Analysis	O
of	O
Proteome	O
Changes	O
in	O
Calu	O
-	O
3	O
Cell	O
Infected	O
by	O
Influenza	B-PATH
A	I-PATH
Virus	O
(	O
H5N1	O
).	O

ABSTRACT	O
:	O
This	O
paper	O
aimed	O
to	O
identify	O
the	O
differentially	O
expressed	O
proteins	O
(	O
DEPs	O
)	O
in	O
Calu	O
-	O
3	O
cells	O
infected	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
subtype	O
H5N1	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
M	O
protein	O
blocks	O
cell	B-PATH
cycle	I-PATH
progression	O
at	O
S	O
-	O
phase	O
and	O
its	O
subcellular	O
localization	O
in	O
the	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

TITLE	O
:	O
SiaÎ±2	O
-	O
3GalÎ²1	O
-	O
Receptor	O
Genetic	O
Variants	O
Are	O
Associated	O
with	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
Severity	O
.	O

ABSTRACT	O
:	O
Different	O
host	O
genetic	O
variants	O
may	O
be	O
related	O
to	O
the	O
virulence	O
and	O
transmissibility	O
of	O
pandemic	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
,	O
influencing	O
events	O
such	O
as	O
binding	O
of	O
the	O
virus	O
to	O
the	O
entry	O
receptor	O
on	O
the	O
cell	O
of	O
infected	O
individuals	O
and	O
the	O
host	O
immune	O
response	O
.	O

This	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
the	O
association	O
of	O
ST3GAL1	O
gene	O
haplotypes	O
on	O
the	O
risk	O
of	O
more	O
severe	O
disease	O
and	O
death	O
in	O
patients	O
infected	O
with	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
.	O

Among	O
HIV	O
+	O
participants	O
,	O
greater	O
WMH	O
and	O
lower	O
anterior	O
corona	O
radiata	O
FA	O
were	O
associated	O
with	O
active	O
hepatitis	B-PATH
C	I-PATH
virus	O
infection	O
,	O
a	O
history	O
of	O
AIDS	O
,	O
and	O
higher	O
current	O
CD4	O
cell	O
count	O
.	O

The	O
other	O
two	O
studies	O
focussed	O
on	O
tuberculosis	B-PATH
transmission	O
control	O
interventions	O
.	O

ABSTRACT	O
:	O
All	O
RNA	O
viruses	O
encode	O
an	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
which	O
in	O
arteriviruses	O
is	O
expressed	O
as	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
nonstructural	O
protein	O
9	O
(	O
nsp9	O
).	O

ABSTRACT	O
:	O
A	O
novel	O
reassortant	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	B-PATH
)	O
virus	O
was	O
found	O
to	O
infect	O
three	O
Chinese	O
residents	O
,	O
the	O
first	O
H7N9	B-PATH
infection	O
in	O
humans	O
in	O
Asia	O
.	O

Viral	O
RNA	O
was	O
extracted	O
from	O
25	O
nasopharyngeal	O
samples	O
for	O
detection	O
of	O
influenza	B-PATH
A	I-PATH
,	O
B	O
and	O
C	O
;	O
parainfluenza	O
1	O
-	O
4	O
;	O
human	O
coronaviruses	O
229E	O
and	O
OC43	O
;	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
rhinovirus	O
.	O

The	O
most	O
common	O
viruses	O
were	O
rhinovirus	O
,	O
coronavirus	O
,	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

ABSTRACT	O
:	O
Despite	O
tremendous	O
progress	O
made	O
toward	O
elimination	O
,	O
measles	B-PATH
continues	O
to	O
pose	O
a	O
great	O
threat	O
to	O
the	O
health	O
of	O
children	O
in	O
developing	O
countries	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
summarize	O
and	O
analyze	O
the	O
clinical	O
characteristics	O
and	O
treatment	O
experience	O
of	O
serious	O
complications	O
of	O
measles	B-PATH
pneumonia	O
in	O
children	O
.	O

The	O
study	O
group	O
comprised	O
58	O
infants	O
with	O
severe	O
measles	B-PATH
pneumonia	O
who	O
were	O
admitted	O
to	O
the	O
Second	O
Pediatric	O
Intensive	O
Care	O
Unit	O
,	O
Shengjing	O
Hospital	O
of	O
China	O
Medical	O
University	O
,	O
from	O
December	O
2013	O
through	O
May	O
2014	O
.	O

Children	O
with	O
measles	B-PATH
pneumonia	O
may	O
experience	O
multiple	O
serious	O
complications	O
,	O
among	O
which	O
ARDS	O
and	O
pneumothorax	O
are	O
particularly	O
serious	O
.	O

The	O
primary	O
diseases	O
were	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
(	O
n	O
=	O
8	O
)	O
and	O
acute	O
lymphoblastic	O
leukemia	O
(	O
n	O
=	O
4	O
).	O

We	O
performed	O
meta	O
-	O
analyses	O
of	O
studies	O
on	O
tuberculosis	B-PATH
,	O
influenza	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
SARS	O
-	O
Coronavirus	O
and	O
pneumonia	O
.	O

Subset	O
analyses	O
identified	O
CCL2	O
as	O
an	O
additional	O
risk	O
factor	O
for	O
tuberculosis	B-PATH
(	O
rs1024611	O
;	O
OR	O
=	O
0	O
.	O
79	O
[	O
0	O
.	O
72	O
-	O
0	O
.	O
88	O
]).	O

However	O
,	O
its	O
influence	O
on	O
cell	B-PATH
cycle	I-PATH
and	O
subcellular	O
structure	O
still	O
require	O
more	O
research	O
.	O

The	O
results	O
showed	O
that	O
PEDV	O
ORF3	O
protein	O
localizes	O
in	O
the	O
cytoplasm	O
and	O
affects	O
cell	B-PATH
cycle	I-PATH
progression	O
by	O
prolonging	O
the	O
S	O
phase	O
.	O

SM	O
is	O
a	O
reversible	O
cardiomyopathy	O
resulting	O
in	O
transient	O
left	O
ventricular	O
dysfunction	O
which	O
has	O
been	O
described	O
to	O
occur	O
in	O
the	O
setting	O
of	O
catecholamine	O
release	B-PATH
during	O
situations	O
of	O
physiologic	O
stress	O
.	O

Air	O
transportation	O
is	O
a	O
major	O
vehicle	O
for	O
the	O
rapid	O
spread	O
and	O
dissemination	O
of	O
communicable	O
diseases	O
,	O
and	O
there	O
have	O
been	O
a	O
number	O
of	O
reported	O
outbreaks	O
of	O
serious	O
airborne	O
diseases	O
aboard	O
commercial	O
flights	O
including	O
tuberculosis	B-PATH
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
influenza	O
,	O
smallpox	O
,	O
and	O
measles	B-PATH
,	O
to	O
name	O
a	O
few	O
.	O

ABSTRACT	O
:	O
Infectious	O
disease	O
outbreaks	O
and	O
epidemics	O
such	O
as	O
those	O
due	O
to	O
SARS	O
,	O
influenza	O
,	O
measles	B-PATH
,	O
tuberculosis	B-PATH
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
have	O
raised	O
concern	O
about	O
the	O
airborne	O
transmission	O
of	O
pathogens	O
in	O
indoor	O
environments	O
.	O

We	O
have	O
developed	O
a	O
method	O
for	O
rapid	O
de	O
novo	O
assembly	O
of	O
the	O
novel	O
influenza	B-PATH
A	I-PATH
H7N9	O
virus	O
genome	O
directly	O
from	O
the	O
tracheal	O
aspirate	O
of	O
a	O
patient	O
using	O
semiconductor	O
sequencer	O
without	O
culture	O
and	O
prior	O
sequence	O
information	O
.	O

Using	O
hemi	O
-	O
nested	O
reverse	O
transcriptase	O
(	O
RT	O
)-	O
PCR	O
amplification	O
of	O
fragments	O
within	O
the	O
highly	O
conserved	O
regions	O
of	O
the	O
respective	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
genes	O
,	O
we	O
detected	O
astrovirus	O
sequences	O
at	O
an	O
overall	O
detection	O
rate	O
of	O
25	O
.	O
8	O
%	O
of	O
the	O
analysed	O
animals	O
,	O
with	O
a	O
maximum	O
of	O
65	O
%	O
in	O
local	O
populations	O
.	O

The	O
Identify	O
-	O
Isolate	O
-	O
Inform	O
(	O
3I	O
)	O
tool	O
,	O
originally	O
conceived	O
for	O
initial	O
detection	O
and	O
management	O
of	O
Ebola	O
virus	O
disease	O
patients	O
in	O
the	O
ED	O
and	O
later	O
adjusted	O
for	O
measles	B-PATH
,	O
can	O
be	O
adapted	O
for	O
real	O
-	O
time	O
use	O
for	O
any	O
emerging	O
infectious	O
disease	O
.	O

Among	O
the	O
49	O
influenza	O
-	O
positive	O
specimens	O
,	O
76	O
%	O
were	O
influenza	B-PATH
A	I-PATH
(	O
19	O
H3N2	O
,	O
17	O
H1N1pdm09	O
,	O
and	O
1	O
not	O
subtyped	O
),	O
and	O
24	O
%	O
were	O
influenza	O
B	O
.	O
Influenza	O
viruses	O
were	O
a	O
frequent	O
cause	O
of	O
SARI	O
in	O
hospitalized	O
patients	O
in	O
Southern	O
Arizona	O
.	O

Among	O
the	O
49	O
influenza	O
-	O
positive	O
specimens	O
,	O
76	O
%	O
were	O
influenza	B-PATH
A	I-PATH
(	O
19	O
H3N2	O
,	O
17	O
H1N1pdm09	O
,	O
and	O
1	O
not	O
subtyped	O
),	O
and	O
24	O
%	O
were	O
influenza	O
B	O
.	O
CONCLUSIONS	O
:	O
Influenza	O
viruses	O
were	O
a	O
frequent	O
cause	O
of	O
SARI	O
in	O
hospitalized	O
patients	O
in	O
Southern	O
Arizona	O
.	O

Of	O
the	O
patients	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
,	O
viral	O
RNA	O
was	O
recovered	O
from	O
the	O
air	O
emitted	O
by	O
9	O
/	O
12	O
patients	O
using	O
the	O
low	O
-	O
volume	O
sampler	O
;	O
no	O
viral	O
RNA	O
was	O
detected	O
from	O
air	O
emitted	O
by	O
patients	O
with	O
influenza	O
B	O
(	O
n	O
=	O
3	O
).	O

RSV	O
,	O
PIVs	O
and	O
coronaviruses	O
were	O
most	O
prevalent	O
in	O
infants	O
less	O
than	O
6	O
months	O
old	O
,	O
whereas	O
MPV	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
were	O
more	O
prominent	O
in	O
children	O
aged	O
7	O
-	O
24	O
and	O
25	O
-	O
60	O
months	O
,	O
respectively	O
.	O

TITLE	O
:	O
Intensive	O
care	O
unit	O
surveillance	O
of	O
influenza	B-PATH
infection	I-PATH
in	O
France	O
:	O
the	O
2009	O
/	O
10	O
pandemic	O
and	O
the	O
three	O
subsequent	O
seasons	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
and	O
many	O
unrelated	O
viruses	O
including	O
rhinovirus	O
,	O
RSV	O
,	O
adenovirus	O
,	O
metapneumovirus	O
and	O
coronavirus	O
share	O
the	O
same	O
seasonality	O
,	O
since	O
these	O
viral	O
acute	O
respiratory	O
tract	O
infections	O
(	O
vARIs	O
)	O
are	O
much	O
more	O
common	O
in	O
winter	O
than	O
summer	O
.	O

The	O
methodology	O
tested	O
on	O
M2	O
from	O
influenza	B-PATH
A	I-PATH
,	O
shows	O
an	O
excellent	O
agreement	O
with	O
established	O
structures	O
.	O

However	O
,	O
pretreatment	O
of	O
mice	O
with	O
imatinib	O
increased	O
lung	O
catalase	O
activity	O
and	O
decreased	O
intravenous	O
LPS	O
-	O
induced	O
lung	O
oxidant	O
injury	O
as	O
measured	O
by	O
Î³	O
-	O
H2AX	O
,	O
a	O
marker	O
of	O
oxidant	O
-	O
induced	O
DNA	O
damage	O
,	O
lung	O
apoptosis	B-PATH
,	O
and	O
pulmonary	O
edema	O
.	O

TITLE	O
:	O
Altered	O
Lipid	O
Composition	O
of	O
Surfactant	O
and	O
Lung	O
Tissue	O
in	O
Murine	O
Experimental	O
Malaria	B-PATH
-	O
Associated	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
-	O
associated	O
acute	O
lung	O
injury	O
(	O
MA	O
-	O
ALI	O
)	O
and	O
its	O
more	O
severe	O
form	O
malaria	B-PATH
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
MA	O
-	O
ARDS	O
)	O
are	O
common	O
,	O
often	O
fatal	O
complications	O
of	O
severe	O
malaria	B-PATH
infections	O
.	O

Based	O
on	O
the	O
analysis	O
of	O
a	O
fragment	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
,	O
phylogenetic	O
analyses	O
show	O
that	O
alpha	O
-	O
CoVs	O
sequences	O
detected	O
in	O
French	O
bats	O
are	O
closely	O
related	O
to	O
other	O
European	O
bat	O
alpha	O
-	O
CoVs	O
.	O

TITLE	O
:	O
Nucleoside	O
Inhibitors	O
of	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
NS5B	O
Polymerase	O
:	O
A	O
Systematic	O
Review	O
.	O

ABSTRACT	O
:	O
Nowadays	O
,	O
a	O
large	O
number	O
of	O
people	O
in	O
the	O
world	O
are	O
suffering	O
from	O
chronic	O
Hepatitis	B-PATH
C	I-PATH
.	O
HCV	O
NS5B	O
polymerase	O
conserved	O
across	O
the	O
identified	O
7	O
HCV	O
genotypes	O
is	O
considered	O
to	O
be	O
the	O
most	O
promising	O
target	O
in	O
combating	O
HCV	O
.	O

ABSTRACT	O
:	O
To	O
establish	O
a	O
characteristic	O
host	O
response	O
to	O
predict	O
the	O
pathogenicity	O
and	O
tissue	O
tropism	O
of	O
infectious	O
bronchitis	O
viruses	O
(	O
IBV	O
),	O
we	O
investigated	O
innate	O
immune	O
responses	O
(	O
IIR	O
)	O
and	O
apoptosis	B-PATH
in	O
chicken	O
embryo	O
kidney	O
cells	O
(	O
CEKC	O
)	O
and	O
tracheal	O
organ	O
cultures	O
(	O
TOC	O
)	O
infected	O
with	O
three	O
IBV	O
strains	O
.	O

Results	O
showed	O
nephropathogenic	O
IBV	O
strains	O
885	O
and	O
QX	O
induced	O
greater	O
apoptosis	B-PATH
in	O
CEKC	O
than	O
M41	O
,	O
which	O
induced	O
greater	O
apoptosis	B-PATH
in	O
TOCs	O
compared	O
to	O
885	O
and	O
QX	O
.	O

In	O
summary	O
,	O
greater	O
levels	O
of	O
apoptosis	B-PATH
and	O
elevated	O
levels	O
of	O
TLR3	O
,	O
MDA5	O
and	O
IFN	O
-	O
Î²	O
expression	O
are	O
associated	O
with	O
increased	O
pathogenicity	O
of	O
IBV	O
strains	O
in	O
renal	O
and	O
tracheal	O
tissues	O
.	O

The	O
user	O
-	O
friendly	O
assay	O
detected	O
and	O
differentiated	O
between	O
four	O
viruses	O
[	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
porcine	O
circovirus	O
type	O
2	O
,	O
porcine	O
respiratory	O
corona	O
virus	O
],	O
four	O
bacteria	O
(	O
Mycoplasma	O
hyopneumoniae	O
,	O
Pasteurella	O
multocida	O
,	O
Salmonella	O
enterica	O
serovar	O
Choleraesuis	O
,	O
Streptococcus	O
suis	O
),	O
and	O
further	O
differentiated	O
between	O
type	O
1	O
and	O
type	O
2	O
PRRSV	O
as	O
well	O
as	O
toxigenic	O
and	O
non	O
-	O
toxigenic	O
P	O
.	O
multocida	O
.	O

As	O
part	O
of	O
prerelease	O
health	O
protocols	O
,	O
samples	O
were	O
obtained	O
from	O
29	O
parrots	O
on	O
three	O
different	O
occasions	O
while	O
in	O
captivity	O
and	O
once	O
after	O
their	O
release	B-PATH
.	O

Treatments	O
for	O
C	O
.	O
psittaci	O
and	O
endoparasites	O
were	O
administered	O
prior	O
to	O
release	B-PATH
,	O
and	O
negative	O
results	O
were	O
obtained	O
in	O
subsequent	O
exams	O
.	O

Additionally	O
,	O
protocols	O
allowed	O
informed	O
decisions	O
to	O
release	B-PATH
candidates	O
,	O
minimized	O
risks	O
,	O
and	O
favored	O
the	O
selection	O
of	O
healthy	O
individuals	O
,	O
thereby	O
contributing	O
to	O
the	O
recovery	O
of	O
this	O
species	O
.	O

This	O
study	O
demonstrates	O
that	O
astrocytic	O
Cx43	O
expression	O
and	O
function	O
can	O
be	O
modulated	O
due	O
to	O
virus	O
stress	O
and	O
can	O
be	O
an	O
appropriate	O
model	O
to	O
understand	O
the	O
basis	O
of	O
cellular	O
mechanisms	O
involved	O
in	O
the	O
alteration	O
of	O
gap	B-PATH
junction	I-PATH
intercellular	O
communication	O
(	O
GJIC	O
)	O
in	O
CNS	O
neuroinflammation	O
.	O

In	O
addition	O
,	O
results	O
show	O
that	O
MHV	O
infection	O
impairs	O
Cx43	O
expression	O
in	O
addition	O
to	O
gap	B-PATH
junction	I-PATH
communication	O
in	O
primary	O
astrocytes	O
.	O

This	O
may	O
provide	O
a	O
basis	O
for	O
understanding	O
how	O
structural	O
alterations	O
of	O
astrocytic	O
gap	O
junctions	O
can	O
disrupt	O
gap	B-PATH
junction	I-PATH
communication	O
between	O
other	O
CNS	O
cells	O
in	O
altered	O
CNS	O
environments	O
due	O
to	O
infection	O
and	O
inflammation	O
.	O

MERS	O
-	O
CoV	O
can	O
also	O
effectively	O
infect	O
human	O
primary	O
T	O
cells	O
and	O
induce	O
massive	O
apoptosis	B-PATH
in	O
these	O
cells	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
induces	O
apoptosis	B-PATH
in	O
swine	O
testicular	O
and	O
LLC	O
porcine	O
kidney	O
cell	O
lines	O
in	O
vitro	O
but	O
not	O
in	O
infected	O
intestinal	O
enterocytes	O
in	O
vivo	O
.	O

Whether	O
AHR	O
can	O
exist	O
in	O
SCD	O
as	O
a	O
distinct	O
entity	O
,	O
separate	O
and	O
independent	O
of	O
asthma	B-PATH
,	O
is	O
unknown	O
.	O

Our	O
goal	O
was	O
to	O
elucidate	O
the	O
prevalence	O
of	O
AHR	O
,	O
as	O
measured	O
by	O
a	O
methacholine	O
challenge	O
test	O
(	O
MCT	O
),	O
in	O
children	O
with	O
SCD	O
who	O
did	O
not	O
have	O
concomitant	O
asthma	B-PATH
or	O
any	O
recent	O
history	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	O
).	O

To	O
determine	O
if	O
AHR	O
was	O
associated	O
with	O
asthma	B-PATH
-	O
like	O
symptoms	O
,	O
we	O
compared	O
the	O
results	O
of	O
the	O
MCT	O
to	O
a	O
validated	O
asthma	B-PATH
questionnaire	O
.	O

The	O
children	O
and	O
/	O
or	O
their	O
parents	O
completed	O
the	O
ISAAC	O
(	O
International	O
Study	O
of	O
Asthma	B-PATH
and	O
Allergies	O
in	O
Children	O
)	O
questionnaire	O
.	O

Nine	O
(	O
31	O
.	O
0	O
%)	O
also	O
reported	O
asthma	B-PATH
-	O
like	O
symptoms	O
on	O
questionnaire	O
.	O

TITLE	O
:	O
Anti	O
-	O
inflammatory	O
effects	O
of	O
indirubin	O
derivatives	O
on	O
influenza	B-PATH
A	I-PATH
virus	O
-	O
infected	O
human	O
pulmonary	O
microvascular	O
endothelial	O
cells	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
poses	O
global	O
threats	O
to	O
human	O
health	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
and	O
multi	O
-	O
organ	O
dysfunction	O
are	O
major	O
complications	O
in	O
patients	O
with	O
severe	O
influenza	B-PATH
infection	I-PATH
.	O

To	O
estimate	O
the	O
attributable	O
fraction	O
(	O
AF	O
)	O
and	O
the	O
detection	O
rate	O
attributable	O
to	O
illness	O
for	O
each	O
of	O
the	O
different	O
respiratory	O
viruses	O
We	O
compared	O
the	O
prevalence	O
of	O
10	O
common	O
respiratory	O
viruses	O
(	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
parainfluenza	O
virus	O
1	O
-	O
3	O
;	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
);	O
adenovirus	O
,	O
rhinovirus	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
and	O
enterovirus	O
)	O
in	O
both	O
HIV	O
positive	O
and	O
negative	O
patients	O
hospitalized	O
with	O
severe	O
acute	O
respiratory	O
illness	O
(	O
SARI	O
),	O
outpatients	O
with	O
influenza	O
-	O
like	O
illness	O
(	O
ILI	O
),	O
and	O
control	O
subjects	O
who	O
did	O
not	O
report	O
any	O
febrile	O
,	O
respiratory	O
or	O
gastrointestinal	O
illness	O
during	O
2012	O
-	O
2015	O
in	O
South	O
Africa	O
.	O

Age	O
distribution	O
of	O
HCoV	O
-	O
NL63	O
infection	O
in	O
hospitalized	O
patients	O
with	O
pneumonia	O
indicated	O
that	O
the	O
group	O
aged	O
16	O
-	O
25	O
years	O
(	O
20	O
%)	O
had	O
the	O
highest	O
positive	O
rate	O
compared	O
with	O
the	O
other	O
groups	O
,	O
and	O
exhibited	O
a	O
similar	O
age	O
-	O
specific	O
pattern	O
to	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
,	O
but	O
not	O
influenza	B-PATH
A	I-PATH
/	O
H3N2	O
and	O
B	O
infections	O
in	O
hospitalized	O
patients	O
.	O

Seasonal	O
prevalence	O
of	O
HCoV	O
-	O
NL63	O
infection	O
was	O
late	O
winter	O
,	O
overlapping	O
the	O
highest	O
peak	O
of	O
the	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
epidemic	O
during	O
December	O
2010	O
to	O
March	O
2011	O
in	O
Taiwan	O
.	O

Co	O
-	O
infection	O
of	O
HCoV	O
-	O
NL63	O
and	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
was	O
detected	O
in	O
three	O
hospitalized	O
patients	O
.	O

Co	O
-	O
infection	O
caused	O
significantly	O
higher	O
rates	O
of	O
breathing	O
difficulties	O
,	O
cough	O
,	O
and	O
sore	O
throat	O
than	O
those	O
of	O
single	O
infection	O
with	O
HCoV	O
-	O
NL63	O
and	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
.	O

(	O
5	O
)	O
There	O
were	O
16	O
hospitalized	O
cases	O
with	O
single	O
infection	O
of	O
HCoVs	O
in	O
this	O
study	O
,	O
of	O
which	O
12	O
cases	O
were	O
diagnosed	O
as	O
bronchopneumonia	O
,	O
3	O
cases	O
developed	O
acute	O
laryngeal	O
obstruction	O
,	O
2	O
cases	O
had	O
acute	O
bronchial	O
asthma	B-PATH
attack	O
.	O

(	O
6	O
)	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
incidence	O
of	O
clinical	O
manifestations	O
(	O
including	O
cough	O
,	O
gasping	O
,	O
dyspnea	O
,	O
fever	O
and	O
abnormality	O
on	O
chest	O
X	O
-	O
ray	O
),	O
complications	O
(	O
including	O
respiratory	O
failure	O
,	O
myocardial	O
damage	O
,	O
and	O
acute	O
bronchial	O
asthma	B-PATH
attack	O
)	O
and	O
mechanical	O
ventilation	O
between	O
hospitalized	O
ALRTI	O
patients	O
with	O
single	O
HCoV	O
infection	O
and	O
193	O
patients	O
with	O
single	O
RSV	O
infection	O
in	O
the	O
same	O
period	O
.	O

The	O
risk	O
factors	O
for	O
severe	O
disease	O
were	O
age	O
<	O
2	O
years	O
,	O
underlying	O
bronchial	O
asthma	B-PATH
and	O
chronic	O
lung	O
disease	O
.	O

A	O
further	O
study	O
showed	O
that	O
the	O
CBP	O
degradation	O
by	O
nsp1	O
was	O
proteasome	B-PATH
-	O
dependent	O
.	O

Further	O
,	O
the	O
presence	O
of	O
asthma	B-PATH
(	O
OR	O
,	O
3	O
.	O
17	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
86	O
-	O
5	O
.	O
46	O
)	O
was	O
independently	O
associated	O
with	O
HRV	O
infection	O
,	O
whereas	O
fever	O
was	O
associated	O
with	O
AdV	O
(	O
OR	O
,	O
3	O
.	O
86	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
31	O
-	O
16	O
.	O
52	O
)	O
and	O
influenza	O
infections	O
(	O
OR	O
,	O
3	O
.	O
74	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
26	O
-	O
16	O
.	O
06	O
).	O

Several	O
viruses	O
including	O
influenza	B-PATH
A	I-PATH
,	O
rhinovirus	O
,	O
and	O
non	O
-	O
MERS	O
coronaviruses	O
had	O
low	O
carriage	O
rates	O
among	O
arriving	O
pilgrims	O
and	O
a	O
statistically	O
significant	O
increase	O
in	O
their	O
carriage	O
rate	O
was	O
observed	O
,	O
following	O
participation	O
in	O
the	O
Hajj	O
.	O

We	O
evaluated	O
the	O
effect	O
of	O
treatment	O
with	O
VIS410	O
,	O
a	O
human	O
monoclonal	O
antibody	O
targeting	O
the	O
HA	O
stem	O
region	O
,	O
on	O
the	O
development	O
of	O
ARDS	O
in	O
BALB	O
/	O
c	O
mice	O
after	O
infection	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
viruses	O
.	O

Nasal	O
and	O
pharyngeal	O
swabs	O
were	O
tested	O
using	O
the	O
PCR	O
method	O
for	O
the	O
following	O
12	O
viruses	O
:	O
influenza	B-PATH
A	I-PATH
,	O
influenza	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
A	O
(	O
RSV	O
A	O
),	O
respiratory	O
syncytial	O
virus	O
B	O
(	O
RSV	O
B	O
),	O
adenovirus	O
,	O
metapneumovirus	O
,	O
coronavirus	O
229E	O
/	O
NL63	O
(	O
hCoV229	O
),	O
coronavirus	O
OC43	O
(	O
hCoVOC43	O
),	O
parainfluenza	O
virus	O
1	O
(	O
PIV	O
-	O
1	O
),	O
parainfluenza	O
virus	O
2	O
(	O
PIV	O
-	O
2	O
),	O
parainfluenza	O
virus	O
3	O
(	O
PIV	O
-	O
3	O
),	O
and	O
rhinovirus	O
A	O
/	O
B	O
.	O
Coinfections	O
were	O
detected	O
in	O
nine	O
(	O
8	O
%)	O
patients	O
.	O

Five	O
of	O
the	O
coinfections	O
were	O
related	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
virus	O
associated	O
with	O
the	O
following	O
other	O
,	O
single	O
or	O
combined	O
,	O
respiratory	O
viruses	O
:	O
influenza	O
B	O
in	O
one	O
case	O
,	O
hCoV229	O
in	O
two	O
cases	O
,	O
hCoV229	O
,	O
RSV	O
A	O
,	O
and	O
PIV	O
-	O
2	O
in	O
one	O
case	O
,	O
and	O
PIV	O
-	O
1	O
,	O
PIV	O
-	O
2	O
,	O
RSV	O
A	O
,	O
RSV	O
B	O
,	O
and	O
adenovirus	O
in	O
one	O
case	O
.	O

Eleven	O
of	O
the	O
new	O
compounds	O
were	O
tested	O
and	O
found	O
active	O
against	O
influenza	B-PATH
A	I-PATH
neuraminidase	O
virus	O
(	O
H3N2	O
).	O

In	O
a	O
severe	O
course	O
of	O
bronchial	O
asthma	B-PATH
GERD	O
was	O
detected	O
3	O
,	O
4	O
times	O
more	O
frequently	O
in	O
the	O
boys	O
,	O
while	O
in	O
a	O
lengthy	O
course	O
of	O
pneumonia	O
with	O
BOS	O
--	O
1	O
,	O
9	O
times	O
more	O
frequently	O
in	O
the	O
girls	O
.	O

Inflammatory	O
responses	O
and	O
oxidative	B-PATH
damage	I-PATH
were	O
significantly	O
decreased	O
,	O
yielding	O
minimal	O
tissue	O
injury	O
.	O

The	O
injection	O
of	O
a	O
lentiviral	O
vector	O
carrying	O
a	O
minigene	O
encoding	O
for	O
a	O
FXN	O
-	O
specific	O
short	O
hairpin	O
ribonucleic	O
acid	O
(	O
shRNA	O
)	O
into	O
the	O
mouse	O
cerebellar	O
cortex	O
triggers	O
a	O
FXN	O
deficit	O
which	O
is	O
accompanied	O
by	O
significant	O
apoptosis	B-PATH
of	O
granule	O
neurons	O
as	O
well	O
as	O
loss	O
of	O
calbindin	O
in	O
Purkinje	O
cells	O
.	O

Moreover	O
,	O
troponin	O
release	B-PATH
can	O
be	O
related	O
to	O
right	O
ventricular	O
dysfunction	O
,	O
thus	O
highlighting	O
the	O
clinical	O
role	O
of	O
echocardiography	O
in	O
ARDS	O
patients	O
.	O

ABSTRACT	O
:	O
Although	O
HIV	O
antibody	O
tests	O
have	O
been	O
widely	O
accepted	O
in	O
clinical	O
diagnosis	O
of	O
HIV	B-PATH
infection	I-PATH
,	O
they	O
may	O
not	O
be	O
sufficient	O
to	O
diagnose	O
all	O
subjects	O
with	O
HIV	B-PATH
infection	I-PATH
.	O

After	O
admission	O
,	O
HIV	B-PATH
infection	I-PATH
was	O
eventually	O
confirmed	O
by	O
plasma	O
HIV	O
RNA	O
testing	O
.	O

This	O
case	O
underscores	O
the	O
importance	O
of	O
plasma	O
RNA	O
test	O
in	O
conjunction	O
with	O
HIV	O
antibody	O
test	O
for	O
some	O
rare	O
patients	O
with	O
HIV	B-PATH
infection	I-PATH
who	O
present	O
with	O
severe	O
immunodeficiency	O
and	O
opportunistic	O
infections	O
or	O
malignancy	O
.	O

Asthma	B-PATH
was	O
the	O
most	O
common	O
co	O
-	O
morbidity	O
affecting	O
5	O
(	O
10	O
.	O
4	O
%)	O
of	O
the	O
48	O
cases	O
with	O
an	O
identified	O
virus	O
.	O

Examples	O
are	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
with	O
acute	O
flare	O
,	O
glomerulonephritis	O
,	O
CNS	O
disorders	O
and	O
catastrophic	O
antiphospholipid	O
syndrome	O
,	O
scleroderma	O
with	O
interstitial	O
lung	O
disease	O
,	O
pulmonary	O
hypertension	O
and	O
renal	O
crisis	O
and	O
polyangiitis	O
with	O
alveolar	O
haemorhage	O
and	O
acute	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
Resistance	O
to	O
Carbohydrate	O
-	O
Binding	O
Agents	O
.	O

TITLE	O
:	O
UK	O
malaria	B-PATH
treatment	O
guidelines	O
2016	O
.	O

ABSTRACT	O
:	O
1	O
.	O
Malaria	B-PATH
is	O
the	O
tropical	O
disease	O
most	O
commonly	O
imported	O
into	O
the	O
UK	O
,	O
with	O
1300	O
-	O
1800	O
cases	O
reported	O
each	O
year	O
,	O
and	O
2	O
-	O
11	O
deaths	O
.	O

Most	O
non	O
-	O
falciparum	O
malaria	B-PATH
cases	O
are	O
caused	O
by	O
Plasmodium	O
vivax	O
;	O
a	O
few	O
cases	O
are	O
caused	O
by	O
the	O
other	O
species	O
of	O
plasmodium	O
:	O
Plasmodium	O
ovale	O
,	O
Plasmodium	O
malariae	O
or	O
Plasmodium	O
knowlesi	O
.	O

Malaria	B-PATH
in	O
children	O
(	O
and	O
sometimes	O
in	O
adults	O
)	O
may	O
present	O
with	O
misleading	O
symptoms	O
such	O
as	O
gastrointestinal	O
features	O
,	O
sore	O
throat	O
or	O
lower	O
respiratory	O
complaints	O
.	O

P	O
.	O
falciparum	O
and	O
P	O
.	O
vivax	O
(	O
depending	O
upon	O
the	O
product	O
)	O
malaria	B-PATH
can	O
be	O
diagnosed	O
almost	O
as	O
accurately	O
using	O
rapid	O
diagnostic	O
tests	O
(	O
RDTs	O
)	O
which	O
detect	O
plasmodial	O
antigens	O
.	O

Most	O
patients	O
treated	O
for	O
P	O
.	O
falciparum	O
malaria	B-PATH
should	O
be	O
admitted	O
to	O
hospital	O
for	O
at	O
least	O
24	O
h	O
as	O
patients	O
can	O
deteriorate	O
suddenly	O
,	O
especially	O
early	O
in	O
the	O
course	O
of	O
treatment	O
.	O

Uncomplicated	O
P	O
.	O
falciparum	O
malaria	B-PATH
should	O
be	O
treated	O
with	O
an	O
artemisinin	O
combination	O
therapy	O
(	O
Grade	O
1A	O
).	O

Severe	O
malaria	B-PATH
is	O
a	O
rare	O
complication	O
of	O
P	O
.	O
vivax	O
or	O
P	O
.	O
knowlesi	O
infection	O
and	O
also	O
requires	O
parenteral	O
therapy	O
.	O

Patients	O
with	O
severe	O
or	O
complicated	O
malaria	B-PATH
should	O
be	O
managed	O
in	O
a	O
high	O
-	O
dependency	O
or	O
intensive	O
care	O
environment	O
.	O

Children	O
with	O
severe	O
malaria	B-PATH
should	O
also	O
be	O
treated	O
with	O
empirical	O
broad	O
spectrum	O
antibiotics	O
until	O
bacterial	O
infection	O
can	O
be	O
excluded	O
(	O
Grade	O
1B	O
).	O

Uncomplicated	O
falciparum	O
malaria	B-PATH
in	O
the	O
second	O
and	O
third	O
trimester	O
of	O
pregnancy	O
should	O
be	O
treated	O
with	O
artemether	O
-	O
lumefantrine	O
(	O
Grade	O
2B	O
).	O

Uncomplicated	O
falciparum	O
malaria	B-PATH
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
should	O
usually	O
be	O
treated	O
with	O
quinine	O
and	O
clindamycin	O
but	O
specialist	O
advice	O
should	O
be	O
sought	O
.	O

Severe	O
malaria	B-PATH
in	O
any	O
trimester	O
of	O
pregnancy	O
should	O
be	O
treated	O
as	O
for	O
any	O
other	O
patient	O
with	O
artesunate	O
preferred	O
over	O
quinine	O
(	O
Grade	O
1C	O
).	O

Either	O
an	O
oral	O
ACT	O
or	O
chloroquine	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
non	O
-	O
falciparum	O
malaria	B-PATH
.	O

Tie2	O
expression	O
declined	O
rapidly	O
in	O
wide	O
-	O
ranging	O
models	O
of	O
leak	O
-	O
associated	O
infections	O
,	O
including	O
anthrax	O
,	O
influenza	O
,	O
malaria	B-PATH
,	O
and	O
sepsis	O
.	O

Influenza	B-PATH
A	I-PATH
infection	O
was	O
observed	O
with	O
the	O
highest	O
rate	O
in	O
both	O
age	O
groups	O
.	O

RESULTS	O
:	O
At	O
least	O
one	O
respiratory	O
tract	O
pathogen	O
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
in	O
78	O
.	O
6	O
%	O
(	O
n	O
=	O
140	O
)	O
of	O
the	O
patients	O
:	O
influenza	B-PATH
A	I-PATH
33	O
.	O
5	O
%,	O
influenza	O
B	O
16	O
.	O
4	O
%,	O
respiratory	O
syncytial	O
virus	O
9	O
.	O
2	O
%,	O
adenovirus	O
7	O
.	O
8	O
%,	O
rhinovirus	O
7	O
.	O
1	O
%,	O
coronavirus	O
7	O
.	O
1	O
%,	O
human	O
metapneumovirus	O
5	O
.	O
7	O
%,	O
human	O
bocavirus	O
5	O
.	O
7	O
%,	O
parainfluenza	O
virus	O
3	O
.	O
5	O
%,	O
coinfection	O
2	O
.	O
8	O
%.	O

M	O
organizes	O
the	O
components	O
of	O
the	O
viral	O
membrane	O
,	O
and	O
interactions	O
of	O
M	O
with	O
itself	O
and	O
with	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
drive	O
virus	O
assembly	O
and	O
budding	B-PATH
.	O

Here	O
,	O
we	O
show	O
that	O
TRIM56	O
puts	O
a	O
check	O
on	O
replication	O
of	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
in	O
cell	O
culture	O
but	O
does	O
not	O
inhibit	O
Sendai	O
virus	O
or	O
human	O
metapneumovirus	O
,	O
two	O
paramyxoviruses	O
.	O

We	O
show	O
here	O
that	O
TRIM56	O
,	O
a	O
tripartite	O
-	O
motif	O
protein	O
,	O
is	O
an	O
intrinsic	O
host	O
restriction	O
factor	O
of	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
.	O

TITLE	O
:	O
[	O
Pulmonary	O
complications	O
of	O
malaria	B-PATH
:	O
An	O
update	O
].	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
the	O
most	O
important	O
parasitic	O
disease	O
worldwide	O
,	O
being	O
a	O
public	O
health	O
challenge	O
in	O
more	O
than	O
90	O
countries	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
is	O
the	O
most	O
severe	O
form	O
within	O
the	O
pulmonary	O
complications	O
of	O
malaria	B-PATH
,	O
with	O
high	O
mortality	O
despite	O
proper	O
management	O
.	O

Here	O
we	O
can	O
now	O
analyze	O
malaria	B-PATH
,	O
blood	O
gases	O
,	O
cell	O
counts	O
,	O
PK	O
-	O
value	O
,	O
liver	O
status	O
,	O
pneumococci	O
and	O
legionella	O
as	O
well	O
as	O
perform	O
routine	O
pre	O
-	O
transfusion	O
testing	O
.	O

In	O
light	O
of	O
the	O
broad	O
antiviral	O
activity	O
of	O
Î²	O
-	O
defensins	B-PATH
,	O
we	O
tested	O
the	O
antiviral	O
activity	O
of	O
11	O
peptides	O
derived	O
from	O
mouse	O
Î²	O
-	O
defensin	O
-	O
4	O
and	O
found	O
that	O
a	O
short	O
peptide	O
,	O
P9	O
,	O
exhibited	O
potent	O
and	O
broad	O
-	O
spectrum	O
antiviral	O
effects	O
against	O
multiple	O
respiratory	O
viruses	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
including	O
influenza	B-PATH
A	I-PATH
virus	O
H1N1	O
,	O
H3N2	O
,	O
H5N1	O
,	O
H7N7	O
,	O
H7N9	O
,	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
The	O
antiviral	O
activity	O
of	O
P9	O
was	O
attributed	O
to	O
its	O
high	O
-	O
affinity	O
binding	O
to	O
viral	O
glycoproteins	O
,	O
as	O
well	O
as	O
the	O
abundance	O
of	O
basic	O
amino	O
acids	O
in	O
its	O
composition	O
.	O

After	O
binding	O
viral	O
particles	O
through	O
viral	O
surface	O
glycoproteins	O
,	O
P9	O
entered	O
into	O
cells	O
together	O
with	O
the	O
viruses	O
via	O
endocytosis	B-PATH
and	O
prevented	O
endosomal	O
acidification	O
,	O
which	O
blocked	O
membrane	O
fusion	O
and	O
subsequent	O
viral	O
RNA	O
release	B-PATH
.	O

The	O
dose	O
of	O
methylprednisolone	O
was	O
tapered	O
to	O
0	O
.	O
25	O
mg	O
/(	O
kg	O
Â·	O
d	O
)	O
after	O
4	O
weeks	O
and	O
was	O
adjusted	O
according	O
to	O
the	O
occurrence	O
and	O
severity	O
of	O
chronic	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
(	O
cGVHD	O
).	O

Data	O
from	O
the	O
GO	O
analysis	O
indicated	O
that	O
the	O
target	O
genes	O
of	O
ribavirin	O
and	O
interferon	O
-	O
Î±	O
as	O
well	O
as	O
the	O
genes	O
from	O
the	O
microarray	O
were	O
mainly	O
enriched	O
in	O
10	O
biological	O
processes	O
,	O
including	O
cellular	O
process	O
,	O
metabolic	O
process	O
,	O
immune	O
system	O
process	O
and	O
biological	O
regulation	O
,	O
et	O
al	O
.	O
Data	O
on	O
drug	O
target	O
genes	O
,	O
first	O
and	O
second	O
cluster	O
of	O
microarray	O
would	O
involve	O
9	O
,	O
3	O
and	O
23	O
signaling	O
pathways	O
respectively	O
,	O
and	O
only	O
the	O
former	O
two	O
showed	O
7	O
common	O
pathways	O
,	O
which	O
were	O
related	O
to	O
pathogen	O
recognition	O
,	O
cytokine	O
release	B-PATH
and	O
autoimmune	O
response	O
.	O

TITLE	O
:	O
High	O
-	O
Resolution	O
Analysis	O
of	O
Coronavirus	O
Gene	O
Expression	O
by	O
RNA	O
Sequencing	O
and	O
Ribosome	B-PATH
Profiling	O
.	O

Ribosome	B-PATH
-	O
protected	O
mRNA	O
fragments	O
are	O
purified	O
,	O
subjected	O
to	O
deep	O
sequencing	O
and	O
mapped	O
back	O
to	O
the	O
transcriptome	O
to	O
give	O
a	O
global	O
""""	O
snap	O
-	O
shot	O
""""	O
of	O
translation	O
.	O

Here	O
we	O
apply	O
ribosome	B-PATH
profiling	O
to	O
cells	O
infected	O
with	O
Murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
,	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
),	O
a	O
model	O
coronavirus	O
in	O
the	O
same	O
genus	O
as	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
The	O
data	O
obtained	O
allowed	O
us	O
to	O
study	O
the	O
kinetics	O
of	O
virus	O
transcription	O
and	O
translation	O
with	O
exquisite	O
precision	O
.	O

Ribosome	B-PATH
pause	O
sites	O
were	O
identified	O
in	O
the	O
virus	O
replicase	O
polyprotein	O
pp1a	O
ORF	O
and	O
investigated	O
experimentally	O
.	O

By	O
sequencing	O
PCR	O
products	O
of	O
the	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
(	O
RdRp	O
),	O
we	O
found	O
a	O
high	O
frequency	O
of	O
infection	O
by	O
a	O
diverse	O
group	O
of	O
coronaviruses	O
in	O
different	O
bat	O
species	O
in	O
the	O
mineshaft	O
.	O

Moreover	O
,	O
melanoma	B-PATH
differentiation	O
-	O
associated	O
protein	O
5	O
(	O
MDA5	O
),	O
laboratory	O
of	O
genetics	O
and	O
physiology	O
2	O
(	O
LGP2	O
),	O
stimulator	O
of	O
IFN	O
genes	O
(	O
STING	O
),	O
and	O
mitochondrial	O
antiviral	O
signaling	O
protein	O
(	O
MAVS	O
),	O
as	O
well	O
as	O
TANK	O
binding	O
kinase	O
1	O
(	O
TBK1	O
),	O
inhibitor	O
of	O
kappaB	O
kinase	O
(	O
IKK	O
)	O
Îµ	O
,	O
IKKÎ±	O
,	O
IKKÎ²	O
,	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
7	O
,	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF	O
-	O
Ä¸B	O
),	O
IFN	O
-	O
Î±	O
,	O
IFN	O
-	O
Î²	O
,	O
various	O
interleukins	O
(	O
ILs	O
),	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
1Î²	O
(	O
MIP	O
-	O
1Î²	O
)	O
were	O
significantly	O
upregulated	O
in	O
the	O
trachea	O
and	O
downregulated	O
in	O
the	O
kidney	O
.	O

Inhaled	O
RBV	O
was	O
used	O
more	O
than	O
oral	O
,	O
and	O
in	O
the	O
post	O
-	O
stem	O
cell	O
transplant	O
population	O
,	O
patients	O
with	O
lower	O
respiratory	O
tract	O
infection	O
(	O
LRTI	O
),	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
,	O
and	O
more	O
recent	O
transplantation	O
were	O
treated	O
at	O
higher	O
rates	O
.	O

Using	O
extensive	O
multiplex	O
PCR	O
diagnostic	O
data	O
generated	O
by	O
the	O
largest	O
NHS	O
board	O
in	O
Scotland	O
,	O
we	O
analysed	O
44230	O
patient	O
episodes	O
of	O
respiratory	O
illness	O
that	O
were	O
simultaneously	O
tested	O
for	O
11	O
virus	O
groups	O
between	O
2005	O
and	O
2013	O
,	O
spanning	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
pandemic	O
.	O

Despite	O
of	O
anti	O
-	O
tuberculosis	B-PATH
therapy	O
,	O
ARDS	O
developed	O
in	O
a	O
few	O
days	O
requiring	O
continuous	O
positive	O
airway	O
pressure	O
treatment	O
.	O

ABSTRACT	O
:	O
To	O
design	O
an	O
alternative	O
vaccine	O
for	O
control	O
of	O
infectious	O
bronchitis	O
in	O
chickens	O
,	O
three	O
recombinant	O
duck	O
enteritis	O
viruses	O
(	O
rDEVs	O
)	O
expressing	O
the	O
N	O
,	O
S	O
,	O
or	O
S1	O
protein	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
constructed	O
using	O
conventional	O
homologous	B-PATH
recombination	I-PATH
methods	O
,	O
and	O
were	O
designated	O
as	O
rDEV	O
-	O
N	O
,	O
rDEV	O
-	O
S	O
,	O
and	O
rDEV	O
-	O
S1	O
,	O
respectively	O
.	O

TITLE	O
:	O
Glycopeptide	O
Antibiotics	O
Potently	O
Inhibit	O
Cathepsin	O
L	O
in	O
the	O
Late	O
Endosome	O
/	O
Lysosome	B-PATH
and	O
Block	O
the	O
Entry	O
of	O
Ebola	O
Virus	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
and	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Despite	O
low	O
vaccine	O
effectiveness	O
of	O
solely	O
one	O
component	O
,	O
A	O
/	O
H3N2	O
/,	O
the	O
vaccine	O
could	O
mitigate	O
or	O
shorten	O
the	O
length	O
of	O
influenza	B-PATH
infection	I-PATH
and	O
reduce	O
the	O
number	O
of	O
severe	O
outcomes	O
and	O
mortality	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
Plasmodium	O
vivax	O
malaria	B-PATH
.	O

TITLE	O
:	O
Disseminated	O
tuberculosis	B-PATH
with	O
acute	O
respiratory	O
distress	O
syndrome	O
lacking	O
granuloma	O
formation	O
in	O
the	O
lung	O
.	O

And	O
compound	O
4d	O
-	O
3	O
showed	O
the	O
most	O
effective	O
anti	O
-	O
HBV	O
activity	O
,	O
performing	O
strong	O
potent	O
inhibitory	O
not	O
only	O
on	O
the	O
secretion	O
of	O
HBsAg	O
(	O
IC50	O
=	O
58	O
.	O
28	O
Î¼M	O
,	O
SI	O
=	O
23	O
.	O
26	O
)	O
and	O
HBeAg	O
(	O
IC50	O
=	O
97	O
.	O
21	O
Î¼M	O
,	O
SI	O
=	O
13	O
.	O
95	O
),	O
but	O
also	O
on	O
the	O
HBV	O
DNA	B-PATH
replication	I-PATH
(	O
IC50	O
=	O
42	O
.	O
28	O
Î¼M	O
,	O
SI	O
=	O
32	O
.	O
06	O
).	O

ABSTRACT	O
:	O
The	O
proteasome	B-PATH
inhibitor	O
bortezomib	O
is	O
indicated	O
for	O
use	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
(	O
MM	O
)	O
patients	O
.	O

Inhibition	O
of	O
the	O
TRAIL	B-PATH
signaling	I-PATH
pathway	I-PATH
has	O
been	O
shown	O
to	O
improve	O
lung	O
injury	O
after	O
influenza	B-PATH
infection	I-PATH
,	O
and	O
future	O
studies	O
will	O
be	O
needed	O
to	O
determine	O
if	O
blocking	O
this	O
pathway	O
is	O
a	O
viable	O
option	O
in	O
the	O
treatment	O
of	O
ARDS	O
.	O

Alveolar	O
serum	O
amyloid	O
P	O
originated	O
,	O
in	O
part	O
,	O
from	O
the	O
release	B-PATH
of	O
serum	O
amyloid	O
P	O
associated	O
with	O
lung	O
connective	O
tissue	O
during	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
This	O
prospective	O
study	O
assessed	O
the	O
incidence	O
,	O
clinical	O
profile	O
and	O
outcome	O
of	O
malarial	O
hepatopathy	O
and	O
its	O
association	O
with	O
other	O
complications	O
in	O
patients	O
with	O
malaria	B-PATH
,	O
proved	O
by	O
peripheral	O
blood	O
smear	O
examination	O
and	O
rapid	O
malaria	B-PATH
test	O
.	O

Of	O
134	O
(	O
falciparum	O
-	O
81	O
,	O
vivax	O
-	O
48	O
and	O
mixed	O
falciparum	O
and	O
vivax	O
-	O
5	O
)	O
malaria	B-PATH
cases	O
,	O
hyperbilirubinemia	O
occurred	O
in	O
41	O
.	O
04	O
%.	O

Malarial	O
hepatopathy	O
was	O
observed	O
in	O
4	O
.	O
47	O
%	O
(	O
falciparum	O
-	O
5	O
and	O
vivax	O
malaria	B-PATH
-	O
1	O
)	O
cases	O
,	O
but	O
had	O
insignificant	O
association	O
with	O
the	O
type	O
of	O
malaria	B-PATH
(	O
p	O
=	O
0	O
.	O
532	O
).	O

Serum	O
bilirubin	O
,	O
AST	O
and	O
ALT	O
levels	O
were	O
higher	O
while	O
age	O
was	O
lower	O
in	O
both	O
overall	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
falciparum	O
malaria	B-PATH
cases	O
with	O
hepatopathy	O
than	O
without	O
hepatopathy	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
).	O

Malarial	O
hepatopathy	O
had	O
significant	O
association	O
with	O
duration	O
of	O
hospitalization	O
,	O
parasite	O
clearance	O
time	O
,	O
fever	O
clearance	O
time	O
and	O
jaundice	O
clearance	O
time	O
in	O
overall	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
falciparum	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
but	O
not	O
vivax	O
malaria	B-PATH
cases	O
(	O
p	O
>	O
0	O
.	O
05	O
each	O
).	O

Thus	O
,	O
hepatocellular	O
dysfunction	O
is	O
common	O
in	O
malaria	B-PATH
but	O
that	O
qualifying	O
as	O
malarial	O
hepatopathy	O
is	O
not	O
common	O
.	O

ABSTRACT	O
:	O
All	O
viruses	O
that	O
carry	O
a	O
positive	O
-	O
sense	O
RNA	O
genome	O
(+	O
RNA	O
),	O
such	O
as	O
picornaviruses	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
dengue	O
virus	O
,	O
and	O
SARS	O
-	O
and	O
MERS	O
-	O
coronavirus	O
,	O
confiscate	O
intracellular	O
membranes	O
of	O
the	O
host	O
cell	O
to	O
generate	O
new	O
compartments	O
(	O
i	O
.	O
e	O
.,	O
replication	O
organelles	O
)	O
for	O
amplification	O
of	O
their	O
genome	O
.	O

Airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
is	O
a	O
recognized	O
treatment	O
for	O
mechanically	O
-	O
ventilated	O
patients	O
with	O
severe	O
hypoxaemia	O
.	O

TITLE	O
:	O
Mitophagy	O
in	O
TGEV	O
infection	O
counteracts	O
oxidative	O
stress	O
and	O
apoptosis	B-PATH
.	O

Here	O
,	O
we	O
report	O
that	O
TGEV	O
induces	O
mitophagy	O
to	O
suppress	O
oxidative	O
stress	O
and	O
apoptosis	B-PATH
induced	O
by	O
viral	O
infection	O
in	O
porcine	O
epithelial	O
cells	O
(	O
IPEC	O
-	O
J2	O
).	O

We	O
observe	O
that	O
TGEV	O
infection	O
induce	O
mitochondrial	O
injury	O
,	O
abnormal	O
morphology	O
,	O
complete	O
mitophagy	O
,	O
and	O
without	O
obvious	O
apoptosis	B-PATH
after	O
TGEV	O
infection	O
.	O

Because	O
the	O
nasopharyngeal	O
seasonal	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
test	O
was	O
positive	O
,	O
the	O
patient	O
was	O
admitted	O
with	O
the	O
diagnosis	O
of	O
acute	O
exacerbation	O
of	O
COPD	O
due	O
to	O
IAV	O
.	O

These	O
results	O
suggest	O
that	O
the	O
alveolar	O
release	B-PATH
of	O
sRAGE	O
may	O
play	O
a	O
protective	O
role	O
against	O
HMGB1	O
as	O
well	O
as	O
exogenous	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
42	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
who	O
presented	O
with	O
severe	O
ARDS	O
from	O
Bordetella	O
pertussis	B-PATH
,	O
5	O
years	O
after	O
bilateral	O
sequential	O
lung	O
transplant	O
for	O
cystic	O
fibrosis	O
.	O

Some	O
clinical	O
situations	O
especially	O
affect	O
RV	O
load	O
during	O
inspiration	O
,	O
for	O
example	O
acute	O
asthma	B-PATH
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Detailed	O
methods	O
are	O
presented	O
for	O
expression	O
,	O
purification	O
,	O
and	O
release	B-PATH
testing	O
of	O
SARS	O
recombinant	O
spike	O
protein	O
antigen	O
,	O
followed	O
by	O
adjuvant	O
formulation	O
and	O
animal	O
testing	O
.	O

The	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
),	O
one	O
of	O
the	O
primary	O
cardiovascular	O
regulatory	O
systems	O
,	O
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
lung	O
disease	O
.	O

Scientists	O
are	O
looking	O
to	O
implement	O
viral	O
sequencing	O
on	O
all	O
negative	O
samples	O
by	O
RT	O
-	O
PCR	O
and	O
they	O
beleive	O
that	O
can	O
be	O
exposed	O
to	O
another	O
level	O
of	O
testing	O
using	O
sequencing	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
or	O
N	O
gene	O
and	O
in	O
this	O
case	O
a	O
positive	O
result	O
is	O
diagnostic	O
.	O

A	O
viral	O
aetiology	O
was	O
detected	O
in	O
half	O
(	O
50	O
.	O
3	O
%)	O
of	O
the	O
cases	O
,	O
with	O
rhinoviruses	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
and	O
H3N2	O
),	O
and	O
influenza	O
B	O
being	O
most	O
frequent	O
.	O

Respiratory	O
tract	O
infections	O
in	O
travellers	O
/	O
pilgrims	O
returning	O
to	O
the	O
UK	O
from	O
the	O
Middle	O
East	O
are	O
mainly	O
due	O
to	O
rhinoviruses	O
,	O
influenza	B-PATH
A	I-PATH
,	O
and	O
influenza	O
B	O
.	O
Whilst	O
MERS	O
-	O
CoV	O
was	O
not	O
detected	O
in	O
the	O
202	O
patients	O
studied	O
,	O
heightened	O
awareness	O
of	O
the	O
possibility	O
of	O
MERS	O
-	O
CoV	O
and	O
continuous	O
proactive	O
surveillance	O
are	O
essential	O
to	O
rapidly	O
identify	O
cases	O
of	O
MERS	O
-	O
CoV	O
and	O
other	O
seasonal	O
respiratory	O
tract	O
viruses	O
such	O
as	O
avian	O
influenza	O
,	O
in	O
patients	O
presenting	O
to	O
hospital	O
.	O

A	O
total	O
of	O
284	O
clinical	O
respiratory	O
specimens	O
and	O
3	O
influenza	B-PATH
A	I-PATH
/	O
H7N9	O
viral	O
culture	O
samples	O
were	O
tested	O
.	O

TITLE	O
:	O
THE	O
PATIENT	O
-	O
DOCTOR	O
-	O
PSYCHOLOGIST	O
TRIANGLE	O
IN	O
A	O
CASE	O
Of	O
SEVERE	O
IMUNOSUPRESSION	O
IN	O
THE	O
HIV	B-PATH
INFECTION	I-PATH
.	O

While	O
the	O
majority	O
of	O
respondents	O
used	O
low	O
-	O
Vt	O
ventilation	O
(	O
81	O
%),	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
86	O
%),	O
recruitment	O
maneuvers	O
(	O
89	O
%),	O
and	O
either	O
bolus	O
or	O
infusion	O
neuromuscular	O
blockade	O
(	O
94	O
%),	O
there	O
was	O
marked	O
variability	O
in	O
the	O
use	O
of	O
specific	O
rescue	O
strategies	O
as	O
tier	O
1	O
or	O
2	O
interventions	O
:	O
prone	O
position	O
(	O
27	O
.	O
8	O
%	O
vs	O
.	O
47	O
.	O
8	O
%,	O
respectively	O
),	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
2	O
.	O
3	O
%	O
vs	O
.	O
51	O
.	O
2	O
%,	O
respectively	O
),	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
49	O
%	O
vs	O
.	O
34	O
.	O
5	O
%,	O
respectively	O
),	O
inhaled	O
vasodilators	O
(	O
30	O
.	O
1	O
%	O
vs	O
.	O
40	O
%,	O
respectively	O
),	O
and	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
7	O
.	O
8	O
%	O
vs	O
.	O
40	O
%,	O
respectively	O
).	O

However	O
,	O
malaria	B-PATH
remains	O
by	O
far	O
the	O
most	O
important	O
cause	O
of	O
death	O
.	O

The	O
review	O
includes	O
verotoxin	O
-	O
producing	O
Escherichia	O
coli	O
O104	O
:	O
H4	O
infections	O
,	O
MERS	O
-	O
CoV	O
infections	O
,	O
Ebola	O
virus	O
disease	O
,	O
malaria	B-PATH
,	O
dengue	O
fever	O
,	O
West	O
Nile	O
fever	O
,	O
chikungunya	O
and	O
cholera	O
.	O

ABSTRACT	O
:	O
The	O
cytoplasmic	O
tails	O
of	O
some	O
coronavirus	O
(	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
proteins	O
contain	O
an	O
endoplasmic	O
reticulum	O
retrieval	O
signal	O
(	O
ERRS	O
)	O
that	O
can	O
retrieve	O
S	O
proteins	O
from	O
the	O
Golgi	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
);	O
this	O
process	O
is	O
thought	O
to	O
accumulate	O
S	O
proteins	O
at	O
the	O
CoV	O
budding	B-PATH
site	O
,	O
the	O
ER	O
-	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
),	O
and	O
to	O
facilitate	O
S	O
protein	O
incorporation	O
into	O
virions	O
.	O

It	O
is	O
associated	O
with	O
a	O
number	O
of	O
conditions	O
including	O
diabetes	O
,	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
,	O
multiple	O
sclerosis	O
,	O
previous	O
abdominal	O
surgeries	O
and	O
connective	O
tissue	O
disorders	O
,	O
including	O
scleroderma	O
and	O
Ehlers	O
-	O
Danlos	O
syndrome	O
.	O

A	O
coupled	O
in	O
silico	O
/	O
in	O
vitro	O
investigation	O
was	O
employed	O
to	O
formulate	O
a	O
molecular	O
rationale	O
explaining	O
the	O
notable	O
affinity	O
of	O
all	O
molecules	O
to	O
BVDV	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
NS5B	O
.	O

TITLE	O
:	O
Conundrum	O
in	O
an	O
asthma	B-PATH
exacerbation	O
.	O

ABSTRACT	O
:	O
A	O
66	O
-	O
year	O
-	O
old	O
man	O
,	O
an	O
asthmatic	O
,	O
presented	O
with	O
symptoms	O
suggestive	O
of	O
an	O
acute	O
exacerbation	O
of	O
asthma	B-PATH
.	O

An	O
alternate	O
diagnosis	O
of	O
acute	O
coronary	O
syndrome	O
with	O
acute	O
pulmonary	O
oedema	O
was	O
made	O
and	O
his	O
asthma	B-PATH
treatment	O
was	O
stopped	O
.	O

SILA	O
is	O
a	O
relatively	O
common	O
complication	O
of	O
salbutamol	O
therapy	O
in	O
moderate	O
/	O
severe	O
asthma	B-PATH
exacerbations	O
.	O

It	O
is	O
caused	O
by	O
a	O
mechanism	O
different	O
from	O
the	O
lactataemia	O
that	O
is	O
associated	O
with	O
septic	O
shock	O
and	O
life	O
-	O
threatening	O
asthma	B-PATH
.	O

The	O
results	O
showed	O
that	O
pretreatment	O
with	O
QF	O
significantly	O
inhibits	O
the	O
release	B-PATH
of	O
cytokines	O
(	O
TNF	O
-	O
Î±	O
and	O
IL	O
-	O
6	O
)	O
and	O
chemokines	O
(	O
IL	O
-	O
8	O
and	O
RANTES	O
),	O
reduces	O
leukocytes	O
recruitment	O
into	O
inflamed	O
tissues	O
and	O
ameliorates	O
pulmonary	O
edema	O
and	O
necrosis	O
.	O

CLA	O
and	O
CGA	O
enhanced	O
the	O
actions	O
of	O
ATG	O
and	O
exhibited	O
synergistic	O
NF	O
-	O
ÎºB	O
inactivation	O
effects	O
possibly	O
via	O
the	O
Ras	O
/	O
MAPK	B-PATH
signaling	I-PATH
pathway	I-PATH
.	O

TITLE	O
:	O
[	O
Plasmodium	O
falciparum	O
malaria	B-PATH
:	O
evaluation	O
of	O
three	O
imported	O
cases	O
].	O

ABSTRACT	O
:	O
Among	O
Plasmodium	O
species	O
the	O
causative	O
agent	O
of	O
malaria	B-PATH
in	O
Turkey	O
is	O
P	O
.	O
vivax	O
,	O
however	O
the	O
incidence	O
of	O
imported	O
falciparum	O
malaria	B-PATH
cases	O
is	O
steadily	O
increasing	O
.	O

P	O
.	O
falciparum	O
may	O
cause	O
severe	O
malaria	B-PATH
with	O
the	O
involvement	O
of	O
central	O
nervous	O
system	O
,	O
acute	O
renal	O
failure	O
,	O
severe	O
anemia	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Furhermore	O
most	O
of	O
the	O
casualties	O
due	O
to	O
malaria	B-PATH
are	O
related	O
with	O
P	O
.	O
falciparum	O
.	O

In	O
this	O
report	O
,	O
three	O
cases	O
,	O
who	O
have	O
admitted	O
to	O
our	O
hospital	O
with	O
three	O
different	O
clinical	O
presentations	O
of	O
falciparum	O
malaria	B-PATH
,	O
and	O
all	O
shared	O
common	O
history	O
of	O
travelling	O
to	O
Africa	O
were	O
presented	O
.	O

However	O
,	O
visual	O
defects	O
due	O
to	O
retinopathy	O
and	O
severe	O
neurocognitive	O
impairment	O
that	O
were	O
thought	O
to	O
be	O
the	O
complications	O
of	O
malaria	B-PATH
continued	O
in	O
his	O
follow	O
-	O
ups	O
.	O

As	O
a	O
result	O
,	O
it	O
should	O
be	O
keep	O
in	O
mind	O
that	O
both	O
the	O
African	O
students	O
who	O
have	O
come	O
to	O
our	O
country	O
for	O
education	O
from	O
endemic	O
regions	O
and	O
as	O
well	O
as	O
the	O
returned	O
citizens	O
of	O
our	O
country	O
who	O
have	O
gone	O
to	O
work	O
in	O
endemic	O
areas	O
,	O
are	O
under	O
risk	O
of	O
malaria	B-PATH
and	O
it	O
is	O
very	O
important	O
to	O
consider	O
malaria	B-PATH
in	O
the	O
distinctive	O
diagnosis	O
of	O
patients	O
with	O
the	O
complaints	O
of	O
fever	O
,	O
headache	O
,	O
nausea	O
,	O
vomiting	O
and	O
muscle	O
pain	O
.	O

ABSTRACT	O
:	O
Bats	O
have	O
been	O
demonstrated	O
to	O
be	O
natural	O
reservoirs	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
CoV	O
.	O
Faecal	O
samples	O
from	O
248	O
individuals	O
of	O
20	O
bat	O
species	O
were	O
tested	O
for	O
partial	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
of	O
CoV	O
and	O
57	O
faecal	O
samples	O
from	O
eight	O
bat	O
species	O
were	O
tested	O
positive	O
.	O

Overall	O
,	O
22	O
contributions	O
covering	O
a	O
broad	O
array	O
of	O
diseases	O
are	O
featured	O
-	O
i	O
.	O
e	O
.	O
clonorchiasis	O
,	O
dengue	O
,	O
hepatitis	O
,	O
human	O
immunodeficiency	O
virus	O
/	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
HIV	O
/	O
AIDS	O
),	O
H7N9	O
avian	O
influenza	O
,	O
lymphatic	O
filariasis	O
,	O
malaria	B-PATH
,	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
rabies	O
,	O
schistosomiasis	O
and	O
tuberculosis	B-PATH
(	O
TB	O
).	O

Lung	O
tissues	O
were	O
harvested	O
for	O
histological	O
and	O
TUNEL	O
staining	O
and	O
western	O
blot	O
for	O
RIP3	O
,	O
p	O
-	O
RIP3	O
,	O
X	O
-	O
linked	O
inhibitor	O
of	O
apoptosis	B-PATH
protein	O
(	O
XIAP	O
),	O
mixed	O
lineage	O
kinase	O
domain	O
-	O
like	O
protein	O
(	O
MLKL	O
),	O
total	O
and	O
cleaved	O
caspases	O
-	O
3	O
/	O
8	O
.	O

In	O
LPS	O
-	O
induced	O
severe	O
ARDS	O
,	O
RIP3	O
knock	O
-	O
out	O
alleviated	O
the	O
hypothermia	O
symptom	O
,	O
increased	O
survival	O
rate	O
and	O
ameliorated	O
the	O
lung	O
tissue	O
injury	O
RIP3	O
depletion	O
also	O
attenuated	O
LPS	O
-	O
induced	O
increase	O
in	O
IL	O
-	O
1Î±	O
/	O
Î²	O
,	O
IL	O
-	O
6	O
and	O
HMGB1	O
release	B-PATH
,	O
decreased	O
tissue	O
MPO	O
activity	O
,	O
and	O
reduced	O
neutrophil	O
influx	O
and	O
total	O
protein	O
concentration	O
in	O
BALF	O
in	O
severe	O
ARDS	O
.	O

Aerosolised	O
bronchodilators	O
are	O
useful	O
in	O
mechanically	O
ventilated	O
patients	O
with	O
asthma	B-PATH
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
but	O
are	O
not	O
recommended	O
for	O
those	O
with	O
ARDS	O
.	O

Furthermore	O
,	O
direct	O
pharmacological	O
inhibition	O
of	O
p38	O
MAPK	O
or	O
JNK1	O
/	O
2	O
activation	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
viral	O
RNA	O
synthesis	O
,	O
viral	O
protein	O
expression	O
,	O
and	O
progeny	O
release	B-PATH
.	O

However	O
,	O
independent	O
treatments	O
with	O
either	O
SAPK	O
inhibitor	O
did	O
not	O
inhibit	O
PEDV	O
-	O
induced	O
apoptotic	O
cell	O
death	O
mediated	O
by	O
activation	O
of	O
mitochondrial	O
apoptosis	B-PATH
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
suggesting	O
that	O
SAPKs	O
are	O
irrelevant	O
to	O
the	O
apoptosis	B-PATH
pathway	O
during	O
PEDV	O
infection	O
.	O

Respiratory	O
tract	O
infections	O
,	O
ENT	O
infections	O
,	O
influenza	O
,	O
pyogenic	O
pneumonia	O
,	O
whooping	O
cough	O
,	O
and	O
tuberculosis	B-PATH
are	O
most	O
frequently	O
observed	O
during	O
the	O
Hajj	O
.	O

RESULTS	O
:	O
Respiratory	O
tract	O
infections	O
,	O
ENT	O
infections	O
,	O
influenza	O
,	O
pyogenic	O
pneumonia	O
,	O
whooping	O
cough	O
,	O
and	O
tuberculosis	B-PATH
are	O
most	O
frequently	O
observed	O
during	O
the	O
Hajj	O
.	O

In	O
the	O
last	O
decade	O
,	O
interfering	O
with	O
microtubule	O
polymerization	O
,	O
a	O
potential	O
orientation	O
to	O
cause	O
cell	B-PATH
cycle	I-PATH
arrest	O
and	O
apoptosis	B-PATH
has	O
become	O
a	O
promising	O
method	O
for	O
cancer	O
therapy	O
.	O

Both	O
SARI	O
and	O
AFI	O
surveillance	O
yielded	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
(	O
3	O
%	O
versus	O
1	O
%),	O
A	O
(	O
H1N1	O
)	O
pdm09	O
(	O
2	O
%	O
versus	O
1	O
%),	O
and	O
influenza	O
B	O
(	O
3	O
%	O
versus	O
4	O
%)	O
in	O
similar	O
proportions	O
.	O

TITLE	O
:	O
Homology	O
-	O
Based	O
Identification	O
of	O
a	O
Mutation	O
in	O
the	O
Coronavirus	O
RNA	O
-	O
Dependent	O
RNA	B-PATH
Polymerase	I-PATH

Specificity	O
of	O
the	O
RT	O
-	O
LAMP	O
assay	O
was	O
validated	O
by	O
cross	O
-	O
reaction	O
with	O
different	O
human	O
coronaviruses	O
,	O
norovirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
and	O
influenza	O
B	O
virus	O
.	O

Recent	O
efforts	O
of	O
antiviral	O
lead	O
discovery	O
for	O
RNA	O
targets	O
have	O
provided	O
drug	O
-	O
like	O
small	O
molecules	O
that	O
inhibit	O
viral	O
replication	O
and	O
include	O
inhibitors	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
severe	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
),	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

Ethanolic	O
extracts	O
from	O
leaves	O
and	O
flowers	O
displayed	O
the	O
highest	O
inhibitory	O
activity	O
against	O
acetylcholinesterase	O
and	O
butyrylcholinesterase	O
,	O
showing	O
potential	O
properties	O
against	O
Alzheimer	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
.	O

With	O
existing	O
multiplexed	O
diagnostic	O
technologies	O
,	O
such	O
a	O
system	O
could	O
be	O
combined	O
with	O
existing	O
public	O
health	O
screening	O
and	O
reference	O
laboratory	O
systems	O
for	O
malaria	B-PATH
,	O
dengue	O
,	O
and	O
common	O
bacteremia	O
or	O
be	O
used	O
to	O
develop	O
such	O
an	O
infrastructure	O
in	O
less	O
-	O
developed	O
locations	O
.	O

The	O
identify	O
-	O
isolate	O
-	O
inform	O
(	O
3I	O
)	O
tool	O
,	O
originally	O
conceived	O
for	O
initial	O
detection	O
and	O
management	O
of	O
Ebola	O
virus	O
disease	O
patients	O
in	O
the	O
ED	O
,	O
and	O
later	O
adjusted	O
for	O
measles	B-PATH
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
,	O
can	O
be	O
adapted	O
for	O
real	O
-	O
time	O
use	O
for	O
any	O
emerging	O
infectious	O
disease	O
.	O

Children	O
who	O
are	O
exposed	O
to	O
secondhand	O
smoke	O
are	O
at	O
increased	O
risk	O
for	O
sudden	O
infant	O
death	O
syndrome	O
,	O
acute	O
respiratory	O
infections	O
,	O
middle	O
ear	O
disease	O
,	O
more	O
severe	O
asthma	B-PATH
,	O
respiratory	O
symptoms	O
,	O
and	O
slowed	O
lung	O
growth	O
(	O
1	O
,	O
2	O
).	O

Remarkable	O
beneficial	O
effects	O
of	O
IL	O
-	O
6	O
blockade	O
therapy	O
using	O
a	O
humanized	O
anti	O
-	O
IL	O
-	O
6	O
receptor	O
antibody	O
,	O
tocilizumab	O
were	O
recently	O
observed	O
in	O
patients	O
with	O
cytokine	O
release	B-PATH
syndrome	O
complicated	O
by	O
T	O
-	O
cell	O
engaged	O
therapy	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
clinical	O
effects	O
of	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
in	O
patients	O
suffering	O
from	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O
e	O
of	O
a	O
patient	O
presented	O
with	O
significant	O
high	O
aminotransferase	O
levels	O
due	O
to	O
the	O
first	O
human	O
R	O
.	O
aeschlimannii	O
infection	O
ever	O
detected	O
in	O
Italy	O
.	O

In	O
the	O
first	O
group	O
(	O
APRV	O
)	O
the	O
airway	O
pressure	O
release	B-PATH
ventilation	O
was	O
used	O
;	O
the	O
second	O
group	O
(	O
SIMV	O
)	O
was	O
ventilated	O
using	O
synchronized	O
intermittent	O
mandatory	O
ventilation	O
mode	O
and	O
positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	O
).	O

Here	O
,	O
we	O
review	O
the	O
strategies	O
exploited	O
by	O
coronavirus	O
to	O
modulate	O
cellular	O
stress	B-PATH
response	I-PATH
pathways	O
.	O

TITLE	O
:	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Infection	O
Inhibits	O
Interferon	B-PATH
Signaling	I-PATH
by	O
Targeted	O
Degradation	O
of	O
STAT1	O
.	O

STAT1	O
downregulation	O
was	O
blocked	O
by	O
a	O
proteasome	B-PATH
inhibitor	O
but	O
not	O
by	O
an	O
autophagy	O
inhibitor	O
,	O
strongly	O
implicating	O
the	O
ubiquitin	O
-	O
proteasome	B-PATH
targeting	O
degradation	O
system	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
infects	O
a	O
variety	O
of	O
animals	O
,	O
birds	O
and	O
humans	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
severe	O
pulmonary	O
tuberculosis	B-PATH
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
:	O
A	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

ABSTRACT	O
:	O
Mortality	O
in	O
patients	O
with	O
pulmonary	O
tuberculosis	B-PATH
remains	O
high	O
,	O
especially	O
in	O
those	O
who	O
develop	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
report	O
on	O
a	O
-	O
48	O
-	O
year	O
-	O
old	O
man	O
with	O
ARDS	O
due	O
to	O
severe	O
pulmonary	O
tuberculosis	B-PATH
who	O
was	O
rescued	O
by	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Whole	O
exome	O
sequencing	O
revealed	O
biallelic	O
missense	O
mutations	O
in	O
the	O
NSMCE3	O
(	O
also	O
known	O
as	O
NDNL2	O
)	O
gene	O
,	O
which	O
encodes	O
a	O
subunit	O
of	O
the	O
SMC5	O
/	O
6	O
complex	O
that	O
is	O
essential	O
for	O
DNA	B-PATH
damage	I-PATH
response	I-PATH
and	O
chromosome	O
segregation	O
.	O

TITLE	O
:	O
Korean	O
Asthma	B-PATH
Guideline	O
2014	O
:	O
Summary	O
of	O
Major	O
Updates	O
to	O
the	O
Korean	O
Asthma	B-PATH
Guideline	O
2014	O
.	O

This	O
guideline	O
focuses	O
on	O
adult	O
patients	O
with	O
asthma	B-PATH
and	O
aims	O
to	O
deliver	O
up	O
to	O
date	O
scientific	O
evidence	O
and	O
recommendations	O
to	O
general	O
physicians	O
for	O
the	O
management	O
of	O
asthma	B-PATH
.	O

Updated	O
issues	O
include	O
recommendations	O
derived	O
using	O
the	O
population	O
,	O
intervention	O
,	O
comparison	O
,	O
and	O
outcomes	O
(	O
PICO	O
)	O
model	O
,	O
which	O
produced	O
20	O
clinical	O
questions	O
on	O
the	O
management	O
of	O
asthma	B-PATH
.	O

This	O
guideline	O
includes	O
clinical	O
assessments	O
,	O
and	O
treatment	O
of	O
asthma	B-PATH
-	O
chronic	O
obstructive	O
pulmonary	O
disease	O
overlap	O
syndrome	O
,	O
management	O
of	O
asthma	B-PATH
in	O
specific	O
conditions	O
including	O
severe	O
asthma	B-PATH
,	O
elderly	O
asthma	B-PATH
,	O
cough	O
variant	O
asthma	B-PATH
,	O
exercise	O
-	O
induced	O
bronchial	O
contraction	O
,	O
etc	O
.	O

The	O
revised	O
Korean	O
Asthma	B-PATH
Guideline	O
is	O
expected	O
to	O
be	O
a	O
useful	O
resource	O
in	O
the	O
management	O
of	O
asthma	B-PATH
.	O

Applying	O
the	O
same	O
process	O
used	O
to	O
trace	O
and	O
notify	O
travelers	O
during	O
routine	O
investigations	O
,	O
such	O
as	O
those	O
for	O
tuberculosis	B-PATH
or	O
measles	B-PATH
,	O
CDC	O
was	O
able	O
to	O
notify	O
most	O
travelers	O
of	O
their	O
potential	O
exposure	O
to	O
MERS	O
-	O
CoV	O
during	O
the	O
first	O
few	O
days	O
of	O
each	O
investigation	O
.	O

This	O
work	O
examines	O
the	O
available	O
strategies	O
for	O
overcoming	O
the	O
obstacles	O
of	O
assembling	O
the	O
long	O
and	O
complex	O
RNA	O
genomes	O
of	O
coronaviruses	O
and	O
reports	O
one	O
-	O
step	O
construction	O
of	O
an	O
infectious	O
clone	O
system	O
for	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
by	O
homologous	B-PATH
recombination	I-PATH
in	O
S	O
.	O
cerevisiae	O
.	O

TITLE	O
:	O
Tubulins	O
interact	O
with	O
porcine	O
and	O
human	O
S	O
proteins	O
of	O
the	O
genus	O
Alphacoronavirus	O
and	O
support	O
successful	O
assembly	O
and	O
release	B-PATH
of	O
infectious	O
viral	O
particles	O
.	O

Furthermore	O
,	O
drug	O
-	O
induced	O
microtubule	O
depolymerization	O
led	O
to	O
changes	O
in	O
spike	O
protein	O
distribution	O
,	O
a	O
reduction	O
in	O
the	O
release	B-PATH
of	O
infectious	O
virus	O
particles	O
and	O
less	O
amount	O
of	O
spike	O
protein	O
incorporated	O
into	O
virions	O
.	O

Patients	O
had	O
history	O
&	O
physical	O
,	O
CRP	O
,	O
hemogram	O
and	O
nasopharyngeal	O
swabs	O
for	O
rhinovirus	O
A	O
/	O
B	O
,	O
influenza	B-PATH
A	I-PATH
/	O
B	O
,	O
adenovirus	O
A	O
/	O
B	O
/	O
C	O
/	O
D	O
/	O
E	O
,	O
coronavirus	O
229E	O
/	O
NL63	O
and	O
OC43	O
,	O
parainfluenza	O
virus	O
1	O
/	O
2	O
/	O
3	O
,	O
respiratory	O
syncytial	O
virusA	O
/	O
B	O
,	O
metapneumovirus	O
and	O
Mycoplasma	O
pneumoniae	O
,	O
Chlamydia	O
pneumoniae	O
,	O
Legionella	O
pneumophila	O
and	O
Bordetella	O
pertussis	B-PATH
by	O
PCR	O
and	O
for	O
ABHS	O
culture	O
.	O

Atypical	O
organisms	O
and	O
Bordetella	O
pertussis	B-PATH
were	O
negative	O
in	O
all	O
but	O
one	O
patient	O
.	O

The	O
role	O
these	O
viruses	O
play	O
in	O
patients	O
with	O
chronic	O
lung	O
disease	O
such	O
as	O
asthma	B-PATH
makes	O
the	O
search	O
for	O
antiviral	O
agents	O
of	O
increased	O
importance	O
.	O

We	O
next	O
showed	O
in	O
vitro	O
that	O
infection	O
of	O
LSECs	O
by	O
the	O
virulent	O
MHV3	O
strain	O
altered	O
their	O
production	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
and	O
promoted	O
higher	O
release	B-PATH
of	O
proinflammatory	O
and	O
procoagulant	O
factors	O
and	O
earlier	O
cell	O
damage	O
than	O
infection	O
by	O
attenuated	O
strains	O
.	O

TITLE	O
:	O
First	O
human	O
case	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N6	O
)	O
in	O
Yunnan	O
province	O
,	O
China	O
.	O

Compared	O
with	O
children	O
with	O
other	O
enteroviruses	O
and	O
rhinoviruses	O
,	O
children	O
with	O
enterovirus	O
D68	O
were	O
more	O
likely	O
to	O
have	O
a	O
history	O
of	O
asthma	B-PATH
(	O
64	O
%	O
vs	O
45	O
%)	O
or	O
multiple	O
prior	O
wheezing	O
episodes	O
(	O
54	O
%	O
vs	O
34	O
%;	O
p	O
<	O
0	O
.	O
01	O
for	O
both	O
).	O

Interestingly	O
,	O
Hx	O
-	O
XO	O
-	O
derived	O
ROS	O
induced	O
the	O
same	O
biphasic	O
effect	O
on	O
the	O
phosphorylation	O
of	O
the	O
focal	B-PATH
adhesion	I-PATH
kinase	O
(	O
FAK	O
),	O
a	O
nonreceptor	O
tyrosine	O
kinase	O
critical	O
for	O
cell	O
adhesion	O
,	O
but	O
not	O
on	O
ERK1	O
/	O
2	O
phosphorylation	O
.	O

TITLE	O
:	O
Trend	O
and	O
manifestations	O
of	O
falciparum	O
malaria	B-PATH
in	O
a	O
tertiary	O
care	O
hospital	O
of	O
India	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
analyze	O
the	O
trend	O
and	O
manifestations	O
of	O
falciparum	O
malaria	B-PATH
in	O
a	O
tertiary	O
care	O
hospital	O
.	O

Manifestations	O
of	O
severe	O
falciparum	O
malaria	B-PATH
included	O
hepatopathy	O
(	O
38	O
%),	O
renal	O
failure	O
(	O
28	O
%),	O
shock	O
(	O
9	O
%),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
7	O
%),	O
hypoglycemia	O
(	O
3	O
%),	O
and	O
severe	O
anemia	O
(	O
1	O
%).	O

Falciparum	O
malaria	B-PATH
is	O
more	O
among	O
younger	O
adult	O
age	O
group	O
and	O
males	O
.	O

Complications	O
and	O
mortality	O
are	O
also	O
more	O
due	O
to	O
falciparum	O
malaria	B-PATH
.	O

CONCLUSIONS	O
:	O
Falciparum	O
malaria	B-PATH
is	O
more	O
among	O
younger	O
adult	O
age	O
group	O
and	O
males	O
.	O

TITLE	O
:	O
Discovery	O
of	O
a	O
Potent	O
Acyclic	O
,	O
Tripeptidic	O
,	O
Acyl	O
Sulfonamide	O
Inhibitor	O
of	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
NS3	O
Protease	O
as	O
a	O
Back	O
-	O
up	O
to	O
Asunaprevir	O
with	O
the	O
Potential	O
for	O
Once	O
-	O
Daily	O
Dosing	O
.	O

TITLE	O
:	O
MERS	O
coronavirus	O
induces	O
apoptosis	B-PATH
in	O
kidney	O
and	O
lung	O
by	O
upregulating	O
Smad7	O
and	O
FGF2	O
.	O

Furthermore	O
,	O
MERS	O
-	O
CoV	O
induced	O
apoptosis	B-PATH
through	O
upregulation	O
of	O
Smad7	O
and	O
fibroblast	O
growth	O
factor	O
2	O
(	O
FGF2	O
)	O
expression	O
in	O
both	O
kidney	O
and	O
lung	O
cells	O
.	O

The	O
following	O
variables	O
that	O
appear	O
to	O
address	O
common	O
symptoms	O
of	O
ME	O
/	O
CFS	O
were	O
studied	O
here	O
:	O
(	O
1	O
)	O
muscle	O
fatigue	O
during	O
exercise	O
has	O
been	O
investigated	O
by	O
monitoring	O
the	O
compound	O
muscle	O
action	O
potential	O
(	O
M	O
-	O
wave	O
);	O
(	O
2	O
)	O
the	O
excessive	O
oxidative	O
stress	B-PATH
response	I-PATH
to	O
exercise	O
was	O
measured	O
via	O
two	O
plasma	O
markers	O
(	O
thiobarbituric	O
acid	O
reactive	O
substances	O
:	O
TBARS	O
;	O
reduced	O
ascorbic	O
-	O
acid	O
:	O
RAA	O
);	O
(	O
3	O
)	O
a	O
potential	O
inflammatory	O
component	O
was	O
addressed	O
via	O
expression	O
of	O
CD26	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
;	O
(	O
4	O
)	O
quality	O
-	O
of	O
-	O
life	O
impairment	O
was	O
assessed	O
using	O
the	O
London	O
Handicap	O
Scale	O
(	O
LHS	O
)	O
and	O
the	O
Medical	O
Outcome	O
Study	O
Short	O
Form	O
-	O
36	O
(	O
SF	O
-	O
36	O
).	O

The	O
impact	O
of	O
such	O
additives	O
on	O
the	O
release	B-PATH
of	O
lactate	O
dehydrogenase	O
(	O
LDH	O
;	O
spectroscopic	O
and	O
electrophoretic	O
assay	O
),	O
alteration	O
of	O
immunity	O
(	O
index	O
of	O
metabolic	O
activity	O
),	O
jejunum	O
histology	O
(	O
light	O
microscopy	O
),	O
and	O
health	O
of	O
conventional	O
piglets	O
from	O
a	O
problematic	O
breed	O
(	O
monitoring	O
of	O
hematology	O
,	O
consistency	O
and	O
moisture	O
of	O
feces	O
and	O
body	O
temperature	O
)	O
were	O
examined	O
.	O

We	O
critically	O
review	O
the	O
literature	O
on	O
the	O
release	B-PATH
of	O
respiratory	O
droplets	O
,	O
their	O
transport	O
and	O
dispersion	O
in	O
the	O
indoor	O
environment	O
,	O
and	O
the	O
ultimate	O
exposure	O
of	O
a	O
susceptible	O
host	O
,	O
as	O
influenced	O
by	O
airflows	O
.	O

Based	O
on	O
the	O
DNA	O
sequence	O
for	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
,	O
the	O
strains	O
isolated	O
from	O
quail	O
clustered	O
within	O
either	O
the	O
Gammacoronavirus	O
or	O
Deltacoronavirus	O
genus	O
,	O
and	O
sequences	O
from	O
both	O
genera	O
were	O
found	O
in	O
one	O
quail	O
sample	O
.	O

TITLE	O
:	O
Intravascular	O
haemolysis	O
with	O
haemoglobinuria	O
in	O
a	O
splenectomized	O
patient	O
with	O
severe	O
Plasmodium	O
knowlesi	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
Haemoglobinuria	O
is	O
an	O
uncommon	O
complication	O
of	O
severe	O
malaria	B-PATH
,	O
reflecting	O
acute	O
intravascular	O
haemolysis	O
and	O
potentially	O
leading	O
to	O
acute	O
kidney	O
injury	O
.	O

An	O
asplenic	O
patient	O
with	O
hyperparasitaemic	O
severe	O
knowlesi	O
malaria	B-PATH
developed	O
haemoglobinuria	O
after	O
treatment	O
with	O
intravenous	O
artesunate	O
.	O

We	O
present	O
a	O
case	O
of	O
acute	O
chest	O
pain	O
in	O
a	O
58	O
-	O
year	O
-	O
old	O
male	O
with	O
severe	O
asthma	B-PATH
,	O
which	O
regressed	O
after	O
sublingual	O
administration	O
of	O
nitroglycerine	O
.	O

TITLE	O
:	O
Cytokine	O
Release	B-PATH
Syndrome	O
After	O
Chimeric	O
Antigen	O
Receptor	O
T	O
Cell	O
Therapy	O
for	O
Acute	O
Lymphoblastic	O
Leukemia	O
.	O

Cytokine	O
release	B-PATH
syndrome	O
,	O
the	O
most	O
severe	O
toxicity	O
,	O
presents	O
a	O
novel	O
critical	O
illness	O
syndrome	O
with	O
limited	O
data	O
regarding	O
diagnosis	O
,	O
prognosis	O
,	O
and	O
therapy	O
.	O

We	O
sought	O
to	O
characterize	O
the	O
timing	O
,	O
severity	O
,	O
and	O
intensive	O
care	O
management	O
of	O
cytokine	O
release	B-PATH
syndrome	O
after	O
chimeric	O
antigen	O
receptor	O
-	O
modified	O
T	O
cell	O
therapy	O
.	O

Eighteen	O
subjects	O
(	O
46	O
%)	O
developed	O
grade	O
3	O
-	O
4	O
cytokine	O
release	B-PATH
syndrome	O
,	O
with	O
prolonged	O
fever	O
(	O
median	O
,	O
6	O
.	O
5	O
d	O
),	O
hyperferritinemia	O
(	O
median	O
peak	O
ferritin	O
,	O
60	O
,	O
214	O
ng	O
/	O
mL	O
),	O
and	O
organ	O
dysfunction	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
nucleoprotein	O
contributes	O
to	O
HMGB1	O
transcription	O
and	O
release	B-PATH
by	O
interacting	O
with	O
C	O
/	O
EBP	O
-	O
Î²	O
.	O

Meanwhile	O
,	O
PEDV	O
infection	O
and	O
overexpression	O
of	O
viral	O
nucleoprotein	O
resulted	O
in	O
the	O
acetylation	O
and	O
release	B-PATH
of	O
high	O
mobility	O
group	O
box	O
1	O
proteins	O
in	O
vitro	O
,	O
an	O
important	O
proinflammatory	O
response	O
mediator	O
,	O
which	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
various	O
inflammatory	O
diseases	O
.	O

Our	O
studies	O
also	O
showed	O
that	O
SIRT1	O
,	O
histone	O
acetyltransferase	O
,	O
and	O
NF	O
-	O
ÎºB	O
regulated	O
the	O
acetylation	O
and	O
release	B-PATH
of	O
HMGB1	O
.	O

Collectively	O
,	O
our	O
data	O
indicate	O
PEDV	O
-	O
N	O
contributes	O
to	O
HMGB1	O
transcription	O
and	O
the	O
subsequent	O
release	B-PATH
/	O
acetylation	O
of	O
HMGB1	O
during	O
PEDV	O
infection	O
.	O

SARS	O
,	O
MERS	O
-	O
CoV	O
,	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
),	O
Ebola	O
virus	O
disease	O
have	O
raised	O
concerns	O
because	O
of	O
their	O
virulence	O
,	O
their	O
mortality	O
,	O
and	O
/	O
or	O
their	O
modality	O
of	O
transmission	O
,	O
or	O
their	O
impact	O
on	O
maternofoetal	O
transmission	O
(	O
Zika	O
virus	O
).	O

It	O
has	O
established	O
strong	O
Polio	O
Laboratory	O
network	O
that	O
contributed	O
to	O
the	O
strengthening	O
of	O
capacities	O
and	O
its	O
expansion	O
to	O
surveillance	O
of	O
other	O
viral	O
priority	O
diseases	O
such	O
as	O
measles	B-PATH
,	O
yellow	O
fever	O
,	O
Influenza	O
,	O
MERS	O
-	O
CoV	O
and	O
Ebola	O
.	O

TITLE	O
:	O
Radiologic	O
manifestations	O
of	O
pulmonary	O
tuberculosis	B-PATH
in	O
patients	O
of	O
intensive	O
care	O
units	O
.	O

ABSTRACT	O
:	O
Tuberculosis	B-PATH
(	O
TB	O
)	O
is	O
a	O
serpent	O
disease	O
with	O
various	O
pulmonary	O
manifestations	O
,	O
and	O
timely	O
diagnosis	O
of	O
the	O
disease	O
is	O
paramount	O
,	O
since	O
delayed	O
treatment	O
is	O
associated	O
with	O
severe	O
morbidity	O
,	O
particularly	O
in	O
intensive	O
care	O
units	O
(	O
ICU	O
).	O

We	O
detected	O
respiratory	O
viruses	O
in	O
169	O
/	O
222	O
(	O
76	O
.	O
1	O
%)	O
samples	O
,	O
mostly	O
rhinovirus	O
(	O
23	O
.	O
4	O
%),	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
21	O
.	O
2	O
%),	O
influenza	O
B	O
virus	O
(	O
12	O
.	O
6	O
%),	O
coronavirus	O
(	O
4	O
.	O
9	O
%)	O
and	O
Human	O
metapneumovirus	O
(	O
3	O
.	O
6	O
%).	O

TITLE	O
:	O
New	O
insights	O
into	O
the	O
interaction	O
between	O
pyrrolyl	O
diketoacids	O
and	O
HIV	O
-	O
1	O
integrase	O
active	O
site	O
and	O
comparison	O
with	O
RNase	O
H	O
.	O
ABSTRACT	O
:	O
HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
inhibitors	O
are	O
one	O
of	O
the	O
most	O
recent	O
innovations	O
in	O
the	O
treatment	O
of	O
HIV	B-PATH
infection	I-PATH
.	O

Rates	O
varied	O
by	O
virus	O
:	O
human	O
rhinovirus	O
(	O
25	O
Â·	O
3	O
%,	O
19	O
/	O
75	O
),	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
30	O
%,	O
3	O
/	O
10	O
),	O
coronavirus	O
(	O
28	O
Â·	O
6	O
%,	O
2	O
/	O
7	O
),	O
human	O
metapneumovirus	O
(	O
28	O
Â·	O
6	O
%,	O
2	O
/	O
7	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
14	O
Â·	O
3	O
%,	O
4	O
/	O
28	O
)	O
and	O
parainfluenza	O
virus	O
(	O
8	O
Â·	O
3	O
%,	O
1	O
/	O
12	O
).	O

The	O
virions	O
entered	O
porcine	O
IECs	O
by	O
membrane	O
fusion	O
and	O
the	O
mature	O
viruses	O
in	O
the	O
vacuoles	O
were	O
transported	O
to	O
the	O
cell	O
membrane	O
before	O
release	B-PATH
.	O

The	O
infections	O
identified	O
included	O
:	O
ARI	O
,	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
),	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
.	O

TITLE	O
:	O
Factors	O
associated	O
with	O
clinical	O
outcome	O
in	O
25	O
patients	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
infection	O
in	O
Guangzhou	O
,	O
China	O
.	O

The	O
present	O
study	O
tested	O
the	O
hypothesis	O
that	O
CTSL	O
protects	O
mice	O
from	O
serious	O
consequences	O
of	O
infection	O
by	O
the	O
orthomyxovirus	O
influenza	B-PATH
A	I-PATH
,	O
which	O
is	O
thought	O
to	O
be	O
activated	O
by	O
host	O
-	O
supplied	O
proteases	O
other	O
than	O
CTSL	O
.	O

However	O
,	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
analyses	O
showed	O
the	O
susceptibility	O
of	O
quail	O
also	O
to	O
Deltacoronaviruses	O
,	O
suggesting	O
that	O
quail	O
and	O
pheasant	O
avian	O
coronaviruses	O
share	O
spike	O
genes	O
identical	O
to	O
chicken	O
IBV	O
spike	O
genes	O
and	O
quail	O
might	O
host	O
Deltacoronavirus	O
.	O

In	O
the	O
current	O
study	O
,	O
in	O
vitro	O
T	O
lymphocyte	O
activation	O
measured	O
by	O
IFNÎ³	O
release	B-PATH
was	O
significantly	O
higher	O
in	O
B2	O
versus	O
B19	O
haplotypes	O
.	O

This	O
study	O
suggests	O
that	O
the	O
demonstrated	O
T	O
lymphocyte	O
activation	O
is	O
in	O
part	O
due	O
to	O
antigen	O
presentation	O
by	O
the	O
macrophages	O
as	O
well	O
as	O
cytokine	O
release	B-PATH
by	O
the	O
infected	O
macrophages	O
,	O
with	O
B2	O
haplotypes	O
showing	O
stronger	O
activation	O
.	O

In	O
contrast	O
,	O
T	O
lymphocytes	O
stimulated	O
by	O
ConA	O
showed	O
greater	O
IFNÎ³	O
release	B-PATH
of	O
B19	O
haplotype	O
cells	O
,	O
further	O
indicating	O
the	O
greater	O
responses	O
in	O
B2	O
haplotypes	O
to	O
infection	O
is	O
due	O
to	O
macrophages	O
,	O
but	O
not	O
T	O
cells	O
.	O

PI4KIIIÎ±	O
is	O
one	O
of	O
four	O
mammalian	O
phosphatidylinositol	O
-	O
4	O
kinases	O
and	O
has	O
recently	O
drawn	O
significant	O
attention	O
as	O
an	O
emerging	O
target	O
for	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
treatment	O
.	O

Besides	O
the	O
well	O
-	O
known	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
Î±	O
/	O
Î²	O
)	O
response	O
,	O
the	O
protein	O
kinase	O
R	O
(	O
PKR	O
)-	O
mediated	O
stress	B-PATH
response	I-PATH
is	O
being	O
recognized	O
as	O
an	O
important	O
innate	O
response	O
pathway	O
.	O

It	O
is	O
unknown	O
whether	O
cellular	O
infection	O
by	O
MERS	O
-	O
CoV	O
activates	O
the	O
stress	B-PATH
response	I-PATH
pathway	O
or	O
whether	O
the	O
virus	O
has	O
evolved	O
strategies	O
to	O
suppress	O
this	O
infection	O
-	O
limiting	O
pathway	O
.	O

This	O
virus	O
also	O
suppressed	O
the	O
dsRNA	O
-	O
independent	O
stress	B-PATH
response	I-PATH
pathway	O
.	O

Thus	O
,	O
MERS	O
-	O
CoV	O
interferes	O
with	O
antiviral	O
stress	O
responses	O
using	O
at	O
least	O
two	O
different	O
mechanisms	O
,	O
with	O
p4a	O
suppressing	O
the	O
PKR	O
-	O
dependent	O
stress	B-PATH
response	I-PATH
pathway	O
,	O
probably	O
by	O
sequestering	O
dsRNA	O
.	O

TITLE	O
:	O
Discovery	O
of	O
Chromane	O
Containing	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
(	O
HCV	O
)	O
NS5A	O
Inhibitors	O
with	O
Improved	O
Potency	O
against	O
Resistance	O
-	O
Associated	O
Variants	O
.	O

Our	O
results	O
revealed	O
that	O
classical	O
apoptosis	B-PATH
associated	O
with	O
the	O
Bax	O
protein	O
does	O
not	O
play	O
a	O
significant	O
role	O
in	O
HCoV	O
-	O
OC43	O
-	O
induced	O
neuronal	O
cell	O
death	O
and	O
that	O
RIP1	O
and	O
MLKL	O
,	O
two	O
cellular	O
proteins	O
usually	O
associated	O
with	O
necroptosis	O
(	O
an	O
RCD	O
back	O
-	O
up	O
system	O
when	O
apoptosis	B-PATH
is	O
not	O
adequately	O
induced	O
),	O
both	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
process	O
.	O

Long	O
oligonucleotides	O
that	O
showed	O
an	O
evident	O
directional	O
change	O
observed	O
in	O
common	O
for	O
the	O
three	O
subtypes	O
corresponded	O
to	O
some	O
of	O
influenza	B-PATH
A	I-PATH
siRNAs	O
,	O
whose	O
activities	O
have	O
been	O
experimentally	O
proven	O
.	O

ABSTRACT	O
:	O
Glioma	B-PATH
tumor	O
suppressor	O
candidate	O
region	O
gene	O
2	O
protein	O
(	O
GLTSCR2	O
)	O
is	O
a	O
nucleolar	O
protein	O
.	O

TITLE	O
:	O
Seasonal	O
Influenza	B-PATH
A	I-PATH
H1N1pdm09	O
Virus	O
and	O
Severe	O
Outcomes	O
:	O
A	O
Reason	O
for	O
Broader	O
Vaccination	O
in	O
Non	O
-	O
Elderly	O
,	O
At	O
-	O
Risk	O
People	O
.	O

ABSTRACT	O
:	O
Recent	O
pandemics	O
of	O
influenza	B-PATH
A	I-PATH
H1N1pdm09	O
virus	O
have	O
caused	O
severe	O
illness	O
,	O
especially	O
in	O
young	O
people	O
.	O

We	O
performed	O
a	O
retrospective	O
observational	O
study	O
of	O
adults	O
hospitalized	O
during	O
the	O
2014	O
season	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
or	O
A	O
(	O
H3N2	O
).	O

We	O
included	O
234	O
patients	O
:	O
146	O
(	O
62	O
.	O
4	O
%)	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
88	O
(	O
37	O
.	O
6	O
%)	O
A	O
(	O
H3N2	O
).	O

Hospitalized	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
were	O
more	O
than	O
twice	O
as	O
likely	O
to	O
have	O
severe	O
influenza	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
determine	O
the	O
frequencies	O
of	O
respiratory	O
tract	O
viruses	O
in	O
patient	O
(	O
acute	O
lower	O
respiratory	O
tract	O
infection	O
[	O
LRTI	O
]	O
or	O
wheezing	O
)	O
and	O
control	O
(	O
history	O
of	O
asthma	B-PATH
without	O
symptoms	O
)	O
groups	O
.	O

The	O
advantage	O
of	O
our	O
study	O
compared	O
with	O
other	O
studies	O
is	O
the	O
inclusion	O
of	O
not	O
only	O
wheezing	O
patients	O
but	O
also	O
children	O
with	O
asthma	B-PATH
without	O
symptom	O
.	O

The	O
higher	O
detection	O
of	O
rhinoviruses	O
both	O
in	O
patient	O
and	O
control	O
groups	O
give	O
rise	O
to	O
thought	O
that	O
these	O
viruses	O
may	O
be	O
responsible	O
for	O
asthma	B-PATH
exacerbations	O
and	O
may	O
be	O
related	O
with	O
long	O
duration	O
of	O
virus	O
shedding	O
.	O

Given	O
the	O
lack	O
of	O
clinical	O
signs	O
,	O
positive	O
antibody	O
titers	O
for	O
Porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
,	O
Porcine	O
parvovirus	O
,	O
and	O
Influenza	B-PATH
A	I-PATH
confirm	O
the	O
efficacy	O
of	O
the	O
herd	O
vaccination	O
program	O
.	O

TITLE	O
:	O
Quantitative	O
structure	O
-	O
activity	O
relationship	O
and	O
molecular	O
docking	O
revealed	O
a	O
potency	O
of	O
anti	O
-	O
hepatitis	B-PATH
C	I-PATH
virus	O
drugs	O
against	O
human	O
corona	O
viruses	O
.	O

Influenza	B-PATH
A	I-PATH
virus	O
accounted	O
for	O
half	O
the	O
isolated	O
viruses	O
,	O
especially	O
subtype	O
A	O
(	O
H1N1	O
)	O
pdm09	O
among	O
patients	O
aged	O
20	O
-	O
59	O
years	O
old	O
,	O
and	O
subtype	O
A	O
(	O
H3N2	O
)	O
in	O
those	O
aged	O
60	O
or	O
over	O
;	O
the	O
most	O
frequently	O
identified	O
respiratory	O
virus	O
among	O
children	O
under	O
five	O
years	O
old	O
was	O
respiratory	O
syncytial	O
virus	O
(	O
65	O
.	O
6	O
%),	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
21	O
.	O
2	O
%);	O
influenza	O
virus	O
circulated	O
in	O
all	O
seasons	O
of	O
the	O
year	O
and	O
its	O
periods	O
of	O
greatest	O
incidence	O
were	O
interspersed	O
with	O
those	O
of	O
higher	O
Respiratory	O
Syncytial	O
Virus	O
activity	O
.	O

RESULTS	O
:	O
Influenza	B-PATH
A	I-PATH
virus	O
accounted	O
for	O
half	O
the	O
isolated	O
viruses	O
,	O
especially	O
subtype	O
A	O
(	O
H1N1	O
)	O
pdm09	O
among	O
patients	O
aged	O
20	O
-	O
59	O
years	O
old	O
,	O
and	O
subtype	O
A	O
(	O
H3N2	O
)	O
in	O
those	O
aged	O
60	O
or	O
over	O
;	O
the	O
most	O
frequently	O
identified	O
respiratory	O
virus	O
among	O
children	O
under	O
five	O
years	O
old	O
was	O
respiratory	O
syncytial	O
virus	O
(	O
65	O
.	O
6	O
%),	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
21	O
.	O
2	O
%);	O
influenza	O
virus	O
circulated	O
in	O
all	O
seasons	O
of	O
the	O
year	O
and	O
its	O
periods	O
of	O
greatest	O
incidence	O
were	O
interspersed	O
with	O
those	O
of	O
higher	O
Respiratory	O
Syncytial	O
Virus	O
activity	O
.	O

Disseminated	O
BCG	O
infection	O
did	O
not	O
resolve	O
despite	O
administration	O
of	O
anti	O
-	O
tuberculosis	B-PATH
drugs	O
and	O
intravenous	O
immune	O
globulins	O
,	O
and	O
she	O
subsequently	O
died	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Successful	O
VV	O
-	O
ECMO	O
treatment	O
in	O
patients	O
with	O
extremely	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
positive	O
results	O
of	O
the	O
CESAR	O
trial	O
have	O
led	O
to	O
an	O
exponential	O
use	O
of	O
the	O
technology	O
in	O
recent	O
years	O
.	O

ABSTRACT	O
:	O
Obesity	O
worsens	O
asthma	B-PATH
control	O
partly	O
through	O
enhanced	O
airway	O
neutrophilia	O
,	O
altered	O
lung	O
mechanics	O
and	O
comorbidities	O
,	O
including	O
obstructive	O
sleep	O
apnea	O
syndrome	O
,	O
gastroesophageal	O
reflux	O
disease	O
and	O
depression	O
.	O

Although	O
controversial	O
,	O
obesity	O
may	O
also	O
cause	O
poorer	O
outcomes	O
in	O
acute	O
asthma	B-PATH
.	O

To	O
investigate	O
the	O
role	O
of	O
IL	O
-	O
17	O
in	O
obese	O
asthma	B-PATH
in	O
both	O
acute	O
and	O
stable	O
settings	O
.	O

Effects	O
of	O
adiposity	O
on	O
acute	O
asthma	B-PATH
remain	O
uncertain	O
.	O

Retrospective	O
review	O
of	O
all	O
patients	O
with	O
acute	O
or	O
acute	O
-	O
on	O
-	O
chronic	O
respiratory	O
failure	O
(	O
due	O
to	O
chronic	O
obstructive	O
pulmonary	O
disease	O
[	O
COPD	O
]	O
with	O
severe	O
hypercapnic	O
respiratory	O
failure	O
when	O
non	O
-	O
invasive	O
ventilation	O
failed	O
;	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
COPD	O
;	O
or	O
asthma	B-PATH
when	O
lung	O
-	O
protective	O
ventilation	O
was	O
not	O
feasible	O
due	O
to	O
hypercapnia	O
)	O
for	O
whom	O
the	O
Hemolung	O
was	O
used	O
.	O

ABSTRACT	O
:	O
Airborne	O
pathogens	O
-	O
either	O
transmitted	O
via	O
aerosol	O
or	O
droplets	O
-	O
include	O
a	O
wide	O
variety	O
of	O
highly	O
infectious	O
and	O
dangerous	O
microbes	O
such	O
as	O
variola	O
virus	O
,	O
measles	B-PATH
virus	O
,	O
influenza	B-PATH
A	I-PATH
viruses	O
,	O
Mycobacterium	O
tuberculosis	B-PATH
,	O
Streptococcus	O
pneumoniae	O
,	O
and	O
Bordetella	O
pertussis	B-PATH
.	O

This	O
review	O
emphasises	O
the	O
role	O
of	O
the	O
tight	B-PATH
junction	I-PATH
of	O
the	O
airway	O
epithelium	O
as	O
the	O
predominating	O
structure	O
conferring	O
epithelial	O
tightness	O
and	O
preventing	O
exudate	O
formation	O
and	O
the	O
impact	O
of	O
inflammatory	O
perturbations	O
on	O
their	O
function	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	O
in	O
Dengue	O
,	O
Malaria	B-PATH
,	O
and	O
Acute	O
Chagas	O
Disease	O
.	O

We	O
present	O
six	O
cases	O
of	O
severe	O
dengue	O
,	O
malaria	B-PATH
,	O
and	O
acute	O
Chagas	O
disease	O
that	O
were	O
treated	O
with	O
ECMO	O
from	O
September	O
2007	O
to	O
September	O
2015	O
.	O

We	O
conclude	O
that	O
ECMO	O
treatment	O
can	O
be	O
beneficial	O
in	O
patients	O
with	O
severe	O
dengue	O
,	O
malaria	B-PATH
,	O
and	O
acute	O
Chagas	O
disease	O
,	O
if	O
complicated	O
by	O
pulmonary	O
or	O
cardiac	O
complications	O
.	O

Three	O
interferon	O
-	O
stimulated	O
gene	O
products	O
,	O
two	O
of	O
which	O
have	O
been	O
reported	O
to	O
target	O
the	O
hepatitis	B-PATH
C	I-PATH
virus	O
replication	O
structures	O
,	O
were	O
tested	O
for	O
their	O
possible	O
involvement	O
,	O
but	O
none	O
of	O
them	O
affected	O
membrane	O
structure	O
formation	O
.	O

TITLE	O
:	O
Targeting	O
Neutrophils	O
to	O
Prevent	O
Malaria	B-PATH
-	O
Associated	O
Acute	O
Lung	O
Injury	O
/	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
in	O
Mice	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
remains	O
one	O
of	O
the	O
greatest	O
burdens	O
to	O
global	O
health	O
,	O
causing	O
nearly	O
500	O
,	O
000	O
deaths	O
in	O
2014	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
role	O
of	O
neutrophils	O
in	O
the	O
pathogenesis	O
of	O
malaria	B-PATH
-	O
associated	O
ALI	O
/	O
ARDS	O
.	O

This	O
study	O
implicates	O
neutrophils	O
and	O
NETs	O
in	O
the	O
genesis	O
of	O
experimentally	O
induced	O
malaria	B-PATH
-	O
associated	O
ALI	O
/	O
ARDS	O
and	O
proposes	O
a	O
new	O
therapeutic	O
approach	O
to	O
improve	O
the	O
prognosis	O
of	O
severe	O
malaria	B-PATH
.	O

After	O
recording	O
clinical	O
and	O
demographic	O
data	O
,	O
twin	O
swabs	O
(	O
nasopharyngeal	O
and	O
throat	O
)	O
were	O
collected	O
from	O
each	O
participant	O
,	O
pooled	O
in	O
viral	O
transport	O
media	O
and	O
tested	O
by	O
real	O
-	O
time	O
RT	O
PCR	O
for	O
MERS	O
-	O
CoV	O
and	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
and	O
their	O
subtypes	O
.	O

TITLE	O
:	O
Association	O
of	O
Heme	O
Oxygenase	O
1	O
with	O
Lung	O
Protection	O
in	O
Malaria	B-PATH
-	O
Associated	O
ALI	O
/	O
ARDS	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
a	O
serious	O
disease	O
,	O
caused	O
by	O
the	O
parasite	O
of	O
the	O
genus	O

There	O
was	O
much	O
improvement	O
with	O
airway	O
pressure	O
release	B-PATH
ventilation	O
mode	O
of	O
ventilation	O
,	O
but	O
the	O
child	O
succumbed	O
to	O
death	O
due	O
to	O
pulmonary	O
hemorrhage	O
.	O

The	O
role	O
of	O
ex	O
vivo	O
infected	O
lung	O
tissue	O
for	O
the	O
investigation	O
of	O
emerging	O
viral	O
zoonosis	O
including	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
is	O
discussed	O
.	O

TITLE	O
:	O
Impact	O
of	O
obstructive	O
sleep	O
apnea	O
on	O
severe	O
asthma	B-PATH
exacerbations	O
.	O

However	O
,	O
the	O
association	O
between	O
OSA	O
and	O
the	O
exacerbation	O
of	O
severe	O
asthma	B-PATH
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
prevalence	O
of	O
OSA	O
in	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
asthma	B-PATH
patients	O
and	O
to	O
prospectively	O
examine	O
the	O
significance	O
of	O
the	O
effect	O
of	O
OSA	O
on	O
severe	O
asthma	B-PATH
exacerbations	O
.	O

One	O
hundred	O
and	O
forty	O
-	O
six	O
patients	O
with	O
asthma	B-PATH
and	O
157	O
matched	O
-	O
controlled	O
individuals	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

The	O
patients	O
with	O
asthma	B-PATH
were	O
prospectively	O
studied	O
for	O
one	O
year	O
,	O
and	O
exacerbation	O
episodes	O
were	O
identified	O
based	O
on	O
the	O
patients	O
'	O
medical	O
histories	O
.	O

The	O
rates	O
of	O
OSA	O
were	O
19	O
.	O
2	O
%	O
(	O
28	O
/	O
146	O
)	O
among	O
the	O
patients	O
with	O
asthma	B-PATH
and	O
9	O
.	O
6	O
%	O
(	O
15	O
/	O
157	O
)	O
among	O
the	O
control	O
individuals	O
(	O
p	O
=	O
0	O
.	O
016	O
).	O

The	O
frequency	O
of	O
severe	O
asthma	B-PATH
exacerbations	O
was	O
significantly	O
higher	O
among	O
the	O
asthma	B-PATH
patients	O
with	O
OSA	O
compared	O
with	O
those	O
who	O
did	O
not	O
have	O
OSA	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
apnea	O
-	O
hypopnea	O
index	O
(	O
AHI	O
)	O
correlated	O
significantly	O
with	O
the	O
number	O
of	O
severe	O
asthma	B-PATH
exacerbations	O
(	O
r	O
=	O
0	O
.	O
507	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0	O
.	O
357	O
-	O
0	O
.	O
637	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

Logistic	O
regression	O
analyses	O
determined	O
that	O
the	O
AHI	O
was	O
significantly	O
associated	O
with	O
the	O
occurrence	O
of	O
severe	O
asthma	B-PATH
exacerbations	O
(	O
odds	O
ratio	O
1	O
.	O
322	O
,	O
95	O
%	O
CI	O
1	O
.	O
148	O
-	O
1	O
.	O
523	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

Patients	O
with	O
asthma	B-PATH
had	O
a	O
high	O
prevalence	O
of	O
OSA	O
,	O
which	O
was	O
an	O
important	O
factor	O
associated	O
with	O
severe	O
asthma	B-PATH
exacerbations	O
.	O

RESULTS	O
:	O
The	O
rates	O
of	O
OSA	O
were	O
19	O
.	O
2	O
%	O
(	O
28	O
/	O
146	O
)	O
among	O
the	O
patients	O
with	O
asthma	B-PATH
and	O
9	O
.	O
6	O
%	O
(	O
15	O
/	O
157	O
)	O
among	O
the	O
control	O
individuals	O
(	O
p	O
=	O
0	O
.	O
016	O
).	O

The	O
genome	O
was	O
comprised	O
of	O
13	O
bp	O
5	O
'-	O
UTR	O
,	O
three	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
including	O
ORF1a	O
encoding	O
serine	O
protease	O
,	O
ORF1b	O
encoding	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
and	O
ORF2	O
encoding	O
capsid	O
protein	O
,	O
and	O
298	O
bp	O
of	O
3	O
'-	O
UTR	O
which	O
harboured	O
two	O
corona	O
virus	O
stem	O
loop	O
II	O
like	O
""""	O
s2m	O
""""	O
motifs	O
and	O
a	O
poly	O
A	O
stretch	O
of	O
19	O
nucleotides	O
.	O

We	O
investigated	O
the	O
prevalence	O
of	O
brain	O
lesions	O
and	O
cognitive	O
dysfunction	O
in	O
survivors	O
from	O
the	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
2009	O
pandemic	O
treated	O
with	O
permissive	O
hypoxaemia	O
during	O
ECMO	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Seven	O
patients	O
treated	O
with	O
ECMO	O
for	O
severe	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
-	O
induced	O
ARDS	O
were	O
studied	O
3	O
.	O
2	O
years	O
after	O
treatment	O
.	O

TITLE	O
:	O
The	O
dangers	O
of	O
accepting	O
a	O
single	O
diagnosis	O
:	O
case	O
report	O
of	O
concurrent	O
Plasmodium	O
knowlesi	O
malaria	B-PATH
and	O
dengue	O
infection	O
.	O

ABSTRACT	O
:	O
Dengue	O
and	O
malaria	B-PATH
are	O
two	O
common	O
,	O
mosquito	O
-	O
borne	O
infections	O
,	O
which	O
may	O
lead	O
to	O
mortality	O
if	O
not	O
managed	O
properly	O
.	O

Plasmodium	O
knowlesi	O
is	O
also	O
a	O
common	O
cause	O
of	O
malaria	B-PATH
in	O
Malaysia	O
with	O
one	O
of	O
the	O
highest	O
rates	O
of	O
mortality	O
.	O

Treating	O
the	O
dengue	O
had	O
so	O
distracted	O
the	O
clinicians	O
that	O
a	O
blood	O
film	O
for	O
the	O
malaria	B-PATH
parasite	O
was	O
not	O
done	O
.	O

Awareness	O
should	O
be	O
raised	O
among	O
health	O
-	O
care	O
workers	O
on	O
the	O
possibility	O
of	O
dengue	O
-	O
malaria	B-PATH
co	O
-	O
infection	O
in	O
this	O
region	O
.	O

The	O
Chinese	O
government	O
and	O
military	O
forces	O
have	O
paid	O
a	O
great	O
deal	O
of	O
attention	O
to	O
infectious	O
disease	O
prevention	O
and	O
control	O
,	O
and	O
using	O
military	O
-	O
civilian	O
cooperation	O
,	O
they	O
have	O
successfully	O
prevented	O
numerous	O
severe	O
epidemic	O
situations	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
),	O
avian	O
influenza	O
H5N1	O
and	O
H7N9	O
,	O
and	O
Ebola	O
hemorrhagic	O
fever	O
,	O
while	O
actively	O
maintained	O
public	O
health	O
,	O
economic	O
development	O
,	O
and	O
national	O
construction	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
uncontrolled	O
asthma	B-PATH
are	O
at	O
a	O
greater	O
risk	O
of	O
asthma	B-PATH
attacks	O
requiring	O
emergency	O
room	O
visits	O
or	O
hospital	O
admissions	O
.	O

Both	O
asthma	B-PATH
and	O
takotsubo	O
cardiomyopathy	O
share	O
the	O
same	O
clinical	O
presentation	O
with	O
dyspnea	O
and	O
chest	O
tightness	O
.	O

In	O
our	O
patient	O
,	O
the	O
electrocardiographic	O
abnormalities	O
,	O
the	O
rapidly	O
reversible	O
distinctive	O
characteristics	O
of	O
echocardiography	O
,	O
and	O
the	O
modest	O
elevation	O
of	O
serum	O
cardiac	O
biomarkers	O
levels	O
,	O
in	O
combination	O
with	O
the	O
presence	O
of	O
a	O
stress	O
trigger	O
(	O
severe	O
asthma	B-PATH
attack	O
),	O
strongly	O
supported	O
the	O
diagnosis	O
of	O
broken	O
heart	O
syndrome	O
.	O

TITLE	O
:	O
Widespread	O
Virus	O
Replication	O
in	O
Alveoli	O
Drives	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
in	O
Aerosolized	O
H5N1	O
Influenza	B-PATH
Infection	I-PATH
of	O
Macaques	O
.	O

Lastly	O
,	O
the	O
layer	O
-	O
by	O
-	O
layer	O
deposition	O
was	O
extended	O
to	O
release	B-PATH
the	O
TMV	O
scaffolds	O
as	O
free	O
-	O
standing	O
biomembranes	O
.	O

Further	O
studies	O
revealed	O
that	O
lipid	O
rafts	O
were	O
not	O
required	O
for	O
IBV	O
genome	O
replication	O
or	O
virion	O
release	B-PATH
at	O
later	O
stages	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
24	O
-	O
year	O
-	O
old	O
female	O
with	O
a	O
history	O
of	O
asthma	B-PATH
and	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
).	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
two	O
decades	O
a	O
number	O
of	O
severe	O
acute	O
respiratory	O
infection	O
outbreaks	O
such	O
as	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
have	O
emerged	O
and	O
presented	O
a	O
considerable	O
global	O
public	O
health	O
threat	O
.	O

Herein	O
,	O
we	O
present	O
a	O
rare	O
case	O
of	O
an	O
advanced	O
HIV	B-PATH
infection	I-PATH
and	O
Rhodoccocus	O
equi	O
(	O
R	O
.	O
equi	O
)	O
pneumonia	O
in	O
a	O
young	O
male	O
who	O
had	O
severe	O
paradoxical	O
immune	O
reconstitution	O
inflammatory	O
syndrome	O
(	O
IRIS	O
).	O

Using	O
confocal	O
and	O
super	O
-	O
resolution	O
imaging	O
and	O
high	O
content	O
single	O
particle	O
tracking	O
,	O
we	O
investigated	O
DENV	O
binding	O
,	O
DC	O
-	O
SIGN	O
surface	O
transport	O
,	O
endocytosis	B-PATH
,	O
as	O
well	O
as	O
cell	O
infectivity	O
.	O

The	O
literature	O
search	O
identified	O
eight	O
articles	O
for	O
review	O
that	O
reported	O
on	O
paramedic	O
exposure	O
trends	O
;	O
the	O
lack	O
of	O
reported	O
blood	O
-	O
borne	O
infections	O
contracted	O
,	O
such	O
as	O
hepatitis	O
B	O
,	O
hepatitis	B-PATH
C	I-PATH
,	O
and	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
);	O
instances	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infections	O
;	O
and	O
the	O
higher	O
prevalence	O
of	O
methicillin	O
-	O
resistant	O
staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
nasal	O
infections	O
amongst	O
paramedics	O
.	O

RESULTS	O
:	O
The	O
literature	O
search	O
identified	O
eight	O
articles	O
for	O
review	O
that	O
reported	O
on	O
paramedic	O
exposure	O
trends	O
;	O
the	O
lack	O
of	O
reported	O
blood	O
-	O
borne	O
infections	O
contracted	O
,	O
such	O
as	O
hepatitis	O
B	O
,	O
hepatitis	B-PATH
C	I-PATH
,	O
and	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
);	O
instances	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infections	O
;	O
and	O
the	O
higher	O
prevalence	O
of	O
methicillin	O
-	O
resistant	O
staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
nasal	O
infections	O
amongst	O
paramedics	O
.	O

Samples	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
were	O
subtyped	O
for	O
A	O
/	O
H1N1pdm09	O
and	O
A	O
/	O
H3N2	O
whereas	O
influenza	O
B	O
samples	O
were	O
subtyped	O
into	O
B	O
/	O
Yamagata	O
and	O
B	O
/	O
Victoria	O
subtypes	O
,	O
using	O
primers	O
and	O
probes	O
recommended	O
by	O
CDC	O
,	O
USA	O
.	O

Respiratory	O
viruses	O
were	O
detected	O
in	O
46	O
(	O
19	O
.	O
7	O
%)	O
cases	O
,	O
influenza	B-PATH
A	I-PATH
/	O
H3N2	O
and	O
rhinoviruses	O
being	O
the	O
most	O
common	O
viruses	O
detected	O
.	O

RESULTS	O
:	O
Respiratory	O
viruses	O
were	O
detected	O
in	O
46	O
(	O
19	O
.	O
7	O
%)	O
cases	O
,	O
influenza	B-PATH
A	I-PATH
/	O
H3N2	O
and	O
rhinoviruses	O
being	O
the	O
most	O
common	O
viruses	O
detected	O
.	O

TITLE	O
:	O
Swine	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
(	O
SIV	O
)	O
infection	O
requiring	O
extracorporeal	O
life	O
support	O
in	O
an	O
immunocompetent	O
adult	O
patient	O
with	O
indirect	O
exposure	O
to	O
pigs	O
,	O
Italy	O
,	O
October	O
2016	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
case	O
of	O
severe	O
swine	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
in	O
an	O
immunocompetent	O
middle	O
-	O
aged	O
man	O
in	O
October	O
2016	O
in	O
Italy	O
who	O
had	O
only	O
indirect	O
exposure	O
to	O
pigs	O
.	O

TITLE	O
:	O
[	O
Systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
presenting	O
as	O
severe	O
alveolar	O
hypoventilation	O
and	O
the	O
shrinking	O
lung	O
syndrome	O
].	O

Although	O
lower	O
than	O
other	O
RNA	O
viruses	O
such	O
as	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
HCoV	O
-	O
OC43	O
did	O
exhibit	O
quasi	O
-	O
species	O
.	O

The	O
rate	O
of	O
nonsynonymous	O
mutations	O
was	O
higher	O
in	O
the	O
HCoV	O
-	O
OC43	O
isolates	O
than	O
in	O
hepatitis	B-PATH
C	I-PATH
(	O
HCV	O
)	O
virus	O
genotype	O
1a	O
isolates	O
analyzed	O
for	O
comparison	O
in	O
this	O
study	O
.	O

Furthermore	O
,	O
resveratrol	O
down	O
-	O
regulated	O
the	O
apoptosis	B-PATH
induced	O
by	O
MERS	O
-	O
CoV	O
in	O
vitro	O
.	O

We	O
examined	O
the	O
prevalence	O
of	O
anxiety	O
symptoms	O
and	O
anger	O
in	O
persons	O
isolated	O
during	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
epidemic	O
both	O
at	O
isolation	O
period	O
and	O
at	O
four	O
to	O
six	O
months	O
after	O
release	B-PATH
from	O
isolation	O
.	O

Anxiety	O
symptoms	O
were	O
evaluated	O
with	O
the	O
Generalized	O
Anxiety	O
Disorder	O
7	O
-	O
item	O
scale	O
and	O
anger	O
was	O
assessed	O
with	O
the	O
State	O
-	O
Trait	O
Anger	O
Expression	O
Inventory	O
at	O
four	O
to	O
six	O
months	O
after	O
release	B-PATH
from	O
isolation	O
for	O
MERS	O
.	O

At	O
four	O
to	O
six	O
months	O
after	O
release	B-PATH
from	O
isolation	O
,	O
anxiety	O
symptoms	O
were	O
observed	O
in	O
3	O
.	O
0	O
%	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
2	O
to	O
3	O
.	O
9	O
%).	O

Risk	O
factors	O
for	O
experiencing	O
anxiety	O
symptoms	O
and	O
anger	O
at	O
four	O
to	O
six	O
months	O
after	O
release	B-PATH
included	O
symptoms	O
related	O
to	O
MERS	O
during	O
isolation	O
,	O
inadequate	O
supplies	O
(	O
food	O
,	O
clothes	O
,	O
accommodation	O
),	O
social	O
networking	O
activities	O
(	O
email	O
,	O
text	O
,	O
Internet	O
),	O
history	O
of	O
psychiatric	O
illnesses	O
,	O
and	O
financial	O
loss	O
.	O

Mental	O
health	O
problems	O
at	O
four	O
to	O
six	O
month	O
after	O
release	B-PATH
from	O
isolation	O
might	O
be	O
prevented	O
by	O
providing	O
mental	O
health	O
support	O
to	O
individuals	O
with	O
vulnerable	O
mental	O
health	O
,	O
and	O
providing	O
accurate	O
information	O
as	O
well	O
as	O
appropriate	O
supplies	O
,	O
including	O
food	O
,	O
clothes	O
,	O
and	O
accommodation	O
.	O

Risk	O
factors	O
for	O
experiencing	O
anxiety	O
symptoms	O
and	O
anger	O
at	O
four	O
to	O
six	O
months	O
after	O
release	B-PATH
included	O
symptoms	O
related	O
to	O
MERS	O
during	O
isolation	O
,	O
inadequate	O
supplies	O
(	O
food	O
,	O
clothes	O
,	O
accommodation	O
),	O
social	O
networking	O
activities	O
(	O
email	O
,	O
text	O
,	O
Internet	O
),	O
history	O
of	O
psychiatric	O
illnesses	O
,	O
and	O
financial	O
loss	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
case	O
report	O
and	O
short	O
literature	O
review	O
.	O

EGCG	O
possesses	O
anti	O
-	O
inflammatory	O
and	O
lung	O
-	O
protective	O
properties	O
,	O
and	O
might	O
act	O
by	O
limiting	O
mtDNA	O
release	B-PATH
after	O
thermal	O
injury	O
.	O

ABSTRACT	O
:	O
Previous	O
reports	O
have	O
demonstrated	O
that	O
the	O
second	O
-	O
generation	O
tetracycline	O
derivative	O
doxycycline	O
(	O
DOX	O
)	O
interrupts	O
mitochondrial	O
proteostasis	O
and	O
physiology	O
,	O
inhibits	O
proliferation	O
of	O
many	O
cell	O
types	O
,	O
and	O
induces	O
apoptosis	B-PATH
.	O

Of	O
note	O
,	O
it	O
was	O
better	O
able	O
to	O
subtype	O
the	O
influenza	B-PATH
A	I-PATH
/	O
H3N2	O
viruses	O
compared	O
with	O
the	O
xTAG	O
RVP	O
FAST	O
v2	O
.	O

ABSTRACT	O
:	O
Positive	O
-	O
strand	O
RNA	O
(+	O
RNA	O
)	O
viruses	O
(	O
e	O
.	O
g	O
.	O
poliovirus	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
dengue	O
virus	O
,	O
SARS	O
-	O
coronavirus	O
)	O
remodel	O
cellular	O
membranes	O
to	O
form	O
so	O
-	O
called	O
viral	O
replication	O
compartments	O
(	O
VRCs	O
),	O
which	O
are	O
the	O
sites	O
where	O
viral	O
RNA	O
genome	O
replication	O
takes	O
place	O
.	O

ABSTRACT	O
:	O
H1N1	O
,	O
a	O
major	O
pathogenic	O
subtype	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
causes	O
a	O
respiratory	O
infection	O
in	O
humans	O
and	O
livestock	O
that	O
can	O
range	O
from	O
a	O
mild	O
infection	O
to	O
more	O
severe	O
pneumonia	O
associated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Porcine	O
Deltacoronavirus	O
nsp5	O
Antagonizes	O
Type	O
I	O
Interferon	B-PATH
Signaling	I-PATH
by	O
Cleaving	O
STAT2	O
.	O

Influenza	O
viruses	O
were	O
found	O
in	O
1026	O
(	O
60	O
.	O
7	O
%)	O
examinees	O
;	O
influenza	B-PATH
A	I-PATH
viruses	O
in	O
712	O
(	O
42	O
.	O
1	O
%)	O
people	O
while	O
pandemic	O
strain	O
of	O
swine	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
and	O
A	O
/	O
H3N2	O
viruses	O
was	O
detected	O
in	O
487	O
(	O
28	O
.	O
8	O
%)	O
and	O
107	O
(	O
6	O
.	O
3	O
%)	O
patients	O
,	O
respectively	O
;	O
influenza	B-PATH
A	I-PATH
subtype	O
was	O
indicated	O
in	O
118	O
(	O
7	O
%)	O
persons	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
virus	O
.	O

Umifenovir	O
therapy	O
substantially	O
reduces	O
the	O
duration	O
of	O
fever	O
and	O
risk	O
of	O
complications	O
,	O
especially	O
in	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
influenza	B-PATH
infection	I-PATH
.	O

TITLE	O
:	O
Sagittal	O
-	O
lung	O
CT	O
measurements	O
in	O
the	O
evaluation	O
of	O
asthma	B-PATH
-	O
COPD	O
overlap	O
syndrome	O
:	O
a	O
distinctive	O
phenotype	O
from	O
COPD	O
alone	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
at	O
investigating	O
the	O
capability	O
of	O
sagittal	O
-	O
lung	O
computed	O
tomography	O
(	O
CT	O
)	O
measurements	O
in	O
differentiating	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
asthma	B-PATH
-	O
COPD	O
overlap	O
syndrome	O
(	O
ACOS	O
).	O

Using	O
PCR	O
analysis	O
for	O
the	O
presence	O
of	O
herpes	O
simplex	O
1	O
and	O
2	O
,	O
adenovirus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
),	O
and	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
,	O
we	O
explored	O
a	O
possible	O
role	O
of	O
viruses	O
in	O
PTA	O
.	O

The	O
relationship	O
between	O
bronchiolitis	O
and	O
asthma	B-PATH
is	O
now	O
better	O
understood	O
thanks	O
to	O
prospective	O
follow	O
up	O
of	O
birth	O
cohorts	O
.	O

The	O
identification	O
of	O
predisposing	O
factors	O
immunological	O
,	O
functional	O
,	O
atopic	O
and	O
genetic	O
,	O
for	O
the	O
onset	O
of	O
asthma	B-PATH
after	O
rhinovirus	O
infection	O
suggests	O
that	O
viral	O
infection	O
reveals	O
a	O
predisposition	O
rather	O
than	O
itself	O
being	O
a	O
cause	O
of	O
asthma	B-PATH
.	O

The	O
role	O
of	O
bacteria	O
in	O
the	O
natural	O
history	O
of	O
asthma	B-PATH
is	O
also	O
beginning	O
to	O
be	O
better	O
understood	O
.	O

The	O
results	O
of	O
the	O
COPSAC	O
Danish	O
cohort	O
have	O
shown	O
the	O
frequency	O
of	O
bacterial	O
identification	O
during	O
wheezy	O
episodes	O
before	O
3	O
years	O
,	O
and	O
the	O
impact	O
of	O
bacterial	O
colonization	O
at	O
the	O
age	O
of	O
one	O
month	O
on	O
the	O
onset	O
of	O
asthma	B-PATH
by	O
age	O
5	O
years	O
.	O

Since	O
the	O
previous	O
meeting	O
,	O
significant	O
progress	O
has	O
been	O
made	O
with	O
regulatory	O
approvals	O
of	O
the	O
first	O
malaria	B-PATH
and	O
dengue	O
vaccines	O
,	O
and	O
the	O
first	O
phase	O
III	O
trials	O
of	O
a	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
vaccine	O
candidate	O
has	O
started	O
in	O
the	O
elderly	O
and	O
pregnant	O
women	O
.	O

Trials	O
of	O
HIV	O
and	O
tuberculosis	B-PATH
vaccine	O
candidates	O
are	O
steadily	O
progressing	O
towards	O
pivotal	O
data	O
points	O
,	O
and	O
the	O
leading	O
norovirus	O
vaccine	O
candidate	O
has	O
entered	O
a	O
phase	O
IIb	O
efficacy	O
study	O
.	O

Tight	B-PATH
Junction	I-PATH
Protein	O
Occludin	O
Is	O
a	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Entry	O
Factor	O
.	O

Our	O
observations	O
are	O
relevant	O
also	O
to	O
other	O
human	O
respiratory	O
viruses	O
of	O
zoonotic	O
origin	O
,	O
particularly	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

ABSTRACT	O
:	O
Viral	O
infections	O
are	O
leading	O
causes	O
of	O
both	O
upper	O
and	O
lower	O
airway	O
acute	O
illness	O
in	O
all	O
age	O
groups	O
of	O
healthy	O
persons	O
,	O
and	O
have	O
also	O
been	O
implicated	O
in	O
the	O
acute	O
exacerbations	O
of	O
chronic	O
respiratory	O
disorders	O
like	O
asthma	B-PATH
and	O
COPD	O
.	O

Moreover	O
,	O
hPIV	O
infection	O
may	O
be	O
associated	O
with	O
viral	O
exacerbations	O
of	O
chronic	O
airway	O
diseases	O
,	O
asthma	B-PATH
or	O
COPD	O
or	O
chronic	O
rhinosinusitis	O
.	O

TITLE	O
:	O
[	O
Severe	O
imported	O
malaria	B-PATH
in	O
adults	O
:	O
a	O
retrospective	O
study	O
of	O
thirteen	O
cases	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
in	O
Marrakech	O
].	O

ABSTRACT	O
:	O
Imported	O
malaria	B-PATH
is	O
being	O
seen	O
with	O
increasing	O
frequency	O
in	O
non	O
-	O
endemic	O
areas	O
.	O

Severe	O
forms	O
represent	O
10	O
%	O
of	O
cases	O
of	O
Plasmodium	O
falciparum	O
malaria	B-PATH
.	O

In	O
Morocco	O
,	O
more	O
than	O
50	O
cases	O
of	O
malaria	B-PATH
occur	O
each	O
year	O
,	O
83	O
%	O
of	O
which	O
with	O
Plasmodium	O
falciparum	O
malaria	B-PATH
.	O

All	O
patients	O
with	O
severe	O
malaria	B-PATH
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
during	O
the	O
period	O
between	O
1	O
November	O
2009	O
and	O
31	O
December	O
2015	O
were	O
enrolled	O
in	O
our	O
study	O
.	O

All	O
patients	O
had	O
been	O
living	O
in	O
sub	O
-	O
Saharan	O
Africa	O
and	O
had	O
no	O
immunity	O
to	O
malaria	B-PATH
.	O

Mortality	O
associated	O
with	O
severe	O
malaria	B-PATH
remains	O
high	O
.	O

Further	O
validation	O
was	O
captured	O
using	O
LysoTracker	O
and	O
lysosome	B-PATH
-	O
associated	O
membrane	O
protein	O
by	O
indirect	O
immunofluorescence	O
labeling	O
in	O
PHEV	O
-	O
infected	O
cells	O
.	O

Mechanistically	O
,	O
neuraminidase	O
inhibition	O
assay	O
and	O
hemagglutination	O
inhibition	O
assay	O
suggested	O
that	O
N30	O
did	O
not	O
directly	O
target	O
the	O
two	O
envelope	O
glycoproteins	O
required	O
for	O
viral	O
adsorption	O
or	O
release	B-PATH
.	O

Like	O
the	O
PLPs	O
of	O
other	O
coronaviruses	O
(	O
CoVs	O
),	O
the	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
PLP	O
catalyzes	O
proteolysis	O
of	O
Gly	O
-	O
Gly	O
dipeptide	O
bonds	O
to	O
release	B-PATH
mature	O
cleavage	O
products	O
.	O

Nine	O
hundred	O
and	O
seventy	O
seven	O
(	O
977	O
)	O
fecal	O
samples	O
were	O
screened	O
for	O
RNA	O
viruses	O
including	O
:	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
),	O
avian	O
paramyxovirus	O
1	O
,	O
avian	O
coronavirus	O
(	O
CoV	O
),	O
and	O
avian	O
astrovirus	O
(	O
AstroV	O
).	O

ABSTRACT	O
:	O
Oseltamivir	O
is	O
widely	O
used	O
in	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viral	O
infections	O
.	O

The	O
three	O
priority	O
endemic	O
zoonoses	O
for	O
the	O
MOHs	O
were	O
leptospirosis	O
,	O
rabies	O
,	O
and	O
brucellosis	O
while	O
the	O
three	O
priorities	O
for	O
the	O
MAgs	O
were	O
brucellosis	O
,	O
rabies	O
,	O
and	O
tuberculosis	B-PATH
.	O

Second	O
,	O
we	O
characterized	O
actively	O
transcribed	O
genomic	O
regions	O
and	O
enhancers	O
in	O
HCoV	O
-	O
229E	O
-	O
infected	O
cells	O
and	O
systematically	O
correlated	O
the	O
genome	O
-	O
wide	O
gene	O
expression	O
changes	O
with	O
the	O
recruitment	O
of	O
Ser5	O
-	O
phosphorylated	O
RNA	B-PATH
polymerase	I-PATH
II	O
and	O
prototypical	O
histone	B-PATH
modifications	I-PATH
(	O
H3K9ac	O
,	O
H3K36ac	O
,	O
H4K5ac	O
,	O
H3K27ac	O
,	O
H3K4me1	O
).	O

We	O
hypothesize	O
that	O
alveolar	O
stretch	O
activates	O
the	O
integrated	O
stress	B-PATH
response	I-PATH
(	O
ISR	O
)	O
pathway	O
and	O
that	O
the	O
chemical	O
inhibition	O
of	O
this	O
pathway	O
mitigates	O
alveolar	O
barrier	O
disruption	O
during	O
stretch	O
and	O
mechanical	O
ventilation	O
.	O

The	O
presence	O
of	O
13	O
different	O
viral	O
pathogens	O
(	O
influenza	B-PATH
A	I-PATH
[	O
H1N1	O
]	O
pdm09	O
;	O
A	O
/	O
H3N2	O
;	O
A	O
/	O
H5	O
;	O
A	O
/	O
H7	O
and	O
B	O
;	O
para	O
influenza	O
1	O
,	O
2	O
,	O
3	O
;	O
RSV	O
;	O
HMPV	O
;	O
adeno	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
CoV	O
and	O
rhino	O
)	O
was	O
tested	O
by	O
conventional	O
/	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

A	O
prominent	O
regulator	O
of	O
disease	O
outcome	O
,	O
especially	O
in	O
-	O
but	O
not	O
limited	O
to	O
-	O
respiratory	O
viral	O
infection	O
,	O
is	O
the	O
IFN	O
-	O
dependent	O
mediator	O
TRAIL	O
(	O
TNF	O
-	O
related	O
apoptosis	B-PATH
-	O
inducing	O
ligand	O
)	O
produced	O
by	O
several	O
cell	O
types	O
including	O
immune	O
cells	O
such	O
as	O
macrophages	O
or	O
T	O
cells	O
.	O

The	O
method	O
was	O
used	O
for	O
screening	O
of	O
synthetic	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
Mycobacterium	O
tuberculosis	B-PATH
(	O
MTB	O
),	O
and	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
DNA	O
based	O
on	O
a	O
colorimetric	O
paper	O
-	O
based	O
analytical	O
device	O
developed	O
using	O
the	O
aforementioned	O
principle	O
.	O

Clinical	O
samples	O
(	O
10	O
individual	O
faecal	O
swabs	O
/	O
flock	O
)	O
were	O
duly	O
processed	O
and	O
examined	O
using	O
molecular	O
methods	O
targeting	O
the	O
conservative	O
regions	O
of	O
viral	O
genomes	O
:	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
of	O
astrovirus	O
,	O
non	O
-	O
structural	O
1	O
gene	O
of	O
parvovirus	O
,	O
non	O
-	O
structural	O
protein	O
4	O
gene	O
of	O
rotavirus	O
,	O
and	O
5	O
'	O
untranslated	O
region	O
fragment	O
of	O
turkey	O
coronavirus	O
.	O

Effective	O
prevention	O
and	O
control	O
strategies	O
are	O
needed	O
for	O
diseases	O
with	O
the	O
highest	O
incidence	O
-	O
including	O
hand	O
,	O
foot	O
,	O
and	O
mouth	O
disease	O
,	O
hepatitis	O
B	O
,	O
and	O
tuberculosis	B-PATH
-	O
and	O
those	O
with	O
the	O
fastest	O
rates	O
of	O
increase	O
(	O
including	O
hydatid	O
disease	O
,	O
hepatitis	B-PATH
C	I-PATH
,	O
and	O
syphilis	O
).	O

ABSTRACT	O
:	O
An	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
was	O
a	O
cause	O
for	O
concern	O
in	O
China	O
in	O
the	O
spring	O
of	O
2013	O
.	O

Two	O
dominant	O
populations	O
within	O
the	O
detected	O
viruses	O
were	O
human	O
rhinoviruses	O
(	O
HRVs	O
;	O
n	O
=	O
14	O
)	O
and	O
human	O
coronavirus	O
NL63	O
(	O
n	O
=	O
8	O
),	O
followed	O
by	O
human	O
parainfluenza	O
virus	O
(	O
HPIV	O
),	O
human	O
parechovirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
and	O
human	O
metapneumovirus	O
.	O

In	O
an	O
immunofluorescence	O
assay	O
,	O
these	O
cardenolides	O
were	O
found	O
to	O
diminish	O
the	O
expressions	O
of	O
TGEV	O
nucleocapsid	O
and	O
spike	O
protein	O
,	O
which	O
was	O
used	O
as	O
an	O
indication	O
for	O
viral	O
replication	O
;	O
block	O
TGEV	O
infection	O
induced	O
apoptosis	B-PATH
and	O
cytopathic	O
effects	O
;	O
and	O
impart	O
the	O
same	O
trend	O
of	O
inhibitory	O
activity	O
against	O
Na	O

Hospitalized	O
children	O
with	O
proven	O
influenza	B-PATH
infection	I-PATH
by	O
polymerase	O
chain	O
reaction	O
on	O
nasopharyngeal	O
swab	O
specimens	O
in	O
our	O
clinic	O
,	O
between	O
December	O
2013	O
and	O
March	O
2016	O
,	O
were	O
enrolled	O
.	O

These	O
children	O
were	O
divided	O
into	O
3	O
groups	O
as	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
(	O
n	O
=	O
42	O
),	O
Influenza	B-PATH
A	I-PATH
/	O
H3N2	O
(	O
n	O
=	O
23	O
),	O
and	O
Influenza	O
B	O
(	O
n	O
=	O
35	O
).	O

Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
infection	O
represented	O
more	O
severe	O
clinical	O
disease	O
.	O

It	O
has	O
been	O
described	O
in	O
several	O
diseases	O
like	O
asthma	B-PATH
,	O
cystic	O
fibrosis	O
,	O
pulmonary	O
infection	O
,	O
cyanotic	O
congenital	O
heart	O
disease	O
and	O
in	O
few	O
young	O
children	O
with	O
homozygous	O
sickle	O
cell	O
disease	O
.	O

Human	O
metapneumovirus	O
(	O
HMPV	O
)	O
was	O
the	O
predominant	O
virus	O
detected	O
in	O
25	O
.	O
7	O
per	O
cent	O
children	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
,	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
and	O
human	O
adenovirus	O
(	O
HAdV	O
)	O
in	O
19	O
.	O
9	O
,	O
11	O
.	O
0	O
and	O
8	O
.	O
8	O
per	O
cent	O
children	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Hyperventilation	O
caused	O
by	O
physical	O
and	O
/	O
or	O
psychological	O
stress	O
may	O
lead	O
to	O
significant	O
respiratory	O
alkalosis	O
and	O
an	O
elevated	O
systemic	O
pH	O
.	O
The	O
alkalotic	O
pH	O
may	O
in	O
turn	O
suppress	O
the	O
normal	O
renal	O
release	B-PATH
of	O
phosphate	O
into	O
the	O
urine	O
,	O
thereby	O
interrupting	O
the	O
endogenous	O
production	O
of	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
(	O
calcitriol	O
).	O

In	O
LPS	O
-	O
treated	O
Raw264	O
.	O
7	O
macrophages	O
,	O
miR	O
-	O
19	O
mimics	O
blocking	O
the	O
down	O
-	O
regulation	O
of	O
LPS	O
-	O
induced	O
p47phox	O
expression	O
,	O
the	O
accumulation	O
of	O
ROS	O
,	O
and	O
the	O
release	B-PATH
of	O
inflammatory	O
cytokines	O
.	O

TITLE	O
:	O
Coronavirus	O
nonstructural	O
protein	O
15	O
mediates	O
evasion	O
of	O
dsRNA	O
sensors	O
and	O
limits	O
apoptosis	B-PATH
in	O
macrophages	O
.	O

Infection	O
of	O
macrophages	O
with	O
N15m1	O
,	O
which	O
expresses	O
an	O
unstable	O
nsp15	O
,	O
or	O
N15m3	O
,	O
which	O
expresses	O
a	O
catalysis	O
-	O
deficient	O
nsp15	O
,	O
activated	O
MDA5	O
,	O
PKR	O
,	O
and	O
the	O
OAS	O
/	O
RNase	O
L	O
system	O
,	O
resulting	O
in	O
an	O
early	O
,	O
robust	O
induction	O
of	O
type	O
I	O
IFN	O
,	O
PKR	O
-	O
mediated	O
apoptosis	B-PATH
,	O
and	O
RNA	B-PATH
degradation	I-PATH
.	O

ABSTRACT	O
:	O
The	O
apoptosis	B-PATH
of	O
pyramidal	O
neurons	O
in	O
CA2	O
and	O
CA3	O
subregions	O
of	O
the	O
hippocampus	O
is	O
induced	O
after	O
infection	O
with	O
Mu	O
-	O
3	O
virus	O
(	O
Mu	O
-	O
3	O
),	O
a	O
neuropathogenic	O
strain	O
of	O
the	O
JHM	O
virus	O
(	O
JHMV	O
),	O
at	O
4	O
-	O
5	O
days	O
post	O
-	O
inoculation	O
(	O
dpi	O
).	O

Therefore	O
,	O
it	O
is	O
considered	O
that	O
the	O
apoptotic	O
lesions	O
occur	O
through	O
the	O
indirect	O
effects	O
of	O
infection	O
,	O
and	O
not	O
as	O
a	O
result	O
of	O
direct	O
infection	O
with	O
Mu	O
-	O
3	O
,	O
similar	O
to	O
the	O
reported	O
neuronal	O
apoptosis	B-PATH
in	O
the	O
hippocampus	O
after	O
other	O
types	O
of	O
infection	O
.	O

The	O
apoptosis	B-PATH
in	O
the	O
pyramidal	O
neurons	O
is	O
accompanied	O
by	O
various	O
types	O
of	O
proinflammatory	O
cytokines	O
depending	O
on	O
the	O
causative	O
agents	O
.	O

The	O
pathogenesis	O
of	O
viral	O
FH	O
includes	O
virus	O
-	O
induced	O
immune	O
activation	O
,	O
inflammation	O
,	O
and	O
subsequent	O
hepatic	O
apoptosis	B-PATH
and	O
necrosis	O
.	O

TITLE	O
:	O
Intrapulmonary	O
Percussive	O
Ventilation	O
as	O
an	O
Airway	O
Clearance	O
Technique	O
during	O
Venoarterial	O
Extracorporeal	O
Life	O
Support	O
in	O
an	O
Infant	O
with	O
Pertussis	B-PATH
.	O

We	O
present	O
a	O
case	O
of	O
a	O
4	O
-	O
week	O
old	O
infant	O
who	O
developed	O
a	O
severe	O
pertussis	B-PATH
infection	O
requiring	O
ECLS	O
.	O

The	O
severity	O
of	O
his	O
illness	O
and	O
pertussis	B-PATH
infection	O
-	O
associated	O
intraluminal	O
bronchiole	O
obstruction	O
made	O
medical	O
management	O
challenging	O
.	O

On	O
the	O
basis	O
of	O
differentially	O
expressed	O
proteins	O
,	O
we	O
propose	O
that	O
PEDV	O
might	O
disrupt	O
apoptosis	B-PATH
and	O
may	O
elicit	O
stronger	O
inflammatory	O
cascades	O
as	O
well	O
.	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	O
of	O
vaccinia	O
virus	O
DNA	O
,	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
,	O
into	O
cells	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	O
-	O
dependant	O
RNA	B-PATH
polymerase	I-PATH
.	O

Expression	O
of	O
GPC3	O
leads	O
to	O
an	O
increased	O
apoptosis	B-PATH
response	O
in	O
human	O
lung	O
carcinoma	O
tumor	O
cells	O
,	O
and	O
is	O
considered	O
to	O
be	O
a	O
candidate	O
lung	O
tumor	O
suppressor	O
gene	O
.	O

During	O
the	O
winter	O
season	O
,	O
viral	O
respiratory	O
pathogens	O
,	O
mainly	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
human	O
metapneumovirus	O
,	O
coronavirus	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
were	O
clinically	O
underdiagnosed	O
in	O
70	O
%	O
of	O
patients	O
positive	O
by	O
the	O
multiplex	O
PCR	O
assay	O
.	O

Hospitalised	O
children	O
and	O
adults	O
(	O
including	O
pregnant	O
women	O
)	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
or	O
B	O
(	O
defined	O
as	O
the	O
presence	O
of	O
hypoxia	O
or	O
tachypnoea	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
two	O
units	O
(	O
or	O
paediatric	O
equivalent	O
)	O
of	O
anti	O
-	O
influenza	O
plasma	O
plus	O
standard	O
care	O
,	O
versus	O
standard	O
care	O
alone	O
,	O
and	O
were	O
followed	O
up	O
for	O
28	O
days	O
.	O

Influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
infection	O
is	O
the	O
cause	O
of	O
a	O
respiratory	O
disease	O
that	O
poses	O
a	O
significant	O
global	O
public	O
health	O
concern	O
.	O

ABSTRACT	O
:	O
Our	O
previous	O
screening	O
of	O
50	O
240	O
structurally	O
diverse	O
compounds	O
led	O
to	O
the	O
identification	O
of	O
39	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
inhibitors	O
(	O
Kao	O
R	O
.	O
Y	O
.,	O
Yang	O
D	O
.,	O
Lau	O
L	O
.	O
S	O
.,	O
Tsui	O
W	O
.	O
H	O
.,	O
Hu	O
L	O
.	O
et	O
al	O
.	O
Nat	O
Biotechnol	O
2010	O
;	O
28	O
:	O
600	O
-	O
605	O
).	O

This	O
inhibitor	O
exhibited	O
low	O
micromolar	O
antiviral	O
activity	O
against	O
various	O
influenza	B-PATH
A	I-PATH
and	O
B	O
virus	O
strains	O
,	O
including	O
the	O
highly	O
pathogenic	O
influenza	B-PATH
A	I-PATH
strains	O
H5N1	O
and	O
H7N9	O
,	O
enterovirus	O
A71	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
rhinovirus	O
A	O
,	O
SARS	O
-	O
and	O
MERS	O
-	O
coronavirus	O
.	O

TITLE	O
:	O
Improvements	O
in	O
brain	O
and	O
behavior	O
following	O
eradication	O
of	O
hepatitis	B-PATH
C	I-PATH
.	O
ABSTRACT	O
:	O
Despite	O
recent	O
advances	O
in	O
treatment	O
,	O
hepatitis	B-PATH
C	I-PATH
remains	O
a	O
significant	O
public	O
health	O
problem	O
.	O

The	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
is	O
known	O
to	O
infiltrate	O
the	O
brain	O
,	O
yet	O
findings	O
from	O
studies	O
on	O
associated	O
neurocognitive	O
and	O
neuropathological	O
changes	O
are	O
mixed	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
septic	O
shock	O
in	O
a	O
cat	O
with	O
disseminated	O
toxoplasmosis	B-PATH
.	O

An	O
endotracheal	O
wash	O
was	O
performed	O
,	O
which	O
confirmed	O
a	O
diagnosis	O
of	O
pulmonary	O
toxoplasmosis	B-PATH
.	O

The	O
clinical	O
and	O
necropsy	O
findings	O
presented	O
here	O
are	O
consistent	O
with	O
ARDS	O
secondary	O
to	O
disseminated	O
toxoplasmosis	B-PATH
in	O
a	O
cat	O
.	O

TITLE	O
:	O
Microtubule	O
-	O
assisted	O
altered	O
trafficking	O
of	O
astrocytic	O
gap	B-PATH
junction	I-PATH
protein	O
connexin	O
43	O
is	O
associated	O
with	O
depletion	O
of	O
connexin	O
47	O
during	O
mouse	O
hepatitis	O
virus	O
infection	O
.	O

Cx43	O
is	O
mainly	O
expressed	O
by	O
astrocytes	O
in	O
the	O
CNS	O
and	O
forms	O
gap	B-PATH
junction	I-PATH
intercellular	O
communications	O
between	O
astrocytes	O
-	O
astrocytes	O
(	O
Cx43	O
-	O
Cx43	O
)	O
and	O
between	O
astrocytes	O
-	O
oligodendrocytes	O
(	O
Cx43	O
-	O
Cx47	O
).	O

ABSTRACT	O
:	O
Intracellular	O
trafficking	O
and	O
localization	O
studies	O
of	O
spike	O
protein	O
from	O
SARS	O
and	O
OC43	O
showed	O
that	O
SARS	O
spike	O
protein	O
is	O
localized	O
in	O
the	O
ER	O
or	O
ERGIC	O
compartment	O
and	O
OC43	O
spike	O
protein	O
is	O
predominantly	O
localized	O
in	O
the	O
lysosome	B-PATH
.	O

A	O
unique	O
GYQEL	O
motif	O
is	O
identified	O
at	O
the	O
cytoplasmic	O
terminal	O
of	O
OC43	O
spike	O
protein	O
which	O
helps	O
in	O
localization	O
in	O
the	O
lysosome	B-PATH
,	O
and	O
a	O
novel	O
KLHYT	O
motif	O
is	O
identified	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
SARS	O
spike	O
protein	O
which	O
helps	O
in	O
ER	O
or	O
ERGIC	O
localization	O
.	O

ABSTRACT	O
:	O
Emerging	O
viruses	O
such	O
as	O
HIV	O
,	O
dengue	O
,	O
influenza	B-PATH
A	I-PATH
,	O
SARS	O
coronavirus	O
,	O
Ebola	O
,	O
and	O
other	O
viruses	O
pose	O
a	O
significant	O
threat	O
to	O
human	O
health	O
.	O

Chloroquine	O
analogs	O
have	O
been	O
used	O
for	O
decades	O
as	O
the	O
primary	O
and	O
most	O
successful	O
drugs	O
against	O
malaria	B-PATH
.	O

In	O
2	O
(	O
15	O
%)	O
CoV	O
-	O
HKU1	O
-	O
positive	O
adults	O
,	O
the	O
only	O
viral	O
coinfection	O
detected	O
was	O
influenza	B-PATH
A	I-PATH
.	O
Coronavirus	O
-	O
HKU1	O
accounted	O
for	O
1	O
.	O
6	O
%	O
of	O
adult	O
respiratory	O
infections	O
and	O
should	O
be	O
considered	O
in	O
differential	O
diagnosis	O
of	O
severe	O
respiratory	O
illnesses	O
among	O
adults	O
.	O

ABSTRACT	O
:	O
Acute	O
outbreaks	O
of	O
respiratory	O
disease	O
in	O
swine	O
at	O
agricultural	O
fairs	O
in	O
Michigan	O
,	O
USA	O
,	O
in	O
2015	O
raised	O
concern	O
for	O
potential	O
human	O
exposure	O
to	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

Testing	O
ruled	O
out	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
identified	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
as	O
the	O
cause	O
of	O
influenza	O
-	O
like	O
illness	O
in	O
the	O
affected	O
swine	O
.	O

Respiratory	O
syncytial	O
virus	O
(	O
29	O
.	O
7	O
%),	O
Influenza	B-PATH
A	I-PATH
(	O
20	O
.	O
5	O
%),	O
rhinovirus	O
(	O
18	O
.	O
9	O
%),	O
adenovirus	O
(	O
10	O
%),	O
human	O
metapneumovirus	O
(	O
8	O
%),	O
parainfluenza	O
(	O
5	O
.	O
2	O
%),	O
coronavirus	O
(	O
6	O
%),	O
and	O
bocavirus	O
(	O
1	O
.	O
6	O
%)	O
were	O
isolated	O
from	O
respiratory	O
samples	O
.	O

Ever	O
wheezing	O
(	O
RR	O
:	O
1	O
.	O
6	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
2	O
.	O
4	O
),	O
parental	O
asthma	B-PATH
(	O
RR	O
:	O
1	O
.	O
5	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
2	O
.	O
2	O
),	O
other	O
allergic	O
diseases	O
in	O
the	O
family	O
(	O
RR	O
:	O
1	O
.	O
8	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
2	O
-	O
2	O
.	O
9	O
)	O
and	O
environmental	O
tobacco	O
smoke	O
(	O
RR	O
:	O
1	O
.	O
6	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
3	O
.	O
5	O
)	O
were	O
more	O
common	O
in	O
the	O
severe	O
pneumonia	O
group	O
.	O

However	O
,	O
parental	O
asthma	B-PATH
,	O
ever	O
wheezing	O
and	O
environmental	O
tobacco	O
smoke	O
exposure	O
are	O
risk	O
factors	O
for	O
severe	O
viral	O
pneumonia	O
in	O
children	O
.	O

TITLE	O
:	O
Asthma	B-PATH
-	O
COPD	O
Overlap	O
Shows	O
Favorable	O
Clinical	O
Outcomes	O
Compared	O
to	O
Pure	O
COPD	O
in	O
a	O
Korean	O
COPD	O
Cohort	O
.	O

ABSTRACT	O
:	O
Comparisons	O
of	O
the	O
characteristics	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
asthma	B-PATH
-	O
COPD	O
overlap	O
syndrome	O
(	O
ACOS	O
)	O
have	O
been	O
the	O
focus	O
of	O
several	O
studies	O
since	O
the	O
diseases	O
were	O
defined	O
by	O
the	O
Global	O
Initiative	O
for	O
Asthma	B-PATH
and	O
Global	O
Initiative	O
for	O
Chronic	O
Obstructive	O
Lung	O
Disease	O
guidelines	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
characteristics	O
of	O
asthma	B-PATH
-	O
COPD	O
overlap	O
(	O
ACO	O
)	O
and	O
COPD	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
and	O
Pulmonary	O
Tuberculosis	B-PATH
Coinfection	O
:	O
Implications	O
for	O
Infection	O
Control	O
.	O

ABSTRACT	O
:	O
Coinfection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
with	O
tuberculosis	B-PATH
(	O
TB	O
)	O
has	O
not	O
been	O
previously	O
reported	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
infection	I-PATH
and	O
pneumonia	O
are	O
known	O
to	O
cause	O
much	O
of	O
their	O
mortality	O
by	O
inducing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
which	O
is	O
the	O
most	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
which	O
is	O
a	O
negative	O
regulator	O
of	O
angiotensin	O
II	O
in	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
,	O
has	O
been	O
reported	O
to	O
have	O
a	O
crucial	O
role	O
in	O
ALI	O
.	O

We	O
compared	O
clinical	O
disease	O
severity	O
and	O
sought	O
clinical	O
and	O
demographic	O
differences	O
between	O
infants	O
with	O
B	O
.	O
pertussis	B-PATH
infection	O
alone	O
and	O
those	O
with	O
respiratory	O
viral	O
coinfections	O
.	O

We	O
enrolled	O
53	O
infants	O
with	O
pertussis	B-PATH
younger	O
than	O
180	O
days	O
(	O
median	O
age	O
58	O
days	O
,	O
range	O
17	O
â	O
109	O
days	O
,	O
64	O
.	O

We	O
tested	O
in	O
naso	O
-	O
pharyngeal	O
washings	O
B	O
.	O
pertussis	B-PATH
and	O
14	O
respiratory	O
viruses	O
with	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
.	O

28	O
/	O
53	O
infants	O
had	O
B	O
.	O
pertussis	B-PATH
alone	O
and	O
25	O
viral	O
coinfection	O
:	O
10	O
human	O
rhinovirus	O
(	O
9	O
alone	O
and	O
1	O
in	O
coinfection	O
with	O
parainfluenza	O
virus	O
),	O
3	O
human	O
coronavirus	O
,	O
2	O
respiratory	O
syncytial	O
virus	O
.	O

No	O
differences	O
were	O
observed	O
in	O
clinical	O
disease	O
severity	O
between	O
infants	O
with	O
B	O
.	O
pertussis	B-PATH
infection	O
alone	O
and	O
those	O
with	O
coinfections	O
.	O

Infants	O
with	O
B	O
.	O
pertussis	B-PATH
alone	O
were	O
younger	O
than	O
infants	O
with	O
coinfections	O
,	O
and	O
less	O
often	O
breastfeed	O
at	O
admission	O
.	O

In	O
this	O
descriptive	O
study	O
,	O
no	O
associations	O
between	O
clinical	O
severity	O
and	O
pertussis	B-PATH
with	O
or	O
without	O
co	O
-	O
infections	O
were	O
found	O
.	O

RESULTS	O
:	O
28	O
/	O
53	O
infants	O
had	O
B	O
.	O
pertussis	B-PATH
alone	O
and	O
25	O
viral	O
coinfection	O
:	O
10	O
human	O
rhinovirus	O
(	O
9	O
alone	O
and	O
1	O
in	O
coinfection	O
with	O
parainfluenza	O
virus	O
),	O
3	O
human	O
coronavirus	O
,	O
2	O
respiratory	O
syncytial	O
virus	O
.	O

Infants	O
with	O
B	O
.	O
pertussis	B-PATH
alone	O
were	O
younger	O
than	O
infants	O
with	O
coinfections	O
,	O
and	O
less	O
often	O
breastfeed	O
at	O
admission	O
.	O

Evidence	O
-	O
based	O
diagnosis	O
,	O
monitoring	O
,	O
and	O
treatment	O
can	O
improve	O
functioning	O
and	O
quality	O
of	O
life	O
in	O
adult	O
patients	O
with	O
asthma	B-PATH
.	O

The	O
diagnosis	O
of	O
asthma	B-PATH
requires	O
these	O
symptoms	O
and	O
demonstration	O
of	O
reversible	O
airway	O
obstruction	O
using	O
spirometry	O
.	O

Inhaled	O
short	O
-	O
acting	O
Î²2	O
-	O
agonists	O
provide	O
rapid	O
relief	O
of	O
acute	O
symptoms	O
,	O
but	O
maintenance	O
with	O
daily	O
inhaled	O
corticosteroids	O
is	O
the	O
standard	O
of	O
care	O
for	O
persistent	O
asthma	B-PATH
.	O

Other	O
controller	O
approaches	O
include	O
long	O
-	O
acting	O
muscarinic	O
antagonists	O
(	O
eg	O
,	O
tiotropium	O
),	O
and	O
biological	O
agents	O
directed	O
against	O
proteins	O
involved	O
in	O
the	O
pathogenesis	O
of	O
asthma	B-PATH
(	O
eg	O
,	O
omalizumab	O
,	O
mepolizumab	O
,	O
reslizumab	O
).	O

Asthma	B-PATH
is	O
characterized	O
by	O
variable	O
airway	O
obstruction	O
,	O
airway	O
hyperresponsiveness	O
,	O
and	O
airway	O
inflammation	O
.	O

Other	O
controller	O
medications	O
,	O
such	O
as	O
long	O
-	O
acting	O
bronchodilators	O
and	O
biologics	O
,	O
may	O
be	O
required	O
in	O
moderate	O
and	O
severe	O
asthma	B-PATH
.	O

Patients	O
with	O
severe	O
asthma	B-PATH
generally	O
benefit	O
from	O
consultation	O
with	O
an	O
asthma	B-PATH
specialist	O
for	O
consideration	O
of	O
additional	O
treatment	O
,	O
including	O
injectable	O
biologic	O
agents	O
.	O

Treating	O
that	O
with	O
steroids	O
compromised	O
her	O
immune	O
system	O
beyond	O
her	O
pre	O
-	O
existing	O
primary	B-PATH
immunodeficiency	I-PATH
status	O
.	O

With	O
the	O
intensification	O
of	O
globalization	O
and	O
increasing	O
gaps	O
between	O
countries	O
,	O
new	O
and	O
reemerging	O
health	O
threats	O
such	O
as	O
HIV	O
/	O
AIDS	O
,	O
tuberculosis	B-PATH
,	O
influenza	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
Ebola	O
,	O
and	O
Zika	O
and	O
a	O
gradual	O
rethinking	O
on	O
security	O
concepts	O
framed	O
a	O
new	O
political	O
context	O
.	O

To	O
determine	O
the	O
genetic	O
relationships	O
of	O
the	O
18	O
sequences	O
obtained	O
in	O
this	O
study	O
and	O
previously	O
known	O
coronaviruses	O
,	O
the	O
nucleotide	O
sequences	O
of	O
a	O
392	O
-	O
nt	O
region	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
were	O
analyzed	O
phylogenetically	O
.	O

TITLE	O
:	O
Dysregulation	O
of	O
pulmonary	O
endothelial	O
protein	O
C	O
receptor	O
and	O
thrombomodulin	O
in	O
severe	O
falciparum	O
malaria	B-PATH
-	O
associated	O
ARDS	O
relevant	O
to	O
hemozoin	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
role	O
of	O
the	O
protein	O
C	O
system	O
,	O
endothelial	O
protein	O
C	O
receptor	O
(	O
EPCR	O
)	O
and	O
thrombomodulin	O
(	O
TM	O
)	O
in	O
the	O
pathogenesis	O
of	O
malaria	B-PATH
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
relation	O
to	O
hemozoin	O
and	O
proinflammatory	O
cytokines	O
-	O
induced	O
type	O
II	O
pneumocyte	O
injury	O
and	O
-	O
aggravated	O
pulmonary	O
resolution	O
.	O

A	O
total	O
of	O
29	O
left	O
-	O
over	O
lung	O
specimens	O
that	O
were	O
obtained	O
from	O
patients	O
who	O
died	O
from	O
severe	O
falciparum	O
malaria	B-PATH
were	O
examined	O
.	O

Moreover	O
,	O
an	O
in	O
vitro	O
analysis	O
demonstrated	O
that	O
interleukin	O
-	O
13	O
and	O
-	O
31	O
and	O
hemozoin	O
induced	O
pneumocytic	O
cell	O
injury	O
and	O
apoptosis	B-PATH
,	O
as	O
assessed	O
by	O
EB	O
/	O
AO	O
staining	O
,	O
electron	O
microscopy	O
and	O
the	O
up	O
-	O
regulation	O
of	O
CARD	O
-	O
9	O
mRNA	O
(	O
caspase	O
recruitment	O
domain	O
-	O
9	O
messenger	O
-	O
ribonucleic	O
acid	O
).	O

The	O
dysregulation	O
of	O
EPCR	O
and	O
TM	O
in	O
the	O
lung	O
,	O
especially	O
in	O
those	O
with	O
increased	O
levels	O
of	O
hemozoin	O
,	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
malaria	B-PATH
-	O
associated	O
ARDS	O
through	O
an	O
apoptotic	O
pathway	O
.	O

There	O
is	O
growing	O
evidence	O
that	O
severe	O
infantile	O
RSV	O
bronchiolitis	O
,	O
a	O
condition	O
characterised	O
by	O
an	O
inflammatory	O
reaction	O
to	O
the	O
virus	O
,	O
is	O
associated	O
with	O
later	O
childhood	O
wheeze	O
in	O
some	O
vulnerable	O
children	O
;	O
however	O
,	O
a	O
direct	O
causal	O
relationship	O
with	O
asthma	B-PATH
has	O
not	O
yet	O
been	O
established	O
.	O

We	O
used	O
non	O
-	O
denaturing	O
purification	O
conditions	O
that	O
allowed	O
the	O
characterization	O
of	O
polypeptide	O
chains	O
of	O
different	O
lengths	O
,	O
mimicking	O
the	O
landscape	O
of	O
the	O
cotranslational	O
fold	O
of	O
a	O
Î²	O
-	O
barrel	O
,	O
and	O
avoiding	O
the	O
major	O
technical	O
hindrances	O
of	O
working	O
with	O
the	O
nascent	O
polypeptide	O
bound	O
to	O
the	O
ribosome	B-PATH
.	O

TITLE	O
:	O
Airway	O
and	O
parenchyma	O
immune	O
cells	O
in	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
viral	O
and	O
non	O
-	O
viral	O
diffuse	O
alveolar	O
damage	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
lung	O
immunopathology	O
of	O
viral	O
(	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
)	O
to	O
non	O
-	O
viral	O
,	O
extrapulmonary	O
aetiologies	O
in	O
autopsy	O
cases	O
with	O
DAD	O
.	O

This	O
enabled	O
the	O
identification	O
of	O
a	O
viral	O
agent	O
in	O
71	O
.	O
3	O
%	O
(	O
231	O
/	O
324	O
)	O
of	O
unidentified	O
surveillance	O
samples	O
,	O
including	O
common	O
respiratory	O
pathogens	O
(	O
100	O
/	O
324	O
;	O
30	O
.	O
9	O
%):	O
enterovirus	O
(	O
16	O
/	O
100	O
;	O
16	O
.	O
0	O
%),	O
coxsackievirus	O
(	O
31	O
/	O
100	O
;	O
31	O
.	O
0	O
%),	O
echovirus	O
(	O
22	O
/	O
100	O
;	O
22	O
.	O
0	O
%),	O
human	O
rhinovirus	O
(	O
3	O
/	O
100	O
;	O
3	O
%),	O
enterovirus	O
genus	O
(	O
2	O
/	O
100	O
;	O
2	O
.	O
0	O
%),	O
influenza	B-PATH
A	I-PATH
(	O
9	O
/	O
100	O
;	O
9	O
.	O
0	O
%),	O
influenza	O
B	O
,	O
(	O
5	O
/	O
100	O
;	O
5	O
.	O
0	O
%),	O
human	O
parainfluenza	O
(	O
4	O
/	O
100	O
;	O
4	O
.	O
0	O
%),	O
human	O
adenovirus	O
(	O
3	O
/	O
100	O
;	O
3	O
.	O
0	O
%),	O
human	O
coronavirus	O
(	O
1	O
/	O
100	O
;	O
1	O
.	O
0	O
%),	O
human	O
metapneumovirus	O
(	O
2	O
/	O
100	O
;	O
2	O
.	O
0	O
%),	O
and	O
mumps	O
virus	O
(	O
2	O
/	O
100	O
;	O
2	O
.	O
0	O
%),	O
in	O
addition	O
to	O
the	O
non	O
-	O
respiratory	O
pathogen	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
(	O
172	O
/	O
324	O
;	O
53	O
.	O
1	O
%)	O
and	O
HSV	O
-	O
1	O
co	O
-	O
infection	O
with	O
respiratory	O
viruses	O
(	O
41	O
/	O
324	O
;	O
12	O
.	O
7	O
%).	O

TITLE	O
:	O
Comparison	O
of	O
mono	O
-	O
and	O
co	O
-	O
infection	O
by	O
swine	O
influenza	B-PATH
A	I-PATH
viruses	O
and	O
porcine	O
respiratory	O
coronavirus	O
in	O
porcine	O
precision	O
-	O
cut	O
lung	O
slices	O
.	O

Here	O
we	O
infected	O
porcine	O
precision	O
-	O
cut	O
lung	O
slices	O
with	O
porcine	O
respiratory	O
coronavirus	O
and	O
two	O
Influenza	B-PATH
A	I-PATH
viruses	O
to	O
analyze	O
if	O
co	O
-	O
infection	O
with	O
these	O
viruses	O
may	O
enhance	O
disease	O
outcome	O
in	O
swine	O
.	O

Cell	O
imaging	O
revealed	O
intracellular	O
peptide	O
aggregates	O
,	O
consistent	O
with	O
their	O
endocytosis	B-PATH
into	O
compartments	O
where	O
CoV	O
entry	O
takes	O
place	O
.	O

TITLE	O
:	O
Increased	O
serum	O
IL	O
-	O
17A	O
and	O
Th2	O
cytokine	O
levels	O
in	O
patients	O
with	O
severe	O
uncontrolled	O
asthma	B-PATH
.	O

ABSTRACT	O
:	O
Asthma	B-PATH
is	O
a	O
syndrome	O
of	O
chronic	O
bronchial	O
inflammation	O
and	O
airway	O
remodelling	O
.	O

Initially	O
,	O
asthma	B-PATH
has	O
been	O
categorized	O
into	O
atopic	O
and	O
nonatopic	O
types	O
,	O
based	O
on	O
antigen	O
-	O
specific	O
IgE	O
levels	O
.	O

Moreover	O
,	O
recently	O
,	O
asthma	B-PATH
has	O
been	O
classified	O
into	O
different	O
endotypes	O
based	O
on	O
its	O
pathophysiology	O
,	O
leading	O
to	O
the	O
selection	O
of	O
the	O
most	O
optimal	O
and	O
effective	O
therapies	O
.	O

In	O
this	O
study	O
,	O
we	O
measured	O
the	O
levels	O
of	O
24	O
cytokines	O
/	O
chemokines	O
in	O
the	O
sera	O
of	O
healthy	O
controls	O
(	O
HCs	O
)	O
(	O
n	O
=	O
34	O
)	O
and	O
patients	O
with	O
asthma	B-PATH
(	O
n	O
=	O
77	O
),	O
that	O
were	O
compared	O
among	O
patient	O
groups	O
with	O
different	O
disease	O
activities	O
and	O
characteristics	O
.	O

The	O
serum	O
levels	O
of	O
nine	O
cytokines	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
asthma	B-PATH
than	O
in	O
HCs	O
,	O
and	O
the	O
levels	O
of	O
IL	O
-	O
17A	O
and	O
SCF	O
were	O
significantly	O
different	O
between	O
uncontrolled	O
and	O
well	O
-	O
controlled	O
patient	O
groups	O
(	O
p	O
=	O
0	O
.	O
003	O
).	O

The	O
IL	O
-	O
17A	O
levels	O
were	O
significantly	O
correlated	O
with	O
those	O
of	O
IL	O
-	O
4	O
,	O
IL	O
-	O
25	O
,	O
IL	O
-	O
10	O
,	O
and	O
IFN	O
-	O
Î³	O
in	O
patients	O
with	O
uncontrolled	O
asthma	B-PATH
,	O
and	O
the	O
patients	O
with	O
the	O
highest	O
levels	O
of	O
all	O
the	O
above	O
cytokines	O
were	O
refractory	O
to	O
high	O
-	O
dose	O
of	O
inhaled	O
corticosteroid	O
therapy	O
and	O
have	O
a	O
history	O
of	O
acute	O
exacerbation	O
within	O
1	O
year	O
,	O
requiring	O
systemic	O
steroid	O
therapy	O
.	O

We	O
evaluated	O
the	O
performance	O
of	O
the	O
PowerChek	O
MERS	O
(	O
upE	O
&	O
ORF1a	O
)	O
real	O
-	O
time	O
PCR	O
Kit	O
(	O
PowerChek	O
MERS	O
assay	O
;	O
Kogene	O
Biotech	O
,	O
Korea	O
)	O
a	O
one	O
-	O
step	O
rRT	O
-	O
PCR	O
assay	O
for	O
the	O
qualitative	O
detection	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
evaluated	O
PowerChek	O
MERS	O
assay	O
performance	O
in	O
comparison	O
with	O
nested	O
RT	O
-	O
PCR	O
and	O
sequencing	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
and	O
N	O
genes	O
.	O

Autophagy	O
was	O
activated	O
by	O
rapamycin	O
at	O
a	O
dose	O
that	O
does	O
not	O
affect	O
cell	O
viability	O
and	O
tight	B-PATH
junction	I-PATH
permeability	O
.	O

We	O
found	O
that	O
the	O
susceptibility	O
of	O
septic	O
mice	O
to	O
Secondary	O
Pseudomonas	O
aeruginosa	O
pneumonia	O
could	O
be	O
down	O
-	O
regulated	O
by	O
ethyl	O
pyruvate	O
treatment	O
and	O
the	O
protective	O
effects	O
of	O
EP	O
may	O
via	O
decreasing	O
lung	O
IL	O
-	O
10	O
and	O
plasma	O
HMGB1	O
expression	O
,	O
inhibiting	O
the	O
function	O
of	O
Tregs	O
and	O
relieving	O
the	O
apoptosis	B-PATH
of	O
splenic	O
immune	O
cells	O
.	O

TITLE	O
:	O
Veno	O
-	O
veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
septic	O
-	O
induced	O
cardiomyopathy	O
due	O
to	O
severe	O
pulmonary	O
tuberculosis	B-PATH
.	O

ABSTRACT	O
:	O
We	O
describe	O
the	O
rare	O
experience	O
of	O
veno	O
-	O
veno	O
-	O
arterial	O
(	O
VVA	O
)	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
a	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
septic	O
-	O
induced	O
cardiomyopathy	O
due	O
to	O
pulmonary	O
tuberculosis	B-PATH
(	O
TB	O
).	O

We	O
enrolled	O
174	O
patients	O
:	O
113	O
had	O
respiratory	O
symptoms	O
/	O
suspected	O
MERS	O
-	O
CoV	O
infection	O
,	O
31	O
had	O
confirmed	O
influenza	B-PATH
A	I-PATH
or	O
B	O
infection	O
,	O
23	O
had	O
a	O
recent	O
confirmed	O
MERS	O
-	O
CoV	O
infection	O
,	O
and	O
7	O
had	O
confirmed	O
MERS	O
-	O
CoV	O
infection	O
1	O
year	O
before	O
.	O

TITLE	O
:	O
Epidemiological	O
and	O
clinical	O
assessment	O
of	O
a	O
shared	O
territorial	O
malaria	B-PATH
guideline	O
in	O
the	O
10	O
years	O
of	O
its	O
implementation	O
(	O
Barcelona	O
,	O
North	O
Metropolitan	O
Area	O
,	O
Catalonia	O
,	O
Spain	O
,	O
2007	O
-	O
2016	O
).	O

ABSTRACT	O
:	O
Malaria	B-PATH
remains	O
a	O
major	O
source	O
of	O
morbi	O
-	O
mortality	O
among	O
travellers	O
.	O

In	O
2007	O
,	O
a	O
consensual	O
multicenter	O
Primary	O
Care	O
-	O
Hospital	O
shared	O
guideline	O
on	O
travel	O
-	O
prior	O
chemoprophylaxis	O
,	O
diagnosis	O
and	O
clinical	O
management	O
of	O
imported	O
malaria	B-PATH
was	O
set	O
up	O
in	O
the	O
Barcelona	O
North	O
Metropolitan	O
area	O
.	O

A	O
total	O
of	O
190	O
malaria	B-PATH
cases	O
,	O
all	O
them	O
imported	O
,	O
have	O
been	O
recorded	O
.	O

The	O
overall	O
estimated	O
malaria	B-PATH
crude	O
incidence	O
was	O
of	O
0	O
.	O
47	O
cases	O
per	O
10	O
,	O
000	O
population	O
/	O
year	O
(	O
95	O
%	O
CI	O
0	O
.	O
34	O
-	O
0	O
.	O
59	O
)	O
with	O
a	O
slight	O
significant	O
positive	O
slope	O
especially	O
at	O
the	O
expense	O
of	O
an	O
increase	O
in	O
Indian	O
sub	O
-	O
continent	O
Plasmodium	O
vivax	O
cases	O
.	O

Severe	O
malaria	B-PATH
was	O
diagnosed	O
in	O
34	O
(	O
17	O
.	O
9	O
%)	O
patients	O
and	O
ICU	O
admittance	O
was	O
required	O
in	O
2	O
.	O
6	O
%	O
of	O
them	O
.	O

Those	O
patients	O
diagnosed	O
with	O
P	O
.	O
falciparum	O
malaria	B-PATH
came	O
more	O
often	O
from	O
sub	O
-	O
Saharan	O
Africa	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
those	O
with	O
P	O
.	O
vivax	O
came	O
largely	O
from	O
the	O
Indian	O
sub	O
-	O
continent	O
(	O
p	O
=	O
0	O
.	O
003	O
).	O

After	O
10	O
years	O
of	O
surveillance	O
,	O
a	O
moderate	O
increase	O
in	O
malaria	B-PATH
incidence	O
was	O
observed	O
,	O
mostly	O
P	O
.	O
vivax	O
cases	O
imported	O
from	O
the	O
Indian	O
sub	O
-	O
continent	O
.	O

Although	O
severe	O
malaria	B-PATH
cases	O
have	O
been	O
frequently	O
reported	O
,	O
none	O
of	O
the	O
patients	O
died	O
and	O
organ	O
sequelae	O
were	O
rare	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
190	O
malaria	B-PATH
cases	O
,	O
all	O
them	O
imported	O
,	O
have	O
been	O
recorded	O
.	O

The	O
most	O
common	O
malignancies	O
were	O
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
30	O
%),	O
solid	O
tumors	O
(	O
20	O
%),	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
(	O
19	O
%),	O
and	O
acute	O
lymphocytic	O
leukemia	O
(	O
13	O
%).	O

Prior	O
history	O
included	O
asthma	B-PATH
and	O
Turner	O
syndrome	O
.	O

TITLE	O
:	O
VÎ³4	O
ABSTRACT	O
:	O
The	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
remains	O
a	O
critical	O
global	O
health	O
concern	O
and	O
causes	O
high	O
levels	O
of	O
morbidity	O
and	O
mortality	O
.	O

Our	O
previous	O
study	O
found	O
that	O
interleukin	O
(	O
IL	O
)-	O
17A	O
production	O
by	O
humans	O
or	O
mice	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
substantially	O
contributes	O
to	O
ALI	O
and	O
subsequent	O
morbidity	O
and	O
mortality	O
.	O

However	O
,	O
the	O
cell	O
types	O
responsible	O
for	O
IL	O
-	O
17A	O
production	O
during	O
the	O
early	O
stage	O
of	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
remained	O
unknown	O
.	O

Field	O
vaccination	O
strategies	O
would	O
greatly	O
benefit	O
by	O
such	O
comparative	O
sequence	O
data	O
being	O
mandatorily	O
submitted	O
to	O
regulators	O
prior	O
to	O
vaccine	O
release	B-PATH
following	O
a	O
successful	O
registration	O
process	O
.	O

TITLE	O
:	O
Infectious	O
Bronchitis	O
Virus	O
Infection	O
Induces	O
Apoptosis	B-PATH
during	O
Replication	O
in	O
Chicken	O
Macrophage	O
HD11	O
Cells	O
.	O

Previous	O
studies	O
have	O
reported	O
that	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
infection	O
can	O
produce	O
cytopathic	O
effects	O
(	O
CPE	O
)	O
and	O
apoptosis	B-PATH
in	O
some	O
mammalian	O
cells	O
and	O
primary	O
cells	O
.	O

However	O
,	O
there	O
is	O
little	O
research	O
on	O
IBV	O
-	O
induced	O
immune	O
cell	O
apoptosis	B-PATH
.	O

The	O
activity	O
of	O
caspases	O
,	O
the	O
inhibitory	O
efficacy	O
of	O
caspase	O
-	O
inhibitors	O
and	O
the	O
expression	O
of	O
apoptotic	O
genes	O
further	O
suggested	O
the	O
activation	O
of	O
apoptosis	B-PATH
through	O
both	O
intrinsic	O
and	O
extrinsic	O
pathways	O
in	O
IBV	O
-	O
infected	O
HD11	O
cells	O
.	O

This	O
study	O
presents	O
a	O
chicken	O
macrophage	O
cell	O
line	O
that	O
will	O
enable	O
further	O
analysis	O
of	O
IBV	O
infection	O
and	O
offers	O
novel	O
insights	O
into	O
the	O
mechanisms	O
of	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
in	O
immune	O
cells	O
.	O

TITLE	O
:	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	O
Virus	O
Enters	O
Neuro	O
-	O
2a	O
Cells	O
via	O
Clathrin	O
-	O
Mediated	O
Endocytosis	B-PATH
in	O
a	O
Rab5	O
-,	O
Cholesterol	O
-,	O
and	O
pH	O
-	O
Dependent	O
Manner	O
.	O

Quantification	O
of	O
infected	O
cells	O
showed	O
that	O
PHEV	O
enters	O
cells	O
by	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
(	O
CME	O
)	O
and	O
that	O
low	O
pH	O
,	O
dynamin	O
,	O
cholesterol	O
,	O
and	O
Eps15	O
are	O
indispensably	O
involved	O
in	O
this	O
process	O
.	O

Intriguingly	O
,	O
PHEV	O
invasion	O
leads	O
to	O
rapid	O
actin	O
rearrangement	O
,	O
suggesting	O
that	O
the	O
intactness	O
and	O
dynamics	O
of	O
the	O
actin	O
cytoskeleton	O
are	O
positively	O
correlated	O
with	O
viral	O
endocytosis	B-PATH
.	O

Across	O
the	O
three	O
countries	O
,	O
there	O
was	O
some	O
inconsistency	O
with	O
regard	O
to	O
the	O
types	O
of	O
products	O
(	O
i	O
.	O
e	O
.	O
masks	O
vs	O
.	O
respirators	O
)	O
recommended	O
for	O
influenza	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
tuberculosis	B-PATH
.	O

Across	O
the	O
three	O
countries	O
,	O
there	O
was	O
some	O
inconsistency	O
with	O
regard	O
to	O
the	O
types	O
of	O
products	O
(	O
i	O
.	O
e	O
.	O
masks	O
vs	O
.	O
respirators	O
)	O
recommended	O
for	O
influenza	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
tuberculosis	B-PATH
.	O

ABSTRACT	O
:	O
We	O
report	O
two	O
cases	O
of	O
severe	O
influenza	B-PATH
infection	I-PATH
imported	O
by	O
tourist	O
patients	O
from	O
their	O
country	O
of	O
origin	O
and	O
developed	O
during	O
travel	O
.	O

While	O
studies	O
have	O
reported	O
cases	O
of	O
influenza	O
infections	O
acquired	O
during	O
travel	O
,	O
here	O
we	O
examine	O
two	O
cases	O
of	O
severe	O
influenza	B-PATH
infection	I-PATH
contracted	O
in	O
the	O
country	O
of	O
origin	O
that	O
led	O
to	O
diagnosis	O
and	O
therapeutic	O
problems	O
in	O
the	O
destination	O
country	O
.	O

A	O
number	O
of	O
studies	O
have	O
focused	O
on	O
influenza	B-PATH
infection	I-PATH
in	O
travelers	O
.	O

The	O
latter	O
situation	O
may	O
lead	O
to	O
1	O
)	O
diagnostic	O
problems	O
during	O
the	O
nonepidemic	O
season	O
or	O
in	O
places	O
where	O
diagnostic	O
techniques	O
are	O
lacking	O
and	O
2	O
)	O
therapeutic	O
difficulties	O
resulting	O
from	O
the	O
unavailability	O
of	O
techniques	O
for	O
the	O
management	O
of	O
severe	O
influenza	B-PATH
infection	I-PATH
in	O
tourist	O
areas	O
.	O

Here	O
,	O
we	O
report	O
two	O
cases	O
of	O
extremely	O
severe	O
influenza	B-PATH
infection	I-PATH
imported	O
by	O
tourists	O
from	O
their	O
country	O
of	O
origin	O
and	O
developed	O
during	O
travel	O
.	O

ABSTRACT	O
:	O
We	O
conducted	O
a	O
retrospective	O
study	O
to	O
compare	O
clinical	O
and	O
laboratory	O
findings	O
between	O
1	O
)	O
severe	O
influenza	B-PATH
A	I-PATH
and	O
mild	O
influenza	B-PATH
A	I-PATH
and	O
2	O
)	O
pandemic	O
2009	O
H1N1	O
(	O
pdm09	O
A	O
/	O
H1	O
)	O
and	O
seasonal	O
H3N2	O
(	O
A	O
/	O
H3	O
)	O
from	O
2009	O
to	O
2010	O
.	O

The	O
detected	O
influenza	O
viruses	O
were	O
Influenza	B-PATH
A	I-PATH
(	O
107	O
,	O
6	O
.	O
5	O
%),	O
pandemic	O
2009	O
H1N1	O
(	O
n	O
=	O
120	O
,	O
7	O
.	O
3	O
%),	O
and	O
Influenza	O
B	O
(	O
n	O
=	O
44	O
,	O
2	O
.	O
7	O
%).	O

Pandemic	O
H1N1	O
was	O
the	O
most	O
common	O
influenza	O
in	O
2015	O
with	O
a	O
peak	O
in	O
peaked	O
October	O
to	O
December	O
and	O
influenza	B-PATH
A	I-PATH
other	O
than	O
H1N1	O
was	O
more	O
common	O
in	O
2016	O
with	O
a	O
peak	O
in	O
August	O
and	O
then	O
October	O
to	O
December	O
.	O

TITLE	O
:	O
Pathogenic	O
CD8	O
ABSTRACT	O
:	O
Malaria	B-PATH
is	O
a	O
severe	O
disease	O
and	O
kills	O
over	O
400	O
,	O
000	O
people	O
each	O
year	O
.	O

Malarial	O
complications	O
are	O
the	O
main	O
cause	O
of	O
death	O
and	O
include	O
cerebral	O
malaria	B-PATH
and	O
malaria	B-PATH
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
MA	O
-	O
ARDS	O
).	O

In	O
this	O
study	O
,	O
several	O
nsps	O
encoded	O
by	O
avian	O
gammacoronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
screened	O
for	O
RNA	O
-	O
binding	O
activity	O
and	O
interaction	O
with	O
its	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
nsp12	O
.	O

With	O
the	O
ongoing	O
outbreaks	O
of	O
measles	B-PATH
in	O
Europe	O
,	O
it	O
is	O
recommended	O
that	O
all	O
pilgrims	O
have	O
an	O
updated	O
immunization	O
against	O
vaccine	O
-	O
preventable	O
diseases	O
(	O
diphtheria	O
,	O
tetanus	O
,	O
pertussis	B-PATH
,	O
polio	O
,	O
measles	B-PATH
and	O
mumps	O
).	O

One	O
or	O
more	O
respiratory	O
viruses	O
were	O
detected	O
in	O
172	O
(	O
46	O
.	O
6	O
%)	O
cases	O
and	O
their	O
prevalence	O
were	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
19	O
.	O
2	O
%),	O
adenovirus	O
(	O
8	O
.	O
7	O
%),	O
human	O
rhinovirus	O
A	O
(	O
7	O
.	O
9	O
%),	O
coronavirus	O
OC43	O
(	O
4	O
.	O
3	O
%),	O
parainfluenza	O
virus	O
1	O
(	O
2	O
.	O
7	O
%),	O
parainfluenza	O
virus	O
3	O
(	O
2	O
.	O
7	O
%),	O
influenza	O
B	O
virus	O
(	O
2	O
.	O
2	O
%),	O
respiratory	O
syncytial	O
virus	O
B	O
(	O
2	O
.	O
2	O
%),	O
human	O
metapneumovirus	O
(	O
1	O
.	O
4	O
%),	O
respiratory	O
syncytial	O
virus	O
A	O
(	O
1	O
.	O
1	O
%),	O
parainfluenza	O
virus	O
2	O
(	O
0	O
.	O
5	O
%)	O
and	O
coronavirus	O
229E	O
(	O
0	O
.	O
5	O
%).	O

We	O
discuss	O
the	O
origins	O
of	O
ROS	O
within	O
the	O
cell	O
,	O
cellular	O
defense	O
mechanisms	O
against	O
oxidative	B-PATH
damage	I-PATH
,	O
the	O
role	O
of	O
ROS	O
in	O
the	O
development	O
of	O
endothelial	O
permeability	O
,	O
and	O
potential	O
therapies	O
targeted	O
at	O
oxidative	O
stress	O
.	O

TITLE	O
:	O
Early	O
Antibody	O
Response	O
Contributes	O
to	O
the	O
Virus	O
Eradication	O
and	O
Clinical	O
Recovery	O
of	O
H7N9	O
Influenza	B-PATH
Infection	I-PATH
.	O

Because	O
no	O
considerable	O
change	O
in	O
IBV	O
N	O
protein	O
and	O
viral	O
RNA	O
levels	O
was	O
detected	O
in	O
total	O
cell	O
lysates	O
prepared	O
from	O
the	O
overexpression	O
,	O
knockdown	O
or	O
cleavage	O
of	O
CD59	O
groups	O
,	O
our	O
data	O
indicated	O
that	O
CD59	O
was	O
involved	O
in	O
IBV	O
particle	O
release	B-PATH
and	O
that	O
IBV	O
had	O
evolved	O
a	O
mechanism	O
to	O
utilize	O
CD59	O
to	O
evade	O
complement	O
-	O
mediated	O
destruction	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
NH	O
ABSTRACT	O
:	O
Neuraminidase	O
inhibitors	O
can	O
deter	O
nascent	O
viruses	O
from	O
infecting	O
intact	O
cells	O
by	O
preventing	O
their	O
release	B-PATH
from	O
host	O
cells	O
.	O

We	O
subsequently	O
identified	O
novel	O
amino	O
acid	O
changes	O
within	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
and	O
nsp14	O
of	O
MHV	O
-	O
ExoN	O
(-)	O
P250	O
that	O
partially	O
accounted	O
for	O
the	O
reduced	O
susceptibility	O
to	O
nucleoside	O
analogues	O
.	O

Using	O
peripheral	O
blood	O
obtained	O
from	O
mature	O
infants	O
with	O
and	O
without	O
NRDS	O
,	O
in	O
tandem	O
with	O
mRNA	O
sequencing	O
(	O
mRNA	O
â	O
seq	O
)	O
analysis	O
,	O
the	O
present	O
study	O
identified	O
that	O
,	O
while	O
cell	B-PATH
cycle	I-PATH
regulation	O
and	O
alveolar	O
surfactants	O
serve	O
a	O
role	O
in	O
deterring	O
the	O
further	O
onset	O
of	O
NRDS	O
,	O
innate	O
and	O
pathogen	O
â	O
induced	O
responses	O
of	O
the	O
immune	O
system	O
are	O
among	O
the	O
most	O
important	O
factors	O
in	O
the	O
pathology	O
.	O

The	O
test	O
results	O
indicated	O
that	O
of	O
the	O
travelers	O
,	O
34	O
tested	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
14	O
for	O
influenza	O
B	O
virus	O
,	O
4	O
for	O
metapneumo	O
virus	O
,	O
2	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
3	O
for	O
human	O
coronavirus	O
.	O

TITLE	O
:	O
Avian	O
infectious	O
bronchitis	O
virus	O
disrupts	O
the	O
melanoma	B-PATH
differentiation	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
signaling	O
pathway	O
by	O
cleavage	O
of	O
the	O
adaptor	O
protein	O
MAVS	O
.	O

ABSTRACT	O
:	O
Melanoma	B-PATH
differentiation	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
and	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
-	O
I	O
(	O
RIG	O
-	O
I	O
)	O
selectively	O
sense	O
cytoplasmic	O
viral	O
RNA	O
to	O
induce	O
an	O
antiviral	O
immune	O
response	O
.	O

TITLE	O
:	O
Intensive	O
care	O
in	O
severe	O
malaria	B-PATH
:	O
Report	O
from	O
the	O
task	O
force	O
on	O
tropical	O
diseases	O
by	O
the	O
World	O
Federation	O
of	O
Societies	O
of	O
Intensive	O
and	O
Critical	O
Care	O
Medicine	O
.	O

ABSTRACT	O
:	O
Severe	O
malaria	B-PATH
is	O
common	O
in	O
tropical	O
countries	O
in	O
Africa	O
,	O
Asia	O
,	O
Oceania	O
and	O
South	O
and	O
Central	O
America	O
.	O

In	O
other	O
regions	O
,	O
adults	O
may	O
also	O
develop	O
cerebral	O
malaria	B-PATH
but	O
neurological	O
sequelae	O
in	O
survivors	O
are	O
rare	O
.	O

Critical	O
care	O
management	O
as	O
per	O
severe	O
sepsis	O
is	O
also	O
applicable	O
to	O
severe	O
malaria	B-PATH
.	O

Blood	O
transfusions	O
may	O
be	O
required	O
and	O
treatment	O
of	O
seizures	O
and	O
raised	O
intracranial	O
pressure	O
is	O
important	O
in	O
cerebral	O
malaria	B-PATH
in	O
children	O
.	O

miR	O
-	O
223	O
blocks	O
bone	O
marrow	O
-	O
derived	O
Ly6G	O
+	O
neutrophil	O
differentiation	O
and	O
inhibits	O
peripheral	O
cytokine	O
release	B-PATH
.	O

In	O
addition	O
,	O
MTD	O
-	O
induced	O
miR	O
-	O
223	O
expression	O
activates	O
a	O
negative	O
feedback	O
pathway	O
that	O
targets	O
the	O
inhibition	O
of	O
NLRP3	O
expression	O
and	O
IL	O
-	O
1Î²	O
release	B-PATH
;	O
therefore	O
,	O
miR	O
-	O
223	O
deficiency	O
can	O
lead	O
to	O
the	O
sustained	O
activation	O
of	O
NLRP3	O
-	O
IL	O
-	O
1Î²	O
.	O

The	O
three	O
-	O
day	O
programme	O
encompassed	O
presentations	O
on	O
some	O
of	O
the	O
clinical	O
features	O
,	O
management	O
,	O
immune	O
responses	O
and	O
virology	O
of	O
respiratory	O
infections	O
,	O
including	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
and	O
A	O
(	O
H7N9	O
)	O
viruses	O
,	O
MERS	O
-	O
CoV	O
,	O
SARS	O
-	O
CoV	O
,	O
adenovirus	O
Type	O
80	O
,	O
enterovirus	O
D68	O
,	O
metapneumovirus	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
).	O

In	O
a	O
large	O
multi	O
-	O
centre	O
European	O
study	O
the	O
prevalences	O
of	O
four	O
key	O
emerging	O
CIRD	O
pathogens	O
;	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
),	O
canine	O
pneumovirus	O
(	O
CnPnV	O
),	O
influenza	B-PATH
A	I-PATH
,	O
and	O
Mycoplasma	O
cynos	O
(	O
M	O
.	O
cynos	O
);	O
were	O
estimated	O
,	O
and	O
risk	O
factors	O
for	O
exposure	O
,	O
infection	O
and	O
clinical	O
disease	O
were	O
investigated	O
.	O

TITLE	O
:	O
Comparative	O
transcriptome	O
analysis	O
reveals	O
induction	O
of	O
apoptosis	B-PATH
in	O
chicken	O
kidney	O
cells	O
associated	O
with	O
the	O
virulence	O
of	O
nephropathogenic	O
infectious	O
bronchitis	O
virus	O
.	O

Gene	O
Ontology	O
(	O
GO	O
)	O
and	O
KEGG	O
pathway	O
enrichment	O
analysis	O
on	O
SCDY2	O
group	O
displayed	O
that	O
the	O
up	O
-	O
regulated	O
DE	O
genes	O
were	O
mainly	O
involved	O
in	O
cell	O
apoptosis	B-PATH
,	O
and	O
the	O
down	O
-	O
regulated	O
genes	O
were	O
involved	O
in	O
metabolic	O
processes	O
and	O
DNA	B-PATH
replication	I-PATH
.	O

Protein	O
-	O
Protein	O
Interaction	O
(	O
PPI	O
)	O
analysis	O
showed	O
that	O
DE	O
genes	O
in	O
SCDY2	O
group	O
formed	O
a	O
network	O
,	O
and	O
the	O
core	O
of	O
the	O
network	O
was	O
composed	O
by	O
cell	O
apoptosis	B-PATH
and	O
immune	O
response	O
proteins	O
.	O

The	O
clustering	O
of	O
gene	O
expression	O
profile	O
among	O
the	O
three	O
virus	O
inoculated	O
groups	O
indicated	O
that	O
the	O
majority	O
of	O
up	O
-	O
regulated	O
DE	O
genes	O
on	O
apoptosis	B-PATH
in	O
very	O
virulent	O
SCDY2	O
group	O
were	O
up	O
-	O
regulated	O
more	O
or	O
less	O
in	O
virulent	O
SCK2	O
group	O
and	O
those	O
down	O
-	O
regulated	O
on	O
innate	O
immune	O
response	O
in	O
SCDY2	O
group	O
were	O
also	O
down	O
-	O
regulated	O
differently	O
in	O
SCK2	O
group	O
.	O

Taken	O
all	O
together	O
,	O
the	O
present	O
study	O
revealed	O
that	O
virulent	O
nephropathogenic	O
IBV	O
infection	O
modified	O
a	O
number	O
of	O
gene	O
expression	O
and	O
induction	O
of	O
apoptosis	B-PATH
in	O
kidney	O
cells	O
may	O
be	O
a	O
major	O
pathogenic	O
determinant	O
for	O
virulent	O
nephropathogenic	O
IBV	O
.	O

Recent	O
experimental	O
studies	O
have	O
illustrated	O
how	O
several	O
regulatory	O
circuits	O
interact	O
during	O
pulmonary	O
inflammation	O
,	O
including	O
the	O
resolution	O
of	O
inflammation	O
,	O
the	O
inflammasome	O
,	O
autophagy	O
and	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Gastrointestinal	O
tuberculosis	B-PATH
following	O
renal	O
transplantation	O
accompanied	O
with	O
septic	O
shock	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
survival	O
case	O
presentation	O
.	O

ABSTRACT	O
:	O
Post	O
-	O
transplant	O
tuberculosis	B-PATH
(	O
PTTB	O
)	O
is	O
a	O
serious	O
opportunistic	O
infection	O
in	O
renal	O
graft	O
recipients	O
with	O
a	O
30	O
-	O
70	O
fold	O
higher	O
incidence	O
compared	O
to	O
the	O
general	O
population	O
.	O

AGP	O
increased	O
1	O
.	O
6	O
-	O
fold	O
at	O
2	O
d	O
PV	O
,	O
(	O
from	O
0	O
.	O
75	O
g	O
/	O
mL	O
in	O
the	O
control	O
group	O
to	O
1	O
.	O
24	O
g	O
/	O
mL	O
in	O
the	O
vaccinated	O
group	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O
In	O
conclusion	O
an	O
immediate	O
but	O
mild	O
APR	O
occurred	O
in	O
the	O
chicks	O
following	O
intraocular	O
vaccination	O
,	O
whereas	O
the	O
stress	B-PATH
response	I-PATH
as	O
measured	O
by	O
H	O
/	O
L	O
ratio	O
seemed	O
to	O
be	O
more	O
specific	O
and	O
sensitive	O
.	O

ABSTRACT	O
:	O
Mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
hepatitis	O
and	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
),	O
a	O
fact	O
closely	O
related	O
to	O
the	O
release	B-PATH
of	O
alarmins	O
such	O
as	O
uric	O
acid	O
and	O
/	O
or	O
high	O
-	O
mobility	O
group	O
box	O
protein	O
1	O
(	O
HMGB1	O
).	O

TITLE	O
:	O
Epidemiology	O
of	O
influenza	O
in	O
West	O
Africa	O
after	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
,	O
2010	O
-	O
2012	O
.	O

Data	O
from	O
these	O
surveillance	O
systems	O
showed	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
circulated	O
in	O
West	O
Africa	O
later	O
than	O
in	O
other	O
regions	O
of	O
the	O
continent	O
.	O

Among	O
influenza	O
-	O
positive	O
SARI	O
patients	O
,	O
132	O
(	O
63	O
%)	O
were	O
influenza	B-PATH
A	I-PATH
[	O
68	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
,	O
64	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)]	O
and	O
77	O
(	O
37	O
%)	O
were	O
influenza	O
B	O
.	O
All	O
eight	O
countries	O
conducted	O
ILI	O
surveillance	O
and	O
collected	O
20	O
,	O
375	O
specimens	O
,	O
of	O
which	O
2278	O
(	O
11	O
%)	O
were	O
positive	O
for	O
influenza	O
viruses	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
estradiol	O
exerts	O
a	O
protective	O
effect	O
on	O
lung	O
edema	O
and	O
cytokine	O
release	B-PATH
caused	O
by	O
intestinal	O
IR	O
in	O
male	O
rats	O
.	O

Treatment	O
with	O
17Î²	O
-	O
estradiol	O
before	O
the	O
induction	O
of	O
intestinal	O
IR	O
prevented	O
the	O
systemic	O
release	B-PATH
of	O
IL	O
-	O
10	O
,	O
CINC	O
-	O
1	O
,	O
and	O
uric	O
acid	O
,	O
but	O
it	O
did	O
not	O
affect	O
the	O
leukocytosis	O
.	O

In	O
addition	O
,	O
17Î²	O
-	O
estradiol	O
significantly	O
prevented	O
the	O
ex	O
-	O
vivo	O
release	B-PATH
of	O
IL	O
-	O
1Î²	O
and	O
VEGF	O
from	O
lung	O
tissue	O
.	O

TITLE	O
:	O
Routes	O
of	O
transmission	O
of	O
influenza	B-PATH
A	I-PATH
H1N1	O
,	O
SARS	O
CoV	O
,	O
and	O
norovirus	O
in	O
air	O
cabin	O
:	O
Comparative	O
analyses	O
.	O

In	O
this	O
study	O
,	O
we	O
proposed	O
a	O
comparative	O
analysis	O
approach	O
and	O
built	O
a	O
model	O
to	O
simulate	O
outbreaks	O
of	O
3	O
different	O
in	O
-	O
flight	O
infections	O
in	O
a	O
similar	O
cabin	O
environment	O
,	O
that	O
is	O
,	O
influenza	B-PATH
A	I-PATH
H1N1	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
),	O
and	O
norovirus	O
.	O

We	O
found	O
that	O
silvestrol	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cap	O
-	O
dependent	O
viral	B-PATH
mRNA	I-PATH
translation	I-PATH
in	O
CoV	O
-	O
infected	O
human	O
embryonic	O
lung	O
fibroblast	O
(	O
MRC	O
-	O
5	O
)	O
cells	O
.	O

MDMA	O
-	O
induced	O
hyponatremia	O
is	O
hypothesized	O
to	O
result	O
from	O
enhanced	O
serotonergic	O
activity	O
and	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
release	B-PATH
in	O
the	O
brain	O
leading	O
to	O
hyperthermia	O
-	O
induced	O
polydipsia	O
and	O
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
(	O
SIADH	O
)	O
secretion	O
.	O

A	O
common	O
but	O
often	O
unrecognized	O
complication	O
of	O
severe	O
hyponatremia	O
is	O
the	O
Ayus	O
-	O
Arieff	O
syndrome	O
where	O
cerebral	O
edema	O
causes	O
neurogenic	O
pulmonary	O
edema	O
via	O
centrally	O
mediated	O
increases	O
in	O
catecholamine	O
release	B-PATH
and	O
capillary	O
injury	O
.	O

Prospective	O
observational	O
study	O
was	O
performed	O
in	O
ICU	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
.	O

Here	O
,	O
we	O
demonstrate	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
an	O
RNA	O
synthesis	O
and	O
proofreading	O
pathway	O
through	O
association	O
of	O
nsp14	O
with	O
the	O
low	O
-	O
fidelity	O
nsp12	O
viral	O
RNA	B-PATH
polymerase	I-PATH
.	O

Nanoengineering	O
also	O
allows	O
HDL	O
reconstitution	O
with	O
core	O
payloads	O
,	O
such	O
as	O
diagnostically	O
active	O
nanocrystals	O
,	O
as	O
well	O
as	O
hydrophobic	O
drugs	O
or	O
controlled	O
release	B-PATH
polymers	O
for	O
therapeutic	O
purposes	O
.	O

The	O
most	O
common	O
agents	O
detected	O
among	O
our	O
surveyed	O
population	O
were	O
:	O
Haemophilus	O
influenzae	O
(	O
67	O
%),	O
Streptococcus	O
pneumoniae	O
(	O
55	O
%),	O
Moraxella	O
catarrhalis	O
(	O
39	O
%),	O
Staphylococcus	O
aureus	O
(	O
37	O
%),	O
Pseudomonas	O
aeruginosa	O
(	O
36	O
%),	O
Human	O
Rhinovirus	O
(	O
25	O
%),	O
influenza	B-PATH
A	I-PATH
(	O
24	O
%),	O
Klebsiella	O
pneumoniae	O
(	O
14	O
%),	O
Enterovirus	O
(	O
15	O
%)	O
and	O
group	O
A	O
Streptococcus	O
(	O
12	O
%).	O

Our	O
epidemiologic	O
investigation	O
demonstrated	O
both	O
age	O
and	O
symptomatic	O
presentation	O
to	O
be	O
associated	O
with	O
a	O
number	O
of	O
detected	O
agents	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
influenza	B-PATH
A	I-PATH
and	O
Plasmodium	O
.	O

TITLE	O
:	O
Outcomes	O
of	O
Acute	O
Kidney	O
Injury	O
in	O
Patients	O
With	O
Severe	O
ARDS	O
Due	O
to	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
Virus	O
.	O

ABSTRACT	O
:	O
The	O
incidence	O
and	O
long	O
-	O
term	O
outcomes	O
of	O
acute	O
kidney	O
injury	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
(	O
pH1N1	O
)	O
have	O
not	O
been	O
examined	O
.	O

This	O
counteracting	O
effect	O
was	O
partially	O
mediated	O
by	O
protein	O
8b	O
/	O
8ab	O
-	O
induced	O
degradation	O
of	O
IRF3	O
in	O
a	O
ubiquitin	O
-	O
proteasome	B-PATH
-	O
dependent	O
manner	O
.	O

ABSTRACT	O
:	O
To	O
establish	O
an	O
association	O
between	O
mitochondrial	O
dysfunction	O
and	O
apoptosis	B-PATH
following	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
infection	O
,	O
HD11	O
avian	O
macrophage	O
cells	O
were	O
infected	O
with	O
the	O
Massachusetts	O
41	O
(	O
M41	O
)	O
strain	O
.	O

Our	O
results	O
show	O
that	O
the	O
M41	O
strain	O
of	O
IBV	O
induced	O
cytopathic	O
effects	O
followed	O
by	O
the	O
release	B-PATH
of	O
new	O
viral	O
particles	O
.	O

The	O
hypothalamus	O
-	O
pituitary	O
-	O
adrenal	O
cortical	O
(	O
HPA	O
)	O
axis	O
and	O
sympathetic	O
-	O
adrenal	O
medulla	O
axis	O
were	O
activated	O
and	O
participated	O
the	O
initiation	O
and	O
progression	O
of	O
the	O
stress	B-PATH
response	I-PATH
through	O
the	O
production	O
of	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
),	O
glucocorticoid	O
(	O
GC	O
),	O
epinephrine	O
and	O
norepinephrine	O
(	O
NE	O
).	O

TITLE	O
:	O
Differential	O
induction	O
of	O
malaria	B-PATH
liver	O
pathology	O
in	O
mice	O
infected	O
with	O
Plasmodium	O
chabaudi	O
AS	O
or	O
Plasmodium	O
berghei	O
NK65	O
.	O

ABSTRACT	O
:	O
Cerebral	O
malaria	B-PATH
and	O
severe	O
anaemia	O
are	O
the	O
most	O
common	O
deadly	O
complications	O
of	O
malaria	B-PATH
,	O
and	O
are	O
often	O
associated	O
,	O
both	O
in	O
paediatric	O
and	O
adult	O
patients	O
,	O
with	O
hepatopathy	O
,	O
whose	O
pathogenesis	O
is	O
not	O
well	O
characterized	O
,	O
and	O
sometimes	O
also	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Here	O
,	O
two	O
species	O
of	O
murine	O
malaria	B-PATH
,	O
the	O
lethal	O
Plasmodium	O
berghei	O
strain	O
NK65	O
and	O
self	O
-	O
healing	O
Plasmodium	O
chabaudi	O
strain	O
AS	O
which	O
differ	O
in	O
their	O
ability	O
to	O
cause	O
hepatopathy	O
and	O
/	O
or	O
ARDS	O
were	O
used	O
to	O
investigate	O
the	O
lipid	O
alterations	O
,	O
oxidative	B-PATH
damage	I-PATH
and	O
host	O
immune	O
response	O
during	O
the	O
infection	O
in	O
relation	O
to	O
parasite	O
load	O
and	O
accumulation	O
of	O
parasite	O
products	O
,	O
such	O
as	O
haemozoin	O
.	O

This	O
study	O
demonstrates	O
that	O
in	O
C57BL	O
/	O
6J	O
mice	O
,	O
depending	O
on	O
the	O
parasite	O
species	O
,	O
malaria	B-PATH
-	O
induced	O
liver	O
pathology	O
results	O
in	O
different	O
manifestations	O
,	O
which	O
may	O
contribute	O
to	O
the	O
different	O
outcomes	O
.	O

TITLE	O
:	O
High	O
Level	O
of	O
Neutrophil	O
Extracellular	O
Traps	O
Correlates	O
With	O
Poor	O
Prognosis	O
of	O
Severe	O
Influenza	B-PATH
A	I-PATH
Infection	O
.	O

Recent	O
studies	O
suggest	O
that	O
MHV	O
infection	O
alters	O
gap	B-PATH
junction	I-PATH
protein	O
connexin	O
43	O
(	O
Cx43	O
)-	O
mediated	O
intercellular	O
communication	O
in	O
brain	O
and	O
primary	O
cultured	O
astrocytes	O
.	O

Alteration	O
of	O
glial	O
-	O
pial	O
gap	B-PATH
junction	I-PATH
intercellular	O
communication	O
(	O
GJIC	O
)	O
in	O
MHV	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
the	O
integrity	O
of	O
BBB	O
.	O

TITLE	O
:	O
Regional	O
,	O
age	O
and	O
respiratory	O
-	O
secretion	O
-	O
specific	O
prevalence	O
of	O
respiratory	O
viruses	O
associated	O
with	O
asthma	B-PATH
exacerbation	O
:	O
a	O
literature	O
review	O
.	O

ABSTRACT	O
:	O
Despite	O
increased	O
understanding	O
of	O
how	O
viral	O
infection	O
is	O
involved	O
in	O
asthma	B-PATH
exacerbations	O
,	O
it	O
is	O
less	O
clear	O
which	O
viruses	O
are	O
involved	O
and	O
to	O
what	O
extent	O
they	O
contribute	O
to	O
asthma	B-PATH
exacerbations	O
.	O

Here	O
,	O
we	O
sought	O
to	O
determine	O
the	O
prevalence	O
of	O
different	O
respiratory	O
viruses	O
during	O
asthma	B-PATH
exacerbations	O
.	O

During	O
asthma	B-PATH
exacerbations	O
,	O
the	O
mean	O
prevalence	O
of	O
AdV	O
,	O
BoV	O
,	O
CoV	O
,	O
CMV	O
,	O
EnV	O
,	O
HSV	O
,	O
IfV	O
,	O
MpV	O
,	O
PiV	O
,	O
RV	O
and	O
RSV	O
was	O
3	O
.	O
8	O
%,	O
6	O
.	O
9	O
%,	O
8	O
.	O
4	O
%,	O
7	O
.	O
2	O
%,	O
10	O
.	O
1	O
%,	O
12	O
.	O
3	O
%,	O
10	O
.	O
0	O
%,	O
5	O
.	O
3	O
%,	O
5	O
.	O
6	O
%,	O
42	O
.	O
1	O
%	O
and	O
13	O
.	O
6	O
%,	O
respectively	O
.	O

Our	O
findings	O
indicate	O
the	O
need	O
to	O
develop	O
prophylactic	O
polyvalent	O
or	O
polyvirus	O
(	O
including	O
RV	O
,	O
EnV	O
,	O
IfV	O
and	O
RSV	O
)	O
vaccines	O
that	O
produce	O
herd	O
immunity	O
and	O
reduce	O
the	O
healthcare	O
burden	O
associated	O
with	O
virus	O
-	O
induced	O
asthma	B-PATH
exacerbations	O
.	O

TITLE	O
:	O
Comparison	O
of	O
Cepheid	O
Â®	O
Xpert	O
Flu	O
and	O
Roche	O
RealTime	O
Ready	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
Detection	O
Set	O
for	O
detection	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
.	O

A	O
total	O
of	O
749	O
suspected	O
MERS	O
-	O
CoV	O
patients	O
presenting	O
at	O
Johns	O
Hopkins	O
Aramco	O
Healthcare	O
,	O
Saudi	O
Arabia	O
,	O
each	O
submitted	O
a	O
clinical	O
sample	O
for	O
influenza	B-PATH
A	I-PATH
reflex	O
testing	O
using	O
the	O
on	O
-	O
site	O
Cepheid	O
Â®	O
Xpert	O
Flu	O
assay	O
and	O
at	O
the	O
Ministry	O
of	O
Health	O
laboratory	O
by	O
the	O
Roche	O
PCR	O
assay	O
.	O

Specificity	O
of	O
the	O
Cepheid	O
Â®	O
Xpert	O
Flu	O
was	O
95	O
.	O
8	O
%	O
for	O
H1N1	O
and	O
94	O
.	O
4	O
%	O
for	O
total	O
influenza	B-PATH
A	I-PATH
.	O
Cepheid	O
Â®	O
Xpert	O
Flu	O
sensitivity	O
for	O
influenza	B-PATH
A	I-PATH
was	O
100	O
%	O
for	O
younger	O
patients	O
(	O
0	O
-	O
19	O
-	O
year	O
age	O
group	O
)	O
but	O
significantly	O
lower	O
both	O
for	O
older	O
patients	O
(	O
68	O
.	O
2	O
%	O
for	O
60	O
-	O
79	O
-	O
year	O
and	O
50	O
%	O
for	O
â¥	O
80	O
-	O
year	O
age	O
groups	O
)	O
and	O
overall	O
for	O
males	O
compared	O
to	O
females	O
(	O
72	O
.	O
6	O
%	O
and	O
94	O
.	O
0	O
%,	O
respectively	O
).	O

Specificity	O
of	O
the	O
Cepheid	O
Â®	O
Xpert	O
Flu	O
test	O
was	O
high	O
;	O
however	O
,	O
sensitivity	O
for	O
total	O
influenza	B-PATH
A	I-PATH
was	O
lower	O
particularly	O
in	O
males	O
and	O
older	O
patients	O
.	O

Specificity	O
of	O
the	O
Cepheid	O
Â®	O
Xpert	O
Flu	O
was	O
95	O
.	O
8	O
%	O
for	O
H1N1	O
and	O
94	O
.	O
4	O
%	O
for	O
total	O
influenza	B-PATH
A	I-PATH
.	O
Cepheid	O
Â®	O
Xpert	O
Flu	O
sensitivity	O
for	O
influenza	B-PATH
A	I-PATH
was	O
100	O
%	O
for	O
younger	O
patients	O
(	O
0	O
-	O
19	O
-	O
year	O
age	O
group	O
)	O
but	O
significantly	O
lower	O
both	O
for	O
older	O
patients	O
(	O
68	O
.	O
2	O
%	O
for	O
60	O
-	O
79	O
-	O
year	O
and	O
50	O
%	O
for	O
â¥	O
80	O
-	O
year	O
age	O
groups	O
)	O
and	O
overall	O
for	O
males	O
compared	O
to	O
females	O
(	O
72	O
.	O
6	O
%	O
and	O
94	O
.	O
0	O
%,	O
respectively	O
).	O

We	O
amplified	O
partial	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
genes	O
of	O
Alpha	O
and	O
Betacoronavirus	O
together	O
with	O
the	O
partial	O
polymerase	O
gene	O
of	O
Paramyxovirus	O
.	O

Viral	O
etiology	O
detected	O
in	O
29	O
.	O
6	O
%	O
of	O
the	O
cases	O
was	O
predominantly	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
and	O
H3N2	O
),	O
and	O
influenza	O
B	O
infection	O
(	O
22	O
%).	O

Respiratory	O
tract	O
infections	O
in	O
travelers	O
/	O
pilgrims	O
returning	O
to	O
Bangladesh	O
from	O
the	O
Middle	O
East	O
are	O
mainly	O
due	O
to	O
influenza	B-PATH
A	I-PATH
and	O
influenza	O
B	O
.	O
Though	O
MERS	O
-	O
CoV	O
was	O
not	O
detected	O
in	O
the	O
81	O
patients	O
tested	O
,	O
continuous	O
screening	O
and	O
surveillance	O
are	O
essential	O
for	O
early	O
detection	O
of	O
MERS	O
-	O
CoV	O
infection	O
and	O
other	O
respiratory	O
pathogens	O
to	O
prevent	O
transmissions	O
in	O
hospital	O
settings	O
and	O
within	O
communities	O
.	O

Notably	O
,	O
however	O
,	O
an	O
analysis	O
of	O
the	O
CoV	O
RNA	B-PATH
polymerase	I-PATH
phylogeny	O
suggested	O
that	O
many	O
such	O
host	O
-	O
jumps	O
likely	O
resulted	O
in	O
short	O
-	O
term	O
spill	O
-	O
over	O
infections	O
,	O
with	O
little	O
evidence	O
for	O
sustained	O
onward	O
transmission	O
in	O
new	O
co	O
-	O
roosting	O
host	O
species	O
.	O

TITLE	O
:	O
Galectin	O
-	O
3	O
Enhances	O
Avian	O
H5N1	O
Influenza	B-PATH
A	I-PATH
Virus	O
-	O
Induced	O
Pulmonary	O
Inflammation	O
by	O
Promoting	O
NLRP3	O
Inflammasome	O
Activation	O
.	O

In	O
addition	O
,	O
the	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
(	O
BMMs	O
)	O
from	O
Gal	O
-	O
3KO	O
mice	O
exhibited	O
reduced	O
oligomerization	O
of	O
apoptosis	B-PATH
-	O
associated	O
speck	O
-	O
like	O
proteins	O
containing	O
caspase	O
-	O
associated	O
recruitment	O
domains	O
and	O
secreted	O
less	O
IL	O
-	O
1Î²	O
compared	O
with	O
BMMs	O
from	O
WT	O
mice	O
.	O

An	O
association	O
was	O
also	O
observed	O
between	O
galectin	O
-	O
3	O
and	O
NLRP3	O
/	O
apoptosis	B-PATH
-	O
associated	O
speck	O
-	O
like	O
proteins	O
containing	O
caspase	O
-	O
associated	O
recruitment	O
domain	O
complex	O
.	O

Markers	O
of	O
muscle	O
proteolysis	O
were	O
not	O
different	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
between	O
treatments	O
within	O
dpi	O
;	O
however	O
,	O
at	O
dpi	O
5	O
,	O
20S	O
proteasome	B-PATH
activity	O
was	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
longissimus	O
dorsi	O
of	O
PEDV	O
pigs	O
compared	O
with	O
Control	O
pigs	O
.	O

PCR	O
and	O
RT	O
-	O
PCR	O
were	O
performed	O
for	O
influenza	B-PATH
A	I-PATH
/	O
B	O
,	O
human	O
parainfluenza	O
virus	O
1	O
-	O
4	O
,	O
adenovirus	O
,	O
human	O
metapneumovirus	O
(	O
HMPV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
rhinovirus	O
,	O
enterovirus	O
,	O
human	O
coronavirus	O
and	O
human	O
Bocavirus	O
(	O
HBoV	O
).	O

The	O
results	O
showed	O
that	O
the	O
expression	O
of	O
RNA	O
virus	O
pattern	O
recognition	O
receptors	O
(	O
TLR3	O
,	O
7	O
,	O
and	O
MDA5	O
),	O
antimicrobial	O
peptides	O
(	O
avian	O
Î²	O
-	O
defensins	B-PATH
,	O
including	O
AvBD1	O
,	O
2	O
,	O
4	O
-	O
6	O
and	O
cathelicidins	O
,	O
including	O
CATH1	O
and	O
3	O
),	O
and	O
interferons	O
(	O
IFNÎ±	O
,	O
Î²	O
,	O
Î³	O
,	O
Î»	O
)	O
were	O
upregulated	O
,	O
and	O
the	O
expression	O
of	O
cyclooxygenase	O
2	O
(	O
PG	O
synthase	O
)	O
and	O
the	O
level	O
of	O
PGE2	O
were	O
increased	O
in	O
the	O
uterine	O
mucosa	O
following	O
aIBV	O
inoculation	O
.	O

TITLE	O
:	O
Measles	B-PATH
-	O
derived	O
vaccines	O
to	O
prevent	O
emerging	O
viral	O
diseases	O
.	O

The	O
measles	B-PATH
vaccine	O
is	O
an	O
efficient	O
,	O
live	O
attenuated	O
,	O
replicating	O
virus	O
that	O
has	O
been	O
safely	O
administered	O
to	O
2	O
billion	O
children	O
over	O
the	O
last	O
40	O
years	O
,	O
affording	O
life	O
-	O
long	O
protection	O
after	O
a	O
single	O
dose	O
.	O

Clinical	O
trials	O
have	O
shown	O
the	O
safety	O
and	O
immunogenicity	O
of	O
this	O
vaccine	O
platform	O
in	O
individuals	O
with	O
preexisting	O
immunity	O
to	O
measles	B-PATH
.	O

A	O
periodical	O
worsening	O
of	O
clinical	O
conditions	O
is	O
common	O
in	O
asthma	B-PATH
,	O
acute	O
respiratory	O
distress	O
syndrome	O
survivors	O
,	O
obstructive	O
sleep	O
apnea	O
syndrome	O
,	O
and	O
pulmonary	O
fibrosis	O
,	O
as	O
well	O
as	O
in	O
patients	O
with	O
severe	O
neuromuscular	O
diseases	O
.	O

VP35	O
is	O
essential	O
for	O
EBOV	O
replication	O
,	O
is	O
a	O
component	O
of	O
the	O
viral	O
RNA	B-PATH
polymerase	I-PATH
and	O
participates	O
in	O
nucleocapsid	O
formation	O
.	O

He	O
presented	O
with	O
severe	O
diarrhoea	O
86	O
days	O
post	O
BMT	O
and	O
was	O
diagnosed	O
with	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
(	O
GVHD	O
)	O
based	O
on	O
skin	O
and	O
rectal	O
biopsies	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
complications	O
occur	O
frequently	O
during	O
the	O
early	O
phase	O
of	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
(	O
AML	O
)	O
but	O
information	O
on	O
the	O
most	O
severe	O
form	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
is	O
lacking	O
.	O

Some	O
of	O
the	O
taxa	O
showing	O
differences	O
in	O
abundance	O
between	O
uninfected	O
piglets	O
and	O
piglets	O
infected	O
with	O
PEDV	O
were	O
associated	O
with	O
cellular	O
transport	O
and	O
catabolism	O
,	O
energy	B-PATH
metabolism	I-PATH
,	O
the	O
biosynthesis	O
of	O
other	O
secondary	O
metabolites	O
,	O
and	O
amino	B-PATH
acid	I-PATH
metabolism	I-PATH
as	O
determined	O
through	O
the	O
prediction	O
of	O
microbial	O
function	O
based	O
on	O
the	O
bacterial	O
16S	O
rRNA	O
gene	O
.	O

In	O
vitro	O
,	O
pneumolysin	O
enhanced	O
endothelial	O
angiopoietin	O
-	O
2	O
release	B-PATH
,	O
angiopoietin	O
-	O
2	O
increased	O
endothelial	O
permeability	O
,	O
and	O
angiopoietin	O
-	O
1	O
reduced	O
pneumolysin	O
-	O
evoked	O
endothelial	O
permeability	O
.	O

TITLE	O
:	O
Reversible	O
platypnoea	O
-	O
orthodeoxia	O
syndrome	O
in	O
post	O
-	O
tuberculosis	B-PATH
bronchial	O
stenosis	O
.	O

ABSTRACT	O
:	O
Bronchial	O
stenosis	O
is	O
known	O
to	O
complicate	O
endobronchial	O
tuberculosis	B-PATH
despite	O
medical	O
therapy	O
.	O

RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
pregnant	O
woman	O
was	O
initiated	O
with	O
ECMO	O
due	O
to	O
severe	O
ARDS	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

TITLE	O
:	O
Whole	O
transcriptome	O
analysis	O
reveals	O
differential	O
gene	O
expression	O
profile	O
reflecting	O
macrophage	O
polarization	O
in	O
response	O
to	O
influenza	B-PATH
A	I-PATH
H5N1	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
Avian	O
influenza	B-PATH
A	I-PATH
H5N1	O
virus	O
can	O
cause	O
lethal	O
disease	O
in	O
humans	O
.	O

To	O
obtain	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
events	O
at	O
the	O
earliest	O
time	O
points	O
,	O
we	O
used	O
RNA	O
-	O
Seq	O
to	O
quantify	O
and	O
compare	O
the	O
host	O
mRNA	O
and	O
miRNA	O
transcriptomes	O
induced	O
by	O
the	O
highly	O
pathogenic	O
influenza	B-PATH
A	I-PATH
H5N1	O
(	O
A	O
/	O
Vietnam	O
/	O
3212	O
/	O
04	O
)	O
or	O
low	O
virulent	O
H1N1	O
(	O
A	O
/	O
Hong	O
Kong	O
/	O
54	O
/	O
98	O
)	O
viruses	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
at	O
1	O
-,	O
3	O
-,	O
and	O
6	O
-	O
h	O
post	O
infection	O
.	O

We	O
observe	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
genes	O
in	O
the	O
RIG	B-PATH
-	I-PATH
I	I-PATH
-	I-PATH
like	I-PATH
receptor	I-PATH
signaling	I-PATH
pathway	I-PATH
.	O

In	O
this	O
study	O
,	O
we	O
designed	O
a	O
new	O
primer	O
set	O
to	O
amplify	O
a	O
668	O
bp	O
-	O
region	O
within	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRP	O
)	O
gene	O
that	O
encodes	O
the	O
most	O
conserved	O
protein	O
domain	O
of	O
Î±	O
-,	O
Î²	O
-,	O
Î³	O
-,	O
and	O
Î´	O
-	O
CoVs	O
.	O

In	O
this	O
study	O
we	O
have	O
examined	O
the	O
subcellular	O
localization	O
and	O
other	O
functions	O
of	O
TGEV	O
nsp7	O
protein	O
through	O
analysis	O
of	O
its	O
effects	O
on	O
cell	O
growth	O
,	O
cell	B-PATH
cycle	I-PATH
progression	O
,	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
expression	O
,	O
and	O
NF	O
-	O
ÎºB	O
activation	O
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
from	O
co	O
-	O
infection	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
H7N9	O
and	O
Mycoplasma	O
pneumoniae	O
:	O
a	O
case	O
report	O
.	O

ABSTRACT	O
:	O
More	O
and	O
more	O
cases	O
of	O
human	O
infections	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
H7N9	O
have	O
been	O
reported	O
since	O
it	O
was	O
first	O
mentioned	O
in	O
2013	O
in	O
China	O
,	O
but	O
concurrence	O
of	O
influenza	B-PATH
A	I-PATH
H7N9	O
with	O
Mycoplasma	O
pneumoniae	O
,	O
however	O
,	O
has	O
never	O
been	O
described	O
.	O

Here	O
,	O
we	O
reported	O
the	O
case	O
of	O
a	O
woman	O
co	O
-	O
infected	O
by	O
influenza	B-PATH
A	I-PATH
H7N9	O
and	O
Mycoplasma	O
pneumoniae	O
,	O
whose	O
treatment	O
process	O
was	O
a	O
little	O
bit	O
longer	O
and	O
a	O
little	O
bit	O
complicated	O
as	O
well	O
.	O

She	O
was	O
diagnosed	O
as	O
having	O
severe	O
influenza	B-PATH
A	I-PATH
H7N9	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
was	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
.	O

In	O
patients	O
with	O
confirmed	O
influenza	B-PATH
A	I-PATH
H7N9	O
infection	O
whose	O
condition	O
worsens	O
again	O
,	O
especially	O
with	O
new	O
infiltration	O
or	O
lung	O
ground	O
-	O
glass	O
infiltration	O
,	O
one	O
should	O
suspect	O
infection	O
by	O
other	O
pathogens	O
such	O
as	O
Mycoplasma	O
pneumoniae	O
.	O

Moreover	O
,	O
addition	O
of	O
LiCl	O
inhibited	O
both	O
early	O
and	O
late	O
cell	O
apoptosis	B-PATH
induced	O
by	O
PEDV	O
.	O

The	O
percent	O
agreement	O
between	O
MAP	O
and	O
clinical	O
results	O
was	O
97	O
%	O
for	O
influenza	B-PATH
A	I-PATH
(	O
73	O
/	O
75	O
),	O
100	O
%	O
(	O
21	O
/	O
21	O
)	O
for	O
influenza	O
B	O
,	O
100	O
%	O
(	O
6	O
/	O
6	O
)	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
and	O
80	O
%	O
(	O
4	O
/	O
5	O
)	O
for	O
negative	O
specimens	O
.	O

Coronaviruses	O
,	O
including	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
fuse	O
at	O
the	O
plasma	O
membrane	O
or	O
use	O
receptor	O
-	O
mediated	O
endocytosis	B-PATH
and	O
fuse	O
with	O
endosomes	O
,	O
depending	O
on	O
the	O
cell	O
or	O
tissue	O
type	O
.	O

TITLE	O
:	O
Comparison	O
of	O
patients	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
clinical	O
features	O
of	O
patients	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	B-PATH
)	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	B-PATH
)	O
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O
The	O
clinical	O
data	O
of	O
18	O
cases	O
of	O
H7N9	B-PATH
and	O
26	O
cases	O
of	O
H1N1	B-PATH
with	O
ARDS	O
were	O
collected	O
and	O
compared	O
in	O
the	O
respiratory	O
intensive	O
care	O
unit	O
(	O
RICU	O
)	O
of	O
Fuzhou	O
Pulmonary	O
Hospital	O
of	O
Fujian	O
from	O
March	O
2014	O
to	O
December	O
2016	O
.	O
Patients	O
with	O
H7N9	B-PATH
had	O
a	O
higher	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
-	O
II	O
score	O
(	O
P	O
<	O
.	O
05	O
)	O
and	O
lung	O
injury	O
score	O
(	O
P	O
<	O
.	O
05	O
).	O

The	O
RNA	B-PATH
polymerase	I-PATH
of	O
respiratory	O
viruses	O
represents	O
an	O
attractive	O
target	O
for	O
nucleoside	O
and	O
nucleotide	O
analogs	O
acting	O
as	O
inhibitors	O
of	O
RNA	O
chain	O
synthesis	O
.	O

NIV	O
use	O
in	O
asthma	B-PATH
was	O
less	O
frequent	O
in	O
Northern	O
European	O
units	O
in	O
comparison	O
to	O
Central	O
and	O
Southern	O
European	O
PICUs	O
(	O
P	O
=	O
0	O
.	O
007	O
).	O

TITLE	O
:	O
DYSFUNCTION	O
OF	O
VARIOUS	O
ORGAN	O
SYSTEMS	O
INDUCED	O
BY	O
SEPSIS	O
WITH	O
UNDERLYING	O
SEVERE	O
MYELOMIC	O
DISEASES	O
AND	O
PROSTATE	B-PATH
CANCER	I-PATH
(	O
CASE	O
REPORT	O
).	O

ABSTRACT	O
:	O
A	O
65	O
-	O
year	O
-	O
old	O
female	O
had	O
been	O
treated	O
rheumatoid	B-PATH
arthritis	I-PATH
(	O
RA	O
),	O
interstitial	O
pneumonia	O
(	O
IP	O
)	O
and	O
nephrotic	O
syndrome	O
with	O
prednisolone	O
and	O
cyclosporine	O
.	O

TITLE	O
:	O
[	O
Asthma	B-PATH
and	O
obesity	O
:	O
preventable	O
therapeutic	O
trap	O
,	O
with	O
careful	O
follow	O
-	O
up	O
].	O

ABSTRACT	O
:	O
Singapore	O
remains	O
vulnerable	O
to	O
worldwide	O
epidemics	O
due	O
to	O
high	O
air	O
traffic	O
with	O
other	O
countries	O
This	O
study	O
aims	O
to	O
measure	O
the	O
public	O
'	O
s	O
awareness	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
and	O
Avian	O
Influenza	B-PATH
A	I-PATH
(	O
H7N9	O
),	O
identify	O
population	O
groups	O
who	O
are	O
uninformed	O
or	O
misinformed	O
about	O
the	O
diseases	O
,	O
understand	O
their	O
choice	O
of	O
outbreak	O
information	O
source	O
,	O
and	O
assess	O
the	O
effectiveness	O
of	O
communication	O
channels	O
in	O
Singapore	O
.	O

TITLE	O
:	O
Severe	O
Plasmodium	O
ovale	O
malaria	B-PATH
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
a	O
young	O
Caucasian	O
man	O
.	O

A	O
37	O
-	O
year	O
old	O
Caucasian	O
man	O
returning	O
home	O
from	O
Angola	O
was	O
admitted	O
for	O
ovale	O
malaria	B-PATH
to	O
the	O
National	O
Institute	O
for	O
Infectious	O
Diseases	O
Lazzaro	O
Spallanzani	O
in	O
Rome	O
,	O
Italy	O
.	O

Ovale	O
malaria	B-PATH
is	O
usually	O
considered	O
a	O
tropical	O
infectious	O
disease	O
associated	O
with	O
low	O
morbidity	O
and	O
mortality	O
.	O

CONCLUSIONS	O
:	O
Ovale	O
malaria	B-PATH
is	O
usually	O
considered	O
a	O
tropical	O
infectious	O
disease	O
associated	O
with	O
low	O
morbidity	O
and	O
mortality	O
.	O

It	O
inhibits	O
the	O
replication	O
of	O
many	O
viruses	O
and	O
ultimately	O
promotes	O
apoptosis	B-PATH
of	O
infected	O
cells	O
,	O
contributing	O
to	O
the	O
control	O
of	O
virus	O
spread	O
.	O

Analysis	O
of	O
cultured	O
patient	O
fibroblasts	O
demonstrated	O
deficient	O
pyruvate	B-PATH
dehydrogenase	I-PATH
(	O
PDH	O
)	O
activity	O
and	O
reduced	O
quantity	O
of	O
protein	O
subunits	O
of	O
mitochondrial	O
complexes	O
I	O
and	O
II	O
,	O
consistent	O
with	O
BOLA3	O
dysfunction	O
.	O

Human	O
coronaviruses	O
(	O
HCoVs	O
[	O
22	O
.	O
0	O
%;	O
55	O
/	O
250	O
]),	O
rhinovirus	O
(	O
7	O
.	O
6	O
%;	O
19	O
/	O
250	O
),	O
and	O
influenza	B-PATH
A	I-PATH
(	O
6	O
.	O
4	O
%;	O
16	O
/	O
250	O
)	O
were	O
most	O
prevalent	O
.	O

TITLE	O
:	O
Recovery	O
of	O
pulmonary	O
functions	O
,	O
exercise	O
capacity	O
,	O
and	O
quality	O
of	O
life	O
after	O
pulmonary	O
rehabilitation	O
in	O
survivors	O
of	O
ARDS	O
due	O
to	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pneumonitis	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
severe	O
influenza	B-PATH
A	I-PATH
H1N1	O
pneumonitis	O
would	O
result	O
in	O
impaired	O
pulmonary	O
functions	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
after	O
hospital	O
discharge	O
.	O

These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
dysregulated	O
host	O
immune	O
responses	O
contribute	O
to	O
the	O
severe	O
outcome	O
of	O
MERS	O
;	O
(	O
2	O
)	O
excessive	O
complement	O
activation	O
,	O
triggered	O
by	O
MERS	O
-	O
CoV	O
infection	O
,	O
promote	O
such	O
dysregulation	O
;	O
and	O
(	O
3	O
)	O
blockade	O
of	O
the	O
C5a	O
-	O
C5aR	O
axis	O
lead	O
to	O
the	O
decreased	O
tissue	O
damage	O
induced	O
by	O
MERS	O
-	O
CoV	O
infection	O
,	O
as	O
manifested	O
by	O
reduced	O
apoptosis	B-PATH
and	O
T	O
cell	O
regeneration	O
in	O
the	O
spleen	O
.	O

We	O
discuss	O
the	O
role	O
that	O
macroautophagy	O
plays	O
in	O
cells	O
infected	O
with	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
hepatitis	O
B	O
virus	O
,	O
rotavirus	O
gastroenteritis	O
,	O
immune	O
cells	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
,	O
and	O
viral	O
respiratory	O
tract	O
infections	O
both	O
influenza	O
virus	O
and	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
associated	O
with	O
a	O
severe	O
pro	O
-	O
inflammatory	O
response	O
;	O
although	O
decreased	O
plasma	O
cholesterol	O
concentration	O
has	O
been	O
linked	O
to	O
systemic	O
inflammation	O
,	O
any	O
association	O
of	O
phospholipid	O
metabolic	B-PATH
pathways	I-PATH
with	O
ARDS	O
has	O
not	O
been	O
characterized	O
.	O

We	O
found	O
that	O
the	O
virus	O
employs	O
caveolin	O
-	O
1	O
dependent	O
endocytosis	B-PATH
for	O
the	O
entry	O
and	O
the	O
scission	O
of	O
virus	O
-	O
containing	O
vesicles	O
from	O
the	O
cell	O
surface	O
is	O
dynamin	O
-	O
dependent	O
.	O

Parainfluenza	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
adenovirus	O
,	O
human	O
metapneumovirus	O
,	O
enterovirus	O
,	O
bocavirus	O
and	O
parechovirus	O
were	O
the	O
remaining	O
detected	O
agents	O
.	O

TITLE	O
:	O
[	O
Role	O
of	O
noninvasive	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
severe	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

ABSTRACT	O
:	O
Human	O
infection	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
is	O
an	O
acute	O
contagious	O
respiratory	O
disease	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
common	O
complication	O
in	O
patients	O
with	O
severe	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
),	O
for	O
whom	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
is	O
an	O
important	O
supportive	O
method	O
.	O

A	O
patient	O
,	O
suffered	O
from	O
severe	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
and	O
complicated	O
with	O
ARDS	O
,	O
was	O
admitted	O
to	O
the	O
Second	O
Affiliated	O
Hospital	O
of	O
Guizhou	O
Medical	O
University	O
in	O
January	O
2017	O
.	O

The	O
result	O
demonstrate	O
that	O
,	O
in	O
patients	O
with	O
conscious	O
state	O
,	O
satisfied	O
expectoration	O
ability	O
and	O
relatively	O
good	O
cooperation	O
,	O
and	O
with	O
close	O
observation	O
of	O
oxygenation	O
and	O
respiratory	O
rate	O
,	O
NIV	O
may	O
be	O
accepted	O
as	O
an	O
effective	O
method	O
for	O
patient	O
with	O
ARDS	O
caused	O
by	O
severe	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
).	O

This	O
article	O
argues	O
that	O
the	O
proliferation	O
of	O
HIV	O
/	O
AIDS	O
-	O
related	O
NGOs	O
in	O
China	O
is	O
largely	O
attributed	O
to	O
the	O
normative	O
and	O
technical	O
effects	O
of	O
HIV	O
/	O
AIDS	O
securitization	O
ushered	O
in	O
by	O
the	O
United	O
Nations	O
Security	O
Council	O
(	O
UNSC	O
)	O
and	O
supported	O
by	O
the	O
Global	O
Fund	O
to	O
Fight	O
AIDS	O
,	O
Tuberculosis	B-PATH
,	O
and	O
Malaria	B-PATH
(	O
hereinafter	O
Global	O
Fund	O
)	O
observed	O
in	O
China	O
.	O

RESULTS	O
:	O
This	O
article	O
argues	O
that	O
the	O
proliferation	O
of	O
HIV	O
/	O
AIDS	O
-	O
related	O
NGOs	O
in	O
China	O
is	O
largely	O
attributed	O
to	O
the	O
normative	O
and	O
technical	O
effects	O
of	O
HIV	O
/	O
AIDS	O
securitization	O
ushered	O
in	O
by	O
the	O
United	O
Nations	O
Security	O
Council	O
(	O
UNSC	O
)	O
and	O
supported	O
by	O
the	O
Global	O
Fund	O
to	O
Fight	O
AIDS	O
,	O
Tuberculosis	B-PATH
,	O
and	O
Malaria	B-PATH
(	O
hereinafter	O
Global	O
Fund	O
)	O
observed	O
in	O
China	O
.	O

These	O
analogs	O
act	O
as	O
an	O
alternative	O
substrate	O
and	O
RNA	O
-	O
chain	O
terminator	O
of	O
viral	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

A	O
focused	O
set	O
of	O
thienyl	O
chalcone	O
derivaties	O
II	O
-	O
VI	O
was	O
screened	O
for	O
selected	O
viruses	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
Herpes	O
simplex	O
virus	O
1	O
(	O
HSV	O
-	O
1	O
),	O
Human	O
cytomegalovirus	O
(	O
HCMV	O
),	O
Dengue	O
virus	O
2	O
(	O
DENV2	O
),	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
,	O
MERS	O
coronavirus	O
,	O
Poliovirus	O
1	O
(	O
PV	O
1	O
),	O
Rift	O
Valley	O
fever	O
(	O
RVF	O
),	O
Tacaribe	O
virus	O
(	O
TCRV	O
),	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEE	O
)	O
and	O
Zika	O
virus	O
(	O
ZIKV	O
)	O
using	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
(	O
NIAID	O
)'	O
s	O
Division	O
of	O
Microbiology	O
and	O
Infectious	O
Diseases	O
(	O
DMID	O
)	O
antiviral	O
screening	O
program	O
.	O

METHODS	O
:	O
A	O
focused	O
set	O
of	O
thienyl	O
chalcone	O
derivaties	O
II	O
-	O
VI	O
was	O
screened	O
for	O
selected	O
viruses	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
Herpes	O
simplex	O
virus	O
1	O
(	O
HSV	O
-	O
1	O
),	O
Human	O
cytomegalovirus	O
(	O
HCMV	O
),	O
Dengue	O
virus	O
2	O
(	O
DENV2	O
),	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
,	O
MERS	O
coronavirus	O
,	O
Poliovirus	O
1	O
(	O
PV	O
1	O
),	O
Rift	O
Valley	O
fever	O
(	O
RVF	O
),	O
Tacaribe	O
virus	O
(	O
TCRV	O
),	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEE	O
)	O
and	O
Zika	O
virus	O
(	O
ZIKV	O
)	O
using	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
(	O
NIAID	O
)'	O
s	O
Division	O
of	O
Microbiology	O
and	O
Infectious	O
Diseases	O
(	O
DMID	O
)	O
antiviral	O
screening	O
program	O
.	O

ABSTRACT	O
:	O
The	O
data	O
characterizing	O
spontaneous	O
infections	O
of	O
Old	O
World	O
monkeys	O
:	O
measles	B-PATH
,	O
poliomyelitis	O
,	O
hepatitis	O
A	O
(	O
HPA	O
),	O
encephalomyocarditis	O
,	O
coronavirus	O
infection	O
,	O
simian	O
hemorrhagic	O
fever	O
(	O
SHF	O
),	O
are	O
presented	O
.	O

The	O
efficiency	O
of	O
poliomyelitis	O
,	O
measles	B-PATH
and	O
HPA	O
vaccines	O
is	O
shown	O
.	O

These	O
pathogens	O
are	O
Yersenia	O
pestis	O
,	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
1	O
,	O
Zaire	O
ebolavirus	O
,	O
Francisella	O
tularensis	O
,	O
dengue	O
virus	O
,	O
human	O
respiratory	O
syncytial	O
virus	O
,	O
measles	B-PATH
virus	O
,	O
Rubella	O
virus	O
,	O
and	O
Bacillus	O
anthracis	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
PEDV	O
infection	O
on	O
the	O
cell	B-PATH
cycle	I-PATH
of	O
Vero	O
cells	O
and	O
p53	O
activation	O
.	O

The	O
results	O
demonstrated	O
that	O
PEDV	O
infection	O
induces	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
G0	O
/	O
G1	O
phase	O
in	O
Vero	O
cells	O
,	O
while	O
UV	O
-	O
inactivated	O
PEDV	O
does	O
not	O
cause	O
cell	B-PATH
cycle	I-PATH
arrest	O
.	O

In	O
addition	O
,	O
PEDV	O
infection	O
of	O
the	O
cells	O
synchronized	O
in	O
various	O
stages	O
of	O
cell	B-PATH
cycle	I-PATH
showed	O
that	O
viral	O
subgenomic	O
RNA	O
and	O
virus	O
titer	O
were	O
higher	O
in	O
the	O
cells	O
released	O
from	O
G0	O
/	O
G1	O
phase	O
synchronized	O
cells	O
than	O
that	O
in	O
the	O
cells	O
released	O
from	O
the	O
G1	O
/	O
S	O
phase	O
and	O
G2	O
/	O
M	O
phase	O
synchronized	O
or	O
asynchronous	O
cells	O
after	O
18	O
h	O
p	O
.	O
i	O
..	O

TITLE	O
:	O
CAR	O
T	O
cell	O
-	O
induced	O
cytokine	O
release	B-PATH
syndrome	O
is	O
mediated	O
by	O
macrophages	O
and	O
abated	O
by	O
IL	O
-	O
1	O
blockade	O
.	O

Influenza	O
predominated	O
in	O
the	O
age	O
-	O
group	O
(â¥	O
10	O
,	O
<	O
18	O
),	O
with	O
4	O
/	O
22	O
samples	O
(	O
18	O
.	O
2	O
%),	O
while	O
in	O
the	O
remaining	O
age	O
-	O
groups	O
(â¥	O
18	O
),	O
HRV	O
was	O
the	O
commonest	O
isolated	O
pathogen	O
,	O
33	O
/	O
286	O
(	O
11	O
.	O
5	O
%),	O
followed	O
by	O
influenza	O
with	O
20	O
(	O
7	O
%)	O
(	O
influenza	B-PATH
A	I-PATH
H1	O
-	O
2009	O
,	O
11	O
/	O
20	O
).	O
In	O
our	O
patient	O
series	O
,	O
HRV	O
seemed	O
to	O
prevail	O
in	O
most	O
age	O
-	O
groups	O
,	O
followed	O
by	O
Adv	O
,	O
although	O
Influenza	O
was	O
the	O
second	O
most	O
frequent	O
pathogen	O
isolated	O
in	O
the	O
age	O
-	O
groups	O
(â¥	O
18	O
).	O

This	O
study	O
identifies	O
silvestrol	O
as	O
a	O
potent	O
inhibitor	O
of	O
the	O
release	B-PATH
of	O
HEV	O
infectious	O
viral	O
particles	O
.	O

TITLE	O
:	O
Could	O
Heme	O
Oxygenase	O
-	O
1	O
Be	O
a	O
New	O
Target	O
for	O
Therapeutic	O
Intervention	O
in	O
Malaria	B-PATH
-	O
Associated	O
Acute	O
Lung	O
Injury	O
/	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
?	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
a	O
serious	O
disease	O
and	O
was	O
responsible	O
for	O
429	O
,	O
000	O
deaths	O
in	O
2015	O
.	O

Acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
)	O
is	O
one	O
of	O
the	O
main	O
clinical	O
complications	O
of	O
severe	O
malaria	B-PATH
;	O
it	O
is	O
characterized	O
by	O
a	O
high	O
mortality	O
rate	O
and	O
can	O
even	O
occur	O
after	O
antimalarial	O
treatment	O
when	O
parasitemia	O
is	O
not	O
detected	O
.	O

We	O
then	O
showed	O
that	O
Ulk1	O
forms	O
a	O
multiprotein	O
complex	O
with	O
TrkA	O
and	O
the	O
early	O
endosome	O
marker	O
Rab5	O
and	O
that	O
Ulk1	O
defects	O
lead	O
to	O
either	O
blocking	O
of	O
NGF	O
/	O
TrkA	O
endocytosis	B-PATH
or	O
premature	O
degradation	O
of	O
pTrkA	O
via	O
constitutive	O
activation	O
of	O
the	O
Rab5	O
GTPase	O
.	O

TGEV	O
entry	O
is	O
via	O
clathrin	O
and	O
caveolin	O
mediated	O
endocytosis	B-PATH
in	O
IPEC	O
-	O
J2	O
cells	O
.	O

TGEV	O
binds	O
with	O
EGFR	O
,	O
and	O
subsequently	O
promotes	O
EGFR	O
internalization	O
by	O
a	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
pathway	O
.	O

Similarly	O
,	O
oseltamivir	O
reduced	O
the	O
replication	O
of	O
influenza	B-PATH
A	I-PATH
viruses	O
in	O
a	O
dose	O
dependent	O
manner	O
and	O
prevented	O
the	O
impairment	O
of	O
the	O
epithelial	O
barrier	O
function	O
and	O
cytotoxicity	O
until	O
4	O
days	O
of	O
infection	O
.	O

In	O
addition	O
we	O
found	O
that	O
Rhinovirus	O
B14	O
,	O
C15	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
induce	O
significant	O
increase	O
of	O
Î²	O
Defensins	B-PATH
2	O
and	O
Cathelicidin	O
release	B-PATH
with	O
different	O
time	O
course	O
.	O

TITLE	O
:	O
Apigenin	O
C	O
-	O
glycosides	O
of	O
Microcos	O
paniculata	O
protects	O
lipopolysaccharide	O
induced	O
apoptosis	B-PATH
and	O
inflammation	O
in	O
acute	O
lung	O
injury	O
through	O
TLR4	O
signaling	O
pathway	O
.	O

Moreover	O
,	O
metabolic	O
profiling	O
of	O
mice	O
serum	O
and	O
subsequent	O
Ingenuity	O
Pathway	O
Analysis	O
suggested	O
that	O
ACGs	O
activated	O
protective	O
protein	O
networks	O
and	O
pathways	O
involving	O
inflammatory	O
regulators	O
and	O
apoptosis	B-PATH
-	O
related	O
factors	O
,	O
such	O
as	O
JNK	O
,	O
ERK1	O
/	O
2	O
and	O
caspase	O
-	O
3	O
/	O
7	O
,	O
suggesting	O
that	O
ACGs	O
-	O
dependent	O
effects	O
were	O
related	O
to	O
MAPKs	O
and	O
mitochondrial	O
apoptosis	B-PATH
pathways	O
.	O

Our	O
study	O
shows	O
for	O
the	O
first	O
time	O
that	O
ACGs	O
inhibit	O
acute	O
inflammation	O
and	O
apoptosis	B-PATH
by	O
suppressing	O
activation	O
of	O
TLR4	O
/	O
TRPC6	O
signaling	O
pathway	O
in	O
a	O
murine	O
model	O
of	O
ALI	O
.	O

Factors	O
attributable	O
for	O
ARDS	O
were	O
malaria	B-PATH
in	O
31	O
patients	O
(	O
26	O
.	O
72	O
%),	O
pneumonia	O
in	O
23	O
(	O
19	O
.	O
82	O
%),	O
sepsis	O
in	O
20	O
(	O
17	O
.	O
2	O
%),	O
dengue	O
in	O
15	O
(	O
12	O
.	O
96	O
%),	O
undiagnosed	O
fever	O
in	O
13	O
(	O
11	O
.	O
1	O
%),	O
leptospirosis	O
in	O
7	O
(	O
6	O
.	O
03	O
%),	O
pancreatitis	O
in	O
3	O
(	O
2	O
.	O
58	O
%),	O
H1N1	O
infection	O
in	O
2	O
(	O
1	O
.	O
72	O
%),	O
urinary	O
tract	O
infection	O
(	O
UTI	O
)	O
in	O
1	O
(	O
0	O
.	O
86	O
%)	O
and	O
UTI	O
with	O
pyelonephritis	O
and	O
Dengue	O
in	O
1	O
(	O
0	O
.	O
86	O
%)	O
patients	O
.	O

Tropical	O
diseases	O
like	O
malaria	B-PATH
,	O
dengue	O
,	O
and	O
leptospirosis	O
were	O
the	O
main	O
factors	O
responsible	O
for	O
ARDS	O
.	O

TITLE	O
:	O
Live	O
-	O
attenuated	O
bivalent	O
measles	B-PATH
virus	O
-	O
derived	O
vaccines	O
targeting	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
induce	O
robust	O
and	O
multifunctional	O
T	O
cell	O
responses	O
against	O
both	O
viruses	O
in	O
an	O
appropriate	O
mouse	O
model	O
.	O

TITLE	O
:	O
Use	O
of	O
ribavirin	O
in	O
viruses	O
other	O
than	O
hepatitis	B-PATH
C	I-PATH
.	O
A	O
review	O
of	O
the	O
evidence	O
.	O

The	O
results	O
showed	O
that	O
TGEV	O
N	O
protein	O
localised	O
in	O
the	O
cytoplasm	O
,	O
inhibited	O
IEC	O
growth	O
,	O
prolonged	O
the	O
S	O
-	O
phase	O
cell	B-PATH
cycle	I-PATH
by	O
down	O
-	O
regulating	O
cell	B-PATH
cycle	I-PATH
protein	O
cyclin	O
A	O
,	O
and	O
was	O
mainly	O
degraded	O
through	O
the	O
proteasome	B-PATH
pathway	O
.	O

To	O
be	O
specific	O
,	O
in	O
IEC	O
,	O
TGEV	O
N	O
protein	O
induces	O
cell	B-PATH
cycle	I-PATH
prolongation	O
at	O
the	O
S	O
-	O
phase	O
,	O
ER	O
stress	O
and	O
up	O
-	O
regulates	O
IL	O
-	O
8	O
expression	O
.	O

Five	O
parasite	O
species	O
namely	O
,	O
Plasmodium	O
falciparum	O
,	O
P	O
.	O
vivax	O
,	O
P	O
.	O
malariae	O
,	O
P	O
.	O
ovale	O
,	O
and	O
P	O
.	O
knowlesi	O
,	O
cause	O
malaria	B-PATH
in	O
humans	O
.	O

Another	O
characteristic	O
feature	O
of	O
P	O
.	O
vivax	O
infection	O
,	O
compared	O
to	O
P	O
.	O
falciparum	O
infection	O
,	O
is	O
persistence	O
of	O
the	O
parasite	O
as	O
dormant	O
liver	O
-	O
stage	O
hypnozoites	O
,	O
causing	O
recurrent	O
episodes	O
of	O
malaria	B-PATH
.	O

Recently	O
,	O
we	O
identified	O
Arf4	O
and	O
Arf5	O
(	O
class	O
II	O
Arfs	O
)	O
as	O
host	O
factors	O
required	O
for	O
the	O
replication	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
a	O
GBF1	O
-	O
dependent	O
virus	O
.	O

ABSTRACT	O
:	O
Since	O
2013	O
,	O
influenza	B-PATH
A	I-PATH
H7N9	O
virus	O
has	O
emerged	O
as	O
the	O
most	O
common	O
avian	O
influenza	O
virus	O
subtype	O
causing	O
human	O
infection	O
,	O
and	O
it	O
is	O
associated	O
with	O
a	O
high	O
fatality	O
risk	O
.	O

ACTB	O
-	O
actin	O
beta	O
;	O
ATG13	O
-	O
autophagy	O
related	O
13	O
;	O
ATG14	O
-	O
autophagy	O
related	O
14	O
;	O
ATG101	O
-	O
autophagy	O
related	O
101	O
;	O
BECN1	O
-	O
beclin	O
1	O
;	O
CVB3	O
-	O
coxsackievirus	O
B3	O
;	O
DMV	O
-	O
double	O
-	O
membraned	O
vesicles	O
;	O
EM	O
-	O
electron	O
microscopy	O
;	O
EMCV	O
-	O
encephalomyocarditis	O
virus	O
;	O
EV	O
-	O
71	O
-	O
enterovirus	O
71	O
;	O
FMDV	O
-	O
foot	O
and	O
mouth	O
disease	O
virus	O
;	O
GFP	O
-	O
green	O
fluorescent	O
protein	O
;	O
MAP1LC3B	O
/	O
LC3B	O
-	O
microtubule	O
associated	O
protein	O
1	O
light	O
chain	O
3	O
beta	O
;	O
MOI	O
-	O
multiplicity	O
of	O
infection	O
;	O
MTOR	O
-	O
mechanistic	O
target	O
of	O
rapamycin	O
kinase	O
;	O
PIK3C3	O
-	O
phosphatidylinositol	O
3	O
-	O
kinase	O
catalytic	O
subunit	O
type	O
3	O
;	O
PRKAA2	O
-	O
protein	O
kinase	O
AMP	O
-	O
activated	O
catalytic	O
subunit	O
alpha	O
2	O
;	O
PSMG1	O
-	O
proteasome	B-PATH
assembly	O
chaperone	O
1	O
;	O
PSMG2	O
-	O
proteasome	B-PATH
assembly	O
chaperone	O
2PV	O
-	O
poliovirus	O
;	O
RB1CC1	O
-	O
RB1	O
inducible	O
coiled	O
-	O
coil	O
1	O
;	O
SQSTM1	O
-	O
sequestosome	O
1	O
;	O
ULK1	O
-	O
unc	O
-	O
51	O
like	O
autophagy	O
activating	O
kinase	O
1	O
;	O
ULK2	O
-	O
unc	O
-	O
51	O
like	O
autophagy	O
activating	O
kinase	O
2	O
;	O
WIPI1	O
-	O
WD	O
repeat	O
domain	O
,	O
phosphoinositide	O
interacting	O
1	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
epidemiology	O
in	O
the	O
Eastern	O
Province	O
of	O
Saudi	O
Arabia	O
.	O

The	O
incidence	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
was	O
higher	O
among	O
younger	O
patients	O
;	O
27	O
.	O
94	O
%	O
of	O
patients	O
in	O
the	O
0	O
-	O
19	O
-	O
year	O
age	O
group	O
tested	O
positive	O
compared	O
to	O
only	O
3	O
.	O
51	O
%	O
of	O
patients	O
in	O
the	O
â¥	O
80	O
-	O
year	O
age	O
group	O
.	O

Younger	O
individuals	O
in	O
the	O
Eastern	O
Province	O
of	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
had	O
a	O
relatively	O
higher	O
risk	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
.	O

RESULTS	O
:	O
The	O
incidence	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
was	O
higher	O
among	O
younger	O
patients	O
;	O
27	O
.	O
94	O
%	O
of	O
patients	O
in	O
the	O
0	O
-	O
19	O
-	O
year	O
age	O
group	O
tested	O
positive	O
compared	O
to	O
only	O
3	O
.	O
51	O
%	O
of	O
patients	O
in	O
the	O
â¥	O
80	O
-	O
year	O
age	O
group	O
.	O

The	O
incidence	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
was	O
higher	O
in	O
Ras	O
Tanura	O
city	O
compared	O
to	O
other	O
locations	O
in	O
the	O
Eastern	O
Province	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	B-PATH
through	O
activation	O
of	O
the	O
cytochrome	O
c	O
-	O
mediated	O
intrinsic	O
mitochondrial	O
pathway	O
.	O

The	O
use	O
of	O
a	O
pan	O
-	O
caspase	O
inhibitor	O
resulted	O
in	O
the	O
inhibition	O
of	O
PDCoV	O
-	O
induced	O
apoptosis	B-PATH
and	O
reduction	O
of	O
PDCoV	O
replication	O
,	O
suggestive	O
of	O
the	O
association	O
of	O
a	O
caspase	O
-	O
dependent	O
pathway	O
.	O

Furthermore	O
,	O
PDCoV	O
infection	O
necessitated	O
the	O
activation	O
of	O
the	O
initiator	O
caspase	O
-	O
9	O
responsible	O
for	O
the	O
intrinsic	O
mitochondrial	O
apoptosis	B-PATH
pathway	O
.	O

Moreover	O
,	O
cyt	O
c	O
release	B-PATH
was	O
completely	O
abrogated	O
in	O
PDCoV	O
-	O
infected	O
cells	O
in	O
the	O
presence	O
of	O
CsA	O
,	O
suggesting	O
the	O
critical	O
role	O
of	O
MPTP	O
in	O
intrinsic	O
apoptosis	B-PATH
in	O
response	O
to	O
PDCoV	O
infection	O
.	O

Altogether	O
,	O
our	O
results	O
indicate	O
that	O
PDCoV	O
infection	O
stimulates	O
MOMP	O
either	O
via	O
Bax	O
recruitment	O
or	O
MPTP	O
opening	O
to	O
permit	O
the	O
release	B-PATH
of	O
apoptogenic	O
cyt	O
c	O
into	O
the	O
cytoplasm	O
,	O
thereby	O
leading	O
to	O
execution	O
of	O
the	O
caspase	O
-	O
dependent	O
intrinsic	O
apoptosis	B-PATH
pathway	O
to	O
facilitate	O
viral	O
replication	O
in	O
vitro	O
.	O

Respiratory	O
function	O
is	O
impaired	O
by	O
alcohol	O
misuse	O
:	O
asthma	B-PATH
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
lung	O
infections	O
,	O
and	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
are	O
more	O
frequent	O
and	O
severe	O
.	O

Excluded	O
were	O
those	O
with	O
suspected	O
or	O
proven	O
cystic	O
fibrosis	O
,	O
pulmonary	O
tuberculosis	B-PATH
,	O
malignancy	O
,	O
immunodeficiency	O
,	O
and	O
congenital	O
heart	O
disease	O
.	O

ABSTRACT	O
:	O
A	O
central	O
goal	O
for	O
reintroduced	O
populations	O
of	O
threatened	O
wood	O
bison	O
(	O
Bison	O
bison	O
athabascae	O
)	O
is	O
to	O
maintain	O
them	O
free	O
of	O
diseases	O
of	O
concern	O
,	O
particularly	O
bovine	O
tuberculosis	B-PATH
(	O
caused	O
by	O
Mycobacterium	O
bovis	O
)	O
and	O
brucellosis	O
(	O
caused	O
by	O
Brucella	O
abortus	O
).	O

Babesiosis	O
'	O
prevalence	O
and	O
presentation	O
have	O
earned	O
it	O
the	O
monikers	O
""""	O
malaria	B-PATH
of	O
the	O
northeast	O
""""	O
and	O
""""	O
Nantucket	O
fever	O
"""."	O

ABSTRACT	O
:	O
Anti	O
-	O
melanoma	B-PATH
differentiation	O
-	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
autoantibodies	O
have	O
been	O
identified	O
as	O
myositis	O
-	O
specific	O
autoantibodies	O
that	O
are	O
often	O
associated	O
with	O
clinically	O
amyopathic	O
dermatomyositis	O
(	O
CADM	O
)	O
and	O
a	O
poor	O
prognosis	O
due	O
to	O
rapidly	O
progressive	O
interstitial	O
lung	O
disease	O
(	O
RP	O
-	O
ILD	O
)	O
in	O
East	O
Asian	O
patients	O
.	O

For	O
coronavirus	O
,	O
we	O
used	O
the	O
spike	O
gene	O
sequences	O
,	O
while	O
for	O
rabies	O
and	O
influenza	B-PATH
A	I-PATH
viruses	O
,	O
we	O
used	O
the	O
more	O
conserved	O
nucleoprotein	O
gene	O
sequences	O
.	O

The	O
results	O
show	O
that	O
the	O
virus	O
hijacks	O
caveolin	O
-	O
dependent	O
endocytosis	B-PATH
to	O
enter	O
cells	O
via	O
endocytic	O
internalization	O
.	O

Here	O
,	O
we	O
show	O
that	O
TMPRSS11A	O
,	O
another	O
member	O
of	O
the	O
TTSP	O
family	O
,	O
cleaves	O
and	O
activates	O
the	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
FLUAV	O
)	O
HA	O
and	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
(	O
MERS	O
-	O
S	O
).	O

By	O
double	O
IF	O
and	O
TUNEL	O
staining	O
,	O
most	O
PDCoV	O
antigen	O
-	O
positive	O
IPEC	O
-	O
J2	O
cells	O
failed	O
to	O
show	O
TUNEL	O
-	O
positive	O
signals	O
,	O
indicating	O
that	O
PDCoV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
may	O
not	O
undergo	O
apoptosis	B-PATH
,	O
but	O
rather	O
necrosis	O
,	O
similar	O
to	O
necrotic	O
cell	O
death	O
of	O
infected	O
enterocytes	O
in	O
vivo	O
.	O

Examination	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
demonstrated	O
yeast	O
cells	O
with	O
broad	O
-	O
based	O
budding	B-PATH
.	O

Equivocal	O
""""	O
and	O
""""	O
no	O
-	O
subtype	O
""""	O
samples	O
by	O
FilmArray	O
mostly	O
represented	O
weak	O
Influenza	B-PATH
A	I-PATH
by	O
laboratory	O
-	O
developed	O
test	O
.	O

TITLE	O
:	O
Hepatitis	B-PATH
C	I-PATH
virus	O
enters	O
liver	O
cells	O
using	O
the	O
CD81	O
receptor	O
complex	O
proteins	O
calpain	O
-	O
5	O
and	O
CBLB	O
.	O

ABSTRACT	O
:	O
Hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
and	O
the	O
malaria	B-PATH
parasite	O
Plasmodium	O
use	O
the	O
membrane	O
protein	O
CD81	O
to	O
invade	O
human	O
liver	O
cells	O
.	O

However	O
,	O
over	O
the	O
last	O
several	O
years	O
it	O
has	O
become	O
apparent	O
that	O
for	O
some	O
picornaviruses	O
,	O
a	O
macroautophagy	O
/	O
autophagy	O
-	O
related	O
pathway	O
can	O
result	O
in	O
release	B-PATH
of	O
virus	O
particles	O
wrapped	O
in	O
a	O
membrane	O
containing	O
autophagic	O
markers	O
.	O

It	O
has	O
been	O
proposed	O
that	O
this	O
enveloped	O
release	B-PATH
predominates	O
within	O
hosts	O
,	O
allowing	O
cell	O
-	O
to	O
-	O
cell	O
movement	O
of	O
virus	O
while	O
minimizing	O
exposure	O
to	O
the	O
immune	O
system	O
.	O

The	O
current	O
work	O
emphasizes	O
on	O
the	O
discovery	O
process	O
of	O
the	O
chalcone	O
in	O
the	O
period	O
of	O
2016	O
to	O
2017	O
on	O
malaria	B-PATH
,	O
trypanosomiasis	O
,	O
leishmaniasis	B-PATH
,	O
filaria	O
,	O
tuberculosis	B-PATH
,	O
netamodes	O
,	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
),	O
Tobacco	O
Mosaic	O
Virus	O
(	O
TMV	O
),	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
),	O
and	O
miscellaneous	O
conditions	O
.	O

TITLE	O
:	O
First	O
tidal	O
volume	O
greater	O
than	O
8	O
mL	O
/	O
kg	O
is	O
associated	O
with	O
increased	O
mortality	O
in	O
complicated	O
influenza	B-PATH
infection	I-PATH
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Severe	O
influenza	B-PATH
infection	I-PATH
causes	O
substantial	O
morbidity	O
and	O
mortality	O
worldwide	O
and	O
remains	O
an	O
important	O
threat	O
to	O
global	O
health	O
.	O

The	O
mean	O
tidal	O
volume	O
(	O
V	O
CONCLUSIONS	O
:	O
First	O
tidal	O
volume	O
,	O
shortly	O
after	O
intubation	O
,	O
greater	O
than	O
8	O
mL	O
/	O
kg	O
PBW	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
mortality	O
in	O
complicated	O
influenza	B-PATH
infection	I-PATH
with	O
ARDS	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
important	O
achievements	O
made	O
by	O
mathematical	O
modeling	O
of	O
viral	O
kinetics	O
on	O
the	O
extracellular	O
,	O
intracellular	O
,	O
and	O
multi	O
-	O
scale	O
level	O
for	O
Human	O
Immunodeficiency	O
Virus	O
,	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
,	O
Influenza	B-PATH
A	I-PATH
Virus	O
,	O
Ebola	O
Virus	O
,	O
Dengue	O
Virus	O
,	O
and	O
Zika	O
Virus	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
all	O
patients	O
admitted	O
to	O
Tunisian	O
intensive	O
care	O
unit	O
with	O
a	O
diagnosis	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
virus	O
infection	O
after	O
the	O
2009	O
influenza	O
pandemic	O
and	O
to	O
analyse	O
their	O
characteristics	O
,	O
predictors	O
of	O
complications	O
and	O
outcome	O
.	O

All	O
patients	O
with	O
influenza	O
>	O
18	O
-	O
years	O
-	O
old	O
hospitalized	O
to	O
the	O
ICU	O
department	O
of	O
Tunisian	O
University	O
hospital	O
of	O
Sousse	O
,	O
between	O
December	O
1	O
,	O
2009	O
and	O
March	O
31	O
,	O
2016	O
,	O
with	O
a	O
positive	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
/	O
09	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
a	O
nasopharyngeal	O
specimen	O
were	O
included	O
,	O
were	O
included	O
.	O

During	O
the	O
reporting	O
period	O
,	O
22	O
deaths	O
in	O
intensive	O
care	O
units	O
(	O
55	O
%)	O
were	O
reported	O
,	O
the	O
median	O
age	O
was	O
53	O
years	O
(	O
IQR	O
37	O
-	O
61	O
),	O
24	O
(	O
61	O
%)	O
were	O
male	O
,	O
The	O
median	O
scores	O
SAPS	O
II	O
and	O
SOFA	O
were	O
respectively	O
29	O
(	O
IQR	O
23	O
-	O
36	O
)	O
and	O
6	O
(	O
IQR	O
3	O
-	O
10	O
),	O
27	O
%	O
had	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
),	O
33	O
.	O
3	O
%	O
diabetic	O
and	O
no	O
patients	O
were	O
vaccinated	O
against	O
influenza	B-PATH
A	I-PATH
.	O
The	O
cause	O
of	O
admission	O
was	O
in	O
72	O
.	O
5	O
%	O
of	O
the	O
cases	O
was	O
hypoxemic	O
pneumonae	O
.	O

To	O
determine	O
if	O
the	O
pathogens	O
adenovirus	O
(	O
ADV	O
),	O
coronavirus	O
(	O
CoV	O
),	O
encephalomyocarditis	O
virus	O
(	O
EMCV	O
),	O
enterovirus	O
(	O
EV	O
),	O
influenza	B-PATH
A	I-PATH
-	O
D	O
(	O
IAV	O
,	O
IBV	O
,	O
ICV	O
,	O
and	O
IDV	O
),	O
porcine	O
circovirus	O
2	O
(	O
PCV2	O
),	O
and	O
porcine	O
rotaviruses	O
A	O
and	O
C	O
(	O
RVA	O
and	O
RVC	O
),	O
are	O
aerosolized	O
at	O
the	O
animal	O
-	O
interface	O
,	O
and	O
if	O
humans	O
working	O
in	O
these	O
environments	O
are	O
carrying	O
these	O
viruses	O
in	O
their	O
nasal	O
airways	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
case	O
of	O
human	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	B-PATH
)	O
virus	O
infection	O
in	O
2013	O
,	O
five	O
H7N9	B-PATH
epidemics	O
have	O
occurred	O
in	O
China	O
,	O
all	O
of	O
which	O
caused	O
severe	O
diseases	O
,	O
including	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
the	O
fatality	O
rates	O
of	O
these	O
epidemics	O
were	O
as	O
high	O
as	O
30	O
-	O
40	O
%.	O

However	O
,	O
binding	O
to	O
the	O
receptor	O
opens	O
up	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
S1	O
,	O
which	O
could	O
promote	O
the	O
release	B-PATH
of	O
the	O
S1	O
-	O
ACE2	O
complex	O
and	O
S1	O
monomers	O
from	O
the	O
prefusion	O
spike	O
and	O
trigger	O
the	O
pre	O
-	O
to	O
postfusion	O
conformational	O
transition	O
.	O

TITLE	O
:	O
Cerebral	O
toxoplasmosis	B-PATH
in	O
a	O
cat	O
with	O
feline	O
leukemia	O
and	O
feline	O
infectious	O
peritonitis	O
viral	O
infections	O
.	O

TITLE	O
:	O
Histopathology	O
of	O
Bordetella	O
pertussis	B-PATH
in	O
the	O
Baboon	O
Model	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
scIAV	O
-	O
S	O
,	O
a	O
single	O
-	O
cycle	O
influenza	B-PATH
A	I-PATH
virus	O
pseudotyped	O
with	O
the	O
spike	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
and	O
demonstrated	O
that	O
this	O
virus	O
could	O
infect	O
cultured	O
cells	O
and	O
trigger	O
massive	O
syncytium	O
formation	O
.	O

Treatment	O
with	O
endocytosis	B-PATH
inhibitors	O
did	O
not	O
affect	O
syncytium	O
formation	O
by	O
infected	O
cells	O
.	O

The	O
most	O
frequent	O
viruses	O
detected	O
as	O
single	O
pathogens	O
were	O
RSV	O
(	O
n	O
=	O
286	O
),	O
rhinovirus	O
/	O
enterovirus	O
(	O
n	O
=	O
251	O
),	O
parainfluenza	O
viruses	O
(	O
n	O
=	O
104	O
),	O
and	O
influenza	B-PATH
A	I-PATH
or	O
B	O
(	O
n	O
=	O
99	O
).	O

TITLE	O
:	O
Management	O
of	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
with	O
H1N1	O
Influenza	O
Virus	O
in	O
Pregnancy	O
:	O
Successful	O
Mechanical	O
Ventilation	O
and	O
Weaning	O
with	O
Airway	O
Pressure	O
Release	B-PATH
Ventilation	O
.	O

The	O
ARDS	O
was	O
successfully	O
managed	O
by	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
).	O

Therefore	O
,	O
the	O
mentioned	O
proteins	O
limit	O
early	O
induction	O
of	O
IFN	O
and	O
cause	O
rapid	O
apoptosis	B-PATH
of	O
macrophages	O
.	O

With	O
this	O
expansion	O
,	O
the	O
global	O
laboratory	O
community	O
has	O
started	O
to	O
focus	O
on	O
laboratory	O
biosafety	O
and	O
biosecurity	O
in	O
order	O
to	O
prevent	O
the	O
accidental	O
and	O
/	O
or	O
intentional	O
release	B-PATH
of	O
these	O
agents	O
.	O

Swabs	O
from	O
surface	O
samples	O
,	O
and	O
air	O
samples	O
were	O
tested	O
by	O
real	O
-	O
time	O
PCR	O
for	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
adenovirus	O
,	O
rhinovirus	O
and	O
coronaviruses	O
(	O
229E	O
,	O
HKU1	O
,	O
NL63	O
and	O
OC43	O
).	O

Among	O
the	O
10	O
respiratory	O
virus	O
findings	O
at	O
various	O
sites	O
,	O
the	O
viruses	O
identified	O
were	O
:	O
rhinovirus	O
(	O
4	O
/	O
10	O
,	O
40	O
%,	O
from	O
surfaces	O
);	O
coronavirus	O
(	O
3	O
/	O
10	O
,	O
30	O
%,	O
from	O
surfaces	O
);	O
adenovirus	O
(	O
2	O
/	O
10	O
,	O
20	O
%,	O
1	O
air	O
sample	O
,	O
1	O
surface	O
sample	O
);	O
influenza	B-PATH
A	I-PATH
(	O
1	O
/	O
10	O
,	O
10	O
%,	O
surface	O
sample	O
).	O

Among	O
the	O
10	O
respiratory	O
virus	O
findings	O
at	O
various	O
sites	O
,	O
the	O
viruses	O
identified	O
were	O
:	O
rhinovirus	O
(	O
4	O
/	O
10	O
,	O
40	O
%,	O
from	O
surfaces	O
);	O
coronavirus	O
(	O
3	O
/	O
10	O
,	O
30	O
%,	O
from	O
surfaces	O
);	O
adenovirus	O
(	O
2	O
/	O
10	O
,	O
20	O
%,	O
1	O
air	O
sample	O
,	O
1	O
surface	O
sample	O
);	O
influenza	B-PATH
A	I-PATH
(	O
1	O
/	O
10	O
,	O
10	O
%,	O
surface	O
sample	O
).	O

ABSTRACT	O
:	O
Six	O
series	O
of	O
semisynthetic	O
lipophilic	O
glycopeptide	O
antibiotic	O
derivatives	O
were	O
evaluated	O
for	O
in	O
vitro	O
activity	O
against	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
.	O

Of	O
the	O
42	O
lipophilic	O
teicoplanin	O
pseudoaglycon	O
derivatives	O
tested	O
,	O
about	O
half	O
showed	O
broad	O
activity	O
against	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
with	O
some	O
of	O
them	O
having	O
reasonable	O
or	O
no	O
cytotoxicity	O
.	O

Multiplex	O
polymerase	O
chain	O
reaction	O
(	O
mPCR	O
)	O
kits	O
were	O
used	O
to	O
detect	O
10	O
viruses	O
[	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
adenovirus	O
(	O
ADV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
A	O
and	O
B	O
,	O
picornavirus	O
,	O
parainfluenza	O
virus	O
(	O
PIV	O
),	O
coronavirus	O
,	O
human	O
metapneumovirus	O
(	O
HMPV	O
),	O
and	O
bocavirus	O
].	O

Patients	O
with	O
influenza	B-PATH
infection	I-PATH
were	O
likely	O
to	O
be	O
taken	O
to	O
emergency	O
rooms	O
and	O
have	O
respiratory	O
failure	O
with	O
higher	O
creatinine	O
kinase	O
levels	O
and	O
lower	O
white	O
blood	O
cell	O
counts	O
.	O

Consequently	O
,	O
Transcription	O
Factor	O
EB	O
(	O
TFEB	O
)	O
translocates	O
to	O
the	O
nucleus	O
increasing	O
the	O
transcription	O
of	O
autophagy	O
-	O
and	O
lysosome	B-PATH
-	O
related	O
genes	O
.	O

MTT	O
assay	O
was	O
performed	O
to	O
test	O
the	O
cytotoxicity	O
of	O
the	O
synthesized	O
Zr	O
QDs	O
against	O
rat	O
brain	O
glioma	B-PATH
C6	O
cells	O
.	O

LPS	O
induced	O
the	O
release	B-PATH
of	O
TNFÎ±	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
8	O
by	O
HLMVECs	O
that	O
were	O
inhibited	O
by	O
sitagliptin	O
.	O

The	O
results	O
of	O
RNA	O
interference	O
(	O
RNAi	O
)	O
experiments	O
showed	O
that	O
one	O
19	O
-	O
nt	O
segment	O
corresponding	O
to	O
SARS	O
-	O
CoV	O
-	O
cpsR	O
-	O
19	O
significantly	O
induced	O
cell	O
apoptosis	B-PATH
.	O

These	O
efforts	O
included	O
a	O
global	O
commitment	O
to	O
immunize	O
the	O
world	O
â	O
s	O
children	O
against	O
the	O
major	O
infections	O
for	O
which	O
vaccines	O
are	O
available	O
and	O
global	O
campaigns	O
to	O
control	O
malaria	B-PATH
and	O
diarrheal	O
disease	O
.	O

For	O
example	O
,	O
in	O
low	O
-	O
income	O
countries	O
(	O
LICs	O
)	O
from	O
2000	O
to	O
2010	O
,	O
the	O
number	O
of	O
deaths	O
before	O
age	O
70	O
years	O
from	O
HIV	O
/	O
AIDS	O
,	O
TB	O
,	O
and	O
malaria	B-PATH
fell	O
by	O
46	O
percent	O
,	O
35	O
percent	O
,	O
and	O
36	O
percent	O
,	O
respectively	O
(	O
Norheim	O
and	O
others	O
2015	O
).	O

Like	O
cocaine	O
,	O
methamphetamine	O
blocks	O
reuptake	O
of	O
monoamine	O
transporters	O
,	O
but	O
also	O
stimulates	O
dopamine	O
release	B-PATH
and	O
has	O
a	O
longer	O
duration	O
of	O
action	O
.	O

We	O
found	O
that	O
even	O
at	O
a	O
very	O
low	O
concentration	O
,	O
Caerin1	O
.	O
1	O
has	O
the	O
ability	O
to	O
destroy	O
the	O
integrity	O
of	O
the	O
virus	O
particles	O
to	O
block	O
the	O
release	B-PATH
of	O
the	O
viruses	O
,	O
resulting	O
in	O
a	O
considerable	O
decrease	O
in	O
PEDV	O
infections	O
.	O

TITLE	O
:	O
Attenuation	O
of	O
Influenza	B-PATH
A	I-PATH
Virus	O
Disease	O
Severity	O
by	O
Viral	O
Coinfection	O
in	O
a	O
Mouse	O
Model	O
.	O

The	O
most	O
frequently	O
detected	O
virus	O
was	O
adenovirus	O
,	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
and	O
influenza	O
B	O
.	O
Detection	O
of	O
more	O
than	O
one	O
virus	O
was	O
present	O
in	O
58	O
.	O
3	O
%	O
of	O
the	O
children	O
with	O
FS	O
,	O
and	O
the	O
most	O
common	O
co	O
-	O
existence	O
was	O
the	O
presence	O
of	O
adenovirus	O
and	O
influenza	O
B	O
.	O
In	O
children	O
younger	O
than	O
12	O
months	O
,	O
Coronavirus	O
OC43	O
was	O
the	O
most	O
common	O
,	O
while	O
influenza	B-PATH
A	I-PATH
was	O
most	O
frequently	O
observed	O
in	O
children	O
older	O
than	O
48	O
months	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
apoptosis	B-PATH
was	O
not	O
completely	O
prevented	O
by	O
caspases	O
inhibitors	O
,	O
suggesting	O
that	O
there	O
may	O
be	O
a	O
caspase	O
-	O
independent	O
pathway	O
involved	O
in	O
TGEV	O
-	O
induced	O
cell	O
apoptosis	B-PATH
.	O

Furthermore	O
,	O
TGEV	O
-	O
induced	O
apoptosis	B-PATH
was	O
blocked	O
by	O
combination	O
of	O
three	O
or	O
more	O
inhibitors	O
,	O
such	O
as	O
pan	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
FMK	O
,	O
NP	O
,	O
ABT	O
-	O
888	O
,	O
PDTC	O
,	O
PFT	O
-	O
Î±	O
,	O
to	O
treat	O
PK	O
-	O
15	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
p53	O
-	O
and	O
ROS	O
-	O
mediated	O
AIF	O
pathway	O
and	O
caspase	O
-	O
dependent	O
pathway	O
were	O
involved	O
in	O
TGEV	O
-	O
induced	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
With	O
outbreaks	O
of	O
new	O
respiratory	O
viruses	O
such	O
as	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
,	O
the	O
nucleic	O
acid	O
-	O
based	O
amplification	O
test	O
was	O
introduced	O
to	O
identify	O
causative	O
agents	O
.	O

ABSTRACT	O
:	O
Ever	O
since	O
the	O
development	O
of	O
the	O
first	O
vaccine	O
more	O
than	O
200	O
years	O
ago	O
,	O
vaccinations	O
have	O
greatly	O
decreased	O
the	O
burden	O
of	O
infectious	O
diseases	O
worldwide	O
,	O
famously	O
leading	O
to	O
the	O
eradication	O
of	O
small	O
pox	O
and	O
allowing	O
the	O
restriction	O
of	O
diseases	O
such	O
as	O
polio	O
,	O
tetanus	O
,	O
diphtheria	O
,	O
and	O
measles	B-PATH
.	O

Nonsense	B-PATH
-	I-PATH
mediated	I-PATH
decay	I-PATH
(	O
NMD	O
)	O
is	O
a	O
eukaryotic	O
RNA	O
surveillance	O
pathway	O
that	O
detects	O
mRNAs	O
harboring	O
aberrant	O
features	O
and	O
targets	O
them	O
for	O
degradation	O
.	O

We	O
report	O
a	O
pediatric	O
case	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
with	O
a	O
good	O
outcome	O
following	O
rapid	O
initiation	O
of	O
vvECMO	O
.	O
This	O
patient	O
was	O
a	O
13	O
-	O
year	O
-	O
old	O
boy	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
influenza	O
virus	O
.	O

Moreover	O
,	O
EC	O
-	O
specific	O
PHD2	O
inducible	O
knockout	O
mice	O
exhibit	O
improved	O
adherens	B-PATH
junction	I-PATH
integrity	O
and	O
endothelial	O
barrier	O
function	O
.	O

Herein	O
,	O
we	O
employed	O
a	O
bioinorganic	O
perspective	O
to	O
develop	O
an	O
SAR	O
for	O
inhibition	O
of	O
the	O
metalloenzyme	O
influenza	O
RNA	B-PATH
polymerase	I-PATH
PA	O

We	O
described	O
the	O
viral	O
detection	O
profile	O
and	O
its	O
association	O
with	O
clinical	O
characteristics	O
in	O
children	O
admitted	O
to	O
the	O
Pediatric	O
Intensive	O
Care	O
Unit	O
(	O
PICU	O
)	O
during	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
.	O

Age	O
â¥	O
50	O
,	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
,	O
corticosteroids	O
,	O
hypoalbuminemia	O
,	O
and	O
inpatient	O
status	O
at	O
the	O
time	O
of	O
infection	O
were	O
independently	O
associated	O
with	O
progression	O
to	O
LRTI	O
.	O

In	O
addition	O
,	O
the	O
appearance	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
2003	O
,	O
widespread	O
and	O
continued	O
outbreaks	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
since	O
2004	O
,	O
the	O
H1N1	O
pandemic	O
in	O
2009	O
and	O
emergence	O
of	O
MERS	O
CoV	O
in	O
2012	O
reflect	O
the	O
seriousness	O
of	O
public	O
health	O
challenges	O
posed	O
by	O
influenza	O
and	O
emerging	O
respiratory	O
infections	O
.	O

The	O
pathophysiology	O
of	O
ARDS	O
involves	O
interactions	O
among	O
multiple	O
mechanisms	O
,	O
including	O
immune	O
cell	O
infiltration	O
,	O
cytokine	O
storm	O
,	O
alveolar	O
-	O
capillary	O
barrier	O
disruption	O
,	O
cell	O
apoptosis	B-PATH
,	O
and	O
the	O
development	O
of	O
fibrosis	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
S1	O
protein	O
is	O
the	O
critical	O
inducer	O
of	O
apoptosis	B-PATH
.	O

The	O
activation	O
or	O
cleavage	O
of	O
main	O
apoptosis	B-PATH
-	O
associated	O
molecular	O
such	O
as	O
AIFM1	O
,	O
caspase	O
-	O
3	O
,	O
caspase	O
-	O
8	O
,	O
caspase	O
-	O
9	O
and	O
PARP	O
in	O
PEDV	O
infected	O
host	O
cells	O
were	O
analyzed	O
by	O
western	O
blotting	O
.	O

Cell	O
apoptosis	B-PATH
induced	O
by	O
PEDV	O
or	O
overexpression	O
non	O
-	O
structural	O
or	O
structural	O
proteins	O
was	O
measured	O
by	O
the	O
flow	O
cytometry	O
assay	O
.	O

PEDV	O
could	O
infect	O
various	O
host	O
cells	O
including	O
Vero	O
,	O
Vero	O
-	O
E6	O
and	O
Marc	O
-	O
145	O
and	O
cause	O
obvious	O
cytopathic	O
effects	O
,	O
including	O
roundup	O
,	O
cell	O
fusion	O
,	O
cell	O
membrane	O
vacuolation	O
,	O
syncytium	O
formation	O
and	O
cause	O
apparent	O
apoptosis	B-PATH
.	O

Overexpression	O
of	O
S1	O
Spike	O
protein	O
of	O
PEDV	O
SM98	O
strain	O
effectively	O
induced	O
host	O
cell	O
apoptosis	B-PATH
,	O
while	O
the	O
expression	O
of	O
the	O
other	O
non	O
-	O
structure	O
proteins	O
(	O
Nsp1	O
-	O
16	O
)	O
and	O
structural	O
proteins	O
(	O
M	O
,	O
N	O
,	O
E	O
,	O
S2	O
and	O
ORF3	O
)	O
has	O
no	O
or	O
less	O
effect	O
on	O
cell	O
apoptosis	B-PATH
.	O

Similarly	O
,	O
expression	O
of	O
S1	O
protein	O
from	O
wild	O
-	O
type	O
strain	O
BJ2011	O
or	O
cell	O
-	O
adapted	O
strain	O
CV777	O
,	O
also	O
induce	O
apoptosis	B-PATH
in	O
transfected	O
cells	O
.	O

S1	O
Spike	O
protein	O
is	O
one	O
of	O
the	O
most	O
critical	O
functional	O
proteins	O
that	O
contribute	O
to	O
cell	O
apoptosis	B-PATH
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
the	O
S1	O
proteins	O
from	O
various	O
coronavirus	O
family	O
members	O
such	O
as	O
TGEV	O
,	O
IBV	O
,	O
CCoV	O
,	O
SARS	O
and	O
MERS	O
could	O
also	O
induce	O
Vero	O
-	O
E6	O
cells	O
apoptosis	B-PATH
.	O

CONCLUSIONS	O
:	O
S1	O
Spike	O
protein	O
is	O
one	O
of	O
the	O
most	O
critical	O
functional	O
proteins	O
that	O
contribute	O
to	O
cell	O
apoptosis	B-PATH
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
the	O
YxxÎ¦	O
motif	O
triggers	O
endocytosis	B-PATH
of	O
S	O
proteins	O
.	O

TITLE	O
:	O
Clinical	O
and	O
Laboratory	O
Features	O
Associated	O
with	O
Acute	O
Kidney	O
Injury	O
in	O
Severe	O
Malaria	B-PATH
.	O

ABSTRACT	O
:	O
Critically	O
ill	O
severe	O
malaria	B-PATH
constitutes	O
one	O
of	O
the	O
major	O
hospital	O
admissions	O
in	O
Indian	O
setting	O
.	O

All	O
adult	O
patients	O
with	O
severe	O
malaria	B-PATH
were	O
studied	O
during	O
2012	O
-	O
2014	O
.	O

ABSTRACT	O
:	O
Broncho	O
-	O
esophageal	O
fistula	O
formation	O
is	O
a	O
rare	O
complication	O
of	O
tuberculosis	B-PATH
,	O
most	O
often	O
seen	O
in	O
immunocompromised	O
patients	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
case	O
of	O
a	O
young	O
non	O
-	O
immunocompromised	O
refugee	O
from	O
Somalia	O
diagnosed	O
with	O
open	O
pulmonary	O
tuberculosis	B-PATH
complicated	O
by	O
extensive	O
osseous	O
involvement	O
and	O
a	O
broncho	O
-	O
esophageal	O
fistula	O
with	O
consecutive	O
aspiration	O
of	O
gastric	O
contents	O
.	O

TITLE	O
:	O
Characterization	O
of	O
rhinovirus	O
C	O
from	O
a	O
4	O
-	O
year	O
-	O
old	O
boy	O
with	O
acute	O
onset	O
dilated	B-PATH
cardiomyopathy	I-PATH
in	O
Jakarta	O
,	O
Indonesia	O
.	O

The	O
major	O
cause	O
of	O
myocarditis	O
in	O
the	O
paediatric	O
population	O
is	O
viral	O
infection	O
,	O
including	O
coxsackievirus	O
B3	O
,	O
adenovirus	O
,	O
herpesvirus	O
,	O
parvovirus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
and	O
hepatitis	O
.	O

We	O
report	O
the	O
possible	O
association	O
of	O
rhinovirus	O
C	O
and	O
myocarditis	O
in	O
a	O
child	O
presenting	O
with	O
acute	O
onset	O
of	O
dilated	B-PATH
cardiomyopathy	I-PATH
.	O

Phylogenetic	O
analyses	O
based	O
on	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
sequences	O
assigned	O
the	O
detected	O
CoV	O
to	O
clade	O
2b	O
within	O
betacoronaviruses	O
,	O
clustering	O
with	O
SARS	O
-	O
like	O
bat	O
CoVs	O
previously	O
reported	O
.	O

TITLE	O
:	O
Empirical	O
systemic	O
anticoagulation	O
is	O
associated	O
with	O
decreased	O
venous	O
thromboembolism	O
in	O
critically	O
ill	O
influenza	B-PATH
A	I-PATH
H1N1	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
with	O
prone	O
position	O
ventilation	O
successfully	O
rescues	O
infantile	O
pertussis	B-PATH
:	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O

ABSTRACT	O
:	O
Bordetella	O
pertussis	B-PATH
can	O
cause	O
fatal	O
illness	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
pulmonary	O
hypertension	O
(	O
PHT	O
).	O

In	O
this	O
patient	O
with	O
severe	O
ARDS	O
caused	O
by	O
Bordetella	O
pertussis	B-PATH
,	O
ECMO	O
was	O
performed	O
for	O
cardiopulmonary	O
support	O
and	O
rescued	O
the	O
infant	O
with	O
severe	O
pertussis	B-PATH
.	O

Influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
were	O
found	O
in	O
120	O
(	O
68	O
.	O
6	O
%)	O
and	O
55	O
(	O
31	O
.	O
4	O
%)	O
specimens	O
,	O
respectively	O
,	O
among	O
which	O
coinfections	O
were	O
found	O
in	O
106	O
(	O
60	O
.	O
6	O
%)	O
specimens	O
.	O

ABSTRACT	O
:	O
Respiratory	O
viral	O
infections	O
are	O
strongly	O
associated	O
with	O
asthma	B-PATH
exacerbations	O
.	O

In	O
addition	O
;	O
viral	O
infection	O
;	O
in	O
combination	O
with	O
genetics	O
;	O
allergen	O
exposure	O
;	O
microbiome	O
and	O
other	O
pathogens	O
;	O
may	O
play	O
a	O
role	O
in	O
asthma	B-PATH
development	O
.	O

In	O
particular	O
;	O
asthma	B-PATH
development	O
has	O
been	O
linked	O
to	O
wheezing	O
-	O
associated	O
respiratory	O
viral	O
infections	O
in	O
early	O
life	O
.	O

Investigators	O
have	O
modeled	O
asthma	B-PATH
exacerbations	O
by	O
infecting	O
mice	O
with	O
allergic	O
airways	O
disease	O
.	O

Small	O
animal	O
models	O
of	O
respiratory	O
viral	O
infection	O
will	O
identify	O
cell	O
and	O
molecular	O
targets	O
for	O
the	O
treatment	O
of	O
asthma	B-PATH
.	O

While	O
TAT	O
peptides	O
facilitate	O
active	O
endocytosis	B-PATH
of	O
the	O
carriers	O
,	O
we	O
observed	O
that	O
these	O
peptides	O
did	O
not	O
promote	O
endosomal	O
escape	O
or	O
enhanced	O
intracellular	O
availability	O
of	O
doxorubicin	O
.	O

TITLE	O
:	O
Point	O
-	O
of	O
-	O
care	O
lung	O
ultrasound	O
for	O
the	O
detection	O
of	O
pulmonary	O
manifestations	O
of	O
malaria	B-PATH
and	O
sepsis	O
:	O
An	O
observational	O
study	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
malaria	B-PATH
or	O
sepsis	O
are	O
at	O
risk	O
of	O
developing	O
life	O
-	O
threatening	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Serial	O
point	O
-	O
of	O
-	O
care	O
lung	O
ultrasound	O
studies	O
were	O
performed	O
on	O
four	O
consecutive	O
days	O
in	O
a	O
planned	O
sub	O
study	O
of	O
an	O
observational	O
cohort	O
of	O
patients	O
with	O
malaria	B-PATH
or	O
sepsis	O
in	O
Bangladesh	O
.	O

Of	O
102	O
patients	O
enrolled	O
,	O
71	O
had	O
sepsis	O
and	O
31	O
had	O
malaria	B-PATH
.	O

This	O
study	O
demonstrates	O
the	O
potential	O
usefulness	O
of	O
point	O
-	O
of	O
-	O
care	O
lung	O
ultrasound	O
to	O
detect	O
lung	O
abnormalities	O
in	O
patients	O
with	O
malaria	B-PATH
or	O
sepsis	O
in	O
a	O
resource	O
-	O
constrained	O
hospital	O
setting	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
,	O
H5N1	O
,	O
H3N2	O
,	O
and	O
H1N1pdm09	O
)	O
and	O
Influenza	O
B	O
are	O
common	O
among	O
the	O
Pakistani	O
population	O
.	O

The	O
interference	O
of	O
influenza	B-PATH
A	I-PATH
viruses	O
and	O
RSV	O
,	O
RSV	O
and	O
rhinoviruses	O
was	O
highlighted	O
.	O

ABSTRACT	O
:	O
Highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
came	O
to	O
the	O
attention	O
of	O
the	O
international	O
sci	O
-	O
entific	O
community	O
for	O
the	O
first	O
time	O
in	O
1997	O
at	O
Hong	O
Kong	O
.	O

Malaria	B-PATH
is	O
most	O
common	O
in	O
travelers	O
returning	O
from	O
sub	O
-	O
Saharan	O
Africa	O
while	O
dengue	O
is	O
most	O
common	O
those	O
returning	O
from	O
Southeast	O
Asia	O
and	O
Latin	O
America	O
.	O

We	O
report	O
here	O
the	O
case	O
of	O
an	O
infant	O
with	O
severe	O
Bordetella	O
pertussis	B-PATH
infection	O
who	O
developed	O
HUS	O
.	O

CONCLUSIONS	O
:	O
This	O
case	O
suggests	O
that	O
pertussis	B-PATH
is	O
a	O
strong	O
trigger	O
of	O
HUS	O
and	O
that	O
complement	O
investigations	O
are	O
necessary	O
to	O
guide	O
treatment	O
and	O
understand	O
the	O
pathophysiology	O
.	O

ABSTRACT	O
:	O
The	O
emerging	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
,	O
a	O
subtype	O
of	O
influenza	O
viruses	O
,	O
was	O
first	O
discovered	O
in	O
March	O
2013	O
in	O
China	O
.	O

Studies	O
have	O
also	O
shown	O
efficacy	O
of	O
gene	O
therapy	O
in	O
clinical	O
trials	O
against	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
as	O
well	O
as	O
models	O
of	O
respiratory	O
diseases	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
measles	B-PATH
and	O
influenza	O
.	O

The	O
TGEV	O
membrane	O
(	O
M	O
)	O
protein	O
is	O
a	O
decisive	O
protein	O
for	O
the	O
proliferation	O
of	O
viral	O
proteins	O
,	O
and	O
is	O
associated	O
with	O
virus	O
assembly	O
and	O
budding	B-PATH
.	O

The	O
overall	O
relative	O
changes	O
for	O
HIV	B-PATH
infection	I-PATH
and	O
AIDS	O
incidence	O
were	O
1	O
.	O
11	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
10	O
-	O
1	O
.	O
13	O
)	O
and	O
1	O
.	O
28	O
(	O
95	O
%	O
CI	O
1	O
.	O
23	O
-	O
1	O
.	O
33	O
),	O
respectively	O
.	O

The	O
overall	O
relative	O
changes	O
for	O
HIV	B-PATH
infection	I-PATH
were	O
1	O
.	O
12	O
(	O
95	O
%	O
CI	O
1	O
.	O
11	O
-	O
1	O
.	O
14	O
)	O
in	O
males	O
and	O
1	O
.	O
10	O
(	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
1	O
.	O
13	O
)	O
in	O
females	O
.	O

ABSTRACT	O
:	O
Enterovirus	O
D68	O
(	O
EV	O
-	O
D68	O
)	O
is	O
a	O
pathogen	O
that	O
causes	O
outbreaks	O
of	O
respiratory	O
illness	O
across	O
the	O
world	O
,	O
mostly	O
in	O
children	O
,	O
and	O
can	O
be	O
especially	O
severe	O
in	O
those	O
with	O
asthma	B-PATH
.	O

TITLE	O
:	O
[	O
The	O
first	O
case	O
of	O
severe	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
in	O
Guangdong	O
Province	O
in	O
2018	O
successfully	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
].	O

TITLE	O
:	O
Infectious	O
bronchitis	O
virus	O
entry	O
mainly	O
depends	O
on	O
clathrin	O
mediated	O
endocytosis	B-PATH
and	O
requires	O
classical	O
endosomal	O
/	O
lysosomal	O
system	O
.	O

By	O
using	O
chemical	O
inhibitors	O
,	O
RNA	O
interference	O
,	O
and	O
dominant	O
negative	O
mutants	O
,	O
we	O
observed	O
that	O
lipid	O
rafts	O
and	O
low	O
pH	O
was	O
indeed	O
required	O
for	O
virus	O
entry	O
;	O
IBV	O
mainly	O
utilized	O
the	O
clathrin	O
mediated	O
endocytosis	B-PATH
(	O
CME	O
)	O
for	O
entry	O
;	O
GTPase	O
dynamin	O
1	O
was	O
involved	O
in	O
virus	O
containing	O
vesicle	O
scission	O
;	O
and	O
the	O
penetration	O
of	O
IBV	O
into	O
cells	O
led	O
to	O
active	O
cytoskeleton	O
rearrangement	O
.	O

By	O
using	O
R18	O
labeled	O
virus	O
,	O
we	O
found	O
that	O
virus	O
particles	O
moved	O
along	O
with	O
the	O
classical	O
endosome	O
/	O
lysosome	B-PATH
track	O
.	O

The	O
incidence	O
of	O
admission	O
due	O
to	O
AMI	O
during	O
an	O
acute	O
viral	O
infection	O
was	O
six	O
times	O
as	O
high	O
during	O
the	O
7	O
days	O
after	O
laboratory	O
confirmation	O
of	O
influenza	B-PATH
infection	I-PATH
as	O
during	O
the	O
control	O
interval	O
(	O
10	O
-	O
fold	O
in	O
influenza	O
B	O
,	O
5	O
-	O
fold	O
in	O
influenza	B-PATH
A	I-PATH
,	O
3	O
.	O
5	O
-	O
fold	O
in	O
respiratory	O
syncytial	O
virus	O
and	O
2	O
.	O
7	O
-	O
fold	O
for	O
all	O
other	O
viruses	O
).	O

However	O
,	O
with	O
the	O
exception	O
of	O
neuraminidase	O
inhibitors	O
for	O
influenza	B-PATH
infection	I-PATH
,	O
there	O
are	O
no	O
accepted	O
treatments	O
.	O

Here	O
,	O
by	O
exploring	O
a	O
lipid	O
library	O
,	O
we	O
show	O
that	O
AM580	O
,	O
a	O
retinoid	O
derivative	O
and	O
RAR	O
-	O
Î±	O
agonist	O
,	O
is	O
highly	O
potent	O
in	O
interrupting	O
the	O
life	O
cycle	O
of	O
diverse	O
viruses	O
including	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

Pathogens	O
were	O
detected	O
in	O
82	O
samples	O
,	O
which	O
included	O
Respiratory	O
syncytial	O
viruses	O
(	O
RSV	O
)	O
A	O
/	O
B	O
(	O
35	O
.	O
4	O
%),	O
Human	O
rhinovirus	O
(	O
25	O
.	O
6	O
%),	O
Adenovirus	O
(	O
22	O
%),	O
Human	O
Parainfluenza	O
viruses	O
(	O
11	O
%),	O
Human	O
bocavirus	O
(	O
9	O
.	O
8	O
),	O
Human	O
metapneumovirus	O
A	O
/	O
B	O
(	O
8	O
.	O
5	O
%),	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm	O
09	O
(	O
6	O
.	O
1	O
%),	O
Parechovirus	O
(	O
3	O
.	O
7	O
%),	O
Human	O
coronaviruses	O
(	O
3	O
.	O
66	O
%),	O
Haemophilus	O
influenzae	O
type	O
b	O
(	O
6	O
.	O
1	O
%),	O
Chlamydia	O
pneumoniae	O
(	O
2	O
.	O
4	O
%)	O
and	O
Mycoplasma	O
pneumoniae	O
(	O
2	O
.	O
4	O
%).	O

Influenza	B-PATH
A	I-PATH
(	O
other	O
than	O
H1N1	O
),	O
Influenza	O
B	O
,	O
Human	O
Coronavirus	O
229E	O
and	O
Enterovirus	O
were	O
not	O
detected	O
.	O

Enrolled	O
patients	O
were	O
initially	O
suspected	O
to	O
have	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infections	O
.	O

Samples	O
were	O
also	O
tested	O
for	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
human	O
respiratory	O
syncytial	O
virus	O
,	O
rhinovirus	O
,	O
metapneumovirus	O
,	O
coronavirus	O
,	O
adenovirus	O
,	O
and	O
parainfluenza	O
viruses	O
.	O

TITLE	O
:	O
Acute	O
exacerbation	O
of	O
idiopathic	O
pulmonary	O
fibrosis	O
induced	O
by	O
pertussis	B-PATH
:	O
the	O
first	O
case	O
report	O
.	O

Here	O
we	O
report	O
two	O
cases	O
of	O
pertussis	B-PATH
infection	O
-	O
induced	O
AE	O
-	O
IPF	O
.	O

Neither	O
patient	O
had	O
received	O
any	O
pertussis	B-PATH
vaccination	O
since	O
adolescence	O
.	O

Both	O
patients	O
were	O
diagnosed	O
with	O
AE	O
-	O
IPF	O
accompanying	O
acute	O
pertussis	B-PATH
infection	O
based	O
on	O
chest	O
computed	O
tomography	O
and	O
serum	O
pertussis	B-PATH
toxin	O
antibody	O
>	O
100	O
EU	O
/	O
mL	O
.	O
Both	O
patients	O
were	O
treated	O
with	O
macrolide	O
antibiotics	O
and	O
systemic	O
corticosteroids	O
.	O

The	O
presence	O
of	O
pertussis	B-PATH
infection	O
in	O
AE	O
-	O
IPF	O
can	O
present	O
a	O
diagnostic	O
challenge	O
,	O
as	O
coughing	O
accompanying	O
pertussis	B-PATH
may	O
be	O
difficult	O
to	O
distinguish	O
from	O
IPF	O
-	O
associated	O
coughing	O
.	O

Since	O
pertussis	B-PATH
can	O
be	O
prevented	O
with	O
vaccination	O
and	O
is	O
expected	O
to	O
be	O
affected	O
by	O
antibiotics	O
,	O
consideration	O
of	O
pertussis	B-PATH
infection	O
as	O
a	O
causative	O
virulent	O
factor	O
of	O
AE	O
-	O
IPF	O
may	O
be	O
important	O
for	O
management	O
of	O
subjects	O
with	O
IPF	O
.	O

ABSTRACT	O
:	O
To	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
Lactobacillus	O
acidophilus	O
(	O
L	O
.	O
acidophilus	O
)	O
S	O
-	O
layer	O
protein	O
antiviral	O
activity	O
,	O
we	O
examined	O
how	O
S	O
-	O
layer	O
protein	O
impacts	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infection	O
and	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
of	O
Vero	O
cells	O
.	O

When	O
PEDV	O
-	O
infected	O
Vero	O
cells	O
were	O
pretreated	O
with	O
S	O
-	O
layer	O
protein	O
,	O
rates	O
of	O
Vero	O
cell	O
apoptosis	B-PATH
were	O
markedly	O
decreased	O
and	O
cell	O
damage	O
was	O
significantly	O
reduced	O
,	O
as	O
evaluated	O
by	O
flow	O
cytometry	O
and	O
microscopy	O
.	O

In	O
addition	O
,	O
the	O
findings	O
suggest	O
that	O
L	O
.	O
acidophilus	O
S	O
-	O
layer	O
protein	O
protects	O
against	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
through	O
reduced	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
3	O
activation	O
in	O
the	O
later	O
stages	O
of	O
infection	O
.	O

Here	O
,	O
serum	O
-	O
derived	O
EVs	O
from	O
severe	O
TBI	O
patients	O
were	O
analyzed	O
for	O
particle	O
size	O
,	O
concentration	O
,	O
origin	O
,	O
and	O
levels	O
of	O
the	O
inflammasome	O
component	O
,	O
an	O
apoptosis	B-PATH
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	O
caspase	O
-	O
recruiting	O
domain	O
(	O
ASC	O
).	O

The	O
pipeline	O
has	O
been	O
validated	O
on	O
human	O
immunodeficiency	O
virus	O
,	O
human	O
parainfluenza	O
virus	O
1	O
-	O
4	O
,	O
human	O
metapneumovirus	O
,	O
human	O
coronaviruses	O
(	O
229E	O
/	O
OC43	O
/	O
NL63	O
/	O
HKU1	O
/	O
SARS	O
/	O
MERS	O
),	O
human	O
enteroviruses	O
/	O
rhinoviruses	O
,	O
measles	B-PATH
virus	O
,	O
mumps	O
virus	O
,	O
Hepatitis	O
A	O
-	O
E	O
Virus	O
,	O
Chikungunya	O
virus	O
,	O
dengue	O
virus	O
,	O
and	O
West	O
Nile	O
virus	O
,	O
as	O
well	O
the	O
human	O
polyomaviruses	O
BK	O
/	O
JC	O
/	O
MCV	O
,	O
human	O
adenoviruses	O
,	O
and	O
human	O
papillomaviruses	O
.	O

TITLE	O
:	O
Customs	O
officers	O
in	O
relation	O
to	O
viral	O
infections	O
,	O
tuberculosis	B-PATH
,	O
psittacosis	O
and	O
environmental	O
health	O
risk	O
.	O

During	O
the	O
recent	O
increased	O
immigration	O
proceedings	O
,	O
customs	O
officers	O
have	O
been	O
involved	O
in	O
detaining	O
unauthorized	O
populations	O
for	O
various	O
infectious	O
diseases	O
,	O
such	O
as	O
tuberculosis	B-PATH
,	O
varicella	O
and	O
measles	B-PATH
.	O

It	O
is	O
predicted	O
that	O
the	O
inherent	O
genetic	O
diversity	O
of	O
CoVs	O
caused	O
by	O
accumulation	O
of	O
point	O
mutations	O
and	O
high	O
frequency	O
of	O
homologous	B-PATH
recombination	I-PATH
is	O
the	O
principal	O
determinant	O
of	O
these	O
competences	O
.	O

This	O
report	O
highlights	O
the	O
recent	O
accomplishments	O
of	O
GVN	O
researchers	O
in	O
several	O
important	O
areas	O
of	O
medical	O
virology	O
,	O
including	O
strategies	O
for	O
the	O
eradication	O
of	O
smallpox	O
,	O
measles	B-PATH
,	O
polio	O
,	O
SARS	O
and	O
vector	O
-	O
borne	O
or	O
zoonotic	O
infections	O
,	O
emergence	O
and	O
intervention	O
strategies	O
for	O
retroviruses	O
and	O
arboviruses	O
,	O
preparedness	O
for	O
outbreaks	O
of	O
Filo	O
-	O
and	O
other	O
hemophilic	O
viruses	O
,	O
pathogenesis	O
,	O
impact	O
and	O
prevention	O
of	O
respiratory	O
viruses	O
,	O
as	O
well	O
as	O
,	O
viruses	O
affecting	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
.	O

TITLE	O
:	O
Malaria	B-PATH
Severity	O
in	O
Mangaluru	O
City	O
in	O
the	O
Southwestern	O
Coastal	O
Region	O
of	O
India	O
.	O

ABSTRACT	O
:	O
Dakshina	O
Kannada	O
district	O
in	O
the	O
Southwestern	O
region	O
of	O
Karnataka	O
state	O
,	O
India	O
,	O
including	O
Mangaluru	O
city	O
is	O
endemic	O
to	O
malaria	B-PATH
.	O

About	O
80	O
%	O
of	O
malaria	B-PATH
infections	O
in	O
Mangaluru	O
and	O
its	O
surrounding	O
areas	O
are	O
caused	O
by	O

The	O
plasma	O
metabolites	O
were	O
detected	O
with	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
),	O
and	O
the	O
relevant	O
metabolic	B-PATH
pathways	I-PATH
were	O
predicted	O
using	O
the	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
database	O
.	O

While	O
highly	O
efficacious	O
,	O
post	O
-	O
infusion	O
T	O
cell	O
activity	O
often	O
results	O
in	O
massive	O
cytokine	O
release	B-PATH
precipitating	O
cytokine	O
release	B-PATH
syndrome	O
(	O
CRS	O
),	O
the	O
signature	O
toxicity	O
of	O
CAR	O
T	O
cells	O
.	O

Lower	O
induction	O
of	O
apoptosis	B-PATH
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	O
CARD	O
(	O
ASC	O
)	O
speck	O
formation	O
and	O
secretion	O
of	O
interleukin	O
-	O
1Î²	O
in	O
response	O
to	O
both	O
'	O
sterile	O
'	O
stimuli	O
and	O
infection	O
with	O
multiple	O
zoonotic	O
viruses	O
including	O
influenza	B-PATH
A	I-PATH
virus	O
(-	O
single	O
-	O
stranded	O
(	O
ss	O
)	O
RNA	O
),	O
Melaka	O
virus	O
(	O
PRV3M	O
,	O
double	O
-	O
stranded	O
RNA	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(+	O
ssRNA	O
)	O
was	O
observed	O
.	O

In	O
in	O
vitro	O
biological	O
evaluation	O
,	O
several	O
derivatives	O
showed	O
good	O
anti	O
-	O
HBV	O
DNA	B-PATH
replication	I-PATH
activity	O
compared	O
to	O
lamivudine	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
mediate	O
oxidative	B-PATH
damage	I-PATH
by	O
oxidizing	O
bio	O
-	O
macromolecules	O
,	O
including	O
lipids	O
,	O
proteins	O
and	O
nucleic	O
acid	O
.	O

TITLE	O
:	O
N	O
-	O
Linked	O
glycosylation	O
of	O
the	O
membrane	O
protein	O
ectodomain	O
regulates	O
infectious	O
bronchitis	O
virus	O
-	O
induced	O
ER	O
stress	B-PATH
response	I-PATH
,	O
apoptosis	B-PATH
and	O
pathogenesis	O
.	O

However	O
,	O
activation	O
of	O
the	O
ER	O
stress	B-PATH
response	I-PATH
was	O
significantly	O
reduced	O
in	O
cells	O
infected	O
with	O
rN3D	O
/	O
N6D	O
,	O
correlated	O
with	O
a	O
lower	O
level	O
of	O
apoptosis	B-PATH
and	O
reduced	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrates	O
that	O
although	O
not	O
essential	O
for	O
replication	O
,	O
glycosylation	O
in	O
the	O
IBV	O
M	O
protein	O
ectodomain	O
plays	O
important	O
roles	O
in	O
activating	O
ER	O
stress	O
,	O
apoptosis	B-PATH
and	O
proinflammatory	O
response	O
,	O
and	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
IBV	O
.	O

Although	O
rhinovirus	O
/	O
enterovirus	O
,	O
coronavirus	O
229E	O
and	O
influenza	B-PATH
A	I-PATH
clearance	O
were	O
respectively	O
70	O
.	O
6	O
%,	O
71	O
.	O
4	O
%	O
and	O
100	O
%	O
on	O
return	O
,	O
overall	O
virus	O
carriage	O
proportion	O
on	O
return	O
was	O
75	O
.	O
0	O
%	O
in	O
pilgrims	O
with	O
influenza	O
-	O
like	O
illness	O
and	O
44	O
.	O
0	O
%	O
in	O
those	O
who	O
have	O
never	O
experienced	O
this	O
symptoms	O
or	O
resolved	O
it	O

A	O
list	O
of	O
TTD	O
includes	O
infections	O
caused	O
by	O
human	O
T	O
-	O
lymphotropic	O
virus	O
1	O
,	O
cytomegalovirus	O
and	O
West	O
Nile	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
malaria	B-PATH
,	O
Chagas	O
disease	O
,	O
babesiosis	O
,	O
leishmaniasis	B-PATH
,	O
variant	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
,	O
Zika	O
,	O
Dengue	O
,	O
Chikungunya	O
,	O
and	O
anaplasmosis	O
.	O

To	O
Protect	O
the	O
Spike	O
Protein	O
and	O
Promote	O
the	O
Release	B-PATH
of	O
Infectious	O
Virus	O
.	O

Severe	O
falciparum	O
malaria	B-PATH
and	O
leptospirosis	O
are	O
urgent	O
differential	O
diagnoses	O
in	O
residents	O
and	O
travellers	O
from	O
appropriate	O
geographical	O
regions	O
.	O

Positive	O
samples	O
were	O
characterized	O
by	O
partial	O
sequencing	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
,	O
and	O
ensuing	O
phylogenetic	O
analysis	O
was	O
performed	O
to	O
investigate	O
the	O
association	O
between	O
virus	O
epidemiology	O
and	O
bird	O
migration	O
routes	O
.	O

There	O
are	O
a	O
few	O
species	O
of	O
rodent	O
-	O
infective	O
malaria	B-PATH
parasites	O
,	O
and	O
mice	O
infected	O
with	O
such	O
parasites	O
are	O
now	O
widely	O
used	O
for	O
screening	O
candidate	O
drugs	O
and	O
vaccines	O
and	O
for	O
studying	O
host	O
immune	O
responses	O
and	O
pathogenesis	O
associated	O
with	O
disease	O
-	O
related	O
complications	O
.	O

Expression	O
studies	O
of	O
the	O
macrodomain	O
-	O
PLP2	O
portion	O
of	O
nsp3	O
indicate	O
that	O
the	O
ts	O
mutations	O
enhance	O
proteasome	B-PATH
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O

Contact	O
data	O
is	O
frequently	O
collected	O
in	O
outbreaks	O
of	O
pathogens	O
spread	O
by	O
close	O
contact	O
,	O
including	O
Ebola	O
virus	O
(	O
EBOV	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
Mycobacterium	O
tuberculosis	B-PATH
(	O
TB	O
),	O
and	O
routinely	O
used	O
to	O
reconstruct	O
transmission	O
chains	O
.	O

ABSTRACT	O
:	O
First	O
-	O
line	O
management	O
of	O
severe	O
asthma	B-PATH
exacerbations	O
include	O
the	O
use	O
of	O
inhaled	O
short	O
-	O
acting	O
Î²	O
-	O
agonists	O
,	O
anticholinergics	O
,	O
and	O
systemic	O
corticosteroids	O
.	O

In	O
infected	O
cells	O
,	O
nsp1	O
engages	O
in	O
a	O
multipronged	O
mechanism	O
to	O
inhibit	O
host	O
gene	O
expression	O
by	O
binding	O
to	O
the	O
40S	O
ribosome	B-PATH
to	O
block	O
the	O
assembly	O
of	O
translationally	O
competent	O
ribosome	B-PATH
,	O
and	O
then	O
inducing	O
endonucleolytic	O
cleavage	O
and	O
the	O
degradation	O
of	O
host	O
mRNAs	O
.	O

These	O
lncRNAs	O
were	O
involved	O
in	O
glycolysis	B-PATH
/	I-PATH
gluconeogenesis	I-PATH
,	O
histidine	B-PATH
metabolism	I-PATH
and	O
pentose	O
and	O
Chloroalkane	B-PATH
and	I-PATH
chloroalkene	I-PATH
degradation	I-PATH
pathway	O
.	O

Nasopharyngeal	O
/	O
oropharyngeal	O
(	O
NP	O
/	O
OP	O
)	O
swabs	O
were	O
collected	O
and	O
samples	O
were	O
tested	O
using	O
RT	O
-	O
PCR	O
for	O
influenza	B-PATH
A	I-PATH
,	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
parainfluenza	O
virus	O
(	O
PIV	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
),	O
adenovirus	O
,	O
bocavirus	O
,	O
coronavirus	O
,	O
enterovirus	O
,	O
rhinovirus	O
,	O
and	O
atypical	O
bacteria	O
.	O

These	O
emerging	O
infections	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
the	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
avian	O
influenza	O
(	O
AI	O
)	O
viruses	O
,	O
have	O
seriously	O
threatened	O
global	O
health	O
and	O
the	O
economy	O
.	O

This	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
roles	O
of	O
host	O
differentially	O
expressed	O
genes	O
on	O
metabolic	B-PATH
pathways	I-PATH
in	O
PDCoV	O
infections	O
.	O

Fatty	O
acid	O
-	O
binding	O
protein	O
1	O
(	O
FABP1	O
)	O
and	O
fatty	O
acid	O
-	O
binding	O
protein	O
3	O
(	O
FABP3	O
)	O
were	O
found	O
to	O
be	O
regulated	O
by	O
PDCoV	O
.	O
These	O
two	O
genes	O
not	O
only	O
mediate	O
fatty	O
acid	O
transportation	O
to	O
different	O
cell	O
organelles	O
such	O
as	O
mitochondria	O
,	O
peroxisome	B-PATH
,	O
endoplasmic	O
reticulum	O
and	O
nucleus	O
,	O
but	O
also	O
modulate	O
fatty	B-PATH
acid	I-PATH
metabolism	I-PATH
and	O
storage	O
as	O
a	O
signaling	O
molecule	O
outside	O
the	O
cell	O
.	O

The	O
genes	O
of	O
FABP	O
family	O
members	O
in	O
the	O
PPAR	B-PATH
signaling	I-PATH
pathway	I-PATH
were	O
the	O
most	O
highly	O
altered	O
and	O
played	O
important	O
roles	O
in	O
metabolism	O
.	O

Additionally	O
,	O
bacterial	O
infections	O
leading	O
to	O
bubonic	O
and	O
pneumonic	O
plague	O
,	O
most	O
notably	O
in	O
Madagascar	O
in	O
2018	O
,	O
as	O
well	O
as	O
malaria	B-PATH
in	O
many	O
tropical	O
countries	O
,	O
melioidosis	O
in	O
south	O
east	O
Asia	O
and	O
tularaemia	O
in	O
northern	O
Europe	O
and	O
North	O
America	O
,	O
have	O
incurred	O
significant	O
morbidity	O
and	O
mortality	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
infections	O
induce	O
apoptosis	B-PATH
in	O
Vero	O
cells	O
via	O
a	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)/	O
p53	O
,	O
but	O
not	O
p38	O
MAPK	O
and	O
SAPK	O
/	O
JNK	O
signalling	O
pathways	O
.	O

Treatment	O
with	O
the	O
p53	O
inhibitor	O
PFT	O
-	O
Î±	O
could	O
significantly	O
inhibit	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
.	O

Treatment	O
with	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
or	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
),	O
significantly	O
inhibited	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
.	O

Moreover	O
,	O
further	O
inhibition	O
tests	O
were	O
established	O
to	O
prove	O
that	O
p53	O
was	O
regulated	O
by	O
ROS	O
in	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
activated	O
p53	O
and	O
accumulated	O
ROS	O
participated	O
in	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
and	O
p53	O
could	O
be	O
regulated	O
by	O
ROS	O
during	O
PEDV	O
infection	O
.	O

Activated	O
p38	O
MAPK	O
and	O
SAPK	O
/	O
JNK	O
exerted	O
no	O
influence	O
on	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
.	O

CS	O
is	O
known	O
to	O
be	O
triggered	O
by	O
massive	O
tumor	O
cell	O
lysis	O
as	O
a	O
result	O
of	O
chemotherapy	O
and	O
cytokine	O
release	B-PATH
,	O
aggravated	O
with	O
alveolar	O
hemorrhage	O
.	O

ORF3a	O
-	O
induced	O
elevation	O
of	O
IL	O
-	O
1Î²	O
secretion	O
was	O
independent	O
of	O
its	O
ion	O
channel	O
activity	O
or	O
absent	O
in	O
melanoma	B-PATH
2	O
but	O
required	O
NLRP3	O
,	O
ASC	O
,	O
and	O
TRAF3	O
.	O

Multiplex	O
PCR	O
was	O
done	O
for	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
,	O
Influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
and	O
Influenza	O
B	O
.	O
A	O
total	O
of	O
200	O
(	O
32	O
%)	O
samples	O
were	O
found	O
to	O
be	O
positive	O
for	O
Influenza	O
viruses	O
.	O

The	O
dominant	O
subtype	O
in	O
our	O
set	O
-	O
up	O
,	O
during	O
winter	O
of	O
2017	O
-	O
2018	O
,	O
was	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
.	O

CONCLUSIONS	O
:	O
The	O
dominant	O
subtype	O
in	O
our	O
set	O
-	O
up	O
,	O
during	O
winter	O
of	O
2017	O
-	O
2018	O
,	O
was	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
.	O

CAD	O
and	O
viral	B-PATH
myocarditis	I-PATH
,	O
at	O
times	O
,	O
can	O
share	O
common	O
presenting	O
symptoms	O
,	O
EKG	O
changes	O
,	O
and	O
laboratory	O
findings	O
.	O

Airway	O
pressure	O
release	B-PATH
ventilation	O
offers	O
an	O
alternative	O
approach	O
to	O
maximize	O
lung	O
recruitment	O
and	O
oxygenation	O
,	O
but	O
clinical	O
trials	O
have	O
not	O
demonstrated	O
a	O
survival	O
benefit	O
of	O
this	O
mode	O
over	O
conventional	O
ventilation	O
strategies	O
.	O

TITLE	O
:	O
von	O
Willebrand	O
factor	O
in	O
experimental	O
malaria	B-PATH
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
MA	O
-	O
ARDS	O
)	O
is	O
a	O
lethal	O
complication	O
of	O
severe	O
malaria	B-PATH
,	O
characterized	O
by	O
marked	O
pulmonary	O
inflammation	O
.	O

Patient	O
studies	O
have	O
suggested	O
a	O
link	O
between	O
von	O
Willebrand	O
factor	O
(	O
VWF	O
)	O
and	O
malaria	B-PATH
severity	O
.	O

Thrombocytopenia	O
was	O
VWF	O
-	O
independent	O
because	O
it	O
was	O
observed	O
in	O
both	O
Vwf	O
This	O
study	O
suggests	O
that	O
parasite	O
load	O
together	O
with	O
malarial	O
anemia	O
,	O
rather	O
than	O
alveolar	O
leakage	O
,	O
might	O
contribute	O
to	O
shortened	O
survival	O
in	O
PbNK65	O
-	O
infected	O
Vwf	O
RESULTS	O
:	O
In	O
accordance	O
with	O
patients	O
with	O
severe	O
malaria	B-PATH
,	O
plasma	O
VWF	O
levels	O
were	O
increased	O
and	O
ADAMTS13	O
activity	O
levels	O
were	O
reduced	O
in	O
experimental	O
MA	O
-	O
ARDS	O
.	O

TITLE	O
:	O
Excess	O
mortality	O
is	O
associated	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
illness	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	B-PATH
)	O
2009	O
(	O
A	O
/	O
H1N1	B-PATH
),	O
influenza	B-PATH
A	I-PATH
H3N2	O
,	O
and	O
influenza	O
B	O
were	O
tested	O
in	O
all	O
patients	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pdm09	O
vaccine	O
reduced	O
the	O
odds	O
of	O
death	O
by	O
78	O
%.	O

TITLE	O
:	O
Association	O
between	O
Inflammatory	O
Cytokine	O
Levels	O
and	O
Thrombocytopenia	O
during	O
ABSTRACT	O
:	O
Thrombocytopenia	O
is	O
a	O
most	O
commonly	O
observed	O
complication	O
during	O
malaria	B-PATH
infections	O
.	O

Inflammatory	O
cytokines	O
such	O
as	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
10	O
have	O
been	O
documented	O
in	O
malaria	B-PATH
induced	O
thrombocytopaenia	O
.	O

In	O
this	O
study	O
,	O
blood	O
samples	O
from	O
627	O
malaria	B-PATH
patients	O
were	O
analyzed	O
for	O
infected	O
parasite	O
species	O
,	O
clinical	O
conditions	O
,	O
platelet	O
levels	O
,	O
and	O
key	O
cytokines	O
that	O
are	O
produced	O
in	O
response	O
to	O
infection	O
;	O
samples	O
from	O
176	O
uninfected	O
healthy	O
individuals	O
were	O
used	O
as	O
controls	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
understand	O
the	O
association	O
of	O
inflammatory	O
cytokine	O
responses	O
with	O
severe	O
malaria	B-PATH
complications	O
and	O
thrombocytopenia	O
.	O

TITLE	O
:	O
ABSTRACT	O
:	O
Toxoplasmosis	B-PATH
is	O
considered	O
as	O
an	O
opportunistic	O
parasitic	O
disease	O
.	O

ABSTRACT	O
:	O
Beta	O
-	O
defensins	B-PATH
contribute	O
to	O
host	O
innate	O
defense	O
against	O
various	O
pathogens	O
,	O
including	O
viruses	O
,	O
although	O
the	O
details	O
of	O
their	O
roles	O
in	O
innate	O
immune	O
cells	O
are	O
unclear	O
.	O

Bacterial	O
Outer	O
Membrane	O
Vesicles	O
(	O
OMVs	O
)-	O
based	O
Dual	O
Vaccine	O
for	O
Influenza	B-PATH
A	I-PATH
H1N1	O
Virus	O
and	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Vaccination	O
is	O
the	O
most	O
functional	O
medical	O
intervention	O
to	O
prophylactically	O
control	O
severe	O
diseases	O
caused	O
by	O
human	O
-	O
to	O
-	O
human	O
or	O
animal	O
-	O
to	O
-	O
human	O
transmissible	O
viral	O
pathogens	O
.	O

Herein	O
,	O
we	O
generated	O
a	O
bacterial	O
outer	O
membrane	O
vesicles	O
(	O
OMVs	O
)-	O
based	O
vaccine	O
presenting	O
the	O
antigenic	O
stable	O
chimeric	O
fusion	O
protein	O
of	O
the	O
H1	O
-	O
type	O
haemagglutinin	O
(	O
HA	O
)	O
of	O
the	O
pandemic	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H1N1	O
)	O
strain	O
from	O
2009	O
(	O
H1N1pdm09	O
)	O
and	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
(	O
OMVs	O
-	O
H1	O
/	O
RBD	O
).	O

His	O
medical	O
history	O
included	O
only	O
malaria	B-PATH
,	O
successfully	O
treated	O
2	O
years	O
ago	O
.	O

Malaria	B-PATH
should	O
be	O
ruled	O
out	O
because	O
of	O
its	O
frequency	O
,	O
without	O
forgetting	O
other	O
common	O
causes	O
of	O
fever	O
familiar	O
to	O
emergency	O
doctors	O
.	O

We	O
found	O
that	O
10	O
mg	O
/	O
kg	O
and	O
50	O
mg	O
/	O
kg	O
NBP	O
significantly	O
prevented	O
LPS	O
-	O
induced	O
increase	O
of	O
W	O
/	O
D	O
ratio	O
of	O
lung	O
,	O
histological	O
injury	O
of	O
lung	O
,	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
release	B-PATH
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
and	O
oxidative	B-PATH
damage	I-PATH
.	O

A	O
71	O
-	O
year	O
-	O
old	O
man	O
with	O
atrial	O
fibrillation	O
,	O
advanced	O
ALS	O
,	O
type	B-PATH
II	I-PATH
diabetes	I-PATH
mellitus	I-PATH
,	O
and	O
hypertension	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
dyspnoea	O
and	O
tachycardia	O
.	O

ABSTRACT	O
:	O
The	O
introduction	O
of	O
blood	O
donor	O
screening	O
by	O
virus	O
nucleic	O
acid	O
amplification	O
technology	O
(	O
NAT	O
)	O
in	O
the	O
mid	O
to	O
late	O
1990s	O
was	O
driven	O
by	O
the	O
so	O
-	O
called	O
AIDS	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
epidemic	O
,	O
with	O
thousands	O
of	O
recipients	O
of	O
infected	O
blood	O
products	O
and	O
components	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
counteracts	O
BST2	O
-	O
mediated	O
restriction	O
of	O
virus	O
-	O
like	O
particle	O
release	B-PATH
.	O

ABSTRACT	O
:	O
BST2	O
/	O
tetherin	O
,	O
an	O
interferon	O
-	O
inducible	O
antiviral	O
factor	O
,	O
can	O
block	O
the	O
cellular	O
release	B-PATH
of	O
various	O
enveloped	O
viruses	O
.	O

ADP	O
-	O
ribosylation	O
plays	O
an	O
important	O
role	O
in	O
several	O
biological	O
processes	O
such	O
as	O
DNA	O
repair	O
,	O
transcription	O
,	O
chromatin	O
remodelling	O
,	O
host	O
-	O
virus	O
interactions	O
,	O
cellular	O
stress	B-PATH
response	I-PATH
and	O
many	O
more	O
.	O

We	O
report	O
three	O
unrelated	O
children	O
with	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
infection	O
manifesting	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
IAV	O
-	O
ARDS	O
),	O
heterozygous	O
for	O
rare	O

This	O
study	O
investigated	O
the	O
presence	O
of	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
adenovirus	O
,	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
human	O
metapneumovirus	O
(	O
HMPV	O
),	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
NL63	O
),	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
FluA	O
)	O
in	O
children	O
with	O
CAP	O
and	O
the	O
contributing	O
risk	O
factors	O
.	O

Aggregated	O
ORF8b	O
induces	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
,	O
lysosomal	O
damage	O
,	O
and	O
subsequent	O
activation	O
of	O
the	O
master	O
regulator	O
of	O
the	O
autophagy	O
and	O
lysosome	B-PATH
machinery	O
,	O
Transcription	O
factor	O
EB	O
(	O
TFEB	O
).	O

TITLE	O
:	O
[	O
Porcine	O
deltacoronavirus	O
induces	O
mitochondrial	O
apoptosis	B-PATH
in	O
ST	O
cells	O
].	O

In	O
ST	O
cells	O
,	O
caspase	O
activity	O
assay	O
showed	O
that	O
the	O
activity	O
of	O
caspase	O
3	O
,	O
caspase	O
8	O
and	O
caspase	O
9	O
increased	O
significantly	O
with	O
the	O
infection	O
of	O
PDCoV	O
,	O
but	O
not	O
observed	O
in	O
UV	O
irradiated	O
PDCoV	O
-	O
infected	O
cells	O
,	O
indicating	O
that	O
PDCoV	O
infection	O
activated	O
both	O
endogenous	O
and	O
exogenous	O
apoptotic	O
pathways	O
in	O
ST	O
cells	O
,	O
and	O
the	O
induction	O
of	O
apoptosis	B-PATH
depended	O
on	O
viral	O
replication	O
.	O

To	O
further	O
investigate	O
the	O
endogenous	O
apoptosis	B-PATH
induced	O
by	O
PDCoV	O
,	O
cytochrome	O
C	O
and	O
apoptosis	B-PATH
-	O
inducing	O
factors	O
in	O
cytoplasm	O
and	O
mitochondria	O
were	O
detected	O
.	O

Compared	O
with	O
normal	O
cells	O
,	O
the	O
amount	O
of	O
cytochrome	O
C	O
released	O
from	O
mitochondria	O
to	O
cytoplasm	O
increased	O
significantly	O
in	O
PDCoV	O
-	O
infected	O
cells	O
,	O
and	O
the	O
release	B-PATH
increased	O
with	O
the	O
prolongation	O
of	O
infection	O
,	O
while	O
the	O
apoptosis	B-PATH
-	O
inducing	O
factor	O
was	O
always	O
localized	O
to	O
mitochondria	O
,	O
suggesting	O
that	O
PDCoV	O
induced	O
apoptosis	B-PATH
was	O
initiated	O
through	O
caspase	O
-	O
dependent	O
mitochondrial	O
apoptosis	B-PATH
pathway	O
by	O
promoting	O
cytochrome	O
C	O
in	O
the	O
mitochondrial	O
membrane	O
gap	O
into	O
the	O
cytosol	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
reveals	O
the	O
mechanism	O
of	O
PDCoV	O
inducing	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Broad	O
spectrum	O
antiviral	O
remdesivir	O
inhibits	O
human	O
endemic	O
and	O
zoonotic	O
deltacoronaviruses	O
with	O
a	O
highly	O
divergent	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

Remdesivir	O
(	O
RDV	O
,	O
GS	O
-	O
5734	O
)	O
is	O
a	O
monophosphoramidate	O
prodrug	O
of	O
an	O
adenosine	O
analog	O
with	O
potent	O
activity	O
against	O
an	O
array	O
of	O
RNA	O
virus	O
families	O
including	O
Filoviridae	O
,	O
Paramyxoviridae	O
,	O
Pneumoviridae	O
,	O
and	O
Orthocoronavirinae	O
,	O
through	O
the	O
targeting	O
of	O
the	O
viral	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
).	O

Virome	O
connectivity	O
was	O
apparent	O
in	O
two	O
well	O
described	O
multi	O
-	O
host	O
virus	O
species	O
-	O
avian	O
coronavirus	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
-	O
and	O
a	O
novel	O
Rotavirus	O
species	O
that	O
were	O
shared	O
among	O
some	O
Anseriform	O
species	O
,	O
while	O
virome	O
heterogeneity	O
was	O
reflected	O
in	O
the	O
absence	O
of	O
viruses	O
shared	O
between	O
Anseriformes	O
and	O
Charadriiformes	O
,	O
as	O
well	O
as	O
differences	O
in	O
viral	O
abundance	O
and	O
alpha	O
diversity	O
among	O
species	O
.	O

ABSTRACT	O
:	O
The	O
6	O
'-	O
fluorinated	O
aristeromycins	O
were	O
designed	O
as	O
dual	O
-	O
target	O
antiviral	O
compounds	O
aimed	O
at	O
inhibiting	O
both	O
the	O
viral	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
and	O
the	O
host	O
cell	O

Swine	O
received	O
severe	O
SII	O
and	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
,	O
n	O
=	O
6	O
),	O
or	O
conventional	O
ARDSNet	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
(	O
CMV	O
,	O
n	O
=	O
8	O
).	O

Such	O
evasion	O
is	O
related	O
to	O
the	O
unstable	O
nature	O
of	O
its	O
RNA	O
,	O
in	O
particular	O
the	O
S	O
glycoprotein	O
encoding	O
gene	O
,	O
which	O
raises	O
great	O
challenges	O
with	O
regard	O
to	O
the	O
control	O
of	O
the	O
disease	O
,	O
along	O
with	O
the	O
lack	O
of	O
proof	O
reading	O
mechanisms	O
of	O
the	O
RNA	B-PATH
polymerase	I-PATH
.	O

TITLE	O
:	O
Effects	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
on	O
tight	B-PATH
junction	I-PATH
protein	O
gene	O
expression	O
and	O
morphology	O
of	O
the	O
intestinal	O
mucosa	O
in	O
pigs	O
.	O

ABSTRACT	O
:	O
Tight	B-PATH
junction	I-PATH
proteins	O
are	O
important	O
for	O
the	O
maintenance	O
and	O
repair	O
of	O
the	O
intestinal	O
mucosal	O
barrier	O
.	O

The	O
present	O
study	O
investigated	O
relationships	O
among	O
tight	B-PATH
junction	I-PATH
protein	O
gene	O
expression	O
,	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infection	O
,	O
and	O
intestinal	O
mucosal	O
morphology	O
in	O
piglets	O
.	O

We	O
compared	O
the	O
expression	O
of	O
six	O
tight	B-PATH
junction	I-PATH
proteins	O
(	O
ZO	O
-	O
1	O
,	O
ZO	O
-	O
2	O
,	O
Occludin	O
,	O
Claudin	O
-	O
1	O
,	O
Claudin	O
-	O
4	O
,	O
and	O
Claudin	O
-	O
5	O
)	O
between	O
seven	O
-	O
day	O
-	O
old	O
piglets	O
infected	O
with	O
PEDV	O
and	O
normal	O
piglets	O
,	O
as	O
well	O
as	O
in	O
PEDV	O
-	O
infected	O
porcine	O
intestinal	O
epithelial	O
cells	O
(	O
IPEC	O
-	O
J2	O
).	O

The	O
expression	O
of	O
six	O
tight	B-PATH
junction	I-PATH
protein	O
genes	O
was	O
lower	O
in	O
PEDV	O
-	O
infected	O
piglets	O
than	O
in	O
the	O
normal	O
animals	O
.	O

In	O
PEDV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
,	O
the	O
mRNA	O
expression	O
of	O
the	O
six	O
tight	B-PATH
junction	I-PATH
proteins	O
showed	O
a	O
downward	O
trend	O
;	O
in	O
particular	O
,	O
the	O
expression	O
of	O
the	O
Occludin	O
and	O
Claudin	O
-	O
4	O
genes	O
was	O
significantly	O
lower	O
(	O
p	O
â¨	O
0	O
.	O
01	O
).	O

These	O
data	O
suggest	O
that	O
the	O
expression	O
of	O
these	O
six	O
tight	B-PATH
junction	I-PATH
proteins	O
,	O
especially	O
Occludin	O
and	O
Claudin	O
-	O
4	O
,	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
intestinal	O
mucosal	O
barrier	O
and	O
resistance	O
to	O
PEDV	O
infection	O
in	O
piglets	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
prevalence	O
of	O
and	O
risk	O
factors	O
for	O
postoperative	O
pulmonary	O
complications	O
(	O
PPCs	O
)	O
in	O
healthy	O
elderly	O
patients	O
with	O
non	B-PATH
-	I-PATH
small	I-PATH
cell	I-PATH
lung	I-PATH
cancer	I-PATH
(	O
NSCLC	O
)	O
to	O
select	O
optimal	O
candidates	O
for	O
surgical	O
resection	O
in	O
this	O
subpopulation	O
.	O

Fraxin	O
might	O
increase	O
the	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
activity	O
to	O
avoid	O
oxidative	B-PATH
damage	I-PATH
.	O

TITLE	O
:	O
The	O
Establishment	O
and	O
Validation	O
of	O
the	O
Human	O
U937	O
Cell	O
Line	O
as	O
a	O
Cellular	O
Model	O
to	O
Screen	O
Immunomodulatory	O
Agents	O
Regulating	O
Cytokine	O
Release	B-PATH
Induced	O
by	O
Influenza	O
Virus	O
Infection	O
.	O

Meanwhile	O
,	O
pathway	O
analysis	O
indicated	O
that	O
the	O
oxidative	B-PATH
phosphorylation	I-PATH
and	O
leukocyte	B-PATH
transendothelial	I-PATH
migration	I-PATH
signalling	O
pathways	O
might	O
be	O
activated	O
in	O
the	O
IBV	O
group	O
.	O

ABSTRACT	O
:	O
We	O
set	O
out	O
to	O
determine	O
the	O
causes	O
of	O
death	O
in	O
childhood	O
-	O
onset	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
(	O
cSLE	O
).	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
has	O
a	O
propensity	O
to	O
infect	O
an	O
immunocompromised	O
host	O
(	O
ICH	O
).	O

However	O
,	O
ICH	O
groups	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
who	O
have	O
received	O
ECMO	O
have	O
recorded	O
mortality	O
up	O
to	O
61	O
%.	O

High	O
index	O
of	O
suspicion	O
for	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
in	O
ICH	O
,	O
early	O
antiviral	O
therapy	O
,	O
and	O
treatment	O
of	O
coinfection	O
is	O
recommended	O
.	O

Through	O
this	O
review	O
,	O
we	O
have	O
attempted	O
to	O
identify	O
clinical	O
and	O
radiological	O
peculiarities	O
in	O
ICH	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
,	O
treatment	O
guidelines	O
,	O
and	O
prognostic	O
factors	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
in	O
ICH	O
may	O
remain	O
clinically	O
silent	O
or	O
mild	O
.	O

CONCLUSIONS	O
We	O
found	O
that	O
CXCL5	O
/	O
CXCR2	O
accelerated	O
the	O
progression	O
of	O
ARDS	O
,	O
partly	O
by	O
upregulation	O
of	O
MMP2	O
and	O
MMP9	O
in	O
lung	O
tissues	O
with	O
the	O
release	B-PATH
of	O
inflammatory	O
factors	O
.	O

ABSTRACT	O
:	O
Overview	O
of	O
influenza	B-PATH
infection	I-PATH
,	O
focusing	O
on	O
outcome	O
and	O
complications	O
in	O
critically	O
ill	O
patients	O
.	O

Pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
circulates	O
seasonally	O
and	O
remains	O
the	O
predominant	O
subtype	O
among	O
intensive	O
care	O
patients	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
case	O
of	O
severe	O
Guillain	O
-	O
Barre	O
syndrome	O
(	O
GBS	O
)	O
associated	O
with	O
chronic	O
active	O
hepatitis	B-PATH
C	I-PATH
and	O
mixed	O
cryoglobulinemia	O
(	O
MC	O
).	O

A	O
56	O
-	O
year	O
-	O
old	O
man	O
developed	O
symmetrical	O
muscle	O
weakness	O
in	O
all	O
extremities	O
,	O
areflexia	O
and	O
sensorial	O
disorder	O
followed	O
by	O
acute	O
respiratory	O
failure	O
associated	O
with	O
chronic	O
active	O
hepatitis	B-PATH
C	I-PATH
,	O
which	O
was	O
confirmed	O
by	O
the	O
presence	O
of	O
anti	O
-	O
HCV	O
antibodies	O
in	O
the	O
serum	O
and	O
persistence	O
of	O
HCV	O
RNA	O
viral	O
load	O
for	O
more	O
than	O
6	O
months	O
.	O

Influenza	B-PATH
A	I-PATH
is	O
the	O
predominant	O
viral	O
etiology	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
adults	O
.	O

Risk	O
factors	O
independently	O
associated	O
with	O
ARDS	O
are	O
age	O
between	O
36	O
and	O
55	O
years	O
old	O
,	O
pregnancy	O
,	O
and	O
obesity	O
,	O
while	O
protective	O
factors	O
are	O
female	O
sex	O
,	O
influenza	O
vaccination	O
,	O
and	O
infections	O
with	O
Influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
or	O
Influenza	O
B	O
viruses	O
.	O

A	O
total	O
of	O
448	O
patients	O
with	O
confirmed	O
viral	O
pneumonia	O
were	O
included	O
,	O
of	O
those	O
,	O
216	O
(	O
48	O
.	O
2	O
%)	O
were	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
non	O
H1N1	O
)/	O
influenza	O
B	O
,	O
150	O
(	O
33	O
.	O
5	O
%)	O
by	O
H1N1	O
,	O
and	O
82	O
(	O
18	O
.	O
3	O
%)	O
by	O
MERS	O
-	O
CoV	O
.	O
The	O
majority	O
of	O
patients	O
presented	O
with	O
fever	O
(	O
82	O
%),	O
shortness	O
of	O
breath	O
(	O
64	O
%),	O
and	O
flu	O
-	O
like	O
symptoms	O
(	O
54	O
.	O
9	O
%),	O
particularly	O
in	O
MERS	O
-	O
CoV	O
infected	O
cases	O
(	O
92	O
%).	O

In	O
the	O
present	O
study	O
,	O
a	O
series	O
of	O
C	O
-	O
28	O
modified	O
pentacyclic	O
triterpene	O
saponins	O
via	O
conjugation	O
with	O
a	O
series	O
of	O
amide	O
derivatives	O
were	O
synthesized	O
and	O
their	O
antiviral	O
activities	O
against	O
influenza	B-PATH
A	I-PATH
/	O
Duck	O
/	O
Guangdong	O
/	O
99	O
virus	O
(	O
H5N1	O
)	O
in	O
MDCK	O
cells	O
were	O
evaluated	O
.	O

TITLE	O
:	O
Using	O
routine	O
testing	O
data	O
to	O
understand	O
circulation	O
patterns	O
of	O
influenza	B-PATH
A	I-PATH
,	O
respiratory	O
syncytial	O
virus	O
and	O
other	O
respiratory	O
viruses	O
in	O
Victoria	O
,	O
Australia	O
.	O

The	O
seasonality	O
of	O
all	O
viruses	O
included	O
was	O
compared	O
with	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
using	O
cross	O
-	O
correlations	O
.	O

Seasonal	O
peaks	O
were	O
observed	O
each	O
year	O
for	O
influenza	B-PATH
A	I-PATH
and	O
RSV	O
and	O
less	O
frequently	O
for	O
influenza	O
B	O
,	O
coronavirus	O
and	O
parainfluenza	O
virus	O
.	O

RSV	O
circulated	O
an	O
average	O
of	O
6	O
weeks	O
before	O
influenza	B-PATH
A	I-PATH
.	O
Co	O
-	O
infection	O
with	O
another	O
respiratory	O
virus	O
was	O
less	O
common	O
with	O
picornavirus	O
,	O
RSV	O
or	O
influenza	B-PATH
A	I-PATH
infection	O
.	O

TITLE	O
:	O
Cricket	O
paralysis	O
virus	O
internal	O
ribosome	B-PATH
entry	O
site	O
-	O
derived	O
RNA	O
promotes	O
conventional	O
vaccine	O
efficacy	O
by	O
enhancing	O
a	O
balanced	O
Th1	O
/	O
Th2	O
response	O
.	O

We	O
found	O
that	O
single	O
strand	O
RNA	O
(	O
termed	O
RNA	O
adjuvant	O
)	O
derived	O
from	O
cricket	O
paralysis	O
virus	O
intergenic	O
region	O
internal	O
ribosome	B-PATH
entry	O
site	O
induced	O
the	O
expression	O
of	O
various	O
adjuvant	O
-	O
function	O
-	O
related	O
genes	O
,	O
such	O
as	O
type	O
1	O
and	O
2	O
interferon	O
(	O
IFN	O
)	O
and	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
),	O
T	O
cell	O
activation	O
,	O
and	O
leukocyte	O
chemotaxis	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
;	O
furthermore	O
,	O
its	O
innate	O
and	O
IFN	O
transcriptome	O
profile	O
patterns	O
were	O
similar	O
to	O
those	O
of	O
a	O
live	O
-	O
attenuated	O
yellow	O
fever	O
vaccine	O
.	O

TITLE	O
:	O
David	O
Versus	O
Goliath	O
:	O
The	O
Clinical	O
Consequences	O
of	O
an	O
Influenza	B-PATH
A	I-PATH
Viral	O
Infection	O
in	O
an	O
Unvaccinated	O
Patient	O
.	O

The	O
latter	O
is	O
a	O
rare	O
subtype	O
of	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
and	O
represents	O
a	O
hematological	O
emergency	O
.	O

Subsequently	O
,	O
confocal	O
microscopy	O
analysis	O
showed	O
that	O
the	O
aggregated	O
ORF3	O
localized	O
in	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
to	O
trigger	O
ER	O
stress	B-PATH
response	I-PATH
via	O
up	O
-	O
regulation	O
of	O
GRP78	O
protein	O
expression	O
and	O
activation	O
of	O
PERK	O
-	O
eIF2Î±	O
signaling	O
pathway	O
.	O

In	O
addition	O
,	O
our	O
results	O
showed	O
that	O
PEDV	O
ORF3	O
could	O
induce	O
the	O
autophagy	O
through	O
inducing	O
conversion	O
of	O
LC3	O
-	O
I	O
to	O
LC3	O
-	O
II	O
,	O
but	O
couldn	O
'	O
t	O
influence	O
the	O
apoptosis	B-PATH
.	O

In	O
-	O
vitro	O
assays	O
demonstrated	O
that	O
miR	O
-	O
150	O
alleviated	O
LPS	O
-	O
induced	O
A549	O
cell	O
apoptosis	B-PATH
,	O
autophagy	O
,	O
and	O
release	B-PATH
of	O
inflammatory	O
cytokines	O
.	O

Coronaviruses	O
bud	O
into	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
),	O
but	O
the	O
mechanisms	O
by	O
which	O
M	O
proteins	O
are	O
transported	O
from	O
their	O
site	O
of	O
synthesis	O
,	O
the	O
ER	O
,	O
to	O
the	O
budding	B-PATH
site	O
remain	O
poorly	O
understood	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
hypericin	O
against	O
infectious	O
bronchitis	O
virus	O
induced	O
apoptosis	B-PATH
and	O
reactive	O
oxygen	O
species	O
in	O
chicken	O
embryo	O
kidney	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
HY	O
showed	O
potential	O
antiviral	O
activities	O
against	O
IBV	O
infection	O
involving	O
the	O
inhibition	O
of	O
apoptosis	B-PATH
and	O
ROS	O
generation	O
in	O
CEK	O
cells	O
.	O

Interest	O
in	O
extracorporeal	O
life	O
support	O
increased	O
with	O
the	O
confluence	O
of	O
2	O
events	O
in	O
2009	O
:	O
(	O
1	O
)	O
the	O
publication	O
of	O
a	O
randomized	O
clinical	O
trial	O
of	O
extracorporeal	O
life	O
support	O
for	O
acute	O
respiratory	O
failure	O
and	O
(	O
2	O
)	O
the	O
use	O
of	O
extracorporeal	O
life	O
support	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
during	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
.	O

Consideration	O
of	O
various	O
differential	O
diagnoses	O
and	O
finally	O
narrowing	O
down	O
to	O
that	O
of	O
stress	O
-	O
induced	O
reversible	O
cardiomyopathy	O
(	O
Takotsubo	O
syndrome	O
)	O
following	O
his	O
intracranial	O
bleed	O
,	O
versus	O
that	O
of	O
coexisting	O
dual	O
pathology	O
-	O
acute	O
brain	O
injury	O
with	O
concomitant	O
acute	O
viral	B-PATH
myocarditis	I-PATH
,	O
deepened	O
our	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
each	O
disease	O
process	O
,	O
and	O
how	O
it	O
possibly	O
interlinks	O
between	O
different	O
organ	O
systems	O
.	O

Much	O
more	O
frequent	O
than	O
primary	B-PATH
immunodeficiency	I-PATH
are	O
recurrent	O
infections	O
(	O
frequently	O
involving	O
the	O
upper	O
respiratory	O
tract	O
),	O
which	O
are	O
less	O
severe	O
and	O
occur	O
under	O
the	O
conditions	O
of	O
an	O
immune	O
system	O
with	O
no	O
apparent	O
major	O
defects	O
.	O

Many	O
viruses	O
have	O
been	O
identified	O
as	O
triggering	O
the	O
autoimmune	O
process	O
,	O
including	O
HIV	O
,	O
MCV	O
,	O
EBV	O
,	O
parvovirus	O
,	O
rubella	O
and	O
measles	B-PATH
.	O

Respiratory	O
viruses	O
were	O
identified	O
in	O
the	O
nasopharyngeal	O
swabs	O
of	O
50	O
patients	O
(	O
45	O
.	O
5	O
%)	O
using	O
the	O
real	O
-	O
time	O
PCR	O
method	O
,	O
with	O
rhinovirus	O
(	O
25	O
%),	O
influenza	B-PATH
A	I-PATH
(	O
13	O
.	O
1	O
%)	O
and	O
coronavirus	O
(	O
11	O
.	O
8	O
%)	O
being	O
the	O
most	O
commonly	O
isolated	O
agents	O
.	O

Ten	O
fragments	O
contiguously	O
spanning	O
the	O
complete	O
IBV	O
genome	O
were	O
amplified	O
and	O
cloned	O
into	O
the	O
vaccinia	O
virus	O
genome	O
by	O
homologous	B-PATH
recombination	I-PATH
.	O

Interestingly	O
,	O
the	O
inhibition	O
of	O
NF	O
-	O
ÎºB	O
by	O
MERS	O
-	O
CoV	O
accessory	O
proteins	O
was	O
mostly	O
at	O
the	O
level	O
of	O
pattern	O
recognition	O
receptors	O
:	O
melanoma	B-PATH
differentiationassociated	O
gene	O
5	O
(	O
MDA5	O
).	O

Exacerbation	O
of	O
COPD	O
and	O
bronchial	O
asthma	B-PATH
occurred	O
in	O
23	O
(	O
16	O
.	O
1	O
%)	O
patients	O
,	O
paresis	O
of	O
the	O
diaphragm	O
-	O
in	O
15	O
(	O
11	O
.	O
7	O
%).	O

The	O
recommended	O
vaccines	O
are	O
influenza	O
,	O
pneumococcal	O
,	O
in	O
addition	O
to	O
full	O
compliance	O
with	O
basic	O
vaccines	O
for	O
all	O
pilgrims	O
against	O
diphtheria	O
,	O
tetanus	O
,	O
pertussis	B-PATH
,	O
polio	O
,	O
measles	B-PATH
,	O
and	O
mumps	O
.	O

Influenza	B-PATH
A	I-PATH
virus	O
was	O
most	O
prevalent	O
and	O
was	O
detected	O
in	O
498	O
(	O
17	O
.	O
4	O
%)	O
samples	O
.	O

Influenza	B-PATH
A	I-PATH
virus	O
remains	O
a	O
top	O
threat	O
to	O
animal	O
and	O
human	O
health	O
,	O
but	O
other	O
pathogens	O
may	O
be	O
disseminated	O
through	O
the	O
exhibition	O
swine	O
population	O
.	O

TITLE	O
:	O
Oseltamivir	O
resistance	O
in	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
French	O
multicenter	O
observational	O
cohort	O
study	O
.	O

Our	O
failure	O
to	O
obtain	O
comprehensive	O
guiding	O
frameworks	O
for	O
application	O
in	O
the	O
Indian	O
context	O
for	O
Ebola	O
,	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
,	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
),	O
and	O
Nipah	O
outbreaks	O
led	O
us	O
to	O
the	O
search	O
outside	O
India	O
for	O
frameworks	O
that	O
have	O
worked	O
in	O
the	O
past	O
.	O

ABSTRACT	O
:	O
An	O
immunocompetent	O
adult	O
with	O
asthma	B-PATH
developed	O
severe	O
human	O
metapneumovirus	O
(	O
HMPV	O
)	O
illness	O
complicated	O
by	O
group	O
A	O
Streptococcus	O
coinfection	O
,	O
progressing	O
to	O
ARDS	O
and	O
shock	O
.	O

ABSTRACT	O
:	O
Growth	O
Hormone	O
-	O
Releasing	O
Hormone	O
(	O
GHRH	O
)	O
regulates	O
the	O
release	B-PATH
of	O
growth	O
hormone	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Although	O
our	O
study	O
did	O
not	O
have	O
the	O
precision	O
to	O
rule	O
out	O
a	O
small	O
,	O
clinically	O
relevant	O
effect	O
,	O
the	O
benefit	O
is	O
insufficient	O
to	O
justify	O
the	O
use	O
of	O
immune	O
plasma	O
for	O
treating	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
.	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
of	O
the	O
National	O
Institutes	O
of	O
Health	O
(	O
Bethesda	O
,	O
MD	O
,	O
USA	O
).	O

TITLE	O
:	O
Measles	B-PATH
outbreak	O
from	O
Hong	O
Kong	O
International	O
Airport	O
to	O
the	O
hospital	O
due	O
to	O
secondary	O
vaccine	O
failure	O
in	O
healthcare	O
workers	O
.	O

In	O
total	O
,	O
29	O
HKIA	O
staff	O
of	O
diverse	O
ranks	O
and	O
working	O
locations	O
were	O
infected	O
with	O
measles	B-PATH
within	O
1	O
month	O
.	O

Significantly	O
fewer	O
affected	O
staff	O
had	O
history	O
of	O
travel	O
than	O
non	O
-	O
HKIA	O
-	O
related	O
measles	B-PATH
patients	O
[	O
10	O
of	O
29	O
(	O
34	O
.	O
5	O
%)	O
vs	O
28	O
of	O
35	O
(	O
80	O
%);	O
P	O
<	O
.	O
01	O
].	O

Despite	O
good	O
herd	O
immunity	O
with	O
overall	O
seroprevalence	O
of	O
>	O
95	O
%	O
against	O
measles	B-PATH
,	O
major	O
outbreaks	O
of	O
measles	B-PATH
occurred	O
among	O
HKIA	O
staff	O
having	O
daily	O
contact	O
with	O
many	O
international	O
pssengers	O
.	O

Lessons	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
measles	B-PATH
outbreaks	O
suggested	O
that	O
an	O
airport	O
can	O
be	O
a	O
strategic	O
epidemic	O
center	O
.	O

RESULTS	O
:	O
In	O
total	O
,	O
29	O
HKIA	O
staff	O
of	O
diverse	O
ranks	O
and	O
working	O
locations	O
were	O
infected	O
with	O
measles	B-PATH
within	O
1	O
month	O
.	O

CONCLUSIONS	O
:	O
Despite	O
good	O
herd	O
immunity	O
with	O
overall	O
seroprevalence	O
of	O
>	O
95	O
%	O
against	O
measles	B-PATH
,	O
major	O
outbreaks	O
of	O
measles	B-PATH
occurred	O
among	O
HKIA	O
staff	O
having	O
daily	O
contact	O
with	O
many	O
international	O
pssengers	O
.	O

Viruses	O
with	O
deletions	O
in	O
the	O
5	O
'	O
UTR	O
and	O
ORF1a	O
exhibited	O
impaired	O
viral	O
release	B-PATH
in	O
Vero	O
cells	O
.	O

It	O
involves	O
the	O
release	B-PATH
of	O
acute	O
-	O
phase	O
reactants	O
which	O
are	O
direct	O
mediators	O
of	O
widespread	O
autonomic	O
,	O
endocrine	O
,	O
hematological	O
and	O
immunological	O
alteration	O
in	O
the	O
subject	O
.	O

TITLE	O
:	O
Clinical	O
outcomes	O
of	O
patients	O
treated	O
with	O
intravenous	O
zanamivir	O
for	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
:	O
a	O
case	O
report	O
series	O
.	O

ABSTRACT	O
:	O
Intravenous	O
(	O
IV	O
)	O
zanamivir	O
could	O
be	O
a	O
suitable	O
alternative	O
for	O
the	O
treatment	O
of	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
in	O
patients	O
who	O
are	O
unable	O
to	O
take	O
oral	O
or	O
inhaled	O
medication	O
,	O
for	O
example	O
,	O
those	O
on	O
mechanical	O
ventilation	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

IV	O
zanamivir	O
could	O
be	O
a	O
good	O
therapeutic	O
option	O
in	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
who	O
are	O
unable	O
to	O
take	O
oral	O
or	O
aerosolised	O
antiviral	O
medication	O
.	O

It	O
is	O
fairly	O
well	O
-	O
accepted	O
in	O
the	O
medical	O
community	O
that	O
GC	O
can	O
be	O
life	O
-	O
saving	O
when	O
used	O
in	O
critically	O
ill	O
patients	O
with	O
severe	O
exacerbations	O
of	O
asthma	B-PATH
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
HIV	O
-	O
associated	O
pneumocystosis	O
,	O
and	O
systemic	O
vasculitides	O
.	O

We	O
report	O
herein	O
that	O
gamma	O
-	O
interferon	O
-	O
inducible	O
lysosomal	O
thiol	O
reductase	O
(	O
GILT	O
),	O
a	O
lysosome	B-PATH
-	O
associated	O
ISG	O
,	O
restricts	O
the	O
infectious	O
entry	O
of	O
selected	O
enveloped	O
RNA	O
viruses	O
.	O

TITLE	O
:	O
Successful	O
Ventilation	O
of	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Complicated	O
by	O
Pneumothorax	O
Using	O
Airway	O
Pressure	O
Release	B-PATH
Ventilation	O
:	O
A	O
Case	O
Report	O
.	O

We	O
had	O
to	O
use	O
'	O
airway	O
pressure	O
release	B-PATH
ventilation	O
'	O
mode	O
in	O
view	O
of	O
severe	O
refractory	O
hypoxemia	O
.	O

Protostemonine	O
(	O
PSN	O
),	O
an	O
active	O
alkaloid	O
mainly	O
isolated	O
from	O
the	O
roots	O
of	O
Stemona	O
sesslifolia	O
,	O
has	O
anti	O
-	O
inflammatory	O
effects	O
on	O
asthma	B-PATH
and	O
gram	O
-	O
negative	O
bacteria	O
-	O
induced	O
ALI	O
.	O

As	O
a	O
key	O
cytoplasmic	O
sensor	O
,	O
melanoma	B-PATH
differentiation	O
-	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
can	O
recognize	O
viral	O
RNA	O
and	O
enhance	O
the	O
antiviral	O
immune	O
response	O
.	O

Met	O
is	O
one	O
of	O
the	O
amino	O
acids	O
that	O
not	O
only	O
play	O
a	O
nutritional	O
role	O
but	O
also	O
participate	O
in	O
and	O
regulate	O
key	O
metabolic	B-PATH
pathways	I-PATH
and	O
immune	O
response	O
.	O

Right	O
ventricular	O
endomyocardial	O
biopsy	O
was	O
performed	O
in	O
dogs	O
with	O
UMRD	O
(	O
dilated	B-PATH
cardiomyopathy	I-PATH
[	O
n	O
=	O
25	O
],	O
atrioventricular	O
block	O
[	O
6	O
],	O
and	O
nonfamilial	O
ventricular	O
[	O
4	O
]	O
and	O
supraventricular	O
arrhythmias	O
[	O
2	O
])	O
or	O
CHD	O
(	O
10	O
)	O
that	O
required	O
right	O
ventricular	O
catheterization	O
.	O

TITLE	O
:	O
Miliary	O
tuberculosis	B-PATH
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
evolution	O
was	O
favorable	O
in	O
77	O
%,	O
with	O
no	O
patient	O
lost	O
to	O
follow	O
-	O
up	O
,	O
but	O
7	O
/	O
24	O
(	O
29	O
%)	O
died	O
,	O
either	O
before	O
the	O
initiation	O
of	O
therapy	O
(	O
Miliary	O
tuberculosis	B-PATH
is	O
an	O
acute	O
and	O
severe	O
form	O
of	O
life	O
-	O
threatening	O
tuberculosis	B-PATH
.	O

TITLE	O
:	O
Clinical	O
features	O
and	O
haematological	O
parameters	O
among	O
malaria	B-PATH
patients	O
in	O
Mangaluru	O
city	O
area	O
in	O
the	O
southwestern	O
coastal	O
region	O
of	O
India	O
.	O

Overall	O
,	O
the	O
clinical	O
features	O
and	O
severity	O
of	O
malaria	B-PATH
in	O
P	O
.	O
vivax	O
and	O
mixed	O
infection	O
patients	O
were	O
comparable	O
to	O
P	O
.	O
falciparum	O
patients	O
,	O
albeit	O
with	O
some	O
significant	O
differences	O
.	O

The	O
clinical	O
complications	O
in	O
severe	O
malaria	B-PATH
cases	O
included	O
thrombocytopenia	O
(	O
50	O
.	O
7	O
%),	O
metabolic	O
acidosis	O
(	O
30	O
.	O
1	O
%),	O
severe	O
anaemia	O
(	O
26	O
.	O
0	O
%),	O
jaundice	O
(	O
21	O
.	O
9	O
%),	O
hepatic	O
dysfunction	O
(	O
15	O
.	O
1	O
%),	O
acute	O
renal	O
failure	O
(	O
6	O
.	O
8	O
%),	O
haematuria	O
(	O
8	O
.	O
2	O
%),	O
hypotension	O
(	O
9	O
.	O
6	O
%),	O
cerebral	O
malaria	B-PATH
(	O
1	O
.	O
4	O
%)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
1	O
.	O
4	O
%).	O

However	O
,	O
a	O
significant	O
number	O
of	O
patients	O
had	O
severe	O
malaria	B-PATH
and	O
required	O
hospital	O
admission	O
indicating	O
that	O
there	O
is	O
a	O
substantial	O
need	O
for	O
creating	O
awareness	O
among	O
vulnerable	O
immigrant	O
population	O
.	O

TITLE	O
:	O
Mortalin	O
restricts	O
porcine	O
epidemic	O
diarrhea	O
virus	O
entry	O
by	O
downregulating	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
.	O

Mechanistically	O
,	O
a	O
biochemical	O
interaction	O
between	O
the	O
carboxyl	O
terminus	O
of	O
mortalin	O
and	O
clathrin	O
heavy	O
chain	O
(	O
CLTC	O
)	O
was	O
been	O
found	O
,	O
and	O
mortalin	O
could	O
induce	O
CLTC	O
degradation	O
through	O
the	O
proteasomal	O
pathway	O
,	O
thereby	O
inhibiting	O
the	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
of	O
PEDV	O
into	O
host	O
cells	O
.	O

These	O
results	O
reveal	O
a	O
new	O
function	O
of	O
mortalin	O
in	O
inhibiting	O
endocytosis	B-PATH
,	O
and	O
provide	O
a	O
novel	O
strategy	O
for	O
treating	O
PEDV	O
infections	O
.	O

No	O
differences	O
was	O
observed	O
in	O
age	O
,	O
family	O
history	O
for	O
atopy	O
and	O
/	O
or	O
asthma	B-PATH
,	O
clinical	O
presentations	O
,	O
chest	O
X	O
-	O
ray	O
,	O
or	O
laboratory	O
findings	O
in	O
children	O
with	O
HBoV	O
alone	O
vs	O
.	O
multiple	O
viral	O
detection	O
.	O

TITLE	O
:	O
A	O
Recombinant	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
Carrying	O
A	O
Short	O
Immunogenic	O
Peptide	O
of	O
MERS	O
-	O
CoV	O
as	O
Bivalent	O
Vaccine	O
in	O
BALB	O
/	O
c	O
Mice	O
.	O

Using	O
the	O
generated	O
chimeric	O
construct	O
,	O
a	O
novel	O
recombinant	O
vaccine	O
strain	O
against	O
pandemic	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H1N1pdm09	O
)	O
and	O
MERS	O
-	O
CoV	O
was	O
generated	O
(	O
chimeric	O
bivalent	O
5	O
+	O
3	O
).	O

Swine	O
worker	O
exposure	O
to	O
porcine	O
coronavirus	O
and	O
emerging	O
influenza	B-PATH
A	I-PATH
viruses	O
was	O
documented	O
in	O
China	O
.	O

Clinicopathological	O
features	O
include	O
fever	O
,	O
vasculitis	O
,	O
and	O
serositis	O
,	O
with	O
or	O
without	O
effusions	O
;	O
all	O
of	O
which	O
indicate	O
a	O
pro	O
-	O
inflammatory	O
state	O
with	O
cytokine	O
release	B-PATH
.	O

Respiratory	O
viruses	O
can	O
also	O
exacerbate	O
asthma	B-PATH
and	O
lead	O
to	O
various	O
types	O
of	O
respiratory	O
distress	O
syndromes	O
.	O

Furthermore	O
,	O
as	O
they	O
can	O
adapt	O
fast	O
and	O
cross	O
the	O
species	O
barrier	O
,	O
some	O
of	O
these	O
pathogens	O
,	O
like	O
influenza	B-PATH
A	I-PATH
and	O
SARS	O
-	O
CoV	O
,	O
have	O
occasionally	O
caused	O
epidemics	O
or	O
pandemics	O
,	O
and	O
were	O
associated	O
with	O
more	O
serious	O
clinical	O
diseases	O
and	O
even	O
mortality	O
.	O

Furthermore	O
,	O
pIL	O
-	O
11	O
was	O
found	O
to	O
inhibit	O
viral	O
infection	O
by	O
preventing	O
PEDV	O
-	O
mediated	O
apoptosis	B-PATH
of	O
cells	O
by	O
activating	O
the	O
IL	O
-	O
11	O
/	O
STAT3	O
signaling	O
pathway	O
.	O

Conversely	O
,	O
application	O
of	O
a	O
STAT3	O
phosphorylation	O
inhibitor	O
significantly	O
antagonized	O
the	O
anti	O
-	O
apoptosis	B-PATH
function	O
of	O
pIL	O
-	O
11	O
and	O
counteracted	O
its	O
inhibition	O
of	O
PEDV	O
.	O

Our	O
data	O
suggest	O
that	O
IL	O
-	O
11	O
is	O
a	O
newfound	O
PEDV	O
-	O
inducible	O
cytokine	O
,	O
and	O
its	O
production	O
enhances	O
the	O
anti	O
-	O
apoptosis	B-PATH
ability	O
of	O
epithelial	O
cells	O
against	O
PEDV	O
infection	O
.	O

This	O
retrospective	O
study	O
enrolled	O
eleven	O
pregnant	O
women	O
with	O
confirmed	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
treated	O
in	O
the	O
Clinic	O
for	O
Infectious	O
and	O
Tropical	O
Diseases	O
,	O
Belgrade	O
,	O
Serbia	O
in	O
a	O
6	O
-	O
years	O
period	O
.	O

We	O
selected	O
17	O
porcine	O
respiratory	O
pathogens	O
(	O
Actinobacillus	O
pleuropneumoniae	O
,	O
Boldetella	O
bronchiseptica	O
,	O
Haemophilus	O
parasuis	O
,	O
Pasteurella	O
multocida	O
,	O
Pasteurella	O
multocida	O
toxin	O
,	O
Streptococcus	O
suis	O
,	O
Mycoplasma	O
hyopneumoniae	O
,	O
Mycoplasma	O
hyorhinis	O
,	O
Mycoplasma	O
hyosynovie	O
,	O
porcine	O
circovirus	O
2	O
,	O
pseudorabies	O
virus	O
,	O
porcine	O
cytomegalovirus	O
,	O
swine	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
porcine	O
reproductive	O
and	O
respiratory	O
virus	O
US	O
strain	O
,	O
EU	O
strain	O
,	O
porcine	O
respiratory	O
coronavirus	O
and	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
)	O
as	O
detection	O
targets	O
and	O
designed	O
novel	O
specific	O
primer	O
-	O
probe	O
sets	O
for	O
seven	O
of	O
them	O
.	O

TITLE	O
:	O
Overexpression	O
of	O
MALAT1	O
Relates	O
to	O
Lung	O
Injury	O
through	O
Sponging	O
miR	O
-	O
425	O
and	O
Promoting	O
Cell	O
Apoptosis	B-PATH
during	O
ARDS	O
.	O

Cell	O
apoptosis	B-PATH
and	O
viability	O
were	O
determined	O
by	O
flow	O
cytometry	O
and	O
MTT	O
assay	O
.	O

Exosomes	O
from	O
ARDS	O
patients	O
delivered	O
less	O
miR	O
-	O
425	O
into	O
A549	O
and	O
HFL	O
-	O
1	O
cells	O
and	O
induced	O
cell	O
apoptosis	B-PATH
via	O
upregulating	O
PTEN	O
.	O

A	O
modulated	O
lipidic	O
corona	O
,	O
as	O
well	O
as	O
,	O
an	O
additional	O
coat	O
with	O
vitamin	O
E	O
were	O
used	O
to	O
extend	O
the	O
drug	O
release	B-PATH
enhance	O
the	O
macrophage	O
uptake	O
.	O

The	O
selected	O
vitamin	O
E	O
coated	O
LPH	O
nanoparticles	O
enriched	O
with	O
lecithin	O
-	O
glyceryl	O
monostearate	O
lipid	O
shell	O
exhibited	O
high	O
entrapment	O
for	O
E	O
(	O
80	O
.	O
47	O
%),	O
a	O
size	O
â¤	O
200	O
nm	O
for	O
liver	O
passive	O
targeting	O
,	O
extended	O
release	B-PATH
over	O
one	O
week	O
,	O
proven	O
serum	O
stability	O
,	O
retained	O
stability	O
after	O
refrigeration	O
storage	O
for	O
6	O
months	O
.	O

TITLE	O
:	O
Specificity	O
,	O
kinetics	O
and	O
longevity	O
of	O
antibody	O
responses	O
to	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
infection	O
in	O
humans	O
.	O

Hospitalized	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
also	O
had	O
a	O
higher	O
risk	O
for	O
intensive	O
care	O
unit	O
admission	O
,	O
death	O
,	O
or	O
both	O
than	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
or	O
B	O
,	O
independent	O
of	O
other	O
factors	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
homologous	B-PATH
recombination	I-PATH
may	O
occur	O
and	O
contribute	O
to	O
the	O
2019	O
-	O
nCoV	O
cross	O
-	O
species	O
transmission	O
.	O

We	O
applaud	O
the	O
rapid	O
release	B-PATH
to	O
the	O
public	O
of	O
the	O
genome	O
sequence	O
of	O
the	O
new	O
virus	O
by	O
Chinese	O
virologists	O
,	O
but	O
we	O
also	O
believe	O
that	O
increased	O
transparency	O
on	O
disease	O
reporting	O
and	O
data	O
sharing	O
with	O
international	O
colleagues	O
are	O
crucial	O
for	O
curbing	O
the	O
spread	O
of	O
this	O
newly	O
emerging	O
virus	O
to	O
other	O
parts	O
of	O
the	O
world	O
.	O

TITLE	O
:	O
A	O
rare	O
case	O
of	O
Reye	O
'	O
s	O
syndrome	O
induced	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
with	O
use	O
of	O
ibuprofen	O
in	O
an	O
adult	O
.	O

Fifty	O
-	O
six	O
percent	O
of	O
samples	O
were	O
PCR	O
positive	O
for	O
viral	O
or	O
bacterial	O
pathogen	O
with	O
Influenza	B-PATH
A	I-PATH
as	O
the	O
predominant	O
virus	O
(	O
44	O
%).	O

Although	O
no	O
cases	O
of	O
MERS	O
were	O
identified	O
,	O
the	O
majority	O
of	O
patients	O
had	O
Influenza	B-PATH
infection	I-PATH
for	O
which	O
oseltamivir	O
treatment	O
was	O
indicated	O
and	O
isolation	O
warranted	O
.	O

Viral	O
activate	O
MCs	O
release	B-PATH
early	O
inflammatory	O
chemical	O
copounds	O
including	O
histamine	O
and	O
protease	O
;	O
while	O
late	O
activation	O
provoke	O
the	O
generation	O
of	O
pro	O
-	O
inflammatory	O
IL	O
-	O
1	O
family	O
members	O
including	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
33	O
.	O

We	O
observed	O
that	O
TGEVs	O
could	O
be	O
internalized	O
through	O
clathrin	O
-	O
and	O
caveolae	O
-	O
mediated	O
endocytosis	B-PATH
,	O
and	O
the	O
internalization	O
of	O
TGEVs	O
was	O
almost	O
completed	O
within	O
~	O
2	O
minutes	O
after	O
TGEVs	O
attached	O
to	O
the	O
cell	O
membrane	O
.	O

Other	O
key	O
drug	O
targets	O
,	O
including	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
and	O
coronavirus	O
main	O
proteinase	O
(	O
3CLpro	O
),	O
share	O
a	O
strikingly	O
high	O
(>	O
95	O
%)	O
homology	O
to	O
SARS	O
-	O
CoV	O
.	O
Herein	O
,	O
we	O
suggest	O
four	O
potential	O
drug	O
candidates	O
(	O
an	O
ACE2	O
-	O
based	O
peptide	O
,	O
remdesivir	O
,	O
3CLpro	O
-	O
1	O
and	O
a	O
novel	O
vinylsulfone	O
protease	O
inhibitor	O
)	O
that	O
could	O
be	O
used	O
to	O
treat	O
patients	O
suffering	O
with	O
the	O
2019	O
-	O
nCoV	O
.	O
We	O
also	O
summarize	O
previous	O
efforts	O
into	O
drugging	O
these	O
targets	O
and	O
hope	O
to	O
help	O
in	O
the	O
development	O
of	O
broad	O
-	O
spectrum	O
anti	O
-	O
coronaviral	O
agents	O
for	O
future	O
epidemics	O
.	O

TITLE	O
:	O
Prevalence	O
and	O
contribution	O
of	O
respiratory	O
viruses	O
in	O
the	O
community	O
to	O
rates	O
of	O
emergency	O
department	O
visits	O
and	O
hospitalizations	O
with	O
respiratory	O
tract	O
infections	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
asthma	B-PATH
.	O

ABSTRACT	O
:	O
The	O
individual	O
and	O
combined	O
contribution	O
of	O
viral	O
prevalence	O
in	O
the	O
community	O
to	O
Emergency	O
Department	O
(	O
ED	O
)	O
visits	O
and	O
hospitalizations	O
with	O
respiratory	O
tract	O
infections	O
(	O
RTIs	O
),	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
asthma	B-PATH
is	O
unclear	O
.	O

The	O
Canadian	O
Institute	O
for	O
Health	O
Information	O
reports	O
daily	O
ED	O
visits	O
and	O
hospitalizations	O
for	O
RTIs	O
,	O
COPD	O
and	O
asthma	B-PATH
as	O
a	O
primary	O
diagnosis	O
.	O

There	O
were	O
4	O
,	O
365	O
,	O
578	O
ED	O
visits	O
with	O
RTIs	O
of	O
which	O
321	O
,	O
719	O
(	O
7	O
.	O
4	O
%)	O
were	O
admitted	O
to	O
hospital	O
;	O
817	O
,	O
141	O
ED	O
visits	O
for	O
COPD	O
of	O
which	O
260	O
,	O
665	O
(	O
31	O
.	O
9	O
%)	O
were	O
admitted	O
and	O
649	O
,	O
666	O
ED	O
visits	O
with	O
asthma	B-PATH
of	O
which	O
68	O
,	O
626	O
(	O
10	O
.	O
6	O
%)	O
were	O
admitted	O
.	O

The	O
percentage	O
of	O
positive	O
tests	O
to	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
and	O
adenovirus	O
prevalence	O
explained	O
57	O
.	O
4	O
%	O
of	O
ED	O
visits	O
and	O
63	O
.	O
8	O
%	O
of	O
hospitalizations	O
for	O
RTI	O
,	O
41	O
.	O
4	O
%	O
of	O
ED	O
visits	O
and	O
39	O
.	O
2	O
%	O
of	O
hospitalizations	O
with	O
COPD	O
but	O
only	O
1	O
.	O
5	O
%	O
of	O
ED	O
visits	O
and	O
2	O
.	O
7	O
%	O
of	O
hospitalizations	O
for	O
asthma	B-PATH
.	O

The	O
further	O
addition	O
of	O
human	O
metapneumovirus	O
,	O
rhinovirus	O
and	O
coronavirus	O
over	O
the	O
final	O
3	O
years	O
accounted	O
for	O
66	O
.	O
7	O
%	O
of	O
ED	O
visits	O
and	O
74	O
.	O
4	O
%	O
of	O
hospitalizations	O
for	O
RTI	O
,	O
52	O
.	O
5	O
%	O
of	O
visits	O
and	O
48	O
.	O
2	O
%	O
of	O
hospitalizations	O
for	O
COPD	O
,	O
and	O
only	O
13	O
.	O
3	O
%	O
of	O
visits	O
and	O
10	O
.	O
4	O
%	O
of	O
hospitalizations	O
for	O
asthma	B-PATH
.	O

Community	O
respiratory	O
viral	O
epidemics	O
are	O
major	O
drivers	O
of	O
ED	O
visits	O
and	O
hospitalizations	O
with	O
RTIs	O
and	O
COPD	O
but	O
only	O
a	O
modest	O
contributor	O
to	O
asthma	B-PATH
.	O

The	O
further	O
addition	O
of	O
human	O
metapneumovirus	O
,	O
rhinovirus	O
and	O
coronavirus	O
over	O
the	O
final	O
3	O
years	O
accounted	O
for	O
66	O
.	O
7	O
%	O
of	O
ED	O
visits	O
and	O
74	O
.	O
4	O
%	O
of	O
hospitalizations	O
for	O
RTI	O
,	O
52	O
.	O
5	O
%	O
of	O
visits	O
and	O
48	O
.	O
2	O
%	O
of	O
hospitalizations	O
for	O
COPD	O
,	O
and	O
only	O
13	O
.	O
3	O
%	O
of	O
visits	O
and	O
10	O
.	O
4	O
%	O
of	O
hospitalizations	O
for	O
asthma	B-PATH
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
associated	O
severe	O
complications	O
;	O
hemolytic	O
uremic	O
syndrome	O
,	O
myocarditis	O
,	O
acute	O
necrotizing	O
encephalopathy	O
.	O

To	O
increase	O
awareness	O
about	O
its	O
serious	O
complications	O
,	O
we	O
report	O
three	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
complicated	O
with	O
hemolytic	O
uremic	O
syndrome	O
,	O
myocarditis	O
and	O
acute	O
necrotizing	O
encephalopathy	O
.	O

In	O
all	O
three	O
cases	O
,	O
nasopharyngeal	O
samples	O
confirmed	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
by	O
antigen	O
test	O
and	O
multiplex	O
PCR	O
detection	O
.	O

Exosomes	O
were	O
isolated	O
via	O
ultracentrifugation	O
;	O
purity	O
was	O
determined	O
using	O
sucrose	O
cushion	O
;	O
and	O
presence	O
of	O
lung	O
self	O
-	O
antigens	O
,	O
20S	O
proteasome	B-PATH
,	O
and	O
viral	O
antigens	O
for	O
rhinovirus	O
,	O
coronavirus	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
were	O
determined	O
using	O
immunoblot	O
.	O

Exosomes	O
containing	O
self	O
-	O
antigens	O
,	O
20S	O
proteasome	B-PATH
,	O
and	O
viral	O
antigens	O
were	O
detected	O
at	O
significantly	O
higher	O
levels	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
serum	O
of	O
recipients	O
with	O
symptomatic	O
respiratory	O
viral	O
infections	O
(	O
n	O
=	O
35	O
)	O
as	O
compared	O
with	O
stable	O
controls	O
(	O
n	O
=	O
32	O
).	O

Circulating	O
exosomes	O
isolated	O
from	O
lung	O
transplant	O
recipients	O
diagnosed	O
with	O
respiratory	O
viral	O
infections	O
contained	O
lung	O
self	O
-	O
antigens	O
,	O
viral	O
antigens	O
,	O
and	O
20S	O
proteasome	B-PATH
and	O
elicited	O
immune	O
responses	O
to	O
lung	O
self	O
-	O
antigens	O
that	O
resulted	O
in	O
development	O
of	O
chronic	O
lung	O
allograft	O
dysfunction	O
in	O
immunized	O
mice	O
.	O

RESULTS	O
:	O
Exosomes	O
containing	O
self	O
-	O
antigens	O
,	O
20S	O
proteasome	B-PATH
,	O
and	O
viral	O
antigens	O
were	O
detected	O
at	O
significantly	O
higher	O
levels	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
serum	O
of	O
recipients	O
with	O
symptomatic	O
respiratory	O
viral	O
infections	O
(	O
n	O
=	O
35	O
)	O
as	O
compared	O
with	O
stable	O
controls	O
(	O
n	O
=	O
32	O
).	O

TITLE	O
:	O
Ruscogenin	O
alleviates	O
LPS	O
-	O
induced	O
pulmonary	O
endothelial	O
cell	O
apoptosis	B-PATH
by	O
suppressing	O
TLR4	O
signaling	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
its	O
most	O
advanced	O
form	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
severe	O
inflammatory	O
pulmonary	O
process	O
triggered	O
by	O
varieties	O
of	O
pathophysiological	O
factors	O
,	O
among	O
which	O
apoptosis	B-PATH
of	O
pulmonary	O
endothelial	O
cells	O
plays	O
a	O
critical	O
role	O
in	O
the	O
progression	O
of	O
ALI	O
/	O
ARDS	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
underlying	O
mechanism	O
in	O
which	O
RUS	O
attenuates	O
LPS	O
-	O
induced	O
pulmonary	O
endothelial	O
cell	O
apoptosis	B-PATH
.	O

Mice	O
were	O
challenged	O
with	O
LPS	O
(	O
5	O
mg	O
/	O
kg	O
)	O
by	O
intratracheal	O
instillation	O
for	O
24	O
h	O
to	O
induce	O
apoptosis	B-PATH
of	O
pulmonary	O
endothelial	O
cells	O
in	O
model	O
group	O
.	O

The	O
results	O
showed	O
that	O
RUS	O
could	O
attenuate	O
LPS	O
-	O
induced	O
lung	O
injury	O
and	O
pulmonary	O
endothelial	O
apoptosis	B-PATH
significantly	O
.	O

In	O
murine	O
lung	O
vascular	O
endothelial	O
cells	O
(	O
MLECs	O
)	O
we	O
further	O
confirmed	O
that	O
RUS	O
(	O
1	O
Î¼mol	O
/	O
L	O
)	O
markedly	O
ameliorated	O
MLECs	O
apoptosis	B-PATH
by	O
suppressing	O
TLR4	O
signaling	O
.	O

By	O
using	O
TLR4	O
knockout	O
mice	O
we	O
found	O
that	O
TLR4	O
was	O
essential	O
for	O
the	O
RUS	O
-	O
mediated	O
eï¬	O
;	O
ect	O
on	O
LPS	O
-	O
stimulated	O
pulmonary	O
endothelial	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Regulation	O
of	O
the	O
ER	O
Stress	B-PATH
Response	I-PATH
by	O
the	O
Ion	O
Channel	O
Activity	O
of	O
the	O
Infectious	O
Bronchitis	O
Coronavirus	O
Envelope	O
Protein	O
Modulates	O
Virion	O
Release	B-PATH
,	O
Apoptosis	B-PATH
,	O
Viral	O
Fitness	O
,	O
and	O
Pathogenesis	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
envelope	O
(	O
E	O
)	O
protein	O
is	O
a	O
small	O
structural	O
protein	O
critical	O
for	O
virion	O
morphogenesis	O
and	O
release	B-PATH
.	O

EIC	O
mutations	O
were	O
also	O
implicated	O
in	O
regulating	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
,	O
induction	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
and	O
viral	O
pathogenicity	O

We	O
applied	O
the	O
procedure	O
to	O
RNAi	O
screening	O
data	O
of	O
four	O
different	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
RNA	O
viruses	O
,	O
Hepatitis	B-PATH
C	I-PATH
virus	O
,	O
Chikungunya	O
virus	O
,	O
Dengue	O
virus	O
and	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
and	O
detected	O
novel	O
host	O
factors	O
,	O
including	O
UBC	O
,	O
PLCG1	O
,	O
and	O
DYRK1B	O
,	O
which	O
are	O
predicted	O
to	O
significantly	O
impact	O
the	O
replication	O
cycles	O
of	O
these	O
viruses	O
.	O

Chloroquine	O
phosphate	O
,	O
an	O
old	O
drug	O
for	O
treatment	O
of	O
malaria	B-PATH
,	O
is	O
shown	O
to	O
have	O
apparent	O
efficacy	O
and	O
acceptable	O
safety	O
against	O
COVID	O
-	O
19	O
associated	O
pneumonia	O
in	O
multicenter	O
clinical	O
trials	O
conducted	O
in	O
China	O
.	O

TITLE	O
:	O
[	O
Several	O
suggestion	O
of	O
operation	O
for	O
colorectal	B-PATH
cancer	I-PATH
under	O
the	O
outbreak	O
of	O
Corona	O
Virus	O
Disease	O
19	O
in	O
China	O
].	O

Patients	O
with	O
colorectal	B-PATH
cancer	I-PATH
should	O
receive	O
operation	O
as	O
soon	O
as	O
possible	O
after	O
elective	O
operation	O
is	O
resumed	O
in	O
each	O
hospital	O
.	O

Based	O
onLaparoscopic	O
colorectal	O
operation	O
experiences	O
,	O
the	O
author	O
suggests	O
that	O
the	O
surgery	O
strategy	O
for	O
colorectal	B-PATH
cancer	I-PATH
patients	O
under	O
the	O
COVID	O
-	O
19	O
situation	O
.	O

Recommending	O
laparoscopy	O
-	O
assisted	O
radical	O
surgery	O
for	O
colorectal	B-PATH
cancer	I-PATH
patients	O
.	O

Asthma	B-PATH
or	O
other	O
allergic	O
diseases	O
were	O
not	O
reported	O
by	O
any	O
of	O
the	O
patients	O
.	O

Allergic	O
diseases	O
,	O
asthma	B-PATH
,	O
and	O
COPD	O
are	O
not	O
risk	O
factors	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
.	O

TITLE	O
:	O
[	O
Thinking	O
of	O
treatment	O
strategies	O
for	O
colorectal	B-PATH
cancer	I-PATH
patients	O
in	O
tumor	O
hospitals	O
under	O
the	O
background	O
of	O
coronavirus	O
pneumonia	O
].	O

By	O
summarizing	O
the	O
research	O
progress	O
and	O
guidelines	O
in	O
recent	O
years	O
in	O
the	O
fields	O
of	O
colorectal	B-PATH
cancer	I-PATH
disease	O
screening	O
,	O
treatment	O
strategies	O
(	O
including	O
early	O
colorectal	B-PATH
cancer	I-PATH
,	O
locally	O
advanced	O
colorectal	B-PATH
cancer	I-PATH
,	O
obstructive	O
colorectal	B-PATH
cancer	I-PATH
,	O
metastatic	O
colorectal	B-PATH
cancer	I-PATH
and	O
the	O
treatment	O
of	O
patients	O
after	O
neoadjuvant	O
therapy	O
),	O
the	O
choice	O
of	O
medication	O
and	O
time	O
limit	O
for	O
adjuvant	O
therapy	O
,	O
the	O
protective	O
measures	O
for	O
patients	O
undergoing	O
emergency	O
surgery	O
,	O
the	O
re	O
-	O
examination	O
of	O
postoperative	O
patients	O
and	O
the	O
protection	O
of	O
medical	O
staff	O
,	O
etc	O
.,	O
authors	O
improve	O
treatment	O
strategies	O
in	O
order	O
to	O
provide	O
more	O
choices	O
for	O
patients	O
to	O
obtain	O
the	O
best	O
treatment	O
under	O
the	O
severe	O
epidemic	O
situation	O
of	O
new	O
coronavirus	O
pneumonia	O
.	O

TITLE	O
:	O
[	O
Standardized	O
diagnosis	O
and	O
treatment	O
of	O
colorectal	B-PATH
cancer	I-PATH
during	O
the	O
outbreak	O
of	O
novel	O
coronavirus	O
pneumonia	O
in	O
Renji	O
hospital	O
].	O

Referring	O
to	O
the	O
""""	O
Diagnosis	O
and	O
Treatment	O
Scheme	O
for	O
NCP	O
(	O
Trial	O
Version	O
4	O
and	O
5	O
")"""	O
and	O
combining	O
the	O
actual	O
practice	O
situation	O
in	O
our	O
hospital	O
with	O
the	O
""""	O
Summary	O
of	O
New	O
Coronavirus	O
Files	O
of	O
Shanghai	O
Renji	O
Hospital	O
""","	O
we	O
summarize	O
how	O
to	O
carry	O
out	O
the	O
clinical	O
practice	O
of	O
colorectal	O
surgery	O
under	O
the	O
situation	O
of	O
the	O
prevention	O
and	O
control	O
of	O
the	O
NCP	O
epidemiology	O
,	O
meanwhile	O
under	O
such	O
situation	O
aiming	O
the	O
procedure	O
of	O
diagnose	O
and	O
treatment	O
for	O
emergency	O
patients	O
with	O
colorectal	O
tumor	O
,	O
we	O
share	O
the	O
experiences	O
of	O
the	O
diagnosis	O
of	O
colorectal	O
tumor	O
,	O
the	O
management	O
of	O
patients	O
with	O
colorectal	B-PATH
cancer	I-PATH
who	O
are	O
scheduled	O
to	O
be	O
admitted	O
for	O
surgery	O
,	O
the	O
protection	O
of	O
wards	O
,	O
the	O
perioperative	O
management	O
.	O

The	O
main	O
points	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
Multidisciplinary	O
team	O
(	O
MDT	O
)	O
must	O
be	O
run	O
through	O
the	O
diagnosis	O
and	O
treatment	O
of	O
colorectal	B-PATH
cancer	I-PATH
.	O

(	O
3	O
)	O
The	O
colorectal	B-PATH
cancer	I-PATH
patients	O
with	O
suspected	O
or	O
confirmed	O
NCP	O
should	O
be	O
placed	O
in	O
the	O
isolated	O
room	O
with	O
separate	O
medical	O
devices	O
,	O
and	O
the	O
operative	O
room	O
with	O
negative	O
pressure	O
(	O
under	O
-	O
5	O
Pa	O
)	O
must	O
be	O
separated	O
.	O

(	O
4	O
)	O
The	O
surgical	O
medical	O
workers	O
who	O
process	O
colorectal	B-PATH
cancer	I-PATH
patients	O
with	O
NCP	O
must	O
be	O
protected	O
by	O
three	O
-	O
level	O
.	O

Acute	O
cor	O
pulmonale	O
is	O
usually	O
secondary	O
to	O
an	O
acute	O
respiratory	O
distress	O
syndrome	O
or	O
to	O
a	O
pulmonary	O
embolism	O
but	O
it	O
can	O
also	O
be	O
seen	O
in	O
primary	O
lactic	O
acidosis	O
,	O
a	O
vaso	O
-	O
occlusive	O
crisis	O
in	O
a	O
patient	O
with	O
sickle	O
cell	O
anaemia	O
,	O
severe	O
acute	O
asthma	B-PATH
,	O
and	O
entry	O
of	O
air	O
or	O
injected	O
crushed	O
tablets	O
into	O
the	O
circulation	O
.	O

Here	O
,	O
we	O
systematically	O
investigated	O
the	O
role	O
of	O
trypsin	O
in	O
PDCoV	O
replication	O
including	O
cell	O
entry	O
,	O
cell	O
-	O
to	O
-	O
cell	O
membrane	O
fusion	O
and	O
virus	O
release	B-PATH
.	O

Furthermore	O
,	O
unlike	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
in	O
which	O
trypsin	O
is	O
important	O
for	O
the	O
release	B-PATH
of	O
virus	O
from	O
infected	O
cells	O
,	O
PDCoV	O
release	B-PATH
was	O
not	O
affected	O
by	O
trypsin	O
.	O

TITLE	O
:	O
Swine	O
acute	O
diarrhea	O
syndrome	O
coronavirus	O
-	O
induced	O
apoptosis	B-PATH
is	O
caspase	O
-	O
and	O
cyclophilin	O
D	O
-	O
dependent	O
.	O

TITLE	O
:	O
The	O
antiviral	O
compound	O
remdesivir	O
potently	O
inhibits	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
from	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

TITLE	O
:	O
AVNP2	O
protects	O
against	O
cognitive	O
impairments	O
induced	O
by	O
C6	O
glioma	B-PATH
by	O
suppressing	O
tumour	O
associated	O
inflammation	O
in	O
rats	O
.	O

Herein	O
,	O
we	O
explored	O
the	O
functionality	O
of	O
AVNP2	O
on	O
inhibiting	O
C6	O
in	O
glioma	B-PATH
-	O
bearing	O
rats	O
.	O

The	O
novel	O
object	O
-	O
recognition	O
test	O
and	O
open	O
-	O
field	O
test	O
showed	O
that	O
AVNP2	O
significantly	O
improved	O
the	O
neuro	O
-	O
behaviour	O
affected	O
by	O
C6	O
glioma	B-PATH
.	O

AVNP2	O
also	O
alleviated	O
the	O
decline	O
of	O
long	B-PATH
-	I-PATH
term	I-PATH
potentiation	I-PATH
(	O
LTP	O
)	O
and	O
the	O
decreased	O
density	O
of	O
dendritic	O
spines	O
in	O
the	O
CA1	O
region	O
induced	O
by	O
C6	O
.	O

TITLE	O
:	O
[	O
Chemotherapy	O
strategy	O
for	O
colorectal	B-PATH
cancer	I-PATH
under	O
the	O
outbreak	O
of	O
novel	O
coronavirus	O
pneumonia	O
].	O

For	O
metastatic	O
colorectal	B-PATH
cancer	I-PATH
(	O
CRC	O
)	O
patients	O
,	O
maintenance	O
therapy	O
is	O
the	O
optimal	O
choice	O
.	O

In	O
this	O
report	O
,	O
we	O
provide	O
comprehensive	O
descriptions	O
on	O
data	O
deposition	O
,	O
management	O
,	O
release	B-PATH
and	O
utility	O
in	O
2019nCoVR	O
,	O
laying	O
important	O
foundations	O
in	O
aid	O
of	O
studies	O
on	O
virus	O
classification	O
and	O
origin	O
,	O
genome	O
variation	O
and	O
evolution	O
,	O
fast	O
detection	O
,	O
drug	O
development	O
and	O
pneumonia	O
precision	O
prevention	O
and	O
therapy	O
.	O

ABSTRACT	O
:	O
Fast	O
point	O
-	O
of	O
-	O
use	O
detection	O
of	O
,	O
for	O
example	O
,	O
early	O
-	O
stage	O
zoonoses	O
,	O
e	O
.	O
g	O
.,	O
Q	O
-	O
fever	O
,	O
bovine	O
tuberculosis	B-PATH
,	O
or	O
the	O
Covid	O
-	O
19	O
coronavirus	O
,	O
is	O
beneficial	O
for	O
both	O
humans	O
and	O
animal	O
husbandry	O
as	O
it	O
can	O
save	O
lives	O
and	O
livestock	O
.	O

Since	O
its	O
release	B-PATH
in	O
2019	O
,	O
we	O
have	O
produced	O
a	O
number	O
of	O
typing	O
tools	O
for	O
emergent	O
viruses	O
that	O
have	O
caused	O
large	O
outbreaks	O
,	O
such	O
as	O
Zika	O
and	O
Yellow	O
Fever	O
Virus	O
in	O
Brazil	O
.	O

Fibrinogen	O
levels	O
,	O
fibrin	O
polymerization	O
,	O
platelet	O
activation	O
,	O
and	O
microparticle	O
release	B-PATH
were	O
increased	O
in	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
compared	O
to	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	O
patients	O
.	O

The	O
current	O
study	O
aims	O
to	O
test	O
anti	O
-	O
HCV	O
drugs	O
against	O
COVID	O
-	O
19	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
).	O

TITLE	O
:	O
[	O
Expert	O
recommendations	O
on	O
the	O
management	O
of	O
patients	O
with	O
advanced	O
non	B-PATH
-	I-PATH
small	I-PATH
cell	I-PATH
lung	I-PATH
cancer	I-PATH
during	O
epidemic	O
of	O
COVID	O
-	O
19	O
(	O
Trial	O
version	O
)].	O

ABSTRACT	O
:	O
To	O
describe	O
experience	O
with	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
in	O
children	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
refractory	O
to	O
conventional	O
low	O
tidal	O
volume	O
ventilation	O
.	O

Evaluation	O
was	O
made	O
of	O
30	O
pediatric	O
patients	O
receiving	O
airway	O
pressure	O
release	B-PATH
ventilation	O
as	O
rescue	O
therapy	O
for	O
severe	O
ARDS	O
.	O

Anti	O
-	O
fibrinolysis	O
and	O
apoptosis	B-PATH
are	O
involved	O
in	O
the	O
progression	O
of	O
PF	O
.	O

Understanding	O
the	O
mechanism	O
of	O
radioprotective	O
effect	O
of	O
curcumin	O
in	O
radiation	O
-	O
induced	O
PF	O
and	O
apoptosis	B-PATH
can	O
lead	O
to	O
the	O
development	O
of	O
an	O
effective	O
therapeutic	O
to	O
combat	O
acute	O
lung	O
injury	O
and	O
fibrosis	O
.	O

The	O
prevalence	O
of	O
bacterial	O
and	O
viral	O
infections	O
continue	O
to	O
increase	O
,	O
because	O
of	O
the	O
acquisition	O
of	O
rhinovirus	O
,	O
coronaviruses	O
(	O
229E	O
,	O
HKU1	O
,	O
OC43	O
),	O
influenza	B-PATH
A	I-PATH
H1N1	O
,	O
Streptococcus	O
pneumoniae	O
,	O
Haemophilus	O
influenzae	O
and	O
Staphylococcus	O
aureus	O
during	O
Hajj	O
.	O

Pneumococcal	O
and	O
Pertussis	B-PATH
vaccines	O
should	O
be	O
recommended	O
for	O
Hajj	O
pilgrims	O
.	O

Hydroxychloroquine	O
shares	O
the	O
same	O
mechanism	O
of	O
action	O
as	O
chloroquine	O
,	O
but	O
its	O
more	O
tolerable	O
safety	O
profile	O
makes	O
it	O
the	O
preferred	O
drug	O
to	O
treat	O
malaria	B-PATH
and	O
autoimmune	O
conditions	O
.	O

Cardiovascular	O
,	O
digestive	O
and	O
endocrine	O
system	O
diseases	O
were	O
commonly	O
reported	O
,	O
except	O
previous	O
chronic	O
pulmonary	O
diseases	O
[	O
e	O
.	O
g	O
.	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
),	O
asthma	B-PATH
,	O
bronchiectasis	O
]	O
that	O
were	O
surprisingly	O
underreported	O
.	O

The	O
influenza	B-PATH
A	I-PATH
virus	O
serology	O
was	O
negative	O
.	O

The	O
genome	O
composition	O
,	O
nucleotide	O
analysis	O
,	O
codon	O
usage	O
indices	O
,	O
relative	O
synonymous	O
codons	O
usage	O
,	O
and	O
effective	O
number	O
of	O
codons	O
(	O
ENc	O
)	O
were	O
analyzed	O
in	O
the	O
four	O
structural	O
genes	O
;	O
Spike	O
(	O
S	O
),	O
Envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
Nucleocapsid	O
(	O
N	O
)	O
genes	O
,	O
and	O
two	O
of	O
the	O
most	O
important	O
nonstructural	O
genes	O
comprising	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
and	O
main	O
protease	O
(	O
Mpro	O
)	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
Beta	O
-	O
CoV	O
from	O
pangolins	O
,	O
bat	O
SARS	O
,	O
MERS	O
,	O
and	O
SARS	O
CoVs	O
.	O

TITLE	O
:	O
Co	O
-	O
infection	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
Influenza	B-PATH
A	I-PATH
Virus	O
in	O
Patient	O
with	O
Pneumonia	O
,	O
China	O
.	O

ABSTRACT	O
:	O
We	O
report	O
co	O
-	O
infection	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
)	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
a	O
patient	O
with	O
pneumonia	O
in	O
China	O
.	O

In	O
this	O
study	O
,	O
19	O
important	O
zoonotic	O
diseases	O
were	O
reported	O
among	O
Iranian	O
camels	O
including	O
listeriosis	O
,	O
leptospirosis	O
,	O
plague	O
,	O
Q	O
fever	O
,	O
brucellosis	O
,	O
campylobacteriosis	O
,	O
tuberculosis	B-PATH
,	O
pasteurellosis	O
,	O
clostridiosis	O
,	O
salmonellosis	O
,	O
Escherichia	O
coli	O
infections	O
,	O
rabies	O
,	O
camelpox	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
,	O
Crimean	O
-	O
Congo	O
haemorrhagic	O
fever	O
,	O
echinococcosis	O
,	O
cryptosporidiosis	O
,	O
toxoplasmosis	B-PATH
and	O
dermatophytosis	O
,	O
most	O
of	O
which	O
belong	O
to	O
bacterial	O
,	O
viral	O
,	O
parasitic	O
and	O
fungal	O
pathogens	O
,	O
respectively	O
.	O

AHCC	O
is	O
an	O
Î±	O
-	O
glucan	O
-	O
based	O
standardized	O
mushroom	O
extract	O
that	O
has	O
been	O
extensively	O
investigated	O
as	O
an	O
immunostimulant	O
both	O
in	O
animals	O
and	O
/	O
or	O
in	O
humans	O
affected	O
by	O
West	O
Nile	O
virus	O
,	O
influenza	O
virus	O
,	O
avian	O
influenza	O
virus	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
papillomavirus	O
,	O
herpes	O
virus	O
,	O
hepatitis	O
B	O
virus	O
and	O
HIV	O
by	O
promoting	O
a	O
regulated	O
and	O
protective	O
immune	O
response	O
.	O

The	O
QIAstat	O
Respiratory	O
Panel	O
Â®	O
assay	O
(	O
QIAstat	O
RP	O
)	O
is	O
a	O
multiplexed	O
in	O
vitro	O
diagnostics	O
test	O
for	O
the	O
rapid	O
simultaneous	O
detection	O
of	O
21	O
pathogens	O
directly	O
from	O
respiratory	O
samples	O
,	O
including	O
human	O
mastadenovirus	O
A	O
-	O
G	O
,	O
primate	O
bocaparvovirus	O
1	O
+	O
2	O
,	O
human	O
coronavirus	O
(	O
HKU1	O
,	O
NL63	O
,	O
OC43	O
,	O
229E	O
),	O
human	O
metapneumovirus	O
A	O
/	O
B	O
,	O
rhinovirus	O
/	O
enterovirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
no	O
subtype	O
,	O
subtype	O
H1	O
,	O
H1N1	O
/	O
2009	O
,	O
H3	O
),	O
influenza	O
B	O
virus	O
,	O
human	O
respirovirus	O
1	O
+	O
3	O
,	O
human	O
orthorubulavirus	O
2	O
+	O
4	O
,	O
human	O
orthopneumovirus	O
,	O
Bordetella	O
pertussis	B-PATH
,	O
Chlamydia	O
pneumoniae	O
,	O
Mycoplasma	O
pneumoniae	O
and	O
Legionella	O
pneumophila	O
.	O

TITLE	O
:	O
Multimodal	O
Therapeutic	O
Approach	O
of	O
Cytokine	O
Release	B-PATH
Syndrome	O
Developing	O
in	O
a	O
Child	O
Given	O
Chimeric	O
Antigen	O
Receptor	O
-	O
Modified	O
T	O
Cell	O
Infusion	O
.	O

A	O
14	O
-	O
year	O
-	O
old	O
boy	O
with	O
refractory	O
B	O
cell	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
given	O
chimeric	O
antigen	O
receptor	O
cells	O
developed	O
severe	O
cytokine	O
release	B-PATH
syndrome	O
7	O
days	O
after	O
the	O
drug	O
product	O
infusion	O
with	O
progressive	O
respiratory	O
failure	O
.	O

Decrease	O
of	O
the	O
inflammatory	O
biomarkers	O
(	O
ferritin	O
,	O
interleukin	O
-	O
6	O
,	O
interleukin	O
-	O
10	O
)	O
in	O
the	O
first	O
96	O
hours	O
associated	O
with	O
a	O
progressive	O
improvement	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
Pao	O
This	O
case	O
suggests	O
that	O
hemoadsorption	O
with	O
cartridge	O
column	O
in	O
combination	O
with	O
continuous	O
renal	O
replacement	O
therapy	O
and	O
tocilizumab	O
is	O
safe	O
and	O
potentially	O
effective	O
in	O
pediatric	O
patients	O
with	O
severe	O
cytokine	O
release	B-PATH
syndrome	O
.	O

For	O
coronaviruses	O
,	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
is	O
an	O
important	O
protease	O
that	O
catalyzes	O
the	O
replication	O
of	O
RNA	O
from	O
RNA	O
template	O
and	O
is	O
an	O
attractive	O
therapeutic	O
target	O
.	O

The	O
binding	O
of	O
COVI	O
-	O
19	O
to	O
the	O
Toll	O
Like	O
Receptor	O
(	O
TLR	O
)	O
causes	O
the	O
release	B-PATH
of	O
pro	O
-	O
IL	O
-	O
1Î²	O
which	O
is	O
cleaved	O
by	O
caspase	O
-	O
1	O
,	O
followed	O
by	O
inflammasome	O
activation	O
and	O
production	O
of	O
active	O
mature	O
IL	O
-	O
1Î²	O
which	O
is	O
a	O
mediator	O
of	O
lung	O
inflammation	O
,	O
fever	O
and	O
fibrosis	O
.	O

Its	O
pathophysiology	O
includes	O
the	O
release	B-PATH
of	O
damage	O
-	O
associated	O
molecular	O
patterns	O
(	O
DAMPs	O
),	O
which	O
propagate	O
tissue	O
injuries	O
by	O
triggering	O
neutrophil	O
extracellular	O
traps	O
(	O
NETs	O
).	O

TITLE	O
:	O
[	O
Challenges	O
and	O
countermeasures	O
on	O
Chinese	O
malaria	B-PATH
elimination	O
programme	O
during	O
the	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
outbreak	O
].	O

If	O
the	O
diagnosis	O
and	O
treatment	O
of	O
malaria	B-PATH
cases	O
as	O
well	O
as	O
the	O
investigation	O
and	O
response	O
of	O
the	O
epidemic	O
foci	O
are	O
not	O
carried	O
out	O
timely	O
,	O
it	O
may	O
endanger	O
patients	O
'	O
lives	O
and	O
cause	O
the	O
possible	O
of	O
secondary	O
transmission	O
,	O
which	O
threatens	O
the	O
achievements	O
of	O
malaria	B-PATH
elimination	O
in	O
China	O
.	O

Due	O
to	O
the	O
extensive	O
spread	O
and	O
high	O
transmission	O
ability	O
of	O
the	O
COVID	O
-	O
19	O
,	O
there	O
is	O
a	O
possibility	O
of	O
virus	O
infections	O
among	O
malaria	B-PATH
cases	O
during	O
the	O
medical	O
care	O
-	O
seeking	O
behaviors	O
and	O
among	O
healthcare	O
professionals	O
during	O
clinical	O
diagnosis	O
and	O
treatment	O
,	O
sample	O
collection	O
and	O
testing	O
and	O
epidemiological	O
surveys	O
.	O

This	O
paper	O
analyzes	O
the	O
challenges	O
of	O
the	O
COVID	O
-	O
19	O
for	O
Chinese	O
malaria	B-PATH
elimination	O
programme	O
,	O
and	O
proposes	O
the	O
countermeasures	O
in	O
response	O
to	O
the	O
COVID	O
-	O
19	O
outbreak	O
,	O
so	O
as	O
to	O
provide	O
the	O
reference	O
for	O
healthcare	O
professionals	O
.	O

TITLE	O
:	O
Accelerated	O
Phase	O
of	O
Atypical	O
Chronic	B-PATH
Myeloid	I-PATH
Leukemia	I-PATH
with	O
Severe	O
Disseminated	O
Intravascular	O
Coagulation	O
at	O
Initial	O
Presentation	O
.	O

Hematopoietic	O
recovery	O
with	O
features	O
of	O
atypical	O
chronic	B-PATH
myeloid	I-PATH
leukemia	I-PATH
(	O
aCML	O
)	O
after	O
induction	O
chemotherapy	O
was	O
a	O
diagnostic	O
clue	O
.	O

A	O
15	O
-	O
year	O
-	O
old	O
Japanese	O
girl	O
with	O
a	O
history	O
of	O
atopic	O
asthma	B-PATH
and	O
dermatitis	O
was	O
admitted	O
to	O
the	O
emergency	O
department	O
with	O
the	O
anaphylactic	O
symptoms	O
of	O
urticaria	O
,	O
skin	O
flushing	O
,	O
throat	O
discomfort	O
,	O
acute	O
dyspnea	O
and	O
severe	O
wheezing	O
that	O
developed	O
shortly	O
after	O
the	O
ingestion	O
of	O
home	O
-	O
cooked	O
buchimgae	O
(	O
Korean	O
pancake	O
)	O
prepared	O
with	O
commercial	O
mixed	O
wheat	O
flour	O
.	O

We	O
focus	O
on	O
the	O
role	O
of	O
lipid	O
structures	O
,	O
such	O
as	O
lipid	O
rafts	O
and	O
cholesterol	O
,	O
involved	O
in	O
the	O
process	O
,	O
mediated	O
by	O
endocytosis	B-PATH
,	O
by	O
which	O
viruses	O
attach	O
to	O
and	O
infect	O
cells	O
.	O

TITLE	O
:	O
Cerebral	O
malaria	B-PATH
and	O
multi	O
-	O
organ	O
dysfunction	O
in	O
an	O
adult	O
woman	O
with	O
Plasmodium	O
falciparum	O
infection	O
imported	O
from	O
Cameroon	O
:	O
a	O
case	O
report	O
ABSTRACT	O
:	O
Malaria	B-PATH
is	O
one	O
of	O
the	O
most	O
life	O
-	O
threatening	O
parasitic	O
diseases	O
caused	O
by	O
the	O
protozoa	O
of	O
the	O
genus	O
Plasmodium	O
,	O
occurring	O
in	O
the	O
tropical	O
and	O
subtropical	O
regions	O
.	O

Misdiagnosed	O
infection	O
can	O
progress	O
to	O
a	O
wide	O
range	O
of	O
life	O
-	O
threatening	O
pathologies	O
,	O
including	O
severe	O
anemia	O
and	O
cerebral	O
malaria	B-PATH
which	O
can	O
lead	O
to	O
death	O
even	O
few	O
days	O
after	O
first	O
symptoms	O
appearance	O
.	O

Cerebral	O
malaria	B-PATH
is	O
rare	O
in	O
adults	O
and	O
most	O
cases	O
are	O
connected	O
to	O
children	O
under	O
5	O
years	O
old	O
living	O
in	O
malaria	B-PATH
endemic	O
areas	O
.	O

The	O
patient	O
had	O
been	O
treated	O
in	O
an	O
intensive	O
care	O
unit	O
because	O
of	O
multi	O
-	O
organ	O
dysfunction	O
as	O
a	O
result	O
of	O
the	O
delayed	O
malaria	B-PATH
diagnosis	O
.	O

The	O
presence	O
of	O
thrombocytopenia	O
,	O
anemia	O
,	O
metabolic	O
acidosis	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
multi	O
-	O
organ	O
dysfunction	O
involving	O
liver	O
,	O
kidneys	O
,	O
and	O
brain	O
created	O
an	O
image	O
of	O
advanced	O
severe	O
malaria	B-PATH
.	O

Loss	O
of	O
consciousness	O
,	O
GCS	O
6	O
,	O
and	O
the	O
presence	O
of	O
asexual	O
Plasmodium	O
falciparum	O
forms	O
in	O
blood	O
films	O
are	O
the	O
evidence	O
of	O
cerebral	O
malaria	B-PATH
.	O

To	O
avoid	O
development	O
of	O
cerebral	O
malaria	B-PATH
,	O
the	O
illness	O
should	O
be	O
diagnosed	O
immediately	O
.	O

Prolonged	O
anemia	O
after	O
treatment	O
can	O
be	O
a	O
consequence	O
of	O
artemisine	O
usage	O
as	O
well	O
as	O
a	O
severe	O
malaria	B-PATH
sequel	O
.	O

By	O
summarizing	O
the	O
research	O
progress	O
and	O
guidelines	O
in	O
recent	O
years	O
in	O
the	O
fields	O
of	O
colorectal	B-PATH
cancer	I-PATH
disease	O
screening	O
,	O
treatment	O
strategies	O
(	O
including	O
early	O
colorectal	B-PATH
cancer	I-PATH
,	O
locally	O
advanced	O
colorectal	B-PATH
cancer	I-PATH
,	O
obstructive	O
colorectal	B-PATH
cancer	I-PATH
,	O
metastatic	O
colorectal	B-PATH
cancer	I-PATH
and	O
the	O
treatment	O
of	O
patients	O
after	O
neoadjuvant	O
therapy	O
),	O
the	O
choice	O
of	O
medication	O
and	O
time	O
limit	O
for	O
adjuvant	O
therapy	O
,	O
the	O
protective	O
measures	O
for	O
patients	O
undergoing	O
emergency	O
surgery	O
,	O
the	O
re	O
-	O
examination	O
of	O
postoperative	O
patients	O
and	O
the	O
protection	O
of	O
medical	O
staff	O
,	O
etc	O
.,	O
authors	O
improve	O
treatment	O
strategies	O
in	O
order	O
to	O
provide	O
more	O
choices	O
for	O
patients	O
to	O
obtain	O
the	O
best	O
treatment	O
under	O
the	O
severe	O
epidemic	O
situation	O
of	O
new	O
coronavirus	O
pneumonia	O
.	O

The	O
radical	O
operation	O
of	O
colorectal	B-PATH
cancer	I-PATH
is	O
semi	O
-	O
elective	O
operation	O
.	O

Based	O
on	O
our	O
experience	O
with	O
laparoscopic	O
colorectal	O
operation	O
,	O
we	O
propose	O
some	O
surgery	O
strategies	O
for	O
colorectal	B-PATH
cancer	I-PATH
patients	O
under	O
the	O
corona	O
virus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
situation	O
:	O
the	O
screening	O
process	O
should	O
be	O
strictly	O
carried	O
out	O
before	O
surgery	O
to	O
reduce	O
the	O
risk	O
of	O
nosocomial	O
infection	O
in	O
the	O
later	O
stage	O
;	O
laparoscopic	O
-	O
assisted	O
surgery	O
is	O
recommended	O
for	O
radical	O
surgery	O
for	O
patients	O
with	O
colorectal	B-PATH
cancer	I-PATH
;	O
strict	O
aerosol	O
management	O
must	O
be	O
made	O
during	O
the	O
operation	O
;	O
natural	O
orifice	O
specimen	O
extraction	O
surgery	O
and	O
transanal	O
total	O
mesorectal	O
excision	O
are	O
should	O
be	O
performed	O
prudently	O
;	O
scientific	O
and	O
reasonable	O
prophylactic	O
stoma	O
should	O
be	O
done	O
;	O
personnel	O
protection	O
in	O
surgical	O
ward	O
and	O
operation	O
room	O
must	O
be	O
strengthened	O
.	O

TITLE	O
:	O
[	O
Standardized	O
diagnosis	O
and	O
treatment	O
of	O
colorectal	B-PATH
cancer	I-PATH
during	O
the	O
outbreak	O
of	O
corona	O
virus	O
disease	O
2019	O
in	O
Renji	O
hospital	O
].	O

Although	O
colorectal	O
surgery	O
is	O
not	O
a	O
front	O
-	O
line	O
subject	O
in	O
the	O
fight	O
against	O
the	O
epidemic	O
,	O
but	O
in	O
this	O
special	O
situation	O
,	O
it	O
is	O
a	O
difficult	O
task	O
to	O
provide	O
the	O
highest	O
quality	O
medical	O
services	O
and	O
ensure	O
the	O
orderly	O
clinical	O
work	O
,	O
on	O
the	O
premise	O
of	O
maximizing	O
the	O
protection	O
for	O
patients	O
and	O
their	O
families	O
,	O
health	O
of	O
medical	O
staff	O
,	O
and	O
the	O
safety	O
of	O
wards	O
and	O
hospitals	O
,	O
We	O
summarize	O
how	O
to	O
carry	O
out	O
the	O
clinical	O
practice	O
of	O
colorectal	O
surgery	O
under	O
the	O
situation	O
of	O
the	O
prevention	O
and	O
control	O
of	O
the	O
COVID	O
-	O
19	O
epidemiology	O
,	O
including	O
the	O
procedures	O
of	O
diagnose	O
and	O
treatment	O
for	O
emergency	O
patients	O
with	O
colorectal	O
tumor	O
,	O
and	O
share	O
the	O
experiences	O
of	O
the	O
diagnosis	O
of	O
colorectal	O
tumor	O
,	O
the	O
management	O
of	O
patients	O
with	O
colorectal	B-PATH
cancer	I-PATH
who	O
are	O
scheduled	O
to	O
be	O
admitted	O
for	O
surgery	O
,	O
the	O
protection	O
of	O
wards	O
,	O
the	O
perioperative	O
management	O
.	O

TITLE	O
:	O
[	O
Chemotherapy	O
strategy	O
for	O
colorectal	B-PATH
cancer	I-PATH
under	O
the	O
outbreak	O
of	O
corona	O
virus	O
disease	O
2019	O
].	O

The	O
most	O
common	O
underlying	O
disease	O
was	O
hematologic	O
malignancies	O
(	O
47	O
.	O
4	O
%),	O
followed	O
by	O
colorectal	B-PATH
cancer	I-PATH
(	O
21	O
%)	O
and	O
lung	O
cancer	O
(	O
15	O
.	O
8	O
%).	O

5	O
out	O
of	O
the	O
115	O
patients	O
confirmed	O
with	O
COVID	O
-	O
19	O
were	O
also	O
diagnosed	O
with	O
influenza	O
virus	O
infection	O
,	O
with	O
three	O
cases	O
being	O
influenza	B-PATH
A	I-PATH
and	O
two	O
cases	O
being	O
influenza	O
B	O
.	O
In	O
this	O
study	O
,	O
we	O
describe	O
the	O
clinical	O
characteristics	O
of	O
those	O
patients	O
who	O
got	O
infected	O
with	O
COVID	O
-	O
19	O
as	O
well	O
as	O
influenza	O
virus	O
.	O

An	O
activated	O
STAT3	O
translocates	O
into	O
the	O
nucleus	O
and	O
combines	O
with	O
DNA	O
to	O
regulate	O
the	O
expression	O
of	O
target	O
genes	O
involved	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
apoptosis	B-PATH
and	O
metastasis	O
.	O

TITLE	O
:	O
Renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
in	O
human	O
coronavirus	O
pathogenesis	O
.	O

TITLE	O
:	O
COVID	O
-	O
19	O
infection	O
and	O
rheumatoid	B-PATH
arthritis	I-PATH
:	O
Faraway	O
,	O
so	O
close	O
!	O

COVID	O
-	O
19	O
pandemic	O
is	O
certainly	O
conditioning	O
the	O
treatment	O
strategy	O
of	O
a	O
complex	O
disorder	O
as	O
rheumatoid	B-PATH
arthritis	I-PATH
(	O
RA	O
),	O
whose	O
infectious	O
risk	O
is	O
increased	O
compared	O
to	O
the	O
general	O
population	O
because	O
of	O
an	O
overall	O
impairment	O
of	O
immune	O
system	O
typical	O
of	O
autoimmune	O
diseases	O
combined	O
with	O
the	O
iatrogenic	O
effect	O
generated	O
by	O
corticosteroids	O
and	O
immunosuppressive	O
drugs	O
.	O

Other	O
viral	O
infections	O
were	O
identified	O
in	O
49	O
%	O
of	O
the	O
patients	O
,	O
with	O
most	O
common	O
pathogens	O
being	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
rhinovirus	O
,	O
metapneumovirus	O
and	O
common	O
coronaviruses	O
,	O
notably	O
HKU1	O
and	O
NL63	O
.	O

TITLE	O
:	O
Renin	B-PATH
-	I-PATH
Angiotensin	I-PATH
System	I-PATH
Blockers	O
and	O
the	O
COVID	O
-	O
19	O
Pandemic	O
:	O

At	O
Present	O
There	O
Is	O
No	O
Evidence	O
to	O
Abandon	O
Renin	B-PATH
-	I-PATH
Angiotensin	I-PATH
System	I-PATH
Blockers	O
.	O

Because	O
the	O
ACE2	O
(	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
)	O
protein	O
is	O
the	O
receptor	O
that	O
facilitates	O
coronavirus	O
entry	O
into	O
cells	O
,	O
the	O
notion	O
has	O
been	O
popularized	O
that	O
treatment	O
with	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
blockers	O
might	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
severe	O
and	O
fatal	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
-	O
2	O
infection	O
.	O

In	O
summary	O
,	O
based	O
on	O
the	O
currently	O
available	O
evidence	O
,	O
treatment	O
with	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
blockers	O
should	O
not	O
be	O
discontinued	O
because	O
of	O
concerns	O
with	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
Chloroquine	O
is	O
a	O
long	O
-	O
established	O
prescription	O
drug	O
that	O
is	O
often	O
used	O
clinically	O
to	O
treat	O
malaria	B-PATH
and	O
connective	O
tissue	O
diseases	O
.	O

The	O
dosage	O
used	O
according	O
to	O
current	O
clinical	O
recommended	O
dosage	O
and	O
course	O
of	O
treatment	O
are	O
larger	O
than	O
that	O
of	O
previous	O
treatment	O
of	O
malaria	B-PATH
.	O

